
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
        <link rel="canonical" href="https://vimbook.beauhilton.com/print_page/">
      
      <link rel="icon" href="../images/vumc-favicon.png">
      <meta name="generator" content="mkdocs-1.3.0, mkdocs-material-8.2.16">
    
    
      
        <title>Print Site - VUMC IM Residency Handbook</title>
      
    
    
      <link rel="stylesheet" href="../assets/stylesheets/main.1c3799f8.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.cc9b2e1e.min.css">
        
      
    
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=IBM+Plex+Sans:300,300i,400,400i,700,700i%7CIBM+Plex+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"IBM Plex Sans";--md-code-font:"IBM Plex Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../css/print-site-enum-headings1.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings2.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings3.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings4.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings5.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings6.css">
    
      <link rel="stylesheet" href="../css/print-site.css">
    
      <link rel="stylesheet" href="../css/print-site-material.css">
    
      <link rel="stylesheet" href="../stylesheets/extra.css">
    
    <script>__md_scope=new URL("/",location),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      
  


  
  


  <script>window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)},ga.l=+new Date,ga("create","UA-105678972-1","auto"),ga("set","anonymizeIp",!0),ga("send","pageview"),document.addEventListener("DOMContentLoaded",function(){document.forms.search&&document.forms.search.query.addEventListener("blur",function(){var e;this.value&&(e=document.location.pathname,ga("send","pageview",e+"?q="+this.value))}),"undefined"!=typeof location$&&location$.subscribe(function(e){ga("send","pageview",e.pathname)})})</script>
  <script async src="https://www.google-analytics.com/analytics.js"></script>


    
    
 <link rel="apple-touch-icon" sizes="256x256" href="/images/apple-touch-icon.png">

  
        <script type="text/javascript">
        document.addEventListener('DOMContentLoaded', function () {
            remove_material_navigation();remove_mkdocs_theme_navigation();generate_toc();
        })
        </script>
        </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber">
  
    
    
      <script>var palette=__md_get("__palette");if(palette&&"object"==typeof palette.color)for(var key of Object.keys(palette.color))document.body.setAttribute("data-md-color-"+key,palette.color[key])</script>
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="VUMC IM Residency Handbook" class="md-header__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../images/vumc-favicon.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            VUMC IM Residency Handbook
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Print Site
            
          </span>
        </div>
      </div>
    </div>
    
      <form class="md-header__option" data-md-component="palette">
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_1">
          
            <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_2" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
            </label>
          
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_2">
          
            <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_1" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
            </label>
          
        
      </form>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
          <a href="javascript:void(0)" class="md-search__icon md-icon" aria-label="Share" data-clipboard data-clipboard-text="" data-md-component="search-share" tabindex="-1">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M18 16.08c-.76 0-1.44.3-1.96.77L8.91 12.7c.05-.23.09-.46.09-.7 0-.24-.04-.47-.09-.7l7.05-4.11c.54.5 1.25.81 2.04.81a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3c0 .24.04.47.09.7L8.04 9.81C7.5 9.31 6.79 9 6 9a3 3 0 0 0-3 3 3 3 0 0 0 3 3c.79 0 1.5-.31 2.04-.81l7.12 4.15c-.05.21-.08.43-.08.66 0 1.61 1.31 2.91 2.92 2.91 1.61 0 2.92-1.3 2.92-2.91A2.92 2.92 0 0 0 18 16.08Z"/></svg>
          </a>
        
        <button type="reset" class="md-search__icon md-icon" aria-label="Clear" tabindex="-1">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="VUMC IM Residency Handbook" class="md-nav__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../images/vumc-favicon.png" alt="logo">

    </a>
    VUMC IM Residency Handbook
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
      

  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        Home
      </a>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2" type="checkbox" id="__nav_2" >
      
      
      
      
        <label class="md-nav__link" for="__nav_2">
          Introduction
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Introduction" data-md-level="1">
        <label class="md-nav__title" for="__nav_2">
          <span class="md-nav__icon md-icon"></span>
          Introduction
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-acknowledgements/" class="md-nav__link">
        Acknowledgements
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-authors-editors-reviewers/" class="md-nav__link">
        Editors, Authors, and Reviewers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-disclaimers/" class="md-nav__link">
        Disclaimers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-rationale/" class="md-nav__link">
        Rationale
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-web-app-setup/" class="md-nav__link">
        Web App Setup
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_3" type="checkbox" id="__nav_3" >
      
      
      
      
        <label class="md-nav__link" for="__nav_3">
          Cardiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Cardiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_3">
          <span class="md-nav__icon md-icon"></span>
          Cardiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-acs/" class="md-nav__link">
        Acute Coronary Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-arrhythmias/" class="md-nav__link">
        Arrhythmias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-atrial-fibrillation-and-flutter/" class="md-nav__link">
        Atrial Fibrillation & Flutter
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-autonomics-and-orthostatics/" class="md-nav__link">
        Autonomics and Orthostatic Hypotension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-bedside-echocardiography/" class="md-nav__link">
        Bedside Echocardiography
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-cardiac-devices/" class="md-nav__link">
        Cardiac Devices
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-chest-pain/" class="md-nav__link">
        Chest Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-chf/" class="md-nav__link">
        Heart Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-ekg/" class="md-nav__link">
        Approach to the ECG
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-inpatient-hypertension/" class="md-nav__link">
        Inpatient Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-pe/" class="md-nav__link">
        Pulmonary Embolism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-rhc/" class="md-nav__link">
        Right Heart Catheterization
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-shock/" class="md-nav__link">
        Cardiogenic Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-syncope/" class="md-nav__link">
        Syncope
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-valvular-heart-disease/" class="md-nav__link">
        Valvular Heart Disease
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_4" type="checkbox" id="__nav_4" >
      
      
      
      
        <label class="md-nav__link" for="__nav_4">
          Critical care
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Critical care" data-md-level="1">
        <label class="md-nav__title" for="__nav_4">
          <span class="md-nav__icon md-icon"></span>
          Critical care
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-abcdef-a2f-bundle/" class="md-nav__link">
        ABCDEF (A2F) Bundle
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-ards/" class="md-nav__link">
        ARDS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-brain-death/" class="md-nav__link">
        Brain Death
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-drips/" class="md-nav__link">
        Drips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-modes-oxygen-delivery/" class="md-nav__link">
        Modes of Oxygen Delivery
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-refractory-hypercapnia/" class="md-nav__link">
        Refractory Hypercapnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-refractory-hypoxemia/" class="md-nav__link">
        Refractory Hypoxemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-sepsis/" class="md-nav__link">
        Sepsis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-shock/" class="md-nav__link">
        Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-temperature-abnormalities/" class="md-nav__link">
        Temperature Abnormalities
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-tracheostomy/" class="md-nav__link">
        Tracheostomy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-vent-settings/" class="md-nav__link">
        Vent Settings
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/main/" class="md-nav__link">
        Management of Shock
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_5" type="checkbox" id="__nav_5" >
      
      
      
      
        <label class="md-nav__link" for="__nav_5">
          Demo
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Demo" data-md-level="1">
        <label class="md-nav__title" for="__nav_5">
          <span class="md-nav__icon md-icon"></span>
          Demo
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../demo/demo-lights/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_6" type="checkbox" id="__nav_6" >
      
      
      
      
        <label class="md-nav__link" for="__nav_6">
          Endocrinology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Endocrinology" data-md-level="1">
        <label class="md-nav__title" for="__nav_6">
          <span class="md-nav__icon md-icon"></span>
          Endocrinology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-adrenal-insufficiency/" class="md-nav__link">
        Adrenal Insufficiency
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-diabetes-inpatient-management/" class="md-nav__link">
        Diabetes: Inpatient Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-dka/" class="md-nav__link">
        DKA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hyperthyroidism/" class="md-nav__link">
        Hyperthyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hypoglycemia/" class="md-nav__link">
        Hypoglycemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hypothyroidism/" class="md-nav__link">
        Hypothyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-steroid-conversions/" class="md-nav__link">
        Steroid Conversions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-stress-dose-steroids/" class="md-nav__link">
        Stress Dose Steroids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-thyroid-nodules/" class="md-nav__link">
        Thyroid Nodules
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-thyroid-storm/" class="md-nav__link">
        Thyroid Storm
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_7" type="checkbox" id="__nav_7" >
      
      
      
      
        <label class="md-nav__link" for="__nav_7">
          Gastroenterology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Gastroenterology" data-md-level="1">
        <label class="md-nav__title" for="__nav_7">
          <span class="md-nav__icon md-icon"></span>
          Gastroenterology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-abdominal-pain/" class="md-nav__link">
        Acute Abdominal Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-diverticulitis/" class="md-nav__link">
        Acute Diverticulitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-pancreatitis/" class="md-nav__link">
        Acute Pancreatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-biliary-disease/" class="md-nav__link">
        Biliary Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-c-diff/" class="md-nav__link">
        C Diff
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-constipation/" class="md-nav__link">
        Constipation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-diarrhea/" class="md-nav__link">
        Diarrhea
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-esophageal-disorders/" class="md-nav__link">
        Esophageal Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-gi-bleeding/" class="md-nav__link">
        GI Bleeding
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-inflammatory-bowel-disease/" class="md-nav__link">
        Inflammatory Bowel Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-intestinal-ischemia/" class="md-nav__link">
        Intestinal Ischemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-nausea-vomiting/" class="md-nav__link">
        Nausea & Vomiting
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-peptic-ulcer-disease/" class="md-nav__link">
        Peptic Ulcer Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-small-bowel-obstruction/" class="md-nav__link">
        Small Bowel Obstruction
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_8" type="checkbox" id="__nav_8" >
      
      
      
      
        <label class="md-nav__link" for="__nav_8">
          Geriatrics
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Geriatrics" data-md-level="1">
        <label class="md-nav__title" for="__nav_8">
          <span class="md-nav__icon md-icon"></span>
          Geriatrics
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-dementia-0/" class="md-nav__link">
        Dementia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-falls/" class="md-nav__link">
        Falls
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-frailty/" class="md-nav__link">
        Frailty
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-malnutrition/" class="md-nav__link">
        Malnutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-medication-management/" class="md-nav__link">
        Medication Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/" class="md-nav__link">
        Urinary Incontinence and Foley Catheter
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_9" type="checkbox" id="__nav_9" >
      
      
      
      
        <label class="md-nav__link" for="__nav_9">
          Hematology oncology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hematology oncology" data-md-level="1">
        <label class="md-nav__title" for="__nav_9">
          <span class="md-nav__icon md-icon"></span>
          Hematology oncology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-anemia/" class="md-nav__link">
        Anemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-anticoagulation/" class="md-nav__link">
        Anticoagulation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-bone-marrow-transplant/" class="md-nav__link">
        Bone Marrow Transplant
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-chemotherapy-toxicity/" class="md-nav__link">
        Chemotherapy Toxicity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-coagulopathies/" class="md-nav__link">
        Coagulopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-dic/" class="md-nav__link">
        DIC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-dvts/" class="md-nav__link">
        DVTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-hypercoagulable-states/" class="md-nav__link">
        Hypercoagulable States
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-leukemia/" class="md-nav__link">
        Leukemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-lymphoma/" class="md-nav__link">
        Lymphoma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-medical-oncology-resources/" class="md-nav__link">
        Medical Oncology Resources
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-myelodysplastic-syndromes/" class="md-nav__link">
        Myelodysplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/" class="md-nav__link">
        Myeloproliferative Neoplasms
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/" class="md-nav__link">
        Neutropenia and Neutropenic Fever
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-oncologic-emergencies/" class="md-nav__link">
        Oncologic Emergencies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-paraneoplastic-syndromes/" class="md-nav__link">
        Paraneoplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/" class="md-nav__link">
        Plasma Cell Dyscrasias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-sickle-cell-crisis/" class="md-nav__link">
        Sickle Cell Crisis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-thrombocytopenia/" class="md-nav__link">
        Thrombocytopenia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-transfusion-medicine/" class="md-nav__link">
        Transfusion Medicine
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_10" type="checkbox" id="__nav_10" >
      
      
      
      
        <label class="md-nav__link" for="__nav_10">
          Hepatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hepatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_10">
          <span class="md-nav__icon md-icon"></span>
          Hepatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-acute-hepatitis-and-abnormal-liver-tests/" class="md-nav__link">
        Acute Hepatitis and Abnormal Liver Tests
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-acute-liver-failure/" class="md-nav__link">
        Acute Liver Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-alcoholic-hepatitis/" class="md-nav__link">
        Alcoholic Hepatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-ascites/" class="md-nav__link">
        Ascites
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-cirrhosis/" class="md-nav__link">
        Cirrhosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-coagulopathy/" class="md-nav__link">
        Coagulopathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatic-encephalopathy/" class="md-nav__link">
        Hepatic Encephalopathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatocellular-carcinoma/" class="md-nav__link">
        Hepatocellular Carcinoma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatorenal-syndrome/" class="md-nav__link">
        Hepatorenal Syndrome
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-liver-transplantation/" class="md-nav__link">
        Liver Transplantation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-medication-pearls/" class="md-nav__link">
        Medication Pearls
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-nash-and-nafld/" class="md-nav__link">
        NASH and NAFLD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-portal-vein-thrombosis/" class="md-nav__link">
        Portal Vein Thrombosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-post-liver-transplant-management/" class="md-nav__link">
        Post-Liver Transplant Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-sbp/" class="md-nav__link">
        SBP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-upper-gi-bleed-cirrhosis/" class="md-nav__link">
        Upper GI Bleed in Cirrhosis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_11" type="checkbox" id="__nav_11" >
      
      
      
      
        <label class="md-nav__link" for="__nav_11">
          Hospital medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hospital medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_11">
          <span class="md-nav__icon md-icon"></span>
          Hospital medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-choosing-wisely/" class="md-nav__link">
        Choosing Wisely
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-guidelines-pregnant-patients/" class="md-nav__link">
        Guidelines for Pregnant Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-lines-and-catheters/" class="md-nav__link">
        Lines and Catheters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-mobility-and-hospital-therapy/" class="md-nav__link">
        Mobility and In-Hospital Therapy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-telemetry/" class="md-nav__link">
        Telemetry
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-utilization-management/" class="md-nav__link">
        Utilization Management
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_12" type="checkbox" id="__nav_12" >
      
      
      
      
        <label class="md-nav__link" for="__nav_12">
          Infectious diseases
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Infectious diseases" data-md-level="1">
        <label class="md-nav__title" for="__nav_12">
          <span class="md-nav__icon md-icon"></span>
          Infectious diseases
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-aids-defining-conditions/" class="md-nav__link">
        AIDS Defining Conditions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-antimicrobial-prophylaxis/" class="md-nav__link">
        Antimicrobial prophylaxis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-bacteremia/" class="md-nav__link">
        Bacteremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-brief-overview-art/" class="md-nav__link">
        Brief Overview of ART
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-cns-infection/" class="md-nav__link">
        CNS Infection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-diabetic-foot-infection/" class="md-nav__link">
        Diabetic Foot Infection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-endocarditis/" class="md-nav__link">
        Endocarditis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-febrile-neutropenia/" class="md-nav__link">
        Febrile Neutropenia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-fungal-infections/" class="md-nav__link">
        Fungal Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-general-tips/" class="md-nav__link">
        General Tips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-gu-infection/" class="md-nav__link">
        GU infection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-hiv-art-general-concepts/" class="md-nav__link">
        HIV & ART General Concepts
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-orthopedic-infection/" class="md-nav__link">
        Orthopedic Infection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-pneumonia/" class="md-nav__link">
        Pneumonia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-ssti/" class="md-nav__link">
        SSTI
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_13" type="checkbox" id="__nav_13" >
      
      
      
      
        <label class="md-nav__link" for="__nav_13">
          Nephrology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Nephrology" data-md-level="1">
        <label class="md-nav__title" for="__nav_13">
          <span class="md-nav__icon md-icon"></span>
          Nephrology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-acute-rejection/" class="md-nav__link">
        Acute Rejection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-aki/" class="md-nav__link">
        AKI
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-approach-ckd/" class="md-nav__link">
        Approach to CKD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-common-side-effects-renal-transplant-immune-suppresants/" class="md-nav__link">
        Common Side Effects of Renal Transplant Immune Suppresants
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hematuria/" class="md-nav__link">
        Hematuria
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypercalcemia/" class="md-nav__link">
        Hypercalcemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyperkalemia/" class="md-nav__link">
        Hyperkalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypernatremia/" class="md-nav__link">
        Hypernatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyperphosphatemia/" class="md-nav__link">
        Hyperphosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypokalemia/" class="md-nav__link">
        Hypokalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypomagnesemia/" class="md-nav__link">
        Hypomagnesemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyponatremia/" class="md-nav__link">
        Hyponatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypophosphatemia/" class="md-nav__link">
        Hypophosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-metabolic-acidosis/" class="md-nav__link">
        Metabolic acidosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-peritonitis-patients-pd/" class="md-nav__link">
        Peritonitis in patients on PD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-renal-replacement-therapy/" class="md-nav__link">
        Renal Replacement Therapy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-transplant-aki/" class="md-nav__link">
        Transplant AKI
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-ua/" class="md-nav__link">
        UA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-uti-renal-transplant/" class="md-nav__link">
        UTI in Renal Transplant
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_14" type="checkbox" id="__nav_14" >
      
      
      
      
        <label class="md-nav__link" for="__nav_14">
          Neurology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Neurology" data-md-level="1">
        <label class="md-nav__title" for="__nav_14">
          <span class="md-nav__icon md-icon"></span>
          Neurology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-aidp/" class="md-nav__link">
        AIDP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-als/" class="md-nav__link">
        ALS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-ams/" class="md-nav__link">
        AMS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-basic-seizures/" class="md-nav__link">
        Seizures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-brain-masses/" class="md-nav__link">
        Brain Masses
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-elevated-icp-and-hydrocephalus/" class="md-nav__link">
        Elevated ICP and Hydrocephalus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-inpatient-headache/" class="md-nav__link">
        Inpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-ms/" class="md-nav__link">
        MS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-myasthenia-etc/" class="md-nav__link">
        Myasthenia etc
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-outpatient-headache/" class="md-nav__link">
        Outpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-parkinson/" class="md-nav__link">
        Parkinson
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-status-epilepticus/" class="md-nav__link">
        Status Epilepticus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-stroke-0/" class="md-nav__link">
        Stroke
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-vertigo/" class="md-nav__link">
        Vertigo
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_15" type="checkbox" id="__nav_15" >
      
      
      
      
        <label class="md-nav__link" for="__nav_15">
          Outpatient medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Outpatient medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_15">
          <span class="md-nav__icon md-icon"></span>
          Outpatient medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-asthma/" class="md-nav__link">
        Asthma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-coding-and-informatics/" class="md-nav__link">
        Coding and Informatics
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-hypertension/" class="md-nav__link">
        Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-lipids/" class="md-nav__link">
        Lipids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-obesitynutrition/" class="md-nav__link">
        Obesity/Nutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-preventative-medicine/" class="md-nav__link">
        Preventative Medicine
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_16" type="checkbox" id="__nav_16" >
      
      
      
      
        <label class="md-nav__link" for="__nav_16">
          Pain and palliative
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pain and palliative" data-md-level="1">
        <label class="md-nav__title" for="__nav_16">
          <span class="md-nav__icon md-icon"></span>
          Pain and palliative
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/" class="md-nav__link">
        Acute and Chronic Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-code-status-discussion/" class="md-nav__link">
        Code Status Discussion
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-death-pronouncement/" class="md-nav__link">
        The Death Pronouncement
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-medications-dying-patients/" class="md-nav__link">
        Medications for Dying Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-opiate-principles/" class="md-nav__link">
        Opiate Principles
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-video-examples-navigating-difficult-conversations/" class="md-nav__link">
        Video Examples for Navigating Difficult Conversations
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_17" type="checkbox" id="__nav_17" >
      
      
      
      
        <label class="md-nav__link" for="__nav_17">
          Physical medicine rehabilitation
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Physical medicine rehabilitation" data-md-level="1">
        <label class="md-nav__title" for="__nav_17">
          <span class="md-nav__icon md-icon"></span>
          Physical medicine rehabilitation
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/" class="md-nav__link">
        Back Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/" class="md-nav__link">
        Knee Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/" class="md-nav__link">
        Neck Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-pmr-consultation/" class="md-nav__link">
        PM&R Consultation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/" class="md-nav__link">
        Rehabilitation Options
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/" class="md-nav__link">
        Shoulder Pain
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_18" type="checkbox" id="__nav_18" >
      
      
      
      
        <label class="md-nav__link" for="__nav_18">
          Procedures
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Procedures" data-md-level="1">
        <label class="md-nav__title" for="__nav_18">
          <span class="md-nav__icon md-icon"></span>
          Procedures
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-anesthesia/" class="md-nav__link">
        Anesthesia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-anticoagulation-parameters/" class="md-nav__link">
        Anticoagulation Parameters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-arterial-line/" class="md-nav__link">
        Arterial Line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-central-line/" class="md-nav__link">
        Central line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-consent/" class="md-nav__link">
        Consent
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-dht/" class="md-nav__link">
        DHT
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-lumbar-puncture/" class="md-nav__link">
        Lumbar Puncture
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-paracentesis/" class="md-nav__link">
        Paracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-thoracentesis/" class="md-nav__link">
        Thoracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-ultrasound-guided-peripheral-iv/" class="md-nav__link">
        Ultrasound-Guided Peripheral IV
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_19" type="checkbox" id="__nav_19" >
      
      
      
      
        <label class="md-nav__link" for="__nav_19">
          Psychiatry
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Psychiatry" data-md-level="1">
        <label class="md-nav__title" for="__nav_19">
          <span class="md-nav__icon md-icon"></span>
          Psychiatry
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-agitation-management/" class="md-nav__link">
        Agitation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-inpatient-insomnia/" class="md-nav__link">
        Inpatient Insomnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-medical-decision-making-capacity/" class="md-nav__link">
        Medical Decision-Making Capacity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-medical-hold/" class="md-nav__link">
        Medical Hold
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-motivational-interviewing/" class="md-nav__link">
        Motivational Interviewing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-personality-disorders/" class="md-nav__link">
        Personality Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-substance-use-disorder/" class="md-nav__link">
        Substance Use Disorder
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_20" type="checkbox" id="__nav_20" >
      
      
      
      
        <label class="md-nav__link" for="__nav_20">
          Pulmonary
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pulmonary" data-md-level="1">
        <label class="md-nav__title" for="__nav_20">
          <span class="md-nav__icon md-icon"></span>
          Pulmonary
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-acute-asthma-exacerbation/" class="md-nav__link">
        Acute Asthma Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-blood-gases/" class="md-nav__link">
        Blood Gases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-cf-exacerbation/" class="md-nav__link">
        CF Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-copd-exacerbation-management/" class="md-nav__link">
        COPD Exacerbation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-cxrs/" class="md-nav__link">
        CXRs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-hemoptysis/" class="md-nav__link">
        Hemoptysis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-home-oxygen-therapies/" class="md-nav__link">
        Home Oxygen Therapies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-hypoxia/" class="md-nav__link">
        Hypoxia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-ild/" class="md-nav__link">
        ILD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pfts/" class="md-nav__link">
        PFTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pleural-effusions/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pulmonary-hypertension/" class="md-nav__link">
        Pulmonary Hypertension
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_21" type="checkbox" id="__nav_21" >
      
      
      
      
        <label class="md-nav__link" for="__nav_21">
          Radiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Radiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_21">
          <span class="md-nav__icon md-icon"></span>
          Radiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-consults-radiology-procedures/" class="md-nav__link">
        Consults for Radiology Procedures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-radiology-exams-diagnosis/" class="md-nav__link">
        Radiology Exams by Diagnosis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_22" type="checkbox" id="__nav_22" >
      
      
      
      
        <label class="md-nav__link" for="__nav_22">
          Rheumatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Rheumatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_22">
          <span class="md-nav__icon md-icon"></span>
          Rheumatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-biologic-overview/" class="md-nav__link">
        Biologic Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-common-rheumatologic-diseases/" class="md-nav__link">
        Common Rheumatologic Diseases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-crystal-arthropathy/" class="md-nav__link">
        Crystal Arthropathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-inflammatory-myopathies/" class="md-nav__link">
        Inflammatory Myopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-rheumatology-lab-testing/" class="md-nav__link">
        Rheumatology Lab Testing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-vasculitis/" class="md-nav__link">
        Vasculitis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_23" type="checkbox" id="__nav_23" >
      
      
      
      
        <label class="md-nav__link" for="__nav_23">
          zCBH
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="zCBH" data-md-level="1">
        <label class="md-nav__title" for="__nav_23">
          <span class="md-nav__icon md-icon"></span>
          zCBH
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../zCBH/cprs/" class="md-nav__link">
        CPRS
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_24" type="checkbox" id="__nav_24" >
      
      
      
      
        <label class="md-nav__link" for="__nav_24">
          Appendices
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Appendices" data-md-level="1">
        <label class="md-nav__title" for="__nav_24">
          <span class="md-nav__icon md-icon"></span>
          Appendices
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-how-discharges-va/" class="md-nav__link">
        "How to" on Discharges at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-how-discharges-vumc/" class="md-nav__link">
        "How to" on Discharges at VUMC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-interns-guide-rotations-va/" class="md-nav__link">
        Interns' Guide to Rotations at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-interns-guide-rotations-vumc/" class="md-nav__link">
        Interns' Guide to Rotations
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-staging-wounds/" class="md-nav__link">
        Staging Wounds
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-uploading-records/" class="md-nav__link">
        Uploading Records
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-va-phone-numbers/" class="md-nav__link">
        VA Phone Numbers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-vumc-phone-directory/" class="md-nav__link">
        VUMC Phone Directory
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    <li class="md-nav__item">
      
      <input class="md-nav__toggle md-toggle" data-md-toggle="toc" type="checkbox" id="__toc">
      
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          Print Site
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        Print Site
      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#" class="md-nav__link">
    1. Home
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-introduction" class="md-nav__link">
    I. Introduction
  </a>
  
    <nav class="md-nav" aria-label="I. Introduction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-acknowledgements" class="md-nav__link">
    2. Acknowledgements
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-authors-editors-reviewers" class="md-nav__link">
    3. Editors, Authors, and Reviewers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-disclaimers" class="md-nav__link">
    4. Disclaimers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-rationale" class="md-nav__link">
    5. Rationale
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-web-app-setup" class="md-nav__link">
    6. Web App Setup
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-cardiology" class="md-nav__link">
    II. Cardiology
  </a>
  
    <nav class="md-nav" aria-label="II. Cardiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-acs" class="md-nav__link">
    7. Acute Coronary Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-arrhythmias" class="md-nav__link">
    8. Arrhythmias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-atrial-fibrillation-and-flutter" class="md-nav__link">
    9. Atrial Fibrillation & Flutter
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-autonomics-and-orthostatics" class="md-nav__link">
    10. Autonomics and Orthostatic Hypotension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-bedside-echocardiography" class="md-nav__link">
    11. Bedside Echocardiography
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-cardiac-devices" class="md-nav__link">
    12. Cardiac Devices
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chest-pain" class="md-nav__link">
    13. Chest Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chf" class="md-nav__link">
    14. Heart Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-ekg" class="md-nav__link">
    15. Approach to the ECG
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-inpatient-hypertension" class="md-nav__link">
    16. Inpatient Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-pe" class="md-nav__link">
    17. Pulmonary Embolism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-rhc" class="md-nav__link">
    18. Right Heart Catheterization
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-shock" class="md-nav__link">
    19. Cardiogenic Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-syncope" class="md-nav__link">
    20. Syncope
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-valvular-heart-disease" class="md-nav__link">
    21. Valvular Heart Disease
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-critical-care" class="md-nav__link">
    III. Critical care
  </a>
  
    <nav class="md-nav" aria-label="III. Critical care">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-abcdef-a2f-bundle" class="md-nav__link">
    22. ABCDEF (A2F) Bundle
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ards" class="md-nav__link">
    23. ARDS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-brain-death" class="md-nav__link">
    24. Brain Death
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-drips" class="md-nav__link">
    25. Drips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-modes-oxygen-delivery" class="md-nav__link">
    26. Modes of Oxygen Delivery
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypercapnia" class="md-nav__link">
    27. Refractory Hypercapnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypoxemia" class="md-nav__link">
    28. Refractory Hypoxemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-sepsis" class="md-nav__link">
    29. Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-shock" class="md-nav__link">
    30. Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-temperature-abnormalities" class="md-nav__link">
    31. Temperature Abnormalities
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-tracheostomy" class="md-nav__link">
    32. Tracheostomy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-vent-settings" class="md-nav__link">
    33. Vent Settings
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-main" class="md-nav__link">
    34. Management of Shock
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-demo" class="md-nav__link">
    IV. Demo
  </a>
  
    <nav class="md-nav" aria-label="IV. Demo">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#demo-demo-lights" class="md-nav__link">
    35. Pleural Effusions
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-endocrinology" class="md-nav__link">
    V. Endocrinology
  </a>
  
    <nav class="md-nav" aria-label="V. Endocrinology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-insufficiency" class="md-nav__link">
    36. Adrenal Insufficiency
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-diabetes-inpatient-management" class="md-nav__link">
    37. Diabetes: Inpatient Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-dka" class="md-nav__link">
    38. DKA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hyperthyroidism" class="md-nav__link">
    39. Hyperthyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypoglycemia" class="md-nav__link">
    40. Hypoglycemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypothyroidism" class="md-nav__link">
    41. Hypothyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-steroid-conversions" class="md-nav__link">
    42. Steroid Conversions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-stress-dose-steroids" class="md-nav__link">
    43. Stress Dose Steroids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-nodules" class="md-nav__link">
    44. Thyroid Nodules
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-storm" class="md-nav__link">
    45. Thyroid Storm
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-gastroenterology" class="md-nav__link">
    VI. Gastroenterology
  </a>
  
    <nav class="md-nav" aria-label="VI. Gastroenterology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-abdominal-pain" class="md-nav__link">
    46. Acute Abdominal Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-diverticulitis" class="md-nav__link">
    47. Acute Diverticulitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-pancreatitis" class="md-nav__link">
    48. Acute Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-biliary-disease" class="md-nav__link">
    49. Biliary Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-c-diff" class="md-nav__link">
    50. C Diff
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-constipation" class="md-nav__link">
    51. Constipation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-diarrhea" class="md-nav__link">
    52. Diarrhea
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-esophageal-disorders" class="md-nav__link">
    53. Esophageal Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-bleeding" class="md-nav__link">
    54. GI Bleeding
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-inflammatory-bowel-disease" class="md-nav__link">
    55. Inflammatory Bowel Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-intestinal-ischemia" class="md-nav__link">
    56. Intestinal Ischemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-nausea-vomiting" class="md-nav__link">
    57. Nausea & Vomiting
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-peptic-ulcer-disease" class="md-nav__link">
    58. Peptic Ulcer Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-small-bowel-obstruction" class="md-nav__link">
    59. Small Bowel Obstruction
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-geriatrics" class="md-nav__link">
    VII. Geriatrics
  </a>
  
    <nav class="md-nav" aria-label="VII. Geriatrics">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-dementia-0" class="md-nav__link">
    60. Dementia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-falls" class="md-nav__link">
    61. Falls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-frailty" class="md-nav__link">
    62. Frailty
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-malnutrition" class="md-nav__link">
    63. Malnutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-medication-management" class="md-nav__link">
    64. Medication Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter" class="md-nav__link">
    65. Urinary Incontinence and Foley Catheter
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hematology-oncology" class="md-nav__link">
    VIII. Hematology oncology
  </a>
  
    <nav class="md-nav" aria-label="VIII. Hematology oncology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anemia" class="md-nav__link">
    66. Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anticoagulation" class="md-nav__link">
    67. Anticoagulation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-bone-marrow-transplant" class="md-nav__link">
    68. Bone Marrow Transplant
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity" class="md-nav__link">
    69. Chemotherapy Toxicity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-coagulopathies" class="md-nav__link">
    70. Coagulopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dic" class="md-nav__link">
    71. DIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dvts" class="md-nav__link">
    72. DVTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-hypercoagulable-states" class="md-nav__link">
    73. Hypercoagulable States
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-leukemia" class="md-nav__link">
    74. Leukemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-lymphoma" class="md-nav__link">
    75. Lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-medical-oncology-resources" class="md-nav__link">
    76. Medical Oncology Resources
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes" class="md-nav__link">
    77. Myelodysplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms" class="md-nav__link">
    78. Myeloproliferative Neoplasms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever" class="md-nav__link">
    79. Neutropenia and Neutropenic Fever
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-oncologic-emergencies" class="md-nav__link">
    80. Oncologic Emergencies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes" class="md-nav__link">
    81. Paraneoplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias" class="md-nav__link">
    82. Plasma Cell Dyscrasias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-sickle-cell-crisis" class="md-nav__link">
    83. Sickle Cell Crisis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-thrombocytopenia" class="md-nav__link">
    84. Thrombocytopenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-transfusion-medicine" class="md-nav__link">
    85. Transfusion Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hepatology" class="md-nav__link">
    IX. Hepatology
  </a>
  
    <nav class="md-nav" aria-label="IX. Hepatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-hepatitis-and-abnormal-liver-tests" class="md-nav__link">
    86. Acute Hepatitis and Abnormal Liver Tests
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-liver-failure" class="md-nav__link">
    87. Acute Liver Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-alcoholic-hepatitis" class="md-nav__link">
    88. Alcoholic Hepatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-ascites" class="md-nav__link">
    89. Ascites
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-cirrhosis" class="md-nav__link">
    90. Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-coagulopathy" class="md-nav__link">
    91. Coagulopathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatic-encephalopathy" class="md-nav__link">
    92. Hepatic Encephalopathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatocellular-carcinoma" class="md-nav__link">
    93. Hepatocellular Carcinoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatorenal-syndrome" class="md-nav__link">
    94. Hepatorenal Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-liver-transplantation" class="md-nav__link">
    95. Liver Transplantation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-medication-pearls" class="md-nav__link">
    96. Medication Pearls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-nash-and-nafld" class="md-nav__link">
    97. NASH and NAFLD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-portal-vein-thrombosis" class="md-nav__link">
    98. Portal Vein Thrombosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-post-liver-transplant-management" class="md-nav__link">
    99. Post-Liver Transplant Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-sbp" class="md-nav__link">
    100. SBP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-upper-gi-bleed-cirrhosis" class="md-nav__link">
    101. Upper GI Bleed in Cirrhosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hospital-medicine" class="md-nav__link">
    X. Hospital medicine
  </a>
  
    <nav class="md-nav" aria-label="X. Hospital medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-choosing-wisely" class="md-nav__link">
    102. Choosing Wisely
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients" class="md-nav__link">
    103. Guidelines for Pregnant Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-lines-and-catheters" class="md-nav__link">
    104. Lines and Catheters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy" class="md-nav__link">
    105. Mobility and In-Hospital Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-telemetry" class="md-nav__link">
    106. Telemetry
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-utilization-management" class="md-nav__link">
    107. Utilization Management
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-infectious-diseases" class="md-nav__link">
    XI. Infectious diseases
  </a>
  
    <nav class="md-nav" aria-label="XI. Infectious diseases">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-aids-defining-conditions" class="md-nav__link">
    108. AIDS Defining Conditions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis" class="md-nav__link">
    109. Antimicrobial prophylaxis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-bacteremia" class="md-nav__link">
    110. Bacteremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-brief-overview-art" class="md-nav__link">
    111. Brief Overview of ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-cns-infection" class="md-nav__link">
    112. CNS Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-diabetic-foot-infection" class="md-nav__link">
    113. Diabetic Foot Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-endocarditis" class="md-nav__link">
    114. Endocarditis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-febrile-neutropenia" class="md-nav__link">
    115. Febrile Neutropenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-fungal-infections" class="md-nav__link">
    116. Fungal Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-general-tips" class="md-nav__link">
    117. General Tips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-gu-infection" class="md-nav__link">
    118. GU infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts" class="md-nav__link">
    119. HIV & ART General Concepts
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-orthopedic-infection" class="md-nav__link">
    120. Orthopedic Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-pneumonia" class="md-nav__link">
    121. Pneumonia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-ssti" class="md-nav__link">
    122. SSTI
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-nephrology" class="md-nav__link">
    XII. Nephrology
  </a>
  
    <nav class="md-nav" aria-label="XII. Nephrology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-acute-rejection" class="md-nav__link">
    123. Acute Rejection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-aki" class="md-nav__link">
    124. AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-approach-ckd" class="md-nav__link">
    125. Approach to CKD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants" class="md-nav__link">
    126. Common Side Effects of Renal Transplant Immune Suppresants
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hematuria" class="md-nav__link">
    127. Hematuria
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypercalcemia" class="md-nav__link">
    128. Hypercalcemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperkalemia" class="md-nav__link">
    129. Hyperkalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypernatremia" class="md-nav__link">
    130. Hypernatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperphosphatemia" class="md-nav__link">
    131. Hyperphosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypokalemia" class="md-nav__link">
    132. Hypokalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypomagnesemia" class="md-nav__link">
    133. Hypomagnesemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyponatremia" class="md-nav__link">
    134. Hyponatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypophosphatemia" class="md-nav__link">
    135. Hypophosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-metabolic-acidosis" class="md-nav__link">
    136. Metabolic acidosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-peritonitis-patients-pd" class="md-nav__link">
    137. Peritonitis in patients on PD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-renal-replacement-therapy" class="md-nav__link">
    138. Renal Replacement Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-transplant-aki" class="md-nav__link">
    139. Transplant AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-ua" class="md-nav__link">
    140. UA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-uti-renal-transplant" class="md-nav__link">
    141. UTI in Renal Transplant
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-neurology" class="md-nav__link">
    XIII. Neurology
  </a>
  
    <nav class="md-nav" aria-label="XIII. Neurology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-aidp" class="md-nav__link">
    142. AIDP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-als" class="md-nav__link">
    143. ALS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ams" class="md-nav__link">
    144. AMS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-basic-seizures" class="md-nav__link">
    145. Seizures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-brain-masses" class="md-nav__link">
    146. Brain Masses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-elevated-icp-and-hydrocephalus" class="md-nav__link">
    147. Elevated ICP and Hydrocephalus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-inpatient-headache" class="md-nav__link">
    148. Inpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ms" class="md-nav__link">
    149. MS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-myasthenia-etc" class="md-nav__link">
    150. Myasthenia etc
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-outpatient-headache" class="md-nav__link">
    151. Outpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-parkinson" class="md-nav__link">
    152. Parkinson
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-status-epilepticus" class="md-nav__link">
    153. Status Epilepticus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-stroke-0" class="md-nav__link">
    154. Stroke
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-vertigo" class="md-nav__link">
    155. Vertigo
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-outpatient-medicine" class="md-nav__link">
    XIV. Outpatient medicine
  </a>
  
    <nav class="md-nav" aria-label="XIV. Outpatient medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-asthma" class="md-nav__link">
    156. Asthma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-coding-and-informatics" class="md-nav__link">
    157. Coding and Informatics
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-hypertension" class="md-nav__link">
    158. Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-lipids" class="md-nav__link">
    159. Lipids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-obesitynutrition" class="md-nav__link">
    160. Obesity/Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-preventative-medicine" class="md-nav__link">
    161. Preventative Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pain-and-palliative" class="md-nav__link">
    XV. Pain and palliative
  </a>
  
    <nav class="md-nav" aria-label="XV. Pain and palliative">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain" class="md-nav__link">
    162. Acute and Chronic Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-code-status-discussion" class="md-nav__link">
    163. Code Status Discussion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-death-pronouncement" class="md-nav__link">
    164. The Death Pronouncement
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-medications-dying-patients" class="md-nav__link">
    165. Medications for Dying Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-opiate-principles" class="md-nav__link">
    166. Opiate Principles
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations" class="md-nav__link">
    167. Video Examples for Navigating Difficult Conversations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-physical-medicine-rehabilitation" class="md-nav__link">
    XVI. Physical medicine rehabilitation
  </a>
  
    <nav class="md-nav" aria-label="XVI. Physical medicine rehabilitation">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain" class="md-nav__link">
    168. Back Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain" class="md-nav__link">
    169. Knee Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain" class="md-nav__link">
    170. Neck Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation" class="md-nav__link">
    171. PM&R Consultation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options" class="md-nav__link">
    172. Rehabilitation Options
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain" class="md-nav__link">
    173. Shoulder Pain
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-procedures" class="md-nav__link">
    XVII. Procedures
  </a>
  
    <nav class="md-nav" aria-label="XVII. Procedures">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anesthesia" class="md-nav__link">
    174. Anesthesia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anticoagulation-parameters" class="md-nav__link">
    175. Anticoagulation Parameters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-arterial-line" class="md-nav__link">
    176. Arterial Line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-central-line" class="md-nav__link">
    177. Central line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-consent" class="md-nav__link">
    178. Consent
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-dht" class="md-nav__link">
    179. DHT
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-lumbar-puncture" class="md-nav__link">
    180. Lumbar Puncture
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-paracentesis" class="md-nav__link">
    181. Paracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-thoracentesis" class="md-nav__link">
    182. Thoracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-ultrasound-guided-peripheral-iv" class="md-nav__link">
    183. Ultrasound-Guided Peripheral IV
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-psychiatry" class="md-nav__link">
    XVIII. Psychiatry
  </a>
  
    <nav class="md-nav" aria-label="XVIII. Psychiatry">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-agitation-management" class="md-nav__link">
    184. Agitation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-inpatient-insomnia" class="md-nav__link">
    185. Inpatient Insomnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-decision-making-capacity" class="md-nav__link">
    186. Medical Decision-Making Capacity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-hold" class="md-nav__link">
    187. Medical Hold
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-motivational-interviewing" class="md-nav__link">
    188. Motivational Interviewing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-personality-disorders" class="md-nav__link">
    189. Personality Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-substance-use-disorder" class="md-nav__link">
    190. Substance Use Disorder
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pulmonary" class="md-nav__link">
    XIX. Pulmonary
  </a>
  
    <nav class="md-nav" aria-label="XIX. Pulmonary">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-acute-asthma-exacerbation" class="md-nav__link">
    191. Acute Asthma Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-blood-gases" class="md-nav__link">
    192. Blood Gases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cf-exacerbation" class="md-nav__link">
    193. CF Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-copd-exacerbation-management" class="md-nav__link">
    194. COPD Exacerbation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cxrs" class="md-nav__link">
    195. CXRs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hemoptysis" class="md-nav__link">
    196. Hemoptysis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-home-oxygen-therapies" class="md-nav__link">
    197. Home Oxygen Therapies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hypoxia" class="md-nav__link">
    198. Hypoxia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-ild" class="md-nav__link">
    199. ILD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pfts" class="md-nav__link">
    200. PFTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pleural-effusions" class="md-nav__link">
    201. Pleural Effusions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pulmonary-hypertension" class="md-nav__link">
    202. Pulmonary Hypertension
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-radiology" class="md-nav__link">
    XX. Radiology
  </a>
  
    <nav class="md-nav" aria-label="XX. Radiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-consults-radiology-procedures" class="md-nav__link">
    203. Consults for Radiology Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-radiology-exams-diagnosis" class="md-nav__link">
    204. Radiology Exams by Diagnosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-rheumatology" class="md-nav__link">
    XXI. Rheumatology
  </a>
  
    <nav class="md-nav" aria-label="XXI. Rheumatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-biologic-overview" class="md-nav__link">
    205. Biologic Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-common-rheumatologic-diseases" class="md-nav__link">
    206. Common Rheumatologic Diseases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-crystal-arthropathy" class="md-nav__link">
    207. Crystal Arthropathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-inflammatory-myopathies" class="md-nav__link">
    208. Inflammatory Myopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-rheumatology-lab-testing" class="md-nav__link">
    209. Rheumatology Lab Testing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-vasculitis" class="md-nav__link">
    210. Vasculitis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-zcbh" class="md-nav__link">
    XXII. zCBH
  </a>
  
    <nav class="md-nav" aria-label="XXII. zCBH">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#zcbh-cprs" class="md-nav__link">
    211. CPRS
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-appendices" class="md-nav__link">
    XXIII. Appendices
  </a>
  
    <nav class="md-nav" aria-label="XXIII. Appendices">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-va" class="md-nav__link">
    212. "How to" on Discharges at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-vumc" class="md-nav__link">
    213. "How to" on Discharges at VUMC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-va" class="md-nav__link">
    214. Interns' Guide to Rotations at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-vumc" class="md-nav__link">
    215. Interns' Guide to Rotations
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-staging-wounds" class="md-nav__link">
    216. Staging Wounds
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-uploading-records" class="md-nav__link">
    217. Uploading Records
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-va-phone-numbers" class="md-nav__link">
    218. VA Phone Numbers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-vumc-phone-directory" class="md-nav__link">
    219. VUMC Phone Directory
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#" class="md-nav__link">
    1. Home
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-introduction" class="md-nav__link">
    I. Introduction
  </a>
  
    <nav class="md-nav" aria-label="I. Introduction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-acknowledgements" class="md-nav__link">
    2. Acknowledgements
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-authors-editors-reviewers" class="md-nav__link">
    3. Editors, Authors, and Reviewers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-disclaimers" class="md-nav__link">
    4. Disclaimers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-rationale" class="md-nav__link">
    5. Rationale
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-web-app-setup" class="md-nav__link">
    6. Web App Setup
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-cardiology" class="md-nav__link">
    II. Cardiology
  </a>
  
    <nav class="md-nav" aria-label="II. Cardiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-acs" class="md-nav__link">
    7. Acute Coronary Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-arrhythmias" class="md-nav__link">
    8. Arrhythmias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-atrial-fibrillation-and-flutter" class="md-nav__link">
    9. Atrial Fibrillation & Flutter
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-autonomics-and-orthostatics" class="md-nav__link">
    10. Autonomics and Orthostatic Hypotension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-bedside-echocardiography" class="md-nav__link">
    11. Bedside Echocardiography
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-cardiac-devices" class="md-nav__link">
    12. Cardiac Devices
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chest-pain" class="md-nav__link">
    13. Chest Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chf" class="md-nav__link">
    14. Heart Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-ekg" class="md-nav__link">
    15. Approach to the ECG
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-inpatient-hypertension" class="md-nav__link">
    16. Inpatient Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-pe" class="md-nav__link">
    17. Pulmonary Embolism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-rhc" class="md-nav__link">
    18. Right Heart Catheterization
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-shock" class="md-nav__link">
    19. Cardiogenic Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-syncope" class="md-nav__link">
    20. Syncope
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-valvular-heart-disease" class="md-nav__link">
    21. Valvular Heart Disease
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-critical-care" class="md-nav__link">
    III. Critical care
  </a>
  
    <nav class="md-nav" aria-label="III. Critical care">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-abcdef-a2f-bundle" class="md-nav__link">
    22. ABCDEF (A2F) Bundle
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ards" class="md-nav__link">
    23. ARDS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-brain-death" class="md-nav__link">
    24. Brain Death
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-drips" class="md-nav__link">
    25. Drips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-modes-oxygen-delivery" class="md-nav__link">
    26. Modes of Oxygen Delivery
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypercapnia" class="md-nav__link">
    27. Refractory Hypercapnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypoxemia" class="md-nav__link">
    28. Refractory Hypoxemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-sepsis" class="md-nav__link">
    29. Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-shock" class="md-nav__link">
    30. Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-temperature-abnormalities" class="md-nav__link">
    31. Temperature Abnormalities
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-tracheostomy" class="md-nav__link">
    32. Tracheostomy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-vent-settings" class="md-nav__link">
    33. Vent Settings
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-main" class="md-nav__link">
    34. Management of Shock
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-demo" class="md-nav__link">
    IV. Demo
  </a>
  
    <nav class="md-nav" aria-label="IV. Demo">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#demo-demo-lights" class="md-nav__link">
    35. Pleural Effusions
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-endocrinology" class="md-nav__link">
    V. Endocrinology
  </a>
  
    <nav class="md-nav" aria-label="V. Endocrinology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-insufficiency" class="md-nav__link">
    36. Adrenal Insufficiency
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-diabetes-inpatient-management" class="md-nav__link">
    37. Diabetes: Inpatient Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-dka" class="md-nav__link">
    38. DKA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hyperthyroidism" class="md-nav__link">
    39. Hyperthyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypoglycemia" class="md-nav__link">
    40. Hypoglycemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypothyroidism" class="md-nav__link">
    41. Hypothyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-steroid-conversions" class="md-nav__link">
    42. Steroid Conversions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-stress-dose-steroids" class="md-nav__link">
    43. Stress Dose Steroids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-nodules" class="md-nav__link">
    44. Thyroid Nodules
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-storm" class="md-nav__link">
    45. Thyroid Storm
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-gastroenterology" class="md-nav__link">
    VI. Gastroenterology
  </a>
  
    <nav class="md-nav" aria-label="VI. Gastroenterology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-abdominal-pain" class="md-nav__link">
    46. Acute Abdominal Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-diverticulitis" class="md-nav__link">
    47. Acute Diverticulitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-pancreatitis" class="md-nav__link">
    48. Acute Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-biliary-disease" class="md-nav__link">
    49. Biliary Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-c-diff" class="md-nav__link">
    50. C Diff
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-constipation" class="md-nav__link">
    51. Constipation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-diarrhea" class="md-nav__link">
    52. Diarrhea
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-esophageal-disorders" class="md-nav__link">
    53. Esophageal Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-bleeding" class="md-nav__link">
    54. GI Bleeding
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-inflammatory-bowel-disease" class="md-nav__link">
    55. Inflammatory Bowel Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-intestinal-ischemia" class="md-nav__link">
    56. Intestinal Ischemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-nausea-vomiting" class="md-nav__link">
    57. Nausea & Vomiting
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-peptic-ulcer-disease" class="md-nav__link">
    58. Peptic Ulcer Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-small-bowel-obstruction" class="md-nav__link">
    59. Small Bowel Obstruction
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-geriatrics" class="md-nav__link">
    VII. Geriatrics
  </a>
  
    <nav class="md-nav" aria-label="VII. Geriatrics">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-dementia-0" class="md-nav__link">
    60. Dementia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-falls" class="md-nav__link">
    61. Falls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-frailty" class="md-nav__link">
    62. Frailty
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-malnutrition" class="md-nav__link">
    63. Malnutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-medication-management" class="md-nav__link">
    64. Medication Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter" class="md-nav__link">
    65. Urinary Incontinence and Foley Catheter
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hematology-oncology" class="md-nav__link">
    VIII. Hematology oncology
  </a>
  
    <nav class="md-nav" aria-label="VIII. Hematology oncology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anemia" class="md-nav__link">
    66. Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anticoagulation" class="md-nav__link">
    67. Anticoagulation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-bone-marrow-transplant" class="md-nav__link">
    68. Bone Marrow Transplant
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity" class="md-nav__link">
    69. Chemotherapy Toxicity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-coagulopathies" class="md-nav__link">
    70. Coagulopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dic" class="md-nav__link">
    71. DIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dvts" class="md-nav__link">
    72. DVTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-hypercoagulable-states" class="md-nav__link">
    73. Hypercoagulable States
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-leukemia" class="md-nav__link">
    74. Leukemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-lymphoma" class="md-nav__link">
    75. Lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-medical-oncology-resources" class="md-nav__link">
    76. Medical Oncology Resources
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes" class="md-nav__link">
    77. Myelodysplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms" class="md-nav__link">
    78. Myeloproliferative Neoplasms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever" class="md-nav__link">
    79. Neutropenia and Neutropenic Fever
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-oncologic-emergencies" class="md-nav__link">
    80. Oncologic Emergencies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes" class="md-nav__link">
    81. Paraneoplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias" class="md-nav__link">
    82. Plasma Cell Dyscrasias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-sickle-cell-crisis" class="md-nav__link">
    83. Sickle Cell Crisis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-thrombocytopenia" class="md-nav__link">
    84. Thrombocytopenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-transfusion-medicine" class="md-nav__link">
    85. Transfusion Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hepatology" class="md-nav__link">
    IX. Hepatology
  </a>
  
    <nav class="md-nav" aria-label="IX. Hepatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-hepatitis-and-abnormal-liver-tests" class="md-nav__link">
    86. Acute Hepatitis and Abnormal Liver Tests
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-liver-failure" class="md-nav__link">
    87. Acute Liver Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-alcoholic-hepatitis" class="md-nav__link">
    88. Alcoholic Hepatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-ascites" class="md-nav__link">
    89. Ascites
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-cirrhosis" class="md-nav__link">
    90. Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-coagulopathy" class="md-nav__link">
    91. Coagulopathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatic-encephalopathy" class="md-nav__link">
    92. Hepatic Encephalopathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatocellular-carcinoma" class="md-nav__link">
    93. Hepatocellular Carcinoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatorenal-syndrome" class="md-nav__link">
    94. Hepatorenal Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-liver-transplantation" class="md-nav__link">
    95. Liver Transplantation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-medication-pearls" class="md-nav__link">
    96. Medication Pearls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-nash-and-nafld" class="md-nav__link">
    97. NASH and NAFLD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-portal-vein-thrombosis" class="md-nav__link">
    98. Portal Vein Thrombosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-post-liver-transplant-management" class="md-nav__link">
    99. Post-Liver Transplant Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-sbp" class="md-nav__link">
    100. SBP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-upper-gi-bleed-cirrhosis" class="md-nav__link">
    101. Upper GI Bleed in Cirrhosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hospital-medicine" class="md-nav__link">
    X. Hospital medicine
  </a>
  
    <nav class="md-nav" aria-label="X. Hospital medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-choosing-wisely" class="md-nav__link">
    102. Choosing Wisely
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients" class="md-nav__link">
    103. Guidelines for Pregnant Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-lines-and-catheters" class="md-nav__link">
    104. Lines and Catheters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy" class="md-nav__link">
    105. Mobility and In-Hospital Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-telemetry" class="md-nav__link">
    106. Telemetry
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-utilization-management" class="md-nav__link">
    107. Utilization Management
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-infectious-diseases" class="md-nav__link">
    XI. Infectious diseases
  </a>
  
    <nav class="md-nav" aria-label="XI. Infectious diseases">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-aids-defining-conditions" class="md-nav__link">
    108. AIDS Defining Conditions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis" class="md-nav__link">
    109. Antimicrobial prophylaxis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-bacteremia" class="md-nav__link">
    110. Bacteremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-brief-overview-art" class="md-nav__link">
    111. Brief Overview of ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-cns-infection" class="md-nav__link">
    112. CNS Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-diabetic-foot-infection" class="md-nav__link">
    113. Diabetic Foot Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-endocarditis" class="md-nav__link">
    114. Endocarditis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-febrile-neutropenia" class="md-nav__link">
    115. Febrile Neutropenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-fungal-infections" class="md-nav__link">
    116. Fungal Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-general-tips" class="md-nav__link">
    117. General Tips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-gu-infection" class="md-nav__link">
    118. GU infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts" class="md-nav__link">
    119. HIV & ART General Concepts
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-orthopedic-infection" class="md-nav__link">
    120. Orthopedic Infection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-pneumonia" class="md-nav__link">
    121. Pneumonia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-ssti" class="md-nav__link">
    122. SSTI
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-nephrology" class="md-nav__link">
    XII. Nephrology
  </a>
  
    <nav class="md-nav" aria-label="XII. Nephrology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-acute-rejection" class="md-nav__link">
    123. Acute Rejection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-aki" class="md-nav__link">
    124. AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-approach-ckd" class="md-nav__link">
    125. Approach to CKD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants" class="md-nav__link">
    126. Common Side Effects of Renal Transplant Immune Suppresants
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hematuria" class="md-nav__link">
    127. Hematuria
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypercalcemia" class="md-nav__link">
    128. Hypercalcemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperkalemia" class="md-nav__link">
    129. Hyperkalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypernatremia" class="md-nav__link">
    130. Hypernatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperphosphatemia" class="md-nav__link">
    131. Hyperphosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypokalemia" class="md-nav__link">
    132. Hypokalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypomagnesemia" class="md-nav__link">
    133. Hypomagnesemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyponatremia" class="md-nav__link">
    134. Hyponatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypophosphatemia" class="md-nav__link">
    135. Hypophosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-metabolic-acidosis" class="md-nav__link">
    136. Metabolic acidosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-peritonitis-patients-pd" class="md-nav__link">
    137. Peritonitis in patients on PD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-renal-replacement-therapy" class="md-nav__link">
    138. Renal Replacement Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-transplant-aki" class="md-nav__link">
    139. Transplant AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-ua" class="md-nav__link">
    140. UA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-uti-renal-transplant" class="md-nav__link">
    141. UTI in Renal Transplant
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-neurology" class="md-nav__link">
    XIII. Neurology
  </a>
  
    <nav class="md-nav" aria-label="XIII. Neurology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-aidp" class="md-nav__link">
    142. AIDP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-als" class="md-nav__link">
    143. ALS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ams" class="md-nav__link">
    144. AMS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-basic-seizures" class="md-nav__link">
    145. Seizures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-brain-masses" class="md-nav__link">
    146. Brain Masses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-elevated-icp-and-hydrocephalus" class="md-nav__link">
    147. Elevated ICP and Hydrocephalus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-inpatient-headache" class="md-nav__link">
    148. Inpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ms" class="md-nav__link">
    149. MS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-myasthenia-etc" class="md-nav__link">
    150. Myasthenia etc
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-outpatient-headache" class="md-nav__link">
    151. Outpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-parkinson" class="md-nav__link">
    152. Parkinson
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-status-epilepticus" class="md-nav__link">
    153. Status Epilepticus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-stroke-0" class="md-nav__link">
    154. Stroke
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-vertigo" class="md-nav__link">
    155. Vertigo
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-outpatient-medicine" class="md-nav__link">
    XIV. Outpatient medicine
  </a>
  
    <nav class="md-nav" aria-label="XIV. Outpatient medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-asthma" class="md-nav__link">
    156. Asthma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-coding-and-informatics" class="md-nav__link">
    157. Coding and Informatics
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-hypertension" class="md-nav__link">
    158. Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-lipids" class="md-nav__link">
    159. Lipids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-obesitynutrition" class="md-nav__link">
    160. Obesity/Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-preventative-medicine" class="md-nav__link">
    161. Preventative Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pain-and-palliative" class="md-nav__link">
    XV. Pain and palliative
  </a>
  
    <nav class="md-nav" aria-label="XV. Pain and palliative">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain" class="md-nav__link">
    162. Acute and Chronic Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-code-status-discussion" class="md-nav__link">
    163. Code Status Discussion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-death-pronouncement" class="md-nav__link">
    164. The Death Pronouncement
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-medications-dying-patients" class="md-nav__link">
    165. Medications for Dying Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-opiate-principles" class="md-nav__link">
    166. Opiate Principles
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations" class="md-nav__link">
    167. Video Examples for Navigating Difficult Conversations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-physical-medicine-rehabilitation" class="md-nav__link">
    XVI. Physical medicine rehabilitation
  </a>
  
    <nav class="md-nav" aria-label="XVI. Physical medicine rehabilitation">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain" class="md-nav__link">
    168. Back Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain" class="md-nav__link">
    169. Knee Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain" class="md-nav__link">
    170. Neck Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation" class="md-nav__link">
    171. PM&R Consultation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options" class="md-nav__link">
    172. Rehabilitation Options
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain" class="md-nav__link">
    173. Shoulder Pain
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-procedures" class="md-nav__link">
    XVII. Procedures
  </a>
  
    <nav class="md-nav" aria-label="XVII. Procedures">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anesthesia" class="md-nav__link">
    174. Anesthesia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anticoagulation-parameters" class="md-nav__link">
    175. Anticoagulation Parameters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-arterial-line" class="md-nav__link">
    176. Arterial Line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-central-line" class="md-nav__link">
    177. Central line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-consent" class="md-nav__link">
    178. Consent
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-dht" class="md-nav__link">
    179. DHT
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-lumbar-puncture" class="md-nav__link">
    180. Lumbar Puncture
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-paracentesis" class="md-nav__link">
    181. Paracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-thoracentesis" class="md-nav__link">
    182. Thoracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-ultrasound-guided-peripheral-iv" class="md-nav__link">
    183. Ultrasound-Guided Peripheral IV
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-psychiatry" class="md-nav__link">
    XVIII. Psychiatry
  </a>
  
    <nav class="md-nav" aria-label="XVIII. Psychiatry">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-agitation-management" class="md-nav__link">
    184. Agitation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-inpatient-insomnia" class="md-nav__link">
    185. Inpatient Insomnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-decision-making-capacity" class="md-nav__link">
    186. Medical Decision-Making Capacity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-hold" class="md-nav__link">
    187. Medical Hold
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-motivational-interviewing" class="md-nav__link">
    188. Motivational Interviewing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-personality-disorders" class="md-nav__link">
    189. Personality Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-substance-use-disorder" class="md-nav__link">
    190. Substance Use Disorder
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pulmonary" class="md-nav__link">
    XIX. Pulmonary
  </a>
  
    <nav class="md-nav" aria-label="XIX. Pulmonary">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-acute-asthma-exacerbation" class="md-nav__link">
    191. Acute Asthma Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-blood-gases" class="md-nav__link">
    192. Blood Gases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cf-exacerbation" class="md-nav__link">
    193. CF Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-copd-exacerbation-management" class="md-nav__link">
    194. COPD Exacerbation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cxrs" class="md-nav__link">
    195. CXRs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hemoptysis" class="md-nav__link">
    196. Hemoptysis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-home-oxygen-therapies" class="md-nav__link">
    197. Home Oxygen Therapies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hypoxia" class="md-nav__link">
    198. Hypoxia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-ild" class="md-nav__link">
    199. ILD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pfts" class="md-nav__link">
    200. PFTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pleural-effusions" class="md-nav__link">
    201. Pleural Effusions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pulmonary-hypertension" class="md-nav__link">
    202. Pulmonary Hypertension
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-radiology" class="md-nav__link">
    XX. Radiology
  </a>
  
    <nav class="md-nav" aria-label="XX. Radiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-consults-radiology-procedures" class="md-nav__link">
    203. Consults for Radiology Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-radiology-exams-diagnosis" class="md-nav__link">
    204. Radiology Exams by Diagnosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-rheumatology" class="md-nav__link">
    XXI. Rheumatology
  </a>
  
    <nav class="md-nav" aria-label="XXI. Rheumatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-biologic-overview" class="md-nav__link">
    205. Biologic Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-common-rheumatologic-diseases" class="md-nav__link">
    206. Common Rheumatologic Diseases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-crystal-arthropathy" class="md-nav__link">
    207. Crystal Arthropathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-inflammatory-myopathies" class="md-nav__link">
    208. Inflammatory Myopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-rheumatology-lab-testing" class="md-nav__link">
    209. Rheumatology Lab Testing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-vasculitis" class="md-nav__link">
    210. Vasculitis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-zcbh" class="md-nav__link">
    XXII. zCBH
  </a>
  
    <nav class="md-nav" aria-label="XXII. zCBH">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#zcbh-cprs" class="md-nav__link">
    211. CPRS
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-appendices" class="md-nav__link">
    XXIII. Appendices
  </a>
  
    <nav class="md-nav" aria-label="XXIII. Appendices">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-va" class="md-nav__link">
    212. "How to" on Discharges at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-vumc" class="md-nav__link">
    213. "How to" on Discharges at VUMC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-va" class="md-nav__link">
    214. Interns' Guide to Rotations at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-vumc" class="md-nav__link">
    215. Interns' Guide to Rotations
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-staging-wounds" class="md-nav__link">
    216. Staging Wounds
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-uploading-records" class="md-nav__link">
    217. Uploading Records
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-va-phone-numbers" class="md-nav__link">
    218. VA Phone Numbers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-vumc-phone-directory" class="md-nav__link">
    219. VUMC Phone Directory
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          <div class="md-content" data-md-component="content">
            <article class="md-content__inner md-typeset">
              
                


<div id="print-site-page" class="print-site-enumerate-headings print-site-enumerate-figures">
        <div id="print-site-banner">
            <p>
    <em>This box will disappear when printing</em>
    <span style="float: right"><a href="https://timvink.github.io/mkdocs-print-site-plugin/">mkdocs-print-site-plugin</a></span>
</p>
<p>
    This page has combined all site pages into one. You can export to PDF using <b>File > Print > Save as PDF</b>.
</p>
<p>
    See also <a href="https://timvink.github.io/mkdocs-print-site-plugin/how-to/export-PDF.html">export to PDF</a> and <a href="https://timvink.github.io/mkdocs-print-site-plugin/how-to/export-HTML.html">export to standalone HTML</a>.
</p>
        </div>
        
        <section class="print-page">
            <div id="print-page-toc" data-toc-depth="3">
                <nav role='navigation' class='print-page-toc-nav'>
                <h1 class='print-page-toc-title'>Table of Contents</h1>
                </nav>
            </div>
        </section>
        <section class="print-page" id="index"><h1 id="index-home">Home<a class="headerlink" href="#index-home" title="Permanent link">&para;</a></h1>
<p>This is the online home of the Vanderbilt Internal Medicine Residency Handbook.</p>
<h1 id="index-dedication">Dedication<a class="headerlink" href="#index-dedication" title="Permanent link">&para;</a></h1>
<p>The authors and editors dedicate the fourth edition of the Housestaff
Handbook to the memory of Dr. Michael Fowler, whose compassion,
sincerity, and commitment to education continue to guide and inspire
us. </p>
<figure>
<p><img alt="QR code for vimbook.org" src="../images/qr-light.svg#only-light" width="300" />
<img alt="QR code for vimbook.org" src="../images/qr-dark.svg#only-dark" width="300" /></p>
<figcaption>QR code link for this online VIMBook</figcaption>
</figure></section>
                        <h1 class='nav-section-title' id='section-introduction'>
                            Introduction <a class='headerlink' href='#section-introduction' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="introduction-introduction-acknowledgements"><h1 id="introduction-introduction-acknowledgements-acknowledgements">Acknowledgements<a class="headerlink" href="#introduction-introduction-acknowledgements-acknowledgements" title="Permanent link">&para;</a></h1>
<p>The Vanderbilt University Medical Center (VUMC) Internal Medicine
Housestaff Handbook began with an Internal Medicine Resident Quality
Improvement Project which was led by Michael J. Neuss, MD, PhD, under
the guidance of Jennifer K. Green, MD, MPH in 2019.</p>
<p>We would like to thank the following individuals for their contributions
to the 4<sup>th</sup> edition of the Housestaff Handbook:</p>
<ul>
<li>The many VUMC residents (past and present) who have meticulously
    authored each section of this handbook.</li>
<li>The VUMC faculty who carefully reviewed each topic for its accuracy.</li>
<li>Leah Brown, MD and Joseph Quintana, MD, the 3<sup>rd</sup> edition's
    co-editors-in-chief, whose guidance was instrumental in the
    transition between editions.</li>
<li>Chase Webber, DO, who was a sounding board for our new ideas
    throughout the year as the Handbook’s faculty advisor.</li>
<li>C. Beau Hilton, MD for his work in updating and improving the online
    version of this handbook.</li>
<li>John McPherson, MD, Kim Rathmell, MD PhD, Kristy Braden and Maria
    Kasel, for their unwavering support.</li>
</ul></section><section class="print-page" id="introduction-introduction-authors-editors-reviewers"><h1 id="introduction-introduction-authors-editors-reviewers-editors-authors-and-reviewers">Editors, Authors, and Reviewers<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-editors-authors-and-reviewers" title="Permanent link">&para;</a></h1>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-editors-in-chief">Editors-in-Chief<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-editors-in-chief" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley, MD &amp; Jennifer Marvin-Peek, MD</p>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-resident-editors">Resident Editors<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-resident-editors" title="Permanent link">&para;</a></h1>
<p>Cardiology: Nicholas King, MD </p>
<p>Critical Care: Raymond Dieter, MD</p>
<p>Endocrinology: Kinsley Ojukwu, MD </p>
<p>Gastroenterology: Taylor Riggs, MD </p>
<p>Geriatrics: Thomas Horton, MD </p>
<p>Hematology/Oncology: Michael LaPelusa, MD</p>
<p>Hepatology: Julie Cui, MD </p>
<p>Hospital Medicine: Soibhan Kelley, MD</p>
<p>Infectious Diseases: Kaitlyn Reasoner, MD</p>
<p>Nephrology: Trey Richardson, MD</p>
<p>Neurology: Hunter Hewitt, MD</p>
<p>Ophthalmology: Jonathan Barnett, MD</p>
<p>Outpatient Medicine: Christina Snider, MD</p>
<p>Palliative Care: Eli Cohen, MD</p>
<p>Physical Medicine &amp; Rehabilitation: 
Jakob Dovgan, MD,
Douglas Bryant, MD,
William Galbraith, DO,
and Nicholas Abramson, MD</p>
<p>Procedures: Katherine Heckman, MD </p>
<p>Psychiatry: Soibhan Kelley, MD</p>
<p>Pulmonary: Taryn Boyle, MD</p>
<p>Radiology: Janesh Lakhoo, MD, MS</p>
<p>Rheumatology: Raeann Whitney, MD  </p>
<p>Toxicology: Jennifer Marvin-Peek, MD</p>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-faculty-reviewers">Faculty Reviewers<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-faculty-reviewers" title="Permanent link">&para;</a></h1>
<p>Cardiology:  David Meoli, MD PhD </p>
<p>Critical Care: Todd Rice, MD</p>
<p>Endocrinology: Laura Heller, MD</p>
<p>Gastroenterology: Patrick Yachimski, MD </p>
<p>Geriatrics: Mariu Duggan, MD, MPH</p>
<p>Hematology/Oncology: Rajiv Agarwal, MD and Benjamin Tillman, MD</p>
<p>Hepatology: Manhal J. Izzy, MD</p>
<p>Hospital Medicine: Chase J. Webber, DO</p>
<p>Infectious Diseases: Milner Staub, MD, MPH and Sean Kelly, MD</p>
<p>Nephrology: JP Arroyo, MD PhD, Edward Gould, MD, and Beatrice Concepcion, MD</p>
<p>Neurology: Christopher Lee, MD</p>
<p>Ophthalmology: John Bond, MD</p>
<p>Outpatient: Jennifer K. Green, MD, MPH</p>
<p>Palliative Care: Mohana Karlekar, MD</p>
<p>Physical Medicine &amp; Rehabilitation: C. J. Plummer, MD</p>
<p>Procedures: Garren Montgomery, MD</p>
<p>Psychiatry: Jonathan Smith, MD and Jose Arriola Vigo MD, MPH</p>
<p>Pulmonary: Meredith Pugh, MD</p>
<p>Radiology: Virginia Planz, MD</p>
<p>Rheumatology: Kevin Byram, MD</p>
<p>Toxicology:  Rebecca E. Bruccoleri, MD and Saralyn R. Williams, MD</p></section><section class="print-page" id="introduction-introduction-disclaimers"><h1 id="introduction-introduction-disclaimers-disclaimers">Disclaimers<a class="headerlink" href="#introduction-introduction-disclaimers-disclaimers" title="Permanent link">&para;</a></h1>
<p>The handbook is not a substitute for clinical judgment and is intended
as an educational guide. Content reflects current national guidelines,
as well as practice at VUMC and the Nashville VA. The handbook is not
intended to replace more comprehensive references or guides.</p>
<p>Images are used sparingly, but when used are created by the
authors themselves, available by public domain, or reproduced under fair
use.</p></section><section class="print-page" id="introduction-introduction-rationale"><h1 id="introduction-introduction-rationale-rationale">Rationale<a class="headerlink" href="#introduction-introduction-rationale-rationale" title="Permanent link">&para;</a></h1>
<p>The aim of this handbook is to provide specific, systems-based guidance
on practice at VUMC and the Nashville VA. We hope to provide readers with direct
and actionable guidance, consolidating the combined wisdom of
generations of residents and faculty experts.</p>
<p>The Handbook represents a coordinated effort to disseminate details of
our practice in a standardized, peer-reviewed format. The guidance
provided by the handbook makes legible evidence-based practice as well
as the oral tradition of a resident guiding an intern, or an attending a
resident. We hope that this handbook will inspire confidence and
learning, whether the reader is an intern on July 1 or a senior resident
who wishes to refresh their memory of a topic.</p></section><section class="print-page" id="introduction-introduction-web-app-setup"><h1 id="introduction-introduction-web-app-setup-web-app-setup">Web App Setup<a class="headerlink" href="#introduction-introduction-web-app-setup-web-app-setup" title="Permanent link">&para;</a></h1>
<p>This site is optimized for use on mobile devices. It is possible to set
up a link from your device's home screen that gives it the look and feel
of a web app.</p>
<ul>
<li>iOS users: Go to <a href="http://vimbook.org/">VIMBook.org</a> . At the bottom
    of the screen, hit the "Share" icon (box with upward facing arrow).
    Hit "Add to Home Screen." Rename it to your liking. The gold
    Vanderbilt icon will appear on your home screen, and you can click
    this icon to be taken directly to the website!</li>
<li>Android users:  Go to <a href="http://vimbook.org/">VIMBook.org</a> . Press
    Menu, then select "Bookmarks." Hold it down until "Add Shortcut to
    Home Screen" appears, and click it. This will place an icon on your
    home screen, and you can click this icon to be taken directly to the
    website!</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Introduction</h1>
                        <h1 class='nav-section-title' id='section-cardiology'>
                            Cardiology <a class='headerlink' href='#section-cardiology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="cardiology-cardiology-acs"><h1 id="cardiology-cardiology-acs-acute-coronary-syndromes">Acute Coronary Syndromes<a class="headerlink" href="#cardiology-cardiology-acs-acute-coronary-syndromes" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="cardiology-cardiology-acs-background">Background<a class="headerlink" href="#cardiology-cardiology-acs-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Completely or partially occluding thrombus on a disrupted
    atherothrombotic coronary plaque leading to myocardial
    ischemia/infarction</li>
<li>STEMI: Elevated troponin &amp; elevation in ST segment or new LBBB with
    symptoms<ul>
<li>> 0.1 mV in at least 2 contiguous leads</li>
<li>Exception, in V2-V3:</li>
<li>> 0.2 mV in men older than 40 y/o</li>
<li>> 0.25 in men younger than 40 y/o</li>
<li>> 0.15 mV in women</li>
</ul>
</li>
<li>NSTEMI: Evidence of myocardial necrosis (elevated troponin) w/o ST
    segment elevation</li>
<li>Unstable Angina: Angina without evidence of myocardial necrosis
    (normal troponin)</li>
<li>Other causes of myocardial injury: coronary spasm, embolism,
    imbalance of oxygen demand and supply 2/2 fever, tachycardia,
    hypo-/hypertension</li>
</ul>
<h2 id="cardiology-cardiology-acs-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-acs-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Classic Angina: dyspnea on exertion, substernal, pressure or
    vice-like quality, improved with rest. Note that response
    nitroglycerin is no longer in the guidelines.</li>
<li>Anginal Equivalents: nausea, weakness, epigastric pain (esp. in age
    > 65 y/o, women, diabetics)</li>
<li>Change in patient’s baseline angina, especially onset at rest</li>
<li>Physical Exam: sinus tachycardia, diaphoresis</li>
<li>If large infarct, can present with symptoms of acute heart failure</li>
</ul>
<h2 id="cardiology-cardiology-acs-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-acs-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG: Compare to prior EKG and assess for<ul>
<li>New ST elevations or ST depressions</li>
<li>T wave inversions: not specific but more concerning if deep (>
    0.3mV)</li>
<li>Biphasic T waves and deep T wave inversions in leads V2 &amp; V3
    (Wellens' sign [LAD])</li>
</ul>
</li>
<li>Cardiac biomarkers: troponin I is most sensitive for myocardial
    injury</li>
<li>ACC/AHA guidelines recommend both EKG and trop q2-6 hours<ul>
<li>Consider this if high suspicion for ACS despite normal initial
    markers</li>
<li>If negative x2, OK to stop trending</li>
</ul>
</li>
<li>Other labs: lipid panel, TSH, A1C</li>
</ul>
<h2 id="cardiology-cardiology-acs-management">Management<a class="headerlink" href="#cardiology-cardiology-acs-management" title="Permanent link">&para;</a></h2>
<h3 id="cardiology-cardiology-acs-stemi">STEMI<a class="headerlink" href="#cardiology-cardiology-acs-stemi" title="Permanent link">&para;</a></h3>
<ul>
<li>STAT page Cardiology on call via Synergy (whether in VA or
    Vanderbilt)</li>
<li>ASAP: aspirin 325mg, heparin drip (high nomogram, with bolus)</li>
<li>Hold P2Y12 receptor blocker until discussed with cards fellow</li>
</ul>
<h3 id="cardiology-cardiology-acs-nstemi">NSTEMI<a class="headerlink" href="#cardiology-cardiology-acs-nstemi" title="Permanent link">&para;</a></h3>
<ul>
<li>Medical management followed by left-heart catheterization within 48
    hours</li>
<li>General: bedrest, telemetry, repeat EKG with recurrent chest pain,
    NPO at midnight</li>
<li>Place cath case request (see “pre-catheterization” management below)</li>
</ul>
<h3 id="cardiology-cardiology-acs-anti-thrombotic-therapy">Anti-thrombotic therapy<a class="headerlink" href="#cardiology-cardiology-acs-anti-thrombotic-therapy" title="Permanent link">&para;</a></h3>
<p>Antiplatelet agents</p>
<ul>
<li>ASA 325 mg loading dose then 81 mg daily after</li>
<li>Do not give P2Y12 receptor blocker until discussed with
        cardiology fellow</li>
<li>Clopidogrel: prodrug that is metabolized to active form (can
            have undermetabolizers), irreversible inhibition</li>
<li>Ticagrelor: reversible inhibitor</li>
<li>Prasugrel: prodrug but more rapidly metabolized than
            clopidogrel with less variation, irreversible inhibition, do
            not use w/ age > 75 or weight \&lt; 60 kg</li>
<li>Prasugrel and ticagrelor are superior to clopidogrel but
            have higher bleeding risk</li>
<li>Cangrelor: IV, rarely used</li>
</ul>
<p>Anti-coagulants</p>
<ul>
<li>Unfractionated heparin drip</li>
<li>Type this in Epic and select “nursing managed” protocol for
        “ACS”</li>
<li>VA: it can be found under the “Orders” tab along the left-hand
        column.</li>
<li>Enoxaparin (LMWH) can be used but requires preserved renal
        function (CrCl > 30) and most interventionalists prefer heparin
        prior to LHC</li>
</ul>
<h3 id="cardiology-cardiology-acs-pre-catheterization-care">Pre-Catheterization Care<a class="headerlink" href="#cardiology-cardiology-acs-pre-catheterization-care" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure pt. is NPO at MN for planned cath</li>
<li>Continue anticoagulation with heparin gtt</li>
<li>Place cardiac catheterization request (must be in cardiology
    context). Can also call cath lab to ensure pt. is scheduled
    appropriately</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-catheterization-care-catheterization-documentation">Post-Catheterization Care Catheterization Documentation<a class="headerlink" href="#cardiology-cardiology-acs-post-catheterization-care-catheterization-documentation" title="Permanent link">&para;</a></h3>
<ul>
<li>The most appropriate guidance for post-cath care is in the cardiac
    catheterization report</li>
<li>VUMC: Epic Cardiac tab Cardiac Catheterization/Intervention Report</li>
<li>VA: Note tab Post-Procedure note and Cardiac Catheterization note</li>
<li>If there is a delay in filing the final report at VUMC: Review the
    Cardiac Catheterization Nursing Documentation which shows if stents
    were deployed</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-catheterization-heparin">Post-Catheterization Heparin<a class="headerlink" href="#cardiology-cardiology-acs-post-catheterization-heparin" title="Permanent link">&para;</a></h3>
<ul>
<li>Medical management w/o intervention: stop heparin unless directed in
    report</li>
<li>If indication for CABG (ex: Left main, proximal LAD), continue
    heparin gtt until surgery</li>
<li>PCI placed: stop heparin and continue/start DAPT as directed by
    cardiology</li>
<li>Other medical indication for anticoagulation (DVT/PE, atrial
    fibrillation): restart ~ six hours after catheterization</li>
</ul>
<h3 id="cardiology-cardiology-acs-cath-site-checks">Cath Site Checks<a class="headerlink" href="#cardiology-cardiology-acs-cath-site-checks" title="Permanent link">&para;</a></h3>
<ul>
<li>6 - 8 hours post catheterization (typically can be signed out as
    0000 cath check), only needed for femoral arterial access</li>
<li>Look, listen, feel: evaluate for hematoma &amp; pseudoaneurysm; call
    fellow if concerned</li>
<li>Small amount of bruising and mild tenderness at the site is normal</li>
<li>Listen above and below the site for a bruit; the area should be soft</li>
<li>Hypotension after femoral access is concerning for RP bleed<ul>
<li>STAT CBC, CT A/P &amp; call the cardiology fellow</li>
</ul>
</li>
<li>Femoral oozing: Cardiology fellow, will need to hold pressure</li>
<li>Radial oozing: instruct nurse to re-inflate the TR band and restart
    the clock on deflation</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-acs-care">Post ACS Care<a class="headerlink" href="#cardiology-cardiology-acs-post-acs-care" title="Permanent link">&para;</a></h3>
<ul>
<li>Echo prior to discharge</li>
<li>DAPT: Aspirin 81 mg daily and P2Y12 agent</li>
<li>Beta blocker in all patients within 24 hours</li>
<li>Metoprolol, carvedilol &amp; bisoprolol have proven mortality benefit
      with reduced EF</li>
<li>High intensity statin (ex: rosuvastatin 40 or atorvastatin 80). See
    outpatient lipids section</li>
<li>ACEi/ARB if anterior STEMI</li>
<li>Lifestyle Modification: weight loss, smoking cessation, diabetes
    control</li>
<li>See heart failure section for management of HFrEF</li>
</ul>
<h3 id="cardiology-cardiology-acs-acs-complications">ACS Complications<a class="headerlink" href="#cardiology-cardiology-acs-acs-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>VT/VF, sinus bradycardia, third-degree heart block, new VSD, LV
    perforation, acute mitral regurgitation, pericarditis and
    cardiogenic shock; More common with STEMI CCU post-cath</li>
</ul>
<h3 id="cardiology-cardiology-acs-additional-information">Additional Information<a class="headerlink" href="#cardiology-cardiology-acs-additional-information" title="Permanent link">&para;</a></h3>
<ul>
<li>Initiate treatment if there is true concern for ACS and bleeding
    risk acceptable, medications can always be discontinued</li>
<li>TIMI score: >2 correlates with ↑ mortality, indicating a need for
    aggressive treatment</li>
<li>ACC Guideline Clinical App is a useful resource with summaries of
    guideline-based recs</li>
</ul></section><section class="print-page" id="cardiology-cardiology-arrhythmias"><h1 id="cardiology-cardiology-arrhythmias-arrhythmias">Arrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-arrhythmias" title="Permanent link">&para;</a></h1>
<p>Kunal Patel, Madeline Rukavina</p>
<hr />
<h2 id="cardiology-cardiology-arrhythmias-acute-management-of-arrhythmias">Acute management of arrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-acute-management-of-arrhythmias" title="Permanent link">&para;</a></h2>
<ul>
<li>12-lead EKG if possible and have defib pads on patient</li>
<li>Is the patient unstable (hypotensive, signs/symptoms of
    hypoperfusion)?</li>
<li>Is the information real?</li>
<li>Review tele strips if stable: VUMC Web Resources -> VUH PIICiX
    Philips Web -> patient selection -> alarm review
    (vuhphilipsweb.app.vumc.org)</li>
<li>Review past EKGs to determine if patient has had this rhythm before</li>
<li>Ensure pt has good IV access</li>
<li>Labs: BMP, Mg, TSH, and &plusmn; troponin, tox screen</li>
</ul>
<hr />
<h2 id="cardiology-cardiology-arrhythmias-bradyarrhythmias">Bradyarrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-bradyarrhythmias" title="Permanent link">&para;</a></h2>
<p>Kunal Patel</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Broadly classified as sinus node dysfunction (pacing defect) or
    atrioventricular block (conduction defect)</li>
<li>Clinical presentation varies widely based on underlying cause,
    timing, degree of block/dysfunction</li>
<li>Unlikely to cause symptoms if HR >50</li>
<li>Symptoms include syncope/presyncope, dyspnea, angina</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-etiologies">Etiologies<a class="headerlink" href="#cardiology-cardiology-arrhythmias-etiologies" title="Permanent link">&para;</a></h3>
<ul>
<li>Infection/sepsis</li>
<li>Ischemia</li>
<li>Rheumatologic/Inflammatory</li>
<li>Post-cardiac surgery</li>
<li>Hypothyroidism</li>
<li>Sleep apnea</li>
<li>Infiltration (amyloid, hemochromatosis)</li>
<li>High vagal tone (pain, nausea)</li>
<li>Medications: Antihypertensives, antiarrhythmics, psychoactive meds,
    anesthetics, cannabis, muscle relaxants, etc.</li>
</ul>
<p>Sinus node dysfunction</p>
<ul>
<li>Symptomatic sinus bradycardia, tachy-brady syndrome, chronotropic
    incompetence, sinus pause, SA exit block</li>
<li>Asymptomatic sinus bradycardia (esp in young/healthy patient) is
    unlikely to be true bradyarrhythmia</li>
</ul>
<p>AV Block</p>
<p><img alt="AV block" src="../images/image2.png" /></p>
<h3 id="cardiology-cardiology-arrhythmias-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-arrhythmias-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>TTE if structural disease suspected</li>
<li>Ambulatory cardiac monitoring if frequently symptomatic</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Avoid nodal blocking agents – Adenosine, Beta-blockers, CCBs,
    Digoxin</li>
<li>Observation if asymptomatic</li>
<li>Treat identified underlying causes</li>
<li>If symptomatic or high-grade block (Mobitz II or complete heart
    block), EP consult for pacemaker evaluation</li>
<li>If unstable:</li>
<li>Atropine (0.5 mg every 3 to 5 minutes; maximum total dose: 3 mg)<ul>
<li>Do NOT use in heart transplant</li>
<li>Call CCU Fellow</li>
<li>Dopamine (5 to 20 mcg/kg/minute) OR Epi (2 to 10 mcg/min)</li>
<li>Transvenous pacing
  (Pacer pads on the defib device are capable of pacing,
  but don’t forget to sedate!)</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-arrhythmias-tachyarrhythmias-narrow-complex">Tachyarrhythmias - Narrow complex<a class="headerlink" href="#cardiology-cardiology-arrhythmias-tachyarrhythmias-narrow-complex" title="Permanent link">&para;</a></h2>
<p>Kunal Patel</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background_1">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Three causes of tachyarrhythmias<ul>
<li>Re-entry: patient with structural heart disease (ex post-infarction
scar)</li>
<li>Abnormal Automaticity: electrolyte abnormalities or acute ischemia
(Purkinje fibers)</li>
<li>Triggered Activity: early and late after depolarizations. Ex:
Hypokalemia, ischemia, infracts, excess calcium and drug toxicity</li>
</ul>
</li>
</ul>
<p>Tachyarrhythmia differential</p>
<p><img alt="tachyarrhythmia" src="../images/image3.png" /></p>
<h3 id="cardiology-cardiology-arrhythmias-evaluation_1">Evaluation<a class="headerlink" href="#cardiology-cardiology-arrhythmias-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Unstable tachyarrhythmia</li>
<li>Start with treatment, determine type later</li>
<li>Synchronized cardioversion: place defibrillator pads, consider
    0.5-2mg IV midazolam for sedation, prepare for synchronized
    cardioversion at 200J (can ↑ to 300-360 J)</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management_1">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Sinus tachycardia<ul>
<li>Almost always secondary</li>
<li>Address underlying causes: fever/sepsis, hypo/hypervolemia, anxiety,
  anemia, PE, ACS, hypoxia, pain, urinary retention, withdrawal</li>
</ul>
</li>
<li>Atrial Fibrillation/Flutter – See Atrial fibrillation section</li>
<li>AVNRT/Orthodromic AVRT<ul>
<li>Look for p buried in QRS, rate 150-250, AVRT will have delta waves
when NSR</li>
<li>Vagal maneuvers (1<sup>st</sup> line): Sit patient upright have them blow into
tip of 10cc syringe for 10-15 seconds rapidly lay supine and raise
legs</li>
<li>Adenosine (2<sup>nd</sup> line): therapeutic (break AVRT/AVNRT) and diagnostic
(allows visualization of underlying rhythm)<ul>
<li>Do NOT give in heart transplant, severe COPD, pre-excitation
causing wide complex tachycardia (WPW antidromic AVRT)</li>
<li>Peripheral line at AC or above w/ arm elevated:
  6mg x1, 6mg x1 (if not effective after 1-2 min),
  12mg x1 (if refractory to 6mg)</li>
<li>Central line: cut dose in half to 3mg x1, 3mg x1, 6mg x1</li>
</ul>
</li>
</ul>
</li>
<li>Multifocal atrial tachycardia<ul>
<li>3 or more p wave morphologies. Seen in cardiac and pulmonary disease</li>
<li>Usually does not cause hemodynamic instability</li>
<li>BBs and non-DHP CCBs can be effective, need to address underlying
  issue</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 24%" />
<col style="width: 31%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Dosing</th>
<th>Benefits</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Metoprolol</td>
<td><p>5mg IV q5m x3</p>
<p>PO metoprolol tartrate 12.5mg q6 hours ↑ every 6 hr to
target</p></td>
<td><p>Good 1st line agent</p>
<p>Less BP effect than dilt</p></td>
<td><p>Hypotension,</p>
<p>Negative inotropy</p></td>
</tr>
<tr class="even">
<td>Diltiazem</td>
<td><p>10-20 mg IV over 2m q15m x2</p>
<p>drip = 5-15 mg/hr</p></td>
<td>Good 1st line w/ normal EF with drip needed</td>
<td><p>Hypotension</p>
<p>Avoid in HFrEF</p></td>
</tr>
<tr class="odd">
<td>Esmolol</td>
<td><p>500 mcg/kg bolus</p>
<p>drip = 50-200 mcg/kg/min</p></td>
<td><p>Rapid onset/offset</p>
<p>RBC metabolism</p></td>
<td>Hypotension</td>
</tr>
<tr class="even">
<td>Amiodarone</td>
<td>150 IV over 10-30m, then 1 mg/m for 6h, then 0.5mg/m for 18h</td>
<td><p>Minimal BP effects</p>
<p>Long lasting; Relatively fast onset (acute effect is mostly beta
blockade)</p></td>
<td><p>Pulmonary and thyroid toxicity</p>
<p>Cardioversion</p></td>
</tr>
<tr class="odd">
<td>Digoxin</td>
<td>500mcg IV x1, then 250mcg IV q6h x2-3</td>
<td>Great for reduced EF, positive inotropy</td>
<td><p>Slow onset</p>
<p>Depends on vagal tone – poor in hyper- adrenergic states</p></td>
</tr>
<tr class="even">
<td>Procainamide</td>
<td>20-50 mg/min loading, 1-4 mg/min maintenance</td>
<td>Use in pre-excitation syndromes (i.e. WPW), does not inhibit AV nodal
conduction</td>
<td><p>Lupus-like syndrome</p>
<p>Hypotension</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-arrhythmias-tachyarrhythmias-wide-complex">Tachyarrhythmias - Wide Complex<a class="headerlink" href="#cardiology-cardiology-arrhythmias-tachyarrhythmias-wide-complex" title="Permanent link">&para;</a></h2>
<p>Madeline Rukavina</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-definitions">Definitions<a class="headerlink" href="#cardiology-cardiology-arrhythmias-definitions" title="Permanent link">&para;</a></h3>
<p>Ventricular tachycardia (VT): a run of 3+ PVCs</p>
<ul>
<li>Sustained VT: VT for 30 seconds or shorter if it requires
    intervention</li>
<li>Nonsustained VT (NSVT): VT for \&lt; 30 seconds</li>
<li>VT storm: 3+ separate episodes of sustained VT within 24 hrs.</li>
</ul>
<p>VT Morphologies</p>
<ul>
<li>Monomorphic VT: similar QRS configuration from beat to beat<ul>
<li>Usually 2/2 scar-mediated VT from prior infarction</li>
</ul>
</li>
<li>Polymorphic VT: a continuously changing QRS configuration from beat
    to beat<ul>
<li>Ischemia until proven otherwise</li>
</ul>
</li>
<li>Torsades de Pointes (TdP): a form of polymorphic VT with a continually
    varying QRS that appears to spiral around the baseline of the ECG in
    a sinusoidal pattern</li>
<li>Ventricular fibrillation (VF): chaotic rhythm characterized by
    undulations that are irregular in timing and morphology, without
    discrete QRS complexes</li>
</ul>
<p>Ventricular Tachycardia vs. SVT with aberrancy</p>
<ul>
<li>VT: The action potential originated in the ventricles (ex: VT)</li>
<li>Supraventricular tachycardia with aberrancy: the action potential
    originates from a focus above the ventricles &amp; conducts through the
    AV node with a delay or block resulting in a wide QRS (mimics VT)</li>
<li>Ex: sinus tachycardia w/ bundle branch block (block may be rate
    dependent), AF w/ LBBB</li>
</ul>
<p>Many ways to differentiate VT vs. SVT w/ aberrancy</p>
<ul>
<li>Consult cardiology for assistance</li>
<li>Look for ECG features suggestive of VT</li>
<li>Very broad complexes >160 ms</li>
<li>RsR’ complex with a taller left rabbit ear In V&frac12;</li>
<li>AV dissociation (P/QRS dissociation)</li>
<li>Capture Beats: native QRS complexes making a cameo during the VT</li>
<li>Fusion Beats: QRS which appears like a signal average of VT and
        native complex</li>
</ul>
<p><img alt="capture beat" src="../images/image4.png" />
<img alt="fusion beat" src="../images/image5.png" /></p>
<ul>
<li>There are more advanced criteria to help distinguish. The aVR
    (Vereckie) criteria is one example that is fast and accurate</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management_2">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management_2" title="Permanent link">&para;</a></h3>
<p>Unstable</p>
<ul>
<li>Sedate with midazolam 1-2mg</li>
<li>Cardioversion for monomorphic VT. Synchronized shock at 100-200J</li>
<li>Defibrillation if VF/polyVT</li>
</ul>
<p>Stable</p>
<ul>
<li>Medications (as below)</li>
</ul>
<table>
<colgroup>
<col style="width: 24%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug Name</th>
<th>Dosing</th>
<th>Mechanism</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Amiodarone</td>
<td>150mg IV over 10 min, then 1mg/min for 6 hours; repeat bolus if VT
recurs</td>
<td><p>Class III</p>
<p>-K+ channel blocker; has class Ia, II, &amp; IV effects</p></td>
<td>Bradycardia, hypotension (acutely)</td>
</tr>
<tr class="even">
<td>Lidocaine</td>
<td>1-1.5 mg/kg (usually 75-100 mg) at a rate of 25-50mg/min; lower
doses of .5-.75mg/kg can be repeated every 5-10 min as needed</td>
<td><p>Class IB</p>
<p>-fast Na+ channel blocker-&gt; slows conduction</p></td>
<td>Slurred speech, AMS, seizures, bradycardia</td>
</tr>
<tr class="odd">
<td>Procainamide</td>
<td>20-50mg/min until arrhythmia terminates or max dose 17mg/kg is
reached</td>
<td><p>Class IA</p>
<p>-fast Na+ channel blocker -&gt; slows conduction</p>
<p>-K+ channel blocker-&gt; prolongs repolarization</p></td>
<td><p>Bradycardia, hypotension, torsades, drug-induced lupus</p>
<p>Avoid in HF pts, prolonged QT</p></td>
</tr>
</tbody>
</table>

<ul>
<li>
<p>Cardioversion If refractory to medical management</p>
</li>
<li>
<p>Treatment of underlying cause if identifiable</p>
<ul>
<li>Ischemia, electrolyte disturbances, heart failure, drugs</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-arrhythmias-premature-ventricular-complexes-pvcs">Premature Ventricular Complexes (PVCs)<a class="headerlink" href="#cardiology-cardiology-arrhythmias-premature-ventricular-complexes-pvcs" title="Permanent link">&para;</a></h2>
<p>Madeline Rukavina</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background_2">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Premature Ventricular Complex (PVC): early ventricular
    depolarization &plusmn; mechanical contraction</li>
<li>PVC burden: % of beats of ventricular origin / total beats over a
    24h period</li>
<li>PVCs are common: Up to 80% of apparently healthy people have PVCs</li>
<li>Normal number of PVCs in an adult is \&lt;500 in 24h</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-etiologies_1">Etiologies<a class="headerlink" href="#cardiology-cardiology-arrhythmias-etiologies_1" title="Permanent link">&para;</a></h3>
<ul>
<li>HTN with LVH, prior MI/scar, HF, myocarditis, ARVC, HCM, idiopathic
    VT, OSA, pHTN, COPD, thyroid disease, substance use (EtOH, nicotine,
    stimulants, caffeine)</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-inpatient-evaluation-management">Inpatient Evaluation &amp; Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-inpatient-evaluation-management" title="Permanent link">&para;</a></h3>
<ul>
<li>12 lead EKG: conduction disease, long QT syndrome, Brugada syndrome,
    ARVC</li>
<li>Labs: K, Mg, TSH, drug screen</li>
<li>Evaluate for QT prolonging agents (risk of Torsades)</li>
<li>Evaluate tele for PVC burden</li>
<li>Inpt consult to EP for PVCs rarely warranted unless significant PVC
    burden (>5 PVC/min, consistently) in setting of reduced LVEF.</li>
<li>For pts with >5 PVC/min or pts with symptoms, discharge with
    Ziopatch (VA) or mobile cardiac telemetry (VU) and obtain TTE if
    none recent.</li>
</ul></section><section class="print-page" id="cardiology-cardiology-atrial-fibrillation-and-flutter"><h1 id="cardiology-cardiology-atrial-fibrillation-and-flutter-atrial-fibrillation-flutter">Atrial Fibrillation &amp; Flutter<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-atrial-fibrillation-flutter" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-background">Background<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-background" title="Permanent link">&para;</a></h2>
<ul>
<li>AF: 12-lead EKG with absence of p-waves and irregularly irregular
    QRS complexes</li>
<li>Flutter: sawtooth atrial F waves (300 BPM) with regular or regularly
    irregular QRS complexes</li>
<li>Ventricular rate ratio of F waves: V waves ~150 (2:1), ~100 (3:1),
    or ~75 (4:1)</li>
<li>3 classifications<ul>
<li>Paroxysmal (terminates within 7 days)</li>
<li>Persistent (persisting beyond 7 days)</li>
<li>Permanent (normal rhythm cannot be restored)</li>
</ul>
</li>
<li>Rapid ventricular response (RVR) is HR > 100 (ie AF/Flutter w/
    tachycardia)</li>
<li>AF/RVR is far more often a consequence of hypotension than the cause
    of it</li>
</ul>
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Causes: Mnemonic “H PIRATES”<ul>
<li>Hypertension</li>
<li>Pneumonia, Pericarditis, Post-op</li>
<li>Ischemia (rare)</li>
<li>Rheumatic Valve</li>
<li>Atrial Myxoma or Accessory Pathway</li>
<li>Thyrotoxicosis</li>
<li>Ethanol or Excess Volume</li>
<li>Sick sinus, Sepsis</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-management">Management<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Treatment goals<ul>
<li>Rate control, Goal HR \&lt; 110 (RACE II)</li>
<li>Rhythm control (if indicated)</li>
<li>Stroke prevention</li>
</ul>
</li>
</ul>
<p>Rate control (inpatient)</p>
<ul>
<li>RVR ~ sinus tach of AF; Always work to address the underlying cause
    (infection, volume overload, etc). Rate control is rarely an
    emergency unless the patient is unstable</li>
<li>If stable with RVR (SBP >90)<ul>
<li>IV if HR > 130 or symptomatic (metop 5 mg IV or dilt 15-20 mg
    IV), otherwise do PO</li>
<li>AV nodal blocking agents<ul>
<li>B-blockers: Start with metop tartrate (titratable)
  consolidate to succinate. Avoid in decompensated or
  borderline HF</li>
<li>Calcium channel blockers (diltiazem): avoid in HFrEF</li>
</ul>
</li>
</ul>
</li>
<li>Peri stable (SBPs 80s-90 with preserved perfusion)<ul>
<li>Amiodarone: Consider if decompensated HF, accessory pathway,
    anti-coagulated. Caution that you may cardiovert pt (stroke
    risk)</li>
</ul>
</li>
<li>Unstable (SBPs \&lt;80)<ul>
<li>Cardioversion</li>
</ul>
</li>
</ul>
<p>Rate control (outpatient)</p>
<ul>
<li>typically achieved with beta blocker therapy,
  metoprolol is most frequently used</li>
</ul>
<p>Rhythm control (inpatient)</p>
<ul>
<li>New onset a-fib (first time diagnosis): most pts will be a candidate
    for trial of cardioversion</li>
<li>If onset clearly within 48 hours, can proceed without TEE. Often TEE
    is done anyway (pt may have had intermittent asymp AF)</li>
<li>If onset >48 hours or unclear, will need TEE to rule out LAA
    thrombus</li>
<li>Pharmacologic options include class 1C: flecainide, propafenone
    (avoid in structural heart disease) and class 3: Amiodarone,
    dronedarone, sotalol, ibutilide, dofetilide (some require loading
    inpt)<ul>
<li>Caution using antiarrhythmics in any pt you wouldn't
    electrically cardiovert without TEE</li>
</ul>
</li>
</ul>
<p>Rhythm control (outpatient)</p>
<ul>
<li>Consider EP consult for ablation in symptomatic paroxysmal or
    persistent AF refractory to anti-arrhythmic drugs, AF in HFrEF, or
    flutter</li>
<li>Stroke Prevention (for AF and flutter)<ul>
<li>CHA2DS2-VASc risk score >2 in M or >3 in F should prompt long term
AC in AF persisting >48 hours</li>
<li>NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred to
warfarin except in moderate to severe MS or mechanical valve</li>
</ul>
</li>
<li>If cardioversion planned for new onset AF, start AC as soon as
    possible<ul>
<li>Post-cardioversion, anticoagulate for at least 4 weeks due to
    atrial stunning and stroke risk</li>
</ul>
</li>
<li>If no contraindications or procedures, continue anticoagulation
    while inpatient</li>
<li>Typically do not need to bridge AC for AF in the setting of
    procedures unless mechanical valve is present. Decide on a case
    by-case basis</li>
<li>Left atrial appendage closure can be considered in those with
    increased risk of bleeding</li>
</ul></section><section class="print-page" id="cardiology-cardiology-autonomics-and-orthostatics"><h1 id="cardiology-cardiology-autonomics-and-orthostatics-autonomics-and-orthostatic-hypotension">Autonomics and Orthostatic Hypotension<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-autonomics-and-orthostatic-hypotension" title="Permanent link">&para;</a></h1>
<p>Leonard Chiu</p>
<hr />
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-background">Background<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Orthostatic Hypotension: SBP ↓ > 20 mmHg, DBP ↓ > 10 mmHg), or HR
    Increase > 30 within 3 min of standing up or head-up tilt to 60% on
    a tilt table</li>
<li>Etiologies: Neurogenic OH (nOH) vs non-neurogenic OH</li>
<li>nOH associated with autonomic failure<ul>
<li>Blunted tachycardia during hypotension characteristic of
    autonomic failure</li>
<li>nOH: If HR rise is \&lt;15</li>
<li>nOH also associated with periods of high BP (supine
    hypertension)</li>
<li>Ex: Neurodegenerative disease, neuropathy (diabetes, amyloid,
    paraneoplastic, etc)</li>
</ul>
</li>
<li>Other causes: volume depletion (most common), medications
    (diuretics, alpha-1 blockers, BB, etc), pump failure (severe AS,
    arrhythmia)</li>
</ul>
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Orthostatic vitals signs (checking supine, sitting, and standing
    with 5-minute wait in each position)</li>
<li>Volume status exam</li>
<li>Labs: CBC, CMP, EKG, TSH, B12, , LFTs,</li>
<li>Consider SPEP/UPEP, paraneoplastic panel, autonomic function testing
    depending on clinical context</li>
<li>Autonomic Function Testing: Available at 4:15pm Tues, Wed, Thurs NPO
    4 hours prior</li>
<li>Hold oral pressors and antihypertensives 12 hours prior</li>
</ul>
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-management">Management<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Conservative:</li>
<li>TED hose and abdominal binder for ambulation</li>
<li>Drink 16oz of fluid 15 min prior to standing</li>
<li>If they have supine HTN, keep HOB 30-45 degrees at all times</li>
<li>Add 2.3-4.6g of salt per day to diet (if no contraindications)</li>
<li>Avoid high temperatures (which cause peripheral vasodilation)</li>
<li>Supine HTN therapies: transdermal nitroglycerin (preferred);
    minoxidil, hydralazine, or clonidine in select patients</li>
</ul>
<p>Orthostatic hypotension pharmacologic therapies</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 22%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Dose</th>
<th>Mechanism</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fludocortisone (Florinef)</td>
<td><p>0.1mg QD</p>
<p>↑ by 0.1 mg</p>
<p>Max: 0.3 mg QD</p></td>
<td>Mineralocorticoid increase blood volume. Enhances sensitivity to
circulating catecholamines</td>
<td><p>Edema</p>
<p>HTN</p>
<p>HypoK</p>
<p>Do not use in CHF</p></td>
</tr>
<tr class="even">
<td>Midodrine</td>
<td><p>2.5mg TID</p>
<p>↑ by 2.5mg</p>
<p>Up to 10mg TID</p></td>
<td>Peripheral-selective α1 agonist → constricts both aa &amp; vv</td>
<td><p>Supine HTN</p>
<p>Pilomotor reactions</p>
<p>Pruritus</p>
<p>GI upset</p>
<p>Avoid in uncontrolled HTN, urinary retention, heart disease</p></td>
</tr>
<tr class="odd">
<td>Droxidopa</td>
<td><p>100mg</p>
<p>↑ by 100mg</p>
<p>Up to 600mg TID</p></td>
<td>NE precursor → carboxylated to NE. Can cross BBB.</td>
<td>Supine HTN, less than midodrine</td>
</tr>
<tr class="even">
<td>Atomoxetine</td>
<td>10mg or 18mg</td>
<td>SNRI</td>
<td>Do not use w/ glaucoma or MAOI</td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-bedside-echocardiography"><h1 id="cardiology-cardiology-bedside-echocardiography-bedside-echocardiography">Bedside Echocardiography<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-bedside-echocardiography" title="Permanent link">&para;</a></h1>
<p>Jamie Pfaff</p>
<hr />
<h2 id="cardiology-cardiology-bedside-echocardiography-finding-an-ultrasound">Finding an Ultrasound<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-finding-an-ultrasound" title="Permanent link">&para;</a></h2>
<ul>
<li>MICU: radiology room behind charge nurse’s desk in middle hallway</li>
<li>VA ICU: In front of resident workspace</li>
<li>8N: Behind nurses station before entering cleaning supply room</li>
<li>8S: In supply closet to left as your walk toward nursing station -
    (door code is 1-3-5)</li>
<li>6MCE: COVID restricted (ask nurses)</li>
<li>CCU/5N only: supply room on left as entering CCU</li>
<li>Round wing: 5<sup>th</sup> floor, ask nurses</li>
</ul>
<h2 id="cardiology-cardiology-bedside-echocardiography-tte-standard-views">TTE Standard Views<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-tte-standard-views" title="Permanent link">&para;</a></h2>
<p><img alt="image" src="../images/image10.jpeg" /></p>
<h3 id="cardiology-cardiology-bedside-echocardiography-parasternal-long">Parasternal long<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-parasternal-long" title="Permanent link">&para;</a></h3>
<p><img alt="image" src="../images/image9.png" />
<img alt="image" src="../images/image8.png" /></p>
<ul>
<li>Probe position: Rotate probe 180 degrees with right edge of
    probe/probe marker pointing toward patient’s left shoulder</li>
<li>
<p>Make sure probe is centered over mitral valve (In right spot if you
    can see MV and AV)</p>
<ul>
<li>Distance separating the anterior MV leaflet from the septal wall
    as measure of LV systolic function (easy evaluation of systolic
    function)</li>
<li>Place M mode spike at tip of mitral leaflet and hit M mode
    (perpendicular to septum)</li>
<li>Identify E point (passive filling of LV) and determine distance
    from interventricular septum (IVS)<ul>
<li>\&lt;7mm = Normal</li>
<li>>10mm = HF</li>
</ul>
</li>
<li>Confounders that elevate EPSS: AR, MS</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-parasternal-short">Parasternal short<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-parasternal-short" title="Permanent link">&para;</a></h3>
<ul>
<li>Probe position: Rotate probe 180 degrees with right edge of
    probe/probe marker pointing toward patient’s left shoulder</li>
<li>Good position to assess EF by visualizing wall thickening</li>
</ul>
<p>Apical four chamber</p>
<ul>
<li>Probe position: Slide down and look near patient’s left nipple (or
    in the intermammary fold after lifting up breast tissue if needed -
    at PMI if able to palpate)</li>
<li>Good to assess EF by visualizing cardiac shortening</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-subxiphoid">Subxiphoid<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-subxiphoid" title="Permanent link">&para;</a></h3>
<ul>
<li>Probe position: Push probe head into patient’s abdomen just below
    xiphoid and flatten probe to make nearly parallel to patient’s
    position, marker to pt’s left</li>
<li>Troubleshooting: shift probe slightly left of midline (toward
    patient’s right) and angle toward heart/right to use liver as
    acoustic window or ask patient to take big breath (moves heart
    closer to probe)</li>
<li>Best window to visualize pericardial effusion</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-ivc">IVC<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-ivc" title="Permanent link">&para;</a></h3>
<figure>
<p><img alt="image" src="../images/image11.jpeg" /></p>
</figure>
<ul>
<li>Probe position: subxiphoid area with probe marker facing toward
    patient’s head tilted slightly left of midline, trace IVC into RA to
    verify correct vessel (vs aorta)</li>
<li>IVC size and collapsibility used as a surrogate for CVP and RAP<ul>
<li>\&lt;2.1 cm and >50% collapse: RAP ~3mmHg</li>
<li>\&lt;2.1 cm and \&lt; 50% collapse or >2.1cm and >50% collapse: RAP
    ~8mmHg</li>
<li>>2.1cm, \&lt;50% collapse: RAP ~ >15mmHg</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-bedside-echocardiography-resources">Resources<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-resources" title="Permanent link">&para;</a></h2>
<ul>
<li><a href="https://www.coreultrasound.com/basic-cardiac-function/">https://www.coreultrasound.com/basic-cardiac-function/</a></li>
<li><a href="http://pie.med.utoronto.ca/tte">http://pie.med.utoronto.ca/tte</a></li>
<li><a href="https://www.echocardiographer.org/TTE.html">https://www.echocardiographer.org/TTE.html</a></li>
<li>App: FATE CARD (Focus Assessed Transthoracic Echocardiography)</li>
</ul></section><section class="print-page" id="cardiology-cardiology-cardiac-devices"><h1 id="cardiology-cardiology-cardiac-devices-cardiac-devices">Cardiac Devices<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-cardiac-devices" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h2 id="cardiology-cardiology-cardiac-devices-types-of-cardiac-implantable-electronic-devices-cied">Types of Cardiac Implantable Electronic Devices (CIED)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-types-of-cardiac-implantable-electronic-devices-cied" title="Permanent link">&para;</a></h2>
<ul>
<li>For Controlling Arrhythmias: Implantable Pulse Generators</li>
<li>Pacemakers: Anti-bradycardia pacing</li>
<li>ICDs: Anti-tachycardia pacing and defibrillation</li>
<li>Biventricular Pacemakers: CRT for ventricular dyssynchrony (LBBB &amp;
    Heart Failure)</li>
<li>Loop Recorders: implantable devices for monitoring arrhythmias (most
    often Afib)</li>
<li>LVADs: augment cardiac output for end-stage heart failure (not
    covered here)</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-pacemakers">Pacemakers<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-pacemakers" title="Permanent link">&para;</a></h3>
<ul>
<li>Provide anti-bradycardia pacing by stimulating myocardium</li>
<li>Peripheral permanent pacemakers (PPMs)</li>
<li>SubQ generator, transvenous leads<ul>
<li>Single chamber RV lead</li>
<li>Dual chamber RV and RA leads</li>
<li>BiV: RV, RA, and LV (coronary sinus) leads</li>
</ul>
</li>
<li>Leadless pacemaker<ul>
<li>Implanted generator in RV</li>
</ul>
</li>
</ul>
<p>Indications</p>
<ul>
<li>Symptomatic Bradycardia</li>
<li>Heart Block: 2<sup>nd</sup> Degree Type II w/ sx or 3<sup>rd</sup> Degree</li>
<li>Sick Sinus Syndrome</li>
<li>Carotid Sinus Syndrome</li>
<li>After catheter ablation of AV node for AF</li>
<li>CRT</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-implantable-cardioverterdefibrillators-icds">Implantable Cardioverter/Defibrillators (ICDs)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-implantable-cardioverterdefibrillators-icds" title="Permanent link">&para;</a></h3>
<ul>
<li>Pacing lead + defibrillation coil</li>
<li>Detect and treat VT/VF v<ul>
<li>Anti-tachycardia pacing (ATP)- attempts to entrain and terminate
    VT</li>
<li>Defibrillation If ATP unsuccessful</li>
</ul>
</li>
</ul>
<p>Indications</p>
<ul>
<li>Primary prevention<ul>
<li>HFrEF<ul>
<li>EF \&lt;35% and NYHA II-III or EF \&lt;30% and NYHA I</li>
<li>Must be >90d from revasc, >40d from MI, and on GDMT</li>
</ul>
</li>
<li>Arrhythmogenic syndromes<ul>
<li>Arrhythmogenic RV cardiomyopathy, Brugada syndrome, HCM and
    cardiac sarcoid with specific risk factors</li>
</ul>
</li>
</ul>
</li>
<li>Secondary prevention<ul>
<li>Hx VF arrest or VT</li>
<li>Inducible VT on EP study with history of syncope</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-cardiac-resynchronization-therapy-crt">Cardiac Resynchronization Therapy (CRT)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-cardiac-resynchronization-therapy-crt" title="Permanent link">&para;</a></h3>
<ul>
<li>BiV pacer that coordinates LV/RV contraction through synchronized
    activation of each ventricle following atrial contraction.</li>
<li>-P: CRT pacing only</li>
<li>-D: ICD function</li>
</ul>
<p>Indications</p>
<ul>
<li>Class I: LBBB and QRS≥150 with EF\&lt;35%, NYHA II- IV, on GDMT, NSR</li>
<li>Class IIa: EF\&lt;35%, NYHA II- IV, on GDMT, NSR AND<ul>
<li>LBBB &amp; QRS 120-149, non-LBBB &amp; QRS≥150, or EF\&lt;35% and expected
    to require >40% ventricular pacing</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-interpreting-pacemaker-codes">Interpreting Pacemaker Codes<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-interpreting-pacemaker-codes" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th></th>
<th>1<sup>st</sup> Letter</th>
<th>2<sup>nd</sup> Letter</th>
<th>3<sup>rd</sup> Letter</th>
<th>4<sup>th</sup> Letter</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: atrial, V: ventricular, D: dual, O: none, I: inhibition, R: rate-adaptive</td>
<td>Chamber Paced</td>
<td>Chamber Sensed</td>
<td>Response to Sensed Beat</td>
<td>Program Features</td>
</tr>
</tbody>
</table>
<h3 id="cardiology-cardiology-cardiac-devices-examples-of-common-pacing-modes">Examples of Common Pacing Modes<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-examples-of-common-pacing-modes" title="Permanent link">&para;</a></h3>
<ul>
<li>VVI: Single RV lead that delivers a beat if no beat sensed. Often
    used with chronic AF with bradycardia</li>
<li>DDDR: Senses and paces both the atria and ventricle. If beat not
    sensed within a predefined interval, beat delivered. R indicates
    rate responsivity (changes rate based on changes in patient
    activity)</li>
<li>Magnet: Paces at a fixed rate without respect to native electrical
    activity (AOO,VOO,DOO). Deactivates ICD shock. Often used in surgery
    or at end of life to avoid ICD shocks</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-additional-configurations">Additional Configurations<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-additional-configurations" title="Permanent link">&para;</a></h3>
<ul>
<li>Epicardial Leads- pacemaker/defibrillator leads attached to outside
    of the heart (requires OR) vs traditional transvenous lead
    placement, which are inserted in the Cath Lab<ul>
<li>Epicardial Leads generally placed in smaller children or during
    cardiac surgery with expected need for pacing/defibrillation</li>
</ul>
</li>
<li>Abandoned leads<ul>
<li>Absolute contraindication to MRI (ungrounded, produces heat and
    thermal Injury In setting of magnetic field)</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-placement-complications">Placement Complications<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-placement-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>Acute: pocket hematoma, pneumothorax, myocardial perforation,
    cardiac tamponade, infection, lead displacement or disconnection</li>
<li>Long-term: secondary device infection, lead fracture (lead lifetime
    10-15 years), insulation failure</li>
</ul>
<p><img alt="image" src="../images/image6.tiff" /></p></section><section class="print-page" id="cardiology-cardiology-chest-pain"><h1 id="cardiology-cardiology-chest-pain-chest-pain">Chest Pain<a class="headerlink" href="#cardiology-cardiology-chest-pain-chest-pain" title="Permanent link">&para;</a></h1>
<p>Nicholas King</p>
<hr />
<h2 id="cardiology-cardiology-chest-pain-chest-pain-angina-framework">Chest Pain / Angina Framework<a class="headerlink" href="#cardiology-cardiology-chest-pain-chest-pain-angina-framework" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Determining likelihood that chest pain has a cardiac etiology
    depends on symptoms and lies on a spectrum</p>
</li>
<li>
<p>Cardiac > possible cardiac > noncardiac is more useful than
    typical vs atypical angina</p>
</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-diagnoses-not-to-miss-the-serious-six">Diagnoses Not to Miss: “The Serious Six”<a class="headerlink" href="#cardiology-cardiology-chest-pain-diagnoses-not-to-miss-the-serious-six" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute Coronary Syndrome</li>
<li>Mediastinitis (e.g, esophageal perforation)</li>
<li>Aortic Dissection/Aneurysm</li>
<li>Cardiac Tamponade</li>
<li>Pulmonary Embolus</li>
<li>Pneumothorax</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-other-differential-diagnoses">Other Differential Diagnoses<a class="headerlink" href="#cardiology-cardiology-chest-pain-other-differential-diagnoses" title="Permanent link">&para;</a></h2>
<ul>
<li>Skin: Laceration, herpes zoster</li>
<li>Subcutaneous: cellulitis, abscess</li>
<li>Musculoskeletal: Costochondritis, fracture, myositis, sprain/strain</li>
<li>Pleural space (no pain receptors in the lung): PNA, tumor, pleuritis</li>
<li>Pericardium: Pericarditis</li>
<li>Heart: Myocarditis, spontaneous coronary artery dissection (SCAD),
    coronary vasospasm, aortic stenosis, stress-induced cardiomyopathy
    (Takotsubo), decompensated heart failure</li>
<li>Esophagus: GERD, esophagitis</li>
<li>Trachea: Tracheitis, tracheal tear</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-physical-exam">Physical Exam<a class="headerlink" href="#cardiology-cardiology-chest-pain-physical-exam" title="Permanent link">&para;</a></h2>
<ul>
<li>Vitals: BP in both arms (do while interviewing - quick, easy,
    inexpensive)</li>
<li>Hemodynamic profile (warm/dry, warm/wet, cold/dry, cold/wet)</li>
<li>Palpate chest: evaluate costochondral junction, subcutaneous
    emphysema, examine skin</li>
<li>Cardiac: murmurs, rub for pericarditis, JVD for heart failure or PE
    with RV strain</li>
<li>Pulm: absent breath sounds for PTX, crackles for left heart failure,
    PNA</li>
<li>Abdomen: abdominal pain mistaken or referred as chest pain</li>
<li>Extremities: asymmetric leg swelling (>2 cm difference) for DVT/PE</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-diagnostic-studies">Diagnostic Studies<a class="headerlink" href="#cardiology-cardiology-chest-pain-diagnostic-studies" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG: ACS (STEMI, new LBBB, ST depressions, T wave Inversions,
    Wellens' sign), pericarditis, pericardial effusion</li>
<li>Labs: Troponin (ACS, PE, myocarditis), CBC, BNP, lactate</li>
<li>CXR: PTX, PNA, dissection, esophageal rupture</li>
<li>Bedside ultrasound: pericardial effusion, R heart strain for PE,
    wall motion abnormality for infarct/ischemia or stress-induced CM,
    valvular disease, lung sliding/PTX</li>
<li>CTA: gold standard for PE. Dissection can be diagnosed w/ CTA, MRA,
    or TEE</li>
</ul>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 19%" />
<col style="width: 19%" />
<col style="width: 20%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5"><br />
Evaluation for Coronary Disease</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Test</td>
<td>Indications</td>
<td>Benefits</td>
<td>Risks</td>
<td>Considerations</td>
</tr>
<tr class="even">
<td>EKG Stress</td>
<td rowspan="6"><p>Low to Intermediate risk patients</p>
<p><em>Do not stress active or suspected ACS</em></p>
<p>Serves as screening with high NPV</p></td>
<td>Functional status w/ Bruce treadmill protocol</td>
<td><p>Exercise tolerance</p>
<p>limits use</p></td>
<td><p>Cannot have LBBB,</p>
<p>nondiagnostic if 85% target HR not achieved</p></td>
</tr>
<tr class="odd">
<td>Dobutamine Echo Stress</td>
<td>More sensitive than EKG</td>
<td>Contraindicated: arrhythmias, LVOT obstruction, HTN, AS</td>
<td><p>Can be useful to eval low grade low flow AS</p>
<p>Hold BB</p></td>
</tr>
<tr class="even">
<td>SPECT stress</td>
<td><p>More sensitive than echo,</p>
<p>Assess viability</p></td>
<td>Adenosine or Regadenason contraindicated in reactive airway
disease</td>
<td>No caffeine or theophylline prior</td>
</tr>
<tr class="odd">
<td>PET stress</td>
<td><p>Better PPV than Echo</p>
<p>Assess viability</p></td>
<td colspan="2">Better for pts with larger abdominal girth (less
diaphragmatic attenuation)</td>
</tr>
<tr class="even">
<td>Cardiac MRI</td>
<td>Assesses viability</td>
<td colspan="2">Can assess nonischemic vs ischemic cardiomyopathy; HR
must be &lt; 70, gold standard for structure and function</td>
</tr>
<tr class="odd">
<td>Coronary CT</td>
<td>Very high NPV for stenosis</td>
<td><p>Contrast media reactions</p>
<p>CIN lower risk than cath</p></td>
<td><p>Might have poor lumen visualization if heavy calcium burden</p>
<p>HR &lt; 70</p></td>
</tr>
<tr class="even">
<td>Coronary Angiogram</td>
<td><p>STEMI</p>
<p>High risk NSTEMI:</p>
<p>Refractory angina, new arrhythmia, cardiogenic shock (HF)</p>
<p>Suspected true ACS</p>
<p>Diagnostic and Therapeutic</p></td>
<td><p>Direct visualization of lumen</p>
<p>Therapeutic PCI</p></td>
<td><p>CIN with contrast</p>
<p>Cath site complications</p>
<p>Rare: SCAD, cholesterol emboli</p></td>
<td><p>Positive Screen (above) necessitates LHC</p>
<p>Case request cath lab</p>
<p>NPO MN prior</p>
<p>Groin check if femoral access</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-chf"><h1 id="cardiology-cardiology-chf-heart-failure">Heart Failure<a class="headerlink" href="#cardiology-cardiology-chf-heart-failure" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-chf-background">Background<a class="headerlink" href="#cardiology-cardiology-chf-background" title="Permanent link">&para;</a></h2>
<p>ACC/AHA Stages of HF</p>
<ul>
<li>Stage A: At risk but without structural heart disease or symptoms</li>
<li>Stage B: + structural HD, - symptoms</li>
<li>Stage C: + structural HD, + prior or current symptoms</li>
<li>Stage D: refractory HF requiring specialized intervention</li>
</ul>
<p>NY Heart Association (NYHA) Functional Classes of HF</p>
<ul>
<li>Class I: Normal physical activity is not limited</li>
<li>Class II: Comfortable at rest; normal physical activity results in
    HF symptoms</li>
<li>Class III: Comfortable at rest; less than normal activity leads to
    HF symptoms</li>
<li>Class IV: Inability to perform any physical activity without
    symptoms</li>
</ul>
<h2 id="cardiology-cardiology-chf-etiologies">Etiologies<a class="headerlink" href="#cardiology-cardiology-chf-etiologies" title="Permanent link">&para;</a></h2>
<ul>
<li>HFrEF (Clinical diagnosis + LVEF \&lt; 40%)<ul>
<li>Ischemic: Obstructive CAD, previous/current myocardial
    infarction</li>
<li>Non-ischemic:<ul>
<li>Load: HTN, valvulopathy</li>
<li>Arrhythmia: tachyarrhythmia, pacemaker induced</li>
<li>Myocardium</li>
</ul>
</li>
<li>Toxins (EtOH, drugs, chemo, radiation),</li>
<li>Inflammatory (infections, AI),</li>
<li>Metabolic (thyroid, thiamine deficiency),</li>
<li>Infiltrative (amyloid, sarcoid, hemochromatosis)</li>
<li>Stress induced/takotsubo CM<ul>
<li>Genetic</li>
<li>Idiopathic</li>
</ul>
</li>
</ul>
</li>
<li>HFpEF: HTN, CAD, obesity, DM, infiltrative, hypertrophic
    cardiomyopathy</li>
</ul>
<p>Causes of Heart Failure Exacerbations (FAILURES)</p>
<ul>
<li>Forgetting medications or taking drugs that can worsen HF (e.g. BB,
    CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab)</li>
<li>Arrhythmia/Anemia: AF, VT, PVCs; Increased arrhythmia burden on
    device check?</li>
<li>Ischemia/Infarction/Infection: myocarditis; Acute vascular
    dysfunction (e.g. endocarditis), especially mitral or aortic
    regurgitation.</li>
<li>Lifestyle choices: Dietary indiscretions - high salt, EtOH,
    excessive fluid intake. Obesity.</li>
<li>Upregulation (of CO): pregnancy and hyperthyroidism</li>
<li>Renal failure: acute, progression of CKD, or insufficient dialysis
    (Increased preload)</li>
<li>Embolus (pulmonary) or COPD (leads to increase right-sided
    afterload)</li>
<li>Stenosis (worsening AS, RAS) leading to hypertensive crisis high
    left-sided afterload</li>
</ul>
<h2 id="cardiology-cardiology-chf-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-chf-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Volume overload: shortness of breath, dyspnea on exertion,
    Orthopnea, PND</li>
<li>Nausea/poor po intake (hepatic and gut congestion)</li>
<li>Confusion (decreased CO)</li>
<li>Exam: Edema (legs, sacrum), rales, S3, S4, murmur (AS, MR), elevated
    JVD, + hepatojugular reflex, ascites</li>
</ul>
<h2 id="cardiology-cardiology-chf-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-chf-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC, CMP, Magnesium, Lactate, TSH, iron studies</li>
<li>Troponin, ECG</li>
<li>BNP (Pro-BNP if on Entresto) – high negative predictive value for HF
    (false negative can occur in obese patients)</li>
<li>CXR – differentiate other causes of dyspnea</li>
<li>TTE</li>
<li>Determine hemodynamic and volume profile<ul>
<li>Cold vs warm</li>
<li>Dry vs wet</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 23%" />
<col style="width: 25%" />
<col style="width: 31%" />
</colgroup>
<thead>
<tr class="header">
<th>Cardiac Index</th>
<th></th>
<th>Euvolemia</th>
<th>Hypervolemia</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Low</td>
<td><p>Warm Extremities</p>
<p>Adequate UOP</p>
<p>Normal PPP</p></td>
<td><p>Warm and Dry</p>
<p>Forrester Class I</p>
<p>Tx: GDMT as tolerated</p></td>
<td><p>Warm and Wet</p>
<p>Forrester Class II</p>
<p>Tx: Diuresis, Vasodilators</p></td>
</tr>
<tr class="even">
<td>Normal</td>
<td><p>Cardiogenic Shock</p>
<p>Cool Extremities</p>
<p>Renal Failure</p>
<p>Narrow PP</p></td>
<td><p>Cold and Dry</p>
<p>Forrester Class III</p>
<p>Tx: Inotropes</p></td>
<td><p>Cold and Wet</p>
<p>Forrester Class IV</p>
<p>Tx: Diuresis +Tailored therapy (+/- vasodilators, inotropes)</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-chf-management">Management<a class="headerlink" href="#cardiology-cardiology-chf-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Telemetry, Daily STANDING weights, 2 L fluid restriction, 2g sodium
    diet, strict I/Os</li>
<li>Diuresis: Place on 2.5 x home dose of IV diuretic, dose BID-TID
    (DOSE Trial)</li>
<li>Goal is to be net negative (generally 1-2 L per day but patient
    dependent)</li>
<li>Check BMP BID and Mg QD, keep K>4 and Mg>2</li>
<li>Low threshold for substantial increase (double) in loop vs
    transition to drip if not diuresing adequately</li>
<li>Can also augment with sequential nephron blockade (thiazides,
    acetazolamide)</li>
<li>Continuation/optimization of GDMT (below)</li>
</ul>
<hr />
<h1 id="cardiology-cardiology-chf-guideline-directed-medical-therapy-for-hfref">Guideline-Directed Medical Therapy for HFrEF<a class="headerlink" href="#cardiology-cardiology-chf-guideline-directed-medical-therapy-for-hfref" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-chf-general-principles">General Principles<a class="headerlink" href="#cardiology-cardiology-chf-general-principles" title="Permanent link">&para;</a></h2>
<ul>
<li>Starting patients on low dose of multiple agents preferred to max
    dose of single agent</li>
<li>D/C summary should have discharge weight, diuretic regimen, and
    renal function</li>
<li>Daily weights at home with rescue diuretic plan (pm dose for 3 lbs
    in 1 day, 5 lbs in 3 days</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Indication</th>
<th>Mechanism/ Benefits</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td colspan="4">Beta Blockers</td>
</tr>
<tr class="even">
<td><p>Carvedilol</p>
<p>Metoprolol succinate</p>
<p>Bisoprolol</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Reduces catecholamine stimulation. Decreased HR, myocardial energy
demand, less adverse remodeling.</td>
<td><p>Avoid if pt is decompensated (cold); “start low and go slow”</p>
<p>Can continue during exacerbation if patient compensated</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARNIs</td>
</tr>
<tr class="even">
<td>Sacubitril/ valsartan</td>
<td><p>HFrEF &lt; 40%</p>
<p>NYHA class II – IV</p>
<p>Used in place of ACE/ARB</p></td>
<td>Prevents vasoactive natriuretic peptide degradation involved in
pathogenesis of HF (+ action of ARB)</td>
<td><p>Need a 36 hr wash-out period if transitioning from ACEi to
ARNI</p>
<p>Hypotension</p>
<p>Risk of angioedema</p></td>
</tr>
<tr class="odd">
<td colspan="4">ACEIs</td>
</tr>
<tr class="even">
<td><p>Lisinopril</p>
<p>Enalapril</p>
<p>Captopril</p>
<p>Ramipril</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Blocks harmful effects of RAAS activation and attenuates adverse
cardiac and vascular remodeling</td>
<td><p>Risk of angioedema</p>
<p>Monitor renal function and K</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARBs</td>
</tr>
<tr class="even">
<td><p>Losartan</p>
<p>Valsartan</p>
<p>Candesartan</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>See ACEIs</td>
<td><p>See ACEIs</p>
<p>Preference for ARB &gt; ACEi if plans to start ARNI</p></td>
</tr>
<tr class="odd">
<td colspan="4">MRAs</td>
</tr>
<tr class="even">
<td><p>Eplerenone</p>
<p>Spironolactone</p></td>
<td><p>NYHA class II-IV and</p>
<p>GFR &gt;30</p></td>
<td>Diuretic and blood pressure lowering effects and blocks deleterious
effects of aldosterone on the heart (including hypertrophy and
fibrosis)</td>
<td>Hyperkalemia – avoid if CrCl &lt;30 or K &gt;5</td>
</tr>
<tr class="odd">
<td colspan="4">SGLT2i</td>
</tr>
<tr class="even">
<td><p>Dapagliflozin</p>
<p>Empagliflozin</p></td>
<td><p>HFrEF &lt;40% with and without DM</p>
<p>NYHA class II-IV</p>
<p>In conjunction with background GDMT</p></td>
<td>Osmotic diuresis and natriuresis, improve myocardial metabolism,
inhibit sodium-hydrogen exchange in myocardium, reduce cardiac
fibrosis</td>
<td><p>UTI/ GU infections</p>
<p>Risk of ketoacidosis (both DKA and euglycemic)</p></td>
</tr>
<tr class="odd">
<td colspan="4">Vasodilators</td>
</tr>
<tr class="even">
<td><p>Hydralazine</p>
<p>Isosorbide Dinitrate</p></td>
<td><p>Persistently symptomatic black patients despite ARNI/ BB/ MRA/
SGLT2i</p>
<p>NYHA class III-IV</p></td>
<td><p>Reduces cardiac afterload and preload and may also enhance nitric
oxide bioavailability</p>
<p>Reduction in mortality for African American patients</p></td>
<td>Hypotension</td>
</tr>
<tr class="odd">
<td colspan="4">Ivabradine</td>
</tr>
<tr class="even">
<td>Ivabradine</td>
<td><p>HFrEF &lt;35%, on maximally tolerated BB, sinus rhythm with HR
&gt; 70</p>
<p>NYHA class II or III</p></td>
<td><p>If current inhibitor involved in SA node activity</p>
<p>Decr HR associated with improved outcomes</p></td>
<td><p>Need sinus rhythm</p>
<p>Caution in sinus node disease and conduction defects</p></td>
</tr>
<tr class="odd">
<td colspan="4">Iron Repletion (IV)</td>
</tr>
<tr class="even">
<td><p>Iron sucrose</p>
<p>Ferric carboxymaltose</p>
<p>Iron dextran</p></td>
<td>Ferritin &lt;100 µg/L or ferritin 100-299 µg/L AND transferrin
saturation &lt;20%</td>
<td><p>Decreases HF hospitalizations</p>
<p>Improves exercise function and QOL</p></td>
<td>Risk of anaphylaxis higher in iron dextran</td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-chf-device-therapies-after-optimization-of-medical-gdmt">Device therapies (after optimization of medical GDMT)<a class="headerlink" href="#cardiology-cardiology-chf-device-therapies-after-optimization-of-medical-gdmt" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac resynchronization therapy (CRT)<ul>
<li>Class I indication: NYHA class II to IV, LVEF ≤35% with QRS ≥150 ms
and left bundle branch block (LBBB)</li>
<li>Class II (consider) If EF \&lt; 35% and:<ul>
<li>QRSd > 150, without LBBB</li>
<li>AF that requires ventricular pacing and AVN ablation</li>
<li>Undergoing placement of device with anticipation of >40%
ventricular pacing</li>
</ul>
</li>
</ul>
</li>
<li>ICD<ul>
<li>Class I indication: NYHA class II – VI with LVEF \&lt;35% (must have
>1yr expected survival and 40+ days from MI)</li>
</ul>
</li>
<li>Mitra Clip<ul>
<li>Criteria: moderate to severe mitral regurgitation (3-4+), on
maximally tolerated GDMT, an ejection fraction >20%, and a left
ventricle end-systolic dimension of less than 7 cm</li>
</ul>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-ekg"><h1 id="cardiology-cardiology-ekg-approach-to-the-ecg">Approach to the ECG<a class="headerlink" href="#cardiology-cardiology-ekg-approach-to-the-ecg" title="Permanent link">&para;</a></h1>
<p>Melis Sahinoz</p>
<hr />
<p>Method = mastery, approach each EKG the same.</p>
<h2 id="cardiology-cardiology-ekg-rate">Rate<a class="headerlink" href="#cardiology-cardiology-ekg-rate" title="Permanent link">&para;</a></h2>
<ul>
<li>Regular rhythms = “Rule of 300” = 300 ÷ (large boxes between QRS
    complexes)</li>
<li>300, 150, 100, 75, 60, 50</li>
<li>Irregular rhythms or severe bradycardia = (total number of QRS
    complexes on ECG) x 6</li>
</ul>
<h2 id="cardiology-cardiology-ekg-rhythm">Rhythm<a class="headerlink" href="#cardiology-cardiology-ekg-rhythm" title="Permanent link">&para;</a></h2>
<ul>
<li>Determine regular vs irregular: calipers or march out QRS complexes
    on paper</li>
<li>Criteria for Sinus rhythm: P before every QRS; Upright P in Lead I,
    II; Negative in aVr</li>
</ul>
<h2 id="cardiology-cardiology-ekg-axis">Axis<a class="headerlink" href="#cardiology-cardiology-ekg-axis" title="Permanent link">&para;</a></h2>
<ul>
<li>Normal: - 30<sup>o</sup> to + 90<sup>o</sup></li>
<li>Quick method: Leads I and II</li>
<li>Normal Axis: Upright in I and II</li>
<li>Left Axis Deviation: Upright in I, down in II<ul>
<li>Causes: LVH, LBBB, Left anterior fascicular block, prior
    inferior MI</li>
</ul>
</li>
<li>Right Axis Deviation: Down in I, up in II<ul>
<li>Causes: RVH, RBBB, Left posterior fascicular block, prior
    lateral MI, PE</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-ekg-intervals">Intervals<a class="headerlink" href="#cardiology-cardiology-ekg-intervals" title="Permanent link">&para;</a></h2>
<ul>
<li>PR Interval: normal 120 – 200 ms<ul>
<li>If \&lt; 120 ms, consider pre-excitation with accessory pathway (i.e.
    WPW)</li>
<li>If > 200 ms, first degree AV block</li>
</ul>
</li>
<li>QRS Complex: 60 – 100 ms (normal)<ul>
<li>100-120 ms: Incomplete BBB or non-specific intraventricular
    conduction delay (IVCD)</li>
<li>> 120ms: complete BBB, ventricular tachycardia, hyperkalemia</li>
</ul>
</li>
<li>QT interval: Normal duration \&lt; 450ms in men and \&lt; 460ms in women<ul>
<li>QT is inversely proportional to HR (QT interval shortens at faster
    HRs)</li>
<li>Quick estimate: normal QT is less than half the preceding RR
    interval</li>
<li>QTc estimates the QT interval at a HR of 60 bpm (to allow for
    comparison across HRs)</li>
<li>A couple formulas exist to calculate QTc:<ul>
<li>QTcB= most commonly used due to simplicity, most accurate HR of
    60</li>
<li>QTcF= more accurate when HR is outside the range of 60-100</li>
</ul>
</li>
<li>Clinically significant when generally QTc > 500 ms</li>
<li>Causes of Prolonged QTc: hereditary, medication-induced
    (anti-emetics, ABX, psychiatric meds), hypokalemia, hypomagnesemia,
    hypocalcemia, ischemia</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-ekg-morphology">Morphology<a class="headerlink" href="#cardiology-cardiology-ekg-morphology" title="Permanent link">&para;</a></h2>
<ul>
<li>P wave: P waves in limb leads should be ≤2.5 small box high and ≤2.5
    small box wide<ul>
<li>Right Atrial Enlargement: Peaked P Wave in Lead II that measures
    >2.5 mm</li>
<li>Left Atrial Enlargement<ul>
<li>Lead II: Bifid P Wave (two humps) with total duration > 110 ms</li>
<li>Lead V1: Biphasic P wave, terminal deflection > 1mm wide and
    deep</li>
</ul>
</li>
<li>If ≥ 3 different P wave morphologies in same lead: wandering atrial
    pacemaker (HR \&lt; 100) or multifocal atrial tachycardia (HR > 100)</li>
</ul>
</li>
<li>QRS complex<ul>
<li>Voltage<ul>
<li>Low voltage: QRS amplitude \&lt; 5mm in limb leads or \&lt; 10mm in
    precordial<ul>
<li>Causes: pericardial effusion, infiltrative cardiomyopathy,
    obesity</li>
</ul>
</li>
<li>Right Ventricular Hypertrophy: Tall R Waves in V1 (> 7mm) and
    right axis deviation</li>
<li>Left Ventricular Hypertrophy: multiple criteria exist<ul>
<li>Sokolow-Lyon criteria is a common example: S in V1 + R in V5
    or V6 >35mm, R in aVL <u>></u>1.1 mV</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Conduction delays<ul>
<li>RBBB: Wide QRS and RSR’ in V1 or V2; deep broad S In lateral
    leads</li>
<li>LBBB: Wide QRS, large S in V1, broad monophasic R wave in
    lateral leads (I, aVL, V6)</li>
</ul>
</li>
<li>R wave progression<ul>
<li>R wave normally gets progressively larger from V1 to V6</li>
<li>If the transition does not occur by V4, this is called "poor R
    wave progression". This is seen in chronic lung disease, LVH,
    left anterior fascicular block, and anterior MI.</li>
</ul>
</li>
<li>Q-wave: Small Q waves are normal in most leads<ul>
<li>Never normal in V1-V3</li>
<li>Pathologic Q waves: > 1 box wide and 2 boxes deep or > 25% height
    of R wave</li>
</ul>
</li>
<li>ST Segment<ul>
<li>ST Elevation: STEMI, LBBB (ST elevation in leads with deep S waves),
    LVH, Ventricular paced rhythm, Pericarditis (associated with PR
    depression), coronary vasospasm, Brugada syndrome</li>
<li>ST Depression: ischemia, reciprocal change in STEMI, posterior
    myocardial infarction (V1-V3), digoxin, hypokalemia</li>
<li>See ACS section for STEMI criteria, Wellens Syndrome</li>
</ul>
</li>
<li>T wave<ul>
<li>Normal T waves are upright in all leads except aVR and V1</li>
<li>Inverted T Waves<ul>
<li>Acute ischemia (if present in contiguous leads), LBBB (in
    lateral leads), RBBB (V1-V3), LVH (‘strain’ pattern similar to
    LBBB), RVH (RV ‘strain’ in V1-V3 or inferior leads), PE (right
    heart strain or part of S1,Q3,T3), intracranial pathology</li>
</ul>
</li>
<li>Peaked T Waves<ul>
<li>Hyperkalemia vs ‘hyperacute’ T waves that precede ST elevation
    and Q waves in STEMI</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-inpatient-hypertension"><h1 id="cardiology-cardiology-inpatient-hypertension-inpatient-hypertension">Inpatient Hypertension<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-inpatient-hypertension" title="Permanent link">&para;</a></h1>
<p>Lee Richardson</p>
<hr />
<h2 id="cardiology-cardiology-inpatient-hypertension-background">Background<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Hypertensive urgency: SBP > 180mmHg/DBP > 120mmHg</li>
<li>Hypertensive emergency: SBP > 180mmHg/DBP > 120mmHg + end organ
    damage</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Are there signs/symptoms of end organ damage?</li>
<li>Neurologic symptoms: agitation, delirium, stupor, seizures, visual
    disturbances</li>
<li>Focal neurologic deficits</li>
<li>Chest pain</li>
<li>Back pain (consider aortic dissection)</li>
<li>Dyspnea (consider pulmonary edema)</li>
<li>BMP, LFTs, Troponin, BNP: Lab findings suggestive of end-organ
    damage</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-management">Management<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Goal is to lower BP back to normal over 24-48 hours</li>
<li>Initial lowering should be 10-20% in minutes if HTN emergency; goal
    should be 10-20% in 2-4 hours if HTN urgency</li>
<li>Typically aim for initial goal BP near 160/110</li>
<li>Exceptions to gradual lowering include:<ul>
<li>Acute stroke: call code stroke, lower ONLY if BP > 185/110 in
    pts under consideration for reperfusion therapy; or BP >
    220/120 in pts not candidates for reperfusion therapy</li>
<li>Aortic dissection: Goal = rapidly lower BP in minutes to target
    of 100-120 systolic to avoid aortic shearing forces</li>
</ul>
</li>
<li>Pharmacologic therapy<ul>
<li>If pt was previously on anti-HTN meds, ensure their home medicines
    have been restarted at appropriate doses, formulation (long acting
    vs. short), and dosing intervals</li>
<li>If pt has a rapid acting anti-HTN med, can consider giving a dose
    early or an “extra dose” and then up titrating their overall daily
    dose</li>
</ul>
</li>
<li>Rescue therapies<ul>
<li>Captopril PO (12.5mg or 25mg dosed Q8H; conversion ratio of
    captopril:lisinopril = 5:1)</li>
<li>Hydralazine PO (10-20mg initial dosing Q6H)</li>
<li>Isosorbide dinitrate PO (5-20mg TID)</li>
<li>Nifedipine XL PO (dose at 30mg initially, max 90 mg BID; NOT
    sublingual)</li>
<li>Labetalol IV (10-40mg initially; dosed up to every 20-30mins)</li>
<li>Hydralazine IV (10-20mg initially; dosed up to every 30 mins).</li>
<li>Nitropaste 1” (can add/wipe away for titration; dose Q6H until
    oral meds can be started for better long-acting control)</li>
</ul>
</li>
<li>Dialysis if missed session</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-additional-information">Additional Information<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Refractory HTN: try additional agents listed above vs. escalation of
    care for drip (nicardipine, nitroglycerin, nitroprusside, esmolol).</p>
</li>
<li>
<p>Most drips that can be done for this indication are done in stepdown
    and usually require no-titration of the infusion and occasionally
    the MD to be bedside to initiate the infusion.</p>
</li>
<li>
<p>This includes diltiazem, labetalol, nitroglycerin, and verapamil
    drips. Nicardipine, esmolol, and nitroprusside drips are not allowed
    on step down.</p>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-pe"><h1 id="cardiology-cardiology-pe-pulmonary-embolism">Pulmonary Embolism<a class="headerlink" href="#cardiology-cardiology-pe-pulmonary-embolism" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="cardiology-cardiology-pe-background">Background<a class="headerlink" href="#cardiology-cardiology-pe-background" title="Permanent link">&para;</a></h2>
<p>A thrombus originating in a deep vein (LE > UE) embolizing to the
    pulmonary arterial circulation.</p>
<ul>
<li>Risk Factors = Virchow’s Triad<ul>
<li>Stasis: immobilization, hospitalization, spinal cord injury, or long
    travel</li>
<li>Hypercoagulable state: cancer, prothrombotic genetic conditions such
    as Factor V Leiden, OCPs, antiphospholipid syndrome, nephrotic
    syndrome, pregnancy, infection, etc.</li>
<li>Endothelial Injury: surgery, trauma</li>
</ul>
</li>
</ul>
<p>Most originate from a DVT in the iliac, femoral, and popliteal veins</p>
<h2 id="cardiology-cardiology-pe-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-pe-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Dyspnea and tachypnea</li>
<li>Respiratory alkalosis on blood gas from hyperventilation</li>
<li>Hypoxemia</li>
<li>Sinus Tachycardia or atrial arrhythmias</li>
<li>Hemoptysis</li>
<li>Lower extremity pain, swelling, and redness – occurs in 50% of pts
    with DVT</li>
<li>RV Failure (large PE) – elevated JVP, hypotension, syncope, R
    parasternal heave, accentuated P2, hepatomegaly</li>
</ul>
<h2 id="cardiology-cardiology-pe-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-pe-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>If hemodynamically unstable and PE suspected, provide hemodynamic
    support (ie. O2, pressors, etc.) and perform emergent bedside TTE</li>
<li>
<p>If no RV strain evident on TTE, low likelihood of hemodynamically
    significant PE. Consider other causes of shock.</p>
</li>
<li>
<p>Hemodynamically stable</p>
<ul>
<li>EKG<ul>
<li>Most commonly sinus tachycardia</li>
<li>Less commonly and indicative of large PE: RAD, RVH, RBBB, RA
    enlargement, S1Q3T3 (deep S in lead I, deep Q and inverted T in
    lead III), TWI in V1-V3</li>
</ul>
</li>
<li>CXR: Typically normal. May see linear atelectasis, pleural effusion,
    PA cutoff sign</li>
<li>Labs: ABG, troponin, BNP</li>
<li>May consider lower extremity dopplers</li>
<li>Imaging vs d-dimer based on pre-test probability:<ul>
<li>Low pre-test probability (use Wells Criteria) d-dimer</li>
<li>For moderate to high pre-test probability CTA Chest PE protocol<ul>
<li>If high pre-test probability or moderate pre-test
    probability with >4 hour delay in work-up, start empiric
    anticoagulation if bleeding risk is acceptable while work-up
    is ongoing</li>
</ul>
</li>
</ul>
</li>
<li>TTE</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-pe-management">Management<a class="headerlink" href="#cardiology-cardiology-pe-management" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>PE Class:</th>
<th>Low risk</th>
<th>Submassive</th>
<th>Massive</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Definition</td>
<td><p>Hemodynamically stable</p>
<p>No evidence of right heart strain or myocardial necrosis on labs or
TTE</p></td>
<td><p>Hemodynamically stable</p>
<p>Evidence of right heart strain or myocardial necrosis: RV strain on
TTE (ex: D-sign), BNP &gt;150, trop &gt;0.05</p></td>
<td><p>Hemodynamically unstable (ex: SBP&lt;90)</p>
<p>Evidence of RV strain</p></td>
</tr>
<tr class="even">
<td>Management</td>
<td><p>Start anticoagulation</p>
<p>LWH or heparin gtt (if renal impairment)</p>
<p>Can also use NOAC. Rivaroxaban &amp; apixaban can be used as initial
management. Edoxaban &amp; dabigatran can be used after 5-10 days of
parenteral therapy</p></td>
<td><p>Provide hemodynamic support, monitor for decompensation</p>
<p>Start anticoagulation with unfractionated heparin gtt</p>
<p>STAT consult cardiology for consideration of catheter directed
thrombolysis (EKOS) or embolectomy</p></td>
<td><p>Provide hemodynamic support.</p>
<p>Start anticoagulation with unfractionated heparin gtt</p>
<p>Page CCU fellow STAT. Consider systemic tPA (this is a
fellow/attending level decision).</p>
<p>Discuss with cardiology catheter directed thrombolysis (EKOS) or
embolectomy</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-pe-tpa-considerations">tPA Considerations<a class="headerlink" href="#cardiology-cardiology-pe-tpa-considerations" title="Permanent link">&para;</a></h2>
<ul>
<li>Dose is 100mg tPA over 2hrs</li>
<li>Most effective within 24 hours but effective up to 14d</li>
<li>Contraindications:<ul>
<li>Absolute:<ul>
<li>CNS Pathology: hemorrhagic or ischemic CVA within 3 mo, AVM,
    CNS neoplasm, recent surgery</li>
<li>Trauma: Recent head trauma w/ fx or injury</li>
</ul>
</li>
<li>Relative<ul>
<li>Surgery: surgery w/in 3 wks</li>
<li>Heme: active bleeding, bleeding diathesis, plt \&lt; 100, oral
    AC</li>
<li>Age: >75 yo, dementia</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-pe-long-term-management">Long-term management<a class="headerlink" href="#cardiology-cardiology-pe-long-term-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Anticoagulation: see “Venous Thromboembolism” in Hematology/Oncology</li>
</ul></section><section class="print-page" id="cardiology-cardiology-rhc"><h1 id="cardiology-cardiology-rhc-right-heart-catheterization">Right Heart Catheterization<a class="headerlink" href="#cardiology-cardiology-rhc-right-heart-catheterization" title="Permanent link">&para;</a></h1>
<p>Pakinam Mekki</p>
<hr />
<h2 id="cardiology-cardiology-rhc-background">Background<a class="headerlink" href="#cardiology-cardiology-rhc-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Pulmonary artery catheter (PAC): Multilumen catheter that sits in
    the right heart to provide invasive measurement of hemodynamic
    parameters</li>
<li>Indications for PAC placement<ul>
<li>Diagnose undifferentiated shock</li>
<li>Severe cardiogenic shock</li>
<li>Diagnose pulmonary hypertension</li>
<li>Diagnose left -> right shunting</li>
<li>Diagnose valvular and pericardial disease</li>
<li>Titrating medications, specifically inotropes, pulmonary
    vasodilators, diuresis</li>
</ul>
</li>
<li>Contraindications to PAC placement<ul>
<li>RA/RV mass or thrombi</li>
<li>Tricuspid or pulmonic valve endocarditis</li>
<li>Mechanical tricuspid or pulmonic valves</li>
<li>Presence of RV assist device</li>
</ul>
</li>
<li>Complications of PAC placement<ul>
<li>Arrythmias: VT, RBBB, 3<sup>rd</sup> degree AV block if preexisting LBBB</li>
<li>Infection (endocarditis of the pulmonary valve)</li>
<li>Bleeding</li>
<li>Pulmonary embolism and pulmonary Infarct</li>
<li>Pneumothorax</li>
<li>Air embolism</li>
<li>Pulmonary artery perforation / rupture</li>
<li>Endocardial/valvular damage</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-rhc-pac-pressure-tracings">PAC Pressure Tracings<a class="headerlink" href="#cardiology-cardiology-rhc-pac-pressure-tracings" title="Permanent link">&para;</a></h2>
<figure>
<p><img alt="image" src="../images/image7.png" /></p>
</figure>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 23%" />
<col style="width: 17%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Definition</th>
<th>Normal "Rule of 5s"</th>
<th><blockquote>
<p>Interpretation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Central Venous Pressure</p>
<p>(CVP)</p></td>
<td>Pressure in superior vena cava, often an indicator of volume
status</td>
<td>0 - 5 mmHg</td>
<td>Elevated CVP is indicative of cardiac dysfunction and/or fluid
retention<br />
<br />
Low CVP is indicative of volume depletion or decreased venous tone</td>
</tr>
<tr class="even">
<td>Right Atrial Pressure (RAP)</td>
<td>Surrogate for preload, should be same as CVP</td>
<td>0 - 5 mmHg</td>
<td>Elevated with disruption in forward cardiac flow or increase in
intravascular volume</td>
</tr>
<tr class="odd">
<td>Right Ventricle Pressure (</td>
<td>Right ventricular systolic and diastolic pressures; RVSP can be
surrogate for PASP</td>
<td>25/5 mmHg</td>
<td>Elevated with diseases that elevate PA pressure and pulmonic valve
disorders. Severe RVP elevations are generally chronic while acute
conditions typically have RVSP &lt;40-50.</td>
</tr>
<tr class="even">
<td>Pulmonary Artery Pressure (PAP)</td>
<td>Measured as systolic, diastolic, and mean pressures. Diagnoses
pHTN.</td>
<td><p>25/10 mmHg</p>
<p>Mean: 10 - 19 mmHg</p></td>
<td>Elevated In acute conditions (PE, hypoxemia induced pulmonary
vasoconstriction) or pHTN (mean PAP &gt; 20 mm Hg)</td>
</tr>
<tr class="odd">
<td>Pulmonary Artery Wedge Pressure (PAWP or wedge)</td>
<td>Pressure measured by wedging the PAC into a small pulmonary arterial
branch; surrogate for left atrial pressures and LVEDP</td>
<td>10 mm Hg</td>
<td>Increased with elevated LVEDP: systolic or diastolic heart failure,
mitral and aortic valve disorders, hypervolemia, R to L shunts,
tamponade, constrictive/restrictive cardiomyopathy</td>
</tr>
<tr class="even">
<td>Thermodilution Cardiac Output &amp; Index</td>
<td>Amount of blood pumped in one min. CI is the cardiac output divided
by body surface area (to standardize for body size)</td>
<td><p>CO: 3.4-15 L/min</p>
<p>CI: 2.8-4.2 L/min/m^2</p></td>
<td><p>Low CI: systolic/diastolic heart failure, severe valvular
disorder (MR, AS), RV failure, pHTN, cardiogenic shock.</p>
<p>Elevated CI (high-output state): sepsis, anemia, thyrotoxicosis, A-V
shunt</p></td>
</tr>
<tr class="odd">
<td><p>Mixed central venous oxyhemoglobin</p>
<p>saturation (SvO2)</p></td>
<td>% of oxygen bound to Hgb in blood returning to the right side of the
heart, reflects total body O2 extraction</td>
<td>65-70%</td>
<td><p>High SvO2 (&gt; 65%) = decreased O2 demand or “high flow” states
seen in distributive shock (sepsis)</p>
<p>Low SvO2 (&lt; 50%) = decreased O2 delivery seen in cardiogenic or
hypovolemic shock. In low SvO2 states, there is less O2 supply to same
demand)</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-rhc-calculating-hemodynamic-parameters-from-pac-pressures">Calculating Hemodynamic Parameters from PAC Pressures<a class="headerlink" href="#cardiology-cardiology-rhc-calculating-hemodynamic-parameters-from-pac-pressures" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 29%" />
<col style="width: 19%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Definition</th>
<th>Normal Values</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fick CO and CI</td>
<td>Calculated CO based on Oxygen consumption (VO2), Hbg, and O2 sats of
arterial and venous blood</td>
<td><p>4-7 L/min</p>
<p>2.5-4 L/min/m<sup>2</sup></p></td>
<td>See "Cardiac Index" above.</td>
</tr>
<tr class="even">
<td>Systemic Vascular Resistance (SVR)</td>
<td>Measurement of afterload; helpful in delineating the etiology of
shock as well as guiding afterload-reduction therapy in HFrEF</td>
<td>700-1200 dynes*s*cm<sup>-5</sup></td>
<td><p>Elevated SVR is seen in hypovolemic, cardiogenic, and obstructive
shock</p>
<p>Decreased SVR is seen in distributive shock (sepsis, anaphylaxis,
neurogenic)</p></td>
</tr>
<tr class="odd">
<td>Transpulmonary gradient (TPG)</td>
<td>Differentiates between pre- and post-capillary pulmonary
hypertension.</td>
<td>&lt; 12 mmHg</td>
<td>A TPG value greater than 12 mmHg indicates that a component of the
pHTN is secondary to pulmonary vascular disease</td>
</tr>
<tr class="even">
<td>Pulmonary Vascular Resistance (PVR)</td>
<td>Gold standard in the estimation of the severity of pre-capillary
pHTN<br />
<br />
Reflects the pressure drop across the pulmonary system only and is
independent of the LA, mitral valve and the LV</td>
<td><p>&lt; 3 Wood Units</p>
<p>30-90 dynes*sec*cm<sup>5</sup></p></td>
<td><p>Elevated PVR (&gt;3 Wood units) suggests pre-capillary pHTN</p>
<p>Normal PVR seen in pulmonary venous hypertension (diastolic
dysfunction)</p></td>
</tr>
<tr class="odd">
<td>Pulmonary artery pulsatility index (PAPi)</td>
<td>Pulmonary pulse pressure relative to preload (RAP), Indicator of RV
function</td>
<td>&gt; 0.9</td>
<td>PAPi &lt; 0.9 predicts in-hospital mortality and/or need for RVAD in
acute MI. Can be decreased in pure RV failure or biventricular
failure</td>
</tr>
<tr class="even">
<td>Cardiac Power</td>
<td>Cardiac output relative to afterload, a measure of LV contractile
reserve</td>
<td>Normal &gt; 1</td>
<td><p>CP&lt; 0.6 strongly suggestive of LV failure</p>
<p>Found to be a strong independent hemodynamic correlate in pts with
cardiogenic shock. Predictor of mortality in CCU</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-shock"><h1 id="cardiology-cardiology-shock-cardiogenic-shock">Cardiogenic Shock<a class="headerlink" href="#cardiology-cardiology-shock-cardiogenic-shock" title="Permanent link">&para;</a></h1>
<p>Ashley Cozart</p>
<hr />
<h2 id="cardiology-cardiology-shock-definition">Definition<a class="headerlink" href="#cardiology-cardiology-shock-definition" title="Permanent link">&para;</a></h2>
<p>Impairment of cardiac output due to primary cardiac disorder that
    results in end-organ hypoperfusion and hypoxia</p>
<h2 id="cardiology-cardiology-shock-etiology">Etiology<a class="headerlink" href="#cardiology-cardiology-shock-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiomyopathic: myocardial infarction with LV dysfunction,
    exacerbation of heart failure, myocarditis, myocardial contusion,
    drug-induced</li>
<li>Arrhythmic: atrial tachycardias (atrial fibrillation/flutter, AVRT,
    AVNRT), ventricular tachycardia and fibrillation, complete heart
    block, second degree heart block</li>
<li>Mechanical: valvular insufficiency, valvular rupture, critical
    valvular stenosis, ventricular septal wall defect, ruptures
    ventricular wall aneurysm, atrial myxoma</li>
</ul>
<h2 id="cardiology-cardiology-shock-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-shock-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Cold (decreased perfusion) due to reduced cardiac output (can be
    wet- increased PCWP OR dry normal PCWP)</li>
<li>Symptoms of volume overload + end-organ hypoperfusion (altered
    mental status, nausea, abdominal pain, decreased urine output)</li>
<li>Hypotension; narrow pulse pressure</li>
</ul>
<h2 id="cardiology-cardiology-shock-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-shock-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG</li>
<li>Labs: CBC, CMP, BNP, troponin, lactate</li>
<li>Evidence of end organ damage: lactic acidosis, acute kidney injury,
    acute liver injury</li>
<li>Echocardiogram: assess EF and valves</li>
<li>LHC If ischemia (see ACS)</li>
<li>Hemodynamic monitoring via Swan-Ganz or PA catheter:<ul>
<li>No benefit for general shock but does improve in-hospital mortality
for those with cardiogenic shock</li>
<li>PA catheter hemodynamic profile:<ul>
<li>Cardiac index \&lt; 2.2, cardiac power \&lt;0.6, SVR 800-1600, SVO2
\&lt;60%</li>
<li>LV-dominant: RA (CVP) \&lt;15, PCWP >18, PAPi >1.5 (pulmonary
artery pulsatility index)</li>
<li>RV-dominant: RA >15, PCWP \&lt;18, PAPi >1.5</li>
<li>Bi-V-dominant: RA >15, PCWP >18, PAPi >1.5</li>
<li>PAPi \&lt; 1 indicates that patient will likely need RV support</li>
<li>CP \&lt; 0.5 strongest independent hemodynamic correlate of
mortality in CS</li>
<li>See right heart cath section for interpreting PA catheter
profiles</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-shock-management-medical-mechanical-circulatory-support">Management (medical &amp; mechanical circulatory support)<a class="headerlink" href="#cardiology-cardiology-shock-management-medical-mechanical-circulatory-support" title="Permanent link">&para;</a></h2>
<h3 id="cardiology-cardiology-shock-medical-management">Medical management<a class="headerlink" href="#cardiology-cardiology-shock-medical-management" title="Permanent link">&para;</a></h3>
<p>Focus on optimizing preload, afterload, and contractility.</p>
<ul>
<li>Preload: IV diuresis</li>
<li>Afterload: IV – nitroglycerine, nitroprusside; PO – hydralazine,
    isosorbide dinitrate; vasoconstricting pressors (phenylephrine,
    vasopressin) if needing BP support</li>
<li>Contractility - Inodilators (increase contractility, decrease
    afterload – milrinone, dobutamine) or inoconstrictors (increase
    contractility and afterload – epinephrine, norepinephrine)</li>
</ul>
<h3 id="cardiology-cardiology-shock-mechanical-circulatory-support-indications">Mechanical circulatory support indications<a class="headerlink" href="#cardiology-cardiology-shock-mechanical-circulatory-support-indications" title="Permanent link">&para;</a></h3>
<ul>
<li>Shock refractory to >1 pressor</li>
<li>Shock 2/2 MI (physiology: unloads LV, increases systemic perfusion,
    increases myocardial perfusion, and provides hemodynamic support
    during PCI)</li>
</ul>
<p>Types of mechanical circulatory support (MCS)</p>
<table>
<colgroup>
<col style="width: 6%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 22%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Intra-aortic Balloon Pump</th>
<th>V-A ECMO</th>
<th>Tandem Heart</th>
<th>Impella</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Dynamics</td>
<td>Inflates during diastole, deflates during systole</td>
<td>Blood from femoral vein is oxygenated and pumped to femoral
artery</td>
<td><p>LV: blood aspirated from LA to femoral artery</p>
<p>RV: blood aspirate from RA to PA</p></td>
<td><p>Impella 2.5, 5.0 &amp; CP: Blood aspirated from LV to aortic
root</p>
<p>Impella RP: Blood aspirated from IVC and delivered to PA</p></td>
</tr>
<tr class="even">
<td>Flow</td>
<td>1 LMP</td>
<td>4.5 LPM</td>
<td>4-5 LPM</td>
<td><p>2.5: 2.5 L/min</p>
<p>CP: 3.33 L/min</p>
<p>5.0: 5 L/min</p>
<p>RP: 4 L/min</p></td>
</tr>
<tr class="odd">
<td>Support</td>
<td>LV</td>
<td>BiV</td>
<td>LV, RV, or BiV</td>
<td>LV or RV (RP)</td>
</tr>
<tr class="even">
<td>Effects</td>
<td><p>Reduces afterload</p>
<p>Increases stroke volume (SV)</p>
<p>Increases coronary perfusion</p>
<p>Reduces LV preload and PCWP</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Reduces SV</p>
<p>Reduces preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
</tr>
<tr class="odd">
<td>Complications</td>
<td><p>Thrombocytopenia</p>
<p>Thrombosis</p>
<p>Arterial obstruction</p>
<p>Aortic rupture or dissection</p>
<p>Air embolism</p></td>
<td><p>Circuit thrombosis</p>
<p>LV dilation</p>
<p>Hypothermia</p>
<p>Gas embolism</p></td>
<td><p>Tamponade d/t perforation</p>
<p>Thrombosis</p>
<p>Embolism (gas or thrombus)</p>
<p>Arterial Shunt</p></td>
<td><p>Pump migration</p>
<p>Hemolysis</p>
<p>Aortic regurg</p>
<p>LV perf</p>
<p>VT/VF</p></td>
</tr>
</tbody>
</table>

<p>Daily management of MCS devices:</p>
<ul>
<li>Ensure optimal placement of device with daily CXR</li>
<li>Anticoagulation (based on device)</li>
<li>Hematoma monitoring at device site</li>
<li>Check distal pulses to monitor for limb ischemia</li>
</ul>
<p>Pearls for MCS</p>
<ul>
<li>MCS devices are contraindicated in following situations: aortic
    regurgitation or metallic aortic valve, aortic aneurysm or
    dissection, severe aortic or peripheral artery disease, left
    ventricular or left atrial thrombi, bleeding diathesis, uncontrolled
    sepsis</li>
<li>ECMO is placed by the cardiac surgery team, once a patient is
    cannulated they will move onto the cardiac surgery team</li>
<li>Impella, tandem heart, and IABPs are placed in the cath lab</li>
<li>MCS is a bridge to recovery/definitive therapy, durable cardiac
    support (VAD), or transplant</li>
</ul></section><section class="print-page" id="cardiology-cardiology-syncope"><h1 id="cardiology-cardiology-syncope-syncope">Syncope<a class="headerlink" href="#cardiology-cardiology-syncope-syncope" title="Permanent link">&para;</a></h1>
<p>Sarah Myers</p>
<hr />
<h2 id="cardiology-cardiology-syncope-background">Background<a class="headerlink" href="#cardiology-cardiology-syncope-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Definition: abrupt, transient loss of consciousness with rapid &amp;
    spontaneous recovery  </li>
<li>Presyncope – symptoms occurring before syncope including
    lightheadedness, tunnel vision/other visual disturbances</li>
</ul>
<h2 id="cardiology-cardiology-syncope-classification">Classification<a class="headerlink" href="#cardiology-cardiology-syncope-classification" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac syncope </li>
<li>Tachyarrhythmias: VT, SVT </li>
<li>Bradyarrhythmias: sinus node dysfunction, AV blocks (high grade) </li>
<li>Structural: Aortic Stenosis, HCM, cardiac tamponade, congenital
    anomalies, masses/tumors </li>
<li>Vascular: Pulmonary embolism, aortic dissection, severe pHTN </li>
<li>Noncardiac syncope</li>
<li>Reflex mediated<ul>
<li>Vasovagal; most common form of reflex mediated syncope<ul>
<li>Can occur sitting/standing or with trigger (stress, pain,
    medical settings)</li>
<li>Classically has prodrome of nausea, diaphoresis, tunnel
    vision followed by hypotension and/or bradycardia</li>
</ul>
</li>
<li>Situational (micturition/defecation/coughing)</li>
<li>Carotid sinus sensitivity syndrome</li>
</ul>
</li>
<li>Orthostatic</li>
<li>Medications (diuretics, nitrates/CCB/alpha blockers, TCAs)</li>
<li>Volume depletion (hemorrhage, dehydration)</li>
<li>Autonomic dysfunction</li>
</ul>
<h2 id="cardiology-cardiology-syncope-differential-diagnosis">Differential diagnosis<a class="headerlink" href="#cardiology-cardiology-syncope-differential-diagnosis" title="Permanent link">&para;</a></h2>
<ul>
<li>Seizure, stroke, metabolic derangements, Intoxication/withdrawal,
    hypoglycemia, head trauma</li>
<li>With rare exceptions, these do not result In complete LOC with
    spontaneous recovery</li>
</ul>
<h2 id="cardiology-cardiology-syncope-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-syncope-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>History and physical are essential for evaluation of a syncopal
    event </li>
<li>Characteristics associated with cardiac syncope </li>
<li>Male, >60, known structural/ischemic heart disease, brief/no
    prodrome, syncope while supine/at rest or during exercise, family hx
    of SCD/premature death, abnormal exam </li>
<li>Characteristics associated with noncardiac syncope</li>
<li>Younger age, syncope while standing or with positional changes,
    prodrome (nausea, vomiting, warmth), specific triggers, previous
    episodes that have been similar  </li>
</ul>
<h2 id="cardiology-cardiology-syncope-workup">Workup<a class="headerlink" href="#cardiology-cardiology-syncope-workup" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG on all patients with syncope, monitor those who are admitted on
    telemetry</li>
<li>CBC, CMP, troponin, BNP (If cardiac cause suspected), POC glucose,
    UDS, orthostatic VS</li>
<li>EEG and neuroimaging if concern for seizure activity or focal neuro
    deficit  </li>
<li>TTE and consider stress testing particularly in exertional syncope  </li>
</ul>
<h2 id="cardiology-cardiology-syncope-management">Management<a class="headerlink" href="#cardiology-cardiology-syncope-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac: managed as indicated based on pathology </li>
<li>
<p>If arrhythmia is suspected but not captured on admission, consider
    discharge with event monitor  </p>
</li>
<li>
<p>Noncardiac</p>
</li>
<li>
<p>Reflex</p>
<ul>
<li>Vasovagal- consider tilt table testing If recurrent or diagnosis
    not clear</li>
<li>Situational- mainly avoiding triggers</li>
<li>Carotid sinus syndrome- may require PPM</li>
</ul>
</li>
<li>
<p>Orthostatic</p>
<ul>
<li>Medication related<ul>
<li>Appropriate to hold potentially offending medications
    (diuretics, vasodilators) during evaluation</li>
<li>Monitor for worsening supine hypertension, arrhythmias, or
    heart failure when holding</li>
</ul>
</li>
<li>Volume depletion; resuscitate as appropriate</li>
<li>Autonomic dysfunction: see autonomics section</li>
</ul>
</li>
<li>
<p>Driving: TN law does not require any MD to inform the state of TLOC </p>
</li>
<li>Should still recommend patients not drive while work-up ongoing.
    Document all conversations about driving with patients</li>
</ul></section><section class="print-page" id="cardiology-cardiology-valvular-heart-disease"><h1 id="cardiology-cardiology-valvular-heart-disease-valvular-heart-disease">Valvular Heart Disease<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-valvular-heart-disease" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper, Marcus Threadcraft</p>
<hr />
<h1 id="cardiology-cardiology-valvular-heart-disease-aortic-stenosis">Aortic stenosis<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-aortic-stenosis" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper </p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>Degenerative calcification of the aortic cusps</li>
<li>Congenital bicuspid aortic valve</li>
<li>Chronic deterioration (calcific)</li>
<li>Prior rheumatic fever/inflammation</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Angina, syncope, exertional dyspnea, heart failure (HF carries worse
    prognosis)</li>
<li>Typically aged 70 – 80 y/o; if bicuspid aortic valve expect 10-20
    yrs earlier</li>
<li>Physical exam: Systolic crescendo-decrescendo murmur that radiates
    towards the carotids</li>
<li>Late peaking murmur, faint or absent S2, or delayed carotid upstroke
    suggest severe AS</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>TTE with doppler is test of choice</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 19%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th>Severity  </th>
<th>Valve Area (cm<sup>2</sup>) </th>
<th>Mean Gradient (mmHg) </th>
<th><p>Velocity  </p>
<p>(m/s) </p></th>
<th>Indexed Valve Area (cm<sup>2</sup>/m<sup>2</sup>)  </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mild  </td>
<td>&gt;1.5 </td>
<td>&lt;20 </td>
<td>2.0-2.9 </td>
<td>&gt;0.85 </td>
</tr>
<tr class="even">
<td>Moderate  </td>
<td>1.0-1.5 </td>
<td>20-39 </td>
<td>3.0-3.9 </td>
<td>0.60-0.85 </td>
</tr>
<tr class="odd">
<td>Severe </td>
<td>&lt;1.0 </td>
<td>&gt;40 </td>
<td>&gt;4.0 </td>
<td>&lt;0.6 </td>
</tr>
<tr class="even">
<td>Critical  </td>
<td>&lt;0.5 </td>
<td>-- </td>
<td>-- </td>
<td>-- </td>
</tr>
</tbody>
</table>

<p>AS stages</p>
<ul>
<li>A: at risk of AS (those with bicuspid anatomy or calcification</li>
<li>B: Asymptomatic non-severe AS</li>
<li>C: asymptomatic AS<ul>
<li>C1: normal EF</li>
<li>C2: abnormal EF<ul>
<li>This stage might benefit from exercise or stress testing to
  elicit symptoms</li>
</ul>
</li>
</ul>
</li>
<li>
<p>D: Symptomatic AS</p>
</li>
<li>
<p>Some with symptomatic AS might not have enough LV reserve to produce
    high velocities and gradients (ex EF of 10% w/ critical valve area)
    = low flow/low gradient AS; consider dobutamine to unmask AS</p>
</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management" title="Permanent link">&para;</a></h2>
<ul>
<li>No proven effective medical therapy</li>
<li>Definitive treatment is valve replacement for:<ul>
<li>Stage D</li>
<li>Stage C with inducible symptoms on stress testing, low EF, or
    undergoing other cardiac procedure</li>
<li>Rapid progression (increase in velocity >0.3m/sec per year)</li>
</ul>
</li>
<li>Consult cardiac surgery for determination of SAVR vs TAVR<ul>
<li>In general, high risk surgical patients benefit most from TAVR</li>
<li>At VUMC: If determined to be intermediate to high operative risk by
    Cardiac Surgery, they will often recommend contacting the TAVR team
    for evaluation</li>
</ul>
</li>
<li>Avoid rapid hemodynamic shifts and aggressive changes in preload or
    afterload</li>
<li>Aim for normotension<ul>
<li>Avoid preferential vasodilators such as
hydralazine or nitroglycerin</li>
<li>Significant vasodilation may ↓ coronary filling pressures ->
myocardial ischemia</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-monitoring">Monitoring<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-monitoring" title="Permanent link">&para;</a></h2>
<ul>
<li>Severe AS: TTE q 6-12 months</li>
<li>Moderate AS: TTE q 1-2 years</li>
<li>Mild AS: TTE q 3-5 years</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-post-avr-anticoagulation">Post AVR anticoagulation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-post-avr-anticoagulation" title="Permanent link">&para;</a></h2>
<ul>
<li>All patients will get 3-6 months of AC s/p AVR</li>
<li>Continued duration based on type of AVR<ul>
<li>Bioprosthetic (TAVR and some SAVRs): antiplatelets alone after
    Initial AC</li>
<li>Mechanical: lifelong AC with warfarin only</li>
</ul>
</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-aortic-regurgitation">Aortic Regurgitation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-aortic-regurgitation" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper </p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology_1">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Primary valve disease (rheumatic disease, bicuspid aortic valve,
    infective endocarditis, syphilis)</li>
<li>Primary aortic root disease (medial degeneration, aortic dissection,
    Marfan’s syndrome, bicuspid aortic valve, syphilis, non-syndromic
    familial)</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_1">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute AR: LV cannot respond to increased volume to maintain stroke
    volume pulmonary edema and cardiogenic shock</li>
<li>Chronic AR: indolent presentation, often patient will develop
    symptoms of heart failure including DoE, orthopnea, PND</li>
<li>Physical exam: “Water-hammer” pulses, wide pulse pressure, laterally
    displaced PMI, high pitched “blowing” decrescendo murmur best heard
    at third intercostal space at left sternal border, S3</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_1">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute severe AR<ul>
<li>Prompt surgical repair</li>
<li>Vasodilators such as nitroprusside and diuretics can be used to
    stabilize patient</li>
</ul>
</li>
<li>
<p>Chronic severe AR</p>
<ul>
<li>Medical management</li>
<li>Early symptoms of exercise intolerance can be treated with
    diuretics</li>
<li>Systolic BP should also be controlled with goal SBP \&lt; 140 in
    chronic AR</li>
</ul>
</li>
<li>
<p>Repeat imaging should be performed 3-6 month to assess for depressed
    LVEF or LV dilation</p>
</li>
<li>
<p>Stages of Chronic AR: Ranging from Stage (A): Asymptomatic but “At
    Risk” AR to Stage (D) Symptomatic Severe AR</p>
<ul>
<li>If symptoms are present, automatically Stage D, otherwise
    Progression through stages is determined by AR Jet Width</li>
</ul>
</li>
<li>Class I indications for Valve Repair:<ul>
<li>Stage D (Symptomatic) or Stage C (Asymptomatic Severe AR)
  with LVEF \&lt; 55%, or are undergoing other
  cardiac surgery</li>
<li>If LVEF > or equal 55%, patients should be considered for
        surgery if LV is dilated (LVESD > 50 mm (class IIa) or LVEDD >
        65 mm (class IIb))</li>
<li>Any patient with progressive AR, even if they do not meet criteria
    for severe AR, should consider valve replacement if undergoing
    cardiac surgery for other reasons</li>
<li>Note: TAVI for isolated chronic AR is challenging 2/2 dilation
        of the aortic annulus and root</li>
</ul>
</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-mitral-regurgitation">Mitral Regurgitation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-mitral-regurgitation" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology_2">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_2" title="Permanent link">&para;</a></h2>
<ul>
<li>Primary MR – caused by direct involvement of the valve apparatus
    (leaflets or chordae tendineae)</li>
<li>Degenerative/myxomatous mitral valve disease (mitral valve prolapse
    with flail leaflet, mitral annular calcification, chordal rupture)</li>
<li>Rheumatic fever</li>
<li>Infective endocarditis</li>
<li>Papillary muscle rupture following acute (inferior) MI</li>
<li>Secondary MR- caused by changes of the LV that lead to valvular
    incompetence</li>
<li>Dilated Cardiomyopathy</li>
<li>HOCM with systolic anterior motion</li>
<li>Coronary Artery Disease or prior MI leading to papillary muscle
    tethering</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_2">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_2" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute MR- sudden onset reduction in forward cardiac flow and left
    atrial/pulmonary vein volume overload</li>
<li>Dyspnea with flash pulmonary edema</li>
<li>Left-sided heart failure</li>
<li>Chronic MR- progressive symptoms d/t cardiac remodeling to
    compensate for mitral flow reversal</li>
<li>Progressively worsening heart failure: dyspnea, orthopnea, PND</li>
<li>LV dilation from volume overload</li>
<li>LA remodeling/dilation leading to afib</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-auscultation">Auscultation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-auscultation" title="Permanent link">&para;</a></h2>
<ul>
<li>Holosystolic Murmur</li>
<li>Best heard at Apex</li>
<li>Radiation to the Axilla</li>
<li>Frequently associated with S3</li>
<li>Murmur may be absent in acute MR due to large regurgitant
    orifice/low velocity regurgitant jet</li>
<li>Increases w/ increased preload or afterload</li>
<li>Pulmonary Rales</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation_1">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>CXR: assess for pulmonary edema, r/o other causes of acute dyspnea</li>
<li>ECG: often non-specific, LVH</li>
<li>Echocardiography: assess valve apparatus, size, and function of
    LA/LV, grade severity of MR</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-chronic-mr-stages">Chronic MR stages<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-chronic-mr-stages" title="Permanent link">&para;</a></h2>
<ul>
<li>A: No symptoms</li>
<li>B: >mild MR w/o hemodynamic changes or symptoms</li>
<li>C: Severe MR w/o symptoms<ul>
<li>C1: preserved EF and normal LV size</li>
<li>C2: reduced EF (\&lt;60%), dilated LV (LVESD > 40mm)</li>
</ul>
</li>
<li>D: Severe/symptomatic</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_2">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_2" title="Permanent link">&para;</a></h2>
<p>Acute hemodynamically significant MR</p>
<ul>
<li>Urgent surgical repair or replacement</li>
<li>Medical stabilization as a bridge to surgery<ul>
<li>Afterload reduction is key to promote forward flow</li>
<li>Vasodilators (nitroprusside, nitroglycerin) reduce afterload</li>
<li>Diuresis to reduce preload and improve pulmonary edema</li>
<li>IABP placement can be used as mechanical afterload reduction</li>
</ul>
</li>
</ul>
<p>Chronic severe primary MR</p>
<ul>
<li>Surgical repair favored over valve replacement</li>
<li>Class I:<ul>
<li>Asymptomatic patients w/ LVEF 30-59% or LVESD > or equal 40mm</li>
<li>Symptomatic patients w/ EF > 30%</li>
</ul>
</li>
<li>Class II:<ul>
<li>A: asymptomatic patients with progressive EF decline or LV
    dilation on serial monitoring; or very severe MR</li>
<li>B: new onset AF</li>
</ul>
</li>
<li>Secondary MR can consider MV repair with persistent class III-IV
    symptoms while on guideline directed medical therapy</li>
<li>In HFrEF, consider MitraClip after volume optimization (see Heart
    Failure section)</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-mitral-stenosis">Mitral Stenosis<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-mitral-stenosis" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h1 id="cardiology-cardiology-valvular-heart-disease-etiology_3">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_3" title="Permanent link">&para;</a></h1>
<p>Characterized by thickened mitral valve leaflets and fused
leaflet tips.</p>
<ul>
<li>Rheumatic Fever (leading cause worldwide)</li>
<li>Calcification of the mitral valve annulus (common in high income
    countries)</li>
<li>Autoimmune Diseases: SLE, Rheumatoid arthritis</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_3">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Progressive symptoms: Asymptomatic Heart Failure</li>
<li>Orthopnea</li>
<li>PND</li>
<li>Hoarseness/Dysphagia (compression of recurrent laryngeal
    nerve/esophagus by enlarged left atrium from pressure overload)</li>
<li>Symptoms of Right Heart Failure</li>
<li>Acute Symptoms may present in settings of increased cardiac output
    (pregnancy, sepsis, or exercise) or tachyarrhythmias</li>
<li>Dyspnea</li>
<li>Fatigue</li>
<li>Palpitations</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-physical-exam">Physical exam<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-physical-exam" title="Permanent link">&para;</a></h2>
<ul>
<li>Low-pitched rumbling, diastolic Murmur, best heard at apex,
    low-pitched, rum<ul>
<li>Loud S1, opening snap after S2</li>
<li>Prominent P2 if pulmonary HTN develops</li>
</ul>
</li>
<li>Pulmonary Rales</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation_2">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation_2" title="Permanent link">&para;</a></h2>
<ul>
<li>CXR: LA enlargement, increased pulmonary vasculature</li>
<li>Echocardiography: thickening of mitral valve leaflets, decreased
    area of valve leaflets, left atrial enlargement</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_3">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Varies between rheumatic MS and calcific MS (in general,
    intervention of calcific MS is very challenging and high risk)</li>
<li>Severe, symptomatic rheumatic MS:<ul>
<li>Percutaneous mitral balloon commissurotomy (PMBC)</li>
<li>Surgical repair/replacement if patient failed PMBC or undergoing
other cardiac surgery</li>
</ul>
</li>
<li>
<p>Calcific MS has a poor prognosis with 5-year survival \&lt;50%,
    Intervention is higher risk and should be reserved for severely
    symptomatic patients</p>
</li>
<li>
<p>No role for commissurotomy with calcific MS</p>
</li>
<li>Surgical valve replacement may be considered for severely
    symptomatic patients (technically challenging)</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-anti-coagulation">Anti-Coagulation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-anti-coagulation" title="Permanent link">&para;</a></h2>
<ul>
<li>Anti-coagulation is indicated if:<ul>
<li>Mechanical prosthetic mitral valve<ul>
<li>Warfarin, goal INR 3-4 lifelong</li>
</ul>
</li>
<li>Bioprosthetic mitral valve replacement<ul>
<li>Warfarin, goal INR 2-3 for first 3-6 months</li>
</ul>
</li>
<li>Atrial Fibrillation regardless of CHADS2VASC score</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Cardiology</h1>
                        <h1 class='nav-section-title' id='section-critical-care'>
                            Critical care <a class='headerlink' href='#section-critical-care' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="critical-care-critical-care-abcdef-a2f-bundle"><h1 id="critical-care-critical-care-abcdef-a2f-bundle-abcdef-a2f-bundle">ABCDEF (A2F) Bundle<a class="headerlink" href="#critical-care-critical-care-abcdef-a2f-bundle-abcdef-a2f-bundle" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCDEF (A2F) Bundle – Kaele Leonard</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Post-Intensive Care Syndrome (PICS): complex constellation of
    cognitive, physical, and psychological impairments that impact most
    survivors of critical illness, leading to disability, frailty, and
    poor quality of life<ul>
<li>Predicted by (1) duration of immobility and (2) delirium; very
    common in ICU pts</li>
<li>Both are reduced by &gt;80% compliance with ABCDEF (A2F) Bundle
    concepts</li>
</ul>
</li>
<li>ABCDEF (A2F) Bundle: Interprofessional, evidence-based safety bundle
    of care principles to help reduce LOS, mortality, bounce-backs, and
    the duration of ICU delirium and coma<ul>
<li>A
    ssess/Prevent/Manage Pain</li>
<li>B
    oth SAT/SBT</li>
<li>C
    hoice of Analgesia and Sedation</li>
<li>D
    elirium—Assess, Prevent, and Manage</li>
<li>E
    arly Mobility and Exercise</li>
<li>F
    amily Engagement and Empowerment</li>
</ul>
</li>
<li>Goal: allow pt to “prove us wrong” about readiness for liberation
    from devices, sedatives, etc.</li>
<li>Evidence
    
    Associated with higher likelihood of ICU and hospital discharge and
    lower likelihood of death, mechanical ventilation, coma, delirium,
    physical restraint, ICU readmission, discharge to a destination
    other than home, and lower cost</li>
</ul>
<p>A</p>
<p>ssess, prevent, and manage pain</p>
<ul>
<li>Tools to assess pain using facial expressions, body movements,
    muscle tension, compliance with ventilator, or vocalization for
    extubated pts<ul>
<li>Behavioral Pain Scale (BPS): scale 0-12, uncontrolled pain ≥ 5</li>
<li>Critical Care Pain Observation Tool (CPOT): scale 0-8,
    uncontrolled pain 3 if non-verbal pt</li>
</ul>
</li>
<li>Uncontrolled pain increases risk for delirium, limits inspiratory
    effort and weaning from ventilator, and limits ability to mobilize</li>
<li>Treatment: multi-modal with parenteral opioids (e.g., fentanyl,
    dilaudid), neuropathic meds (e.g., gabapentin, ketamine), adjunctive
    non-opioids analgesics (e.g., acetaminophen, NSAIDs),
    nonpharmacologic interventions (repositioning, heat/cold)</li>
</ul>
<p>B</p>
<p>oth spontaneous awakening trials (SATs) and spontaneous breathing trials
(SBTs)</p>
<ul>
<li>SATs = daily sedative interruptions<ul>
<li>RN-driven protocol involving safety checklist: no active
    seizures, alcohol withdrawal, agitation, paralytics, myocardial
    infarction, or increased ICP</li>
<li>If pass SAT, then proceed to SBT</li>
<li>If fail SAT (anxiety, agitation, pain, resp distress)
    
    restart sedation at ½ doses</li>
</ul>
</li>
<li>SBTs = PS ventilation (Fi02 ≤ 50%, PEEP ≤ 7.5; typically 40% and
    5/5) for ≥ 30 minutes<ul>
<li>RT or physician/APP-driven protocol with safety screen: passed
    SAT, O2 sat ≥ 88%, inspiratory efforts, no myocardial ischemia,
    no/low vasopressor support</li>
<li>If pass SBT, physician/APP judgment on extubation</li>
<li>If fail SBT (RR &gt; 35 or \&lt; 8, O2 sat \&lt; 88%, resp distress,
    mental status change)
    
    restart full ventilatory support</li>
</ul>
</li>
<li>Evidence:<ul>
<li>Liberated pts from mechanical ventilation 3 days sooner,
    decreased ICU and hospital length of stay by 4 days, and 14%
    absolute reduction in mortality at 1 year</li>
</ul>
</li>
</ul>
<p>C</p>
<p>hoice of analgesia and sedation</p>
<ul>
<li>Richmond Agitation-Sedation Scale (RASS): sedation and level of
    arousal assessment tool (Figure 1)<ul>
<li>Target light sedation of RASS -1 to 0 with goal of (1) pt
    following commands without agitation and (2) limiting
    immobilization</li>
<li>Over-sedation:  hold sedatives till target, then restart at ½
    prior dose</li>
</ul>
</li>
<li>Analgosedation with focus on treating pain first and then adding
    sedation meds PRN</li>
<li>Sedatives: dexmedetomidine (dex) or propofol &gt;>> benzodiazepines<ul>
<li>Benzodiazepines increase risk of delirium in a dose-dependent
    fashion</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/RASS.png" data-entity-type="file" data-entity-uuid="b4f171d6-4f6d-4465-922f-f0ef907d7a36" alt="RASS" /></p>
<p>Figure 1:</p>
<p>Richmond Agitation-Sedation Scale (RASS)</p>
<p>D</p>
<p>elirium - assess, prevent, and manage</p>
<ul>
<li>Screening for delirium: q4hr using CAM-ICU (Figure 2)<ul>
<li>Affects 60-80% of ventilated pts and associated with increased
    morbidity and mortality, longer ICU and hospital length of stay,
    long-term cognitive dysfunction</li>
</ul>
</li>
<li>Risk factors and treatment: see Delirium topic under Geriatrics<ul>
<li>Dr. Dre mnemonic: <strong><u>D</u></strong> isease <strong><u>r</u></strong> emediation
    (heart failure, COPD, and sepsis), <strong><u>D</u></strong> rug <strong><u>r</u></strong>
    emoval (benzos, anticholinergics, steroids) and <strong><u>E</u></strong>
    nvironment (hearing aids, eye glasses, mobilize the pt,
    normalize sleep wake cycle)</li>
</ul>
</li>
</ul>
<p>E</p>
<p>arly mobility and Exercise</p>
<ul>
<li>Prolonged immobilization during critical illness leads to
    ICU-acquired weakness, associated with worse outcomes:
    ↑
    mechanical ventilation, increased hospital length of stay, greater
    mortality, and greater disability</li>
<li>Consult PT/OT to initiate rehab at the beginning of critical illness<ul>
<li>Can be done safely in pts receiving advanced support</li>
<li>↓
    duration of delirium,
    ↓
    ICU and hospital length of stay, and improved return to
    independent functional status</li>
</ul>
</li>
</ul>
<p>F</p>
<p>amily engagement and empowerment</p>
<ul>
<li>Especially important when pts are unable to communicate themselves</li>
<li>Incorporate family at the bedside and on rounds to learn pt
    preferences and values, engage in shared-decision making, and
    address questions and concerns<ul>
<li>Associated with greater satisfaction with care and increased
    feelings of inclusion, respect, and understanding of the pt’s
    care</li>
<li>Can facilitate family decision to transition to comfort-focused
    care</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/CAMICUpng.png" data-entity-type="file" data-entity-uuid="7c1bfb8b-e2c5-42b1-b8c5-0b4882314d1d" alt="CAM ICU" /></p>
<p>Figure 2:</p>
<p>Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)</p></section><section class="print-page" id="critical-care-critical-care-ards"><h1 id="critical-care-critical-care-ards-ards">ARDS<a class="headerlink" href="#critical-care-critical-care-ards-ards" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Respiratory Distress Syndrome (ARDS) – Judd Heideman</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>A syndrome of diffuse inflammation and injury of the alveoli and
    capillary endothelium leading to fluid and protein accumulation in
    the interstitium and alveoli, pulmonary edema, and hypoxemic
    respiratory failure; 30-50% mortality rate</li>
<li>Triggers:<ul>
<li>Pulmonary<ul>
<li>Pneumonia (viral and bacterial)</li>
<li>Aspiration</li>
<li>Direct inhalation injury</li>
<li>Primary graft dysfunction of pulmonary transplant</li>
<li>Lung contusion</li>
</ul>
</li>
<li>Extra-pulmonary<ul>
<li>​​​​​
    Sepsis (most common cause)</li>
<li>Trauma</li>
<li>Pancreatitis</li>
<li>Massive blood transfusions/TRALI</li>
<li>Burns</li>
<li>HSCT</li>
<li>Drugs (amiodarone, chemotherapy, cocaine, opioids)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Diagnosis: Berlin Criteria</p>
<ul>
<li>
<p>New or worsening respiratory symptoms beginning within one week
    of diagnosis</p>
</li>
<li>
<p>New bilateral opacities present on chest radiograph or CT chest</p>
</li>
<li>
<ul>
<li>Not explained by effusions, collapse of lobe/lung, or
        nodules</li>
</ul>
</li>
</ul>
</li>
<li>
<ul>
<li>Absence of left heart failure or volume overload</li>
</ul>
</li>
<li>
<p>Severity: based on PaO2/FiO2 ratio with a PEEP ≥ 5 cm H2O</p>
<ul>
<li>PaO2 = arterial partial pressure of O2 (requires ABG)</li>
<li>FiO2 = fraction of inspired oxygen (expressed as a decimal
    between 0.21 and 1.0)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>PaO2/FiO2 ratio</td>
<td>PEEP</td>
</tr>
<tr>
<td>Mild</td>
<td>201-300</td>
<td>≥5</td>
</tr>
<tr>
<td>Moderate</td>
<td>101-200</td>
<td>≥5</td>
</tr>
<tr>
<td>Severe</td>
<td>\&lt;100</td>
<td>≥5</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Frequently requires intubation; non-invasive ventilation not a great
    treatment</li>
<li>Low tidal volume (Vt) ventilation<ul>
<li>Goal <strong>Vt = 4-8 mL/kg</strong> of <strong>predicted</strong> body weight (obese pts
    don’t have bigger lungs)</li>
<li>Predicted body weight is based on <strong>height</strong> and gender of pt<ul>
<li>
<ul>
<li>Males = 50 + 2.3 (height in inches – 60)</li>
<li>Females = 45.5 + 2.3 (height in inches – 60)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Plateau pressure goal: ≤30 cm H2O</li>
<li>Oxygenation goal: PaO2 55-80 or SpO2 88-95%</li>
<li>pH goal: ≥7.20, “permissive hypercapnia”</li>
<li>Treat the underlying cause (see “Triggers” above)</li>
<li>See below for further management of refractory hypoxemia</li>
</ul>
<p>At VUMC:</p>
<ul>
<li>To find FiO2, go to Summary tab &gt; Flowsheet, look under “Resp
    support”</li>
<li>To order ABGs, search “resp care” and click on “Adult Respiratory
    Lab Panel (aka Respiratory care)” &gt; arterial blood gas labs &gt; Blood
    gas arterial<ul>
<li>RT labs performed much faster in the MICU than on the floor</li>
<li>Consider A-line if checking 2 or more times/day</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-brain-death"><h1 id="critical-care-critical-care-brain-death-brain-death">Brain Death<a class="headerlink" href="#critical-care-critical-care-brain-death-brain-death" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain Death – Amelia Muhs</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Brain death = legal death; time of death is the time of the brain
    death exam</li>
<li>It is not required that neurology is consulted, but they often are</li>
<li>Must complete declaration of brain death note in Epic</li>
<li>Apnea testing and brain death determination<ul>
<li>An attending MUST be present for apnea testing and brain death
    exam</li>
<li>If loved ones are present for apnea testing, it may be helpful
    to explain the process to them. Family may expect that the pt’s
    heart will stop during testing. Explain that brain activity is
    not required to keep the heart beating. Explain that at the end
    of the test, the pt will be reconnected to the ventilator.
    Communication is VERY important.</li>
</ul>
</li>
<li>Organ donation caveats<ul>
<li>TDS number: 1-800-969-4438 – call early</li>
<li>Discussions about organ donation should take place between
    Tennessee Donor Services (TDS) and the surrogate. You SHOULD NOT
    be having extensive conversations with the surrogate about
    donation. Direct questions to TDS.</li>
<li>After a pt is declared brain dead, if they will be a donor, TDS
    will usually take over medical management of the pt. This can
    get confusing, so make sure to be in contact with the TDS
    representative with any questions</li>
</ul>
</li>
</ul>
<p>Checklist for Determination of Brain Death (American Academy of
Neurology)</p>
<p>1. Prerequisites (all must be checked)</p>
<ul>
<li>Coma, irreversible and cause known</li>
<li>Neuroimaging explains coma – usually CT or MRI</li>
<li>CNS depressant drug effect absent (if indicated, toxicology screen;
    if barbiturates given, serum level \&lt;10
    μ
    g/mL)</li>
<li>No evidence of residual paralytics (electrical stimulation if
    paralytics used)</li>
<li>Absence of severe acid-base, electrolyte, endocrine abnormality</li>
<li>Normothermia or mild hypothermia (core temp &gt;36°C)</li>
<li>SBP ≥100 mm Hg</li>
<li>No spontaneous respirations</li>
</ul>
<p>2. Examination (all must be checked) – Attending MUST be present for
brain death exam</p>
<ul>
<li>Pupils nonreactive to bright light</li>
<li>Corneal reflex absent</li>
<li>Oculocephalic reflex absent (tested only if C-spine integrity
    ensured)</li>
<li>Oculovestibular reflex absent</li>
<li>No facial movement to noxious stimuli at supraorbital nerve or TMJ</li>
<li>Gag reflex absent</li>
<li>Cough reflex absent to tracheal suctioning</li>
<li>Absence of motor response to noxious stimuli in all four limbs
    (spinal reflexes permissible)</li>
</ul>
<p>3. Apnea testing (all must be checked) – The RTs know how to do this
and should be at the bedside with you. Attending MUST be present.</p>
<ul>
<li>Pt is hemodynamically stable</li>
<li>Ventilator adjusted to provide normocarbia (PaCO2 35–45 mm Hg)</li>
<li>Pt preoxygenated with 100% FiO2 for &gt;10 minutes to PaO2 &gt;200 mm Hg</li>
<li>Pt well-oxygenated with a positive end-expiratory pressure (PEEP) of
    5 cm of water</li>
<li>Provide oxygen via a suction catheter to the level of the carina at
    6 L/min or attach T-piece with continuous positive airway pressure
    (CPAP) at 10 cm H2O</li>
<li>Disconnect ventilator</li>
<li>Spontaneous respirations absent.</li>
<li>Arterial blood gas drawn at 8–10 minutes, pt reconnected to
    ventilator<ul>
<li>PCO2 ≥60 mm Hg, or 20 mm Hg rise from normal baseline value; OR:</li>
<li>Apnea test aborted. – abort if spontaneous respirations present,
    pt develops hemodynamic instability, or becomes hypoxic</li>
</ul>
</li>
</ul>
<p>4. Ancillary testing (only one needs to be performed; to be ordered
only if clinical examination cannot be fully performed due to pt
factors, or if apnea testing inconclusive or aborted)</p>
<ul>
<li>Cerebral angiogram</li>
<li>HMPAO SPECT (Single photon emission computed tomography)</li>
<li>EEG &amp; TCD (transcranial Doppler)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-drips"><h1 id="critical-care-critical-care-drips-drips">Drips<a class="headerlink" href="#critical-care-critical-care-drips-drips" title="Permanent link">&para;</a></h1>
<p>MICU/CCU Drips – Blake Funke</p>
<ul>
<li>Most of these have ordersets in Epic, you can choose “Do Not
    Titrate” (used sparingly when initiating on the floor) or “Titration
    Allowed” (to be used in ICU for nurse titration)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasopressors:</td>
<td>Vasopressors:</td>
<td>Vasopressors:</td>
<td>Vasopressors:</td>
<td>Vasopressors:</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>Receptors</td>
<td>Indications</td>
<td>Considerations</td>
</tr>
<tr>
<td>Norepinephrine (Levophed)</td>
<td>1 – 100 mcg/min</td>
<td>αα1 > β1</td>
<td>1<sup>st</sup> line septic shock</td>
<td>Peripheral ischemia, skin necrosis</td>
</tr>
<tr>
<td>Phenylephrine (Neosynephrine)</td>
<td>Bolus: 0.05 – 0.5 mg q 10-15 min Infusion: 40-360 mcg/min</td>
<td>αα1</td>
<td>Used for periprocedural hypotension(Neostick) or pts w/ tachyarrhythmias</td>
<td>Reflex bradycardia Peripheral ischemia, skin necrosis</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>1 – 40 mcg/min</td>
<td>αα1=β1=β2</td>
<td>Post PEA arrest Anaphylaxis Septic shock (severe) Cardiac shock</td>
<td>Tachy-arrhythmias, Peripheral ischemia, skin necrosis</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>0.04 U/min (no titration); start at NE > 50</td>
<td>V1, V2, V3</td>
<td>2<sup>nd</sup> line septic shock, Right heart failure</td>
<td>Hyponatremia Bradycardia</td>
</tr>
<tr>
<td>ANG II *needs approval by Dr. Rice or Dr. Semler</td>
<td>20 – 40 ng/kg/min</td>
<td>ANG II</td>
<td>Refractory vasodilatory shock *typically multiple pressors at high doses</td>
<td>Thrombosis: pt MUST have chemical DVT ppx; contraindicated in heart failure</td>
</tr>
<tr>
<td>Dopamine</td>
<td>2 – 20 mcg/kg/min</td>
<td>Dopamine (1-5 mcg) > β1 (5-10 mcg) >α1 (&gt;10mcg)</td>
<td>Hypotension Cardiac shock Renal protection</td>
<td>Tachy-arrhythmias (↑ risk )) Peripheral ischemia, skin necrosis</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>2.5 – 20 mcg/kg/min</td>
<td>β1 >>> β2</td>
<td>Cardiogenic shock</td>
<td>Vasodilation Hypotension Tachycardia Tachyphylaxis</td>
</tr>
<tr>
<td>Milrinone</td>
<td>0.375 – 0.75 mcg/kg/min</td>
<td>PDE-3</td>
<td>Cardiogenic shock</td>
<td>Hypotension Renally cleared</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
<td>Sedatives/Anxiolytics:</td>
</tr>
<tr>
<td>Drug</td>
<td>Drug</td>
<td>Dose</td>
<td>Dose</td>
<td>Class</td>
<td>Class</td>
<td>Metabolism</td>
<td>Side Effects</td>
</tr>
<tr>
<td>Propofol</td>
<td>Infusion: 5 – 150 mcg/kg/min</td>
<td>Infusion: 5 – 150 mcg/kg/min</td>
<td>General anesthetic (GABA R agonist)</td>
<td>General anesthetic (GABA R agonist)</td>
<td>Hepatic Renal (minor)</td>
<td>Hepatic Renal (minor)</td>
<td>Severe Hypotension bradycardia Propofol infusion syndrome</td>
</tr>
<tr>
<td>Dexmedetomidine (Precedex)</td>
<td>Infusion: 0.1 – 1.5 mcg/kg/h</td>
<td>Infusion: 0.1 – 1.5 mcg/kg/h</td>
<td>Central αα2 agonist</td>
<td>Central αα2 agonist</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hypotension Bradycardia</td>
</tr>
<tr>
<td>Midazolam (Versed)</td>
<td>Push: 0.5 – 5 mg Infusion: 0.25 – 5 mg/h (no max dose)</td>
<td>Push: 0.5 – 5 mg Infusion: 0.25 – 5 mg/h (no max dose)</td>
<td>Benzodiazepine</td>
<td>Benzodiazepine</td>
<td>Hepatic &amp; Renal</td>
<td>Hepatic &amp; Renal</td>
<td>Hypotension</td>
</tr>
<tr>
<td>Lorazepam (Ativan)</td>
<td>Push: 0.5 – 10 mg Infusion: 0.5 – 5 mg/h (no max dose)</td>
<td>Push: 0.5 – 10 mg Infusion: 0.5 – 5 mg/h (no max dose)</td>
<td>Benzodiazepine</td>
<td>Benzodiazepine</td>
<td>Hepatic</td>
<td>Hepatic</td>
<td>Hypotension Propylene glycol carrier - AG acidosis</td>
</tr>
<tr>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesic:</td>
<td>Analgesic:</td>
<td>Analgesic:</td>
<td>Analgesic:</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>Metabolism</td>
<td>Side effects</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Push: 25 – 100 mcg Infusion: 25 – 400 mcg/h</td>
<td>Hepatic</td>
<td>Hypotension, Serotonin syndrome, chest wall rigidity at high doses</td>
</tr>
<tr>
<td>Morphine</td>
<td>Push: 1 – 5 mg q1-2h prn Infusion: 1 – 5 mg/h</td>
<td>Hepatic/Renal</td>
<td>Hypotension (profound), itching, constipation, HA; avoid in renal failure</td>
</tr>
<tr>
<td>Hydromorphone (Dilaudid)</td>
<td>Push: 0.25 – 1 q1-2h prn Infusion: 0.5 – 3 mg/h</td>
<td>Hepatic</td>
<td>Hypotension, respiratory depression, itching</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Arrhythmics:</td>
<td>Anti-Arrhythmics:</td>
<td>Anti-Arrhythmics:</td>
<td>Anti-Arrhythmics:</td>
<td>Anti-Arrhythmics:</td>
</tr>
<tr>
<td>Drug</td>
<td>Dose</td>
<td>Indications</td>
<td>Side effects</td>
<td>Comments</td>
</tr>
<tr>
<td>Adenosine</td>
<td>6 – 12 mg IV rapid push and flush; may repeat x2</td>
<td>PSVT conversion</td>
<td>Complete AV nodal blockade</td>
<td>10 second half-life Must have continuous EKG/tele monitor</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>ACLS: 300 mg IV push Non-emergent: 150 mg over 10 min then 0.5 mg/min</td>
<td>Vtach/Vfib Afib</td>
<td>Pulm, ophthalmic and thyroid toxicity w/ chronic use</td>
<td>Less hypotensive effect than other agents Safe in heart failure</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>Push: 10 – 20 mg q15 min x 2 if no response Infusion: 5 – 15 mg/h</td>
<td>Afib Aflutter PSVT</td>
<td>Bradycardia Hypotension</td>
<td>Avoid use in pts with HFrEF</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>ACLS: 1 mg/kg x 1 Infusion: 1 – 4 mg/min</td>
<td>Vtach</td>
<td>Bradycardia Heart block</td>
<td>Avoid use in liver failure or heart failure</td>
</tr>
<tr>
<td>Procainamide</td>
<td>15 mg/kg over 30 min then 1 – 6 mg/min</td>
<td>Vtach Refractory afib</td>
<td>Bradycardia Hypotension</td>
<td>Drug-induced lupus Cytopenias</td>
</tr>
</tbody>
</table></section><section class="print-page" id="critical-care-critical-care-modes-oxygen-delivery"><h1 id="critical-care-critical-care-modes-oxygen-delivery-modes-of-oxygen-delivery">Modes of Oxygen Delivery<a class="headerlink" href="#critical-care-critical-care-modes-oxygen-delivery-modes-of-oxygen-delivery" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modes of Oxygen Delivery – Blake Funke</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple Delivery Systems</td>
<td>Simple Delivery Systems</td>
<td>Simple Delivery Systems</td>
<td>Simple Delivery Systems</td>
<td>Simple Delivery Systems</td>
</tr>
<tr>
<td>System</td>
<td>L/min</td>
<td>% O2</td>
<td>Indications</td>
<td>Comments</td>
</tr>
<tr>
<td>Blow by</td>
<td>NaN</td>
<td>21-100%</td>
<td>Trach collar</td>
<td>NaN</td>
</tr>
<tr>
<td>Nasal cannula</td>
<td>1-8</td>
<td>25 – 45%</td>
<td>Hypoxemia</td>
<td>NaN</td>
</tr>
<tr>
<td>Large bore nasal cannula</td>
<td>Up to 15</td>
<td>Up to 65%</td>
<td>Hypoxemia</td>
<td>Can be identified by larger bore tubing (often green) and nose piece. Colloquially referred to as HFNC, but true HFNC = optiflow</td>
</tr>
<tr>
<td>Venturi mask</td>
<td>4 to 15</td>
<td>24 – 50%</td>
<td>NaN</td>
<td>Actual FiO2 is dependent on pt effort</td>
</tr>
<tr>
<td>Non-rebreather</td>
<td>10 to 15</td>
<td>65-95%</td>
<td>Severe hypoxemia</td>
<td>Often used as a bridge to higher level of O2 therapy</td>
</tr>
<tr>
<td>HFNC: Optiflow, AirVo, Vapotherm</td>
<td>Up to 60</td>
<td>30-100%</td>
<td>Severe hypoxemia</td>
<td>Delivers 0.5-1 cm/H2O of PEEP per 10L of flow</td>
</tr>
</tbody>
</table>
<p>**Use of all of the above modes of O2 requires a spontaneously
breathing pt</p>
<p>Non-invasive positive pressure ventilation:</p>
<ul>
<li>CPAP<ul>
<li>Indications: obstructive sleep apnea, tracheomalacia</li>
<li>Settings: CPAP, FiO2</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>BiPAP<ul>
<li>Indications: hypercapnic respiratory failure (RF), hypoxic RF,
    pulmonary edema, obstructive sleep apnea, obesity
    hypoventilation syndrome, RF 2/2 neuromuscular disease</li>
<li>Settings: IPAP, EPAP, FiO2, RR (sometimes)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>Invasive positive-pressure ventilation</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode</td>
<td>You set</td>
<td>Not set</td>
<td>Comments</td>
</tr>
<tr>
<td>Pressure support (PS)</td>
<td>PEEP PS above PEEP FiO2</td>
<td>TV RR Inspiratory flow</td>
<td>Similar to Bipap. Frequently used for vent weaning / SBT. Requires spontaneously breathing pt.</td>
</tr>
<tr>
<td>Volume Control (AC/VC)</td>
<td>PEEP RR TV Inspiratory flow FiO2</td>
<td>Inspiratory pressure</td>
<td>Mandates a minute ventilation; limits volutrauma (i.e. can guarantee LTVV) **Primary mode used in MICU (mode used in major ARDS trials)</td>
</tr>
<tr>
<td>SIMV</td>
<td>PEEP RR TV PS above PEEP FiO2</td>
<td>NaN</td>
<td>Pt gets VC breath for set rate, but if tries to breath over this will get PS breath; VC and PS breaths are synchronized when able</td>
</tr>
<tr>
<td>Pressure Control (AC/PC)</td>
<td>RR Inspiratory Pressure PEEP Inspiratory Time (or I:E ratio) FiO2</td>
<td>TV</td>
<td>Minimizes barotrauma (i.e. sets a max inspiratory pressure)  does not guarantee a specific minute ventilation (must monitor PCO2 with blood gases) Does not have natural ventilator alarms for protection – need to increase low minute ventilation alarm threshold</td>
</tr>
<tr>
<td>PRVC</td>
<td>PEEP RR TV Inspiratory flow Pressure max FiO2</td>
<td>NaN</td>
<td>Adaptive pressure control (NOT actually a volume control mode); tries to limit both barotrauma and volutrauma but if in conflict, minute ventilation will drop (i.e. need to monitor PCO2 with blood gases like any other PC mode) Con: More the pt works, the less the ventilator does</td>
</tr>
<tr>
<td>APRV / Bilevel</td>
<td>PEEP (PLow) Pressure High Time Low Time High FiO2</td>
<td>TV</td>
<td>Long periods of inspiratory holds and very brief expirations (i.e. releases) Often difficult to ventilate pts on this mode</td>
</tr>
</tbody>
</table></section><section class="print-page" id="critical-care-critical-care-refractory-hypercapnia"><h1 id="critical-care-critical-care-refractory-hypercapnia-refractory-hypercapnia">Refractory Hypercapnia<a class="headerlink" href="#critical-care-critical-care-refractory-hypercapnia-refractory-hypercapnia" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory Hypercapnia – Amelia Muhs</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Inadequate clearance of CO2 leading to respiratory acidosis (pH ≤
    7.20) despite maximum RR&amp;TV (i.e. minute ventilation) tolerated
    without causing barotrauma or autoPEEP</li>
<li>Common causes:<ul>
<li>Obstructive lung disease (COPD, emphysema, asthma)</li>
<li>Hypoventilation (sleep apnea, obesity, sedative medications (ie
    opiates), neuromuscular weakness, chest wall trauma,
    ascites/pleural effusion)</li>
<li>Increased CO2 load (shock, sepsis, malignant hyperthermia)</li>
</ul>
</li>
<li>Presentation:<ul>
<li>Shortness of breath</li>
<li>AMS, somnolence</li>
<li>Hypoxemia</li>
<li>Tachycardia, hypertension (in some cases)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical exam, mental status, recent medications</li>
<li>ABG or VBG – if
    á
    PCO2 and normal pH, always treat the pH and not the PCO2 (i.e., may
    be compensated chronic hypercarbia and blowing off more CO2 may be
    harmful)</li>
</ul>
<p>Management Algorithm</p>
<p>1.  Special considerations</p>
<ul>
<li>If history of OSA, make sure they are on home CPAP/BiPAP</li>
<li>If opiate related trial narcan</li>
<li>Bronchodilators for reactive airway diseases</li>
</ul>
<p>2.  BiPAP</p>
<ul>
<li>Contraindicated if pt unable to remove BiPAP mask on their own</li>
<li>Increase MV by increasing
    Δ
    between IPAP/EPAP or increasing RR</li>
</ul>
<p>3.  Mechanical ventilation</p>
<ul>
<li>Allows you to control rate and tidal volume (in Volume Control
    modes)</li>
<li>NOTE: some pts have higher minute ventilation on their own compared
    to mechanical ventilation (e.g., DKA); pt-specific considerations
    regarding intubation</li>
<li>We generally use volume control modes (i.e. VC/AC)
    
    VUMC medicine residents and MICU staff tend to be most familiar with
    this mode<ul>
<li>Volume control guarantees a MV</li>
<li>NOTE: PRVC is actually a pressure-control mode, does NOT
    guarantee MV</li>
</ul>
</li>
<li>Increase RR<ul>
<li>30-35 is about as high as you can go</li>
<li>Need to keep in mind I/E time
    
    avoids breath stacking/autoPEEP</li>
<li>AutoPEEP = gas trapped in the lungs</li>
<li>Some signs of autoPEEP include worsening hypotension and the
    expiratory limb on the flow waveform on the vent not returning
    to zero</li>
</ul>
</li>
<li>Increase TV
    
    we usually start at 4-6mL/kg IBW. You can consider increasing to
    8mL/kg IBW as long as plateau pressures remain \&lt; 30 cm H2O<ul>
<li>Goal peak pressures ≤ 35 cm H2O / plateau pressures ≤ 30 cm H2O</li>
</ul>
</li>
<li>ARDS
    
    permissive hypercapnia (goal pH ≥ 7.2)</li>
</ul>
<p>4. V-V ECMO / Extracorporeal carbon dioxide removal (ECCO2R)</p>
<ul>
<li>Indications for hypercapnia:<ul>
<li>Severe dynamic hyperinflation and/or severe respiratory acidosis</li>
<li>pH ≤ 7.25 with PaCO2 ≥ 60 for 6 hr with RR at 35/min and TV
    increased to target maximum MV while keeping plateau pressure ≤
    32 cm H2O</li>
</ul>
</li>
<li>Similar considerations and contraindications as refractory hypoxemia
    (see above)<ul>
<li>Benefits Reduces work of breathing</li>
<li>Promotes early ventilator weaning/extubating
    
    allows early mobilization and recovery</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-refractory-hypoxemia"><h1 id="critical-care-critical-care-refractory-hypoxemia-refractory-hypoxemia">Refractory Hypoxemia<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-refractory-hypoxemia" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractory Hypoxemia – Amelia Muhs</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Inadequate arterial oxygenation despite high levels of inspired O2
    or the development of barotrauma in mechanically ventilated pts</li>
<li>Generally start to consider the interventions below if needing
    FiO2 &gt;80%</li>
<li>Differential:<ul>
<li>Worsening underlying primary process (e.g. progressive ARDS)</li>
<li>PE</li>
<li>Pneumothorax</li>
<li>ET tube obstruction/malposition</li>
<li>Fluid overload</li>
<li>Ventilator-associated Pneumonia</li>
<li>New ARDS</li>
</ul>
</li>
</ul>
<p>Evaluation:</p>
<ul>
<li>Always get CXR STAT if pt has new or worsening O2 requirement</li>
<li>ABG is frequently very helpful as well</li>
<li>Can use POCUS to check for lung sliding (pneumothorax) or RV
    enlargement/septal bowing/McConnell’s sign (RV strain in PE)</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Remember – if at any point the pt is rapidly decompensating, you can
    always disconnect them from the vent and bag them until they
    recover/while calling for help</p>
</li>
<li>
<p>Early consideration of ECMO consult in appropriate pts (discuss with
    MICU fellow)</p>
<ul>
<li>After talking with the fellow/attending, you can start process
    by placing “Inpatient consult to ECMO adult” in Epic</li>
</ul>
</li>
<li>
<p>Optimize fluid status
    
    consider diuresis/dialysis if not making urine</p>
</li>
<li>
<p>Consider higher PEEP strategy</p>
<ul>
<li>Increased PEEP
    
    higher mean airway pressure, generally improves oxygenation
    especially with diffuse pulmonary pathologies<ul>
<li>
<ul>
<li>Exceptions may include certain focal/shunt pathologies
        (e.g. dense lobar PNA)</li>
<li>Worsening oxygenation may occur with overdistension of
    alveoli
    
    increase dead space ventilation; generally determined
    empirically at the bedside</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<ul>
<li>Titrate up slowly; generally do not exceed PEEP 18
        -   -   Limited by high plateau pressures/barotrauma,
                overdistension/dead space ventilation, decreased
                preload/venous return</li>
<li>ARDSnet FiO2/PEEP Tables: We usually use the Lower PEEP table</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/PEEP.png" data-entity-type="file" data-entity-uuid="418b5c83-23a6-49ec-8e5a-ed9b46c242ad" alt="PEEP" /></p>
<ul>
<li>Other recruitment maneuvers<ul>
<li>Reposition pt – can try elevating HOB or positioning so “good
    lung” is down</li>
<li>If concern for mucus plug, consider need for bronch</li>
<li>If concern for significant atelectasis can try recruitment
    maneuvers with the vent including sustained inflation (setting
    expiratory pressure to ~30 for ~30 seconds) and PEEP titration
    (setting PEEP to 20-25 and decreasing by 2cm at a time) – <strong>call
    the fellow before attempting</strong></li>
</ul>
</li>
</ul>
<p>Management Algorithm:</p>
<p>1.  Inhaled vasodilators</p>
<ul>
<li>VUMC formulary preference: inhaled epoprostenol (aka Flolan)</li>
<li>Alternatives: inhaled milrinone, inhaled nitric oxide</li>
<li>Data suggest improved PaO2/FiO2; large RCT without evidence for
    mortality benefit</li>
</ul>
<p>2.  Deep sedation (RASS -4 or -5)</p>
<ul>
<li>Promotes ventilator synchrony</li>
</ul>
<p>3.  Neuromuscular blockade (paralysis) – call your fellow before doing
this</p>
<ul>
<li>Rationale: maximal vent synchrony (eliminates residual chest
    wall/diaphragm tone)</li>
<li>Pt MUST be RASS -5 (need analgesia + sedation, cannot achieve with
    dexmedetomidine alone, which does not have amnestic properties)</li>
<li>Trial one time IV push of vecuronium 0.1 mg/kg</li>
<li>If improved vent synchrony/oxygenation, consider cisatracurium
    (Nimbex) drip</li>
<li>Data are mixed
    
    ACURASYS 2010 (improved 90-day mortality but underpowered likely
    overestimating benefit); ROSE 2019 (no difference in 90-day
    mortality)</li>
</ul>
<p>4.  Prone positioning (Need attending approval)</p>
<ul>
<li>Pts with moderate to severe ARDS (PaO2/FiO2 ratio \&lt; 150)</li>
<li>At VUMC, we use regular ICU beds and manually flip pts; cycle prone
    16 hrs/supine 8 hrs</li>
<li>When proning or supining a pt, always have a provider who can
    intubate in the room in case unplanned extubation occurs (anesthesia
    or pulm attending)</li>
<li>Considerations: need a team of people to reposition, high risk of ET
    tube malposition, difficult to access lines/perform procedures, high
    risk of pressure injuries</li>
<li>Data: PROSEVA 2013
    
    proning improved 28-day mortality; study complicated by imbalances
    between groups</li>
</ul>
<p>5.  Alternative ventilator modes (usually Pressure Control or
APRV/BiLevel/BiVent)</p>
<ul>
<li>Always ask for help from a fellow or attending before switching to a
    mode that you do not know how to trouble shoot!</li>
<li>APRV/BiVent should be avoided in people with bad obstructive lung
    disease, hemodynamic instability, refractory hypercarbia</li>
</ul>
<p>6.  Venovenous (V-V) ECMO</p>
<ul>
<li>Indications for hypoxemia:<ul>
<li>PaO2/FiO2 \&lt; 50 with FiO2 &gt;80% for &gt;3 hrs OR</li>
<li>PaO2/FiO2 \&lt; 80 with FiO2 &gt;80% for &gt;6 hrs AND</li>
<li>Mechanical ventilation ≤ 1 week</li>
</ul>
</li>
<li>Absolute Contraindications:<ul>
<li>Poor short-term prognosis (e.g. metastatic cancer)</li>
<li>Irreversible, devastating neurologic pathology</li>
<li>Chronic respiratory insufficiency without the possibility for
    transplant</li>
</ul>
</li>
<li>Goal must be clear upfront
    
    bridge to recovery, transplant, or transplant decision</li>
<li>Can calculate RESP score
    
    predicts in-hospital survival with ECMO</li>
<li>CONSULT EARLY if a pt may be a candidate; does not commit pt to
    procedure but allows ECMO team to assist with evaluation</li>
<li>Data:<ul>
<li>CESAR 2009
    
    improved 6-month survival without severe disability</li>
<li>EOLIA 2018
    
    no mortality benefit but 28% crossover from control to ECMO arm
    dilutes potential effects</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-sepsis"><h1 id="critical-care-critical-care-sepsis-sepsis">Sepsis<a class="headerlink" href="#critical-care-critical-care-sepsis-sepsis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis – Kaele Leonard</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Sepsis-3: organ dysfunction from dysregulated host response to
    infection</li>
<li>Acute change in baseline SOFA score ≥2</li>
<li>Sequential Organ Failure Assessment (SOFA) score: P/F ratio, Plts,
    Tbili, SBP, GCS, Cr</li>
<li>"Quick" SOFA (qSOFA): ≥2 of AMS (GCS≤13), SBP≤100 mmHg, RR≥22/min</li>
<li>Septic shock = sepsis + vasopressors + lactate &gt;2 meq/dL</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Cultures prior to antibiotics if possible (but don’t delay
    antibiotics just to get cultures): obtain blood Cx x2 (peripheral
    vein via venipuncture preferred), urine Cx, etc.</li>
<li>Consider sputum Cx, paracentesis, thoracentesis, wound Cx, LP, joint
    aspiration</li>
<li>Lactate (even if not hypotensive)</li>
<li>Imaging: x-ray or CT of potential source</li>
</ul>
<p>Management</p>
<ul>
<li>Source control: Remove old lines, Chest tube for empyema, Drain
    abscesses</li>
</ul>
<!-- -->

<ul>
<li>Early antibiotics: START EARLY—each hour of delay of antibiotics
    ↑
    mortality by ~7%<ul>
<li>Target organisms most likely to cause infection in suspected
    organ; if source unknown, start empiric broad-spectrum</li>
<li>MRSA coverage
    
    vancomycin/daptomycin/linezolid/ceftaroline</li>
<li>Pseudomonas coverage
    
    zosyn/cefepime/meropenem /cipro/gentamicin</li>
<li>Pneumonia: add atypical coverage (azithromycin/levaquin; 2<sup>nd</sup>
    line doxycyline)</li>
<li>Fungal coverage for Candida: if neutropenic, TPN, abdominal
    surgery, prior antibiotics, &gt;1 site colonized
    
    fluconazole, micafungin for Candida glabrata ( or resistant
    strains)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Resuscitation<ul>
<li>IV fluid: give 1-3 L (≥30 mL/kg of body weight) of IV balanced
    crystalloid</li>
<li>Only give blood if Hb \&lt; 7, unless evidence of bleeding, severe
    hypoxemia, or myocardial ischemia</li>
<li>Monitor HR, BP, mental status, urine output – do NOT give
    beta-blockers to slow HR in the setting of sepsis unless
    dangerously high and limiting diastolic filling (discuss with
    fellow), this is an appropriate stress response</li>
<li>Assess fluid responsiveness by US IVC (mixed data), pulse
    pressure, leg raise</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Vasopressors<ul>
<li>Start if MAP not responsive to fluid resuscitation</li>
<li>Target MAP &gt; 65mmHg, also monitor mental status, serum lactate,
    and urine output; may need higher goal with pts with chronic HTN</li>
<li>Start with norepinephrine -- via central line, PICC, port; can
    run through peripheral IV up to 15 mcg/min for up to 48 hours<ul>
<li>
<ul>
<li>SOAP II trial -- norepinephrine &gt; dopamine (less
        arrhythmias)</li>
<li>No upper limit of NE but can cause peripheral ischemia
    with prolonged use</li>
</ul>
</li>
</ul>
</li>
<li>Add vasopressin at fixed dose of 0.04 units/min when NE dose &gt;=
    50 mcg/min<ul>
<li>
<ul>
<li>VASST trial: possible benefit for pts on 5-15 of NE;
        however, this was opposite of hypothesis and vasopressin
        is expensive</li>
</ul>
</li>
</ul>
</li>
<li>Add epinephrine or dobutamine when low cardiac output</li>
<li>Add phenylephrine for pts with tachyarrhythmias</li>
<li>Rarely use dopamine</li>
<li>Consider Angiotensin II (discuss with fellow, needs MICU
    leadership approval)
    
    contraindicated with CHF and DVT/PE/clots/hypercoagulability</li>
<li>Consider steroids if vasopressors failing or on steroids
    chronically
    
    hydrocortisone 100mg IV q8hr or 50mg IV q6hr (see Endocrine
    Section)</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-shock"><h1 id="critical-care-critical-care-shock-shock">Shock<a class="headerlink" href="#critical-care-critical-care-shock-shock" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management of Shock – Alex Toporex, Soibhan Kelley</td>
</tr>
<tr>
<td>Distributive Shock</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Pathophysiology: severe, peripheral vasodilation<ul>
<li>CO/CI increased, SVR decreased, PCWP and RAP normal to low</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Etiologies: sepsis (far and away the most common cause of
    distributive shock), anaphylaxis, neurogenic, adrenal insufficiency,
    pancreatitis</li>
</ul>
<!-- -->

<ul>
<li>Signs/symptoms:<ul>
<li>Sepsis: localizing signs of infection; tachycardic, tachypnic,
    may be hypo/hyperthermic; POCUS with hyperdynamic cardiac
    function</li>
<li>Anaphylaxis: history of anaphylaxis; urticaria, edema, diarrhea,
    wheezing on exam</li>
<li>Neurogenic: history of CNS trauma; focal neurologic deficits on
    exam</li>
<li>Adrenal insufficiency: hx chronic steroid use, may have GI
    symptoms, hyponatremia (common), hyperkalemia (rare),
    hypoglycemia, hypo/hyperthermia, NAGMA</li>
<li>Pancreatitis: abdominal pain, elevated lipase, evidence on CT
    scan</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Sepsis: see sepsis section</li>
<li>Anaphylaxis: 0.3mg IM epinephrine ASAP to be repeated q5-15min x 3;
    after third IM epi, consider IVF and epi gtt if persistent
    hypotension. Adjuncts: albuterol nebs for bronchospasm, H1 and H2
    blockers (Benadryl 25-50mg IV, ranitidine 50mg IV), &plusmn;
    glucocorticoids (methylprednisolone 1mg/kg). EPINEPHRINE SAVES
    LIVES.</li>
<li>Neurogenic: caution with IVF resuscitation, which can worsen
    cerebral and spinal cord edema; preferred pressors are
    norepinephrine and phenylephrine; for neurogenic shock 2/2 spinal
    cord pathology, consider higher MAP goal 85-90 mmHg</li>
<li>Adrenal insufficiency: initiate stress dose steroids with
    hydrocortisone 100mg IV q8hr or 50mg q6hr; can also trial stress
    dose steroids on pts on 2-3 pressors</li>
<li>Pancreatitis: IVF (though at risk for over-resuscitation) +
    pressors; trend H/H and Ca; treat complications (necrotizing
    pancreatitis, abdominal compartment syndrome); address underlying
    etiology (gallstones, hypertriglyceridemia, hypercalcemia)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiogenic Shock</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Pathophysiology: CO/CI decreased, SVR increased, PCWP and RAP
    elevated (left heart failure) or PCWP low/normal and RAP elevated
    (right heart failure)</li>
<li>Etiologies: Cardiomyopathy (LHF, RHF or biventricular), Arrhythmia,
    Mechanical such as acute AR (ex: dissection) or MR (ex: ruptured
    papillary muscle)</li>
</ul>
<p>Presentation</p>
<ul>
<li>Edematous, elevated JVP, “cold and wet”; hypoxia w/crackles and pulm
    edema on CXR; mixed venous sat \&lt; 50-60%; POCUS with plump,
    non-compressible IVC, reduced EF, and B-lines</li>
</ul>
<p>Management</p>
<p>Immediate assessment for acute ischemic event</p>
<ul>
<li>Pulmonary artery catheters may be helpful for titrating therapies</li>
<li>Hallmark therapies:<ul>
<li>
<ul>
<li>
<ul>
<li>Preload
            
            aggressive diuresis, frequently need bumex or lasix gtt
        -   Inotropy
            
            dobutamine or milrinone gtt, both can cause arrhythmias,
            hypotension, reflex tachycardia; epi is also a good
            choice and a more familiar choice for MICU staff.
            Caution with milrinone in renal dysfunction.
        -   Afterload Reduction
            
            nitroglycerine gtt; hydralazine + ISDN for PO options;
            treat hypotension with pressors/inotropes if needed</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Acute Right Heart Failure is highly susceptible to R-sided coronary
    ischemia, consider vasopressin as beneficial in improving R-sided
    coronary blood flow</li>
</ul>
<!-- -->

<ul>
<li>Arrhythmia: See mgmt in “arrhythmia,” In general, unstable
    tachyarrhythmia
    
    cardioversion. Unstable bradyarrhythmia
    
    pacing. Avoid negative inotropes (BB, CCB)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypovolemic Shock</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Etiologies: Hemorrhagic and non-hemorrhagic</li>
</ul>
<!-- -->

<ul>
<li>Signs/symptoms:<ul>
<li>Hemorrhagic: Common sources include GI, retroperitoneal (*needs
    high index of suspicion), traumatic. Other sources of
    significant hemorrhage include intraabdominal, thighs, thorax.</li>
<li>Non-hemorrhagic: generally 2/2 GI losses—history of diarrhea,
    emesis; can also be 2/2 decreased PO intake</li>
<li>POCUS with thin, collapsible IVC</li>
</ul>
</li>
</ul>
<p>Management (Hemorrhagic)</p>
<ul>
<li>Ensure good access with two large-bore (at least 18G) IVs ideally in
    AC or above; Cordis or MAC CVC (can also use dialysis catheter, if
    necessary)</li>
<li>Hyperacute bleed:<ul>
<li>1:1:1 ratio FFP:Plt:RBC (balanced resuscitation), massive
    transfusion protocol (MTP)</li>
<li>Monitor iCa and replete (citrated blood products will deplete
    Ca)</li>
<li>Minimize crystalloid, if possible, w/primary use to prevent
    immediate hemodynamic collapse (contributes to coagulopathy,
    hypothermia, acidemia, trauma/surgery)</li>
<li>Permissive hypotension until source control/transfusions with
    arterial bleeds (high MAP/SBP &rarr; clot destabilization); trend
    POC lactate/exam to guide</li>
<li>Acute traumatic arterial bleed or post-partum hemorrhage
    consider TXA (1-2 gm bolus)</li>
<li>Reverse anticoagulation, if applicable</li>
<li>Vasopressors &rarr; generally poorly effective, would start with
    norepinephrine</li>
<li>Source control &rarr; GI, IR, or EGS</li>
</ul>
</li>
<li>Variceal bleed: See GI Bleeding section for specific management</li>
</ul>
<p>Management (Non-Hemorrhagic)</p>
<ul>
<li>Aggressive IVF resuscitation (balanced crystalloid); target MAP ≥65</li>
<li>Can support BP during resuscitation with pressors (usually
    norepinephrine)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive Shock</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Etiologies:<ul>
<li>Massive pulmonary embolism, tension pneumothorax, and cardiac
    tamponade</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Signs/symptoms:<ul>
<li>Pulmonary embolism: acute hypotension, known DVT, evidence of R
    heart strain on EKG, POCUS w/enlarged RV, septal bowing,
    McConnell’s sign,
    ↑
    BNP, PE on CTA</li>
<li>Tension pneumothorax: history of COPD or fibrotic lung disease,
    ventilated pts w/ high peak pressures, unilateral decreased BS
    on auscultation and tympany on percussion, POCUS without lung
    sliding, CXR w/ PTX and mediastinal shift</li>
<li>Cardiac tamponade: elevated JVP, muffled heart sounds, pulsus
    paradoxus, POCUS with diastolic collapse of RV and large
    pericardial effusion (best in subcostal window)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Massive pulmonary embolism: see Pulmonary Embolism Section for
    specific management</li>
<li>Tension PTX: needle decompression using 14-16G needle into the
    second intercostal space at the midclavicular line; call thoracic
    surgery or fellow for chest tube ASAP</li>
<li>Cardiac tamponade: STAT page cardiology or cardiothoracic surgery;
    can temporize hypotension with IVF resuscitation—500-1L IVF boluses
    (may not work if pt is euvolemic or hypervolemic); no proven benefit
    from inotropy (e.g., dobutamine)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-temperature-abnormalities"><h1 id="critical-care-critical-care-temperature-abnormalities-temperature-abnormalities">Temperature Abnormalities<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-temperature-abnormalities" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temperature Abnormalities – Soibhan Kelley</td>
</tr>
<tr>
<td>Hypothermia</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Core temperature \&lt;35°C (95°F)</li>
<li>Mild 32-35C (90-95F), moderate 28-32C (82-90F), or severe \&lt;28C
    (82F) &plusmn; pulseless</li>
<li>Ensure thermometer is “low-reading”; standard thermometers not
    accurate</li>
<li>Core temperature can be measured w/  bladder catheter probe or
    esophageal probe (may be falsely
    ↑
    if heated oxygen being delivered); Rectal temp can be used but is
    less accurate</li>
</ul>
<!-- -->

<ul>
<li>Etiologies:<ul>
<li>Heat loss: Environmental, burns, iatrogenic (CRRT, cold IVF,
    massive transfusion protocol), vasodilatory drugs/toxins</li>
<li>Decreased heat production: endocrinopathies (hypothyroidism,
    adrenal insufficiency, hypopituitarism, hypoglycemia), thiamine
    deficiency</li>
<li>Impaired regulation: Spinal cord injury, hypothalamic lesions,
    other CNS insults, drugs (classes including antihyperglycemics,
    beta blockers, sedatives, ETOH, alpha agonists, general
    anesthetics)</li>
<li>Multiple mechanisms: sepsis, pancreatitis, DKA</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Infectious work-up</li>
<li>POC blood glucose, TSH/FT4, cortisol, lipase, UA, UDS, EtOH level,
    additional tox as appropriate, DKA work-up if relevant</li>
<li>Physical exam + history for exposures and trauma</li>
<li>CBC, CMP, Lactate, Blood Gas (ABG preferred), CK, PT/PTT, Fibrinogen</li>
<li>EKG</li>
</ul>
<p>Management</p>
<ul>
<li>Treat underlying cause [see appropriate sections]</li>
<li>Mild hypothermia:<ul>
<li>Passive external rewarming (PER): blankets, increase ambient
    temperature</li>
<li>Note that PER requires sufficient underlying physiologic reserve
    to generate heat. This is often impaired in elderly pts,
    malnutrition, sepsis</li>
</ul>
</li>
<li>Moderate hypothermia, refractory mild hypothermia, or cardiovascular
    instability:<ul>
<li>Active external rewarming (AER): forced warm air (ie Bair
    Hugger), heated blankets, heat lamps, hot packs (consider burn
    risk)</li>
</ul>
</li>
<li>Severe hypothermia or refractory moderate hypothermia:<ul>
<li>Active core rewarming: Warmed IV crystalloid (limited rewarming
    potential unless large volume but will decrease ongoing losses),
    warmed humidified inspired air, warmed bladder lavage</li>
<li>More extreme methods such as peritoneal/thoracic lavage more
    likely to be used in severe environmental cases in ED</li>
</ul>
</li>
<li>Pulseless severe hypothermia (“You aren’t dead unless you are warm
    and dead”)<ul>
<li>Continue CPR until re-warmed as severe hypothermia is
    neuroprotective and pts can have good neurologic outcomes
    despite hours of CPR</li>
<li>ACLS medications and shocks will have poor effectiveness;
    prioritize circulation (i.e. chest compressions) and rewarming</li>
<li>Consider ECMO (likely venoarterial if pulseless); would need
    transfer to CVICU</li>
</ul>
</li>
<li>Identify and manage complications:  bradycardia/heart block,
    arrhythmias, shock, coagulopathy/DIC, rhabdo; rebound
    hyperkalemia/hypoglycemia with rewarming</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever and Hyperthermia</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>
<p>Fever: T &gt;38.0°C (100.4°F) driven by hypothalamus activity in
    response to systemic triggers (i.e. cytokines); may use lower
    threshold for immunocompromised pts</p>
</li>
<li>
<p>Hyperthermia: T &gt;41.0 C (105.8°F) uncontrolled heat production with
    failure of thermoregulate</p>
</li>
<li>
<p>Infectious etiologies:</p>
<ul>
<li>Considerations in the ICU include central-line associated blood
    stream infection, catheter-associated UTI, pneumonia (including
    ventilator-associated), sinusitis (esp in pts with NGT or ETT),
    clostridium difficile, acalculous cholecystitis</li>
</ul>
</li>
<li>
<p>Non-infectious etiologies:</p>
<ul>
<li>Drug fever<ul>
<li>Difficult to distinguish from other causes; Can begin
    hrs-wks after starting a drug</li>
<li>Sources: antibiotics (penicillins, cephalosporins,
    sulfonamides), anticonvulsants (phenytoin, carbamazepine,
    phenobarbital), allopurinol, heparin, dexmedetomidine</li>
<li>Drugs of abuse with sympathomimetic activity (cocaine, meth,
    ecstasy)</li>
<li>Anticholinergic or salicylate intoxication</li>
</ul>
</li>
</ul>
</li>
<li>
<ul>
<li>Idiosyncratic drug reactions
        -   Serotonin syndrome
        -   Neuroleptic malignant syndrome
        -   Malignant hyperthermia</li>
</ul>
</li>
<li>
<ul>
<li>Transfusion reactions</li>
<li>PE/DVT</li>
<li>Endocrine: hyperthyroidism/thyroid storm, adrenal insufficiency</li>
<li>CNS pathology (intracranial bleed/stroke, particularly
    hypothalamic region)</li>
<li>Malignancy</li>
<li>Heat stroke (exertional or non-exertional)</li>
<li>Other inflammatory states  Pancreatitis, gout, pericarditis,
    pneumonitis</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Infectious work-up &plusmn; LP; may consider pan-scan if unable to
    identify source</li>
<li>POC glucose, BMP, LFT, Mg/Phos, CBC w/diff</li>
<li>Consider coags + fibrinogen (DIC), CK/UA (rhabdo), UDS,
    acetaminophen and salicylate levels, TSH/FT4, cortisol, lipase, ABG</li>
<li>Review medication list
    
    antibiotics, serotonergic drugs, anti-psychotics, recent sedation
    for OR or recently intubated with succinylcholine, dexmedetomidine</li>
<li>Consider CT/MRI head</li>
</ul>
<p>Management</p>
<ul>
<li>Treat underlying etiology [see appropriate sections]<ul>
<li>Serotonin syndrome
    
    stop serotonergic drugs; add cyproheptadine</li>
<li>Malignant hyperthermia
    
    activate malignant hyperthermia team; add dantrolene</li>
</ul>
</li>
<li>Cooling<ul>
<li>Target \&lt;38.0°C (100.4°F)</li>
<li>Surface cooling:<ul>
<li>
<ul>
<li>Ice (bath, or ice packs more likely in our MICU)</li>
<li>Evaporative cooling with misted lukewarm water and fan</li>
</ul>
</li>
</ul>
</li>
<li>Internal cooling:<ul>
<li>
<ul>
<li>Cold IV fluids</li>
<li>Dry ventilation (evaporative)
    
    non-humidified nasal cannula or vent circuit</li>
</ul>
</li>
</ul>
</li>
<li>Avoid shivering
    
    give opiates (except in serotonin syndrome), precedex, propofol,
    benzos, ketamine</li>
</ul>
</li>
<li>Antipyretics<ul>
<li>Acetaminophen, NSAIDs</li>
<li>Block prostaglandin-mediated temperature elevations</li>
<li>Effective for most causes of fever
    
    infection, pancreatitis, DVT/PE, pneumonitis</li>
<li>AVOID for true hyperthermia (ineffective and potentially
    harmful)
    
    neuroleptic malignant syndrome, malignant hyperthermia,
    serotonin syndrome, heat stroke</li>
</ul>
</li>
<li>Monitor for complications<ul>
<li>Rhabdo, DIC, arrhythmias</li>
</ul>
</li>
<li>If high suspicion for infection and not improving on antibiotics,
    consider other infectious etiologies including fungal (ex: candida)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-tracheostomy"><h1 id="critical-care-critical-care-tracheostomy-tracheostomy">Tracheostomy<a class="headerlink" href="#critical-care-critical-care-tracheostomy-tracheostomy" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tracheostomy – Jared Freitas</td>
</tr>
</tbody>
</table>
<p>Indications for Tracheostomy</p>
<ul>
<li>prolonged mechanical intubation and weaning</li>
<li>acute airway obstructions (head and neck cancers)</li>
<li>tracheal stenosis</li>
<li>trauma</li>
<li>neuromuscular disease</li>
</ul>
<p>Benefits of Tracheostomy vs ET tube</p>
<ul>
<li>improved pt comfort and decreased need for sedation</li>
<li>reduced laryngeal damage</li>
<li>increased ability to communicate (i.e. speaking valve)</li>
<li>may decrease risk of developing ventilator associated pneumonia
    (mixed data)</li>
<li>may reduce time to wean from the vent and decrease time in the
    hospital (mixed data)</li>
</ul>
<p>Timing of Tracheostomy:</p>
<ul>
<li>no mortality difference or
    ↓
    in hospital length of stay b/w  early (day 4) vs late (day 10)</li>
<li>Generally performed after 2 weeks of intubation, but not backed by
    data</li>
<li>Pts that might get tracheostomy earlier: anticipated prolonged
    mechanical ventilation (i.e. those with acute neurologic injury
    affecting spinal cord)</li>
</ul>
<p>Types of Tracheostomy Tubes:</p>
<ul>
<li>Different brands: most common in hospital = Shiley</li>
<li>Components:<ul>
<li>Faceplate: keeps tube in place, has the model and size on it</li>
<li>Inner cannula: can be removed, cleaned and replaced in case of
    obstruction</li>
<li>Cuff (may or may not have): allows for positive pressure and for
    pt to be ventilated; may prevent some aspiration</li>
<li>Fenestration (may or may not have): allow speaking without valve</li>
</ul>
</li>
<li>Common sizes:<ul>
<li>Initial: 8-0; Standard downsizing: 6-0</li>
<li>Lengths: standard vs. larger XLT (P = longer proximal end, D =
    longer distal end)</li>
</ul>
</li>
<li>Presenting on ICU rounds = size/cuff status/brand (e.g. 8-0 cuffed
    shiley)</li>
</ul>
<p>Speaking Valves:</p>
<ul>
<li>Passy Muir Valve (PMV)
    
    one-way button-shaped valve placed on the outer portion of the
    trach; air moves in with inspiration but is blocked and thus
    funneled up through the vocal cords during exhalation allowing for
    phonation</li>
<li>Contraindication: have severe upper airway obstruction or aspiration
    risk, copious secretions, decreased cognitive status, severe medical
    instability, or inability to tolerate cuff deflation (need PPV)</li>
<li>IMPORTANT SAFETY PRINCIPLE
    : cuff must be deflated, since air needs to be able to travel back
    up the airway, if the cuff is not deflated and you put the PMV on,
    then pt cannot exhale</li>
</ul>
<p>Maintenance of Tracheostomy Tubes:</p>
<ul>
<li>Inner cannula should be cleaned 2-3 times per day</li>
<li>Daily stoma care should be initiated to prevent pressure ulcers and
    stoma infections</li>
<li>As needed suctioning for secretions</li>
</ul>
<p>Complications and airway emergencies in a tracheostomy pt:</p>
<ul>
<li>Hemorrhage (mild bleeding from surface vessels and granulation
    tissue is common, major bleeding is rare
    
    think erosion into brachiocephalic [innominate] artery)</li>
<li>Airway damage
    
    subglottic or tracheal stenosis; tracheobronchitis</li>
<li>Fistulas (tracheoarterial, tracheoesophageal)</li>
<li>Unintended tracheostomy tube dislodgement:<ul>
<li>Bag mask (use hand/gauze to occlude stoma) or intubate from
    above (i.e. through the mouth); if complete laryngectomy then
    must use stoma</li>
<li>Fresh trach (≤ 14 days): do NOT replace due to risk of
    misplacement into the mediastinum and loss of airway; airway
    management from above</li>
<li>Older trach: can be replaced at bedside with obturator by
    trained staff</li>
<li>All pts with trachs have a yellow sign above bed with date,
    type, size of trach as well as a replacement trach with
    obturator in the room</li>
</ul>
</li>
</ul>
<p>Strategies for Prolonged Ventilator Weaning</p>
<ul>
<li>Typically done in a step wise fashion: move from mainly VC or PC
    setting
    
    pressure support
    
    trach collar (blow by oxygen)
    
    capping trials
    
    once passed capping trials successfully can possibly proceed to
    decannulation</li>
<li>After being on trach collar successfully, then can consider
    downsizing the trach</li>
</ul>
<p>Causes of Prolonged Weaning</p>
<ul>
<li>Cardiovascular: HF or ischemia
    
    may need diuresis or antiplatelet</li>
<li>Metabolic: check and replete phos, Mg, Ca, thyroid (all re:
    diaphragm weakness)</li>
<li>Sepsis: anaerobic state that drives metabolic acidosis leading to
    difficulty ventilating</li>
<li>Psychological: managing anxiety related to vent and handling
    secretions is important</li>
<li>Nutrition: protein catabolism can lead to diaphragmatic weakness</li>
<li>Physical deconditioning: PT to treat ICU polymyopathy and overall
    functional status</li>
</ul>
<p>Secretion Management</p>
<ul>
<li>Respiratory hygiene (“pulmonary toilet”): heated vent, guaifenesin,
    hypertonic saline, duonebs, cough assist device, appropriate
    suctioning (too much = worsen secretions), acapella, inspiratory
    spirometer, hyperinflation therapy</li>
</ul></section><section class="print-page" id="critical-care-critical-care-vent-settings"><h1 id="critical-care-critical-care-vent-settings-vent-settings">Vent Settings<a class="headerlink" href="#critical-care-critical-care-vent-settings-vent-settings" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Vent Management – Eddie Qian</td>
</tr>
</tbody>
</table>
<p>Ventilator Settings:</p>
<ul>
<li>FiO2 or Fraction of inspired oxygen (%)</li>
<li>PEEP or Positive End Expiratory Pressure (mmHg)</li>
<li>RR or respiratory rate (breaths per minute)</li>
<li>Vt or Tidal volume (mL) [in VC modes or PRVC]</li>
<li>Pressure Support above PEEP [in PC/PS modes]</li>
<li>Flow rate: how fast a volume is delivered; adjusting this variable
    changes the inspiratory to expiratory (I:E) time in volume control
    ventilator modes</li>
<li>Trigger: what initiates a breath; time, flow, or pressure (pt
    triggers are flow and pressure)</li>
<li>Cycle: when to stop delivering breath; time (pressure control
    modes), flow (pressure support modes), or volume (volume control
    modes)</li>
<li>Alarms: peak pressure, low pressure, minute ventilation, pt
    disconnect</li>
</ul>
<p>Static Ventilator Readouts:</p>
<ul>
<li>Plateau pressure (P <sub>plat</sub> ): measure with inspiratory hold
    (i.e. breath held at the end of inspiration and pressure measured);
    assesses static lung compliance</li>
<li>Auto-PEEP: measure with expiratory hold; occurs when volume of
    previous breath is not entirely expelled before the next breath is
    initiated</li>
</ul>
<p>Dynamic Ventilator Readouts:</p>
<ul>
<li>Measured RR: in most modes, pt may trigger breaths above set RR; if
    set and measured RR match, 2/2
    ↓
    respiratory drive (over sedated, neurologic injury) or iatrogenic
    over-ventilation</li>
<li>VTi / VTe: tidal volume of inspiration (VTi) and expiration (VTe);
    VTi should approximately equal VTe, if not then concern for air leak
    (e.g. cuff leak or pneumothorax) or auto-PEEP</li>
<li>Minute ventilation: calculated from VTe x RR; higher MV = more CO2
    clearance</li>
<li>Peak pressure: highest pressure reached in the entire ventilator
    cycle</li>
</ul>
<p>Critical Non-ventilator Hemodynamic Readouts:</p>
<ul>
<li>SpO2: if poor waveform or discordant with PaO2, may need serial ABG</li>
<li>HR: quickest indicator of emergencies such as pneumothorax, PE,
    ventilator disconnection</li>
<li>Blood pressure (cuff or arterial line): positive pressure
    ventilation decreases preload and decreases afterload; depending on
    the underlying pt physiology, increases in positive pressure may be
    detrimental or beneficial for BP</li>
</ul>
<p>Ventilator troubleshooting:</p>
<ul>
<li>Peak Pressure Alarm: either a problem with the ability of the lung
    to stretch (compliance) or with airflow in the tubing (resistance);
    the inspiratory hold will remove the movement of air and give you a
    plateau pressure; if plateau pressure is high lung compliance is the
    issue, if it is normal airflow (resistance) is the issue.<ul>
<li>Compliance Issues: processes filling the alveoli (ARDS, DAH,
    pulmonary edema), abdominal compartment syndrome,
    circumferential burn, kyphosis, obesity, PTX, mainstem
    intubation</li>
<li>Resistance Issues: bronchospasm, mucous plug, biting the tube,
    kink in the tubing from the endotracheal tube to the machine,
    water in the tubing</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Low Minute Ventilation Alarm (this reports EXHALED minute
    ventilation): either your pt is apneic or there is a leak in your
    system and remember the system may also be in the pt; fix the leak;
    if they are not on a mode with a set RR, please ask for this to be
    switched.<ul>
<li>This should also be the alarm for ventilator disconnection.</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Refractory hypoxemia: see dedicated section below</li>
<li>At the VA, you may adjust the vents as your discretion but always
    inform the RT as a courtesy</li>
<li>At VUMC, do NOT adjust the ventilator, please ask RT to make
    adjustments<ul>
<li>There are many trials going on at the VUMC MICU that you do not
    want to interfere with</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-main"><h1 id="critical-care-main-management-of-shock">Management of Shock<a class="headerlink" href="#critical-care-main-management-of-shock" title="Permanent link">&para;</a></h1>
<p>Alex Toporex, Soibhan Kelley</p>
<hr />
<h2 id="critical-care-main-distributive-shock">Distributive Shock<a class="headerlink" href="#critical-care-main-distributive-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background">Background<a class="headerlink" href="#critical-care-main-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Pathophysiology: severe, peripheral vasodilation</li>
<li>CO/CI increased, SVR decreased, PCWP and RAP normal to low</li>
<li>Etiologies: sepsis (most common), anaphylaxis, neurogenic, adrenal
    insufficiency, pancreatitis</li>
<li>Signs/symptoms:<ul>
<li>Sepsis: localizing signs of infection; tachycardia, tachypnea, may
    be hypo/hyperthermic; POCUS with hyperdynamic cardiac function</li>
<li>Anaphylaxis: history of anaphylaxis; urticaria, edema, diarrhea,
    wheezing on exam</li>
<li>Neurogenic: history of CNS trauma; focal neurologic deficits on exam</li>
<li>Adrenal insufficiency: hx chronic steroid use, may have GI symptoms,
    hyponatremia (common), hyperkalemia (rare), hypoglycemia,
    hypo/hyperthermia, NAGMA</li>
<li>Pancreatitis: abdominal pain, elevated lipase, evidence on CT scan</li>
</ul>
</li>
</ul>
<h3 id="critical-care-main-management">Management<a class="headerlink" href="#critical-care-main-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Sepsis: see sepsis section</li>
<li>Anaphylaxis: 0.3mg IM epinephrine ASAP to be repeated q5-15min x 3;
    after third IM epi, consider IVF and epi gtt if persistent
    hypotension. Adjuncts: albuterol nebs for bronchospasm, H1 and H2
    blockers, &plusmn; glucocorticoids (methylprednisolone 1mg/kg).
    EPINEPHRINE SAVES LIVES.</li>
<li>Neurogenic: caution with IVF resuscitation, can worsen cerebral and
    spinal cord edema; preferred pressors are norepinephrine and
    phenylephrine; for neurogenic shock 2/2 spinal cord pathology,
    consider higher MAP goal 85-90 mmHg</li>
<li>Adrenal insufficiency: stress dose steroids with hydrocortisone
    100mg IV q8hr or 50mg q6hr</li>
<li>Pancreatitis: IVF + pressors; trend H/H and Ca; treat complications
    (necrotizing pancreatitis, abdominal compartment syndrome); address
    underlying etiology (see GI section)</li>
</ul>
<h2 id="critical-care-main-cardiogenic-shock">Cardiogenic Shock<a class="headerlink" href="#critical-care-main-cardiogenic-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_1">Background<a class="headerlink" href="#critical-care-main-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Pathophysiology: CO/CI decreased, SVR increased, PCWP and RAP
    elevated (left heart failure) or PCWP low/normal and RAP elevated
    (right heart failure)</li>
<li>Etiologies: Cardiomyopathy (LHF, RHF or biventricular), arrhythmia,
    mechanical such as acute AR (ex: dissection) or MR (ex: ruptured
    papillary muscle)</li>
</ul>
<h3 id="critical-care-main-presentation">Presentation<a class="headerlink" href="#critical-care-main-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Edematous, elevated JVP, “cold and wet”; hypoxia w/crackles and pulm
    edema; mixed venous sat \&lt; 50-60%; POCUS with plump,
    non-compressible IVC, reduced EF, and B-lines</li>
</ul>
<h3 id="critical-care-main-management_1">Management<a class="headerlink" href="#critical-care-main-management_1" title="Permanent link">&para;</a></h3>
<p>See cardiogenic shock in cardiology section</p>
<h2 id="critical-care-main-hypovolemic-shock">Hypovolemic Shock<a class="headerlink" href="#critical-care-main-hypovolemic-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_2">Background<a class="headerlink" href="#critical-care-main-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Etiologies: Hemorrhagic and non-hemorrhagic</li>
<li>Signs/symptoms:<ul>
<li>Hemorrhagic: Common sources include GI, retroperitoneal (*needs
    high index of suspicion), traumatic, intraabdominal, thighs, thorax</li>
<li>Non-hemorrhagic: 2/2 GI losses or decreased PO intake</li>
</ul>
</li>
<li>POCUS with thin, collapsible IVC</li>
</ul>
<h3 id="critical-care-main-management-hemorrhagic">Management (Hemorrhagic)<a class="headerlink" href="#critical-care-main-management-hemorrhagic" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure good access with two large-bore (at least 18G) IVs ideally in
    AC or above; Cordis or MAC CVC (can also use dialysis catheter, if
    necessary)</li>
<li>Hyperacute bleed:<ul>
<li>1:1:1 ratio FFP:Plt:RBC (balanced resuscitation), massive
    transfusion protocol (MTP)</li>
<li>Monitor iCa and replete (citrated blood products will deplete Ca)</li>
<li>Minimize crystalloid if possible, w/primary use to prevent immediate
    hemodynamic collapse (contributes to coagulopathy, hypothermia,
    acidemia, trauma/surgery)</li>
<li>Permissive hypotension until source control/transfusions with
    arterial bleeds (high MAP/SBP -> clot destabilization); trend POC
    lactate/exam to guide</li>
<li>Acute traumatic arterial bleed or post-partum hemorrhage consider
    TXA (1-2 gm bolus)</li>
<li>Reverse anticoagulation, if applicable</li>
<li>Vasopressors -> generally poorly effective, would start with
    norepinephrine</li>
<li>Source control -> GI, IR, or EGS</li>
</ul>
</li>
<li>Variceal bleed: See GI Bleeding section for specific management</li>
</ul>
<h3 id="critical-care-main-management-non-hemorrhagic">Management (Non-Hemorrhagic)<a class="headerlink" href="#critical-care-main-management-non-hemorrhagic" title="Permanent link">&para;</a></h3>
<ul>
<li>Aggressive IVF resuscitation (balanced crystalloid); target MAP ≥65</li>
<li>Can support BP during resuscitation with pressors (usually
    norepinephrine)</li>
</ul>
<h2 id="critical-care-main-obstructive-shock">Obstructive Shock<a class="headerlink" href="#critical-care-main-obstructive-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_3">Background<a class="headerlink" href="#critical-care-main-background_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Etiologies: Massive pulmonary embolism, tension pneumothorax, and cardiac
    tamponade</li>
<li>Signs/symptoms:<ul>
<li>Pulmonary embolism: acute hypotension, known DVT, evidence of R
    heart strain on EKG, POCUS w/enlarged RV, septal bowing, McConnell’s
    sign, ↑ BNP, PE on CTA</li>
<li>Tension pneumothorax: history of COPD or fibrotic lung disease,
    ventilated pts w/ high peak pressures, unilateral decreased BS on
    auscultation and tympany on percussion, POCUS without lung sliding,
    CXR w/ PTX and mediastinal shift</li>
<li>Cardiac tamponade: elevated JVP, muffled heart sounds, pulsus
    paradoxus, POCUS with diastolic collapse of RV and large pericardial
    effusion (best in subcostal window)</li>
</ul>
</li>
</ul>
<h3 id="critical-care-main-management_2">Management<a class="headerlink" href="#critical-care-main-management_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Massive pulmonary embolism: see Pulmonary Embolism Section for
    specific management</li>
<li>Tension PTX: needle decompression using 14-16G needle into the
    second intercostal space at the midclavicular line; call trauma
    surgery or fellow for chest tube ASAP</li>
<li>Cardiac tamponade: STAT page cardiology or cardiothoracic surgery;
    can temporize hypotension with IVF resuscitation—500-1L IVF boluses
    (may not work if pt is euvolemic or hypervolemic); no proven benefit
    from inotropy (e.g., dobutamine)</li>
</ul>
<h1 id="critical-care-main-sepsis">Sepsis<a class="headerlink" href="#critical-care-main-sepsis" title="Permanent link">&para;</a></h1>
<p>Charlie Oertli</p>
<hr />
<h2 id="critical-care-main-background_4">Background<a class="headerlink" href="#critical-care-main-background_4" title="Permanent link">&para;</a></h2>
<p>Most recent definition (Sepsis-3): organ dysfunction from
    dysregulated host response to infection</p>
<ul>
<li>2021 Surviving Sepsis Guidelines: SIRS, MEWS, NEWS superior to qSOFA
    for <u>screening</u> sepsis</li>
<li>SIRS ≥2 of any of: 1) RR>20, 2) T \&lt;36 or >38, 3) HR >90, 4) WBC
    \&lt;4 or >12 or >10% bands</li>
<li>Septic Shock = sepsis + vasopressors + lactate >2 meq/dL (Sepsis 3
    definition)</li>
<li>Alternate screening systems you may see which are more
    <u>specific</u> and better at prognosis of in hospital mortality
    than SIRS:<ul>
<li>Acute change in baseline SOFA score ≥2: P/F ratio, Plts, Tbili, SBP,
    GCS, Cr</li>
<li>"Quick" SOFA (qSOFA): ≥2 of AMS (GCS≤13), SBP≤100 mmHg, RR≥22/min</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-evaluation">Evaluation<a class="headerlink" href="#critical-care-main-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Cultures prior to antibiotics if possible (but don’t delay
    antibiotics just to get cultures)</li>
<li>Consider sputum Cx, paracentesis, thoracentesis, wound Cx, LP, joint
    aspiration</li>
<li>Lactate (even if not hypotensive)</li>
<li>Imaging: x-ray, CT, or US of potential source</li>
</ul>
<h2 id="critical-care-main-management_3">Management<a class="headerlink" href="#critical-care-main-management_3" title="Permanent link">&para;</a></h2>
<p>Source control: Remove old lines, chest tube for empyema, drain
    abscesses, etc</p>
<p>Antibiotics</p>
<ul>
<li>Early antibiotics: within 1 hour if septic shock, within 3 hours if
    sepsis</li>
<li>Target organisms most likely to cause infection in suspected organ;
    if source unknown, start empiric broad-spectrum</li>
<li>MRSA coverage - vancomycin/daptomycin/linezolid/ceftaroline</li>
<li>Pseudomonas coverage - zosyn/cefepime/meropenem /cipro/gentamicin</li>
<li>Pneumonia: add atypical coverage (azithromycin/levaquin; 2<sup>nd</sup> line
    doxycycline if prolonged QTC or elderly) if severe or being admitted
    to the ICU</li>
<li>Fungal coverage for Candida: if neutropenic, TPN, abdominal surgery,
    prior antibiotics</li>
<li>De-escalation: Once source is controlled, if abx duration is unknown
    use procalcitonin, culture susceptibilities, and clinical evaluation
    to help guide de-escalation</li>
</ul>
<p>Resuscitation</p>
<div class="highlight"><pre><span></span><code>- Give 1-3 L (≥30 mL/kg of body weight) of IV balanced crystalloid
    within first 3 hours
- Only give blood if Hb \&lt; 7, unless evidence of bleeding or
    myocardial ischemia
- Monitor HR, BP, mental status, urine output – do NOT give
    beta-blockers to slow HR in the setting of sepsis unless dangerously
    high and limiting diastolic filling (discuss with fellow), this is
    an appropriate stress response
- Assess fluid responsiveness by leg raise (if BP improves with leg
    raise, give more fluids). Other options US IVC (mixed data), pulse
    pressure
</code></pre></div>
<p>Vasopressors</p>
<ul>
<li>Start if MAP not responsive to fluid resuscitation</li>
<li>Target MAP > 65mmHg, also monitor mental status, serum lactate, and
    urine output; may need higher goal for pts with chronic HTN</li>
<li>Start with norepinephrine -- via central line, PICC, or port. Can
    run through peripheral IV (at least 18g, proximal to wrist) up to 15
    mcg/min for up to 48 hours if no central access<ul>
<li>SOAP II trial: norepinephrine > dopamine (less arrhythmias)</li>
<li>No upper limit of NE but can cause peripheral ischemia with
    prolonged use</li>
</ul>
</li>
<li>Add vasopressin at fixed dose of 0.04 units/min when NE dose >= 50
    mcg/min<ul>
<li>VASST trial: possible benefit for pts on 5-15 of NE; however,
    this was opposite of hypothesis and vasopressin is expensive</li>
</ul>
</li>
<li>Add epinephrine or dobutamine if low cardiac output</li>
<li>Add phenylephrine for pts with tachyarrhythmias (reflex bradycardia)</li>
<li>Consider Angiotensin II (discuss with fellow, needs MICU leadership
    approval) contraindicated with CHF and
    DVT/PE/clots/hypercoagulability</li>
<li>Consider steroids if vasopressors failing or on steroids chronically
    hydrocortisone 100mg IV q8hr or 50mg IV q6hr for 5 to 7 days</li>
</ul>
<h1 id="critical-care-main-temperature-abnormalities">Temperature Abnormalities<a class="headerlink" href="#critical-care-main-temperature-abnormalities" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley</p>
<hr />
<h2 id="critical-care-main-hypothermia">Hypothermia<a class="headerlink" href="#critical-care-main-hypothermia" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_5">Background<a class="headerlink" href="#critical-care-main-background_5" title="Permanent link">&para;</a></h3>
<ul>
<li>Core temperature \&lt;35°C (95°F). Mild 32-35C (90-95F), moderate
    28-32C (82-90F), or severe \&lt;28C (82F) &plusmn; pulseless</li>
<li>Ensure thermometer is “low-reading,” standard thermometers not
    accurate</li>
<li>Core temperature can be measured w/ bladder catheter probe or
    esophageal probe (may be falsely ↑ if heated oxygen being
    delivered). Rectal temp can be used but is less accurate</li>
<li>Etiologies:<ul>
<li>Heat loss: Environmental, burns, iatrogenic (CRRT, cold IVF, massive
    transfusion protocol), vasodilatory drugs/toxins</li>
<li>Decreased heat production: endocrinopathies (hypothyroidism, adrenal
    insufficiency, hypopituitarism, hypoglycemia), thiamine deficiency</li>
<li>Impaired regulation: Spinal cord injury, hypothalamic lesions, drugs
    (classes including antihyperglycemics, beta blockers, sedatives,
    ETOH, alpha agonists, general anesthetics)</li>
<li>Multiple mechanisms: sepsis, pancreatitis, DKA</li>
</ul>
</li>
</ul>
<h3 id="critical-care-main-evaluation_1">Evaluation<a class="headerlink" href="#critical-care-main-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Infectious work-up</li>
<li>POC blood glucose, TSH/FT4, cortisol, lipase, UA, UDS, EtOH level,
    additional tox as appropriate, DKA work-up if relevant</li>
<li>Physical exam + history for exposures and trauma</li>
<li>CBC, CMP, Lactate, ABG, CK, PT/PTT, Fibrinogen</li>
<li>EKG</li>
</ul>
<h3 id="critical-care-main-management_4">Management<a class="headerlink" href="#critical-care-main-management_4" title="Permanent link">&para;</a></h3>
<ul>
<li>Treat underlying cause [see appropriate sections]</li>
<li>Mild hypothermia:<ul>
<li>Passive external rewarming (PER): blankets, increase ambient
    temperature</li>
<li>Note that PER requires sufficient underlying physiologic reserve to
    generate heat. This is often impaired in elderly pts, malnutrition,
    sepsis</li>
</ul>
</li>
<li>Moderate hypothermia, refractory mild hypothermia, or cardiovascular
    instability:<ul>
<li>Active external rewarming (AER): forced warm air (ie Bair Hugger),
    heated blankets, heat lamps, hot packs (consider burn risk)</li>
</ul>
</li>
<li>Severe hypothermia or refractory moderate hypothermia:<ul>
<li>Active core rewarming: Warmed IV crystalloid (limited rewarming
    potential unless large volume but will decrease ongoing losses),
    warmed humidified inspired air, warmed bladder lavage</li>
<li>More extreme methods such as peritoneal/thoracic lavage more likely
    to be used in severe environmental cases in ED</li>
</ul>
</li>
<li>Pulseless severe hypothermia (“You aren’t dead unless you are warm
    and dead”)<ul>
<li>Continue CPR until re-warmed as severe hypothermia is
    neuroprotective and pts can have good neurologic outcomes despite
    hours of CPR</li>
<li>ACLS medications and shocks will have poor effectiveness; prioritize
    circulation (i.e. chest compressions) and rewarming</li>
<li>Consider ECMO (likely venoarterial if pulseless); would need
    transfer to CVICU</li>
</ul>
</li>
<li>Identify and manage complications: bradycardia/heart block,
    arrhythmias, shock, coagulopathy/DIC, rhabdo; rebound
    hyperkalemia/hypoglycemia with rewarming</li>
</ul>
<h2 id="critical-care-main-fever-and-hyperthermia">Fever and Hyperthermia<a class="headerlink" href="#critical-care-main-fever-and-hyperthermia" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_6">Background<a class="headerlink" href="#critical-care-main-background_6" title="Permanent link">&para;</a></h3>
<ul>
<li>Fever: T >38.0°C (100.4°F) driven by hypothalamus activity in
    response to systemic triggers (i.e. cytokines); may use lower
    threshold for immunocompromised pts</li>
<li>Hyperthermia: T >41.0 C (105.8°F) uncontrolled heat production with
    failure of thermoregulation</li>
<li>Infectious etiologies:<ul>
<li>Considerations in the ICU include central-line associated blood
stream infection, catheter-associated UTI, pneumonia (including
ventilator-associated), sinusitis (esp in pts with NGT or ETT),
<em>clostridium difficile</em>, acalculous cholecystitis</li>
</ul>
</li>
<li>Non-infectious etiologies:</li>
<li>Drug fever<ul>
<li>Difficult to distinguish from other causes; Can begin hrs-wks
    after starting a drug</li>
<li>Sources: antibiotics (penicillins, cephalosporins,
    sulfonamides), anticonvulsants (phenytoin, carbamazepine,
    phenobarbital), allopurinol, heparin, dexmedetomidine</li>
<li>Drugs of abuse with sympathomimetic activity (cocaine, meth,
    ecstasy)</li>
<li>Anticholinergic or salicylate intoxication</li>
</ul>
</li>
<li>Idiosyncratic drug reactions<ul>
<li>Serotonin syndrome</li>
<li>Neuroleptic malignant syndrome</li>
<li>Malignant hyperthermia</li>
</ul>
</li>
<li>Transfusion reactions</li>
<li>PE/DVT</li>
<li>Endocrine: hyperthyroidism/thyroid storm, adrenal insufficiency</li>
<li>CNS pathology (intracranial bleed/stroke, particularly hypothalamic
    region)</li>
<li>Malignancy</li>
<li>Heat stroke (exertional or non-exertional)</li>
<li>Other inflammatory states: Pancreatitis, gout, pericarditis,
    pneumonitis</li>
</ul>
<h3 id="critical-care-main-evaluation_2">Evaluation<a class="headerlink" href="#critical-care-main-evaluation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Infectious work-up &plusmn; LP; may consider pan-scan if unable to
    identify source</li>
<li>POC glucose, BMP, LFT, Mg/Phos, CBC w/diff</li>
<li>Consider coags + fibrinogen (DIC), CK/UA (rhabdo), UDS,
    acetaminophen and salicylate levels, TSH/FT4, cortisol, lipase, ABG</li>
<li>Review medication list: antibiotics, serotonergic drugs,
    anti-psychotics, recent sedation for OR or recently intubated with
    succinylcholine, dexmedetomidine</li>
<li>Consider CT/MRI head</li>
</ul>
<h3 id="critical-care-main-management_5">Management<a class="headerlink" href="#critical-care-main-management_5" title="Permanent link">&para;</a></h3>
<ul>
<li>Treat underlying etiology [see appropriate sections]</li>
<li>Serotonin syndrome -> stop serotonergic drugs; add cyproheptadine</li>
<li>Malignant hyperthermia ->activate malignant hyperthermia team; add
    dantrolene</li>
<li>Cooling<ul>
<li>Target \&lt;38.0°C (100.4°F)</li>
<li>Surface cooling: Ice (bath, or ice packs more likely in our MICU),
    evaporative cooling with misted lukewarm water and fan</li>
<li>Internal cooling:
    Cold IV fluids
    (pharmacy keeps ~3L of cold LR on-hand, they will cool more if you call down and ask),
    dry ventilation (evaporative) with non-humidified nasal cannula or vent circuit</li>
<li>Avoid shivering -> give opiates (except in serotonin syndrome),
    precedex, propofol, benzos, ketamine</li>
</ul>
</li>
<li>Antipyretics<ul>
<li>Acetaminophen, NSAIDs</li>
<li>Block prostaglandin-mediated temperature elevations</li>
<li>Effective for most causes of fever- infection, pancreatitis, DVT/PE,
    pneumonitis</li>
<li>AVOID for true hyperthermia (ineffective and potentially harmful)
    -> neuroleptic malignant syndrome, malignant hyperthermia,
    serotonin syndrome, heat stroke</li>
</ul>
</li>
<li>Monitor for complications<ul>
<li>Rhabdo, DIC, arrhythmias</li>
</ul>
</li>
<li>If high suspicion for infection and not improving on antibiotics,
    consider other infectious etiologies including fungal (ex: candida)</li>
</ul>
<h1 id="critical-care-main-modes-of-oxygen-delivery">Modes of Oxygen Delivery<a class="headerlink" href="#critical-care-main-modes-of-oxygen-delivery" title="Permanent link">&para;</a></h1>
<p>Blake Funke</p>
<hr />
<table>
<thead>
<tr>
<th>System</th>
<th>L/min</th>
<th>% O2</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blow by (ex: Trach collar)</td>
<td></td>
<td>21-100%</td>
<td></td>
</tr>
<tr>
<td>Nasal cannula</td>
<td>1-8</td>
<td>25 – 45%</td>
<td></td>
</tr>
<tr>
<td>Large bore nasal cannula</td>
<td>Up to 15</td>
<td>Up to 65%</td>
<td>Can be identified by larger bore tubing (often green) and nose piece. Colloquially referred to as HFNC at VUMC, but true HFNC = optiflow</td>
</tr>
<tr>
<td>Venturi mask</td>
<td>4 to 15</td>
<td>24 – 50%</td>
<td>Actual FiO2 is dependent on patient effort</td>
</tr>
<tr>
<td>Non-rebreather</td>
<td>10 to 15</td>
<td>65-95%</td>
<td>Often used as a bridge to higher level of O2 therapy</td>
</tr>
<tr>
<td>HFNC: Optiflow, AirVo</td>
<td>Up to 60</td>
<td>30-100%</td>
<td>Delivers 0.5-1 cm/H2O of PEEP per 10L of flow</td>
</tr>
<tr>
<td><em>*Use of all of these modes requires a spontaneously breathing patient</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h2 id="critical-care-main-non-invasive-positive-pressure-ventilation">Non-invasive positive pressure ventilation<a class="headerlink" href="#critical-care-main-non-invasive-positive-pressure-ventilation" title="Permanent link">&para;</a></h2>
<ul>
<li>CPAP<ul>
<li>Indications: obstructive sleep apnea, tracheomalacia</li>
<li>Settings: CPAP, FiO2</li>
</ul>
</li>
<li>BiPAP<ul>
<li>Indications: hypercapnic respiratory failure (RF), hypoxic RF,
    pulmonary edema, obstructive sleep apnea, obesity hypoventilation
    syndrome, RF 2/2 neuromuscular disease</li>
<li>Settings: IPAP, EPAP, FiO2, RR (sometimes)</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 19%" />
<col style="width: 16%" />
<col style="width: 44%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4">Invasive positive-pressure ventilation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mode</td>
<td>You set</td>
<td>Not set</td>
<td>Comments</td>
</tr>
<tr class="even">
<td>Pressure support (PS)</td>
<td><p>PEEP</p>
<p>PS above PEEP</p>
<p>FiO2</p></td>
<td><p>TV</p>
<p>RR</p>
<p>Inspiratory flow</p></td>
<td>Similar to Bipap. Frequently used for vent weaning / SBT. Requires
spontaneously breathing pt</td>
</tr>
<tr class="odd">
<td>Volume Control (AC/VC)</td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>Inspiratory flow</p>
<p>FiO2</p></td>
<td>Inspiratory pressure</td>
<td><p>Mandates a minute ventilation; limits volutrauma (i.e. can
guarantee low tidal volume ventilation)</p>
<p>Primary mode used in MICU (mode used in major ARDS trials)</p></td>
</tr>
<tr class="even">
<td><p>SIMV</p>
<p>Synchronized Intermittent Mandatory Ventilation</p></td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>PS above PEEP</p>
<p>FiO2</p></td>
<td></td>
<td>Pt gets VC breath for set rate, but if tries to breath over this
will get PS breath; VC and PS breaths are synchronized when able</td>
</tr>
<tr class="odd">
<td>Pressure Control (AC/PC)</td>
<td><p>RR</p>
<p>Inspiratory Pressure</p>
<p>PEEP</p>
<p>Inspiratory Time (or I:E ratio)</p>
<p>FiO2</p></td>
<td>TV</td>
<td><p>Minimizes barotrauma (i.e. sets a max inspiratory pressure) does
not guarantee a specific minute ventilation (must monitor PCO2 with
blood gases)</p>
<p>Does not have natural ventilator alarms for protection – need to
increase low minute ventilation alarm threshold</p></td>
</tr>
<tr class="even">
<td><p>PRVC</p>
<p>Pressure Regulated Volume Control</p></td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>Inspiratory flow</p>
<p>Pressure max</p>
<p>FiO2</p></td>
<td></td>
<td><p>Adaptive pressure control (NOT actually a volume control mode);
tries to limit both barotrauma and volutrauma but if in conflict, minute
ventilation will drop (i.e. need to monitor PCO2 with blood gases like
any other PC mode)</p>
<p>Con: More the pt works, the less the ventilator does</p></td>
</tr>
<tr class="odd">
<td>APRV / Bilevel</td>
<td><p>PEEP (PLow)</p>
<p>Pressure High</p>
<p>Time Low</p>
<p>Time High</p>
<p>FiO2</p></td>
<td>TV</td>
<td><p>Long periods of inspiratory holds and very brief expirations
(i.e. releases), for refractory hypoxemia.</p>
<p>Often difficult to ventilate pts on this mode</p></td>
</tr>
</tbody>
</table>

<h1 id="critical-care-main-introduction-to-vent-management">Introduction to Vent Management<a class="headerlink" href="#critical-care-main-introduction-to-vent-management" title="Permanent link">&para;</a></h1>
<p>Jared Freitas</p>
<hr />
<h2 id="critical-care-main-ventilator-settings">Ventilator Settings<a class="headerlink" href="#critical-care-main-ventilator-settings" title="Permanent link">&para;</a></h2>
<ul>
<li>See table in Modes of Oxygen Delivery for variables adjusted
    in each ventilator mode</li>
<li>Trigger: what initiates a breath; time, flow, or pressure (pt
    triggers are flow and pressure)</li>
</ul>
<h2 id="critical-care-main-static-ventilator-readouts">Static Ventilator Readouts<a class="headerlink" href="#critical-care-main-static-ventilator-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>Plateau pressure (Pplat): measure with inspiratory hold, assesses
    static lung compliance</li>
<li>Auto-PEEP: measure with expiratory hold; occurs when volume of
    previous breath is not entirely expelled before the next breath is
    initiated</li>
</ul>
<h2 id="critical-care-main-dynamic-ventilator-readouts">Dynamic Ventilator Readouts<a class="headerlink" href="#critical-care-main-dynamic-ventilator-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>Measured RR: in most modes, pt may trigger breaths above set RR; if
    set and measured RR match consider ↓ respiratory drive (sedation,
    neurologic injury) or iatrogenic over-ventilation</li>
<li>VTi / VTe: tidal volume of inspiration (VTi) and expiration (VTe)</li>
<li>VTi should approximately equal VTe, if not then concern for air leak
    (e.g. cuff leak or pneumothorax) or auto-PEEP</li>
<li>Minute ventilation: calculated from VTe x RR; higher MV = more CO2
    clearance</li>
<li>Peak pressure: highest pressure reached in the entire ventilator
    cycle</li>
</ul>
<h2 id="critical-care-main-critical-non-ventilator-hemodynamic-readouts">Critical Non-ventilator hemodynamic readouts<a class="headerlink" href="#critical-care-main-critical-non-ventilator-hemodynamic-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>SpO2: if poor waveform or discordant with PaO2, may need serial ABG</li>
<li>HR: quickest indicator of emergencies such as pneumothorax, PE,
    ventilator disconnection</li>
<li>Blood pressure: positive pressure ventilation decreases preload and
    afterload; depending on the underlying pt physiology, increases in
    positive pressure may be detrimental or beneficial for BP</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 21%" />
<col style="width: 57%" />
</colgroup>
<thead>
<tr class="header">
<th>Alarm Type</th>
<th>What is causing the alarm?</th>
<th>Troubleshooting</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>High Peak Pressure</td>
<td>Static compliance issue (stretch of the lung-doesn’t change with
airflow) versus dynamic compliance issue (resistance of the circuit when
there is air flowing)</td>
<td><p>Step 1: Check plateau pressure by performing inspiratory hold.
Must be in VC mode.</p>
<p><strong>High Peak and Low Plateau</strong> = Dynamic compliance issue
High Resistance</p>
<ul>
<li><p>Check circuit tubing for excess water condensation or a kink. Ask
RT to disconnect and clear circuit</p></li>
<li><p>Check if patient is biting ETT bite block, pain
control/sedation</p></li>
<li><p>Incline suction to clear secretions or proximal mucous
plug</p></li>
<li><p>Auscultate for wheezing or stridor to indicate bronchospasm or
airway obstruction-&gt;give bronchodilators</p></li>
</ul>
<p><strong>High Peak and High Plateau</strong> = Static compliance issue
Worsening alveolar process</p>
<ul>
<li><p>Emergencies to quickly assess for:</p></li>
</ul>
<ul>
<li><p>Tension pneumothorax (exam, US for lung sliding, CXR)</p></li>
<li><p>Main stem intubation (ask about any tube migration, listen to
breath sounds, CXR)</p></li>
</ul>
<ul>
<li><p>Consider worsening alveolar process leading to decreased lung
compliance: worsening pulmonary edema, PNA, DAH, ARDS or other
non-alveolar process such as new pleural effusion, obesity,
intraabdominal hypertension/compartment syndrome</p></li>
</ul>
<ul>
<li><p>CXR, US to assess for b-lines, tracheal aspirate, bronch,
etc</p></li>
<li><p>Treat according to etiology (chest tube, reposition ETT,
diuresis, abx, etc)</p></li>
</ul></td>
</tr>
<tr class="even">
<td>Low Tidal Volume/Low Minute Ventilation (VE)</td>
<td>Pt is not getting the desired tidal volume/VE that was set in the
vent parameters. The alarm reports exhaled VE. May cause inadequate
ventilation, CO2 retention, potentially hypoxia</td>
<td><p><strong>Compare inspiratory tidal volumes (Vti) with expiratory
tidal volumes (Vte) on the ventilator. If Vti&gt;Vte, check for a leak
in the system</strong></p>
<ul>
<li><p>Have RT check all connections</p></li>
<li><p>Listen for a cuff leak – can have RT check a cuff pressure and if
low then re-inflate-&gt;sometimes need to do an ETT exchange</p></li>
<li></li>
</ul>
<p><strong>If low tidal volumes and no leak (ie. Vti = Vte) and RR
WNL</strong></p>
<ul>
<li><p>Pt may need more support, ie switching to a different vent mode
(PS to PRVC). Discuss with RT or fellow</p></li>
</ul>
<p><strong>If low RR and no leak and Vt at goal</strong></p>
<ul>
<li><p>Patient may be oversedated</p></li>
<li><p>Ensure pt has a back-up rate in case they aren’t triggering the
vent-&gt;may need to switch vent modes for this (i.e. take off pressure
support) or increase set/ventilator respiratory rate</p></li>
</ul></td>
</tr>
<tr class="odd">
<td>Apnea</td>
<td>No breaths are being triggered by the vent your patient is NOT
breathing this is an emergency</td>
<td><p>***<strong>Check that patient hasn't self-extubated, trach hasn't
fallen out, or been unhooked from vent***</strong></p>
<p>If self-extubated or tracheostomy decannulated, then immediately
start bagging the patient (may need to bag from trach stoma if s/p
laryngectomy). Have nurse call staff assist so that patient can be
re-intubated if necessary or have trach team called to replace a fresh
(&lt;7 days old) trach</p></td>
</tr>
</tbody>
</table>

<h1 id="critical-care-main-acute-respiratory-distress-syndrome-ards">Acute Respiratory Distress Syndrome (ARDS)<a class="headerlink" href="#critical-care-main-acute-respiratory-distress-syndrome-ards" title="Permanent link">&para;</a></h1>
<p>Judd Heideman</p>
<hr />
<h2 id="critical-care-main-background_7">Background<a class="headerlink" href="#critical-care-main-background_7" title="Permanent link">&para;</a></h2>
<ul>
<li>A syndrome of diffuse inflammation and injury of the alveoli and
    capillary endothelium leading to fluid and protein accumulation in
    the interstitium and alveoli, pulmonary edema, and hypoxemic
    respiratory failure; 30-50% mortality rate</li>
<li>Triggers:</li>
<li>Pulmonary<ul>
<li>Pneumonia (viral and bacterial) • Lung contusion</li>
<li>Direct inhalation injury • Aspiration</li>
<li>Primary graft dysfunction of pulmonary transplant</li>
</ul>
</li>
<li>Extra-pulmonary<ul>
<li>Sepsis (most common cause) • HSCT</li>
<li>Trauma • Burns</li>
<li>Massive blood transfusions/TRALI • Pancreatitis</li>
<li>Drugs (amiodarone, chemotherapy, cocaine, opioids)</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-evaluation_3">Evaluation<a class="headerlink" href="#critical-care-main-evaluation_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Diagnosis: Berlin Criteria</li>
<li>New or worsening respiratory symptoms beginning within one week of
    diagnosis</li>
<li>New bilateral opacities present on chest radiograph or CT chest<ul>
<li>Not explained by effusions, collapse of lobe/lung, or nodules</li>
</ul>
</li>
<li>Absence of left heart failure or volume overload</li>
<li>Severity: based on PaO2/FiO2 ratio with a PEEP ≥ 5 cm H2O</li>
<li>PaO2 = arterial partial pressure of O2 (requires ABG)</li>
<li>FiO2 = fraction of inspired oxygen (expressed as a decimal between
    0.21 and 1.0)</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th>PaO2/FiO2 ratio</th>
<th>PEEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>201-300</td>
<td>≥5</td>
</tr>
<tr>
<td>Moderate</td>
<td>101-200</td>
<td>≥5</td>
</tr>
<tr>
<td>Severe</td>
<td>\&lt;100</td>
<td>≥5</td>
</tr>
</tbody>
</table>
<h2 id="critical-care-main-management_6">Management<a class="headerlink" href="#critical-care-main-management_6" title="Permanent link">&para;</a></h2>
<ul>
<li>Frequently requires intubation; non-invasive ventilation not a great
    treatment</li>
<li>Low tidal volume (Vt) ventilation mortality benefit</li>
<li>Goal Vt = 4-8 mL/kg of <em>predicted</em> body weight (obese patients don’t
    have bigger lungs)</li>
<li>Plateau pressure goal: ≤30 cm H2O</li>
<li>Oxygenation goal: PaO2 55-80 or SpO2 88-95%</li>
<li>pH goal: ≥7.20, “permissive hypercapnia”</li>
<li>Treat the underlying cause (see “Triggers” above)</li>
</ul>
<h1 id="critical-care-main-refractory-hypoxemia">Refractory Hypoxemia<a class="headerlink" href="#critical-care-main-refractory-hypoxemia" title="Permanent link">&para;</a></h1>
<p>Amelia Muhs</p>
<hr />
<h2 id="critical-care-main-background_8">Background<a class="headerlink" href="#critical-care-main-background_8" title="Permanent link">&para;</a></h2>
<ul>
<li>Inadequate arterial oxygenation despite high levels of inspired O2
    or the development of barotrauma in mechanically ventilated pts</li>
<li>Generally start to consider the interventions below if needing FiO2
    >80%</li>
<li>Differential:<ul>
<li>Worsening underlying primary process (e.g. progressive ARDS)</li>
<li>PE</li>
<li>Pneumothorax</li>
<li>Fluid overload</li>
<li>Ventilator-associated Pneumonia</li>
<li>New ARDS</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-evaluation_4">Evaluation<a class="headerlink" href="#critical-care-main-evaluation_4" title="Permanent link">&para;</a></h2>
<ul>
<li>Always get CXR STAT if pt has new or worsening O2 requirement</li>
<li>ABG is frequently helpful as well</li>
<li>Can use POCUS to check for lung sliding (pneumothorax) or RV
    enlargement/septal bowing/McConnell’s sign (RV strain in PE)</li>
</ul>
<h2 id="critical-care-main-initial-management">Initial management<a class="headerlink" href="#critical-care-main-initial-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Remember – if at any point the pt is rapidly decompensating, you can
    always disconnect them from the vent and bag them until they
    recover/while calling for help</li>
<li>Early consideration of ECMO consult in appropriate pts (discuss with
    MICU fellow)</li>
<li>Optimize fluid status consider diuresis/dialysis if not making urine</li>
<li>Consider higher PEEP strategy</li>
<li>Increased PEEP higher mean airway pressure, generally improves
    oxygenation especially with diffuse pulmonary pathologies<ul>
<li>Exceptions may include certain focal/shunt pathologies (e.g.
    dense lobar PNA)</li>
<li>Worsening oxygenation may occur with overdistension of alveoli
    increase dead space ventilation; generally determined
    empirically at the bedside</li>
</ul>
</li>
<li>Titrate up slowly; generally do not exceed PEEP 18<ul>
<li>Limited by high plateau pressures/barotrauma,
    overdistension/dead space ventilation, decreased preload/venous
    return</li>
</ul>
</li>
<li>
<p>ARDSnet FiO2/PEEP Tables: At VUMC we typically use the Lower PEEP
    table</p>
</li>
<li>
<p>Other recruitment maneuvers</p>
<ul>
<li>Reposition pt – can try elevating HOB or positioning so “good lung”
    is down</li>
<li>If concern for mucus plug, consider need for bronch</li>
<li>If concern for significant atelectasis can try recruitment maneuvers
    with the vent including sustained inflation (setting expiratory
    pressure to ~30 for ~30 seconds) and PEEP titration (setting PEEP
    to 20-25 and decreasing by 2cm at a time) – call the fellow before
    attempting</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-management-algorithm-for-refractory-hypoxemia">Management Algorithm for Refractory Hypoxemia<a class="headerlink" href="#critical-care-main-management-algorithm-for-refractory-hypoxemia" title="Permanent link">&para;</a></h2>
<ul>
<li>Inhaled vasodilators: Distribute preferentially to well-ventilated
    alveoli local vasodilation improved V/Q matching</li>
<li>VUMC formulary preference: inhaled epoprostenol (aka Flolan)</li>
<li>Alternatives: inhaled milrinone, inhaled nitric oxide</li>
<li>Data suggest improved PaO2/FiO2; large RCT without evidence for
    mortality benefit</li>
<li>Deep sedation (RASS -4 or -5)<ul>
<li>Promotes ventilator synchrony</li>
</ul>
</li>
<li>Neuromuscular blockade (paralysis) – call your fellow before doing
    this<ul>
<li>Rationale: maximal vent synchrony (eliminates residual chest
    wall/diaphragm tone)</li>
<li>Pt MUST be RASS -5 (need analgesia + sedation)</li>
<li>Trial one time IV push of vecuronium 0.1 mg/kg</li>
<li>If improved vent synchrony/oxygenation, consider cisatracurium
    (Nimbex) drip</li>
<li>Data are mixed ACURASYS 2010 (improved 90-day mortality but
    underpowered likely overestimating benefit); ROSE 2019 (no
    difference in 90-day mortality)</li>
</ul>
</li>
<li>Prone positioning (Need attending approval)<ul>
<li>Pts with moderate to severe ARDS (PaO2/FiO2 ratio \&lt; 150)</li>
<li>At VUMC, we use regular ICU beds and manually flip pts; cycle prone
    16 hrs/supine 8 hrs</li>
<li>When proning or supining a pt, always have a provider who can
    intubate in the room in case unplanned extubation occurs</li>
<li>Considerations: need a team of people to reposition, high risk of ET
    tube malposition, difficult to access lines/perform procedures, high
    risk of pressure injuries</li>
<li>Data: PROSEVA 2013 proning improved 28-day mortality; study
    complicated by imbalances between groups</li>
</ul>
</li>
<li>Alternative ventilator modes (usually Pressure Control or
    APRV/BiLevel/BiVent)</li>
<li>APRV/BiVent should be avoided in people with bad obstructive lung
    disease, hemodynamic instability, refractory hypercarbia</li>
<li>Venovenous (V-V) ECMO<ul>
<li>Indications for hypoxemia:<ul>
<li>PaO2/FiO2 \&lt; 50 with FiO2 >80% for >3 hrs OR</li>
<li>PaO2/FiO2 \&lt; 80 with FiO2 >80% for >6 hrs AND</li>
<li>Mechanical ventilation ≤ 1 week</li>
</ul>
</li>
<li>Absolute Contraindications:<ul>
<li>Poor short-term prognosis (e.g. metastatic cancer)</li>
<li>Irreversible, devastating neurologic pathology</li>
<li>Chronic respiratory insufficiency without the possibility for
    transplant</li>
</ul>
</li>
<li>Can calculate RESP score predicts in-hospital survival with ECMO</li>
<li>CONSULT EARLY if a pt may be a candidate; allows ECMO team to assist
    with evaluation</li>
<li>Data:<ul>
<li>CESAR 2009: improved 6-month survival without severe disability</li>
<li>EOLIA 2018 : no mortality benefit but 28% crossover from control
    to ECMO arm dilutes potential effects</li>
</ul>
</li>
</ul>
</li>
</ul>
<h1 id="critical-care-main-refractory-hypercapnia">Refractory Hypercapnia<a class="headerlink" href="#critical-care-main-refractory-hypercapnia" title="Permanent link">&para;</a></h1>
<p>Amelia Muhs</p>
<hr />
<h2 id="critical-care-main-background_9">Background<a class="headerlink" href="#critical-care-main-background_9" title="Permanent link">&para;</a></h2>
<ul>
<li>Inadequate clearance of CO2 leading to respiratory acidosis (pH ≤
    7.20) despite maximum RR&amp;TV (i.e. minute ventilation) tolerated
    without causing barotrauma or autoPEEP</li>
<li>Common causes:<ul>
<li>Obstructive lung disease (COPD, emphysema, asthma)</li>
<li>Hypoventilation (sleep apnea, obesity, sedative medications (ie
    opiates), neuromuscular weakness, chest wall trauma, ascites/pleural
    effusion)</li>
<li>Increased CO2 load (shock, sepsis, malignant hyperthermia)</li>
</ul>
</li>
<li>Presentation:<ul>
<li>Shortness of breath</li>
<li>AMS, somnolence</li>
<li>Hypoxemia</li>
<li>Tachycardia, hypertension (in some cases)</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-evaluation_5">Evaluation<a class="headerlink" href="#critical-care-main-evaluation_5" title="Permanent link">&para;</a></h2>
<ul>
<li>Physical exam, mental status, recent medications</li>
<li>ABG or VBG – if increased PCO2 and normal pH, always treat the pH
    and not the PCO2 (i.e., may be compensated chronic hypercarbia and
    blowing off more CO2 may be harmful)</li>
</ul>
<h2 id="critical-care-main-management-algorithm">Management Algorithm<a class="headerlink" href="#critical-care-main-management-algorithm" title="Permanent link">&para;</a></h2>
<ul>
<li>Special considerations<ul>
<li>If history of OSA, make sure they are on home CPAP/BiPAP</li>
<li>If opiate related trial narcan</li>
<li>Bronchodilators for reactive airway diseases</li>
</ul>
</li>
<li>BiPAP<ul>
<li>Contraindicated if pt unable to remove BiPAP mask on their own</li>
<li>Increase MV by increasing Δ between IPAP/EPAP or increasing RR</li>
</ul>
</li>
<li>Mechanical ventilation<ul>
<li>Allows you to control rate and tidal volume (in Volume Control
    modes)</li>
<li>NOTE: some pts have higher minute ventilation on their own compared
    to mechanical ventilation (e.g., DKA); pt-specific considerations
    regarding intubation</li>
<li>To increase minute ventilation and CO2 clearance:<ul>
<li>Increase RR<ul>
<li>30-35 is about as high as you can go</li>
<li>Need to keep in mind I/E time to avoid breath
    stacking/autoPEEP (gas trapped in lungs)</li>
<li>Some signs of autoPEEP include worsening hypotension and the
    expiratory limb on the flow waveform on the vent not
    returning to zero</li>
</ul>
</li>
<li>Increase TV we usually start at 4-6mL/kg IBW. You can consider
    increasing to 8mL/kg IBW as long as plateau pressures remain \&lt;
    30 cm H2O<ul>
<li>Goal peak pressures ≤ 35 cm H2O / plateau pressures ≤ 30 cm
    H2O</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>ARDS permissive hypercapnia (goal pH ≥ 7.2)</li>
<li>V-V ECMO / Extracorporeal carbon dioxide removal (ECCO2R)</li>
<li>Indications for hypercapnia:<ul>
<li>Severe dynamic hyperinflation and/or severe respiratory acidosis</li>
<li>pH ≤ 7.25 with PaCO2 ≥ 60 for 6 hr with RR at 35/min and TV
    increased to target maximum MV while keeping plateau pressure ≤
    32 cm H2O</li>
<li>Similar considerations and contraindications as refractory hypoxemia
(see above)</li>
<li>Benefits: Reduces work of breathing, promotes early ventilator
    weaning/extubating allows early mobilization and recovery</li>
</ul>
</li>
</ul>
<h1 id="critical-care-main-tracheostomy">Tracheostomy<a class="headerlink" href="#critical-care-main-tracheostomy" title="Permanent link">&para;</a></h1>
<p>Jared Freitas</p>
<hr />
<h2 id="critical-care-main-indications">Indications<a class="headerlink" href="#critical-care-main-indications" title="Permanent link">&para;</a></h2>
<ul>
<li>Prolonged mechanical intubation and weaning</li>
<li>Tracheal stenosis</li>
<li>Acute airway obstructions (head and neck cancers)</li>
<li>Trauma</li>
<li>Neuromuscular disease</li>
</ul>
<h2 id="critical-care-main-benefits-of-tracheostomy-vs-et-tube">Benefits of Tracheostomy vs ET tube<a class="headerlink" href="#critical-care-main-benefits-of-tracheostomy-vs-et-tube" title="Permanent link">&para;</a></h2>
<ul>
<li>Improved pt comfort and decreased need for sedation</li>
<li>Reduced laryngeal damage</li>
<li>Increased ability to communicate (i.e. speaking valve)</li>
<li>May decrease risk of developing ventilator associated pneumonia
    (mixed data)</li>
<li>May reduce time to wean from the vent and decrease time in the
    hospital (mixed data)</li>
</ul>
<h2 id="critical-care-main-timing">Timing<a class="headerlink" href="#critical-care-main-timing" title="Permanent link">&para;</a></h2>
<ul>
<li>No mortality difference or ↓ in hospital length of stay for early
    (day 4) vs late (day 10)</li>
<li>Generally performed after 2 weeks of intubation, but not backed by
    data</li>
<li>Pts that might get tracheostomy earlier: anticipated prolonged
    mechanical ventilation (i.e. those with acute neurologic injury
    affecting spinal cord)</li>
</ul>
<h2 id="critical-care-main-types-of-tracheostomy-tubes">Types of Tracheostomy Tubes<a class="headerlink" href="#critical-care-main-types-of-tracheostomy-tubes" title="Permanent link">&para;</a></h2>
<ul>
<li>Different brands: most common in hospital = Shiley</li>
<li>Components:<ul>
<li>Faceplate: keeps tube in place, has the model and size on it</li>
<li>Inner cannula: can be removed, cleaned and replaced in case of
    obstruction</li>
<li>Cuff (may or may not have): allows for pt to be ventilated; may
    prevent some aspiration</li>
<li>Fenestration (may or may not have): allow speaking without valve</li>
</ul>
</li>
<li>Common sizes:<ul>
<li>Initial: 8-0; Standard downsizing: 6-0</li>
<li>Lengths: standard vs. larger XLT (P = longer proximal end, D =
    longer distal end)</li>
</ul>
</li>
<li>Presenting on ICU rounds = size/cuff status/brand (e.g. 8-0 cuffed
    shiley)</li>
</ul>
<h2 id="critical-care-main-speaking-valves">Speaking Valves<a class="headerlink" href="#critical-care-main-speaking-valves" title="Permanent link">&para;</a></h2>
<ul>
<li>Passy Muir Valve (PMV): one-way valve placed on the outer portion of
    the trach; air moves in with inspiration but is blocked and thus
    funneled up through the vocal cords during exhalation allowing for
    phonation</li>
<li>Contraindication: severe upper airway obstruction or aspiration
    risk, copious secretions, decreased cognitive status, severe medical
    instability, or inability to tolerate cuff deflation</li>
<li>IMPORTANT SAFETY PRINCIPLE: cuff must be deflated, since air needs
    to be able to travel back up the airway, if the cuff is not deflated
    and you put the PMV on, then pt cannot exhale</li>
</ul>
<h2 id="critical-care-main-maintenance-of-tracheostomy-tubes">Maintenance of Tracheostomy Tubes<a class="headerlink" href="#critical-care-main-maintenance-of-tracheostomy-tubes" title="Permanent link">&para;</a></h2>
<ul>
<li>Inner cannula should be cleaned 2-3 times per day</li>
<li>Daily stoma care should be initiated to prevent pressure ulcers and
    stoma infections</li>
<li>As needed suctioning for secretions</li>
</ul>
<h2 id="critical-care-main-complications-and-airway-emergencies-in-a-tracheostomy-pt">Complications and airway emergencies in a tracheostomy pt<a class="headerlink" href="#critical-care-main-complications-and-airway-emergencies-in-a-tracheostomy-pt" title="Permanent link">&para;</a></h2>
<ul>
<li>Hemorrhage (mild bleeding from surface vessels and granulation
    tissue is common, major bleeding is rare think erosion into
    brachiocephalic [innominate] artery)</li>
<li>Airway damage subglottic or tracheal stenosis; tracheobronchitis</li>
<li>Fistulas (tracheoarterial, tracheoesophageal)</li>
<li>Unintended tracheostomy tube dislodgement:<ul>
<li>Bag mask (use hand/gauze to occlude stoma) or intubate from above
    (i.e. through the mouth); if complete laryngectomy then must use
    stoma</li>
<li>Fresh trach (≤ 14 days): do NOT replace due to risk of misplacement
    into the mediastinum and loss of airway; airway management from
    above</li>
<li>Older trach: can be replaced at bedside with obturator by trained
    staff</li>
<li>All pts with trachs have a yellow sign above bed with date, type,
    size of trach as well as a replacement trach with obturator in the
    room</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-secretion-management">Secretion Management<a class="headerlink" href="#critical-care-main-secretion-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Respiratory hygiene (“pulmonary toilet”): heated vent, guaifenesin,
    hypertonic saline, duonebs, cough assist device, appropriate
    suctioning (too much = worsen secretions), acapella, inspiratory
    spirometer</li>
</ul>
<h1 id="critical-care-main-abcdef-a2f-bundle">ABCDEF (A2F) Bundle<a class="headerlink" href="#critical-care-main-abcdef-a2f-bundle" title="Permanent link">&para;</a></h1>
<p>Kaele Leonard</p>
<hr />
<h2 id="critical-care-main-background_10">Background<a class="headerlink" href="#critical-care-main-background_10" title="Permanent link">&para;</a></h2>
<ul>
<li>Post-Intensive Care Syndrome (PICS): complex constellation of
    cognitive, physical, and psychological impairments that impact most
    survivors of critical illness, leading to disability, frailty, and
    poor quality of life</li>
<li>Predicted by (1) duration of immobility and (2) delirium</li>
<li>Both are reduced by >80% compliance with ABCDEF (A2F) Bundle
    concepts</li>
<li>ABCDEF (A2F) Bundle: Interprofessional, evidence-based safety bundle
    of care principles to help reduce LOS, mortality, bounce-backs, and
    the duration of ICU delirium and coma</li>
<li>Goal: allow pt to “prove us wrong” about readiness for liberation
    from devices, sedatives, etc.</li>
</ul>
<p>**A**ssess, prevent, and manage pain</p>
<ul>
<li>Tools to assess pain using facial expressions, body movements,
    muscle tension, compliance with ventilator, or vocalization for
    extubated pts</li>
<li>Ex: Critical Care Pain Observation Tool (CPOT): scale 0-8,
    uncontrolled pain 3</li>
<li>Uncontrolled pain increases risk for delirium, limits inspiratory
    effort &amp; weaning from ventilator, and limits ability to mobilize</li>
<li>Treatment: multi-modal: parenteral opioids, neuropathic meds (e.g.,
    gabapentin, ketamine), adjunctive non-opioids analgesics (e.g.,
    acetaminophen, NSAIDs), nonpharmacologic interventions
    (repositioning, heat/cold)</li>
</ul>
<p>**B**oth spontaneous awakening trials (SATs) and spontaneous breathing
trials (SBTs)</p>
<ul>
<li>SATs = daily sedative interruptions</li>
<li>RN-driven protocol involving safety checklist: no active seizures,
    alcohol withdrawal, agitation, paralytics, myocardial infarction, or
    increased ICP</li>
<li>If pass SAT, then proceed to SBT</li>
<li>If fail SAT (anxiety, agitation, pain, resp distress) restart
    sedation at ½ doses</li>
<li>SBTs = PS ventilation (Fi02 ≤ 50%, PEEP ≤ 7.5; typically 40% and
    5/5) for ≥ 30 minutes</li>
<li>RT or physician/APP-driven protocol with safety screen: passed SAT,
    O2 sat ≥ 88%, inspiratory efforts, no myocardial ischemia, no/low
    vasopressor support</li>
<li>If pass SBT, physician/APP judgment on extubation</li>
<li>If fail SBT (RR > 35 or \&lt; 8, O2 sat \&lt; 88%, resp distress, mental
    status change) restart full ventilatory support</li>
<li>Evidence:<ul>
<li>Liberated pts from mechanical ventilation 3 days sooner, decreased
    ICU and hospital length of stay by 4 days, and 14% absolute
    reduction in mortality at 1 year</li>
</ul>
</li>
</ul>
<p>**C**hoice of analgesia and sedation</p>
<ul>
<li>Richmond Agitation-Sedation Scale (RASS): sedation &amp; level of
    arousal assessment tool (Figure 1)</li>
<li>Target light sedation of RASS -1 to 0 with goal of (1) pt following
    commands without agitation and (2) limiting immobilization</li>
<li>Over-sedation: hold sedatives till target, then restart at ½ prior
    dose</li>
<li>Analgosedation with focus on treating pain first and then adding
    sedation meds PRN</li>
<li>Sedatives: dexmedetomidine (dex) or propofol >>> benzodiazepines</li>
<li>Benzodiazepines increase risk of delirium in a dose-dependent
    fashion</li>
</ul>
<figure>
<p><img alt="Richmond Agitation-Sedation Scale" src="../images/image12.png" />
  </p>
<figcaption> Figure 1: Richmond Agitation-Sedation Scale (RASS) Delirium - assess, prevent, and manage</figcaption>
</figure>
<p>**D**elirium- assess, prevent, and manage</p>
<ul>
<li>Screening for delirium: q4hr using CAM-ICU (Figure 2)</li>
<li>Affects 60-80% of ventilated pts and associated with increased
    morbidity and mortality, longer ICU and hospital length of stay,
    long-term cognitive dysfunction</li>
<li>Risk factors and treatment: see Delirium section in Psychiatry</li>
</ul>
<p>**E**arly mobility and exercise</p>
<ul>
<li>Prolonged immobilization during critical illness leads to
    ICU-acquired weakness, associated with worse outcomes: ↑ mechanical
    ventilation, increased hosp length of stay, greater mortality, and
    greater disability</li>
<li>Consult PT/OT to initiate rehab at the beginning of critical illness</li>
<li>Can be done safely in pts receiving advanced support</li>
</ul>
<p>**F**amily engagement and empowerment</p>
<ul>
<li>Especially important when pts are unable to communicate themselves</li>
<li>Incorporate family at the bedside and on rounds to learn pt
    preferences and values, engage in shared-decision making, and
    address questions and concerns</li>
</ul>
<figure>
<p><img alt="ABCDEF" src="../images/image13.png" />
  </p>
<figcaption></figcaption>
</figure>
<h1 id="critical-care-main-brain-death">Brain Death<a class="headerlink" href="#critical-care-main-brain-death" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="critical-care-main-background_11">Background<a class="headerlink" href="#critical-care-main-background_11" title="Permanent link">&para;</a></h2>
<ul>
<li>Brain death= complete and permanent loss of brain function. Defined
    by coma with loss of capacity for consciousness, brainstem reflexes,
    and the ability to breathe independently</li>
</ul>
<p>Checklist for Determination of Brain Death (American Academy of
Neurology)</p>
<ol>
<li>Prerequisites (all must be checked)<ul>
<li>Coma, irreversible and cause known</li>
<li>Neuroimaging explains coma – usually CT or MRI</li>
<li>Absence of CNS depressing drugs</li>
<li>No evidence of residual paralytics (electrical stimulation if
    paralytics used)</li>
<li>Absence of severe acid-base, electrolyte, endocrine abnormality</li>
<li>Normothermia or mild hypothermia (core temp >36°C)</li>
<li>SBP ≥100 mm Hg</li>
<li>No spontaneous respirations</li>
</ul>
</li>
<li>Examination (all must be checked) – Attending MUST be present for
brain death exam</li>
</ol>
<figure>
<p><img alt="brain death" src="../images/image14.png" />
  </p>
<figcaption>Greer DM, Determination of Brain Death. *NEJM.* 2021;385;2554-61. doi:
0.1056/NEJMcp2025326</figcaption>
</figure>
<ol>
<li>Apnea testing (all must be checked) – Attending MUST be present<ul>
<li>Pt is hemodynamically stable</li>
<li>Ventilator adjusted to provide normocarbia (PaCO2 35–45 mm Hg)</li>
<li>Preoxygenate with 100% FiO2 and PEEP of 5 cm water for >10 minutes
    to PaO2 >200 mmHg</li>
<li>Provide oxygen via a suction catheter to the level of the carina at
    6 L/min or attach T-piece with continuous positive airway pressure
    (CPAP) at 10 cm H2O</li>
<li>Disconnect ventilator</li>
<li>Spontaneous respirations absent</li>
<li>Arterial blood gas drawn at 8–10 minutes, patient reconnected to
    ventilator</li>
<li>PCO2 ≥60 mm Hg, or 20 mm Hg rise from normal baseline value; OR:</li>
<li>Apnea test aborted due to spontaneous respirations present,
    hemodynamic instability, or hypoxia</li>
</ul>
</li>
<li>Ancillary testing (Order one test if clinical examination cannot be
fully performed due to patient factors or if apnea testing
inconclusive/aborted)<ul>
<li>Cerebral angiogram</li>
<li>HMPAO SPECT (Single photon emission computed tomography)</li>
<li>EEG &amp; TCD (transcranial Doppler)</li>
</ul>
</li>
</ol>
<h2 id="critical-care-main-organ-donation-caveats">Organ donation caveats<a class="headerlink" href="#critical-care-main-organ-donation-caveats" title="Permanent link">&para;</a></h2>
<ul>
<li>Discussions about organ donation should take place between Tennessee
    Donor Services (TDS) and the surrogate. You SHOULD NOT be having
    conversations with the surrogate about donation. Direct questions to
    TDS.</li>
</ul>
<h1 id="critical-care-main-micuccu-drips">MICU/CCU Drips<a class="headerlink" href="#critical-care-main-micuccu-drips" title="Permanent link">&para;</a></h1>
<p>Patrick Barney</p>
<hr />
<p>Most have order sets in Epic. Typically choose “Titration Allowed” in
ICU</p>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 17%" />
<col style="width: 16%" />
<col style="width: 23%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5">Vasopressors:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Receptors</td>
<td>Indications</td>
<td>Considerations</td>
</tr>
<tr class="even">
<td><strong>Norepinephrine (Levophed)</strong></td>
<td>1 – 100 mcg/min</td>
<td>αα1 &gt; β1</td>
<td>1st line septic shock</td>
<td>Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="odd">
<td><strong>Phenylephrine (Neosynephrine)</strong></td>
<td><p>Bolus: 0.05 – 0.5 mg q 10-15 min</p>
<p>Infusion: 40-360 mcg/min</p></td>
<td>αα1</td>
<td>Periprocedural hypotension (Neostick), pts w/ tachyarrhythmias,
Critical AS or HOCM with severe LVOT obstruction and shock</td>
<td>Reflex bradycardia, Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="even">
<td><strong>Epinephrine</strong></td>
<td>1 – 40 mcg/min</td>
<td>αα1=β1=β2</td>
<td>Post PEA arrest, Anaphylaxis, Septic shock (severe), Cardiogenic
shock</td>
<td>Tachy-arrhythmias, Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="odd">
<td><strong>Vasopressin</strong></td>
<td>0.04 U/min (no titration)</td>
<td>V1, V2, V3</td>
<td>2nd line septic shock, Right heart failure</td>
<td>Hyponatremia, Bradycardia</td>
</tr>
<tr class="even">
<td><p><strong>ANG II</strong></p>
<p><strong>*needs approval MICU leadership</strong></p></td>
<td>20 – 40 ng/kg/min</td>
<td>ANG II</td>
<td>Refractory vasodilatory shock</td>
<td>Thrombosis pt MUST have chemical DVT ppx. Contraindicated in heart
failure</td>
</tr>
<tr class="odd">
<td><strong>Dopamine</strong></td>
<td>2 – 20 mcg/kg/min</td>
<td>Dopamine (1-5 mcg) &gt; β1 (5-10 mcg) &gt;α1 (&gt;10mcg)</td>
<td>Hypotension, Cardiogenic shock</td>
<td>Tachy-arrhythmias, Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="even">
<td><strong>Dobutamine</strong></td>
<td>2.5 – 20 mcg/kg/min</td>
<td>β1 &gt;&gt;&gt; β2</td>
<td>Cardiogenic shock</td>
<td>Vasodilation Hypotension, Tachycardia, Tachyphylaxis</td>
</tr>
<tr class="odd">
<td><strong>Milrinone</strong></td>
<td>0.375 – 0.75 mcg/kg/min</td>
<td>PDE-3</td>
<td>Cardiogenic shock</td>
<td>Hypotension, Renally cleared</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 11%" />
<col style="width: 9%" />
<col style="width: 12%" />
<col style="width: 11%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="8">Sedatives/Anxiolytics:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td colspan="2">Dose</td>
<td colspan="2">Class</td>
<td colspan="3">Side effects</td>
</tr>
<tr class="even">
<td><strong>Propofol</strong></td>
<td colspan="2">Infusion: 5 – 150 mcg/kg/min</td>
<td colspan="2">General anesthetic (GABA R agonist)</td>
<td colspan="3"><p>Severe hypotension, bradycardia,
hypertriglyceridemia, propofol infusion syndrome (rare)</p>
<p>Monitor for toxicity with q4 day TGs and CK</p></td>
</tr>
<tr class="odd">
<td><strong>Dexmedetomidine (Precedex)</strong></td>
<td colspan="2">Infusion: 0.1 – 1.5 mcg/kg/h</td>
<td colspan="2">Central αα2 agonist</td>
<td colspan="3">Hypotension, bradycardia</td>
</tr>
<tr class="even">
<td><strong>Midazolam (Versed)</strong></td>
<td colspan="2"><p>Push: 0.5 – 5 mg</p>
<p>Infusion: 0.25 – 5 mg/h (no max dose)</p></td>
<td colspan="2">Benzodiazepine</td>
<td colspan="3">Hypotension, risk of BNZ withdrawal if used for long
periods with sudden discontinuation</td>
</tr>
<tr class="odd">
<td><strong>Lorazepam (Ativan)</strong></td>
<td colspan="2"><p>Push: 0.5 – 10 mg</p>
<p>Infusion: 0.5 – 5 mg/h (no max dose)</p></td>
<td colspan="2">Benzodiazepine</td>
<td colspan="3">Hypotension. propylene glycol carrier - AGMA</td>
</tr>
<tr class="even">
<td><strong>Ketamine</strong></td>
<td colspan="2"><p>Push: 1-2mg/kg</p>
<p>Infusion: 0.2mg/kg/hr, titrate by 0.1 q15min</p></td>
<td colspan="2">NDMA antagonist</td>
<td colspan="3"><p>Delirium/hallucination – use caution in patients with
psychiatric hx, hypertension, tachycardia</p>
<p>Pretreat with 0.4mg IV glycopyrrolate to avoid
hyper-salivation</p></td>
</tr>
<tr class="odd">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 29%" />
<col style="width: 48%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Analgesic:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Side effects</td>
</tr>
<tr class="even">
<td><strong>Fentanyl</strong></td>
<td><p>Push: 25 – 100 mcg</p>
<p>Infusion: 25 – 400 mcg/h</p></td>
<td>Hypotension, Serotonin syndrome, chest wall rigidity at high
doses</td>
</tr>
<tr class="odd">
<td><strong>Morphine</strong></td>
<td><p>Push: 1 – 5 mg q1-2h prn</p>
<p>Infusion: 1 – 5 mg/h</p></td>
<td>Hypotension (profound), itching, constipation, HA; avoid in renal
failure</td>
</tr>
<tr class="even">
<td><strong>Hydromorphone (Dilaudid)</strong></td>
<td><p>Push: 0.25 – 1 q1-2h prn</p>
<p>Infusion: 0.5 – 3 mg/h</p></td>
<td>Hypotension, respiratory depression, itching</td>
</tr>
</tbody>
</table>

<table style="width:100%;">
<colgroup>
<col style="width: 16%" />
<col style="width: 15%" />
<col style="width: 19%" />
<col style="width: 13%" />
<col style="width: 16%" />
<col style="width: 18%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="6">Anti-hypertensives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Class/MOA</td>
<td>Dose</td>
<td>Indications</td>
<td>Side effects</td>
<td>Comments</td>
</tr>
<tr class="even">
<td><strong>Esmolol</strong></td>
<td>Beta blocker</td>
<td><p>Bolus: 1mg/kg over 30s</p>
<p>Infusion: 50-300mcg/kg/min (max 300)</p></td>
<td>Aortic dissection, HTN emergency</td>
<td>Bradycardia, hypotension</td>
<td>Titrate to desired BP or HR. Caution in HFrEF</td>
</tr>
<tr class="odd">
<td><strong>Nicardipine</strong></td>
<td>CCB</td>
<td>Infusion: 5-15mg/hr (max 15)</td>
<td>HTN emergency</td>
<td>Bradycardia, hypotension</td>
<td>Titrate to desired BP, avoid in HFrEF</td>
</tr>
<tr class="even">
<td><strong>Nitroprusside</strong></td>
<td>Metabolized to NO vasodilatory effect (arterial roughly =
venous)</td>
<td>Infusion: 0.3mcg/kg/min; titrate q2min to max 10mcg/kg/min</td>
<td>HTN E, flash pulmonary edema, HFrEF for afterload reduction</td>
<td>Hypotension, cyanide toxicity</td>
<td>Contraindicated in hepatic and renal failure</td>
</tr>
<tr class="odd">
<td><strong>Nitroglycerin</strong></td>
<td>NO mediated venous &gt; arterial vasodilation</td>
<td>Infusion: start 0.25mcg/kg/min, titrate by 1mcg/kg/min q15min (max
10mcg/kg/min)</td>
<td>Refractory angina, flash pulmonary edema, HTN emergency</td>
<td>Hypotension, headache, palpitations</td>
<td>Contraindicated in severe RHF and concurrent use of PDE-5
inhibitor</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 17%" />
<col style="width: 15%" />
<col style="width: 20%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5">Anti-Arrhythmics:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Indications</td>
<td>Side effects</td>
<td>Comments</td>
</tr>
<tr class="even">
<td><strong>Adenosine</strong></td>
<td>6 – 12 mg IV rapid push and flush; may repeat x2</td>
<td>PSVT conversion</td>
<td>Complete AV nodal blockade</td>
<td><p>10 second half-life</p>
<p> Must have continuous EKG/tele monitor</p></td>
</tr>
<tr class="odd">
<td><strong>Amiodarone</strong></td>
<td><p>ACLS: 300 mg IV push</p>
<p>Non-emergent: 150 mg over 10 min then 0.5 mg/min</p></td>
<td>Vtach/Vfib, Afib</td>
<td>Pulm, ophthalmic and thyroid toxicity w/ chronic use</td>
<td>Less hypotension than other agents, safe in heart failure. May
chemically cardiovert patients, caution if off therapeutic AC</td>
</tr>
<tr class="even">
<td><strong>Diltiazem</strong></td>
<td><p>Push: 10 – 20 mg q15 min x 2 if no response</p>
<p>Infusion: 5 – 15 mg/h</p></td>
<td>Afib, Aflutter, PSVT</td>
<td>Bradycardia, hypotension</td>
<td>Avoid use in pts with HFrEF</td>
</tr>
<tr class="odd">
<td><strong>Lidocaine</strong></td>
<td><p>ACLS: 1 mg/kg x 1</p>
<p>Infusion: 1 – 4 mg/min</p></td>
<td>Vtach</td>
<td>Bradycardia, Heart block</td>
<td>Avoid use in liver failure/ Okay for HFrEF. Often 1<sup>st</sup>
line CCU med for VT/ May need to check levels if using for longer than
24 hours</td>
</tr>
<tr class="even">
<td><strong>Procainamide</strong></td>
<td>15 mg/kg over 30 min then 1 – 6 mg/min</td>
<td>Vtach, refractory afib</td>
<td>Bradycardia, hypotension</td>
<td>Drug-induced lupus, cytopenias</td>
</tr>
</tbody>
</table>

<h1 id="critical-care-main-intubation-and-extubation">Intubation and Extubation<a class="headerlink" href="#critical-care-main-intubation-and-extubation" title="Permanent link">&para;</a></h1>
<p>Daniel Motta-Calderon</p>
<hr />
<h2 id="critical-care-main-intubation">Intubation<a class="headerlink" href="#critical-care-main-intubation" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-background_12">Background<a class="headerlink" href="#critical-care-main-background_12" title="Permanent link">&para;</a></h3>
<ul>
<li>Intubation is the definitive therapy for patients with worsening
    respiratory failure</li>
<li>Indications for intubation- hypoxic or hypercarbic respiratory
    failure, airway protection</li>
</ul>
<h3 id="critical-care-main-intubation-checklist">Intubation checklist<a class="headerlink" href="#critical-care-main-intubation-checklist" title="Permanent link">&para;</a></h3>
<ul>
<li>Prepare the patient<ul>
<li>IV access: at least two large bore IV access sites.</li>
<li>Optimize position: Supine sniffing position</li>
<li>Assess the airway: Assess for difficult intubation predictors
    (opening mouth \&lt;3cm, Mallampati ≥ III, neck circumference >40cm,
    thyromental distance \&lt;6cm, head-neck extension \&lt;30 degrees)</li>
<li>Optimal pre-oxygenation: using FiO2 100% (facemask, high flow
    nasal cannula)</li>
<li>Optimize medical status: resuscitation, temporize hyperkalemia,
    Hb >7</li>
</ul>
</li>
<li>Prepare the equipment<ul>
<li>Monitoring: SpO2, capnography, telemetry, BP</li>
<li>Equipment: bag valve mask, 2 endotracheal tubes (ETT) with cuffs
    checked, direct laryngoscope, videolaryngoscope, bougie/stylet,
    working suction, supraglottic airway, oropharyngeal airway</li>
<li>Medications: paralytic (ex: rocuronium, succinylcholine),
    induction sedative (ex: etomidate, ketamine, propofol), analgesics
    (ex: fentanyl), maintenance sedative, IVF hanging in room, pressors
    (ex: Neostick)</li>
</ul>
</li>
<li>Prepare the team<ul>
<li>First and second intubators, RT, RN, someone to monitor hemodynamics</li>
</ul>
</li>
</ul>
<h3 id="critical-care-main-rapid-sequence-intubation-rsi">Rapid-sequence intubation (RSI)<a class="headerlink" href="#critical-care-main-rapid-sequence-intubation-rsi" title="Permanent link">&para;</a></h3>
<ul>
<li>Preferred method of induction, associated with increased
    first-attempt success and fewer intubation-related complications</li>
<li>Simultaneous IV administration of rapidly acting paralytic and
    induction agents to achieve sedation and paralysis</li>
</ul>
<h3 id="critical-care-main-post-intubation">Post-intubation<a class="headerlink" href="#critical-care-main-post-intubation" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure correct placement of ETT with capnography and confirming
    bilateral breath sounds</li>
<li>Secure ETT with taping, tying or tube holder</li>
<li>Obtain post-placement CXR</li>
</ul>
<h3 id="critical-care-main-immediate-complications-of-intubation">Immediate complications of intubation<a class="headerlink" href="#critical-care-main-immediate-complications-of-intubation" title="Permanent link">&para;</a></h3>
<ul>
<li>Aspiration: Suction airway, ideally prior to initiation of positive
    pressure ventilation to prevent distal movement of aspirated
    contents. Cricoid pressure maneuver historically used to reduce risk
    but unclear if it works so often not performed</li>
<li>Cardiovascular collapse: May be hypotension or sympathetic surge
    (hypertension, tachycardia, arrhythmias). Manage with
    fluids/pressors if need, rule out other causes (ex: hypoxia, PTX)</li>
<li>Hypoxemia: Preoxygenate with 100% FiO2 to minimize risk. Rescue
    maneuvers with bag mask ventilation if needed</li>
<li>Mechanical injury: Dental, soft tissue, tracheal, laryngeal.
    Retrieve any dislodged teeth, suction blood</li>
</ul>
<h2 id="critical-care-main-extubation">Extubation<a class="headerlink" href="#critical-care-main-extubation" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-main-is-the-patient-ready-to-be-extubated">Is the patient ready to be extubated?<a class="headerlink" href="#critical-care-main-is-the-patient-ready-to-be-extubated" title="Permanent link">&para;</a></h3>
<ul>
<li>Are they oxygenating well? SpO2 ≥90% with FiO2 ≤50% and PEEP ≤8cm
    H20</li>
<li>Has the underlying cause of their respiratory failure improved?</li>
<li>Did patient pass their SBT?<ul>
<li>See ABCDEF Bundle section for details on SBT</li>
</ul>
</li>
<li>Is patient able to protect their airway?</li>
<li>Is the patient on a stable pressor requirement or no pressors?</li>
<li>Is patient coughing and clearing secretions?</li>
<li>Is patient off sedation, alert and following commands?</li>
<li>Positive cuff leak? (See below for steps)</li>
<li>Consider calculating the rapid shallow breathing index (RSBI):
    RR/tidal volume (L)<ul>
<li>Set PS at 0cm H2O, and PEEP at 5cm H2O and, measure VT &amp; RR for
    one minute.</li>
<li>RSBI ≥ 105 predicts likely failure to wean. The use of a RSBI is
    attending dependent at Vanderbilt and is not frequently
    calculated when assessing readiness for extubation</li>
</ul>
</li>
</ul>
<h3 id="critical-care-main-post-extubation-complications">Post-extubation complications<a class="headerlink" href="#critical-care-main-post-extubation-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>Post-extubation stridor: 2/2 laryngeal edema</li>
<li>Positive cuff leak test= high risk methylprednisolone 20 mg i.v. q4h
    x 4 prior to extubation to prevent</li>
<li>If after extubation: Methylprednisolone 40 mg i.v. x1 dose + inhaled
    racemic epinephrine. If stridor >60minutes, consider reintubation</li>
<li>Cuff leak test:<ul>
<li>Suction secretions and set the ventilator into the AC mode</li>
<li>Inflate the cuff and record inspiratory and expiratory VT to
    evaluate for differences between the two volumes</li>
<li>Deflate the cuff record the expiratory VT over the next six
    breathing cycles. Average the three lowest expiratory VT values</li>
<li>The cuff leak volume is the difference between the inspiratory
    VT (measured before the cuff was deflated) and the averaged
    expiratory VT. If the difference is \&lt;100cc, this is considered
    failure but is not an absolute contradiction to extubation</li>
</ul>
</li>
<li>Post-extubation respiratory failure<ul>
<li>Recurrent hypoxic or hypercarbic respiratory failure</li>
<li>Assess for aggravating factors (volume overload, shock, AMS, etc)</li>
<li>For hypercarbic respiratory failure, may trial BiPAP. If
    unsuccessful reintubate</li>
<li>Preventative post-extubation BiPAP not routinely used in all
    patients but <em>consider</em> in select populations at high risk for
    failure: severe COPD with preexisting chronic hypercarbia during
    SBT, patients intubated for cardiogenic pulmonary edema</li>
</ul>
</li>
</ul>
<h1 id="critical-care-main-ultrasound-in-critical-care">Ultrasound in Critical Care<a class="headerlink" href="#critical-care-main-ultrasound-in-critical-care" title="Permanent link">&para;</a></h1>
<p>Audrey White</p>
<hr />
<h2 id="critical-care-main-volume-assessment">Volume assessment<a class="headerlink" href="#critical-care-main-volume-assessment" title="Permanent link">&para;</a></h2>
<ul>
<li>IVC measurements</li>
<li>Clinical Questions: Will the patient respond to fluid resuscitation?
    Is CVP low or high?</li>
<li>Protocol: See cardiology POCUS section</li>
<li>Limitations: Non applicable in patients with elevated abdominal
    pressure or abdominal contractions during measurement</li>
<li>Troubleshooting: Use the liver as a window to the IVC to avoid bowel
    gas. Start at the right mid-axillary line with the leading edge
    toward the head of the patient, and fan to view the IVC in
    longitudinal axis.</li>
</ul>
<h2 id="critical-care-main-lung-assessment">Lung Assessment<a class="headerlink" href="#critical-care-main-lung-assessment" title="Permanent link">&para;</a></h2>
<ul>
<li>Lung ultrasound relies on recognition of ultrasound artifacts to
    identify normal and pathologic findings.</li>
<li>Normal findings<ul>
<li>“Bat sign”: Ultrasound cannot penetrate reflective rib surface,
    casting a vertical shadow</li>
<li>A- lines: hyperechoic horizontal lines descending from the
    pleural line at regular intervals. This reverberation artifact
    occurs in normal aerated lung</li>
</ul>
</li>
<li>Pathologic findings<ul>
<li>B-lines, comet tails: Vertical hyperechoic lines which (1)
    extend from the pleural line through the depth of the image, (2)
    move with lung sliding, and (3) obliterate A lines. Multiple B
    lines indicates excess interstitial fluid</li>
<li>Lung rockets: >3 B lines indicates interstitial syndrome. Most
    common cause is acute pulmonary edema, also consider ARDS, PNA,
    pulmonary fibrosis, &amp; pulmonary contusion. Helps distinguish CHF
    vs COPD exacerbation in patients with dyspnea</li>
<li>Loss of lung sliding, barcode sign: The shimmering, twinkling
    appearance of the dynamic aerated lung is lost. Can confirm in
    M-mode with barcode sign- smooth homogenous lines indicating no
    movement of lung tissue. Lung sliding=suspicion for PTX but NOT
    specific unless can identify lung point</li>
<li>Lung Point: The precise location where the lung detaches from
    the pleura can sometimes be identified. Can confirm in M-mode
    which will show “barcode” and “seashore” patterns adjacent. 100%
    specific for pneumothorax</li>
<li>Pleural effusion, jellyfish sign: Anechoic fluid is visualized
    between the diaphragm and dynamic lung</li>
</ul>
</li>
<li>Probe: linear or phased array</li>
<li>Protocol<ul>
<li>Adjust the depth to ~10cm to start. Position the probe vertically
    on the midclavicular line. Slide the probe so that the hyperechoic
    pleural line is visualized between rib shadows. Note
    presence/absence of A lines, B lines, lung sliding, and alveolar
    consolidation</li>
<li>Repeat on the opposite side and lower anterior lung fields</li>
<li>Repeat on the right and left mid-axillary line, upper and lower
        lung fields. Look for pleural effusion between the diaphragm and
        lung</li>
<li>Repeat on the posterior lung fields if indicated to complete a
        12-zone lung examination</li>
</ul>
</li>
</ul>
<h2 id="critical-care-main-cardiovascular">Cardiovascular<a class="headerlink" href="#critical-care-main-cardiovascular" title="Permanent link">&para;</a></h2>
<p>Goal-directed echocardiography for acute shock</p>
<ul>
<li>Pericardial tamponade<ul>
<li>Apical 4 chamber (A4C): pericardial effusion, may see end diastolic
    collapse of right atrium</li>
<li>Parasternal long (PLAX): pericardial effusion will appear anterior
    to thoracic descending aorta, may see collapsing right ventricle</li>
<li>False positives: pericardial cyst, pericardial fat pad, pleural
    effusion (posterior to thoracic descending aorta on PLAX)</li>
</ul>
</li>
<li>Acute cor pulmonale<ul>
<li>PLAX, PSAX: paradoxical septal motion, D shaped left ventricle,
    dilated RV</li>
<li>A4C: end-diastolic RV area : LV area > 1</li>
<li>Subxiphoid (SUX): dilated IVC</li>
</ul>
</li>
<li>LVEF- see cardiology section</li>
</ul>
<h2 id="critical-care-main-abdominal-assessments">Abdominal assessments<a class="headerlink" href="#critical-care-main-abdominal-assessments" title="Permanent link">&para;</a></h2>
<ul>
<li>FAST exam</li>
<li>Clinical questions: Is there fluid in the peritoneal or pericardial
    spaces?</li>
<li>Probe: curvilinear or phased array</li>
<li>Protocol<ul>
<li>Start on abdominal mode at depth 21-25cm. Assess for pericardial
    effusion in SUX view</li>
<li>Reduce depth to 12-16cm and place probe on the right anterior
    axillary line between ribs 8-12 with the indicator toward the
    patient’s head. Sweep medially to identify the right kidney.
    Assess for anechoic fluid in Morrison’s pouch between the kidney
    and liver, subdiaphragmatic space, and paracolic gutter. Rock
    the probe to assess for fluid cephalad to the diaphragm. Slide
    inferiorly to confirm no fluid around the inferior pole of the
    kidney</li>
<li>Place probe on the left anterior axillary line between ribs 8-11
    with the leading edge toward the patient’s head. Sweep medially
    to identify the left kidney. Assess for anechoic fluid in the
    splenorenal interface, subdiaphragmatic space, pleural space,
    paracolic gutter, and left kidney inferior pole</li>
<li>Place probe midline just superior to the pubic symphysis.
    Identify the bladder in longitudinal and transverse view. Assess
    for fluid outside the bladder wall and in the pouch of Douglas
    (females) or rectovesicular space (males)</li>
</ul>
</li>
<li>Limitations: Cannot detect retroperitoneal bleed. False positives
    from ascites, pleural effusion, subcapsular hematoma, ruptured
    cysts, physiologic fluid in pouch of Douglas, epicardial fat pad.
    Exam may be indeterminant if significant bowel gas or obesity</li>
<li>Small bowel obstruction assessment<ul>
<li>Overall SBO ultrasound has ~92% sensitivity and ~97% specificity
    to detect SBO and greater diagnostic accuracy than abdominal XR</li>
<li>Probe: curvilinear</li>
<li>Protocol: Have the patient lie supine and relax the abdominal wall.
    Place the probe vertically on the abdomen and sweep across all four
    quadrants in sagittal view. Repeat in transverse view. Measure small
    bowel wall thickness and diameter using the caliper tool</li>
<li>Signs of SBO:<ul>
<li>Diameter > 2cm • Decreased peristalsis</li>
<li>Wall thickness > 4mm • Back and forth stool movement</li>
<li>Tanga sign: In severe SBO, may see triangular pocket hypoechoic
    free fluid surrounding the small bowel near the obstruction</li>
</ul>
</li>
</ul>
</li>
<li>Renal ultrasound<ul>
<li>Protocol is similar to FAST exam. Fan the probe through each kidney
    in sagittal and transverse view to assess for dilation of the
    collecting ducts. To move the kidney inferiorly, ask the patient to
    take a deep breath</li>
<li>Bilateral hydronephrosis and full bladder suggests urinary
    obstruction distal to the ureter</li>
<li>Unilateral hydronephrosis suggests nephrolithiasis or ureteral
    obstruction</li>
<li>Limitations: Renal US has a reported sensitivity of 70% and
    specificity of 75% to detect nephrolithiasis compared to CT</li>
</ul>
</li>
</ul>
<h1 id="critical-care-main-running-codes">Running Codes<a class="headerlink" href="#critical-care-main-running-codes" title="Permanent link">&para;</a></h1>
<p>Jacqueline Visina</p>
<hr />
<h2 id="critical-care-main-arrival-to-a-code">Arrival to a Code<a class="headerlink" href="#critical-care-main-arrival-to-a-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Questions to answer when you arrive: Is someone running the code?
    Who is doing compressions? Do we have pads on the patient? What is
    our IV access?</li>
<li>Take charge: establish if anyone is actively running the code, if
    someone is running the code, introduce yourself and ask how you may
    be helpful. If someone is NOT, have someone begin chest compressions
    IMMEDIATELY and assume responsibility for the running the code</li>
<li>IV access: IV access preferred, if no immediate IV access, place IO</li>
<li>Obtain a brief medical history and events surrounding the code and
    the patient’s code status</li>
<li>Have someone find the nearest crash cart and get pads on the patient
    as soon as possible</li>
</ul>
<h2 id="critical-care-main-running-the-code">Running the Code<a class="headerlink" href="#critical-care-main-running-the-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Assess the rhythm</li>
<li>If Vfib/VT- immediately shock</li>
<li>For polymorphic VT, this is ischemia until proven otherwise unless
    the patient is on a large amount of QTc prolonging medications.</li>
<li>If PEA/Asystole- resume compressions, give Epi 1mg ASAP</li>
<li>Strong ACLS</li>
<li>Q2min- pulse check, rhythm check, shock?</li>
<li>Remember the two interventions with proven mortality benefit are
    high quality chest compressions and early defibrillation. Do not
    interrupt these actions for other things</li>
<li>Monitor the quality of chest compressions</li>
<li>Warn resuscitators when shock is being delivered</li>
<li>Consider Advanced Airway</li>
<li>Remember chest compressions save lives. Not intubation. Do not stop
    compressions for intubation</li>
<li>Stay Calm</li>
<li>Closed Loop communication- continue giving instructions, use names,
    minimize interruptions</li>
<li>Do not move from foot of bed if you are running the code</li>
<li>Ensure delivery of adequate compressions. Avoid excessive
    ventilation</li>
<li>If you are running the code, it is helpful to maintain a constant
    verbal running summary of interventions that have been tried and the
    course of the code</li>
<li>Have a member of the team locate an ultrasound for line placement
    and diagnostics</li>
<li>Allow family to be present</li>
<li>H’s and T’s: Treat Reversible Factors</li>
<li>Some of the fellows here will empirically give 2 grams of magnesium,
    1 amp of D50, 1 amp of bicarb, and 1g calcium chloride at the onset
    of the code irrespective of presenting rhythm</li>
<li>Can send Labs – ask for a “loaded gas”. This will usually be a
    VBG/ABG with lactate, K, Ca, and Hgb. Often information does not
    result quick enough to change immediate management. Have someone
    look up most recent labs in Epic (looking for recent hyperK,
    acidosis)</li>
</ul>
<h2 id="critical-care-main-terminating-a-code">Terminating a Code<a class="headerlink" href="#critical-care-main-terminating-a-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Consider initial rhythm, patient comorbidities, cardiac vs
    non-cardiac arrest, bedside echo findings. ROSC or rhythm changes
    during code?</li>
<li>Persistent ETCO2\&lt; 10mmHg after 20min CPR has minimal survival</li>
<li>Ask your team if they have any other therapies that they feel would
    be indicated</li>
<li>Ask if anyone remains in favor of continuing CPR</li>
<li>When unanimous, terminate the code and announce time of death. Thank
    your team. Take a moment of silence for the deceased patient</li>
</ul>
<h2 id="critical-care-main-post-arrest-care">Post-Arrest Care<a class="headerlink" href="#critical-care-main-post-arrest-care" title="Permanent link">&para;</a></h2>
<ul>
<li>Immediately following ROSC is the most dangerous point of ACLS</li>
<li>Airway: Secure airway if not done during code, ensure RT avoids
    hypoxia or hyperoxia</li>
<li>BP: MAPs>65, IVF and/or pressors if needed</li>
<li>If on floor, prioritize moving patient to a unit for ongoing care
    once hemodynamically stable enough for transfer. Would not delay for
    other diagnostics/interventions (lines, CXR, etc)</li>
<li>Cardiac: obtain EKG. Assess if urgent cardiac intervention is
    required for STEMI vs unstable cardiogenic shock vs VT storm or Vfib</li>
<li>Neuro: if not following commands, consider TTM. TTM is still
    performed at VUMC with a strict protocol and inclusion criteria. If
    there is any question about TTM eligibility, page the CCU fellow</li>
<li>Send rainbow labs (CBC, CMP, Mg, coags, trop, lactate, VBG/ABG).
    Treat rapidly reversible causes</li>
<li>CXR</li>
<li>Propofol/fentanyl infusion if the patient is intubated. Pressor of
    choice post ROSC is usually levophed</li>
<li>If not done during the code, usually central access will be obtained
    and an arterial line will be placed</li>
</ul>
<h2 id="critical-care-main-intern-role-during-codes">Intern role during codes<a class="headerlink" href="#critical-care-main-intern-role-during-codes" title="Permanent link">&para;</a></h2>
<ul>
<li>maintain hand on femoral pulse</li>
<li>place IO if needed</li>
<li>have access to the patient’s chart to answer questions that arise during the code.</li>
<li>If family is not available, looking up primary contact information is invaluable.</li>
<li>In the MICU, your role is to grab the yellow IO kit prior to leaving for the code</li>
</ul>
<h2 id="critical-care-main-family-presence-during-cpr">Family presence during CPR<a class="headerlink" href="#critical-care-main-family-presence-during-cpr" title="Permanent link">&para;</a></h2>
<p>Studies show that it reduces the frequency of
PTSD-related symptoms and does not interfere with medical efforts</p>
<table>
<thead>
<tr>
<th>Treatable Causes of Cardiac Arrest: The H’s and T’s</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>H’s</td>
<td>T’s</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Toxins</td>
</tr>
<tr>
<td>Hypovolemia</td>
<td>Tamponade</td>
</tr>
<tr>
<td>H+</td>
<td>Tension Pneumothorax</td>
</tr>
<tr>
<td>Hypo/Hyper K</td>
<td>Thrombosis: Pulmonary</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Thrombosis: Coronary</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Critical care</h1>
                        <h1 class='nav-section-title' id='section-demo'>
                            Demo <a class='headerlink' href='#section-demo' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="demo-demo-lights"><h1 id="demo-demo-lights-pleural-effusions">Pleural Effusions<a class="headerlink" href="#demo-demo-lights-pleural-effusions" title="Permanent link">&para;</a></h1>
<p>Author: Eddie Qian</p>
<h2 id="demo-demo-lights-background">Background<a class="headerlink" href="#demo-demo-lights-background" title="Permanent link">&para;</a></h2>
<p>There is a normal influx of fluid into the pleural space due to
leaky capillary membranes and the pleural space’s negative pressure.
This fluid is constantly reabsorbed by lymphatics. An imbalance in
the system will result in accumulation.</p>
<p>Some examples:</p>
<ul>
<li>Increased Influx: increased filtration from the capillaries from
        high intravascular hydrostatic pressure (i.e., heart failure,
        renal failure, volume overload) or low intravascular oncotic
        pressure</li>
<li>Other liquid entry into the pleural space through anatomic
        deficits: <abbr title="Cerebrospinal Fluid">CSF</abbr>, chyle, urine, blood, ascites (the diaphragm is
        naturally porous and pleural effusions with ascites are not uncommon)</li>
<li>Decreased Efflux: obstruction of the parietal pleural stoma
        (from protein or cellular debris in exudative pleural effusions)</li>
<li>Increased systemic venous pressure (lymphatic system drains into
        systemic venous circulation, so if there is high venous
        pressure this prevents the lymphatics from draining
        appropriately)</li>
</ul>
<h2 id="demo-demo-lights-evaluation">Evaluation<a class="headerlink" href="#demo-demo-lights-evaluation" title="Permanent link">&para;</a></h2>
<h3 id="demo-demo-lights-imaging">Imaging<a class="headerlink" href="#demo-demo-lights-imaging" title="Permanent link">&para;</a></h3>
<ul>
<li>CXR: lateral decubitus position (if effusion moves with gravity,
        suggests free flowing)</li>
<li>Ultrasound: assess size, location, loculations (fibrinous
        septations which may prevent simple drainage)</li>
<li>CT Chest with contrast (not always indicated; helpful to eval
        septations)</li>
</ul>
<h3 id="demo-demo-lights-thoracentesis-see-procedures-section">Thoracentesis (see <a href="#procedures-procedures-thoracentesis">Procedures section</a>)<a class="headerlink" href="#demo-demo-lights-thoracentesis-see-procedures-section" title="Permanent link">&para;</a></h3>
<p>Will it change management?</p>
<p>If septated or empyema,  consider pulm consult for chest tube.</p>
<p>Orders:</p>
<ul>
<li>Always: Pleural <abbr title="Lactate Dehydrogenase">LDH</abbr>, protein, cell count/diff, culture</li>
<li>Don’t forget serum <abbr title="Lactate Dehydrogenase">LDH</abbr> &amp; protein!</li>
<li>Consider: pleural cytology, hematocrit, triglycerides, glucose,
        amylase</li>
</ul>
<p>Interpretation:</p>
<table>
<thead>
<tr>
<th>Lights Criteria</th>
<th>&gt;=1 of the following = exudative</th>
</tr>
</thead>
<tbody>
<tr>
<td>pleural protein : serum protein</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> : serum <abbr title="Lactate Dehydrogenase">LDH</abbr></td>
<td>&gt; 0.60</td>
</tr>
<tr>
<td>pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> : upper limit of normal of serum <abbr title="Lactate Dehydrogenase">LDH</abbr></td>
<td>&gt; 0.66</td>
</tr>
</tbody>
</table>
<ul>
<li>Lights criteria: &gt;=1 of the following to be considered an
        exudative effusion</li>
<li>Pleural to serum protein ratio &gt; 0.5</li>
<li>Pleural to serum <abbr title="Lactate Dehydrogenase">LDH</abbr> ratio &gt; 0.6</li>
<li>Pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> &gt; &#8532; upper limit of normal range of serum <abbr title="Lactate Dehydrogenase">LDH</abbr></li>
<li>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis
        (caused by increased intrapleural negative pressure),
        hypoalbuminemia, renal failure</li>
<li>Exudative: infections (bacterial, TB, fungal), malignant,
        rheumatologic, PE</li>
</ul>
<p>Pearls about initial tests:</p>
<ul>
<li>Protein: &gt;5 think TB or malignancy, =&lt; 0.5 think urine, <abbr title="Cerebrospinal Fluid">CSF</abbr>,
            peritoneal dialysate</li>
<li>Glucose: =&lt; 60 think about malignancy, TB,
                rheumatologic, and less specific hemothorax or
                parapneumonic</li>
<li>Cell count/differential: polys represent an acute
                process, monocytes represent a chronic process,
                lymphocytes think about TB or malignancy, eosinophils
                think about air/blood, TB, malignancy, asbestos, drugs</li>
<li>Two separate processes may co-occur and a transudate may mask an
                exudative effusion; if  concerned for this and you have clinical
                stability, trial diuresis prior to thoracentesis.</li>
</ul>
<details class="info">
<summary>References</summary>
<p><a href="https://doi.org/10.7326/0003-4819-77-4-507">Lights Criteria Original Paper</a></p>
</details></section><h1 class='nav-section-title-end'>Ended: Demo</h1>
                        <h1 class='nav-section-title' id='section-endocrinology'>
                            Endocrinology <a class='headerlink' href='#section-endocrinology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="endocrinology-endocrinology-adrenal-insufficiency"><h1 id="endocrinology-endocrinology-adrenal-insufficiency-adrenal-insufficiency">Adrenal Insufficiency<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-adrenal-insufficiency" title="Permanent link">&para;</a></h1>
<p>Adrenal Insufficiency – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>Differential: Primary (Adrenals) vs Secondary (Pituitary):<ul>
<li>Exogenous steroid use (&gt;10 mg for &gt;3wks) undergoing severe
    physiologic stress or sudden discontinuation of steroid</li>
<li>Critical Illness (not consensus)</li>
<li>Autoimmune Adrenal Insufficiency</li>
<li>Infection/Infiltration: tuberculosis, sarcoidosis, malignancy</li>
<li>Hemorrhage (Waterhouse-Friderichsen syndrome)</li>
<li>Pituitary mass/tumor, infarct, infiltration, surgery</li>
<li>Trauma</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Generalized weakness, lightheaded, abdominal pain, nausea, weight
    loss, fatigue</li>
<li>Symptoms are often vague and non-specific. More common in chronic
    disease</li>
<li>Lab Abnormalities: Hyponatremia, Hyperkalemia, Hypoglycemia</li>
<li>Shock (adrenal crisis) unresponsive to vasopressors, volume, or
    refractory</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Inpatient Setting: ACTH stimulation test and ACTH lvl with baseline
    lab draw</li>
<li>High-dose stimulation 250 mcg:
    #
    cortisol
    ≥
    18-20 rules out primary, most secondary</li>
<li>Outpatient Setting: morning serum cortisol concentration (&gt;15 mcg/dL
    wnl) for screening<ul>
<li>ACTH stimulation for confirmation</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If concerned about adrenal crisis, treat and figure out testing
    later):</li>
<li>When to consult/refer to Endocrine:<ul>
<li>If testing is abnormal</li>
<li>If clinical suspicion is high and testing is indeterminate</li>
</ul>
</li>
<li>Adrenal Crisis:<ul>
<li>BMP, glucose monitoring, ACTH level, serum cortisol/ACTH
    stimulation test</li>
<li>Fluid resuscitation: isotonic fluid (2-3 L). do not use
    hypotonic saline</li>
<li>Dexamethasone 4 mg immediately then q12h or other stress dose
    steroid</li>
<li>ACTH stimulation (confirmatory)</li>
<li>Consult Endocrine</li>
<li>Further workup of cause, mineralocorticoid replacement</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-diabetes-inpatient-management"><h1 id="endocrinology-endocrinology-diabetes-inpatient-management-diabetes-inpatient-management">Diabetes: Inpatient Management<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-diabetes-inpatient-management" title="Permanent link">&para;</a></h1>
<p>Inpatient Diabetes Mellitus (DM) – Will Bassett</p>
<p>Blood glucose (BG) goal:</p>
<ul>
<li>Wards
    : \&lt;140 mg/dL fasting; \&lt;180 mg/dL random; increase for elderly,
    “sicker” patients</li>
<li>ICU
    : 140-180 mg/dL (NICE-SUGAR Trial)</li>
<li>Avoiding moderate-severe hypoglycemia in ill patients is more
    important than ideal BG</li>
</ul>
<p>History: Year of dx, prior DM meds, current meds, last A1c (date and
value), home BG readings, history of hypoglycemia, # of hospitalizations
for diabetes, history of DKA, history of nephropathy, neuropathy,
retinopathy or foot disease.</p>
<p>Initial orders:</p>
<ul>
<li>HOLD
    all home oral diabetes meds</li>
<li>Dose reduce home insulin (typically to 50-60% of home dose) for
    changes in diet and renal function. For AKI consider reducing by
    more<ul>
<li>Do NOT hold basal for T1DM- would not reduce \&lt;80% of home dose
    in most cases</li>
</ul>
</li>
<li>Sliding Scale Insulin (Order set “SUBCUTANEOUS INSULIN ORDER(S)”)<ul>
<li>Hemoglobin A1c: can consider if none in last 3 months and
    concern for poor outpatient control. Does not routinely affect
    inpatient management</li>
<li>Fingerstick blood glucose: Typically AC/HS (before meals and
    nightly)</li>
<li>Hypoglycemia management: Select all of these</li>
<li>Basal insulin:<ul>
<li>T <strong>ype 2 DM</strong> , consider
    ↓
    home dose (50-60% to home dose) as often inpatients have
    reduced PO intake and
    ↓
    renal function</li>
<li>Type 1 DM
    , DO NOT hold basal insulin, and avoid
    ↓
    \&lt; 80% of home dose</li>
<li>Unnecessary if no home basal insulin</li>
</ul>
</li>
<li>Insulin lispro meal:
    ↓
    home dose by &frac12;, can also d/c, do not give while NPO</li>
<li>Lispro insulin correction scale: Start with Low or Medium
    sliding scale and
    ↑
    prn</li>
</ul>
</li>
<li>Carb-controlled or carb-restricted diet</li>
</ul>
<p>Adjustments:</p>
<ul>
<li>In
    EPIC, go to Summary tab and search “glucose” for BG trends and
    insulin dosing (Easiest to follow this tab if you ask for All
    results and expand the view fully on the right)</li>
<li>If BGs persistently &gt;200<ul>
<li>Calculate all insulin needs over 24h (basal + mealtime + sliding
    scale)<ul>
<li>Give 50% as basal Lantus and other 50% as mealtime doses</li>
<li>Ex: 10 basal + 0 mealtime + 14 sliding scale total = 12
    Lantus + 4 w/ each meal</li>
<li>If new to basal, safe start is Lantus 0.2 un/kg daily if
    normal GFR (lowest dose 10 un for T2DM, only brittle T1DM
    may need lower)</li>
</ul>
</li>
<li>Can also address mealtime and nightly glucose separately<ul>
<li>If AM glucoses are high, but prandials well controlled,
    consider increasing basal</li>
<li>If controlled in AM but elevated with meals, consider
    increasing mealtime</li>
</ul>
</li>
</ul>
</li>
<li>If BGs \&lt; 70<ul>
<li>If overnight/AM, reduce basal</li>
<li>If daytime, reduce mealtime and sliding scale</li>
<li>Less is more! Blood glucose in the 200s is better than the 50s</li>
<li>If endocrine consulted (“Glucose management services) for inpt
    glucose mgmt, please notify &gt;24h prior to d/c if you want
    recommended d/c regimen!</li>
</ul>
</li>
</ul>
<p>Steroid-induced Hyperglycemia:</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>Steroids increase insulin resistance
                →
                elevated postprandial BG most notable
            -   2-3 fold
                ↑
                in TDD insulin usually required w/ high dose
                (prednisone &gt; 20 mg)
            -   Common approaches:</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Double prandial + correction dose (basal the same)</p>
</li>
<li>
<p>Modified basal bolus regimen (30% basal, 70% bolus)</p>
</li>
<li>
<p>Add NPH (weight + dose based, per below*)— If on prednisone
    once daily (and not already on MDI), can add NPH once daily
    (give at same time as prednisone d/t similar pharmacologic
    profile if terms of peak effect and duration)</p>
<ul>
<li>prednisone 10 mg = 0.1 u/kg NPH</li>
<li>prednisone 20 mg = 0.2 u/kg NPH up to max dose NPH 0.4 un/kg
    daily (w/ prednisone)</li>
<li>*lower dose
    if AKI</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>VA tips:  At the VA, NPH is formulary rather than Lantus. If a pt
    takes Lantus at home, this can be continued, but otherwise you will
    need to place a PADR consult. NPH’s duration of action is shorter
    than Lantus (12-18 hrs if normal GFR) and in most cases should be
    dosed Q12h. The conversion is done by taking total Lantus dose and
    dividing it two doses.</li>
<li>Ex: home Lantus 20 units qhs
    →
    NPH 10 units BID</li>
<li>Patients
    getting tube feeds:<ul>
<li>Best with continuous tube feeds to give regular insulin q6h (not
    TIDAC since they don’t have  distinct “meals”); you can titrate
    rapidly, turn off safely (e.g procedures)</li>
<li>Then consolidate for bolus feedings based on 24-hour insulin
    needs prior to d/c</li>
</ul>
</li>
<li>Patients with insulin pumps
    :<ul>
<li>If a patient has a pump and supplies, reasonably controlled BG,
    is willing and able to manage pump then s/he can keep the pump
    on</li>
<li>Still order POC BG checks ACHS for nurse to chart and fill out
    MedEx pump contract</li>
<li>Consult Endocrine routinely</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-dka"><h1 id="endocrinology-endocrinology-dka-dka">DKA<a class="headerlink" href="#endocrinology-endocrinology-dka-dka" title="Permanent link">&para;</a></h1>
<p>Diabetic Ketoacidosis (DKA) – Will Bassett</p>
<p>Background</p>
<ul>
<li>Classically
    in type 1 diabetes but can also occur in insulin-dependent type 2
    diabete</li>
<li>Definition:
    ↑
    blood glucose (typically &gt;350) w/ high anion gap and ketones in
    blood/urine</li>
<li>If glucose is significantly elevated but no ketones/anion gap
    present, you likely have HHS<ul>
<li>↑
    serum osm and BG &gt; 600 commonly seen</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Workup aimed at discovering the underlying cause (The "I’s"):<ul>
<li>I
    nfection/ <strong>I</strong> nflammation - CBC, CXR, UA/UCx, LFTs; consider
    BCx, lipase (pancreatitis). NB leukocytosis will be present in
    most DKA pts</li>
<li>I
    schemia (MI, CVA, mesenteric ischemia) - EKG, Troponin, CT if
    clinical suspicion</li>
<li>I
    ntoxication - Ethanol (can cause ketosis with or without
    acidosis)</li>
<li>I
    mpregnation - Beta HCG if appropriate</li>
<li>I
    nsulin-openia/ <strong>I</strong> atrogenic: steroids, other meds, insulin
    delivery failure (pump failure, insulin degraded by heat, etc)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>ABG (for pH), serum osmolality</li>
<li>Check a phosphate at least once to ensure severe hypophosphatemia
    (\&lt;1mg/dL)</li>
<li>Remember to correct sodium for hyperglycemia (Na + 2.4 mEq *
    (BG-100))</li>
</ul>
<p>Management</p>
<ul>
<li>Initial monitoring: Q2h BMPs (monitor K closely), Q1h fingersticks<ul>
<li>Can space less frequently once gap is closed x 2 and patient off
    insulin infusion</li>
</ul>
</li>
<li>Ensure IV access and make NPO</li>
<li>Start IV fluids, insulin, and potassium as below<ul>
<li>Lactated ringers’ preferred fluid if no contraindication</li>
<li>Dextrose gtt should be started when BG \&lt;200</li>
<li>Turn off insulin drip when anion gap is closed on 2 consecutive
    BMPs</li>
</ul>
</li>
<li>Once BG\&lt;200 can start clear liquid diet and advance as tolerated.
    When pt is able to tolerate PO, dextrose infusion can stop</li>
<li>Consult endocrinology early, even though you’ve got it under control</li>
<li>Management algorithm on next page (Diabetes Care. 2009 Jul; 32(7):
    1335–1343)</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Patients on insulin drip can be admitted to stepdown (8MCE) with
    order set</li>
<li>“ADULT DKA RESUSCITATION ADMISSION ORDERS”</li>
<li>Start subcutaneous long-acting insulin as soon as insulin drip/IV
    insulin is started. Either home long-acting insulin (reduced for NPO
    if necessary) or, if insulin naive, Lantus 0.2-0.3 u/kg/day (0.1 if
    AKI in T1DM, 0.3 if obese-- can possibly take more but safe start)</li>
<li>Make sure PRN dextrose source is ordered for all patients on insulin
    drip</li>
<li>Pts are usually deficient in total body K <sup>+</sup> , even if
    serum [K <sup>+</sup> ] is high</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-hyperthyroidism"><h1 id="endocrinology-endocrinology-hyperthyroidism-hyperthyroidism">Hyperthyroidism<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-hyperthyroidism" title="Permanent link">&para;</a></h1>
<p>Hyperthyroidism – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>Low TSH and High T4 and/or T3 (primary):
    Graves’ disease, Toxic goiter, TSH-producing adenoma, hyperemesis
    gravidarum, subacute granulomatous thyroiditis, amiodarone,
    radiation, excessive replacement, struma ovarii</li>
<li>Low TSH/Normal T4 and T3
    : Subclinical hyperthyroidism, central hypothyroidism, non-thyroidal
    illness, recovery from hyperthyroidism, pregnancy (physiologic)</li>
<li>Subclinical Hyperthyroidism
    : repeat testing to verify abnormality is not transient</li>
</ul>
<p>Presentation</p>
<ul>
<li>Anxiety/emotional lability, weight loss, heat intolerance, tremor,
    palpitations, increased appetite, unexplained weight loss, new onset
    atrial fibrillation, myopathy, gynecomastia, menstrual disorder,
    rapid speech, exophthalmos, tachycardia, pretibial myxedema, tremor,
    hyperreflexia, lid lag, changes to hair or skin</li>
</ul>
<p>Evaluation</p>
<ul>
<li>TSH
    , free T4, free T3 (only T3 or T4 may be elevated, though both often
    are)<ul>
<li>Biotin affects assay, causes falsely
    ↓
    TSH and falsely
    ↑
    FT4/FT3</li>
</ul>
</li>
<li>CBC: May have a normocytic anemia due to increased plasma volume</li>
</ul>
<p>Management</p>
<ul>
<li>Thyrotropin antibodies (Graves: specific test, not sensitive)</li>
<li>Radioiodine uptake scan if thyrotropin antibodies negative</li>
<li>Thyroidal blood flow evaluation on US (pregnancy)</li>
<li>Treatment: methimazole, PTU, Radioiodine ablation, surgery<ul>
<li>Pts should be referred to endocrinology for treatment plan based
    on work up</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-hypoglycemia"><h1 id="endocrinology-endocrinology-hypoglycemia-hypoglycemia">Hypoglycemia<a class="headerlink" href="#endocrinology-endocrinology-hypoglycemia-hypoglycemia" title="Permanent link">&para;</a></h1>
<p>Hypoglycemia – Will Bassett</p>
<p>Background</p>
<ul>
<li>
<p>Definition
    : BG \&lt;70 mg/dL on any measurement</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>Generally worse outcomes than hyperglycemia
        -   Causes:</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Inflammation</p>
<ul>
<li>Sudden
    blood glucose drops in previously well controlled patient
    may indicate a new inflammatory process (infection,
    pancreatitis, sepsis etc.)</li>
<li>Check vitals and assess for new symptoms</li>
</ul>
</li>
<li>
<p>Iatrogenic (insulin dose not adjusted for AKI or NPO)</p>
<ul>
<li>Can
    consider
    reduction of basal insulin and/or consider holding prandial
    insulin</li>
<li>If
    patient
    is NPO, consider maintenance D5W/D5LR infusion</li>
</ul>
</li>
<li>If
patient
is NPO, schedule blood glucose checks at a regular interval ​​​​​​
Can present with Sudden tremor, palpitations, delirium, dizziness,
AMS</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Give PO carbohydrate load (15-20g oral glucose) if pt is alert and
    tolerates PO</li>
<li>Repeat measurement after 15 minutes and treat again as needed</li>
<li>Give IV D50 if severe (\&lt;50), or cannot take PO</li>
<li>Give glucagon 0.5-1mg SQ/IM if no IV access and impaired
    consciousness<ul>
<li>Effect is transient and IV access should be obtained ASAP for
    glucose infusion</li>
</ul>
</li>
<li>Do NOT hold basal for T1DM: treat the low, then reduce dose if
    needed (not necessary if low caused by high mealtime or SSI). In
    general, doses need not be reduced by &gt; 30%</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-hypothyroidism"><h1 id="endocrinology-endocrinology-hypothyroidism-hypothyroidism">Hypothyroidism<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-hypothyroidism" title="Permanent link">&para;</a></h1>
<p>Hypothyroidism – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>Elevated TSH and Low FT4 (primary hypothyroidism
    ):<ul>
<li>Hashimoto’s (autoimmune) thyroiditis, Iodine deficiency, drugs
    (amiodarone, dopamine antagonists), adrenal insufficiency,
    thyroid hormone resistance (genetic), non-thyroidal illness
    (recovery phase), post-surgery or ablation for hyperthyroidism</li>
</ul>
</li>
<li>Elevated TSH and Normal FT4
    : subclinical hypothyroidism</li>
<li>Low-Normal TSH, Low FT4
    : central hypothyroidism, sick euthyroid</li>
</ul>
<p>Presentation</p>
<ul>
<li>Often
    non-specific and vague: Fatigue, cold intolerance, weight gain,
    constipation, dry skin, myalgia, edema menstrual irregularities,
    depression, mental dysfunction</li>
<li>Goiter, bradycardia, diastolic hypertension, delayed relaxation
    following reflex testing</li>
<li>Lab abnormalities: microcytic anemia, hypercholesterolemia,
    hyponatremia, elevated CK</li>
</ul>
<p>Evaluation</p>
<ul>
<li>TSH: If elevated repeat TSH and obtain T4</li>
<li>Lipid panel, CBC, BMP</li>
</ul>
<p>Management</p>
<ul>
<li>Required if
    ↓
    T4, significantly
    ↑
    TSH (&gt;10), or symptoms with any lab abnormality</li>
<li>Titrate therapy to a normal TSH (unless central hypothyroidism, then
    target Free T4 levels)</li>
<li>Observation of asymptomatic pts w/ subclinical hypothyroidism
    (normal T4, mild
    ↑
    TSH)</li>
<li>Treatment is with formulation of T4 (full replacement is
    approximately 1.6 mcg/kg/day)</li>
<li>Initial Dose:<ul>
<li>Young/healthy patients: full anticipated dose</li>
<li>Older patients or patients w CAD: 25-50 mcg daily</li>
</ul>
</li>
<li>Increased doses will be required in the following:<ul>
<li>Pregnancy</li>
<li>Estrogen therapy</li>
<li>Weight gain ​​​​​​​</li>
<li>PPI therapy</li>
<li>GI disorders
    ↓
    absorption</li>
<li>Ferrous sulfate therapy</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Pts should take Levothyroxine alone, 1 hr prior to eating to ensure
    appropriate absorption</li>
<li>Of note, missed doses can be taken along with the next dose</li>
<li>Symptoms improve in 2-3 weeks. TSH steady state requires 6 weeks</li>
<li>Dose can be titrated every 6 weeks based on TSH (standard
    management)</li>
<li>Can titrate dose in 4 weeks in pregnancy, or in 2-4 weeks for
    profoundly hypothyroid pts, with titration based on Free T4 rather
    than TSH</li>
<li>Pregnancy: signs and symptoms are similar. Pregnancy causes lab
    changes due to differing levels thyroid binding globulin. Use tables
    based on trimester to interpret values<ul>
<li>TPO antibody testing should be conducted if abnormal as this
    affects risk of complications.</li>
<li>Referral to endocrine for close monitoring and adjustment to
    avoid fetal complications</li>
<li>Pts are at
    ↑
    risk for preeclampsia, placental abruption, preterm
    labor/delivery</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-steroid-conversions"><h1 id="endocrinology-endocrinology-steroid-conversions-steroid-conversions">Steroid Conversions<a class="headerlink" href="#endocrinology-endocrinology-steroid-conversions-steroid-conversions" title="Permanent link">&para;</a></h1>
<p>Steroid Conversion Chart – Neil Phillips</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Name</td>
<td>Equivalent doses (mg)</td>
<td>Anti-inflammatory activity relative to hydrocortisone</td>
<td>Duration of action (hrs)</td>
</tr>
<tr>
<td>Hydrocortisone (cortisol)</td>
<td>20</td>
<td>1</td>
<td>8 to 12</td>
</tr>
<tr>
<td>Cortisone acetate</td>
<td>25</td>
<td>0.8</td>
<td>8 to 12</td>
</tr>
<tr>
<td>Prednisone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>0.75</td>
<td>30</td>
<td>36 to 72</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.6</td>
<td>30</td>
<td>36 to 72</td>
</tr>
</tbody>
</table></section><section class="print-page" id="endocrinology-endocrinology-stress-dose-steroids"><h1 id="endocrinology-endocrinology-stress-dose-steroids-stress-dose-steroids">Stress Dose Steroids<a class="headerlink" href="#endocrinology-endocrinology-stress-dose-steroids-stress-dose-steroids" title="Permanent link">&para;</a></h1>
<p>Stress Dose Steroids – Griffin Bullock</p>
<p>Primary Options</p>
<ul>
<li>Dexamethasone 4 mg IV: does not affect cortisol assays, ideal if
    diagnosis uncertain</li>
<li>Hydrocortisone 100 mg IV bolus then 50 mg q8h until stable: greater
    mineralocorticoid activity. Ideal if adrenal insufficiency
    known/confirmed or if hyperkalemic (K&gt;6.0)</li>
</ul>
<p>When to Use</p>
<ul>
<li>Concern for Adrenal Crisis</li>
<li>Patients with known adrenal insufficiency:<ul>
<li>Minor Illness:
    ↑
    dose x3 for 3 d or until clinically improved/ acute
    stress/illness resolved</li>
</ul>
</li>
<li>Surgery: dependent on severity of operation<ul>
<li>Minor (e.g. hernia repair): hydrocortisone 25 mg for 1 day</li>
<li>Moderate (e.g. cholecystectomy): 50-75 mg day of surgery and
    post-op day 1</li>
<li>Major (e.g. CABG): 100-150 mg daily 2-3 days</li>
<li>Trauma, critical illness, or unclear give stress dose</li>
<li>Pregnancy: hydrocortisone 25 mg q6h during labor. If prolonged
    hydrocortisone 100 mg q6h at the time of delivery</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-thyroid-nodules"><h1 id="endocrinology-endocrinology-thyroid-nodules-thyroid-nodules">Thyroid Nodules<a class="headerlink" href="#endocrinology-endocrinology-thyroid-nodules-thyroid-nodules" title="Permanent link">&para;</a></h1>
<p>Thyroid Nodules – Terra Swanson</p>
<p>Background</p>
<ul>
<li>~50% of adults will have a thyroid nodule on ultrasound</li>
<li>Benign
    : goiter, cyst, inflammatory, Hashimoto’s, follicular adenoma
    (microadenoma)</li>
<li>Malignant
    : follicular, papillary, medullary, anaplastic, metastatic, thyroid
    lymphoma</li>
<li>RF for malignancy: Age \&lt;30 years; hx of head or neck radiation;
    family Hx of thyroid cancer</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Initial work-up after a nodule is found (either clinically or
    incidentally on imaging):<ul>
<li>TSH, Free T4</li>
<li>Thyroid US</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If Low TSH: Likely
    a hyperfunctioning nodule (benign in 95% of cases)<ul>
<li>Order Iodine-123 or technetium-99m thyroid scan<ul>
<li>If <strong>hyperfunctioning</strong>
    →
    measure T3/free T4 if
    ↑
    , treat for hyperthyroidism</li>
<li>If <strong>non-functioning</strong>
    →
    proceed as if TSH were normal</li>
</ul>
</li>
</ul>
</li>
<li>Normal or elevated TSH:<ul>
<li>FNA indicated based on U/S findings listed below (determined by
    TI-RADS system)<ul>
<li>Nodules &gt;1 cm that have high- or intermediate-suspicion
    pattern</li>
<li>Nodules &gt;1.5 cm that have low-suspicion pattern</li>
<li>Nodules <u>></u> 2 cm that have very-low-suspicion pattern</li>
</ul>
</li>
<li>FNA cytology determines the plan of action:<ul>
<li>Benign → periodic US monitoring at 12-24 months, then at
    increasing interval</li>
<li>Indeterminate → repeat FNA in 3-12 months</li>
<li>Malignant
    →
    surgical referral</li>
</ul>
</li>
</ul>
</li>
<li>Nodules that do not meet FNA criteria, US findings determine the
    timing for follow-up imaging:<ul>
<li>High suspicion: 6-12 months</li>
<li>Low to intermediate suspicion: 12-24 months</li>
<li>Nodules &gt;1 cm with very
    ↓
    suspicion OR pure cyst:  &gt;24 months if at al</li>
</ul>
</li>
<li>​​​​​​​
    Nodules <u>\&lt;</u> 1 cm with very
    ↓
    suspicion OR pure cyst:
    no further imaging necessary</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-thyroid-storm"><h1 id="endocrinology-endocrinology-thyroid-storm-thyroid-storm">Thyroid Storm<a class="headerlink" href="#endocrinology-endocrinology-thyroid-storm-thyroid-storm" title="Permanent link">&para;</a></h1>
<p>Thyroid Storm – Gaby Schroeder</p>
<p>Background</p>
<ul>
<li>Diagnosis: based on recognition of exaggerated signs/symptoms of
    thyrotoxicosis leading to multi-organ dysfunction in the setting of
    precipitating event</li>
<li>Common
    Precipitants: Grave’s Disease, Surgery, Trauma, Pregnancy, stress,
    Infection, MI/PE, medication non-compliance, iodine loads</li>
<li>Use
    Burch-Wartofsky Point Scale (BWPS); available on MD Calc<ul>
<li>>45 highly suggestive</li>
<li>25-44 impending storm</li>
<li>\&lt;25 unlikely to represent storm</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>ENDOCRINE
    EMERGENCY, if suspected should get Endocrine Consult ASAP</li>
<li>Therapies directed towards thyroid gland:<ul>
<li>PTU: Preferred, 500-1000mg loading dose, followed by 250mg q4 -6
    hours (PO, rectal)</li>
<li>Methimazole: q4-6 hours, dose varies (PO, rectal, IV)</li>
</ul>
</li>
<li>Therapies directed toward decreasing T4 to T3 conversion:<ul>
<li>Propranolol (60-80mg PO q4)</li>
<li>Hydrocortisone (300mg x1, 100mg q8)<ul>
<li>Treats high incidence of co-existing adrenal insufficiency</li>
</ul>
</li>
</ul>
</li>
<li>Cholestyramine 4g QID can be considered to reduce enteric
    recirculation</li>
<li>Refractory Storm: Plasmapheresis and Plasma Exchange</li>
<li>Supportive care and identify precipitating factor</li>
<li>Close hemodynamic monitoring, may need vasopressors (likely ICU)</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Endocrinology</h1>
                        <h1 class='nav-section-title' id='section-gastroenterology'>
                            Gastroenterology <a class='headerlink' href='#section-gastroenterology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="gastroenterology-gastroenterology-acute-abdominal-pain"><h1 id="gastroenterology-gastroenterology-acute-abdominal-pain-acute-abdominal-pain">Acute Abdominal Pain<a class="headerlink" href="#gastroenterology-gastroenterology-acute-abdominal-pain-acute-abdominal-pain" title="Permanent link">&para;</a></h1>
<p>Acute Abdominal Pain – Alex Mamunes</p>
<p>General Approach:</p>
<ul>
<li>Rule out life threatening causes:<ul>
<li>Obstruction, Perforation, Dissection, AAA rupture, Inferior MI,
    Ectopic Pregnancy</li>
</ul>
</li>
<li>History: pain quality/timing/location/severity, aggravating and
    alleviating factors (eating, bowel movements, position),
    Nausea/Emesis, bowel changes, flatus &amp; prior episodes</li>
<li>Initial labs: CBC, BMP, LFTs, INR, lactate, lipase, U/A, urine hCG (
    ♀ childbearing age</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>System</td>
<td>Causes</td>
<td>Common features</td>
<td>Workup</td>
</tr>
<tr>
<td>Esophagus</td>
<td>Esophagitis – GERD, EOE, candida, HSV, CMV, pill, functional</td>
<td>Epigastric, nocturnal reflux, odynophagia, dysphagia, thrush, immunocompromised</td>
<td>Trial PPI, nystatin swish and swallow, consider EGD</td>
</tr>
<tr>
<td>Stomach</td>
<td>Dyspepsia</td>
<td>Epigastric, indigestion, bloating</td>
<td>H. pylori testing, Trial PPI, ± EGD</td>
</tr>
<tr>
<td>Stomach</td>
<td>Peptic ulcer disease</td>
<td>NSAID use, better or worse w/ food, ± melena</td>
<td>CBC, H. pylori testing, EGD</td>
</tr>
<tr>
<td>Stomach</td>
<td>Gastritis</td>
<td>NSAID use, ETOH abuse, burning epigastric pain</td>
<td>NaN</td>
</tr>
<tr>
<td>Liver</td>
<td>Hepatitis: Ischemic, Viral, ETOH, trauma, toxins, autoimmune, congestive</td>
<td>RUQ pain ± jaundice EtOH, Tylenol or IVDU</td>
<td>LFTs, INR, ETOH, tylenol lvl, viral panel, RUQ U/S + dopplers; CT</td>
</tr>
<tr>
<td>Spleen</td>
<td>Splenomegaly: increased size, infarct, abscess</td>
<td>LUQ pain</td>
<td>Physical exam, CT</td>
</tr>
<tr>
<td>Biliary</td>
<td>Biliary colic</td>
<td>Overweight, ♀, 40’s, lasts hrs, worse with food, RUQ pain  scapula</td>
<td>LFTs, RUQ U/S</td>
</tr>
<tr>
<td>Biliary</td>
<td>Cholecystitis</td>
<td>RUQ (Murphy’s sign), nausea, emesis with fever</td>
<td>NaN</td>
</tr>
<tr>
<td>Biliary</td>
<td>Choledocholithiasis</td>
<td>RUQ, n/v with jaundice</td>
<td>CBC, LFTs, RUQ U/S, blood cx</td>
</tr>
<tr>
<td>Biliary</td>
<td>Ascending cholangitis</td>
<td>RUQ, N/V, jaundice, fever; hypotension, AMS</td>
<td>NaN</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Acute or Chronic Pancreatitis; Complications (fluid, collection, necrosis, pseudocyst)</td>
<td>ETOH use, gallstones, epigastric pain back, nausea, emesis Chronic pancreatitis: calcifications on CT</td>
<td>Lipase, CT A/P (rarely necessary within 24-48 hrs), RUQ U/S for gallstones</td>
</tr>
<tr>
<td>Intestines</td>
<td>Gastroenteritis</td>
<td>Nausea, emesis, sick contact, undercooked food, travel</td>
<td>Supportive care</td>
</tr>
<tr>
<td>Intestines</td>
<td>Diverticulitis</td>
<td>Older, h/o diverticulosis, LLQ pain with fever</td>
<td>CBC (leukocytosis) CT A/P w contrast</td>
</tr>
<tr>
<td>Intestines</td>
<td>Constipation</td>
<td>h/o IBS, narcotic use, unable to pass stool</td>
<td>KUB</td>
</tr>
<tr>
<td>Intestines</td>
<td>Bowel Obstruction/Ileus</td>
<td>Prior hernia, abd surgery or malignancy, pain, nausea, emesis, distention inability to pass stool or flatus</td>
<td>KUB (air fluid levels) CT is more sensitive If concerned, page EGS and consider NGT to suction</td>
</tr>
<tr>
<td>Intestines</td>
<td>Acute Small Bowel Mesenteric Ischemia</td>
<td>Vascular disease, A-Fib, dissection, thrombosis, rapid onset, severe, periumbilical with n/v, recent hypotensive episode, post-prandial</td>
<td>CBC (leukocytosis) BMP (metabolic acidosis), Lactate CT A/P w contrast (CTA if suspicion)</td>
</tr>
<tr>
<td>Intestines</td>
<td>Colonic Mesenteric Ischemia: ischemic colitis</td>
<td>Cramping pain, laterally (most often left), urge to defecate + hematochezia</td>
<td>CBC, BMP, Lactate CT A/P w contrast No colonoscopy</td>
</tr>
<tr>
<td>Intestines</td>
<td>Appendicitis</td>
<td>Periumbilical to RLQ with n/v, later fever</td>
<td>CBC, Lactate, CT A/P w/contrast</td>
</tr>
<tr>
<td>Intestines</td>
<td>IBD Flare</td>
<td>H/o Crohn’s or UC, Abd pain, fever, diarrhea, hematochezia</td>
<td>CBC, Lactate, CTE, ESR, CRP, C-diff GIPP</td>
</tr>
<tr>
<td>Intestines</td>
<td>C. diff colitis</td>
<td>Antibiotic exposure, diarrhea, abdominal cramping</td>
<td>C-diff PCR, CBC (leukocytosis) KUB (megacolon)</td>
</tr>
<tr>
<td>Intestines</td>
<td>Ogilvie’s syndrome</td>
<td>Pseudo-obstruction in elderly pt, signs of obstruction w/o mechanical cause</td>
<td>CBC, lactate, CT A/P w contrast</td>
</tr>
<tr>
<td>Intestines</td>
<td>Volvulus</td>
<td>Progressive abdominal pain, nausea, distention, constipation, vomiting</td>
<td>CBC, lactate CT A/P w contrast</td>
</tr>
<tr>
<td>Intestines</td>
<td>Typhlitis</td>
<td>Neutropenia, abdominal pain (often RLQ), fever</td>
<td>CBC with diff, CTE, blood cx, C-diff; empiric abx</td>
</tr>
<tr>
<td>OBGYN</td>
<td>Ectopic pregnancy</td>
<td>Sexually active, 6-7 wks after LMP, RLQ or LLQ pain + vaginal bleeding</td>
<td>Urine hCG, pelvic US, CBC, T&amp;S</td>
</tr>
<tr>
<td>OBGYN</td>
<td>Pelvic inflammatory disease, endometritis Tubo-ovarian abscess</td>
<td>Sexually active, h/o STI, purulent discharge, cervical motion tenderness, ± fever</td>
<td>Pelvic exam w/ culture, GC probe, pelvic US</td>
</tr>
<tr>
<td>OBGYN</td>
<td>Ovarian torsion</td>
<td>Young, sudden onset &amp; severe, often with n/v</td>
<td>Pelvic US w/ doppler</td>
</tr>
<tr>
<td>Kidney Kidney (Continued)</td>
<td>Nephrolithiasis</td>
<td>h/o kidney stones, Crohn’s disease, sharp flank pain, paroxysms, ± hematuria</td>
<td>U/A, CT A/P without contrast</td>
</tr>
<tr>
<td>Kidney Kidney (Continued)</td>
<td>UTI</td>
<td>Suprapubic pain, dysuria, cloudy urine, new odor</td>
<td>U/A with culture</td>
</tr>
<tr>
<td>Kidney Kidney (Continued)</td>
<td>Pyelonephritis</td>
<td>Flank pain, fever/chills, CVA tenderness, usually UTI symptoms</td>
<td>U/A with culture, BMP CT A/P w/contrast</td>
</tr>
<tr>
<td>Kidney Kidney (Continued)</td>
<td>Urinary Retention</td>
<td>Older pt, male with BPH, anticholinergics</td>
<td>Post-void residual</td>
</tr>
<tr>
<td>Kidney Kidney (Continued)</td>
<td>Renal infarct</td>
<td>h/o vascular disease or A-fib, acute flank pain with n/v, &plusmn; fever, HTN</td>
<td>CBC, BMP, UA, ECG (r/o a-fib) CT A/P w contrast</td>
</tr>
<tr>
<td>Vascular</td>
<td>Myocardial infarction</td>
<td>CAD risk factors, DoE, epigastric, diaphoresis</td>
<td>ECG, troponin</td>
</tr>
<tr>
<td>Vascular</td>
<td>Aortic Dissection</td>
<td>Vascular Risk factors, sudden onset, tearing pain back</td>
<td>CT dissection rule out</td>
</tr>
<tr>
<td>Vascular</td>
<td>AAA rupture</td>
<td>Vascular risk factors, sudden onset  back, hypotensive, pulsatile abdominal mass</td>
<td>CT A/P w contrast, consult vascular surgery</td>
</tr>
<tr>
<td>MSK/skin</td>
<td>Herpes zoster</td>
<td>Immunocompromised, dermatomal dist. rash, burning pain</td>
<td>Physical exam Vesicle PCR for zoster</td>
</tr>
<tr>
<td>MSK/skin</td>
<td>Muscle strain</td>
<td>h/o trauma, overuse, heavy exercise, worse with twisting or bending</td>
<td>Physical exam; rest, NSAIDs</td>
</tr>
<tr>
<td>MSK/skin</td>
<td>Hernia</td>
<td>Bulge, worse w/valsalva</td>
<td>CT A/P non con</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Pneumonia</td>
<td>Productive cough, fever</td>
<td>CXR, CBC, sputum cx</td>
</tr>
<tr>
<td>Pulmonary</td>
<td>Pulmonary embolus</td>
<td>Tachycardia, tachypnea, hypoxemia</td>
<td>ECG, trop, BNP CTA chest</td>
</tr>
<tr>
<td>Functional</td>
<td>IBS, depression, dyspepsia, anxiety Abdominal migraine, Functional</td>
<td>Image negative Negative w/u</td>
<td>Above w/u</td>
</tr>
<tr>
<td>Other</td>
<td>Adrenal crisis</td>
<td>Hypotension, fatigue, lethargy, n/v, weight loss, hyperpigmentation</td>
<td>BMP (↓Na, ↑K, ↓ Glu) Cort. stim</td>
</tr>
<tr>
<td>Other</td>
<td>Intra-abdominal abscess</td>
<td>Prior intra-abdominal disease or surgery, fever</td>
<td>CBC, blood cx CT A/P contrast</td>
</tr>
<tr>
<td>Other</td>
<td>DKA</td>
<td>Nausea, emesis, general abdominal pain</td>
<td>CBC, BMP, U/A β – hydroxy butyrate</td>
</tr>
<tr>
<td>Other</td>
<td>Hypercalcemia</td>
<td>N/V, constipation, ↑ thirst, ↑ urination, bone pain, muscle weakness, confusion, fatigue</td>
<td>BMP, ionized calcium, PTH, Vit D, PTHrp</td>
</tr>
<tr>
<td>Other</td>
<td>Acute intermittent porphyria</td>
<td>Severe, poorly localized with motor/sensory neuropathy, red urine, tachycardia</td>
<td>Urinary PBG</td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-acute-diverticulitis"><h1 id="gastroenterology-gastroenterology-acute-diverticulitis-acute-diverticulitis">Acute Diverticulitis<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-acute-diverticulitis" title="Permanent link">&para;</a></h1>
<p>Acute Diverticulitis – Michael Koenig</p>
<p>Background</p>
<ul>
<li>Inflammation
    and/or infection of a diverticulum, a small out-pouching along wall
    of colon</li>
<li>Ddx
    : (see approach to abdominal pain)</li>
<li>Presence of colonic flora on Urine culture suggests colo-vesical
    fistula</li>
<li>Most pts w/ uncomplicated diverticulitis have significant
    improvement 2-3 d after IV abx</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lower abdominal pain (85% LLQ), tenderness to palpation on exam,
    N/V, low-grade fever, change in bowel habits (constipation or
    diarrhea)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, CMP, Lipase, U/A,
    β
    - hCG</li>
<li>Imaging
    : CT abdomen/pelvis with oral and IV contrast<ul>
<li>
<ul>
<li>CT findings: localized bowel wall thickening (&gt;4mm),
        paracolic fat stranding, presence of colonic diverticula</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>IVF, pain control</li>
<li>Bowel rest vs. clear liquids (advance diet as tolerated)</li>
<li>IV antibiotics: should cover GNRs and anaerobic organisms<ul>
<li>
<ul>
<li>Zosyn, cefepime + metronidazole, or meropenem (if high risk
        for organisms w/ESBL)</li>
</ul>
</li>
</ul>
</li>
<li>Continue IV abx until abdominal pain/tenderness is resolved (usually
    3-5 days), then transition to oral: cipro + metronidazole or
    Augmentin to complete 10-14 d course</li>
<li>Criteria for discharge:<ul>
<li>
<ul>
<li>Resolution of vital sign abnormalities (fever, tachycardia,
        hypotension)</li>
<li>Resolution of severe abdominal pain</li>
<li>Improvement of leukocytosis</li>
<li>Able to tolerate oral diet</li>
</ul>
</li>
</ul>
</li>
<li>Colonoscopy after complete resolution of symptoms (6 – 8 weeks) to
    definitively rule out presence of underlying colorectal cancer
    (unless performed in last year)</li>
</ul>
<p>Additional Information</p>
<p>Complications:</p>
<ul>
<li>Pts who fail to improve or deteriorate require repeat imaging</li>
<li>Abscess
    
    cont. Abx &amp; Percutaneous drainage (if possible) for abscesses
    <u>></u> 4 cm<ul>
<li>
<ul>
<li>Surgery if no improvement 2-3 days after drainage</li>
</ul>
</li>
</ul>
</li>
<li>Obstruction: radiographic differentiation between acute
    diverticulitis and colon cancer is difficult; thus surgical
    resection of bowel is needed to relieve obstruction and r/o cancer</li>
<li>Fistula: Rarely heal spontaneously, require surgical correction</li>
<li>Bladder (65%), vagina (25%), small bowel (7%), uterus (3%)</li>
<li>
<p>Perforation:</p>
<ul>
<li>
<ul>
<li>Microperforation (contained perforation):
        -   Presence
            of small amount of air bubbles, but no oral contrast
            outside of colon on CT
        -   Most
            treated with IV abx and bowel rest similar to
            uncomplicated diverticulitis
            -</li>
</ul>
</li>
<li>
<p>Frank perforation:</p>
<ul>
<li>I
    ntraabdominal free
    air, diffuse peritonitis
    
    requires <strong>emergency surgery</strong></li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-acute-pancreatitis"><h1 id="gastroenterology-gastroenterology-acute-pancreatitis-acute-pancreatitis">Acute Pancreatitis<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-acute-pancreatitis" title="Permanent link">&para;</a></h1>
<p>Acute Pancreatitis – Alex Wiles</p>
<p>Background</p>
<ul>
<li>Common causes <strong>:</strong> Gallstones (40%), EtOH (30%), smoking</li>
<li>Other causes <strong>:</strong> post-ERCP, pancreatic cancer/obstruction, blunt
    abdominal trauma, hypertriglyceridemia (TG &gt;1000), hypercalcemia,
    drugs (thiazides, protease inhibitors, azathioprine, 6MP), mumps,
    Coxsackie, vasculitis, pregnancy, genetic (PRSS1, SPINK1, CFTR),
    autoimmune (IgG4), scorpion venom</li>
<li>Most important intervention during the first 12 – 24 hr and has
    direct effect on mortality<ul>
<li>SIRS leads to 3<sup>rd</sup> spacing and dehydration</li>
</ul>
</li>
<li>Several scoring systems:</li>
<li>BISAP (BUN &gt;25, Impaired mental status, SIRS, Age&gt;60, Pleural
    effusion)<ul>
<li>0 – 2
    
    Mortality \&lt; 2%; 3 - 5
    
    Mortality &gt; 15 %</li>
</ul>
</li>
<li>APACHE II (MD Calc, several factors)<ul>
<li>Decreasing values = mild attack; increasing values = severe
    attack</li>
<li>0 – 8
    
    Mortality \&lt;4%;  &gt; 8
    
    Mortality 11 – 18 %</li>
</ul>
</li>
<li>Ranson’s Criteria (MD Calc, severity at 0 and 48 hours)<ul>
<li>\&lt; 3
    
    Mortality 0 – 3 %; <u>></u> 3
    
    Mortality 11 – 15 %; <u>></u> 6
    
    Mortality 40 %</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Atlanta criteria requires two of three (PIE)<ul>
<li>Pain characteristic of pancreatitis (sharp, epigastric,
    radiating to back)</li>
<li>Imaging characteristic of pancreatitis (US, CT, MRI)</li>
<li>Enzymes (lipase or amylase) &gt;3x ULN (use lipase, much more
    specific)</li>
<li>*If pain is characteristic and lipase &gt; 3xULN, no need for CT
    A/P</li>
</ul>
</li>
<li>Grading Severity:<ul>
<li>Mild: no organ failure or systemic complications</li>
<li>Moderate: transient organ failure (\&lt;48 hours)</li>
<li>Severe: persistent organ failure (&gt;48 hours)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Lipase, CBC, CMP, lipid panel, lactate, direct bilirubin</li>
<li>Obtain RUQ U/S for <strong>all</strong> <strong>pts</strong> , evaluates for gallstones</li>
<li>CT A/P w/  IV contrast<ul>
<li>Reserved for patients not improving at 48-72 hour to assess for
    complications</li>
<li>If performed at onset, underestimates severity (necrosis takes
    72 hours from onset)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Fluids, Fluids, Fluids
    :</li>
<li>First 12-24 hrs: LR at 200 to 500 cc/hr, or 5-10 cc/kg / hr (2.5 – 4
    L within first 24 hrs)</li>
<li>Follow HCT and BUN as markers for successful fluid resuscitation<ul>
<li>Aggressive IVF in first 24 hours reduces both morbidity and
    mortality</li>
<li>Persistent hemoconcentration at 24 hr associated w/ necrotizing
    pancreatitis</li>
</ul>
</li>
<li>Pain Control:<ul>
<li>Common starting narcotic regimen is oxycodone 10 mg q6H PRN and
    hydromorphone 0.5 mg q3h - q4h for breakthrough (can refer to
    inpatient pain control section)</li>
<li>Consider consult to acute pain service for assistance</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Nutrition:<ul>
<li>NPO but start PO diet as soon as patient can tolerate (even
    within 24 hours)</li>
<li>Clear liquid diet or mechanical soft and advance as tolerated</li>
<li>Low fat diet (Fatty acids  CCK → trypsinogen to trypsin)</li>
<li>If NPO &gt; 72 hours, attempt PO and if fail, place Dobhoff for
    enteral nutrition at latest by day five… outcomes with
    NG/NJ &gt;>> TPN</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Antibiotics:<ul>
<li>Fever, leukocytosis common, not an indication for ABX as the
    necrosis is <strong>sterile</strong></li>
<li>Infection of the necrosis should be suspected w/ <strong>failure to
    improve 7 days after</strong> onset<ul>
<li>Cefepime + Flagyl or carbapenem</li>
</ul>
</li>
<li>EUS or IR guided drain for aspirate: only done if fluid is
    walled-off—at least 4 weeks</li>
<li>Infected pseudocysts or walled-off pancreatic necrosis may
    require prolonged course of ABX and serial imaging</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>If choledocholithiasis suspected
    
    ERCP</li>
<li>If the diagnosis is in question
    
    MRCP</li>
<li>If biliary sludge but no stones on U/S, still consider
    cholecystectomy (likely microlithiasis)</li>
<li>Complications:<ul>
<li>ARDS, abdominal compartment syndrome, AKI, DIC</li>
<li>\&lt; 4 weeks after pancreatitis: Peripancreatic fluid collection,
    acute necrotic collection</li>
<li>> 6 weeks after pancreatitis: Pancreatic pseudocyst, walled-off
    necrosis (WON)</li>
<li>Most fluid collections should be followed over time as acute
    collections can resolve and are unable to be sampled safely with
    EUS</li>
</ul>
</li>
<li>
<p>Gallstone pancreatitis:</p>
<ul>
<li>
<p>All pts should have cholecystectomy once recovered (recurrence
    is 25-30%)</p>
</li>
<li>
<p>Performed during initial admission in cases of mild acute
    pancreatitis</p>
</li>
<li>
<ul>
<li>Consider age or co-morbid illness precludes fitness for
        surgery; consult EGS</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-biliary-disease"><h1 id="gastroenterology-gastroenterology-biliary-disease-biliary-disease">Biliary Disease<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-biliary-disease" title="Permanent link">&para;</a></h1>
<p>Biliary Disease – Alex Wiles</p>
<p>Pearls:</p>
<ul>
<li>ERCP
    is not available <strong>at VA</strong> : requires fee-basis consult to VUMC,
    contact GI to arrange<ul>
<li>Prior cholecystectomy
    
    CBD normally dilates to 10 mm, not pathologic</li>
<li>Expect some CBD dilation after stent placement, pneuomobilia
    often occurs as well</li>
<li>CBD dilation classically &gt; 6mm, but CBD dilates with age: 70 yo
    
    7mm, 80 yo
    
    8mm; opiates can also cause biliary dilatation</li>
<li>CT has low sensitivity for stones, so get the RUQ U/S</li>
</ul>
</li>
</ul>
<p>Biliary Colic</p>
<ul>
<li>Transient biliary obstruction typically at the GB neck without GB
    inflammation (no fever)</li>
<li>Presentation: Constant (not colicky) intense, dull RUQ pain and N/V
    for 30 minutes to 6 hours, then resolves, provoked by fatty foods
    (CCK), absent Murphy’s sign<ul>
<li>Evaluation: Normal (CBC, LFTs, Lipase, Lactate)</li>
</ul>
</li>
<li>Imaging: RUQ U/S: cholelithiasis (stones in GB)<ul>
<li>Management: Elective cholecystectomy as outpatient</li>
</ul>
</li>
</ul>
<p>Acute Calculous Cholecystitis</p>
<p>-
-   Inflammation of the GB (obstructing stone in the GB neck or cystic
    duct)
-   Ddx: PUD, pancreatitis, choledocholithiasis, ascending cholangitis,
    IBD, Fitz-Hugh Curtis
-   Presentation: Severe constant RUQ pain, fever/chills, N/V, + Murphy
    sign
-   Evaluation: CBC (leukocytosis), CMP (mild AST/ALT
    ↑
    , nL bili), Lipase, Lactate, BCx x2
-   Imaging: RUQ U/S: gallstones + GB wall thickening or pericholecystic
    edema
    -   If U/S non-diagnostic (no stones or GB inflammation)
        
        HIDA Scan (lack of GB filling)</p>
<p>Management: NPO, IVF, IV Abx until resolved or surgical removal</p>
<p>-
-   Urgent Cholecystectomy (\&lt;72H) with EGS;
    -   If poor surgical candidate: Cholecystostomy with IR; endoscopic
        drainage options for selected patients (i.e. poor surgical
        candidates also with ascites)
    -   Complications: gangrenous cholecystitis, perforation,
        emphysematous cholecystitis, chole-cysto-enteric fistula,
        gallstone ileus</p>
<p>Acute Acalculous Cholecystitis:</p>
<p>-
-   Inflammation of the GB without obstructing stone (due to stasis and
    ischemia)
-   Presentation: Seen in critically ill/ICU pts; similar history as
    above; may present as unexplained fever or RUQ mass (rarely
    jaundice)
-   Ddx: calculous cholecystitis, pancreatitis, hepatic abscess
-   Evaluation: Same as acute calculous cholecystitis
-   Imaging: GB wall thickening, pericholecystic edema, intramural gas,
    GB distention</p>
<p>Management: Supportive care, antibiotics, GB drainage</p>
<p>-
-   IVF, correct electrolyte abnormalities, NPO
-   Broad spectrum antibiotic coverage
-   Place CT-guided procedure consult for cholecystostomy placement
-   Consult EGS if necrosis, perforation, or emphysematous changes
    present</p>
<p>Choledocholithiasis:</p>
<p>-
-   Obstruction of biliary outflow by CBD stone without inflammation (no
    fever)
    -   Impacted cystic duct stone (cholecystitis) or compressing CBD
        (Mirizzi syndrome)
-   Presentation: RUQ pain (can be painless), N/V and jaundice
-   Evaluation: CMP and D-bili (Bili/ALP/ GGT
    ↑↑↑
    , AST/ALT mild
    ↑
    ), CBC (Leukocytosis suggests cholangitis), Lipase
-   Imaging: RUQ U/S: dilated CBD (ULN is 6mm)
    
    MRCP/EUS vs ERCP (see below)
    -   MRCP preferred given non-invasive but has lower sensitivity for
        smaller stones (consider EUS if still have suspicion despite
        negative MRCP)</p>
<p>Management</p>
<p>-
-   NPO &amp; IVF, pain control PRN
-   Guidelines recommend use of RUQ U/S and LFTs to help decide on MRCP
    vs ERCP based on likelihood of CBD stone.  You must be confident
    there is a CBD stone prior to ERCP given risks associated with
    procedure
-   High Risk: presence of any of the three following criteria
    
    consider urgent ERCP
    -   CBD stone seen on imaging
    -   Ascending Cholangitis
    -   TBili &gt; 4 <strong>AND</strong> CBD dilation (&gt; 6 mm, unless prior
        cholecystectomy or elderly)
        -   Intermediate Risk: warrants further evaluation with either
            MRCP or EUS prior to ERCP or cholecystectomy with
            intraoperative cholangiogram (obtain MRCP if overnight,
            discuss with GI fellow)
            -   CBD Dilation; Age &gt; 55
            -   Abnormal liver enzymes (CBD stone can cause any pattern
                of LFT abnormalities)
        -   Low Risk: for patients with symptomatic cholelithiasis and
            no risk factors as above; no further evaluation required,
            can go to cholecystectomy <u>+</u> IOC</p>
<p>Acute Cholangitis:</p>
<p>-
-   Bacterial infection of biliary tract 2/2 obstruction or prior
    instrumentation (ERCP)
-   In ERCP-naïve pts, this is typically in setting of
    choledocholithiasis
-   Pts with malignant obstruction typically do not develop cholangitis
-   Presentation: Charcot triad (RUQ P, F/C, Jaundice); Reynolds’ Pentad
    (AMS, Hypotension)
-   Evaluation: CBC, CMP (D bili, ALP
    ↑↑↑
    ) Blood Cultures, Lipase, Lactate
    -   CRP, AST/ALT can be
        ↑↑
        as well
-   Imaging: RUQ U/S: dilated CBD (ULN is 6mm), no need for MRCP/EUS
    -   Consider MRCP overnight if ERCP is not being done emergently</p>
<p>Management: NPO, IVF, IV Abx; Consult GI for urgent ERCP (generally
within 24 hr)</p>
<p>-
-   If ERCP not feasible or fails to establish biliary drainage, can
    consider EUS-guided biliary drainage, percutaneous transhepatic
    cholangiography, or surgical decompression
-
-   Antibiotics for Biliary Disease (IDSA Guidelines):
    -   Mild to moderate acute cholecystitis (stable):
        -   Ceftriaxone 2g daily, Cefazolin 1-2g q8H
    -   Cholangitis or Severe acute cholecystitis (unstable or
        immunocompromised):
        -   Covering for GNRs and Anaerobes; 3 options:
            -   Zosyn 3.375g q8H, Meropenem 1g q8H or Cipro 500 q12H and
                Flagyl 500 q8H
            -   Healthcare-associated Biliary infections: consider
                Vancomycin (order w/ PK consult)</p></section><section class="print-page" id="gastroenterology-gastroenterology-c-diff"><h1 id="gastroenterology-gastroenterology-c-diff-c-diff">C Diff<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-c-diff" title="Permanent link">&para;</a></h1>
<p>Clostridioides difficile Infections – Matthew Meyers</p>
<p>Background</p>
<ul>
<li>Clostridioides difficile is the causative bacteria for
    antibiotic-associated colitis</li>
<li>Always consider C. diff in a hospitalized patient with unexplained
    leukocytosis</li>
<li>Microbiology: Anaerobic gram-positive, spore-forming,
    toxin-producing bacillus<ul>
<li>
<ul>
<li>Outside colon, exists in spore form – resistant to heat,
        acid, and antibiotics (why we must wash our hands)</li>
<li>Spores are transferred from environment to person, once in
    intestine convert to functional vegetative, toxin-producing
    forms
    
    susceptible to antibiotics</li>
<li>To be pathogenic, must release toxins to causes colitis and
    diarrhea</li>
</ul>
</li>
</ul>
</li>
<li>Risk Factors: Antibiotic use (during use or typically up to 1 month
    after use), age &gt;65, hospitalization, PPI use, enteral feeding,
    obesity, stem cell transplant, chemo, IBD, cirrhosis</li>
</ul>
<p>Presentation</p>
<ul>
<li>Spectrum from asymptomatic carrier to fulminant colitis with toxic
    megacolon<ul>
<li>
<ul>
<li>Non-severe disease: watery diarrhea (&gt;3 stools in 24 hours),
        lower abdominal pain, nausea,
        ±
        fever, leukocytosis (WBC \&lt;15,000)</li>
<li>Severe disease: diarrhea, diffuse abdominal pain, abdominal
    distention, fever, lactic acidosis, AKI (Cr &gt; 1.5), marked
    leukocytosis (sometimes &gt;40,000)</li>
<li>Fulminant disease: above + hypotension/shock, ileus (rare),
    or megacolon</li>
</ul>
</li>
</ul>
</li>
<li>Recurrent disease: resolution of symptoms on therapy followed by
    reappearance of symptoms within 2-8 weeks after stopping therapy;
    (Up to 25% of patients have recurrence)</li>
<li>If symptoms never resolve, consider refractory C. diff or
    alternative diagnosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Several options for lab testing but we have algorithm at VUMC: PCR
    for toxigenic strains (very sensitive, can detect asymptomatic
    carriers w/o toxin production); with reflex EIA (enzyme immunoassay)
    for toxins A and B (specificity of 99%)<ul>
<li>PCR (+)/Toxin (-) = carrier</li>
<li>PCR (+ )/Toxin (+) = treat</li>
<li>PCR (-) – no treatment</li>
</ul>
</li>
<li>Obtain KUB at least; prefer CT if suspicious for severe disease</li>
<li>Endoscopy: Typically used when alternative diagnosis is suspected;
    not warranted for classical symptoms, positive laboratory tests, or
    clinical response to treatment</li>
</ul>
<p>Management</p>
<ul>
<li>Contact precautions until at least 48 hours after diarrhea resolves</li>
<li>Classify patient disease severity to guide treatment algorithm</li>
<li>Indications for EGS consult: intestinal perforation, toxic
    megacolon - 7 cm diameter in colon or &gt;12 cm diameter in cecum</li>
<li>Do not repeat stool testing – 50% remain positive after treatment up
    to 6 weeks later</li>
<li>Initial episode with non-severe disease: Vancomycin 125 mg (some GI
    providers use 250) PO QID x 10 days or fidaxomicin 200 mg PO BID x
    10 days (less recurrence, more $$$)</li>
<li>Initial episode with severe disease: above and, if not improving
    after 3-5 days, consider both oral vanc and fidaxomicin, consider
    longer course than 10 days based on severity of disease and
    improvement</li>
<li>Initial episode with fulminant disease: vancomycin 500 mg PO QID AND
    metronidazole 500 mg IV q 8 hours</li>
<li>If ileus, consider use of rectal vancomycin and fecal microbiota
    transplant</li>
<li>Surgery: EGS consult if any of the following are present:<ul>
<li>Hypotension, lactic acidosis (&gt;2.2), WBC &gt; 20,000, Fever &gt;=
    38.5C, ileus, abdominal distension, peritoneal signs, admission
    to MICU, mental status changes, end-organ failure, or failure to
    improve after 3-5 days</li>
</ul>
</li>
<li>Recurrent disease:<ul>
<li>First – oral vancomycin as above (pulse-tapered regimen) or
    fidaxomicin</li>
<li>Second – vancomycin (pulse-tapered), fidaxomicin, or combo
    vancomycin
    
    rifaximin</li>
<li>Third – consider fecal microbiota transplant (currently on hold
    per FDA mandate)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-constipation"><h1 id="gastroenterology-gastroenterology-constipation-constipation">Constipation<a class="headerlink" href="#gastroenterology-gastroenterology-constipation-constipation" title="Permanent link">&para;</a></h1>
<p>Constipation – Jacob Parnell</p>
<p>Background</p>
<ul>
<li>Always consider if pt is at risk for obstruction (see SBO section)</li>
<li>Lactulose can cause severe cramping and bloating frequently</li>
<li>Can exchange PEG for lactulose in cirrhosis (but usually more
    bloating)<ul>
<li>Titrate lactulose BID to QID until 3-4 BMs achieved in cirrhosis</li>
</ul>
</li>
<li>Combination therapy usually most effective</li>
<li>In pts with renal dysfunction/CKD, avoid Fleet enemas (sodium
    phosphate load)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Typical causes: medications (opioids, antidepressants, iron,
    anticholinergics)<ul>
<li>Poor diet (low-fiber), low fluid intake, reduced mobility, acute
    illness, electrolyte disturbances, IBS, GI disease (IBD, colon
    cancer)</li>
</ul>
</li>
<li>Clinically diagnosis, no need for KUB/CT scans unless obstruction
    suspected</li>
<li>Consider BMP to evaluate electrolytes</li>
<li>Rectal exam can be used to exclude obstructing rectal mass or fecal
    impaction</li>
</ul>
<p>Management</p>
<ul>
<li>Stop any above offending meds as possible</li>
<li>Increase water intake</li>
<li>Escalating pathway for constipation:<ul>
<li>Senna BID + PEG (can give several times a day)
    
    try bisacodyl suppository
    
    then finally can try enema—tap water enema or SMOG enema
    (saline, mineral oil, glycerine)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>Laxatives</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Examples</td>
<td>Effects</td>
</tr>
<tr>
<td>Bulking-agent</td>
<td>Psyllium seed (Metamucil)</td>
<td>Absorb water and ↑ fecal bulk</td>
</tr>
<tr>
<td>Osmotic Laxatives</td>
<td>Polyethylene glycol (PEG) (Miralax, Golytely), Lactulose Mag citrate</td>
<td>Poorly absorbed sugars or saline are hyperosmotic—pull fluid into GI tract</td>
</tr>
<tr>
<td>Stimulant Laxative</td>
<td>Senna, Bisacodyl (Dulcolax)</td>
<td>Stimulates release of electrolytes by the mucosa</td>
</tr>
<tr>
<td>Stool Softener</td>
<td>Docusate (Colace, Phillips)</td>
<td>Minimal efficacy if any</td>
</tr>
<tr>
<td>Emollient</td>
<td>Mineral oil</td>
<td>Lubricates stool</td>
</tr>
<tr>
<td>Enema</td>
<td>Tap water, soap sud, lactulose (never use Fleet enema)</td>
<td>Helps stimulate stool release</td>
</tr>
<tr>
<td>Opioid antagonist</td>
<td>methylnaltrexone</td>
<td>Important role in narcotic-induced constipation and paralytic ileus</td>
</tr>
<tr>
<td>Acetylcholinesterase inhibitor</td>
<td>Neostigmine: indicated in Ogilvie’s syndrome if cecal diameter >12 cm. Relative contraindications include recent MI, acidosis, asthma, bradycardia, PUD, and beta-blockers. Decompression with colonoscopy used for select cases of Ogilvie’s refractory to medical management.</td>
<td>Administer 2 mg via slow IV over 5 min (monitor for bradycardia hypotension, asystole, seizures)</td>
</tr>
</tbody>
</table>
<p>Additional Information</p>
<ul>
<li>“The hand that writes for opioids is also the hand that writes for a
    bowel regimen”<ul>
<li>Senna
    BID <strong>+ PEG</strong> daily (up to TID)</li>
<li>If severe constipation already developed, do above plus try
    <strong>methylnaltrexone</strong></li>
</ul>
</li>
<li>CF pts (at risk for distal intestinal obstructive syndrome or DIOS)<ul>
<li>Not treated as true obstruction but rather like constipation</li>
<li>PEG (QID) or just order “golytely” prep as if for colonoscopy
    preparation</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-diarrhea"><h1 id="gastroenterology-gastroenterology-diarrhea-diarrhea">Diarrhea<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-diarrhea" title="Permanent link">&para;</a></h1>
<p>Diarrhea – Claudio Tombazzi</p>
<p>Background</p>
<ul>
<li>>3 BM/day OR abnormally loose stool</li>
<li>Acute (\&lt;2 weeks), persistent (2-4 weeks), or chronic (&gt;4 weeks)</li>
<li>95% of acute diarrhea is self-limited &amp; no additional treatment
    needed</li>
<li>Most cases of acute diarrhea are due to infections</li>
<li>Non-infectious etiologies become more common with increasing
    duration</li>
<li>Voluminous watery diarrhea more likely disorder of small bowel</li>
<li>Small volume frequent diarrhea more likely disorder of Colon</li>
<li>Nocturnal diarrhea suggests an inflammatory or secretory etiology</li>
</ul>
<p>Acute Diarrhea</p>
<ul>
<li>Watery diarrhea: viral gastroenteritis (norovirus, rotavirus,
    enteric adenovirus), C. diff, C. perfringens, S. Aureus, Bacillus
    cereus, enterotoxigenic E. coli, Cryptosporidium, Listeria,
    Cyclospora, vibrio cholerae (Giardia is typically more chronic),
    Tropheryma whipplei</li>
<li>Inflammatory diarrhea: Salmonella, Campylobacter, Shigella, EHEC,
    Yersinia, E histolytica, invasive viruses (CMV, HSV), Non-cholera
    vibrio</li>
<li>SARS-CoV-2 has been shown to cause GI symptoms such as diarrhea and
    N/V<ul>
<li>Medications (see below)</li>
<li>Any antibiotic can cause C. diff; the longer the treatment, the
    more likely</li>
<li>Most common to cause C. diff:
    Clindamycin &gt;Penicillins/Ceph/Fluoroquinolones</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Evaluate for red flags (BATS are Vulnerable vampires)<ul>
<li>B
    loody stools, <strong>A</strong> ntibiotics/Recent hospitalization</li>
<li>T
    oo many stools: &gt;6 unformed stools/day, <strong>S</strong> epsis (Fever)/
    <strong>S</strong> evere abdominal pain</li>
<li>Vulnerables
    (Age &gt;70 yr, immunocompromised, IVDU, IBD, pregnant, travel</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>CBC w/ diff, BMP (eval for leukocytosis, AKI, electrolyte
        abnormalities)</li>
<li>C. diff  PCR</li>
<li>CRP/ESR (if inflammatory)</li>
<li>GIPP  (consider for patients with red flag symptoms (see above))</li>
<li>CT A/P if abdominal pain present</li>
<li>CT Enterography if concern for IBD</li>
<li>Blood Cultures (if febrile)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Systemic complications (dehydration, AKI, electrolyte
    abnormalities/acidosis)<ul>
<li>PO intake (with solute i.e. Gatorade) or IVF if severe/unable to
    tolerate PO</li>
<li>Monitor and replace electrolytes</li>
<li>Downsides of abx: can precipitate <strong>HUS</strong> if 0157:H7, can
    prolong carrier state if salmonella, can precipitate C. diff</li>
<li>Empiric antibiotic therapy ONLY if toxic appearance or high
    concern for progressive illness/decompensation<ul>
<li>Ciprofloxacin 500 mg BID or levofloxacin 500 mg daily x 3-5
    days</li>
<li>Azithromycin 500 mg daily x 3 days</li>
<li>Ampicillin + gentamicin used for pregnant women to cover for
    Listeria</li>
</ul>
</li>
</ul>
</li>
<li>Symptomatic therapy (Okay to use if C. diff ruled out)<ul>
<li>Loperamide 4mg x1, 2mg after each loose stool (maximum 16mg/day)
    for 2 days</li>
<li>Lomotil 5mg every 6 hours until control achieved (can alternate
    with loperamide)</li>
<li>Probiotics may be helpful</li>
</ul>
</li>
<li>C. diff positive (see section below)</li>
</ul>
<p>Approach to Chronic Diarrhea</p>
<p>Watery</p>
<ul>
<li>Secretory<ul>
<li>Microscopic Colitis</li>
<li>Bile acid malabsorption</li>
<li>Carcinoid</li>
<li>Crohn’s disease (early ileocolitis)</li>
<li>Gastrinoma</li>
<li>VIPoma</li>
<li>Mastocytosis</li>
<li>Addison’s disease</li>
<li>Medication induced: antibiotics (i.e. Augmentin), caffeine,
    colchicine, NSAIDs, antineoplastics, antiarrhythmics (digoxin),
    metformin, carbamazepine</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Motility<ul>
<li>Hyperthyroidism</li>
<li>Diabetes</li>
<li>Amyloidosis</li>
<li>Systemic Scleroderma</li>
<li>Medications: macrolides, metoclopramide, bisacodyl, senna,
    pyridostigmine</li>
</ul>
</li>
<li>Osmotic<ul>
<li>Lactose Intolerance</li>
<li>Bile salt diarrhea</li>
<li>Sugar alcohols: Sorbitol, mannitol, xylitol</li>
<li>Medications: citrates, lactulose, magnesium-containing antacids,
    mycophenolate, antibiotics (i.e. ampicillin, clindamycin),
    methyldopa, quinidine, propranolol, hydralazine, procainamide</li>
</ul>
</li>
<li>Functional: IBS</li>
</ul>
<p>Fatty (steatorrhea): ​​​​​​​</p>
<ul>
<li>Malabsorption<ul>
<li>Celiac disease</li>
<li>Gastric bypass</li>
<li>Short bowel syndrome</li>
<li>Tropical Sprue</li>
<li>Whipple disease</li>
<li>Small intestinal bacterial overgrowth (SIBO)</li>
<li>Post-infectious malabsorptive diarrhea</li>
<li>Maldigestion</li>
<li>Pancreatic insufficiency</li>
<li>Hepatobiliary disorders</li>
</ul>
</li>
</ul>
<p>Inflammatory:</p>
<ul>
<li>Diverticulitis</li>
<li>Ischemic colitis</li>
<li>Neoplasia</li>
<li>Radiation colitis</li>
<li>Arsenic poisoning</li>
<li>Microscopic colitis</li>
<li>Invasive infections: bacterial (tuberculosis, yersinosis), viral
    (CMV, HSV),</li>
<li>parasites (amebiasis, strongyloidiasis)</li>
</ul>
<!-- -->

<ul>
<li>Inflammatory bowel disease (Crohn’s disease, Ulcerative Colitis)</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Age of onset &gt; 50</li>
<li>Rectal bleeding or melena</li>
<li>Nocturnal pain or diarrhea</li>
<li>Progressive abdominal pain</li>
<li>1 <sup>st</sup> degree relative with IBD or colorectal cancer
    Unexplained weight loss, fever, systemic symptoms</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>Labs: CBC w/ diff, CMP, ESR/CRP, TSH, celiac serologies if high
        suspicion (anti-TTG)</li>
<li>Spot fecal elastase Steatorrhea (greasy, malodorous stools that
    float)Colonoscopy indicated if alarm symptoms are present, &gt;50
    yo and hasn’t had one, or \&lt;50 yo and concern for IBD, CMV,
    ischemic colitis or microscopic colitis.</li>
<li>If concern for IBS: Rome IV criteria (abdominal pain 1d/week for
    3 months with &#8532; of the follow: related to defecation, change
    in stool frequency, change in stool form)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>IBS: trial elimination diet/low FODMAP, antidiarrheals</li>
<li>Pancreatic insufficiency: enzyme replacement (Creon), consult
    nutrition for assistance</li>
<li>Celiac: eliminate gluten, will need outpatient nutrition
    follow-up</li>
<li>Bile acid malabsorption: can try cholestyramine (can affect
    absorption of other meds)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-esophageal-disorders"><h1 id="gastroenterology-gastroenterology-esophageal-disorders-esophageal-disorders">Esophageal Disorders<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-esophageal-disorders" title="Permanent link">&para;</a></h1>
<p>Esophageal Disorders – Caroline Barrett</p>
<p>Dysphagia</p>
<p>-</p>
<ul>
<li>
<p>Oropharyngeal dysphagia = difficulty initiating a swallow</p>
</li>
<li>
<ul>
<li>Associated with coughing, choking, nasopharyngeal regurgitation,
        and aspiration</li>
</ul>
</li>
</ul>
<p>-</p>
<ul>
<li>
<p>Causes: Structural (Zenker’s diverticula, malignancy, goiter,
    stricture, radiation injury, infection), Neuromuscular (stroke,
    Parkinson disease, dementia, ALS, MS) Esophageal dysphagia:
    Difficulty swallowing several seconds after initiation; associated
    w/sensation of food getting stuck in esophagus</p>
</li>
<li>
<ul>
<li>Foreign body: Inability to swallow solids and/or liquids,
        including oral secretions</li>
<li>Most common foreign body = food in esophagus</li>
</ul>
</li>
</ul>
<p>-</p>
<ul>
<li>
<p>Dysphagia
    to solids = mechanical obstruction</p>
</li>
<li>
<ul>
<li>Progressive: esophageal stricture, peptic stricture, esophageal,
        cancer</li>
<li>Intermittent: esophageal ring/web, eosinophilic esophagitis
    (particularly in young pts)</li>
</ul>
</li>
</ul>
<p>-</p>
<ul>
<li>
<p>Dysphagia
    to solids and liquids = motility disorder</p>
</li>
<li>
<ul>
<li>Causes: achalasia, scleroderma, distal esophageal spasm (DES),
        hypercontractile (nutcracker) esophagus</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<p>-
-   If oropharyngeal dysphagia: videofluoroscopic modified barium
    swallow and fiberoptic endoscopic evaluation of swallowing (FEES)
-   When to order barium esophagram:
    -   Pre-endoscopy if clinical history suspicious for proximal
        esophageal lesion (i.e. Zenker’s) or known complex stricture
        (post-caustic injury or radiation)
        -   Don’t order if a food impaction is suspected or if imminent
            endoscopy
    -   Post-endoscopy if mechanical obstruction is still suspected (EGD
        can miss lower esophageal rings or extrinsic esophageal
        compression)
-   EGD if concerns for mechanical obstruction
-   Manometry for motility disorders</p>
<p>Management</p>
<p>-
-   Food impaction: IV glucagon to relax lower esophageal sphincter to
    allow food passage
    -   Otherwise, requires urgent upper endoscopy for removal
-   Additional management is specific to the final diagnosis</p>
<p>Odynophagia</p>
<p>-
-   Pain with swallowing
-   Associated with esophagitis</p>
<p>PIECE</p>
<p>mnemonic for esophagitis:</p>
<p>-</p>
<ul>
<li>P
    ill-induced: NSAIDs, ART, KCl, doxycycline, bisphosphonates<ul>
<li>Discontinue culprit med or substitute with liquid formulation;
    prevent by taking culprit meds w/ 8oz water and sit upright for
    30 mins after</li>
</ul>
</li>
</ul>
<p>-</p>
<ul>
<li>
<p>I
    nfectious: usually in immunosuppressed pts</p>
<ul>
<li>Candida esophagitis: most common in HIV or heme malignancies,
    pts on antibiotics and steroid use<ul>
<li>Can exist without OP thrush.</li>
<li>Diagnosis: white mucosal plaque-like lesions on EGD
    
    biopsy and culture</li>
</ul>
</li>
<li>HSV esophagitis. Occurs most commonly in solid organ, BMT
    transplant recipients, and immunosuppressed patients<ul>
<li>Diagnosis: well-circumscribed ulcers on EGD, biopsy or
    brushings of ulcer edge</li>
<li>Rx: acyclovir 400mg PO five times daily for 14-21 days
    (immunocompromised) or acyclovir 5mg/kg IV q8h for 7-14 days
    if unable to tolerate PO; 200mg PO five times daily or 400mg
    PO three times daily for 7-10 days (immunocompetent)</li>
</ul>
</li>
</ul>
</li>
<li>
<ul>
<li>CMV esophagitis: suspect in HIV pts w/ CD4\&lt;50
        -   Diagnosis: linear/longitudinal ulcers on EGD, biopsy
        -   Rx: ganciclovir 5mg/kg IV q12h for 21-42 days; change to PO
            once pt able to tolerate; If contraindication to ganciclovir
            (leukopenia, thrombocytopenia) can use foscarnet. PO
            valganciclovir can be used in patients who can tolerate and
            absorb oral medications. Treatment duration is 3-6 weeks
            based on expert opinion and response to disease</li>
<li>​​​​​​​
    E
    osinophilic esophagitis (see below)</li>
<li>C
    austic: alkali-induced injury, acid-induced injury, acute period
    (several days) following esophageal radiofrequency ablation for
    Barrett’s.</li>
</ul>
</li>
<li>
<p>-</p>
<ul>
<li>G <strong>E</strong> RD (see below)</li>
</ul>
</li>
</ul>
<p>GERD</p>
<p>Background</p>
<p>-
-   Condition that develops when reflux of stomach contents causes sxs
    and/or complications
-   Classified base on appearance of esophageal mucosa on EGD
    -   Erosive esophagitis: endoscopically visible breaks in distal
        esophageal mucosa <u>+</u> GERD
    -   Nonerosive reflux disease: presence of sxs of GERD w/o
         esophageal mucosal injury</p>
<p>Presentation</p>
<p>-
-   Esophageal symptoms: heartburn, regurgitation, chest pain,
    dysphagia, globus sensation, odynophagia
    -   Extra-esophageal symptoms: cough, hoarseness
    -   Complications: Esophageal stricture, Barrett’s esophagus,
        esophageal adenocarcinoma</p>
<p>Evaluation</p>
<p>-</p>
<ul>
<li>
<p>Dx can often be made clinically in pts with classic heartburn and/or
    regurgitation</p>
</li>
<li>
<p>If dx uncertain, can perform ambulatory pH monitoring <u>+</u>
    impedance</p>
</li>
<li>
<p>EGD indicated for the following:</p>
</li>
<li>
<ul>
<li>Presence of alarm features (dysphagia, persistent vomiting, GI
        cancer in 1º relative, odynophagia, GI bleeding, weight loss,
        iron deficiency anemia, ≥age <u>></u> 60 y/o with new-onset
        GERD symptoms)</li>
<li>Risk factors for Barrett’s esophagus (duration of GERD at least
    5-10 years [must be present], &gt;50 yo, male, white, hiatal
    hernia, obesity, nocturnal reflux, tobacco use, first-degree
    relative w/ Barrett’s and/or adenocarcinoma)</li>
<li>Abnormal UGI tract imaging (i.e. luminal abnormalities).</li>
<li>Continued sxs despite adequate PPI therapy</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>-
-   Lifestyle and dietary modifications in all pts (weight loss; elevate
    HOB; avoid precipitants such as fatty foods, caffeine, alcohol,
    spicy foods, large meals, late night meals)
    -   Mild/intermittent sxs (\&lt;2 episodes/wk) and no erosive
        esophagitis
        
        step-up therapy q4-8 wks until sxs are controlled, then continue
        for at least 8 wks:
    -   Low-dose H2RA prn
        
        standard dose H2RA BID (min 2 wks)
        
        discontinue H2RA and start daily low dose PPI
        
        standard dose PPI
-   Frequent sxs (&gt;2 episodes/wk, and/or severe sxs that impair QOL)
    
    step-down therapy in order to optimize sx relief
    -   Standard-dose PPI daily (8 wks)
        
        low-dose PPI daily
        
        H2RA (if mild/intermittent sxs)
        
        stop if asymptomatic
        -   PPIs should be prescribed at lowest dose and for shortest
            duration appropriate
        -   Taper if taking for &gt;6 months and plan to discontinue</p>
<p>Additional Information</p>
<ul>
<li>Erosive esophagitis and Barrett’s esophagus:<ul>
<li>Require maintenance acid suppression with a standard dose PPI
    daily given likelihood of recurrent sxs and complications if
    stopped</li>
</ul>
</li>
<li>Recurrent Symptoms (&#8532; of pts with nonerosive reflux disease
    relapse when acid suppression is discontinued):<ul>
<li>If ≥3 months after discontinuing
    
    repeat 8 week course</li>
<li>If \&lt;3 months of discontinuing
    
    EGD (if not already performed) to r/o other etiologies or
    complications</li>
</ul>
</li>
<li>Medications:<ul>
<li>Low dose H2RA: famotidine 10mg BID</li>
<li>Standard dose H2RA: famotidine 20mg BID</li>
<li>Low dose PPI: omeprazole 10 mg daily</li>
<li>Standard dose PPI: omeprazole 20 mg daily</li>
</ul>
</li>
</ul>
<p>Eosinophilic Esophagitis</p>
<p>Background</p>
<ul>
<li>Pt usually with a hx of asthma/allergies/eczema</li>
<li>Dysphagia (most commonly to solid foods), food impaction, central
    chest pain, GERD/refractory heartburn, upper abdominal pain</li>
</ul>
<p>Evaluation</p>
<p>-</p>
<ul>
<li>
<p>Diagnostic criteria</p>
</li>
<li>
<ul>
<li>Sxs related to esophageal dysfunction</li>
<li>EGD with &gt;15 eos/hpf on biopsy and exclusion of other causes (no
    longer requires PPI trial as pts who are PPI-responsive do not
    appear to be clinically distinct from those who are
    PPI-nonresponsive)</li>
<li>Exclusion of other causes that may be responsible for or
    contributing to sxs and esophageal eosinophilia<ul>
<li>50-60% pts will have elevated serum IgE lvl, peripheral
    eosinophilia can be seen but is generally mild.</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>-
-   Standard dose PPI for 8 weeks &plusmn; elimination diet
    
    if still symptomatic after 4 weeks, increase PPI to BID
    
    if responsive, continue PPI at lowest dose possible for sx control
-   Alternative treatment is swallowed budesonide or fluticasone
-   Intermittent dilation of strictures to relieve dysphagia, but no
    effect on underlying inflammation
-   Should undergo evaluation by allergist, given strong association
    with allergies</p></section><section class="print-page" id="gastroenterology-gastroenterology-gi-bleeding"><h1 id="gastroenterology-gastroenterology-gi-bleeding-gi-bleeding">GI Bleeding<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-gi-bleeding" title="Permanent link">&para;</a></h1>
<p>GI Bleeding – Matthew Meyers</p>
<p>Background</p>
<ul>
<li>Intraluminal blood loss anywhere from the nasopharynx/oral cavity to
    the anus</li>
<li>Don’t forget epistaxis or oropharyngeal bleeding as possible source
    of melena</li>
<li>IV PPI prior to endoscopy may
    ↓
    need for endoscopic therapy but does not impact transfusion
    requirement, rebleeding risk, need for surgical intervention, or
    mortality</li>
<li>Classification: relative location to the Ligament of Treitz (LoT)</li>
<li>Upper = proximal to LoT<ul>
<li>PUD, gastritis (alcohol, stress, NSAIDs, ASA), esophagitis,
    variceal bleed, Mallory-Weiss tear, AVM, Dieulafoy’s lesion,
    aorto-enteric fistula, gastric antral vascular ectasias,
    malignancy</li>
</ul>
</li>
<li>Lower = distal to LoT<ul>
<li>Diverticular bleed, ischemic/infectious/IBD/radiation colitis,
    malignancy, angiodysplasia, anorectal (hemorrhoids, anal
    fissure), Meckel’s diverticulum, post-polypectomy bleed</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Hematemesis (very specific for upper GI bleed), hematochezia
    (usually lower although brisk upper possible), melena (usually
    upper), coffee-ground emesis, epigastric/abdominal pain, acute or
    chronic, hx of GI bleed and prior endoscopies, NSAID use, alcohol
    use, anticoagulant use, hx of cirrhosis</li>
<li>Exam: VITALS – assess stability to determine resuscitation needs,
    MICU vs. floor; orthostatic vs, rectal exam every time (smear stool
    on white tissue paper to look for melena), look for signs of
    cirrhosis (jaundice, palmar erythema, ascites, spider angiomata)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC, PT/INR, CMP, Lactic Acid, Blood Gas</li>
<li>EGD: usually best</li>
<li>Difficulty localizing GIB: pill-capsule, balloon enteroscopy
    Meckel’s scan, tagged RBC scan</li>
<li>Massive lower GI bleeds will require arteriography</li>
</ul>
<p>Management</p>
<ul>
<li>Secure airway (intubation) if comatose, extremely combative, or
    massive hematemesis</li>
<li>At least 2 large bore IV’s (&gt; 18 gauge) – ask nurses directly to
    ensure these are placed</li>
<li>Maintain active type and screen</li>
<li>Bolus IVF to maintain MAP &gt;65H/H monitoring q6-q12 hours;
    transfusions as indicated</li>
<li>IV PPI (pantoprazole) 40 mg BID if thought to be upper/possible
    ulcer</li>
<li>If possibility of variceal bleed: Octreotide IV 50 mcg x1 then 50
    mcg/hr drip x 3-5 days</li>
<li>NPO if unstable vs. clear liquids (no reds or purples) until morning
    for EGD</li>
<li>Never give prep to a patient for colonoscopy (GoLytely) without
    discussing with GI fellow</li>
<li>Consult gastroenterology to facilitate endoscopy</li>
<li>If endoscopy is unable to stop bleeding
    
    IR is next who can embolize</li>
<li>If embolization fails
    
    EGS for source removal</li>
</ul>
<p>Additional Information:</p>
<ul>
<li>Any upper GI bleed in a cirrhotic: will require SBP prophylaxis (see
    Hepatology)</li>
<li>If a source of bleeding cannot be found on both upper and lower
    endoscopy and still bleeding, ask about push enteroscopy, capsule
    endoscopy, and/or balloon enteroscopy</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-inflammatory-bowel-disease"><h1 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-inflammatory-bowel-disease">Inflammatory Bowel Disease<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-inflammatory-bowel-disease" title="Permanent link">&para;</a></h1>
<p>Inflammatory Bowel Disease – Francesca Raffa</p>
<p>Background</p>
<ul>
<li>Ulcerative colitis (UC): colon only (can be backwash ileitis);
    <strong>contiguous</strong> lesions; <strong>mucosal</strong> inflammation</li>
<li>Crohn’s disease (CD): any part of the GI tract; “ <strong>skip</strong>
    <strong>lesions</strong> ”; <strong>transmural</strong> inflammation</li>
<li>Important historical considerations to include in your documentation
    and presentation:<ul>
<li>Location of disease (CD: LB/SB, LB only, SB only; UC: proctitis,
    left-sided or pancolitis)</li>
<li>Complications: Fistulizing, strictures, perianal, prior
    surgeries, current IBD treatment</li>
<li>Include last endoscopies and imaging findings; current and prior
    IBD treatment and reason for transition (SEs, failure), primary
    IBD provider</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>UC: frequent diarrhea (often bloody), tenesmus, urgency, abdominal
    pain; may have fever, malaise, and weight loss<ul>
<li>Complications: severe bleeding/anemia, fulminant colitis, toxic
    megacolon</li>
</ul>
</li>
<li>CD: abdominal pain, nausea/vomiting, fever, malaise, weight loss;
    May also have diarrhea (± bloody depending on CD location)<ul>
<li>Complications: fistulas (entero-enteric, entero-vesicular,
    entero-cutaneous, rectovaginal, perianal, retroperitoneal),
    abscesses, strictures, obstruction</li>
</ul>
</li>
<li>Extra-intestinal (EI): arthritis, sacro-iliitis, uveitis,
    episcleritis, aphthous ulcers, erythema nodosum, pyoderma
    gangrenosum, PSC (esp. UC), nephrolithiasis, thromboembolism</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, CMP, CRP, ESR,
    ±
    blood cultures</li>
<li>If diarrhea: GI Pathogen panel and C. diff</li>
<li>If anemic: obtain iron studies and type &amp; screen</li>
<li>If weight loss or concern for malnutrition: albumin, pre-albumin,
    Vitamin D, B12, folate</li>
<li>Imaging:<ul>
<li>
<ul>
<li>CT Enterography (oral contrast) preferred in CD, for
        luminal/extra-luminal complic.</li>
<li>How to order CTE: “CT abdomen pelvis enterography”, order
    barium (Volumen) 0.1% oral suspension x2, 1 <sup>st</sup>
    dose to be given by nurse 60 min before study, 2
    <sup>nd</sup> study to be given 30 min before (nurse should
    be in contact with CT tech)Management</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Acute Flare</p>
<ul>
<li>Pain control:
    usually a major component of hospital course<ul>
<li>
<ul>
<li>Avoid NSAIDs, oral pain medications are preferred</li>
<li>If pain is difficult to control, consider Acute Pain Service
    consult</li>
<li>Narcotics and Imodium are contraindicated in toxic megacolon</li>
</ul>
</li>
</ul>
</li>
<li>Antibiotics: appropriately treat infections (intra-abdominal or
    perianal abscess) with antibiotics (consider prior culture data,
    often use cipro/flagyl)</li>
<li>VTE Prophylaxis: All IBD patients, even if having blood in stool
    (unless requiring transfusion) as they are at much higher risk of
    VTE</li>
<li>Nutrition: Nutrition consult for all IBD patients; For severe
    malnutrition or if prolonged bowel rest is needed, TPN is sometimes
    initiated (discuss w/ fellow or attending before placing a TPN
    consult); If TPN needed, will require PICC line</li>
<li>Anemia:
    Ferritin \&lt;100 or iron sat \&lt;20 with ferritin \&lt;300,
    consider iron infusions (if no bacteremia) or transfuse for severe
    anemia</li>
<li>Smoking Cessation (esp. with CD): discuss smoking cessation &amp;
    consult tobacco cessation</li>
<li>Consult Colorectal Surgery (not EGS):  SBO, toxic megacolon, bowel
    perforation, peritonitis</li>
</ul>
<p>Immunosuppression: (</p>
<p>Infections must be ruled out and/or treated before starting)</p>
<ul>
<li>First, steroids: methylprednisolone (Solumedrol)- often 20 mg BID
    for three days<ul>
<li>
<ul>
<li>Transition to oral (40 mg prednisone daily) once clinically
        improved/tolerating PO; typically prescribe a prolonged
        taper on discharge (often down by 5 mg every week)</li>
<li>If severe proctitis: consider rectal steroids
    (hydrocortisone enema/foam)</li>
</ul>
</li>
</ul>
</li>
<li>Second
    , if lack of response: additional medical therapy (biologics), bowel
    rest with TPN, or surgical intervention<ul>
<li>
<ul>
<li>Infliximab (Inflectra) is available at VUMC</li>
<li>If patient fails to respond to steroids, should consider
    possibility of CMV colitis (usually evaluated by biopsy on
    flex sig or colonoscopy)</li>
<li>Biologic workup <strong>:</strong> prior to initiating a biologic, all
    patients must have the following negative studies within the
    last year: Quantiferon Gold and CXR, Hepatitis B serologies,
    HIV, urine histoplasma Ag (some providers)</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-intestinal-ischemia"><h1 id="gastroenterology-gastroenterology-intestinal-ischemia-intestinal-ischemia">Intestinal Ischemia<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-intestinal-ischemia" title="Permanent link">&para;</a></h1>
<p>Intestinal Ischemia</p>
<p>– Michael Koenig</p>
<p>Acute Mesenteric Ischemia</p>
<ul>
<li>Sudden
    onset
    ↓
    or absence of blood flow to the small intestines</li>
<li>Mesenteric Arterial Occlusion:<ul>
<li>
<ul>
<li>Arterial
        Embolism:
        Associated with cardiac arrhythmias (atrial fibrillation),
        valvular
        disease
        , endocarditis, ventricular aneurysm, aortic
        atherosclerosis, and aortic aneurysm</li>
<li>Arterial thrombosis: Most commonly from atherosclerotic
    disease; can also be 2/2 abdominal trauma, infection or
    dissection</li>
</ul>
</li>
</ul>
</li>
<li>Venous
    thrombosis:<ul>
<li>
<ul>
<li>Associated
        w/ hypercoagulable states, malignancy, prior abdominal
        surgery, abdominal mass
        
        venous compression, intra-abdominal inflammatory processes</li>
</ul>
</li>
</ul>
</li>
<li>Non occlusive mesenteric ischemia:<ul>
<li>
<ul>
<li>Intestinal
        hypoperfusion and vasoconstriction; associated w/ decreased
        cardiac output, sepsis, vasopressor use</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Early
    : Abdominal pain is most common symptom, abdominal distension<ul>
<li>
<ul>
<li>Abdominal
        tenderness
        is not prominent early (“pain out of proportion to the
        exam”)</li>
</ul>
</li>
</ul>
</li>
<li>Arterial
    occlusion: Sudden onset, severe periumbilical pain, nausea and
    emesis</li>
<li>Venous
    thrombosis: More insidious onset abdominal pain, waxing and waning</li>
<li>Nonocclusive
    mesenteric ischemia: variable location and severity of abdominal
    pain;  often overshadowed by a precipitating disorder</li>
<li>Late: As transmural bowel infarction develops, abdomen becomes
    distended, bowel sounds become absent, and peritoneal signs develop</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Type and Screen, Lactic acid, BMP, CBC</li>
<li>Imaging:
    KUB: Normal in &gt; 25% of cases<ul>
<li>
<ul>
<li>Ileus
        w/ distended bowel loops, bowel wall thickening,
        ±
        pneumatosis intestinalis</li>
<li>Free
    intraperitoneal air
    
    immediate abdominal exploration</li>
</ul>
</li>
</ul>
</li>
<li>CT Angiography: no oral contrast, obscures mesenteric vessels,
    ↓
    bowel wall enhancement<ul>
<li>
<ul>
<li>Focal
        or segmental bowel wall thickening, intestinal pneumatosis,
        portal vein gas, porto-mesenteric thrombosis, mesenteric
        arterial calcification, mesenteric artery occlusion</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>General: IVFs, NPO, hemodynamic monitoring and support (try to avoid
    vasoconstricting agents), anticoagulation, broad-spectrum
    antibiotics, pain control</li>
<li>If develops peritonitis or evidence of perforation on CT
    
    EGS consult for surgery</li>
<li>Mesenteric arterial embolism: Embolectomy vs. local infusion of
    thrombolytic agent</li>
<li>Mesenteric arterial thrombosis: Surgical revascularization vs.
    thrombolysis with endovascular angioplasty and stenting</li>
<li>Venous thrombosis: Anticoagulation; possible thrombolysis if
    persistent symptoms</li>
<li>Nonocclusive occlusion: Treat underlying cause, stop
    vasoconstriction meds, consider intra-arterial vasodilator infusion.
    D/c anticoagulation once ischemic etiologies are excluded</li>
</ul>
<p>Chronic Mesenteric Ischemia</p>
<ul>
<li>↓
    blood flow to intestines, typically caused by atherosclerosis of
    mesenteric vessel</li>
<li>Also known as intestinal angina</li>
<li>High-grade mesenteric vascular stenoses in at least two major
    vessels (celiac, SMA, or IMA) must be established</li>
<li>Ddx: Malignancy, chronic cholecystitis, chronic pancreatitis, IBD,
    PUD</li>
</ul>
<p>Presentation</p>
<ul>
<li>Recurrent dull, crampy, postprandial abdominal pain</li>
<li>Pts develop food aversion and often have associated weight loss</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CT angiogram abdomen/pelvis is preferred (&gt;90% sensitivity and
    specificity)</li>
<li>Can also consider duplex U/S and gastric tonometry</li>
</ul>
<p>Management</p>
<ul>
<li>Conservative management if asymptomatic: smoking cessation and
    secondary prevention to limit progression of atherosclerotic disease</li>
<li>Nutritional evaluation</li>
<li>Revascularization (open vs. endovascular) is indicated if symptoms
    are present<ul>
<li>Mesenteric angioplasty and stenting is first-line therapy</li>
<li>Goal is to prevent future bowel infarction</li>
</ul>
</li>
</ul>
<p>Ischemic Colitis</p>
<ul>
<li>Sudden, transient reduction in blood flow to colon</li>
<li>Typically at “watershed” regions of colon, such as the splenic
    flexure and rectosigmoid junction</li>
<li>Most often nonocclusive (95% of cases) and affects older adults</li>
<li>Risk factors: ACS, hemodialysis, shock, aortoiliac instrumentation,
    cardio pulmonary bypass, extreme exercise (marathon running)</li>
<li>Ddx: Small bowel ischemia, infectious colitis, IBD</li>
</ul>
<p>Presentation</p>
<ul>
<li>Rapid onset, mild cramping abdominal pain, associated with urge to
    defecate, hematochezia</li>
<li>Tenderness present (typically over left side)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Lactic acid (nonspecific but elevated), LDH, CPK, CBC
    (leukocytosis), BMP (metabolic acidosis)</li>
<li>KUB; if peritonitis or signs of severe ischemia
    →
    surgery</li>
<li>CT abdomen/pelvis w/ IV contrast (and oral contrast if patient can
    tolerate)<ul>
<li>Edema and bowel wall thickening in segmental pattern (suggests
    transient ischemia and subsequent reperfusion)</li>
</ul>
</li>
<li>Consider CTA abdomen/pelvis if suspicion for vascular occlusion</li>
<li>Colonoscopy confirms diagnosis.<ul>
<li>Edematous, friable mucosa; erythema; and interspersed pale
    areas; bluish hemorrhagic nodules representing submucosal
    bleeding</li>
<li>Segmental distribution, abrupt transition between injured and
    non-injured mucosa, rectal sparing, and single linear ulcer
    along longitudinal axis of colon</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>General: IVFs, bowel rest</li>
<li>Broad Spectrum Antibiotics: zosyn alone or CTX + flagyl</li>
<li>Risk Stratify: associated factors which predict poor outcomes<ul>
<li>Male gender</li>
<li>SBP \&lt;90</li>
<li>HR &gt;100</li>
<li>WBC &gt;15,000</li>
<li>Hgb \&lt;12</li>
<li>Na \&lt;136</li>
<li>BUN &gt;20</li>
<li>LDH &gt;350</li>
<li>Isolated right-sided colonic involvement</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Abdominal pain with rectal bleeding</li>
<li>Mild colonic ischemia (no above risk factors):
    sigmoidoscopy/colonoscopy and biopsy<ul>
<li>Observation/supportive care; can discontinue antibiotics if no
    ulceration</li>
</ul>
</li>
<li>Moderate colonic ischemia (1-3 risk factors)
    →
    if there is evidence of mesenteric arterial or venous occlusion then
    start systemic anticoagulation &plusmn; vascular intervention<ul>
<li>If no vascular occlusion, then management is the same as mild
    colonic ischemia</li>
</ul>
</li>
<li>Severe colonic ischemia (peritoneal signs, pneumoperitoneum,
    pneumatosis, portal venous gas on imaging; gangrene or pancolonic
    ischemia on colonoscopy; &gt;3 risk factors)
    :
    consult EGS
    for
    abdominal exploration and segmental resection</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-nausea-vomiting"><h1 id="gastroenterology-gastroenterology-nausea-vomiting-nausea-vomiting">Nausea &amp; Vomiting<a class="headerlink" href="#gastroenterology-gastroenterology-nausea-vomiting-nausea-vomiting" title="Permanent link">&para;</a></h1>
<p>Nausea &amp; Vomiting – Michael J. Neuss</p>
<p>General Approach:</p>
<ul>
<li>VOMIT mnemonic (see below)</li>
<li>Several antiemetics can prolong QT interval (see below).
    Caution is advised when QTc is prolonged (&gt;450 in men and &gt;470 in
    women), particularly if hypokalemia, hypomagnesemia, or if taking
    multiple medications with QT prolonging effects.</li>
<li>Consider drug use and withdrawal, medication effects, cardiac
    ischemia, pregnancy, abdominal pathology, adrenal insufficiency, CNS
    lesion, anxiety, severe pain</li>
<li>Labs: BMP, hepatic functional panel, lactate, amylase/lipase, TSH,
    cortisol (AM vs cort stim), troponin,
    β
    hCG, U/A, UDS</li>
<li>EKG (know QT, eval for ischemia), KUB/upright, Small bowel
    follow-through (SBFT)</li>
<li>CT A/P, CNS imaging (CT vs MRI; eval for mets in oncology pts)</li>
<li>EGD has limited utility unless mechanical gastric outlet obstruction
    is suspected</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>VOMIT</td>
<td>VOMIT</td>
<td>Etiologies</td>
<td>Management</td>
</tr>
<tr>
<td>Vestibular &amp; Vertigo</td>
<td>Labyrinthitis, Vestibular neuritis, Meniere’s disease Cerebellar stroke</td>
<td>Labyrinthitis, Vestibular neuritis, Meniere’s disease Cerebellar stroke</td>
<td>- Scopolamine, diphenhydramine - Check for nystagmus, truncal ataxia, focal deficits; consider CNS imaging if high risk - VUMC: consider referral to Pi β Phi for vertigo</td>
</tr>
<tr>
<td>Obstruction</td>
<td>Adhesions, hernia, volvulus, constipation Gastric outlet obstruction (pyloric stenosis from malignancy or PUD)</td>
<td>Adhesions, hernia, volvulus, constipation Gastric outlet obstruction (pyloric stenosis from malignancy or PUD)</td>
<td>- Bowel Obstruction: KUB (about 80% sensitive) vs. CT A/P, Surgical consultation (general surgery at VA and EGS at VUMC) - SBFT – both diagnostic and therapeutic - Bowel rest, NGT (if tolerated/indicated), bowel regimen - Gastric outlet obstruction: Inflammation may respond to acid suppression and NGT to suction - Endoscopic dilation, surgery or stenting</td>
</tr>
<tr>
<td>Motility</td>
<td>GERD, Gastroparesis, autonomic dysfunction (e.g. in diabetics)</td>
<td>GERD, Gastroparesis, autonomic dysfunction (e.g. in diabetics)</td>
<td>- If GERD, trial of PPI and de-escalate to H2 blocker once able - Metoclopramide (caution due to side effects, erythromycin second line) - Consider gastric emptying study (limited sensitivity &amp; specificity ONLY outpt off narcotics) - Consider autonomics evaluation</td>
</tr>
<tr>
<td>Meds</td>
<td>Antibiotics, SSRI, Opioids cannabinoid hyperemesis</td>
<td>Antibiotics, SSRI, Opioids cannabinoid hyperemesis</td>
<td>- UDS, CSMD search - Careful med review - Ondansetron - Cannabinoid hyperemesis syndrome: hot showers cyclically. Stop cannabis</td>
</tr>
<tr>
<td>Inflammation or Infection</td>
<td>Gastroenteritis, PUD, hepatitis, pyelonephritis, nephrolithiasis, cholecystitis, pancreatitis</td>
<td>Gastroenteritis, PUD, hepatitis, pyelonephritis, nephrolithiasis, cholecystitis, pancreatitis</td>
<td>- Ondansetron, other agents acceptable - Treat underlying problem</td>
</tr>
<tr>
<td>Toxins</td>
<td>Uremia, ketoacidosis, hypercalcemia, chemotherapy</td>
<td>Uremia, ketoacidosis, hypercalcemia, chemotherapy</td>
<td>- Ondansetron, others acceptable - Treat underlying problem - Pre-treatment for chemo ( usually part of chemo order sets)</td>
</tr>
<tr>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Emetics</td>
<td>Anti-Emetics</td>
<td>Anti-Emetics</td>
<td>Anti-Emetics</td>
</tr>
<tr>
<td>Med (by class)</td>
<td>Dose</td>
<td>Side effects?</td>
<td>QT?</td>
</tr>
<tr>
<td>Serotonin antagonists</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Ondansetron (Zofran)</td>
<td>4-8mg PO/IV q6h</td>
<td>Constipation, headache</td>
<td>++</td>
</tr>
<tr>
<td>Granisetron (Kytril)1</td>
<td>2 mg PO x1, 1 mg PO BID pre-chemo, daily patch, OR 10mcg/kg pre-chemo</td>
<td>‘’</td>
<td>++</td>
</tr>
<tr>
<td>Dopamine antagonists</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Prochlorperazine (Compazine)</td>
<td>5-10 mg PO q6h, 2.5 – 10 mg IV q6h, 25 mg PR q6h</td>
<td>EPS, less sedation than anti-H</td>
<td>+</td>
</tr>
<tr>
<td>Haloperidol (Haldol)</td>
<td>0.5-1 mg PO/IV q6h</td>
<td>‘’</td>
<td>++</td>
</tr>
<tr>
<td>Zyprexa (Olanzapine)2</td>
<td>2.5-10mg PO q6H</td>
<td>‘’</td>
<td>+</td>
</tr>
<tr>
<td>Metoclopramide (Reglan)</td>
<td>10 mg PO/IV q6h</td>
<td>EPS, dystonia, tardive dyskinesia</td>
<td>+</td>
</tr>
<tr>
<td>GABAergic</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Lorazepam (Ativan)</td>
<td>0.5-2mg PO; 0.25 – 1 mg IV q6h</td>
<td>Sedation, delirium</td>
<td>-</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Promethazine (Phenergan)</td>
<td>12.5 - 25mg PO/IV q6h OR 25 mg PR q6h</td>
<td>Sedation, EPS (DA antagonist as well)</td>
<td>+</td>
</tr>
<tr>
<td>Diphenhydramine (Benadryl)</td>
<td>25-50mg PO/IV q6h</td>
<td>Sedation, delirium, urinary retention, ileus</td>
<td>-</td>
</tr>
<tr>
<td>Meclizine (Antivert)</td>
<td>25 – 50 mg PO qday</td>
<td>‘’</td>
<td>-</td>
</tr>
<tr>
<td>Anticholinergics</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Scopolamine (Hyoscine)</td>
<td>1.5 mg patch q3day</td>
<td>‘’</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Dexamethasone (Decadron)3</td>
<td>20 mg PO or IV for CINV; can give with Ondansetron 8-18 mg or Granisetron 10mcg/kg IV or 2 mg PO if high severity CINV</td>
<td>Hyperglycemia, fluid retention</td>
<td>-</td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-peptic-ulcer-disease"><h1 id="gastroenterology-gastroenterology-peptic-ulcer-disease-peptic-ulcer-disease">Peptic Ulcer Disease<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-peptic-ulcer-disease" title="Permanent link">&para;</a></h1>
<p>Peptic Ulcer Disease – Michelle Izmaylov</p>
<p>Background</p>
<ul>
<li>Ulceration in the GI tract wall extending through the muscularis
    mucosa into deeper layers</li>
<li>Most common in the stomach and proximal duodenum</li>
<li>Less common in the lower esophagus, the distal duodenum, or the
    jejunum<ul>
<li>↑
    suspicion for unopposed hypersecretory states, like
    Zollinger-Ellison syndrome</li>
<li>Causes: NSAID use and Helicobacter pylori &gt;> steroids,
    malignancy and acute stress</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Episodic gnawing or burning epigastric pain, 2 - 5 hr after meals,
    nausea, vomiting, heartburn, bloating, postprandial belching, and
    loss of appetite</li>
<li>Nocturnal pain: acid is secreted in absence of a food buffer</li>
<li>Classic teaching for ulcers:
    Gastric (pain worse w/eating); Duodenal (pain better w/eating)</li>
<li>May be asymptomatic until complications such as hemorrhage or
    perforation</li>
<li>Alarm features
    : unintentional weight loss, persistent vomiting, melena,
    progressive dysphagia, early satiety, recurrent vomiting, palpable
    abdominal mass, lymphadenopathy, family history of upper
    gastrointestinal cancer, and iron deficiency anemia</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC</li>
<li>H Pylori testing: if no strong NSAID use history<ul>
<li>Urea breath or stool antigen (pt needs to d/c PPI for 1-2 weeks,
    to avoid false - for both)</li>
</ul>
</li>
<li>EGD: if alarm features or patient is older than 55</li>
</ul>
<p>Management</p>
<ul>
<li>General: treat underlying cause (i.e. H. pylori, stop NSAIDs, etc),
    encourage smoking cessation, and limit alcohol intake to 1
    drink/day.</li>
<li>If complicated peptic ulcer (i.e. bleeding, perforation, or gastric
    outlet obstruction):<ul>
<li>IV PPI (if bleeding, cont IV PPI for 72 hrs after endoscopic
    treatment then &rarr;  oral PPI )</li>
<li>EGD to determine etiology and for possible treatment</li>
<li>Repeat EGD if indicated (see below)</li>
</ul>
</li>
<li>If uncomplicated peptic ulcer (not caused by H. pylori):<ul>
<li>Antisecretory therapy with oral PPI (i.e. omeprazole 20 to 40 mg
    daily):<ul>
<li>If caused by NSAIDs: Duration: \&lt;1 cm ulcer
    
    4-6 wks; ≥1 cm ulcer
    
    6-8 wks</li>
<li>If not caused by NSAIDs, Duration:<ul>
<li>Duodenal ulcer: 4 weeks</li>
<li>Gastric ulcer: 8 weeks</li>
<li>Evaluate for other etiologies</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>If ulcer caused by H. pylori:<ul>
<li>Treat with PPI BID for 14 days with an appropriate combination
    antibiotic regimen.</li>
<li>Confirm H. pylori eradication (via stool antigen test, urease
    breath test, or EGD &gt;4 weeks after compl
    etion of therapy). If not eradicated, retreat</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>Continue maintenance PPI therapy (omeprazole 20 mg daily) for the
    following:</p>
<ul>
<li>Peptic ulcer &gt;2 cm and age &gt;50 or multiple co-morbidities</li>
<li>Frequently recurrent peptic ulcers (&gt;2 in one year)</li>
<li>H. pylori-negative, NSAID-negative ulcer disease</li>
<li>Failure to eradicate H. pylori (including salvage therapy)</li>
<li>Condition requiring long term aspirin/NSAID use</li>
<li>Persistent ulcer on repeat EGD (if performed)</li>
</ul>
</li>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>Indications for repeat EGD (8-12 weeks):</p>
<ul>
<li>Persistent/recurrent sxs despite medical therapy</li>
<li>Complicated ulcer (bleeding), with evidence of ongoing bleeding</li>
<li>Giant gastric ulcer (&gt;2 cm) or features of malignancy at index
    endoscopy</li>
<li>Gastric ulcer that was not biopsied or inadequately sampled on
    initial EGD</li>
<li>Gastric ulcer in pt w/risk factors for gastric cancer (&gt;50
    yo, H. pylori, immigrant from high prevalence area [Japan,
    Korea, Taiwan, Costa Rica], FHx, presence of gastric atrophy,
    adenoma, dysplasia, intestinal metaplasia)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-small-bowel-obstruction"><h1 id="gastroenterology-gastroenterology-small-bowel-obstruction-small-bowel-obstruction">Small Bowel Obstruction<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-small-bowel-obstruction" title="Permanent link">&para;</a></h1>
<p>Small Bowel Obstruction (SBO) – Alex Wiles</p>
<p>Background</p>
<p>-
-   Risk Factors: prior abdominal surgeries (adhesions), malignancy,
    hernia, intestinal inflammation (IBD)/stricture, radiation, abscess,
    foreign bodies
-   Indicators for bowel ischemia: fever, leukocytosis, tachycardia,
    peritonitis
-   Ddx: early appendicitis, large bowel obstruction, Ogilvie’s, DKA,
    Pancreatitis, IBD, Gastric outlet obstruction</p>
<p>Presentation</p>
<p>-
-   Nausea, Emesis, intermittent colic, bloating, constipation
-   Obstipation if completely obstructed, loss of flatulence
-   Exam: classically with “tinkling” bowel sounds, tympanic abdomen,
    distended abdomen</p>
<p>Evaluation</p>
<p>-
-   CBC, BMP, lipase, hepatic function panel, lactate (sensitive, not
    specific for ischemia)
-   Start with KUB to r/o perforation but typically will require CT
    (x-ray only ~80% sensitive)
-   CT abdomen/pelvis with IV contrast is optimal study if adequate
    renal function
    -   No oral contrast (American College of Radiology (ACR)
        Appropriateness Criteria) as it will not aid diagnosis and can
        lead to aspiration; IV helps evaluate ischemia
    -   Key word: transition point
    -   Non-specific signs of bowel inflammation: bowel wall thickening,
        submucosal edema</p>
<p>Management</p>
<p>-
-   Use Small Bowel Obstruction admission order set (surgery order set)
-   Consult EGS: if any concern for SBO,  evaluate need for urgent
    surgery
    -   Surgical indications
        
        complete obstruction, CT with ischemia, perforation
-   Gastric decompression: place NGT (prevent aspiration)
-   NPO until obstruction relieved and NGT removed
-   Fluids: two large bore IVs (nursing communication); LR bolus +
    maintenance while NPO
-   If no resolution of partial obstruction at 48 hours:
    -   Fluoroscopy Upper GI small bowel ft (follow through)
        -   In comments, write “Gastrografin contrast” (water-soluble
            contrast) which osmotically reduces bowel wall edema and
            aids peristalsis
        -   If gastrografin reaches the colon within 24 hours, it
            predicts clinical resolution of SBO without surgery
        -   Note this can also be therapeutic for pSBO and get bowels
            moving
-   Signs of resolution of SBO:
    -   Decrease in the volume of nasogastric tube output
    -   Decrease in abdominal distension or passage of flatus/stool per
        rectum</p></section><h1 class='nav-section-title-end'>Ended: Gastroenterology</h1>
                        <h1 class='nav-section-title' id='section-geriatrics'>
                            Geriatrics <a class='headerlink' href='#section-geriatrics' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="geriatrics-geriatrics-dementia-0"><h1 id="geriatrics-geriatrics-dementia-0-dementia">Dementia<a class="headerlink" href="#geriatrics-geriatrics-dementia-0-dementia" title="Permanent link">&para;</a></h1>
<p>Dementia</p>
<p>Background</p>
<ul>
<li>Alzheimer’s Disease (AD): short-term memory deficits prominent</li>
<li>Frontotemporal Dementia: behavioral (aggressive or disinhibited),
    language (primary progressive aphasias) or memory (Alzheimer’s/FTD
    overlap) variants</li>
<li>Lewy Body Dementia: hallucinations, memory difficulties with
    atypical Parkinsonism early</li>
<li>Posterior Cortical Atrophy: visual difficulties and ocular apraxia
    preceding memory problems</li>
<li>Creutzfeldt-Jakob Disease (CJD): manifests with subacute cognitive
    decline, seizures, vision loss, personality changes. Can develop
    startle myoclonus</li>
<li>Corticobasal degeneration: focal neurologic changes with
    parkinsonism</li>
<li>Neurosyphilis: rare, but treatable, present with a range of
    cognitive changes. Develop meningovascular encephalitis. Pts can
    develop an arteritis, headache and hydrocephalus.</li>
<li>Normal Pressure Hydrocephalus (NPH): “wet, wacky and wobbly” meaning
    incontinence, gait apraxia and cognitive changes (usually frontal
    symptoms)</li>
<li>Autoimmune Dementias: includes limbic encephalitis (like NMDA) where
    there are memory and personality changes, autonomic changes,
    hallucinations and seizures</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Aging</td>
<td>Mild Cognitive Impairment</td>
<td>Alzheimer’s Dementia (DSM IV Diagnostic Crit.)</td>
</tr>
<tr>
<td>- Mild decline in memory - More effort/time needed to recall new info - New learning slowed but well compensated by lists, calendars, etc. + - No impairment in social &amp; occupation functioning</td>
<td>- Subjective complaint of cognitive decline in at least one domain (Memory, executive function, language, or visuospatial perception) + - Cognitive decline is noticeable and measurable + - No impairment in social &amp; occupation functioning</td>
<td>- Memory impairment + - Aphasia (language disturbance) OR - Apraxia (impaired motor ability despite normal motor function) OR - Agnosia (failure to recognize or identify objects despite intact sensory function OR - Disturbed executive functioning + - Causes significant impairment in social &amp; occupation functioning + - Other medical &amp; psychiatric conditions, including delirium, have been excluded</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Alzheimer’s Disease</td>
<td>Vascular Dementia</td>
<td>Lewy Body Dementia</td>
<td>Frontotemporal Dementia</td>
</tr>
<tr>
<td>Onset</td>
<td>Gradual</td>
<td>Sudden or stepwise</td>
<td>Gradual</td>
<td>Gradual (age \&lt; 60)</td>
</tr>
<tr>
<td>Cognitive Domains &amp; Symptoms</td>
<td>Memory, language, visuospatial</td>
<td>Depends on location of ischemia</td>
<td>Memory, visuospatial</td>
<td>Executive dysfunction, personality changes, disinhibition, language, &plusmn; memory</td>
</tr>
<tr>
<td>Motor Symptoms</td>
<td>Rare early Apraxia later</td>
<td>Correlates with ischemia</td>
<td>Parkinsonism</td>
<td>None</td>
</tr>
<tr>
<td>Progression</td>
<td>Gradual (over 8-10 years)</td>
<td>Gradual or stepwise with further ischemia</td>
<td>Gradual, but faster than Alzheimer’s disease</td>
<td>Gradual, but faster than Alzheimer’s disease</td>
</tr>
<tr>
<td>Imaging</td>
<td>Possible global atrophy</td>
<td>Cortical or subcortical on MRI</td>
<td>Possible global atrophy</td>
<td>Atrophy in frontal &amp; temporal lobes</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>MINI-COG: Screening test for cognitive impairment (highly sensitive)<ul>
<li>Ask pt to remember three words (banana, sunrise, chair). Ask pt
    to repeat immediately</li>
<li>Ask pt to draw clock. After numbers are on the face, ask pt to
    draw hands to read 10 minutes after 11:00<ul>
<li>Correct is all numbers in right position AND hands pointing
    to the 11 and the 2</li>
</ul>
</li>
<li>Ask pt to recall the three words</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/minicog.png" data-entity-type="file" data-entity-uuid="eb496c53-6380-4d92-b242-1121854a0ae0" alt="MINI COG" /></p>
<ul>
<li>MOCA: Montreal Cognitive Assessment<ul>
<li>Lengthier test of cognition (highly specific for cognitive
    impairment)</li>
<li>Useful for detecting subtle deficits as in Mild Cognitive
    Impairment (MCI)</li>
<li>Scores:<ul>
<li>18-25: Mild cognitive impairment</li>
<li>10-17: Moderate cognitive impairment</li>
<li>\&lt;10: Severe cognitive impairment</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Rule out reversible causes of dementia-like symptoms: <strong>DEMENTIA</strong><ul>
<li><strong>​​​​​​​</strong>
    D
    rugs</li>
<li>E
    motional (depression)</li>
<li>M
    etabolic (CHF, COPD, CKD, OSA)</li>
<li>E
    ndocrine (Hypothyroidism, Hyperparathyroidism, Hyponatremia)</li>
<li>N
    utrition (B12 deficiency)</li>
<li>T
    rauma (chronic SDH)</li>
<li>I
    nfection</li>
<li>A
    rterial (vascular)</li>
</ul>
</li>
<li>B12, thyroid studies</li>
<li>RPR, HIV testing in at-risk patient groups<ul>
<li>Neuropsych testing can be done for more clear patterns of
    dysfunction
    ​​​​​​​</li>
</ul>
</li>
<li>MRI brain with contrast if concerned for inflammatory or infectious
    causes<ul>
<li>CJD: cortical ribboning on DWI with T2 hyperintensity in the
    thalamus and basal ganglia</li>
<li>Sulcal crowding and bowing of the corpus callosum can be seen in
    NPH on imaging</li>
</ul>
</li>
<li>ADMARK testing looks at tau and amyloid levels, also of limited help</li>
</ul>
<p>Management</p>
<ul>
<li>Targeting Cognitive Impairment<ul>
<li>Cholinesterase Inhibitors: Donepezil, rivastigmine</li>
<li>NMDA antagonists: Memantine<ul>
<li>Indicated in moderate to severe AD in combination with
    cholinesterase inhibitors</li>
<li>Fewer SE than cholinergic medications</li>
</ul>
</li>
<li>Vitamin supplementation (i.e. Vitamin E)<ul>
<li>Unclear benefit in delaying progression of dementia</li>
</ul>
</li>
</ul>
</li>
<li>Targeting Behaviors<ul>
<li>Depression: Treat with antidepressants (SSRI’s)</li>
<li>Sleep Disturbance: Mirtazapine (7.5 mg nightly) or Trazodone (25
    mg nightly)</li>
<li>Agitation: Try SSRI (citalopram, sertraline)<ul>
<li>Consider antipsychotics (black box warning increased risk of
    death in elderly)</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-falls"><h1 id="geriatrics-geriatrics-falls-falls">Falls<a class="headerlink" href="#geriatrics-geriatrics-falls-falls" title="Permanent link">&para;</a></h1>
<p>Falls</p>
<p>Background</p>
<ul>
<li>Screen annually: Ask if elderly pts had falls in the past year<ul>
<li>History of fall is a strong risk factor for future falls</li>
<li>Recommended History Screening Tool:  CDC STEADI Algorithm</li>
</ul>
</li>
<li>Physical Exam Screening Tools:<ul>
<li>If potentially unstable injuries (new spine fracture or lower
    extremity fracture): push ortho to clear the patient for
    mobility</li>
<li>If no potentially unstable injuries, attempt to get the patient
    out of bed<ul>
<li>If lying down, have them lift each leg off the bed</li>
<li>If they can do this, ask them to sit up on side of bed</li>
<li>If they can do this, ask them to stand</li>
<li>If they can do this without assistance, then observe them
    walk</li>
</ul>
</li>
<li>The Timed “up and Go” Test (TUG) tool for fall risk<ul>
<li>Have the patient rise from sitting in a chair, walk 10 feet
    forward, turn around, walk back to chair, and sit down</li>
<li>Patients who require &gt; 10 seconds are at increased risk for
    falls</li>
</ul>
</li>
</ul>
</li>
<li>Med Rec:<ul>
<li>Antipsychotics, antidepressants, anticholinergics, anxiolytics,
    sedatives/hypnotics, anti-hypertensives, antiarrhythmics,
    steroids, statins all can increase risk of falls</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Rule out other causes: Cardiac, Neurologic, Infectious</li>
<li>Check Vitamin D levels (goal &gt; 30)<ul>
<li>Supplement (800-1000 IU daily) if at increased fall risk</li>
</ul>
</li>
<li>Assess visual acuity (e.g. expedite cataract surgery)</li>
<li>Hearing assessment (audiology screen)</li>
<li>Consult Inpatient PT/OT</li>
<li>Recommend non-skid shoes with a backing (sneaker)</li>
<li>Home health PT or OT for home safety evaluation at discharge<ul>
<li>Modify extrinsic risk factors for falls: removal of fall
    hazards, placement of hand rails</li>
</ul>
</li>
<li>Referral to Exercise programs: At VUMC = Dayani Center “Ambulatory
    Referral to Medical Fitness” outpatient order</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-frailty"><h1 id="geriatrics-geriatrics-frailty-frailty">Frailty<a class="headerlink" href="#geriatrics-geriatrics-frailty-frailty" title="Permanent link">&para;</a></h1>
<p>Functional Status and Frailty</p>
<p>Background</p>
<ul>
<li>Frailty
    : Syndrome of physiological decline in late life, characterized by
    marked vulnerability to adverse health outcomes</li>
<li>Functional status: Ability to perform activities necessary in daily
    life (ADL)</li>
<li>Pts should be encouraged to exercise as tolerated, with a low
    threshold to refer to PT/OT</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Order Vitamin D &amp; B-12 levels</li>
<li>Vulnerable Elders Scale-13: Identifies community dwelling pts at
    risk for decline over 5 yrs</li>
<li>Fried Frailty Tool: Identifies frailty in community dwelling elders
    (1 -2 = prefrail; &gt; 3 = frail)<ul>
<li>Fatigue:  are you Fatigued?</li>
<li>Resistance: are you unable to climb a flight of stairs?</li>
<li>Aerobic: are you unbale to walk a block ?</li>
<li>Illness: Do you have more than 5 illnesses ?</li>
<li>Loss: Have you lost more than 5% of weight in 6 months?</li>
</ul>
</li>
</ul>
<p>​​​​​​​</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic ADL’s</td>
<td>Instrumental ADL’s</td>
<td>Advanced ADL’s</td>
</tr>
<tr>
<td>Feeding Continence Transferring Toileting Dressing Bathing</td>
<td>Using the telephone Shopping Preparing food Housekeeping &amp; Laundry Driving Handling medications Handling finances</td>
<td>Fulfill societal, community and family roles Participate in recreational tasks</td>
</tr>
</tbody>
</table>
<p>-</p></section><section class="print-page" id="geriatrics-geriatrics-malnutrition"><h1 id="geriatrics-geriatrics-malnutrition-malnutrition">Malnutrition<a class="headerlink" href="#geriatrics-geriatrics-malnutrition-malnutrition" title="Permanent link">&para;</a></h1>
<p>Malnutrition</p>
<p>Background</p>
<ul>
<li>Needs to meet two or more of following criteria:<ul>
<li>Insufficient energy intake</li>
<li>Weight loss</li>
<li>Loss of muscle mass</li>
<li>Loss of subcutaneous fat</li>
<li>Localized fluid accumulation that may mask weight loss</li>
<li>Diminished functional status as measured in handgrip strength</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Reversible causes of malnutrition:
    ​​​​​​​<ul>
<li>Food security (poverty)</li>
<li>Dental status (dentition, gum health)</li>
<li>Dietary restrictions</li>
<li>Food-related functional status (shop, prepare meals, feed self)</li>
<li>Depression</li>
<li>Dementia</li>
<li>Alcoholism</li>
<li>Swallowing ability</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Assess for depression</li>
<li>Screening with Mini Nutritional Assessment (good sensitivity and
    specificity)</li>
<li>Order: CBC, CMP, TSH</li>
<li>Nutritional deficiencies: B12, folate, vitamin D</li>
<li>Consider CT CAP depending on history<ul>
<li>
<ul>
<li>Refeeding: K, Phos, Mg BID until stable and no longer having
        to replete Consider antipsychotics (black box warning
        increased risk of death in elderly)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Manage Reversible causes of malnutrition as above</li>
<li>Medications: consider Remeron (7.5 mg nightly)</li>
<li>Nutritional Supplementation: oral enteral supplements (i.e.
    nutritional shakes)</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-medication-management"><h1 id="geriatrics-geriatrics-medication-management-medication-management">Medication Management<a class="headerlink" href="#geriatrics-geriatrics-medication-management-medication-management" title="Permanent link">&para;</a></h1>
<p>Medication Management</p>
<ul>
<li>Medication Reconciliation Upon Admission<ul>
<li>Evaluating
    for Polypharmacy – Beer’s Criteria</li>
</ul>
</li>
<li>Avoid Prescribing Defaults:<ul>
<li>NSAID
    can lead to gastritis, which can lead to prescription of PPI</li>
<li>Diuretic
    can lead to urinary incontinence, which can lead to prescription
    of oxybutynin</li>
<li>HCTZ
    can lead to hyperuricemia which can lead to prescription of
    allopurinol</li>
</ul>
</li>
<li>Discharge Tips for med adherence: provide pillboxes &amp; arrange
    blister packs for meds</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter"><h1 id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-urinary-incontinence-and-foley-catheter">Urinary Incontinence and Foley Catheter<a class="headerlink" href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-urinary-incontinence-and-foley-catheter" title="Permanent link">&para;</a></h1>
<p>Urinary Incontinence and Foley Catheters</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Types of UI</td>
<td>Mechanism</td>
<td>Associated Symptoms</td>
</tr>
<tr>
<td>Stress</td>
<td>Incompetent urethral sphincter (post-prostatectomy)</td>
<td>UI w/ physical exertion (cough, laughter, sneeze)</td>
</tr>
<tr>
<td>Urge</td>
<td>↑ bladder contraction from detrusor instability (infection, stone, T2DM, caffeine, meds, BPH</td>
<td>Frequency, nocturia, sudden urge</td>
</tr>
<tr>
<td>Overflow</td>
<td>↓ contractility/outlet obstruction (BPH, anticholinergic medications, T2DM, pelvic trauma, spinal cord disease, MS, polio)</td>
<td>Hesitancy, weak stream, sense of incomplete emptying</td>
</tr>
<tr>
<td>Functional</td>
<td>Physical, emotional, or cognitive disability</td>
<td>Depression, pain, evidence of physical, sensory or cognitive impairment</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Medication Reconciliation:<ul>
<li>Alcohol
    , α-Adrenergic agonists, α-Adrenergic blockers, ACE inhibitors,
    Anticholinergics, Antipsychotics, Calcium channel blockers, oral
    estrogen, GABAergic agents, NSAID’s, narcotics</li>
</ul>
</li>
<li>Order Hemoglobin A1C, Electrolytes (particularly Calcium), UA</li>
<li>R/o retention using PVR</li>
<li>Rectal exam to r/o fecal impaction</li>
</ul>
<p>Management</p>
<ul>
<li>Skin care for urinary incontinence:<ul>
<li>Barrier creams: Venelex, petroleum, zinc oxide</li>
<li>Diapers only when up out of bed</li>
<li>Chucks while in bed (don’t hold moisture up close to the skin
    like diapers do)</li>
<li>Offer toileting Q1-2hours</li>
</ul>
</li>
<li>Indications for a foley:<ul>
<li>Inability to void</li>
<li>Need for accurate UOP monitoring when patient unable to comply</li>
<li>Urinary Incontinence AND open sacral or perineal wound</li>
<li>Perioperative Use</li>
<li>Comfort care at end of life</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Geriatrics</h1>
                        <h1 class='nav-section-title' id='section-hematology-oncology'>
                            Hematology oncology <a class='headerlink' href='#section-hematology-oncology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hematology-oncology-hematologyoncology-anemia"><h1 id="hematology-oncology-hematologyoncology-anemia-anemia">Anemia<a class="headerlink" href="#hematology-oncology-hematologyoncology-anemia-anemia" title="Permanent link">&para;</a></h1>
<p>Anemia – Margaret Wheless</p>
<p>General Approach to Diagnosis</p>
<ul>
<li>First evaluate RI (decreased production) vs ↑RI (loss vs hemolysis)<ul>
<li>Reticulocyte
    index &gt; 2%: see below</li>
<li>RI \&lt; 2%:  hypoproliferative
    
    stratify based on RBC size<ul>
<li>Microcytic
    vs. Normocytic vs. Macrocytic</li>
<li>Exception to ↓RI is thalassemia where RI can be slightly ↑</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Symptoms: fatigue/malaise, DOE, angina (if CAD)</li>
<li>Hx of systemic illness, ETOH abuse, Family History</li>
<li>Signs:<ul>
<li>Pallor
    , tachycardia, orthostatic hypotension, purpura, glossitis,
    koilonychia (IDA)</li>
<li>Jaundice (2/2 hemolysis)</li>
<li>Splenomegaly: suggests ex
    tramedullary hematopoiesis or sequestration</li>
<li>Neurologic
    symptoms:
    suggests
    B12 deficiency</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, reticulocyte count, peripheral blood smear, Iron studies
    (TIBC, Ferritin)</li>
<li>Hemolysis labs: Bilirubin, LDH, haptoglobin</li>
<li>Nutritional studies: B12, folate</li>
</ul>
<p>Reticulocyte Index > 2%</p>
<p>Background</p>
<ul>
<li>Consumption vs Blood loss</li>
<li>Loss: acute bleed vs iatrogenic from labs</li>
<li>Hemolysis:
    Microangiopathic hemolytic anemia (MAHA), autoimmune hemolytic
    anemia, intrinsic RBC defects</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LDH, ↑indirect bilirubin, ↓haptoglobin, PT/PTT</li>
<li>Peripheral
    blood smear: looking for schistocytes</li>
<li>Consider
    direct antiglobulin test (DAT) if suspicion for autoimmune cause</li>
</ul>
<p>Extrinsic RBC causes:</p>
<ul>
<li>If
    schistocytes
    ± thrombocytopenia = MAHA: TTP, DIC, HUS, HELLP,
    mechanical valves, malignant HTN, cocaine, scleroderma renal crisis<ul>
<li>Check Cr and Plt count to evaluate for TTP</li>
<li>mechanical valves, malignant HTN, cocaine, scleroderma renal
    crisis</li>
</ul>
</li>
<li>If
    DAT
    positive = AIHA</li>
<li>Order
    cold agglutinin titer</li>
</ul>
<p>Intrinsic RBC causes:</p>
<ul>
<li>Sickle
    cell disease: chronic hemolysis + splenic sequestration crisis where
    RI is
    ↑
    vs aplastic crisis where RI is
    ↓
    (see sickle cell section)</li>
<li>Hereditary
    spherocytosis</li>
<li>Hereditary
    elliptocytosis</li>
<li>PNH
    (generally see pancytopenia, RI is lower than expected for severity
    of anemia)</li>
<li>G6PD
    : bite cells, Heinz bodies on PBS
    : Usually
    precipitated by drugs: nitrofurantoin,
    dapsone
    , sulfonamides, rasburicase, primaquine</li>
</ul>
<p>Management</p>
<ul>
<li>MAHA: Caused by DIC, TTP, HUS<ul>
<li>DIC: sepsis, malignancy, pregnancy<ul>
<li>Treat underlying cause</li>
<li>If active bleeding: FFP, cryoprecipitate (to keep
    fibrinogen&gt;100) and platelets</li>
</ul>
</li>
<li>TTP: Order ADAMTS13<ul>
<li>Will need PLEX</li>
</ul>
</li>
<li>If concern for TTP you should immediately consult Heme and
    NephrologyHUS: + shiga toxin, AKI, diarrhea</li>
<li>Other: mechanical valves, malignant HTN, cocaine, scleroderma
    renal crisis<ul>
<li>Treat underlying cause</li>
</ul>
</li>
</ul>
</li>
<li>Autoimmune
    hemolytic anemia (AIHA):<ul>
<li>Cold
    : IgM binds at temp \&lt;37<ul>
<li>Caused
    by lymphoproliferative disorder (Waldenstrom
    ’
    s), mycoplasma, EBV, HIV</li>
<li>Consult heme. Treat underlying
    . Consider rituximab (steroids don
    ’
    t work)</li>
</ul>
</li>
<li>Warm
    : IgG<ul>
<li>Idiopathic
    or associated with lymphoma, SLE, drugs, babesiosis, HIV</li>
<li>Can use steroids, IVIG, ritux</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>RBC Size Framework</p>
<p>Normocytic Anemia: MCV 80-100</p>
<ul>
<li>Look for pancytopenia (eg. something else may be happening in the
    BM, splenic
    sequestration
    , PNH, etc)</li>
<li>Anemia
    of chronic disease may also be microcytic</li>
<li>Mixed
    macrocytic/microcytic disease: look for ↑RDW</li>
<li>CKD: low Erythropoietin (EPO) levels</li>
<li>Endocrine disease: ↓metabolic demand/O2 requirement</li>
<li>Pure red cell aplasia: associated with destructive Ab (CLL, thymoma,
    parvovirus, autoimmune)</li>
<li>Bone marrow biopsy may be indicated if normocytic with low RI
    without an identifiable cause or anemia associated with other
    cytopenia’s</li>
</ul>
<p>Microcytic anemia: MCV \&lt;80</p>
<p>(Mnemonic: SALTI)</p>
<ul>
<li>Sideroblastic, anemia of chronic disease, lead poisoning,
    thalassemia and iron-deficiency</li>
<li>See Table</li>
</ul>
<table>
<thead>
<tr>
<th>Disease</th>
<th>Etiology</th>
<th>Evaluation</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sideroblastic</td>
<td>MDS Idiopathic ETOH, Lead, Isoniazid, Cu deficiency</td>
<td>Social hx, work, TB, consider Lead level Fe:↑↑ ferritin:↑nl or ↑ TIBC: nl Smear: basophilic stippling BMbx: ringed sideroblasts</td>
<td>NaN</td>
</tr>
<tr>
<td>Anemia of chronic disease</td>
<td>Chronic inflammation, malignancy, HIV autoimmune dz, Inflammation (IL6, TNF α)↓</td>
<td>Fe/TIBC >18% Fe: ↓↓ ferritin:↑↑ TIBC:↓↓</td>
<td>Tx: underlying dz EPO if Hgb \&lt;10 and serum EPO \&lt;500 Replete Fe if ferritin \&lt;100 or TIBC \&lt;20%</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>↓ synthesis of α or β chains leads to ↓ erythropoiesis and ↑ hemolysis</td>
<td>Family Hx of anemia Mentzer’s index: MCV/RBC \&lt;13 = thalassemia Normal Fe studies; can mimic microcytic anemia and Fe overload from transfusions Diagnosis: Hb electrophoresis</td>
<td>α thal more common in Asian/African descent β thal common in Mediterranean descent Tx: transfusions, folate, Fe chelator depending on severity</td>
</tr>
<tr>
<td>Iron (Fe) deficiency</td>
<td>Chronic bleeding: colon cancer heavy menstrual periods, cirrhosis (portal gastropathy) Supply: malnutrition, Crohn’s dz, celiac dz, subtotal gastrectomy Demand: pregnancy</td>
<td>Fe/TIBC \&lt;18% Fe:↓↓ TIBC:↑ nl to ↑ ferritin: \&lt; 15, \&lt;41 w/co-morb. Mentzer’s index: >13 Consider celiac testing based on clinical suspicion Investigate for GIB or sources of blood loss</td>
<td>Oral Fe: 6wks to correct anemia, 6mo to replete stores; dose every other day ( ↑ absorption w/ ↓ GI side effects); add Vit C for ↑ absorption If can’t tolerate PO consider IV Fe (Avoid when bacteremic HFrEF: IV Fe if ferritin \&lt;100 OR 100-300 w/ Fe sat \&lt;20%</td>
</tr>
</tbody>
</table>
<p>Macrocytic Anemia: MCV >100</p>
<ul>
<li>Non-megaloblastic:<ul>
<li>ETOH:
    BM suppression, macrocytosis independent from cirrhosis or
    vitamin deficiency</li>
<li>Liver disease</li>
<li>Hypothyroidism</li>
<li>MDS</li>
<li>Medications that impair DNA synthesis: zidovudine, 5-FU,
    hydroxyurea, ara-C, AZT</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Megaloblastic<ul>
<li>B12 deficiency<ul>
<li>Total body stores last 2-3 yr; absorbed in terminal ileum,
    requires IF</li>
<li>Can have neurologic changes (subacute combined
    degeneration); paresthesias, ataxia, dementia (reversible
    with early treatment)</li>
<li>Etiology: malnutrition (alcoholics, vegan), pernicious
    anemia, gastrectomy, Crohn’s disease, chronic pancreatitis,
    celiac disease (8-41% of pt)</li>
<li>Dx:
    ↓
    B12,
    ↑
    MMA,
    ↑
    homocysteine</li>
<li>If B12 low normal but have neuro sx, can get MMA to help
    confirm dx<ul>
<li>Tx: either monthly IM or sublingual B12 (oral not
    absorbed if no IF)</li>
</ul>
</li>
</ul>
</li>
<li>Folate deficiency<ul>
<li>Total body stores last 2-3 mo; absorbed mostly in jejunum</li>
<li>Etiology: malnutrition, decreased absorption (celiac disease
    2/2 damaged jejunum), impaired metabolism (MTX, TMP),
    ↑requirement (hemolysis, malignancy, dialysis)</li>
<li>Dx: ↓folate, ↑homocysteine but wnl MMA</li>
<li>Tx: PO folate 1-4 mg daily</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-anticoagulation"><h1 id="hematology-oncology-hematologyoncology-anticoagulation-anticoagulation">Anticoagulation<a class="headerlink" href="#hematology-oncology-hematologyoncology-anticoagulation-anticoagulation" title="Permanent link">&para;</a></h1>
<p>Anticoagulation – Madeleine Turcotte</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent</td>
<td>Dose</td>
<td>Renal Dose</td>
<td>Prophylaxis</td>
<td>Monitoring</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>80 U/kg bolus, then 18 U/kg/hr</td>
<td>No change necessary</td>
<td>5000 U q8 hr</td>
<td>PTT (automatic in order set)</td>
</tr>
<tr>
<td>Enoxaparin (Lovenox)</td>
<td>1 mg/kg q 12 hr</td>
<td>1 mg/kg daily</td>
<td>40 mg daily or 30 mg BID</td>
<td>LMWH level (anti-Xa level) Best checked 4 hr after 4<sup>th</sup> dose</td>
</tr>
<tr>
<td>Warfarin (Coumadin)</td>
<td>Start 2-5mg daily and monitor INR Can consult Pharmacy</td>
<td>No change necessary</td>
<td>NaN</td>
<td>PT/INR Use Chromogenic Factor X assay if pt has APLS</td>
</tr>
<tr>
<td>Dabigatran (Pradaxa)</td>
<td>After 5 days of a parenteral AC, 150 mg BID</td>
<td>Avoid use</td>
<td>NaN</td>
<td>Can test drug level if concerned (Any DOAC)</td>
</tr>
<tr>
<td>Rivaroxaban (Xarelto)</td>
<td>15 mg BID x21 d then 20 mg daily</td>
<td>Avoid use in CrCl\&lt;30</td>
<td>10mg QD</td>
<td>NaN</td>
</tr>
<tr>
<td>Apixaban (Eliquis)</td>
<td>10mg BID x7d, then 5mg BID</td>
<td>VTE: No adjustment</td>
<td>2.5 mg BID</td>
<td>A Fib: 2.5mg BID, if 2 of the following: Cr 1.5, Age > 80 Weight \&lt; 60kg</td>
</tr>
<tr>
<td>Edoxaban (Savaysa)</td>
<td>After 5 days of a parenteral AC, 60 mg daily</td>
<td>30 mg for CrCl 15-50 Avoid if CrCl > 95</td>
<td>NaN</td>
<td>Best studied option in renal dysfunction</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAC/DOAC</td>
<td>Warfarin</td>
</tr>
<tr>
<td>Quick onset/offset, fixed dosing</td>
<td>Antidote/reversal agent available</td>
</tr>
<tr>
<td>Reduced incidence of hemorrhagic stroke</td>
<td>Measurable levels of anticoagulation effect</td>
</tr>
<tr>
<td>Fewer drug interactions, no food interaction</td>
<td>Strongest evidence in patients with ESRD</td>
</tr>
<tr>
<td>No need for routine monitoring</td>
<td>Lower risk of GI bleeding (varies)</td>
</tr>
<tr>
<td>Monthly cost $350-450 but discounts available</td>
<td>Monthly cost: $4</td>
</tr>
</tbody>
</table>
<p>Additional Information</p>
<ul>
<li>VA favors dabigatran among DOACs<ul>
<li>Dabigatran cannot be stored in a pill box</li>
<li>PADR for apixaban citing “patient uses a pillbox and cannot use
    dabigatran”</li>
</ul>
</li>
<li>Concomitant Malignancy: favor LMWH, can also use apixaban</li>
<li>Renal dysfunction: favor warfarin, apixaban or edoxaban</li>
<li>Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)</li>
<li>Pregnancy: LMWH (other agents may cross the placenta)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Agent / Duration</td>
<td>Other Notes</td>
</tr>
<tr>
<td>VTE</td>
<td>Any agent Duration: See VTE section</td>
<td>See Deciding between Agents</td>
</tr>
<tr>
<td>Atrial Fib (non-valvular)</td>
<td>Apixaban or dabigatran Duration: Indefinite CHADSVASc > 2, Consider if score of 1</td>
<td>All DOACs: ↓ rates of ICH Apixaban &amp; dabigatran: superior to warfarin in preventing stroke</td>
</tr>
<tr>
<td>Artificial Heart Valves</td>
<td>Warfarin Target INR depends on type of valve If the pt has concurrent Afib, may need higher INR goal Duration: Mechanical, Indefinite Surgically placed bioprosthetic, 3-6 months</td>
<td>DOACs contraindicated with mechanical valves! Bioprosthetic valves: DOACs okay if coexisting indication No AC after TAVR unless patient has other indication</td>
</tr>
<tr>
<td>ACS</td>
<td>PCI: Heparin or LMWH until PCI Fibrinolytic: 2-8 days after fibrinolysis</td>
<td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
</tr>
<tr>
<td>ACS</td>
<td>No PCI: rivaroxaban 2.5 mg BID for 1 year, then reassess risk/benefit</td>
<td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
</tr>
<tr>
<td>LV Thrombus</td>
<td>Warfarin superior Duration: At least 3 months</td>
<td>AC can also be considered in patients with MI who are at high risk for LV thrombus: LVEF \&lt;30% w/ antero-apical wall motion abnormalities</td>
</tr>
<tr>
<td>Portal Vein Thrombus</td>
<td>Any agent DOAC preferred In cirrhosis (INR may not reflect level of anticoagulation) Duration: 3-6 months, or indefinitely if pt has permanent thrombotic risk factors</td>
<td>Consider bleeding risk: large esophageal varices</td>
</tr>
<tr>
<td>Thrombophilia</td>
<td>Any agent (DOACs less effective in APS) Duration: 6 months after any thrombosis Lifelong if recurrent, life-threatening, or unprovoked</td>
<td>Antiphospholipid antibody syndrome: lifelong warfarin for any thrombosis that is otherwise unprovoked</td>
</tr>
</tbody>
</table>
<p>Transitioning Between Anticoagulants with DOACs</p>
<ul>
<li>LMWH
    to Warfarin<ul>
<li>Warfarin and LMWH given simultaneously until INR is therapeutic
    for 24 hours</li>
</ul>
</li>
<li>Warfarin
    to DOAC<ul>
<li>Start
    DOAC when INR \&lt; 2.0</li>
</ul>
</li>
<li>DOAC
    to Warfarin<ul>
<li>High Risk DVT/PE – start LMWH or UFH, then start Warfarin</li>
<li>Low to Moderate Risk DVT/PE – Start warfarin while patient on
    DOAC, Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4</li>
</ul>
</li>
<li>LMWH
    to DOAC<ul>
<li>Stop LMWH and start DOAC when due for next dose of LMWH (within
    2 hrs)</li>
</ul>
</li>
<li>DOAC
    to LMWH<ul>
<li>Stop
    DOAC and start LMWH when due for next DOAC dose</li>
</ul>
</li>
<li>UFH
    to DOAC<ul>
<li>Start
    DOAC when IV stopped (30 min prior to cessation if high risk for
    thrombosis)</li>
<li>DOAC
    to UFH</li>
<li>Start IV heparin with bolus when next DOAC dose is due</li>
</ul>
</li>
</ul>
<p>Peri-Procedural Management of Anticoagulation</p>
<ul>
<li>Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay &gt;12 hours</li>
<li>For those at high risk of thromboembolism:<ul>
<li>Consider continuing AC for low-bleeding-risk procedures, i.e.
    dental procedures, cutaneous biopsy/excision, ICD placement,
    endovascular procedures.</li>
<li>Can bridge with LMWH or heparin drip</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Stop before procedure</td>
<td>Restart after procedure</td>
</tr>
<tr>
<td>Warfarin</td>
<td>5 days prior, check INR day of</td>
<td>12 to 24 hours after</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Apixaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Heparin</td>
<td>Stop infusion 4-5 hours prior</td>
<td>24 hours after</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>24 hours prior (hold evening dose if BID dosing, give half of AM dose if daily dosing)</td>
<td>24 hours after, (48-72 hours if high bleeding risk)</td>
</tr>
</tbody>
</table>
<p>Strategies for Reversal of Anticoagulation</p>
<p>Warfarin</p>
<ul>
<li>Vitamin
    K: onset at 12 hours but takes 24-48 hrs for full effect<ul>
<li>Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30
    minutes</li>
<li>Intracranial
    bleed, bleed with hemodynamic instability, emergent procedure
    Non-life threatening<ul>
<li>INR \&lt;5: Vitamin K not recommended</li>
<li>INR 5-10: Vitamin K 1-5 mg IV or PO</li>
<li>INR &gt;10: Vitamin K 5mg PO or 5 mg IV</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Prior to surgery
        -   Rapid reversal INR &gt; 5: 5mg Vit K IV (24 hours prior to
            procedure)</li>
<li>FFP<ul>
<li>15 ml/kg (i.e. 4 units/70 kg person) if need reversal \&lt;24
    hrs, plus give Vitamin K</li>
</ul>
</li>
<li>KCentra ($$$): Contains Factors II, VII, IX, and X with Protein
    C, Protein S, and heparin<ul>
<li>Given instead of plasma when insufficient time for
    plasma/Vit K to work</li>
<li>Avoid giving this in HIT</li>
<li>Administer with Vitamin K</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Dabigatran</p>
<ul>
<li>Idarucizumab
    ($$$) will reverse if prolonged thrombin time – Consult Hematology</li>
</ul>
<p>Xa</p>
<p>drugs</p>
<p>(Rivaroxaban, apixaban, edoxaban)</p>
<ul>
<li>FEIBA
    (Factor VIII inhibitor bypassing activity) – can promote coagulation
    but is not a reversal agent; limited data to support use</li>
<li>Consult Hematology before using; andexanet alfa is not yet available
    here</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-bone-marrow-transplant"><h1 id="hematology-oncology-hematologyoncology-bone-marrow-transplant-bone-marrow-transplant">Bone Marrow Transplant<a class="headerlink" href="#hematology-oncology-hematologyoncology-bone-marrow-transplant-bone-marrow-transplant" title="Permanent link">&para;</a></h1>
<p>Bone Marrow Transplant – Michael LaPelusa</p>
<p>Background</p>
<ul>
<li>Donor selection<ul>
<li>Autologous: self, no matching required</li>
<li>Allogeneic: non-self, matching based on HLA (more matching -&gt;
    less GVHD risk)<ul>
<li>Matched-related donor (MRD): fully matched sibling</li>
<li>Matched-unrelated donor (MUD): From NMDP database</li>
<li>Haploidentical: Half matched sibling or parent</li>
</ul>
</li>
</ul>
</li>
<li>Source of stem cells:<ul>
<li>Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells
    vs umbilical cord</li>
<li>Timeline for transplant:T -14 d: cell mobilization and
    collection (G-CSF used to help mobilize stem cells)</li>
<li>T -8 d to T-3d: conditioning regimen, initiation of GVHD ppx,
    TLS ppx and sinusoidal obstruction syndrome ppx</li>
<li>T = 0 d: transplant</li>
<li>T +7 d to T +30 d: engraftment</li>
</ul>
</li>
</ul>
<p>Complications/Adverse Effects:</p>
<ul>
<li>Infectious
    : Neutropenic fever, typhlitis, GNR, HSV, respiratory/enteral
    viruses (adenovirus, RSV, parainfluenza), Aspergillus, Candida</li>
<li>Non
    -infectious<ul>
<li>Nausea, vomiting, mucositis</li>
<li>Cytopenia’s: Transfuse as needed (plt &gt;10, hematocrit &gt;21)</li>
<li>Hepatic
    veno-occlusive disease/sinusoidal obstructive syndrome:<ul>
<li>2/2 cytotoxic venule damage from chemo resulting in thrombi
    formation</li>
<li>Diagnosis: T Bili &gt;2, hepatomegaly/RUQ pain, weight gain &gt;
    2-5%</li>
<li>Evaluation: RUQ US with doppler</li>
<li>Treatment: Per heme attending; Consider defibrotide</li>
</ul>
</li>
<li>Graft failure – primary (persistent neutropenia without
    engraftment) or secondary (delayed pancytopenia 2/2 immune
    phenomena or infection after engraftment)</li>
<li>Engraftment
    syndrome:<ul>
<li>Pathophys: PMN recovery -&gt; cytokine storm -&gt; vascular leak</li>
<li>Symptoms: fever, tachycardia, hypotension, SOB, pulmonary
    edema, rash, weight gain, bone pain, confusion</li>
<li>Diagnosis: clinical; Workup specific symptoms</li>
<li>Treatment: high-dose IV steroids</li>
</ul>
</li>
<li>Acute GVHD:<ul>
<li>Only in allogenic; Increased risk with more HLA mismatch</li>
<li>Pathophys: donor T cells attack recipient (Th1-mediated)</li>
<li>Symptoms: skin rash, cholestatic liver injury, diarrhea</li>
<li>Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)<ul>
<li>If refractory: mycophenolate, etanercept, ruxolitinib,
    antithymocyte globulin</li>
</ul>
</li>
</ul>
</li>
<li>Chronic GVHD (typically after T+100d s/p allo)<ul>
<li>Can involve all organs but typically see a scleroderma-like
    picture (xerophthalmia, xerostomia dysphagia, arthritis,
    skin changes, malar rash, obliterative bronchiolitis,
    cholestatic liver injury, cytopenia’s)</li>
<li>Treatment: steroids (also photophoresis for skin), consider
    trials of ruxolitinib, ibrutinib, rituximab if refractory</li>
</ul>
</li>
<li>PTLD</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-chemotherapy-toxicity"><h1 id="hematology-oncology-hematologyoncology-chemotherapy-toxicity-chemotherapy-toxicity">Chemotherapy Toxicity<a class="headerlink" href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity-chemotherapy-toxicity" title="Permanent link">&para;</a></h1>
<p>Chemotherapy Toxicities - Beau Hilton</p>
<ul>
<li>The role of Intern/Resident on the Hematology/Oncology services is
    largely to work with the fellow to monitor and manage adverse
    effects of chemotherapy</li>
<li>Concerns about specific immune-related adverse event: refer to
    “Toxicities associated with checkpoint inhibitor immunotherapy,” on
    UpToDate</li>
<li>Treatment of immune checkpoint inhibitor toxicities: “Management of
    Immunotherapy-Related Toxicities” in the NCCN Guidelines for
    Supportive Care section</li>
</ul>
<p>Neutropenia:</p>
<ul>
<li>Chemotherapy-associated: usually 5-18 days after treatment</li>
<li>Cancer infiltrate of bone marrow</li>
<li>New occult infection: especially EBV, CMV</li>
<li>Patients can be safely discharged with ANC &gt; 500</li>
</ul>
<p>Mucositis:</p>
<ul>
<li>Worst in pts receiving concurrent radiation to head and neck,
    rectum, prostate</li>
<li>Begins shortly after chemo dose, usually peaks on day 7</li>
<li>High risk: bleomycin, cytarabine, anthracyclines, etoposide, 5-FU,
    methotrexate</li>
<li>Treatment: “Salt and soda” rinses (1 tsp salt, 1 tsp baking sode in
    1-quart water, swish and spit 5 times per day), viscous lidocaine,
    capsaicin candy, Magic Mouthwash</li>
</ul>
<p>Immune Checkpoint Inhibitor Toxicities:</p>
<p>Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild
adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg) for
severe adverse events</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event Type</td>
<td>Incidence with anti-CTLA-4 (ipilimumab)</td>
<td>Incidence with anti‐PD1/PD‐L1 (nivolumab, pembrolizumab)</td>
</tr>
<tr>
<td>Skin (pruritus, acne, TEN)</td>
<td>30%</td>
<td>30%</td>
</tr>
<tr>
<td>Colitis</td>
<td>25%</td>
<td>5%</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>20%</td>
<td>20%</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>10%</td>
<td>1%</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>10%</td>
<td>rare</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>2-5%</td>
<td>2-5%</td>
</tr>
<tr>
<td>Myocarditis (fatality&gt;25%)</td>
<td>\&lt;1%</td>
<td>\&lt;1%</td>
</tr>
<tr>
<td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
<td>\&lt;1%</td>
<td>\&lt;1%</td>
</tr>
</tbody>
</table>
<p>Chemotherapeutic Agent</p>
<p>Toxicities</p>
<table>
<thead>
<tr>
<th>Organ System</th>
<th>Agent</th>
<th>Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agents</td>
<td>Busulfan</td>
<td>Pulmonary fibrosis or diffuse alveolar hemorrhage (8%)</td>
</tr>
<tr>
<td>Alkylating Agents</td>
<td>Cyclophosphamide</td>
<td>Myopericarditis. Hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, Tx: Mesna</td>
</tr>
<tr>
<td>Alkylating Agents</td>
<td>Ifosfamide</td>
<td>Encephalopathy (tx: methylene blue)</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
<td>Coronary vasospasm (ppx: CCB); palmar-plantar erythrodysesthesia</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cladribine, pentostatin</td>
<td>Dose reduced for CrCl</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cytarabine (Ara-C)</td>
<td>Irreversible cerebellar ataxia (if high dose, neuro checks required). Conjunctivitis (prevent with prophylactic steroid eye drops)</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Gemcitabine</td>
<td>Transient transaminitis. Decrease dose only if hyperbilirubinemia.</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Methotrexate</td>
<td>Hepatotoxicity, renal failure, high dose requires leucovorin</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Anthracyclines (doxorubicin, duanorubicin, idarubicin)</td>
<td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Bleomycin</td>
<td>Pulmonary fibrosis (10%). Potentiated with G-CSF</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Alemtuzumab</td>
<td>Severe and prolonged cytopenias</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Bevacizumab</td>
<td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Rituximab</td>
<td>Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy</td>
</tr>
<tr>
<td>Platinum Agents</td>
<td>Cisplatin, oxaliplatin, carboplatin</td>
<td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity- >85% oxaliplatin (parasthesias, cold sensitivity, cramps), neuropathy, ototoxicity</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetaxel, paclitaxel</td>
<td>Hypersensivitivy reaction. Often require premedication with steroids and H1/H2 blockers.</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td>Irinotecan, topotecan, etoposide</td>
<td>Irinotecan- acute diarrhea can be treated with atropine</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td>Imatinib, Dasatinib, Nilotinib, Bosutinib</td>
<td>Qtc prolongation, pulmonary effusion, hepatotoxicity</td>
</tr>
<tr>
<td>Vinca alkaloid</td>
<td>Vincristine</td>
<td>Peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hematology-oncology-hematologyoncology-coagulopathies"><h1 id="hematology-oncology-hematologyoncology-coagulopathies-coagulopathies">Coagulopathies<a class="headerlink" href="#hematology-oncology-hematologyoncology-coagulopathies-coagulopathies" title="Permanent link">&para;</a></h1>
<p>Coagulopathies – Jason Jones</p>
<ul>
<li>If you have a pt with pathological bleeding, first determine
    <strong>platelet vs coagulation</strong> disorder</li>
<li>Platelet Disorders: Skin/Mucous membrane bleeding; Petechiae; Often
    mild bleeding following surgery and tends to immediately follow
    surgery</li>
<li>Coagulation defect: Bleeding deep in soft tissues (muscles/joints);
    hemarthroses, hematomas; Tend to have delayed bleeding after surgery
    that can be severe<ul>
<li>Coagulopathies can be divided into <strong>Hereditary</strong> vs
    <strong>Acquired</strong> causes</li>
</ul>
</li>
</ul>
<p>Hereditary</p>
<p>Hemophilia A (Factor VIII Deficiency) and Hemophilia B (Factor IX
Deficiency)</p>
<ul>
<li>Inherited in X-linked Recessive pattern</li>
<li>Diagnosis: Isolated prolonged PTT with normalization upon mixing
    study</li>
<li>Management
    : purified/recombinant Factor VIII or IX. Desmopressin for mild
    disease</li>
<li>If you have patient with hemophilia who needs a procedure/surgery or
    is acutely ill, this requires consult to benign hematology</li>
</ul>
<p>von Willebrand Disease (vWD)</p>
<ul>
<li>Can be hereditary (common) or acquired</li>
<li>Abnormal quantity or function of von Willebrand Factor (vWF) needed
    for platelet function</li>
<li>Type 1 (most common): Quantitative defect. Low quantity, normal
    function of vWF</li>
<li>Type 2: Qualitative defect. Normal quantity, abnormal function of
    vWF. In Type 2A, large multimer formation is impaired</li>
<li>Type 3 (rarest): Complete absence of vWF
    
    phenotypically similar to hemophilia A</li>
<li>Order in Epic: vW Profile = vWF Ag, Factor VIII Activity, Ristocetin
    Cofactor Activity</li>
<li>Management
    : Desmopressin (DDAVP) can be useful as prophylaxis or treatment</li>
</ul>
<p>Acquired</p>
<p>Coagulation Factor Inhibitors</p>
<ul>
<li>Associated with autoimmune disease (paraneoplastic vs. autoantibody)</li>
<li>Seen in hemophilia due to frequent treatments with recombinant
    factors (alloantibody)</li>
<li>Diagnosis: Elevated PTT that does not normalize with mixing study</li>
<li>Management
    : Immunosuppression with steroids; cyclophosphamide &plusmn; rituximab<ul>
<li>Consult
    Hematology early (rare disorder with major bleeding
    complications)</li>
</ul>
</li>
</ul>
<p>Vitamin K Deficiency</p>
<ul>
<li>Caused by malnutrition, liver disease, or iatrogenic with warfarin</li>
<li>Causes deficiency of Vit K dependent coagulation factors (Factors
    II, VII, IX, X)</li>
<li>Diagnosis: elevated PT, if severe may have prolonged PTT as well</li>
<li>Vitamin K deficiency will correct in the lab in a mixing study</li>
<li>Management
    : Replace vitamin K, see "Transfusion" section for more details</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-dic"><h1 id="hematology-oncology-hematologyoncology-dic-dic">DIC<a class="headerlink" href="#hematology-oncology-hematologyoncology-dic-dic" title="Permanent link">&para;</a></h1>
<p>Disseminated <span id="DIC"></span> Intravascular Coagulation (DIC) -
Eric Singhi</p>
<p>Background</p>
<ul>
<li>Concurrent activation of the coagulation pathway and fibrinolytic
    pathway</li>
<li>Widespread endothelial injury + exposure to circulating
    procoagulants
    
    activation of coagulation cascade
    
    thrombin production in small and medium-sized vessels</li>
<li>Consumption of platelets, fibrin, and coagulation factors -&gt;
    fibrinolysis -&gt; end organ damage and hemolysis</li>
<li>Etiologies:<ul>
<li>Infection/Sepsis, Liver disease, Pancreatitis, Trauma</li>
<li>Malignancies: mucin-secreting pancreatic/gastric adenocarcinoma,
    brain tumors, prostate cancer, all acute leukemias, acute
    promyelocytic leukemia</li>
<li>Obstetric complications (i.e. preeclampsia/eclampsia, placental
    abruption)</li>
<li>Acute hemolytic transfusion reaction (i.e. ABO incompatible
    transfusion)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exam:  petechiae, bleeding (mucosal, IV site, surgical wound site,
    hematuria), ecchymoses, thrombosis (i.e. cold, pulseless
    extremities)</li>
<li>CBC,  PT/INR, aPTT, Fibrinogen, D-Dimer, Peripheral Blood Smear</li>
<li>“DIC labs” = q6h fibrinogen, PT/INR, aPTT (space out when lower
    risk)</li>
<li>Findings suggestive of DIC: thrombocytopenia, prolonged aPTT and
    PT/INR, hypofibrinogenemia, elevated D-dimer, fibrin degradation
    products, schistocytes</li>
</ul>
<p>Management</p>
<ul>
<li>Treat the underlying cause!</li>
<li>Hemodynamic support (i.e. hypotension): Intravenous fluid
    resuscitation</li>
<li>Vitamin K for INR &gt; 1.7 or bleeding</li>
<li>If bleeding consider FFP, Vitamin K to correct coagulopathy</li>
<li>Hypofibrinogenemia treatment: Cryoprecipitate 5-10 units if
    fibrinogen \&lt; 100</li>
<li>Thrombocytopenia treatment: plt transfusion as normally indicated</li>
<li>DVT ppx if not bleeding and plt &gt; 50</li>
<li>VTE: anticoagulation if plt &gt; 50 and no massive bleeding</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-dvts"><h1 id="hematology-oncology-hematologyoncology-dvts-dvts">DVTs<a class="headerlink" href="#hematology-oncology-hematologyoncology-dvts-dvts" title="Permanent link">&para;</a></h1>
<p>Deep Vein Thromboses – Trey Richardson</p>
<ul>
<li>Background:
    Incidence of 1-2 per 1,000 people per year</li>
<li>Depending on the study and population, associated with a 15%
    mortality rate</li>
<li>70% of patients with PE have a detectable DVT</li>
<li>List of deep veins<ul>
<li>Distal Lower Ext.: Posterior tibial, Anterior tibial, Peroneal,
    Gastrocnemius, Soleus veins</li>
<li>Proximal Lower Ext.: External, Internal, and Common iliac;
    Common, superficial, and deep femoral veins; Popliteal vein</li>
<li>Upper extremity: Radial, ulnar, brachial, axillary, and
    subclavian veins</li>
</ul>
</li>
<li>Risk Factors for Provoked DVT/PE – Known Event<ul>
<li>Major risk factors: major surgery &gt;30 minutes, hospitalization &gt;
    3 days, C-section</li>
<li>Minor Risk Factors: Surgery \&lt;30 minutes, Hospitalization \&lt;3
    days, pregnancy, estrogen therapy, reduced mobility &gt;3 days,
    infection in past 3 months</li>
</ul>
</li>
<li>Persistent risk factors: Malignancy (active), inflammatory bowel
    disease, hereditary thrombophilia, CHF</li>
<li>Active cancer (LR of 2.6) recent trauma/surgery or immobilization
    (LR of 1.6 each) are the clinical scenarios when suspicion should be
    the highest</li>
</ul>
<p>Presentation</p>
<ul>
<li>Asymmetric calf swelling of &gt; 2cm sensitivity/specificity for DVT of
    60-70% and a likelihood ratio (LR) of 2.1</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Wells’ Criteria for DVT can help guide diagnostic testing<ul>
<li>If a patient has a low pre-test probability, a negative D-dimer
    can rule out DVT</li>
<li>In a high pre-test probability patient a negative D-dimer is
    less helpful</li>
</ul>
</li>
<li>Whole-leg (common femoral to deep calf veins) ultrasounds with
    doppler</li>
</ul>
<p>Management</p>
<ul>
<li>Prophylaxis<ul>
<li>Padua score: Score &gt; 4 high risk; A score \&lt;4 low risk for
    thrombosis</li>
</ul>
</li>
<li>Choice of anticoagulation for treatment: (See anticoagulation
    section)</li>
<li>Duration of treatment<ul>
<li>Provoked: 3-6 mos or until provoking factor (trauma, surgery,
    malignancy) is removed<ul>
<li>Pts w/high risk cancers require more tailored therapy since
    the provoking factor is the malignancy itself. GI
    malignancies tend to be the highest risk.</li>
</ul>
</li>
<li>Unprovoked: Requires life-long anticoagulation along with
    assistance from hematology</li>
<li>Recurrent: Even if they have all ben provoked, requires
    life-long treatment<ul>
<li>Close follow-up with hematology</li>
</ul>
</li>
<li>Distal:  Limited data, but can treat for 3 months or monitor for
    resolution with serial US</li>
<li>Upper Extremity: Treat as DVT for at least 3 months</li>
<li>Superficial vein : treat for 3 mo, if within 2 cm of junction w/
    deep vein (high risk of propagation)</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Decision to screen for hyper-coagulable disorders based on age
    (\&lt;45), history of prior DVTs, family hx of clotting disorders, and
    hx of thrombi in atypical locations (arterial)</li>
<li>If no contraindications (acute bleeding, planned procedure,
    thrombocytopenia etc.) then most patients will tolerate prophylaxis</li>
<li>Follow up ultrasound<ul>
<li>Limited data regarding utility of follow up ultrasound but may
    be warranted if patient at high risk for post-thrombotic
    complications or has persistent symptoms</li>
</ul>
</li>
<li>What about IVC filters?<ul>
<li>In patients at high risk for DVT and in whom anti-coagulation is
    contraindicated (thrombocytopenia, recent intra-cranial bleed,
    recent GI bleed) placement of a retrievable IVC filter should be
    discussed with IR</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-hypercoagulable-states"><h1 id="hematology-oncology-hematologyoncology-hypercoagulable-states-hypercoagulable-states">Hypercoagulable States<a class="headerlink" href="#hematology-oncology-hematologyoncology-hypercoagulable-states-hypercoagulable-states" title="Permanent link">&para;</a></h1>
<p>Hypercoagulable States – Chris Cann</p>
<p>Background</p>
<ul>
<li>Virchow’s triad: 1. Hypercoagulability 2. Blood flow stasis 3.
    Endothelial injury</li>
<li>Diagnostic thrombophilia testing indications:<ul>
<li>Idiopathic or recurrent VTE</li>
<li>First VTE at \&lt;40 years old</li>
<li>VTE in the setting of strong family history</li>
<li>VTE in unusual vascular site (cerebral, renal, mesenteric)</li>
<li>Recurrent pregnancy loss</li>
</ul>
</li>
<li>Separated into Acquired and Hereditary factors:<ul>
<li>Hereditary: Factor V Leiden, Prothrombin mutation, Protein C/S
    deficiency, Antithrombin deficiency</li>
<li>Acquired
    :<ul>
<li>APLS</li>
<li>HIT</li>
<li>Major surgery/trauma</li>
<li>Nephrotic Syndrome</li>
<li>Smoking</li>
<li>Pregnancy</li>
<li>Oral Contraceptives</li>
<li>Immobilization (bedridden, hip/knee replacement) Infection
    in past 3 months</li>
<li>Active malignancy</li>
<li>Estrogen replacement therapy</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Testing: all specific testing for hereditary disorders and APS
    should be performed at least 4-6 weeks after an acute thrombotic
    event or discontinuation of anticoagulant/thrombolytic therapies to
    avoid interference</li>
</ul>
<p>Antiphospholipid antibody syndrome (APLS):</p>
<p>Background</p>
<ul>
<li>Most
    common acquired factor (anti-phospholipid antibodies present in 3-5%
    population)</li>
<li>Recurrent
    pregnancy loss, provoked DVT in young, unprovoked VTE and arterial
    thrombosis in young, thrombosis unusual sites, thrombosis in
    autoimmune disease</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Positive for at least 1 lab criterion on at least 2 occasions, at
    least 12 weeks apart:<ul>
<li>Lupus
    anticoagulant: can occur in relation to drugs or infection;
    transient are associated with thrombotic risk</li>
<li>Anticardiolipin
    antibodies</li>
<li>B2GP1
    (anti-beta2-glycoprotein) antibodies</li>
</ul>
</li>
<li>Must also meet at least 1 of the following clinical criteria:<ul>
<li>Vascular
    thrombosis: DVT, arterial thrombosis, or small vessel thrombosis
    of any organ</li>
<li>Pregnancy
    loss: there are specific criteria for this – consult UpToDate or
    other resource</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Aspirin for primary prevention; warfarin for treatment (INR 2-3)</li>
<li>Do NOT use DOACs for APLS (see TRAPS trial: rivaroxaban inferior to
    warfarin)</li>
<li>Rituximab for recurrent thrombosis despite anticoagulation
    (controversial)</li>
</ul>
<p>Heparin-induced thrombocytopenia (HIT)</p>
<p>Type</p>
<p>1: Mild and self-limited (not immune-mediated)</p>
<ul>
<li>Occurs within the first 2 days of first-time exposure</li>
<li>Platelet count normalizes with continued heparin therapy</li>
</ul>
<p>Type 2 (what we typically refer to as HIT): Immune mediated</p>
<ul>
<li>Fall in plt 30% to over 50% (even if plt count &gt;150) and/or
    thrombotic event has occurred</li>
<li>4-10 days after new exposure to heparin derivative OR≤</li>
<li>1 day after restarting heparin derivative that had been used 30-100
    days prior<ul>
<li>If exposed to heparin within 100 days, will have platelet drop
    within 24 hr</li>
</ul>
</li>
<li>Frequency: unfractionated heparin &gt; LMWH;  Surgical wards &gt;  medical
    wards</li>
<li>50% will have thrombotic event in 30 days if HIT is untreated, with
    20% mortality</li>
<li>Arterial thrombi are common in HIT</li>
<li>HIT results from antibodies to complexes of platelet factor 4 (PF4)
    and heparin, further activating platelets (the activated platelets
    aggregate causing thrombocytopenia)</li>
</ul>
<p>Evaluation</p>
<ul>
<li><span id="FourT"></span>
    4T score (0-8 points):<ul>
<li>Thrombocytopenia (0-2 pts): degree and nadir of platelet count
    drop</li>
<li>Timing (0-2 pts): timing of fall after initial or recurrent
    heparin exposure</li>
<li>Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing
    lesions, acute systemic reaction to heparin</li>
<li>Other causes of thrombocytopenia (0-2 pts): more points if no
    alternate cause</li>
</ul>
</li>
<li>Solid-phase ELISA for heparin-PF4 antibodies: ​​​​​​​<ul>
<li>0.2-0.4 is indeterminate</li>
<li>> 0.4 is positive</li>
<li>> 1.4 HIT is likely</li>
<li>> 2 confirms HIT ​​​​​​​</li>
<li>The lab at VUMC will perform functional SRA reflexively for all
    values &gt;0.2</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>0-3 points: Low concern for HIT; can restart heparin</li>
<li>4-5 points: Intermediate probability (~10%) - hold heparin, <strong>start
    non-heparin anticoagulant</strong></li>
<li>6 points: High probability (~50%) - hold heparin, <strong>start
    non-heparin anticoagulant</strong></li>
<li>Argatroban (direct thrombin inhibitor) for prophylaxis and treatment
    of thrombosis<ul>
<li>Avoid platelet transfusions as can increase thrombogenic effect</li>
<li>Avoid warfarin until complete platelet recovery as may cause
    microthrombosis</li>
</ul>
</li>
<li>Hematology consult for all confirmed HIT</li>
</ul>
<p>Factor V Leiden mutation</p>
<p>Evaluation</p>
<ul>
<li>Activated protein C resistance assay<ul>
<li>APC ratio in patient vs normal</li>
<li>normal &gt;2.0, heterozygotes 1.5-2.0, homozygotes \&lt;1.5</li>
</ul>
</li>
<li>FVL mutation is then determined via PCR</li>
<li>Screen with APC assay rather than PCR initially; cost effective</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population<ul>
<li>VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</li>
</ul>
</li>
<li>Avoid OCPs: increased risk for VTE</li>
</ul>
<p>Prothrombin gene mutation</p>
<p>Evaluation: PCR of G20210A mutation (2-4% Europeans carry mutation)</p>
<p>Management: VTE treatment same as general population &amp; Avoid OCPs</p>
<p>Protein C &amp; S Deficiency</p>
<p>Background</p>
<ul>
<li>Autosomal dominant; first event occurs between 10-50 years of age</li>
<li>Synthesized in liver and Vit K dependent, therefore low levels in
    hepatic dysfunction and warfarin use/vitamin K deficiency</li>
<li>Protein C: low in settings of thrombosis, DIC, nephrotic syndrome,
    intra/post-op</li>
<li>Protein S : low in infectious (HIV) and autoimmune processes (IBD)</li>
<li>Protein S decreases during pregnancy (decreased free Protein S,
    normal total Protein S)<ul>
<li>Do not misdiagnose a pregnant patient with PS deficiency</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional Protein C &amp; S assays<ul>
<li>Used for screening prior to use of immunologic methods to
    measure free protein levels</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population</li>
<li>Avoid OCPs</li>
<li>High risk patients may require protein C concentrate prior to
    surgery</li>
<li>Increased risk of warfarin-induced skin necrosis</li>
</ul>
<p>Antithrombin deficiency</p>
<p>Background</p>
<ul>
<li>Autosomal dominant, does not skip generations</li>
<li>VTE in unusual sites (cerebral sinuses, renal veins)</li>
<li>Present \&lt; 50 y/o, but rarely in first two decades</li>
<li>Decreased in liver disease, nephrotic syndrome, protein losing
    enteropathy, burn, trauma, bypass surgery, metastatic tumors,
    premenopausal, OCP use, pregnancy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional antithrombin activity (AT-heparin cofactor assay)</li>
<li>Then perform antigen quantity testing</li>
</ul>
<p>Management</p>
<ul>
<li>Can use Argatroban as does not require antithrombin function</li>
<li>Warfarin preferred in VTE (titrate up based on expression of
    antithrombin deficiency)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-leukemia"><h1 id="hematology-oncology-hematologyoncology-leukemia-leukemia">Leukemia<a class="headerlink" href="#hematology-oncology-hematologyoncology-leukemia-leukemia" title="Permanent link">&para;</a></h1>
<p>Acute Leukemia - Robert Corty</p>
<p>Background</p>
<ul>
<li>Unchecked proliferation of WBC precursors causes marrow failure</li>
<li>Can be fatal in days to months</li>
<li>Pt’s with suspected acute leukemia require hospitalization for
    urgent diagnosis &amp; treatment</li>
<li>APL has both the highest in-hospital mortality &amp; highest cure rate</li>
<li>Types:<ul>
<li>AML
    = Acute Myeloid Leukemia – most common</li>
<li>APL
    = acute promyelocytic leukemia
    
    translocation (15;17)</li>
<li>ALL
    = acute lymphocytic leukemia</li>
</ul>
</li>
<li>Risk Factors:<ul>
<li>ionizing radiation</li>
<li>chemical exposures(e.g benzene)</li>
<li>HIV</li>
<li>immunosuppression</li>
<li>myeloproliferative disorders</li>
<li>aplastic anemia</li>
<li>chemotherapy, specifically, alkylating agents and topoisomerase
    inhibitors</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Leukocytosis, often blastocytosis: leukemia cutis, gingival
    hypertrophy, leukostasis</li>
<li>Functional Leukopenia, often neutropenia: recurrent infections</li>
<li>Anemia: fatigue, pallor, dyspnea</li>
<li>Thrombocytopenia: gingival bleeding, epistaxis, petechiae,
    ecchymoses, menorrhagia</li>
<li>Extramedullary hematopoiesis: splenomegaly, hepatomegaly,
    lymphadenopathy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Diagnosis of acute leukemia requires one of the following:<ul>
<li>20% blasts in peripheral blood</li>
<li>> 20% blasts in bone marrow biopsy</li>
<li>Any pathognomonic cytogenetic abnormality of t(8;21), inv(16),
    t(15;17)</li>
</ul>
</li>
<li>Check for the presence of these time-sensitive conditions.<ul>
<li>DIC – check fibrinogen, PT, PTT, platelets</li>
<li>TLS – check uric acid, phosphate, LDH, K+</li>
<li>Neutropenic fever – check temp, neutrophil count</li>
<li>Leukostasis  (see below)</li>
<li>Presumptive APL – promyelocytes on diff, DIC or Auer rods on
    smear</li>
</ul>
</li>
<li>Confirm if peripheral flow cytometry ordered/in process</li>
</ul>
<!-- -->

<ul>
<li>Use hematology admission order set<ul>
<li>Set RBC and Plt transfusion thresholds</li>
<li>Order nurse-driven electrolyte repletion</li>
<li>ECG and TTE to establish pre-chemotherapy cardiac function</li>
<li>Daily labs: CBC, TLS, DIC</li>
<li>TLS prophylaxis</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Page heme fellow<ul>
<li>Discuss chemo plan and order double lumen PICC for reliable
    access</li>
<li>If findings suggest APL discuss starting ATRA</li>
<li>Subspecialized lab tests: bone marrow biopsy, cytogenetics, FISH</li>
</ul>
</li>
<li>Monitor for Common Complications/Emergencies: (see individual
    sections)<ul>
<li>TLS, DIC, Febrile Neutropenia, Leukostasis</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Obtain blood product consent on admission</li>
<li>APL Specific findings: promyelocytes on differential or Auer rods on
    smear</li>
<li>Differentiation syndrome: promyelocytes differentiate<ul>
<li>Symptoms and signs: fever, SOB, Hypotn, peripheral edema,
    pleural effusion, AKI</li>
<li>Diagnosis: No defined criteria.  If suspicious, discuss with
    hematology fellow</li>
<li>Management: <strong>steroids</strong> .  If critically ill, <strong>hold</strong> <strong>ATRA</strong>
    <strong>and</strong> <strong>ATO</strong> and consider <strong>hydroxyurea</strong></li>
</ul>
</li>
</ul>
<p>Leukemia Treatment Overview</p>
<ul>
<li>General strategy is to use “induction” chemo to try to induce
    clinicopathologic (as opposed to molecular) “remission”</li>
<li>Defined as absence of symptoms, normal CBC, and \&lt; 5% blasts in bone
    marrow (on day 28)</li>
<li>Then waiting in hospital until neutrophil count &gt; 500 (typically ~3
    weeks)</li>
<li>From there, bone marrow transplant (for high risk disease) or
    “consolidation” chemo for normal-risk or low-risk disease</li>
</ul>
<p>AML</p>
<p>Induction</p>
<ul>
<li>Typical is “7+3” i.e. idrarubicin on days 1-3 and cytarabine on days
    1-7</li>
<li>If therapy-related AML, MDS-related AML, or AML with cytogenetics
    similar to MDS, use “Vyxeos” which is liposomal daunorubicin and
    cytarabine on days 1, 3, and 5</li>
<li>If low-risk dz (t(8;21) or inv(16)), use cytarabine on days 1-7, and
    3 days of low-dose daunorubicin + gemtuzumab-ozogamicin</li>
<li>There are other induction regimens that can be used depending on
    specific cytogenetics and patient frailty, which is beyond beyond
    the scope of the handbook</li>
</ul>
<p>Consolidation</p>
<ul>
<li>Typically  “HiDAC”(high-dose Ara-C – brand name for cytarabine)<ul>
<li>Generally too toxic for pts with age &gt; 60, so a dose reduction
    is used</li>
</ul>
</li>
<li>In the case of relapse, typical treatment is a different high-dose
    chemo and BMT if possible</li>
</ul>
<p>ALL</p>
<ul>
<li>Typical induction is “HyperCVAD” (hyper-fractionated
    cyclophosphamide, vincristine, doxorubicin (“A” due to trade name
    Adriamycin), and dexamethasone</li>
<li>If t(9;22) (known as Philadelphia chromosome), use tyrosine kinase
    inhibitor (TKI)</li>
<li>If CD20+, use rituximab (requires CNS prophylaxis)</li>
</ul>
<p>Common Chemotherapy Regimens for Leukemia Encountered as Inpatient</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regimen</td>
<td>Components</td>
<td>Use</td>
</tr>
<tr>
<td>7+3</td>
<td>Cytarabine (Ara-C) x 7 d &amp; Anthracycline (e.g. idarubicin x3 d)</td>
<td>AML induction</td>
</tr>
<tr>
<td>Vyxeos</td>
<td>Cytarabine + liposomal daunorubicin</td>
<td>AML-MRC or t-AML</td>
</tr>
<tr>
<td>CLAG-M</td>
<td>Cladribine, cytarabine (Ara-C), Filgrastim (G-CSF), mitoxantrone</td>
<td>AML induction (relapsed/refractory)</td>
</tr>
<tr>
<td>HIDAC</td>
<td>High-dose cytarabine</td>
<td>AML consolidation</td>
</tr>
<tr>
<td>ATRA</td>
<td>All-trans retinoic acid given with arsenic trioxide (ATO)</td>
<td>APL (APML)</td>
</tr>
<tr>
<td>HyperCVAD/MA</td>
<td>CVAD = Cyclophosphamide, vincristine, doxorubicin, dexamethasone MA = methotrexate/cytarabine (Given as alternating cycles)</td>
<td>ALL</td>
</tr>
<tr>
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone</td>
<td>NHL</td>
</tr>
<tr>
<td>R-EPOCH</td>
<td>Etoposide plus the drugs above (dosing is different)</td>
<td>NHL</td>
</tr>
<tr>
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hematology-oncology-hematologyoncology-lymphoma"><h1 id="hematology-oncology-hematologyoncology-lymphoma-lymphoma">Lymphoma<a class="headerlink" href="#hematology-oncology-hematologyoncology-lymphoma-lymphoma" title="Permanent link">&para;</a></h1>
<p>Lymphoma - Margaret Wheless</p>
<p>Background</p>
<ul>
<li>Malignancy of lymphoid cells comprising multiple different cancers
    of the immune system depending on the subtype and stage of
    development of cell/tissue involved</li>
<li>Characterized by lymphadenopathy &amp; constitutional “B” symptoms:<ul>
<li>Fevers, drenching night sweats and weight loss</li>
</ul>
</li>
<li>Branch point of diagnosis:<ul>
<li>Hodgkin: 10% - superficial, nodal disease with orderly spread</li>
<li>Non
    -Hodgkin: 90% - diffuse, nodal and extranodal disease with
    noncontiguous spread</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>B symptoms; pruritus (10-15% of pt with HL); history of radiation</li>
<li>Lymphadenopathy: painless, firm, fixed, &gt;1cm</li>
<li>Exam: head &amp; neck, tonsils, axilla, testes, liver, spleen</li>
<li>CBC, CMP, LDH, Uric Acid</li>
<li>HBV, HCV,  HIV, EBV, Quant gold, Treponemal Ab, ANA</li>
<li>Imaging: CXR
    
    most will eventually need PET-CT; MRI brain if neuro symptoms</li>
<li>Diagnosis requires tissue<ul>
<li>Excisional
    Lymph node biopsy (surg onc. Consult)</li>
<li>Core biopsy (CT guided procedure consult)</li>
</ul>
</li>
<li>Ann Arbor Staging System: I. 1 LN region<ul>
<li>II. &gt;2 LN regions, same side of diaphragm</li>
<li>III. LN regions on both sides of diaphragm</li>
<li>IV. Dissem dz w/ 1+ extralymphatic organ</li>
</ul>
</li>
</ul>
<p>Non-Hodgkin Lymphoma (NHL)</p>
<p>Background</p>
<ul>
<li>65 y/o, M&gt;F, 85-90% B-cell</li>
<li>Associated with immunodeficiency (HIV, post-transplant), autoimmune
    disease (both the disease and immunosuppression), infection (EBV,
    HTLV-1, H pylori,  HCV, Borrelia, C</li>
<li>psittacosis, Coxiella)</li>
<li>Stratify into:<ul>
<li>Good prognosis
    :
    waxing/waning LAD, cytopenias, hepatomegaly or splenomegaly</li>
<li>Poor
    prognosis
    : Aggressive presentation: fever, night sweats, weight loss, TLS</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good Prognosis</td>
<td>Good Prognosis</td>
<td>Good Prognosis</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Key Features</td>
<td>Workup/Treatment</td>
</tr>
<tr>
<td>Follicular Lymphoma</td>
<td>20-30% of NHL T (14; 18) bcl-2 over expression; CD19+, 20+, 10+, CD5-, CD23- Grading based on # large cells 1: \&lt;25%, 2: 25-50%, 3. >50% (grade 3= closer to DLBCL)</td>
<td>Watchful waiting Treatment: bulky LAD symptomatic disease End-organ damage Cytopenia’s Excision or radiation (stage I) Bendamustine-R (B-R) or RCHOP (&gt; I)</td>
</tr>
<tr>
<td>Marginal Zone Lymphoma</td>
<td>Usually located in the GI, thyroid, orbit, lung, breast, salivary glands</td>
<td>Treatment: Treat H pylori if MALT Treat HCV if splenic Extranodal MALT: B-R, rituximab x 4 doses</td>
</tr>
<tr>
<td>Mycosis Fungoides Sezary syndrome</td>
<td>Skin plaques with atypical CD4+ cells May progress to Sezary syndrome aka T cell leukemia</td>
<td>Workup: Skin biopsy Treatment: Light therapy, topical steroids, superficial radiation</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Aggressive/Poor Prognosis</td>
<td>NaN</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Key Features</td>
<td>Workup/Treatment</td>
</tr>
<tr>
<td>DLBCL</td>
<td>~25% of NHL; CD20+, CD45+ CD5+ confers the worst prognosis Can arise as transformation from low- grade lymphoma (Richter’s transformation) 60% present with advanced disease Risk factors for CNS disease: involvement of testicle, paranasal sinus, epidural space, bone marrow or >1 extra nodal sites + ↑LDH CNS disease needs IT and systemic MTX</td>
<td>If PET/CT reveals BM disease then no need for biopsy Tx: RCHOP vs DA-R-EPOCH (double hit) Use IPI prognostic scoring</td>
</tr>
<tr>
<td>Mantle Cell Lymphoma</td>
<td>7% NHL; CD20+, CD200+ T(11;14) =↑Cyclin D1 M&gt;F; avg age ~50-60s Most present with diffuse disease Blastoid variant more often involves CNS</td>
<td>Dx: pathology from bx Use MIPI prognostic tool Treatment: Aggressive: R-hyperCVAD-M/ara-C Poor PS: BR &amp; Rituximab</td>
</tr>
<tr>
<td>Double or Triple Hit Lymphoma</td>
<td>Similar to DLBCL with combination of bcl-2, bcl-6, or myc aberrations conveying double or triple hits Very aggressive needs intrathecal ppx even if no evidence of CNS disease</td>
<td>PET/CT for staging; if no evidence of BM involvement on PET, will need biopsy Tx: Da-R-EPOCH vs R hyperCVAD/MA vs R-CODOX-M/ IVAC</td>
</tr>
<tr>
<td>Burkitt Lymphoma</td>
<td>MYC translocation - most commonly t (8;14) with path showing classic “starry-sky” Rapidly growing tumors HIV: CNS relapse is 30-50% if no CNS ppx 1. Endemic (African jaw); often EBV/CD21+ 2. Sporadic (in the US): median age 30 at dx; present w/ abdominal masses &amp; metastasis 3. Immunodeficiency-related (often seen with CD4 counts >200); more often involve LN, CNS, and BM</td>
<td>R-EPOCH vs R-CODOX-M/IVAC Everyone gets CNS prophylaxis TLS prophylaxis for all pts Everyone will need TTE before anthracycline-based chemo</td>
</tr>
<tr>
<td>Lymphoblastic Lymphoma</td>
<td>Express TdT+ (cyclin D1 -) Aggressive; often present with mediastinal mass and CNS involvement Consider empiric allopurinol before starting chemotherapy</td>
<td>Treated like acute leukemias Will need LP with IT chemo</td>
</tr>
<tr>
<td>Anaplastic Large Cell Lymphoma (ALCL)</td>
<td>\&lt; 2% of NHL Primary cutaneous variant can arise from existing mycosis fungoides Worse outcome predictor includes increased β-2 microglobulin >3 and age >40</td>
<td>Use IPI prognostic tool Treatment: check CD30 &plusmn; status - CD30+: BV(brentuximab)+ CHP (cyclophosphamide, doxorubicin, prednisone) CD30-: CHOP + etoposide</td>
</tr>
</tbody>
</table>
<p>Hodgkin Lymphoma (HL)</p>
<p>Background</p>
<ul>
<li>Bimodal Distritbution: 15-35 y/o and &gt;50; M&gt;F</li>
<li>CD15+, CD30+ (Reed Sternberg cells “owl eyes”)</li>
<li>Associated with EBV in immunocompromised pt</li>
<li>4 classical types<ul>
<li>Nodular sclerosing (60-80%): young adult, F&gt;M, low stage,
    mediastinal LAD, collagen bands</li>
<li>Lymphocyte rich (5%): best prog</li>
<li>Lymphocyte depleted (\&lt;1%): worst prognosis, older, M&gt;F,
    disseminated, HIV+, diffuse positive and RS cells</li>
<li>Mixed (15-30%): older, M&gt;F, intermediate prognosis</li>
</ul>
</li>
<li>1 nonclassical (5%): nodular lymphocyte predominant, peripheral LN</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lymphadenopathy (usually contiguous), generalized pruritus,
    Incidental mediastinal mass</li>
<li>B-Symptoms: fevers, night sweats, weight loss</li>
</ul>
<p>Evaluation</p>
<ul>
<li>IPS negative prognostic calculator: albumin \&lt;4, hemoglobin \&lt;10.5,
    male, stage IV by Ann Arbor, age&gt;45, WBC count&gt; 15K, lymphocyte \&lt;8%</li>
</ul>
<p>Management</p>
<ul>
<li>Stage I-II: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
    ± RT</li>
<li>Stages III-IV: ABVD x6 or escalated BEACOPP (bleo, etop, doxo,
    cyclophos, vinc, procarbazine, prednisone)</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Pts will need TTE prior to chemo given the use of anthracycline</li>
<li>Increased risk of secondary cancers (~25% of pt with 40% increased
    risk over next 40 years)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-medical-oncology-resources"><h1 id="hematology-oncology-hematologyoncology-medical-oncology-resources-medical-oncology-resources">Medical Oncology Resources<a class="headerlink" href="#hematology-oncology-hematologyoncology-medical-oncology-resources-medical-oncology-resources" title="Permanent link">&para;</a></h1>
<p>Medical Oncology Resources – Eric Lander</p>
<p>VUMC Oncology Rotation Tips:</p>
<p>The inpatient oncology rotation involves complex decisions often
resulting from advancing diseases. The question “What do you want?” is
too simple. Rather, it should be “Given your current circumstance, and
given our choices, which path would you prefer to take?” Patients want
advice from their outpatient doctors who have been caring for them for
years. Therefore, treatment and goals discussions often must pass
through the inpatient attending to the outpatient attending. Be sure to
define how communication with this primary oncologist will be handled.</p>
<p>Oncology summary sentence in presentation:</p>
<ol>
<li>Cancer type and stage (at diagnosis – *stage never changes even if
    progressed*)</li>
<li>Pertinent tumor genetic information</li>
<li>Any relevant surgeries (e.g. resections)</li>
<li>Most recent treatment</li>
<li>Trajectory of disease (e.g. progressive, improving, or stable)</li>
<li>Patient’s primary oncologist</li>
</ol>
<p>Ex: Ms. X is a 64 y/o female w/ stage IIIa adenocarcinoma of the lung
post resection now with metastases to the spine (patient of Dr. Y)
admitted w/intractable back pain and leg weakness. Full NGS at diagnosis
with no actionable mutations, and was 40% positive for PDL1. No previous
chemo.</p>
<p>NCCN:</p>
<p>National Comprehensive Cancer Center Network: (</p>
<p><a href="https://www.nccn.org/">https://www.nccn.org/</a></p>
<p>): consensus based treatment guidelines for most hematopoietic and solid
tumors.  Free for house staff.</p></section><section class="print-page" id="hematology-oncology-hematologyoncology-myelodysplastic-syndromes"><h1 id="hematology-oncology-hematologyoncology-myelodysplastic-syndromes-myelodysplastic-syndromes">Myelodysplastic Syndromes<a class="headerlink" href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes-myelodysplastic-syndromes" title="Permanent link">&para;</a></h1>
<p>Myelodysplastic Syndromes – Peter Hanna</p>
<p>Background</p>
<ul>
<li>MDS is a <strong>malignant</strong> clonal myeloid disorder resulting in
    ineffective hematopoiesis leading to peripheral cytopenia’s and a
    risk of transformation to acute myeloid leukemia (AML)</li>
<li>The bone marrow is <strong>hypercellular and dysplastic</strong> usually</li>
<li>20% of cases have hypocellular marrow and look like aplastic anemia</li>
<li>Usually idiopathic, a disease of the elderly (median onset at
    age 70)</li>
<li>The WHO has several classification schemes for MDS</li>
<li>Most important for classification is the percent of blasts in the
    bone marrow</li>
<li>Note &gt;20% blasts in marrow = AML. Thus MDS &amp; AML are on a continuum</li>
</ul>
<p>Presentation</p>
<ul>
<li>50% asymptomatic; Symptoms can include nonspecific but gradual
    fatigue, weakness</li>
<li>Dysplastic cells do not work properly
    
    infections and bleeding are more likely</li>
<li>B symptoms like fever or weight loss
    
    more consistent with myeloproliferative disorder</li>
<li>Macrocytic anemia is most common finding; followed by bicytopenia or
    pancytopenia<ul>
<li>Isolated neutropenia or thrombocytopenia are unusual</li>
</ul>
</li>
<li>Ask about secondary causes:<ul>
<li>Exposure to chemicals (benzene, crude oil/gasoline industry,
    cigarette smoke), chemotherapy, radiation</li>
<li>Medications, alcohol use, chronic infections (HIV)
    
    marrow toxicity/dysplasia</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Goal
    is to rule out reversible causes of dysplasia and cytopenias</li>
<li>CBC w/differential, Peripheral Smear, B12, Folate, HIV<ul>
<li>May consider Copper &amp; Zinc (send out labs, are expensive and
    rare)</li>
</ul>
</li>
<li>Dysplastic changes on peripheral smear: hypogranulated/hyposegmented
    neutrophils, hypogranulated platelets and macrocytosis of RBCs<ul>
<li>Circulating myeloblasts can be seen</li>
</ul>
</li>
<li>Final diagnosis made by Bone marrow Biopsy</li>
</ul>
<p>Management</p>
<ul>
<li>Molecular characteristics define the “risk” of the disease
    
    dictates treatments</li>
<li>Prognostic scoring tools: revised international prognostic staging
    system (R-IPSS)</li>
<li>Management general paradigm:<ul>
<li>Asymptomatic: with
    low-risk disease = monitoring</li>
<li>Low-risk disease
    + symptoms due to anemia only
    
    transfusions, erythrocyte stimulating agents, and treatment with
    Luspatercept</li>
<li>MDS with isolated del(5q):
    treated with lenalidomide</li>
<li>High-risk patients
    :  treated with hypomethylating agents</li>
<li>Only curative intervention = hematopoietic stem cell transplant
    (HSCT)</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-myeloproliferative-neoplasms"><h1 id="hematology-oncology-hematologyoncology-myeloproliferative-neoplasms-myeloproliferative-neoplasms">Myeloproliferative Neoplasms<a class="headerlink" href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms-myeloproliferative-neoplasms" title="Permanent link">&para;</a></h1>
<p>Myeloproliferative Neoplasms (MPNs)—Christina Snider</p>
<p>Background</p>
<ul>
<li>MPNs = chronic myeloid disorders caused by abnormal proliferation of
    mature bone marrow cell lineages (granulocytes, erythrocytes, or
    megakaryocytes)</li>
<li>MPNs differ from myelodysplastic syndrome (MDS)—cells in MPNs are
    normally developed (i.e. not dysplastic)</li>
<li>Four “classic” MPNs: polycythemia vera, essential thrombocythemia,
    primary myelofibrosis and chronic myeloid leukemia (CML)</li>
</ul>
<p>Polycythemia Vera (PV)</p>
<ul>
<li>Polycythemia is a general term: Men = Hb/Hct &gt; 16.5/49%;  Women =
    Hb/Hct &gt; 16/48%</li>
<li>Relative polycythemia
    = Concentrated H/H due to decreased plasma volume<ul>
<li>Diuretic use, vomiting, diarrhea;  H/H should normalize with
    fluid resuscitation</li>
</ul>
</li>
<li>Absolute polycythemia
    = Increased RBC mass<ul>
<li>Primary
    polycythemia: 2/2 Inherited/acquired mutation in RBC progenitor</li>
<li>Secondary polycythemia: Increase in RBC mass due to elevated
    serum EPO<ul>
<li>Hypoxia/cardiopulmonary associated (chronic pulmonary
    disease, R-to-L cardiac shunts, sleep apnea, obesity
    hypoventilation syndrome, chronic carbon monoxide poisoning,
    including heavy smoking)</li>
<li>Kidney associated causes (following renal transplant, renal
    artery stenosis, hydronephrosis)</li>
<li>Autonomous EPO production from an EPO-producing tumors
    (rare)</li>
<li>Steroid Use</li>
</ul>
</li>
</ul>
</li>
<li>Epidemiology: Median age of diagnosis is 60 years; 25% cases present
    at age \&lt;50 years.</li>
<li>>95% PV pts have <em>JAK2</em> V617F mutation, but <em>JAK2</em> V617F mutation
    is not specific to PV and can be seen in other MPNs</li>
</ul>
<p>Presentation</p>
<ul>
<li>Incidentally elevated H/H</li>
<li>Splenomegaly, generalized pruritus (post-warm bath/shower), unusual
    thrombosis</li>
<li>Erythromelalgia: intermittent occurrence of red, hot, painful
    extremities</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC with differential and peripheral smear</li>
<li>EPO level</li>
<li>Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</li>
<li>Peripheral blood screen for <em>JAK2</em> V617F mutation</li>
</ul>
<p>Management</p>
<ul>
<li>PV treatment aims to prevent thrombosis and bleeding events.</li>
<li>Phlebotomy: maintain Hct \&lt;45% (One unit 500 mL decreases Hct by 3%)</li>
<li>ASA 81 mg for thrombosis prevention and symptom control</li>
<li>Hydroxyurea: indicated for high-risk patients (&gt;60 years old or with
    history of thrombosis)</li>
<li>Interferon-alfa, busulfan, or ruxolitinib: indicated in select
    high-risk patients</li>
</ul>
<p>Essential thrombocythemia (ET)</p>
<p>Background</p>
<ul>
<li>Clonal stem cell disorder w/ increased platelet counts (&gt;450k/uL)</li>
<li>Risks of thrombosis and hemorrhage</li>
<li>Median age of diagnosis: 60 years; Twice as common in females.</li>
</ul>
<p>Presentation</p>
<ul>
<li>Incidental thrombocytosis on CBC</li>
<li>Splenomegaly, unusual thrombosis, and erythromelalgia</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Screen for conditions that cause reactive thrombocytosis: Chronic
    inflammatory diseases, infections, bleeding/hemolysis, iron
    deficiency, post splenectomy</li>
<li>CBC with smear (platelet anisocytosis) ranging from very small to
    giant platelets</li>
<li>CMP, LDH, Uric Acid, iron studies</li>
<li>BCR ABL1 testing may be sent to exclude CML</li>
<li>Bone marrow biopsy with staining, cytogenetics, and molecular
    testing for JAK2 mutations</li>
</ul>
<p>Management</p>
<ul>
<li>Avoid ASA 81 in patients with platelet counts &gt;1 million/uL microL
    complicated by acquired von Willebrand syndrome due to increased
    risk of bleeding</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of ET</td>
<td>Treatment of ET</td>
<td>Treatment of ET</td>
</tr>
<tr>
<td>Risk Score (IPSET-thrombosis)</td>
<td>Features</td>
<td>Treatment</td>
</tr>
<tr>
<td>High</td>
<td>Hx of thrombosis and/or >age 60 with JAK2 V617F mutation</td>
<td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation &plusmn;antiplatelet agent</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Age >60, no JAK2 V617F mutation, no history of thrombosis</td>
<td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation &plusmn;antiplatelet agent</td>
</tr>
<tr>
<td>Low</td>
<td>Age =\&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</td>
<td>Observation vs. daily ASA 81</td>
</tr>
<tr>
<td>Very Low</td>
<td>Age =\&lt;60, no JAK2 V617F mutation, no history of thrombosis</td>
<td>Observation vs. daily ASA 81</td>
</tr>
</tbody>
</table>
<p>Primary Myelofibrosis (PMF)</p>
<p>Background</p>
<ul>
<li>Clonal proliferation of myeloid cells with variable morphologic
    maturity resulting in reactive marrow fibrosis and extramedullary
    hematopoiesis</li>
<li>Least favorable prognosis out of MPN</li>
</ul>
<p>Presentation</p>
<ul>
<li>Fatigue, weight loss, low grade fever, bone pain, and night sweats</li>
<li>Marked splenomegaly &plusmn;hepatomegaly (due to extramedullary
    hematopoiesis)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>smear: teardrop shaped RBCs (dacrocytes)</li>
<li>Bone marrow biopsy: “dry tap” due to extensive reticulin and/or
    collagen fibrosis</li>
<li>mutually exclusive mutations in JAK2, MPL, or CALR</li>
</ul>
<p>Management</p>
<ul>
<li>Low risk patients: Observe if asymptomatic</li>
<li>Cure by allogenic HCT transplantation in young, high risk patients</li>
<li>Complex treatment options, consult Hematology</li>
<li>Treatment of anemias include transfusion support</li>
<li>Surgical splenectomy if abdominal pain or transfusion dependent
    anemia</li>
</ul>
<p>Chronic Myelogenous Leukemia (CML)</p>
<p>Background</p>
<ul>
<li>Definition: MPN overproduction of myeloid stem cells that can
    differentiate</li>
<li>Chronic phase: 85% of pts<ul>
<li>Fatigue, weight loss, bleeding</li>
<li>Abdominal fullness and early satiety due to splenomegaly</li>
<li>WBC on CBC is typically &gt;100k, and smear shows neutrophilic
    cells in all stages of maturation with \&lt;2% blasts</li>
</ul>
</li>
<li>Accelerated phase: Refractory leukocytosis, 10-19% blasts in
    peripheral blood or bone marrow, worsening peripheral basophilia,
    thrombocytopenia</li>
<li>Blast phase = acute leukemia. &gt;20% blasts in peripheral blood or
    bone marrow, extramedullary proliferation of blasts</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Typical findings in blood and bone marrow and confirmation of
    Philadelphia chromosome ( <em>BCR-ABL1</em> fusion gene) via conventional
    cytogenetics, FISH, or rt-PCR</li>
</ul>
<p>Management</p>
<ul>
<li>Hydroxyurea can be used to reduce WBC while awaiting confirmation</li>
<li>Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib,
    nilotinib, and ponatinib</li>
<li>Allogenic hematopoietic cell transplantation: Curative option for
    pts in accelerated and blast phase, as well as young pts w/chronic
    phase CML who do not respond to TKI therapy</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever"><h1 id="hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever-neutropenia-and-neutropenic-fever">Neutropenia and Neutropenic Fever<a class="headerlink" href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever-neutropenia-and-neutropenic-fever" title="Permanent link">&para;</a></h1>
<p>Neutropenia &amp; Neutropenic Fever – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>Neutrope
    nia: absolute neutrophil count (ANC) \&lt; 1500<ul>
<li>Severe neutropenia: absolute neutrophil count (ANC) \&lt;500 [Use
    manual count if available]</li>
<li>Typically
    requires immediate evaluation and often hospitalization</li>
<li>>500 is threshold for allowing pt’s to return home after
    chemo-induced neutropenia</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Causes</td>
<td>Example(s)</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Drug-associated</td>
<td>Cytotoxic or immunosuppressive agents Methimazole, PTU, Colchicine Macrolides, Bactrim, Dapsone, Vancomycin Amphotericin, Acyclovir, Ganciclovir TCAs, Clozapine, Carbamazepine, Valproate ACEI, Digoxin, Propranolol, Procainamide</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Radiation exposure</td>
<td>NaN</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Malignancies</td>
<td>Leukemias, MDS</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Infection</td>
<td>Hepatitis, HIV, EBV, CMV Rickettsia, Tularemia, Typhoid, TB</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Nutritional deficiency</td>
<td>Vitamin B12, Folate, Copper</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Other</td>
<td>Aplastic anemia Benign ethnic neutropenia</td>
</tr>
<tr>
<td>Redistribution</td>
<td>Splenomegaly</td>
<td>Margination &amp; sequestration</td>
</tr>
<tr>
<td>Congenital</td>
<td>Genetics</td>
<td>Benign ethnic neutropenia, familial neutropenia</td>
</tr>
<tr>
<td>Immune destruction</td>
<td>Autoimmune disorders</td>
<td>RA, SLE</td>
</tr>
<tr>
<td>Immune destruction</td>
<td>Other</td>
<td>Autoimmune neutropenia</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>ANC \&lt;500<ul>
<li>Check all lines/IVs for erythema and induration daily</li>
<li>Check mouth for mucositis, mouth care after meals and before bed</li>
<li>Assess for Neutropenic Fever &amp; Complications – see below</li>
<li>Evaluate for indications for prophylaxis – see below</li>
<li>Provide Neutropenic Precautions:<ul>
<li>Neutropenic
    diet: low microbial diet</li>
<li>Idea
    is to prevent food-borne illness, however has not been shown
    to decrease infection risk in meta-analyses</li>
<li>No raw, or undercooked foods</li>
<li>No deli meats, seafood, salad bars, unpasteurized products
    or raw sprouts</li>
<li>No digital rectal exams or enemas/suppositories (risk of
    bacterial translocation)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Neutropenic Fever</p>
<ul>
<li>ANC \&lt;500 and T&gt; 100.4 °F or 38.0 °C</li>
<li>Neutropenic pts are unable to mount an adequate immune response and
    can become critically ill very quickly</li>
<li>Do not wait for a temp re-check, you need to start antibiotics
    immediately</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Chest X-ray</li>
<li>Two sets of blood cultures (one from PICC/port if present)</li>
<li>Urinalysis AND urine culture (not the reflex order set)</li>
<li>If diarrhea, get C. diff PCR</li>
<li>If abdominal pain, get CT A/P with IV contrast</li>
</ul>
<p>Management</p>
<ul>
<li>Empirically treat with Cefepime</li>
<li>Indications for Vancomycin:<ul>
<li>Hemodynamically unstable</li>
<li>Severe mucositis</li>
<li>Focal consolidation on CXR</li>
<li>Erythema/induration around line</li>
<li>Concern for skin/soft tissue infection</li>
<li>GPCs in blood</li>
<li>Fever continues &gt;24h on cefepime</li>
</ul>
</li>
<li>Additional Coverage:<ul>
<li>If abdominal pain/diarrhea: Flagyl 500mg q8h</li>
<li>Concern for C-diff: PO Vancomycin 125mg q6h</li>
<li>Still fevering on Cefepime at 72 hrs (differs by attending)
    
    Meropenem</li>
</ul>
</li>
<li>Fungal coverage: Consider if risk factors (TPN) or persistent fevers
    (&gt;72hrs)<ul>
<li>Micafungin 100 mg IV daily or Voriconazole 200mg PO BID</li>
</ul>
</li>
</ul>
<p>Neutropenic Complications</p>
<p>Mucositis</p>
<ul>
<li>Can
    range from mouth soreness to severe erosions preventing
    eating/drinking</li>
<li>Can
    become secondarily infected with Candida, HSV<ul>
<li>Management
    :<ul>
<li>Routine oral care with a soft toothbrush to remove plaque</li>
<li>Oral rinses with saline and/or sodium bicarbonate</li>
<li>Magic mouthwash for symptomatic relief (or viscous lidocaine
    at the VA)</li>
<li>Typically recovers quickly when ANC &gt; 500</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Neutropenic</p>
<p>enterocolitis (Typhlitis)</p>
<ul>
<li>Life
    -threatening bacterial translocation due to breakdown of gut-mucosal
    barrier</li>
<li>Presentation
    :
    Abdominal pain + fever<ul>
<li>&plusmn; abdominal distension, nausea, vomiting, watery and/or bloody
    diarrhea</li>
</ul>
</li>
<li>Diagnosis
    :
    CT
    A/P with contrast, consider C. diff PCR if diarrhea</li>
<li>Treatment
    :<ul>
<li>Cefepime/Flagyl OR Zosyn</li>
<li>If no perforation/abscess on CT scan, typically continue until
    14 days after ANC recovers &gt;500 and abdominal pain resolves</li>
<li>Can change to cipro/flagyl once ANC &gt;500</li>
<li>If perforation/abscess: will need imaging to confirm resolution,
    and longer duration of abx</li>
</ul>
</li>
</ul>
<p>Neutropenic Prophylaxis</p>
<ul>
<li>Used
    if ANC is expected to be \&lt; 500 for &gt; 7 days</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Most Common Regimen</td>
<td>Alternatives</td>
</tr>
<tr>
<td>Bacterial</td>
<td>Levofloxacin 500mg PO daily</td>
<td>Cefdinir 300mg PO BID</td>
</tr>
<tr>
<td>Viral</td>
<td>Valacyclovir 500mg PO BID</td>
<td>Acyclovir 400mg PO BID (adjust for renal dysfunction)</td>
</tr>
<tr>
<td>Fungal</td>
<td>Fluconazole 400mg PO daily</td>
<td>Posaconazole 300 PO BID x2 days 300 daily (AML induction for aspergillus) Micafungin 50mg IV daily</td>
</tr>
<tr>
<td>PJP (if steroids)</td>
<td>Inhaled pentamidine 300 mg monthly</td>
<td>Dapsone (check G6PD) Avoid Bactrim (risk of myelosuppression)</td>
</tr>
</tbody>
</table>
<p>Filgrastim (G-CSF – Neupogen/Zarxio)</p>
<ul>
<li>Induces bone marrow production of Neutrophils</li>
<li>Can be given for chemo-induced neutropenia in non-AML malignancies</li>
<li>Sometimes given in AML in certain regimens like CLAG-M</li>
<li>Dose: either 300mcg or 480mcg (rounded from 5 mcg/kg/day)</li>
<li>Common side effects: fatigue, nausea</li>
<li>PEG-filgrastim (Neulasta): long-acting version that is only given as
    an outpatient</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-oncologic-emergencies"><h1 id="hematology-oncology-hematologyoncology-oncologic-emergencies-oncologic-emergencies">Oncologic Emergencies<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-oncologic-emergencies" title="Permanent link">&para;</a></h1>
<p>Madeleine Turcotte</p>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-leukostasis">Leukostasis<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-leukostasis" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Respiratory: dyspnea, hypoxia (note CXR may be normal)<ul>
<li>PaO2 by ABG often falsely low dt WBC consuming O2 <em>in vitro</em> .
    Trust SpO2.</li>
</ul>
</li>
<li>CNS: headache, AMS, vision changes, dizziness, tinnitus, gait
    instability, neuro deficit</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>CBC with diff and peripheral blood smear</li>
<li>Imaging: CT head to evaluate neuro deficit and to check for ICH</li>
<li>Chest X-Ray vs CT chest to evaluate dyspnea</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Page hematology fellow for guidance if you feel this dx is likely</li>
<li>Hydrea (discuss with fellow) Hydrea 50 – 100 mg/kg/day divided
    between bid dosing</li>
<li>Emergent cytoreduction<ul>
<li>Leukapheresis: page nephrology and place dialysis catheter</li>
</ul>
</li>
<li>Chemotherapy per hematology fellow</li>
<li>Transfer/admit to ICU</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-tumor-lysis-syndrome-bradley-christensen">Tumor Lysis Syndrome - Bradley Christensen<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-tumor-lysis-syndrome-bradley-christensen" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Lysis of malignant cells either spontaneously or in response to
    chemotherapy causing release of K, Phos, nucleic acids, and
    cytokines</li>
<li>Consequences:<ul>
<li>Hyperkalemia- most urgent and immediately life threatening</li>
<li>Hyperphosphatemia- binds Ca2+ and leads to CaP crystal
    deposition-&gt; AKI, HypoCa</li>
<li>Hyperuricemia (from breakdown of DNA)-&gt;precipitation in renal
    tubules-&gt;AKI</li>
<li>Hypotension, AKI from cytokine release</li>
</ul>
</li>
<li>Laboratory TLS (at least
    two within 2d before or 7d after start of chemotherapy):<ul>
<li>Uric acid ≥ 8 mg/dL, Ca2+ ≤ 7 mg, K+ ≥ 6 mEq/L, or PO43- ≥ 4.5
    mg/dL /dL</li>
<li>OR &gt; 25% change from baseline in these values</li>
</ul>
</li>
<li>Clinical TLS: laboratory TLS + AKI, arrhythmia, seizure, tetany,
    death</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_1">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Risk Stratification:<ul>
<li>Highest risk <strong>after</strong> tarting chemotherapy, but can occur spontaneously</li>
</ul>
</li>
<li>Tumor characteristics which confer a <strong>higher risk</strong> of developing
    TLS:<ul>
<li>High (&gt;5% risk): ALL (WBC&gt; 100K or LDH 2x ULN), AML (WBC&gt; 100K),
    Burkitt’s (III/IV or LDH≥2xULN, DLBCL with bulky disease,
    intermediate risk + AKI/CKD</li>
<li>Intermediate: ALL (WBC\&lt;100K, LDH \&lt;2x ULN), AML (WBC 25-100K),
    Burkitt’s LDH\&lt;2x ULN), DLBCL (non-bulky, LDH&gt;ULN), CLL (if tx
    with fludarabine, rituximab, lenalidomide, or venetoclax +LN
    5-10 cm or ALC≥25K), plasma cell leukemia, rare chemo-sensitive
    solid tumors (small cell)</li>
<li>Low: all others</li>
</ul>
</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_1">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_1" title="Permanent link">&para;</a></h3>
<p>Prevention:</p>
<ul>
<li>High risk:  q8h TLS labs, IVF (±loop diuretic if volume overload),
    allopurinol, ± rasburicase</li>
<li>Intermediate – q8h TLS labs, IVF, allopurinol</li>
<li>Low – daily TLS labs, IVF<ul>
<li>Significant hydration: goal to maintain UOP 80-100 mL/hr</li>
<li>Allopurinol: 300 mg PO BID for CrCl &gt; 20 mL/min, UpToDate renal
    dosing if lower</li>
<li>Rasburicase ($$$): contraindicated in G6PD (send G6PD if not
    urgent and AA, Asian or Jewish descent)<ul>
<li>Given if uric acid &gt; 8 mg/dL: get fellow approval before ordering</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Treatment: (Can use as night/cross cover handoff)</p>
<ul>
<li>K <sup>+</sup> <u>></u> 5.5:  STAT EKG. Kayexalate 30g orally or
    60g per rectum (unless contraindicated) x1<ul>
<li>Give 10 U insulin/1 amp D50</li>
<li>If EKG changes, then calcium gluconate and D5W at 100 mL/hr with
    repeat BG in 1 hr</li>
</ul>
</li>
<li>Uric acid <u>></u> 8 with 25% change from baseline: page hematology
    fellow to discuss rasburicase</li>
<li>PO4 <u>></u> 4.5 with 25% change from baseline: start/↑ phos binder (sevelamer)<ul>
<li>Dialysis may be necessary in patients with poor renal function.</li>
</ul>
</li>
<li>IV calcium: do not administer unless symptomatic AND
    hyperphosphatemia is corrected<ul>
<li>With high phos, IV calcium can lead to calcium deposition and
    renal failure</li>
</ul>
</li>
<li>Hemodialysis: pt with anuria, refractory hyperkalemia, and
    symptomatic hypocalcemia</li>
<li>Consequence of WBC’s plugging up microvasculature</li>
<li>Most common in AML with hyperleukocytosis (defined as WBC &gt; 100K/µL) If cell not sticky (CLL) generally not going to cause despite high
    WBC count.</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-superior-vena-cava-svc-syndrome">Superior Vena Cava (SVC) Syndrome<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-superior-vena-cava-svc-syndrome" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_1">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Commonly Associated Malignancies: Lung Cancer, Non-Hodgkin or Hodgkin
    Lymphoma, Mediastinal Germ Cell Tumors, Thymic Malignancies</li>
<li>Partial or complete obstruction of the SVC impedes blood return from
    the upper extremities, head, neck, and brain resulting in upstream
    congestion</li>
<li>Can be 2/2 a mass in the mediastinum or thrombosis (foreign body i.e. catheter)</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_1">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Facial or neck swelling without generalized edema</li>
<li>Sense of head fullness, exacerbated by leaning forward or lying
    down, which may indicate cerebral edema</li>
<li>Pulmonary symptoms including dyspnea, stridor, hoarseness, cough -
    due to edema narrowing the nasal passages and larynx or mechanical
    airway obstruction</li>
<li>Physical Exam: facial and neck edema particularly of the eye lids in
    the morning, distended neck and chest veins; can also sometimes see
    upper extremity swelling, papilledema, plethora. Look for associated
    lymph node enlargement anywhere particularly including
    supraclavicular, cervical and axillary region</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_2">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>AFP, β-hCG if no tissue Dx</li>
<li>CXR: may show mass, perihilar or mediastinal disease</li>
<li>Contrasted CT scan ± CT Venography:  Phased to get a view of clot
    contribution to obstruction  guides decision regarding anticoagulation or stenting<ul>
<li>Radiology attending can coordinate with techs (requires verbal direct
    request)</li>
</ul>
</li>
<li>MRI/MRV may provide additional information (often not possible due
    to pt too sick)</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_2">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Assess airway and prepare for intubation if needed</li>
<li>Keep head of bed elevated</li>
<li>Thrombosis:<ul>
<li>Removal of lines/catheters associated with thrombus</li>
<li>Consideration of anticoagulation (risks vs benefits patient
    dependent)</li>
</ul>
</li>
<li>Tumor compression: the type of tumor guides treatment (tissue biopsy
    is key)</li>
<li>Stat/urgent consultations:<ul>
<li>Interventional radiology for possible stenting/dilatation</li>
<li>Radiation oncology- for radiation therapy</li>
<li>Interventional pulmonology – for help with tissue dx</li>
<li>Medical oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-spinal-cord-compression">Spinal Cord Compression<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-spinal-cord-compression" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_2">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Malignancies where cord compression is most common:</li>
<li>Multiple Myeloma, Lymphoma (both Hodgkin and NHL), Lung, Breast,
    Prostate Cancer</li>
<li>Tumor mass &amp; compressed and often displaced bone  impinges thecal sac or nerve roots spinal cord or any spinal nerves including the cauda equina</li>
<li>Impingement causes pain and can lead to neurologic dysfunction</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_2">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Back pain, motor or sensory deficits</li>
<li>Cauda Equina syndrome  bowel or bladder incontinence, ataxia</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_3">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Neurologic exam with sensation testing seeking level below an
    identified dermatome</li>
<li>Lab testing: If no known malignancy check CBC, CMP, SPEP, and (in
    males) PSA</li>
<li>Bladder US if suspicion or retention with or without overflow
    incontinence</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_3">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_3" title="Permanent link">&para;</a></h3>
<ul>
<li>If suspected, MRI without and with contrast best for diagnosis; if
    patient unable to have MRI, CT myelography may be considered</li>
<li>Immediate high dose steroids (dosing is controversial with
    recommendations ranging from 4 to 100 mg of <strong>dexamethasone</strong> q6h -
    choice of dexamethasone is to minimize mineralocorticoid effects.
    Most common dosing is 10mg IV x1 followed by 4mg IV q6h)</li>
<li>Consider stat/urgent consultation with:<ul>
<li>Neurosurgery for diagnostic/therapeutic intervention</li>
<li>Radiation oncology- for radiation therapy</li>
<li>Medical oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
<li>Ensure regular neuro-vascular checks and close monitoring.</li>
<li>Early PT if LE weakness</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-brain-metastases">Brain Metastases<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-brain-metastases" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_3">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Common Malignancies: Lung (NSCLC), breast, kidney, colorectal
    carcinomas &amp; melanomas</li>
<li>Significantly more common than primary brain tumors</li>
<li>Occur in 10 - 30% of adults w/systemic malignancies</li>
<li>80% of brain mets occur in the cerebrum at grey/white matter
    junction</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_3">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Highly variable: so consider brain mets any cancer pt w/ neurologic
    or behavioral changes</li>
<li>Headache: worse in the mornings, with bending over or with valsalva</li>
<li>Nausea/vomiting</li>
<li>Cognitive dysfunction: changes in memory, mood or personality</li>
<li>Focal neurologic deficits</li>
<li>Signs of elevated ICP: papilledema, vision changes, drowsiness,
    presyncope<ul>
<li>Seizures</li>
<li>Stroke (particularly in melanoma, choriocarcinoma, thyroid &amp;
    renal carcinomas)</li>
</ul>
</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_4">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_4" title="Permanent link">&para;</a></h3>
<ul>
<li>STAT CT if concerned for stroke or elevated ICP</li>
<li>MRI with contras: most sensitive, can differentiate b/w metastases
    vs. other lesions<ul>
<li>Suggestive
    features: multiple lesions, location, circumscribed margins,
    vasogenic edema</li>
</ul>
</li>
<li>If pt has no known primary tumor: consider CT C/A/P &plusmn; PET to
    identify primary</li>
<li>Biopsy with histopathology &amp; IHC: if diagnosis in doubt or if only a
    single lesion is present</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_4">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_4" title="Permanent link">&para;</a></h3>
<ul>
<li>If severe HA, N/V, focal deficits: systemic glucocorticoids<ul>
<li>Dexamethasone 10mg IV x1 followed by 4mg IV q6h (can be PO if
    tolerated)</li>
</ul>
</li>
<li>Stat/urgent consults:<ul>
<li>Neurosurgery
    – for diagnostic/therapeutic intervention</li>
<li>Radiation
    oncology – for radiation therapy</li>
<li>Medical
    oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
<li>Ensure regular neuro-vascular checks and close monitoring</li>
<li>Do not perform LP without input from neurology</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-paraneoplastic-syndromes"><h1 id="hematology-oncology-hematologyoncology-paraneoplastic-syndromes-paraneoplastic-syndromes">Paraneoplastic Syndromes<a class="headerlink" href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes-paraneoplastic-syndromes" title="Permanent link">&para;</a></h1>
<p>Paraneoplastic Syndromes – Justin Lo</p>
<p><span id="Paraneoplastic"></span></p>
<p>Hypercalcemia of malignancy</p>
<p>Background</p>
<ul>
<li>Caused
    by PTHrP production, osteolytic lesions, and/or rarely exogenous Vit
    D</li>
<li>PTHrP
    
    Breast cancer, NSCLC (squamous)</li>
<li>Osteolysis
    
    Multiple Myeloma, Breast Cancer;</li>
<li>Exogenous Vit D
    
    Lymphoma</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Correct [Ca <sup>+2</sup> ] for hypoalbuminemia: add 0.8 x (4.0 –
    albumin)</li>
<li>Send basic hyperCa <sup>+2</sup> work-up – PTH, Vit D, etc (see
    hypercalcemia section)</li>
<li>PTHrP is called “Parathyroid Hormone-related Peptide-ARUP” in Epic</li>
</ul>
<p>Management</p>
<ul>
<li>First-line: IVF without calcium such as Normosol
    
    goal urinary output of 150-200 mL/hr<ul>
<li>Strict I/Os; Cautious IV fluids if pt w/cardiac or renal
    dysfunction</li>
<li>Add Furosemide if hypervolemic (do not empirically start)</li>
</ul>
</li>
<li>Second-line: Zoledronic acid 4mg IV (takes 24-48 hours to see
    effect)</li>
<li>AMS or severe hypercalcemia (&gt;14mg/dL): calcitonin 4 IU/kg (req.
    attending approval)</li>
<li>Monitor creatinine, calcium and potassium</li>
<li>Begin treatment for underlying malignancy ASAP</li>
</ul>
<p>SIADH</p>
<p>Background</p>
<ul>
<li>Euvolemic hypotonic hyponatremia with urine sodium &gt;20 and typically
    urine Osm &gt;100</li>
<li>Associated with: SCLC (most common), head/neck cancers, breast
    cancer</li>
<li>See "Nephrology" for additional information</li>
</ul>
<p>Management</p>
<ul>
<li>Free water restriction to 800mL/day</li>
<li>Refractory: salt supplementation (e.g. salt tabs) &plusmn; loop diuretic</li>
</ul>
<p>Carcinoid Syndrome</p>
<p>Background</p>
<ul>
<li>Episodic
    flushing, diarrhea, wheezing/SOB due to secretion of histamine &amp;
    serotonin</li>
<li>Most common: Neuroendocrine tumors – GI (often with mets to liver
    and lung)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urine: UR 5-HIAA (ARUP)</li>
<li>Imaging to identify tumor(s) (CT chest/abdomen/pelvis)</li>
</ul>
<p>Management</p>
<ul>
<li>Short-term treatment: subQ or IV octreotide (see UpToDate for
    dosing)</li>
<li>Antidiarrheals (Imodium, Lomotil, etc.) to slow transit</li>
<li>Long-term treatment: depot (IM) forms of octreotide and lanreotide</li>
</ul>
<p>Autoimmune encephalitis, encephalomyelitis, and myelitis</p>
<p>Background</p>
<ul>
<li>Encephalopathy (limbic or brainstem), &plusmn; myelitis (limb ataxia,
    sensory deficits)</li>
<li>Associated with small cell lung cancer and checkpoint inhibitor
    therapy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LP: make sure to order CSF oligoclonal bands &amp; CSF IgG index</li>
<li>“Paraneoplastic AutoAb Eval-MAYO” (add "CSF" to the front of the
    order name if for LP)</li>
<li>NMDA-R can be ordered as a standalone test</li>
<li>CT head</li>
<li>EEG if concern for subclinical seizures</li>
</ul>
<p>Management:</p>
<p>Consult Neurology, for possible immunosuppressive therapy (steroids,
IVIG)</p>
<p>Lambert-Eaton myasthenic syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>Muscle
    weakness due to autoantibody against calcium channels resulting in
    ↓
    ACh release</li>
<li>Associated
    with SCLC (most common) &amp; lymphoma</li>
</ul>
<p>Presentation: Proximal muscle weakness, diminished DTRs</p>
<p>Evaluation</p>
<ul>
<li>Nerve conduction studies: EMG w/ NCV</li>
<li>Serum “Paraneoplastic AutoAb Eval-MAYO”</li>
</ul>
<p>Management:</p>
<p>Consult Neurology</p></section><section class="print-page" id="hematology-oncology-hematologyoncology-plasma-cell-dyscrasias"><h1 id="hematology-oncology-hematologyoncology-plasma-cell-dyscrasias-plasma-cell-dyscrasias">Plasma Cell Dyscrasias<a class="headerlink" href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias-plasma-cell-dyscrasias" title="Permanent link">&para;</a></h1>
<p>Plasma Cell Dyscrasias – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>A heterogenous group of benign, premalignant, and malignant
    conditions characterized by clonal proliferation of plasma cells</li>
<li>Results in production of monoclonal immunoglobulins or polypeptides
    (i.e. monoclonal proteins, or M-protein) in serum and/or urine</li>
<li>Includes monoclonal gammopathy of undetermined significance (MGUS),
    smoldering myeloma (SMM), multiple myeloma (MM), Waldenstrom’s
    macroglobulinemia (WM), extra-medullary plasmacytoma, AL
    amyloidosis, POEMS syndrome, Castleman’s disease</li>
<li>Complications: Increased infectious risk, renal failure,
    hyperviscosity syndrome, malignant hypercalcemia, pain crisis from
    bony disease</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Signs</td>
</tr>
<tr>
<td>Fatigue, weakness, weight loss Bone pain Paresthesias, neuropathy, radiculopathy Visual disturbances (if hyperviscosity present) Lymphadenopathy (uncommon) Fever (uncommon)</td>
<td>Anemia (Hgb \&lt;10) Renal insufficiency (Cr > 2) Hypercalcemia (Ca > 11.5) Elevated protein gap (Total protein - Alb > 4) Osteolytic bone lesions (typically central) Unexplained heavy proteinuria Rouleux formation on blood smear</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>CBC
    w/ diff, BMP (for Ca, Cr)</li>
<li>SPEP with immunofixation, UPEP (24 hour urine) with immunofixation,
    urinalysis, serum free light chains (FLC)</li>
<li>Quantitative immunoglobulins (IgA, IgM, IgG, IgD, IgE)</li>
<li>If  Hgb \&lt;10, Cr &gt;2, Ca &gt;11.5, M-protein &gt;1.5, non-IgG M-spike,
    abnormal FLC ratio:<ul>
<li>Bone marrow biopsy + cytogenetics, peripheral blood smear review</li>
<li>LDH, albumin, CRP,
    β
    2-microglobulin, serum viscosity</li>
<li>Skeletal survey</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional Tips for Lab Interpretation</td>
<td>Additional Tips for Lab Interpretation</td>
<td>Additional Tips for Lab Interpretation</td>
</tr>
<tr>
<td>SPEP/UPEP</td>
<td>Free light chains (FLC)</td>
<td>Urinalysis</td>
</tr>
<tr>
<td>Immunofixation determines clonality (e.g. mono or polyclonal) Monoclonal spike >1.5 is indicative of underlying dyscrasia Polyclonal spike suggests infectious, inflammatory, or reactive etiology</td>
<td>Ratio of kappa/lambda >3 highly suggestive of plasma cell dyscrasia -Ratio 1.65 to 3 can be due to infectious process or renal insufficiency Helpful in pts that only produce bence jones protein (FLC w/o heavy chain) which isn’t seen on SPEP</td>
<td>Detects albumin, not light chains In myeloma cast nephropathy, get negative dipstick since proteinuria is from FLC (i.e. Bence Jones proteinuria) In AL amyloid, dipstick will be positive 2/2 albumin loss from nephrotic syndrome</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Monoclonal Gammopathy of Unknown Significance (MGUS)</td>
<td>Smoldering Multiple Myeloma (SMM)</td>
<td>Multiple Myeloma (MM)</td>
</tr>
<tr>
<td>% Plasma Cells in BM</td>
<td>\&lt;10%</td>
<td>10-60%</td>
<td>≥ 10% (typically >30%)</td>
</tr>
<tr>
<td>Monoclonal Protein</td>
<td>IgG, IgA, IgM: 1.5 -3</td>
<td>IgG or IgA >3</td>
<td>IgG or IgA >3</td>
</tr>
<tr>
<td>Laboratory studies</td>
<td>Normal Hgb, Ca, Cr</td>
<td>Normal Hgb, Ca, Cr</td>
<td>↓Hgb, ↑Ca, ↑Cr</td>
</tr>
<tr>
<td>Symptoms</td>
<td>None</td>
<td>None</td>
<td>Lytic bone lesions, fatigue</td>
</tr>
<tr>
<td>Prognosis</td>
<td>1% / year progression to MM</td>
<td>10% / year progression to MM</td>
<td>R-ISS staging (see below)</td>
</tr>
<tr>
<td>Monitoring and/or Treatment</td>
<td>Monitoring only Yearly: Symptom check SPEP, FLC, CBC, BMP</td>
<td>Monitoring only In 2-3 months, repeat SPEP, FLC, CBC, BMP Yearly skeletal survey</td>
<td>Chemotherapy, plus SCT for eligible patients</td>
</tr>
</tbody>
</table>
<p>Multiple Myeloma</p>
<p>Evaluation</p>
<ul>
<li>Diagnosis requires:<ul>
<li>One of:<ul>
<li>Clonal
    bone marrow plasma cells &gt;10%</li>
</ul>
</li>
<li>Biopsy
    proven extramedullary plasmacytoma (tumor of plasma cells) AND
    ≥1 myeloma-defining event:<ul>
<li>One or more of the CRAB criteria</li>
<li>Clonal
    bone m
    arrow plasma cells ≥ 60%</li>
<li>Serum
    FLC ratio ≥ 100 or ≤0.01</li>
<li>>1
    focal
    lesion larger than 5mm on MRI</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Active disease: induction includes a proteasome inhibitor
    (bortezomib or carfilzomib)</li>
<li>Consolidation therapy includes SCT for eligible patients \&lt;65-70
    years old</li>
<li>Maintenance therapy is often given indefinitely, typically
    lenalidomide and/or bortezomib</li>
<li>VTE prophylaxis if on an immunomodulatory agent with 2 VTE risk
    factors<ul>
<li>If only 0-1
    VTE
    risk factors
    
    aspirin</li>
</ul>
</li>
<li>Supportive Care: EPO for anemia, analgesia ± radiotherapy for bone
    pain, vaccinations</li>
<li>Bisphosphonate (ideally zoledronic acid)</li>
<li>(Val)Acyclovir ppx if on bortezomib</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Prognosis<ul>
<li>Revised Multiple Myeloma International Staging System (R-ISS)
    (available on MD Calc)<ul>
<li>Serum
    β
    2-microglobulin (indicator of plasma cell turnover)</li>
<li>Serum albumin</li>
<li>Serum LDH</li>
</ul>
</li>
<li>Cytogenetic markers from biopsy</li>
</ul>
</li>
</ul>
<p>Lymphoplasmacytic Lymphoma</p>
<p>Waldenstrom’s Macroglobulinemia (IgM)</p>
<p>Presentation</p>
<ul>
<li>Hyper-viscosity syndrome
    : blurred vision, dizziness, diplopia, ataxia, vertigo stroke, coma</li>
<li>Peripheral neuropathy</li>
<li>Retinal changes: dilated veins, hemorrhages, papilledema</li>
<li>Cryoglobulinemia: large IgM complexes precipitate out in the cold,
    causing Raynaud's, urticaria, purpura, acral cyanosis, tissue
    necrosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Requires: IgM monoclonal gammopathy on SPEP,  BM biopsy w/≥10%
    plasma cells, and MYD88 mutation detected</li>
<li>CBC, coagulation studies, cryoglobulins, IgM,
    β
    2-microglobulin</li>
<li>Serum viscosity (If \&lt;4 symptoms are rare, If &gt;6 typically
    symptomatic)</li>
</ul>
<p>Management</p>
<ul>
<li>Only treated if symptomatic</li>
<li>If Hyper-viscosity syndrome treatment in Plasma Exchange</li>
<li>Induction: may include bendamustine &plusmn; rituximab if IgM level is
    \&lt;4000 (Rituximab can temporarily
    ↑
    IgM and
    ↑
    risk of hyperviscosity syndrome)</li>
<li>Monitor response with: IgM levels, monoclonal IgM on SPEP</li>
</ul>
<p>Other Plasma Cell Dyscrasias</p>
<p>Light Chain (AL) Amyloidosis</p>
<ul>
<li>Extracellular deposition of misfolded light chains</li>
<li>Most commonly kidney &amp; heart</li>
<li>Features:
    ​​​​​​​<ul>
<li>Nephrotic syndrome</li>
<li>Restrictive CM</li>
<li>Peripheral neuropathy</li>
<li>Hepatomegaly</li>
<li>Macroglossia</li>
<li>Easy bruising/bleeding</li>
<li>Orthostasis</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Diagnosis:<ul>
<li>Need
    ALL
    4:
    ​​​​​​​<ul>
<li>Amyloid related systemic syndrome</li>
<li>Positive congo red staining on any tissue</li>
<li>Evidence that amyloid is light chain related</li>
<li>Evidence of monoclonal plasma cell disorder ​​​​​​​</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>POEMS Syndrome</p>
<ul>
<li>Unknown, possibly chronic overproduction of pro-inflammatory
    cytokines such as <strong>VEGF</strong></li>
<li>Features:
    P
    olyneuropathy, <strong>O</strong> rganomegaly, <strong>E</strong> ndocrinopathy, <strong>M</strong>
    onoclonal protein (usually
    λ
    light chain), <strong>S</strong> kin changes</li>
<li>Diagnosis:<ul>
<li>Mandatory Criteria
    ​​​​​​​<ul>
<li>Peripheral neuropathy</li>
<li>Monoclonal plasma cell disorder ​​​​​​​</li>
</ul>
</li>
<li>Major Criteria (need &#8531;)<ul>
<li>Osteosclerotic lesions, VEGF, Castleman disease</li>
</ul>
</li>
<li>​​​​​​​
    Minor Criteria (need &#8537;)<ul>
<li>​​​​​​​
    Organomegaly</li>
<li>Volume overload</li>
<li>Endocrinopathy</li>
<li>Skin changes</li>
<li>Papilledema</li>
<li>Thrombocytosis or polycythemia</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Castleman Disease</p>
<ul>
<li>Angiofollicular lymph node hyperplasia</li>
<li>Antibodies to HHV-8 implicated in &gt;50% of cases</li>
<li>Features
    : <strong>Lymphadenopathy</strong> , Fever, night sweats, fatigue, Fluid
    accumulation</li>
<li>Skin findings: violaceous Lymph node biopsy w/characteristic
    hematopathology papules</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-sickle-cell-crisis"><h1 id="hematology-oncology-hematologyoncology-sickle-cell-crisis-sickle-cell-crisis">Sickle Cell Crisis<a class="headerlink" href="#hematology-oncology-hematologyoncology-sickle-cell-crisis-sickle-cell-crisis" title="Permanent link">&para;</a></h1>
<p>S <span id="Sickle_cell"></span> ickle Cell Crisis – Michael J. Neuss</p>
<p>Background</p>
<ul>
<li>Present with severe pain in bone, joints, chest, abdomen</li>
<li>Causes: (
    HIDISC) <strong>H</strong> ypoxia, <strong>I</strong> schemia, <strong>D</strong> ehydration, <strong>I</strong>
    nfection, <strong>S</strong> tress, <strong>C</strong> old</li>
<li>Cant Miss:<ul>
<li>Acute
    chest: hypoxia + fever + chest pain + new infiltrate on CXR</li>
<li>PE (ACS less likely in these patients); avascular necrosis of
    hip, priapism, stroke</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Labs: LDH (high), Hgb/Hct (low; check vs baseline), retic, smear,
    WBC</li>
<li>If febrile: UA + Blood cultures</li>
<li>Send Hgb S level, and compare to baseline w/ other hospital
    admissions</li>
<li>Imaging: CXR, MRI for hip pain, Abdominal U/S or CT abdomen</li>
<li>Maintain active type and <em>cross</em> given probability of antibodies</li>
</ul>
<p>Management</p>
<p>General:</p>
<ul>
<li>Look for a care coordination yellow note in the Summary Tab<ul>
<li>Heme clinic will have specific management preferences for
    individual patients</li>
</ul>
</li>
<li>Maintain hydration, IVF at 150-200 cc/hr (if no contraindication)</li>
<li>Oxygen:
    goal sat ~95% (higher O2 goal will help to prevent further
    sickling!)</li>
<li>Continue folic acid 1 mg qDay</li>
<li>Continue hydroxyurea if uncomplicated pain crisis<ul>
<li>Hold if counts suppressed or concern for infection</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If in the MICU: consider discussion for plasma exchange (if Hgb SS
    or SC or S-Thal)</li>
<li>Transfuse: Simple transfusion if Hgb lower than baseline and/or
    complications<ul>
<li>Avoid transfusions when able, given risk of antibody formation</li>
</ul>
</li>
</ul>
<p>Pain:</p>
<ul>
<li>Will
    generally require opiates, likely initiation of PCA</li>
<li>All
    SS patients should have <strong>pain plans</strong> ; inpatient pain plans are in
    the <strong>problem list under sickle cell disease</strong> or in the <strong>care
    coordination</strong> section of Epic</li>
<li>Outpatient
    plans (to which you will transition pts back prior to discharge) are
    not standardized in location, but can be under Media (with a pain
    contract) or found in notes</li>
</ul>
<p>Acute</p>
<p>chest:</p>
<ul>
<li>Consult Hematology at time of admission</li>
<li>D5 &frac12; NS @ 150-250 cc/hr</li>
<li>Transfuse hgb to &gt;10</li>
<li>PCA w/ dilaudid</li>
<li>Abx for CAP (vs HAP if risk factors) ± bronchodilators</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-thrombocytopenia"><h1 id="hematology-oncology-hematologyoncology-thrombocytopenia-thrombocytopenia">Thrombocytopenia<a class="headerlink" href="#hematology-oncology-hematologyoncology-thrombocytopenia-thrombocytopenia" title="Permanent link">&para;</a></h1>
<p>Thrombocytopenia – Robert Dunn</p>
<p>Background</p>
<ul>
<li>Platelet
    count \&lt;150 k/µL (mild), 50-100 k/µL (moderate), \&lt;50 k/µL (severe)</li>
<li>Framework for differential: Platelet
    Consumption, sequestration, or destruction</li>
<li>Causes
    to consider:<ul>
<li>Can’t Miss Diagnoses: TTP, HUS, HELLP, DIC, HIT</li>
<li>Splenomegaly can represent: Plt sequestration, cirrhosis, portal
    hypertension</li>
<li>Drug-induced: (
    Antibiotics, heparin, chemo, GpIIb/IIIa antagonists,
    H2-antagonists)</li>
<li>Rheumatologic cause – SLE and sarcoidosis</li>
<li>Sepsis, independent of DIC</li>
<li>Immune thrombocytopenia (ITP) is a diagnosis of exclusion</li>
<li>Massive physiologic consumption: large hematoma, active
    hemorrhage</li>
<li>Cirrhosis – results in low thrombopoietin (TPO)</li>
<li>Chronic alcohol use – direct marrow suppression</li>
<li>Infections: HIV, HCV, EBV, Parvovirus, Rickettsia, H. pylori</li>
<li>Bone marrow failure: aplastic anemia, MDS, leukemia,
    chemotherapy</li>
<li>Dilutional: fluid resuscitation and massive transfusion</li>
<li>Platelet clumping (lab artifact)</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Petechiae
    (lower legs typical site; in mouth = wet purpura)</li>
<li>Overt bleeding,
    mucosal bleeding, epistaxis (seen when \&lt;20 k/µL ),
    Splenomegaly</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CMP, CBC w/diff, peripheral smear, citrated platelet count, immature
    patelet fraction (IPF)</li>
<li>LDH, Fibrinogen, PT/aPTT</li>
<li>Determine timing of decline<ul>
<li>Look
    at other cell lines - never normal to have two cytopenia’s</li>
<li>Review
    recent initiation of drugs: (heparin, antibiotics, and
    chemotherapy)</li>
</ul>
</li>
<li>Consider abdominal ultrasound to look for splenomegaly and liver
    pathology</li>
<li>Infectious work up (HIV, HCV)</li>
<li>Calculate 4T Score and consider your pretest probability for HIT
    testing<ul>
<li>HIT
    Ab: ELISA is first test – only run once/day at VUMC so order
    early if considering</li>
<li>Reflex Serotonin release assay (SRA) for confirmation</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Plt
    \&lt;50k<ul>
<li>Discontinue pharmacologic DVT prophylaxis</li>
<li>If on anticoagulation
    : consider risk/benefits of continued anticoagulation<ul>
<li>Can
    transfuse plt’s if AC is mandatory</li>
</ul>
</li>
</ul>
</li>
<li>Plt
    \&lt;10k<ul>
<li>Transfuse
    platelets given risk of spontaneous intracranial hemorrhage</li>
<li>In pt’s with HIT or TTP, there is theoretical concern that
    transfusing plt can “fuel the fire”
    and lead to more thrombosis<ul>
<li>Therefore,
    bleeding with HIT or TTP, discuss with Hematology before
    transfusion</li>
</ul>
</li>
</ul>
</li>
<li>HIT<ul>
<li>If pretest probability is high or HIT is confirmed</li>
<li>Stop Unfractionated and low molecular weight heparin products</li>
<li>Start Argatroban gtt</li>
</ul>
</li>
<li>If schistocytes present on peripheral smear = TTP<ul>
<li>Contact Nephrology and Hematology for PLEX</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Clumping on lab draws:<ul>
<li>Obtain Citrated platelet (“blue top” tube – CPRS refers to it as
    a blue top platelet count)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If
    no
    resolution, obtain a "Gold top" LAB 301 in Epic (Named: Plt count)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-transfusion-medicine"><h1 id="hematology-oncology-hematologyoncology-transfusion-medicine-transfusion-medicine">Transfusion Medicine<a class="headerlink" href="#hematology-oncology-hematologyoncology-transfusion-medicine-transfusion-medicine" title="Permanent link">&para;</a></h1>
<p>Transfusion Medicine – R. Dixon Dorand</p>
<p>VUMC: search “Blood” and select General Blood Administration – follow
prompts</p>
<p>For emergent transfusions, call the blood bank (615-322-2233)</p>
<ul>
<li>RNs on 10T and 11N can follow transfusion protocols for pRBCs and
    Plts – enter as a Nursing Communication or as part of the
    Hematology/Oncology Admission Order set.</li>
<li>Nurses will NOT check post-transfusion levels unless you specify to
    do so; this is only needed in specific scenarios (e.g. “platelet
    refractoriness”)</li>
<li>At VUMC, all special processing of blood products (such as
    irradiation) will be decided by blood bank based on special
    considerations listed in order set. Examples include: stem cell
    transplant, hematologic malignancy, or thalassemia</li>
<li>Patients with
    frequent transfusions (e.g. sickle cell hemoglobinopathy) should
    have an RBC Extended Phenotype ordered (once) for minor RBC antigens
    to avoid immunization and antibody development to these proteins</li>
<li>You may ask the VUMC hematology lab to email you pictures of the
    peripheral smear</li>
</ul>
<p>VA: Orders Tab – Blood Bank Orders – follow prompts to select
appropriate product. Must order both the blood product AND the
transfusion order (“Transfuse blood”)</p>
<ul>
<li>You need to specify all special processing such as irradiation</li>
<li>To order a Type &amp; Screen as a lab, you must go to Blood Bank Orders</li>
<li>Type &amp; Screen and Transfusion results are under the Blood tab in
    Results</li>
</ul>
<p>Remember:</p>
<ul>
<li>You must send Type and Screen &amp; consent the patient</li>
<li>To consent at VUMC, use Medex. To consent at the VA, use iMedConsent</li>
<li>On Brittingham or BMT, all blood products must be irradiated. This
    will happen at VUMC if you
    select the right indication for blood; at the VA you must still
    specify this.</li>
</ul>
<p>Red Blood Cell Transfusion</p>
<ul>
<li>Volume
    200-300 mL per unit prbc</li>
<li>In general, 1 unit of packed RBCs increases Hgb by 1g/dL and hct by
    ~3%</li>
<li>Assessment
    of the post-transfusion Hgb can be performed 15 min following
    transfusion, but ideally 1 hour after completion</li>
</ul>
<p>Indications:</p>
<ul>
<li>Hgb \&lt;9-10 g/dL – Acute coronary syndrome</li>
<li>Hgb \&lt;8 g/dL or Hct \&lt;25 – Bone marrow failure or receiving
    antineoplastic therapy<ul>
<li>Also
    sometimes
    used in pts with pre-existing CAD</li>
</ul>
</li>
<li>Hgb \&lt;7 g/
    dL or Hct \&lt;21 – ICU, GI Bleeding, Oncology patient on Treatment</li>
</ul>
<p>Indications for Platelets</p>
<ul>
<li>\&lt;11 k/µL – all patients, reduce risk of spontaneous hemorrhage (use
    on BMT, Brittingham)</li>
<li>\&lt;20 k/µL – patients receiving induction chemotherapy with a fever</li>
<li>\&lt;50 k/µL – active bleeding, scheduled to undergo select invasive
    procedure</li>
<li>\&lt;100 k/µL – CNS hemorrhage, intrathecal catheter<ul>
<li>This is also the threshold used for most Neurosurgical
    procedures</li>
</ul>
</li>
</ul>
<p>Fresh Frozen Plasma (FFP) &amp; Cryoprecipitate (Cryo)</p>
<p>Cryoprecipitate: FFP enriched for von Willebrand factor, factor VIII,
factor XIII, and fibrinogen</p>
<p>FFP:</p>
<ul>
<li>Once thawed, must be used in 24 hrs (due to decline in labile
    coagulation factors)</li>
<li>Must be ABO compatible but not crossmatched or Rh typing</li>
<li>Only administer FFP if INR ≥1.7 (FFP will not fix an INR \&lt; 1.7)</li>
</ul>
<p>Indications for transfusion:</p>
<p>- Bleeding:</p>
<ul>
<li>FFP If INR &gt;1.7</li>
<li>Cryoprecipitate if fibrinogen \&lt;100.</li>
</ul>
<p>- DIC:</p>
<ul>
<li>Fibrinogen \&lt;100: Transfuse 5 – 10 units cryoprecipitate and repeat
    fibrinogen. If bleeding, consider raising transfusion threshold of
    cryoprecipitate to fibrinogen \&lt;150</li>
<li>For
    elevated INR, consider FFP transfusion. Thresholds for doing this
    vary by attending</li>
</ul>
<p>- Cirrhosis <strong>:</strong></p>
<ul>
<li>General concept: PT/INR, aPTT are unreliable markers for bleeding.
    Fibrinogen ≤100 – 120 or thromboelastography are better surrogates
    for bleeding risk</li>
<li>Transfuse fibrinogen ≤100 – 120 if the patient is actively bleeding
    or about to undergo a procedure or surgery other than paracentesis</li>
<li>Transfuse FFP based on hepatology team preference (generally few
    indications for FFP)</li>
</ul>
<p>Transfusion Premedication &amp; Reactions</p>
<ul>
<li>If you are concerned about a serious transfusion reaction, pause the
    transfusion and contact the blood bank asap</li>
<li>Order the transfusion reaction blood testing in Epic. You will send
    a CBC, the bag of blood products, and the completed form to the
    blood bank for analysis</li>
</ul>
<p>Premedication:</p>
<ul>
<li>Only
    if history of severe reaction<ul>
<li>Diphenhydramine 25-50mg IV</li>
<li>Acetaminophen 650 mg PO</li>
<li>Meperidine
    25-50 mg IV (optional for chills)</li>
<li>Hydrocortisone 50 mg IV (optional, for severe reactions or
    reactions despite acetaminophen and diphenhydramine)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction</td>
<td>Signs &amp; Symptoms</td>
<td>Etiology</td>
<td>Clinical Action</td>
</tr>
<tr>
<td>Allergic (mild)</td>
<td>Pruritus, hives limited to small area</td>
<td>Antibodies to transfused plasma proteins</td>
<td>Pause transfusion. Administer antihistamines. Resume transfusion if improved; NO samples necessary. If no improvement in 30 min treat as moderate to severe.</td>
</tr>
<tr>
<td>Allergic (moderate to severe)</td>
<td>Generalized hives (&gt;&#8532; body surface), bronchospasm &amp; dyspnea, abdominal pain, hypotension, nausea, anaphylaxis</td>
<td>Antibodies to transfused plasma proteins usually IgE but can also be IgA, Possible allergen in blood product</td>
<td>Administer antihistamines, epinephrine, vasopressors and corticosteroids as needed. Send product to blood bank.</td>
</tr>
<tr>
<td>Febrile Non-Hemolytic</td>
<td>Rise of temp >1°C, chills, rigors, anxiety.</td>
<td>Cytokines released from residual white blood cells in the blood product</td>
<td>Mild: administer antipyretics as needed</td>
</tr>
<tr>
<td>Acute Hemolytic</td>
<td>Hemoglobinemia / uria, fever, chills, anxiety, shock, flank pain, chest pain, unexplained bleeding, cardiac arrest</td>
<td>Intravascular hemolysis usually due to ABO incompatibility; Recheck for patient ID or clinical error. This is an emergency.</td>
<td>Treat shock w/vasopressors; maintain airway; administer fluids and maintain brisk diuresis; monitor for AKI. If DIC present, consider heparin. Administer blood products as needed after etiology is clear.</td>
</tr>
<tr>
<td>Septic</td>
<td>Rise of temp > 2°C, sudden hypotension or hypertension, shock</td>
<td>Micro-organism (i.e. bacteria) in donor bag (Greater risk in apheresis vs. RBC)</td>
<td>Send bag/tubing to transfusion medicine. Order BCx. Broad spectrum abx Pressor support if necessary.</td>
</tr>
<tr>
<td>TRALI – Transfusion Related Acute Lung Injury</td>
<td>Acute respiratory distress usually within 1-2 hours of transfusion. Non-cardiogenic pulmonary edema unresponsive to diuretics; Dx of exclusion.</td>
<td>Usually donor HLA antibodies from transfused plasma. Recipient has corresponding antigens; causes neutrophil activation that results in extravasation of fluid into air spaces</td>
<td>Respiratory support! Most will resolve within 24-96 hours. Steroids, diuretics: no known benefit.</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Hematology oncology</h1>
                        <h1 class='nav-section-title' id='section-hepatology'>
                            Hepatology <a class='headerlink' href='#section-hepatology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hepatology-hepatology-acute-hepatitis-and-abnormal-liver-tests"><h1 id="hepatology-hepatology-acute-hepatitis-and-abnormal-liver-tests-acute-hepatitis-and-abnormal-liver-tests">Acute Hepatitis and Abnormal Liver Tests<a class="headerlink" href="#hepatology-hepatology-acute-hepatitis-and-abnormal-liver-tests-acute-hepatitis-and-abnormal-liver-tests" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approach to Acute Liver Injury – Jacob Parnell</td>
</tr>
</tbody>
</table>
<p>Backgroun</p>
<p>d</p>
<ul>
<li>Acute liver injury (ALI) = elevated aminotransferases + INR &gt;1.5 but
    NO hepatic encephalopathy
    (HE indicates acute liver failure; see below)</li>
<li>Alcoholic hepatitis (AH), though similar, is considered a separate
    process</li>
<li>The primary abnormality in congestive hepatopathy is
    hyperbilirubinemia, with mild elevations of AST/ALT or alkaline
    phosphatase though has a variable presentation</li>
<li>R-factor
    <strong>= (ALT/uln ALT) / (ALP/uln ALP)</strong> ;  Objectively differentiates
    patterns below<ul>
<li>R &gt; 5 = hepatocellular injury;   R\&lt;2 = cholestatic injury;   R
    2-5 = mixed injury</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular Injury: R factor > 5 (Primary elevation of AST/ALT)</td>
<td>Hepatocellular Injury: R factor > 5 (Primary elevation of AST/ALT)</td>
<td>Hepatocellular Injury: R factor > 5 (Primary elevation of AST/ALT)</td>
</tr>
<tr>
<td>Acute Viral Hepatitis</td>
<td>Hep A<span class="arithmatex">\(, B\*\)</span>, C*, D, E EBV, CMV, HSV, VZV</td>
<td>Viral serologies; (Hep A panel, Hep B panel, Hep C Ig, EBV Ig, CMV PCR, IgM, IgG); hx of tattoos, IVDU, piercings, blood transfusion prior to 1990s, intranasal cocaine use and mass vaccinations (in 3<sup>rd</sup> world countries)</td>
</tr>
<tr>
<td>Acetaminophen intoxication$</td>
<td>NaN</td>
<td>Acetaminophen lvl Aspirin lvl</td>
</tr>
<tr>
<td>NASH – Non-alcoholic steatohepatitis*</td>
<td>Fatty infiltration of liver</td>
<td>ALT&gt;AST; metabolic syndrome; rarely acute always \&lt;400</td>
</tr>
<tr>
<td>Autoimmune hepatitis*</td>
<td>Autoantibodies and high serum globulins</td>
<td>Anti-smooth muscle (f-actin), ANA, ANCA, anti-liver/kidney microsomes soluble liver-pancreas IgG</td>
</tr>
<tr>
<td>Toxins</td>
<td>Ethanol, cocaine, mushroom</td>
<td>UDS, ethanol level, Peth lvl, AST&gt;ALT in 2:1 ratio- suspect alcohol (\&lt;400 or even 300 per ACG)</td>
</tr>
<tr>
<td>DILI – Drug Induced Liver Injury*$</td>
<td>Many drugs</td>
<td>Common: antibiotics (eg beta-lactams, quinolones, others), NSAIDs, anti-epileptics, macrolides, isoniazid, SSRIs *Query NIH Liver Tox database: <a href="https://www.livertox.nih.gov">https://www.livertox.nih.gov</a></td>
</tr>
<tr>
<td>Ischemic Liver Injury (Shock Liver)$</td>
<td>hemorrhage, sepsis</td>
<td>AST > ALT, high LDH, history of hypotension</td>
</tr>
<tr>
<td>HELLP Syndrome, Acute Fatty Liver of Pregnancy</td>
<td>Pregnancy</td>
<td>Pregnancy testing; urgent delivery</td>
</tr>
<tr>
<td>Wilson’s Disease*</td>
<td>Copper overload</td>
<td>Ceruloplasmin level (screening), 24h urine copper (confirmation), quantitative copper on liver biopsy</td>
</tr>
<tr>
<td>Hemochromatosis*</td>
<td>Iron overload</td>
<td>Ferritin, iron level; does not cause acute liver injury, usually mild to moderate chronic elevation. HFE testing for confirmation of main types</td>
</tr>
<tr>
<td>Alpha-1-antitrypsin deficiency*</td>
<td>-</td>
<td>AAT phenotype, only acute in children</td>
</tr>
<tr>
<td>Budd-Chiari Syndrome*</td>
<td>Hepatic vein obstruction</td>
<td>Ultrasound of abdomen w/ doppler, CT w/ contrast</td>
</tr>
<tr>
<td>Portal vein thrombosis*</td>
<td>-</td>
<td>Ultrasound of abdomen w/ doppler, CT w/ contrast, MRI</td>
</tr>
</tbody>
</table>
<p>*May present as chronic liver injury as well <sup>$</sup> May present
with AST/ALT >1000</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholestatic Injury: R Factor \&lt; 2 (Primarily elevated Alkaline phosphatase)</td>
<td>Cholestatic Injury: R Factor \&lt; 2 (Primarily elevated Alkaline phosphatase)</td>
<td>Cholestatic Injury: R Factor \&lt; 2 (Primarily elevated Alkaline phosphatase)</td>
</tr>
<tr>
<td>Acute biliary obstruction</td>
<td>Gallstones</td>
<td>abdominal ultrasound, MRCP, ERCP</td>
</tr>
<tr>
<td>Primary Sclerosing Cholangitis*</td>
<td>Autoimmune, associated with IBD</td>
<td>MRCP, ERCP</td>
</tr>
<tr>
<td>Primary Biliary Cirrhosis*</td>
<td>Autoimmune</td>
<td>Anti-mitochondrial antibody</td>
</tr>
<tr>
<td>DILI – Drug-induced liver injury*$</td>
<td>Many drugs, consult livertox website</td>
<td>Common: Augmentin, Bactrim, amiodarone, Imuran</td>
</tr>
<tr>
<td>Malignancy*</td>
<td>Pancreas, cholangiocarcinoma</td>
<td>CT abdomen, ERCP</td>
</tr>
</tbody>
</table>
<p>*May present as chronic liver injury <sup>$</sup> May present with
AST/ALT >1000</p>
<p>Isolated Hyperbilirubinemia:</p>
<ul>
<li>Differentiate direct vs indirect bilirubin<ul>
<li>Direct bilirubin, refer to cholestatic</li>
<li>Indirect: Gilbert versus hemolysis (send LDH, haptoglobin, retic
    count, peripheral smear)</li>
</ul>
</li>
</ul>
<p>Consider non-hepatic causes of elevated liver chemistries</p>
<ul>
<li>Thyroid disorder</li>
<li>Celiac disease</li>
<li>Tick-borne infection</li>
<li>Rhabdomyolysis, hemolysis (AST&gt;>ALT)</li>
</ul></section><section class="print-page" id="hepatology-hepatology-acute-liver-failure"><h1 id="hepatology-hepatology-acute-liver-failure-acute-liver-failure">Acute Liver Failure<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-acute-liver-failure" title="Permanent link">&para;</a></h1>
<p>Acute Liver Failure  (ALF)– Judd Heideman , Hannah Lomzenski</p>
<p>Background</p>
<ul>
<li>Elevated aminotransferases</li>
<li>INR
    ≥
    1.5</li>
<li>Hepatic encephalopathy/altered mental status</li>
<li>Timing/onset
    \&lt; 28 weeks (otherwi
    se consider acute-on-chronic liver failure/cirrhosis)</li>
<li>Acute liver injury (ALI) = elevated aminotransferases + INR &gt;1.5 but
    NO hepatic encephalopathy (see above)</li>
<li>Pts with acute presentation of chronic autoimmune hepatitis,
    hepatitis B infection, Wilson disease, and Budd-Chiari syndrome are
    considered to have ALF if they develop HE, despite the presence of a
    pre-existing liver disease in the context of appropriate
    abnormalities in liver blood tests and coagulation profile</li>
<li>For DILI, consider recently added medications</li>
<li>Drugs Associated with DILI (search LiverTox database for the pts
    meds and likelihood of DILI)<ul>
<li>Hepatocellular pattern
    : acarbose,
    Acetaminophen, Allopurinol, Amiodarone, Baclofen, Bupropion,
    Fluoxetine, HAART (Nevirapine), Kava kava, Isoniazid,
    Ketoconazole, Lisinopril, Losartan, Methotrexate, NSAIDs,
    Omeprazole, Oxacillin/Nafcillin, Paroxetine, Pyrazinamide,
    Propylthiouracil, Rifampin, Risperidone, Sertraline, Statins,
    Tetracycline, Trazodone, Valproic Acid</li>
<li>Mixed pattern
    : Amitriptyline,
    Azathioprine, Captopril, Carbamazepine, Clindamycin,
    Cyproheptadine, Enalapril, Flutemide, Nitrofurantoin,
    Phenobarbital, Phenytoin, Sulfonamides, Trazodone, Verapamil</li>
<li>Cholestatic
    <strong>pattern</strong> : Amoxicillin-clavulanic acid,
    Anabolic steroids, Chlorpromazine, Clopidogrel, Oral
    contraceptives, Erythromycins, Estrogens, Irbesartan,
    Mirtazapine, Phenothiazines, Terbinafine, Tricyclics</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Etiologies of Acute Liver Failure</td>
<td>Common Etiologies of Acute Liver Failure</td>
<td>Common Etiologies of Acute Liver Failure</td>
</tr>
<tr>
<td>Acetaminophen (most common in US)</td>
<td>DILI (see DILI chart below)</td>
<td>Viral Hepatitis (most common worldwide): HAV, HBV, HEV</td>
</tr>
<tr>
<td>Autoimmune Hepatitis</td>
<td>Ischemia (Shock Liver)</td>
<td>Budd Chiari</td>
</tr>
<tr>
<td>Wilson Disease</td>
<td>Malignant Infiltration</td>
<td>Sepsis</td>
</tr>
<tr>
<td>Mushroom (Amanita phalloides) poisoning</td>
<td>Acute fatty liver of pregnancy or HELLP</td>
<td>Heat stroke (can be seen w/MDMA use)</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Consult hepatology early! (assist with workup AND for transplant
    evaluation)</li>
<li>Labs:<ul>
<li>CBC w/diff, CMP, Mg, Phos, T&amp;S, BCx, UCx</li>
<li>PT/INR, aPTT, Fibrinogen (to assess for DIC/coagulopathy)</li>
<li>Amylase, lipase (to look for complications of ALF like
    pancreatitis)</li>
<li>Acetaminophen level (needs to be drawn at least 4hrs after last
    known ingestion)</li>
<li>Salicylate level, UDS</li>
<li>Viral Hepatitis Serologies</li>
<li>HAV IgM  (“Hepatitis A Pnl”), HBV sAg, sAb, cIgM (all in
    “Hepatitis B Panel”), HCV IgG (“Hepatitis C IgG”; consider PCR
    Qt if HCV IgG positive), Hepatitis D if known HBV (Misc
    Reference Test), Hepatitis E if travel to southeast Asia or
    pregnant (“Hepatitis E IgM- ARUP”)</li>
<li>EBV Qt, CMV Qt, HSV &frac12; Qt, VZV IgM/IgG</li>
<li>Beta-hCG for females of childbearing age</li>
<li>ANA, ASMA</li>
<li>Anti-LKM-1 Ab associated with more indolent autoimmune
    hepatitis/chronic liver disease (type 2 autoimmune hepatitis)
    and generally does not cause ALF</li>
<li>ABG with arterial lactate, ammonia</li>
<li>Arterial ammonia &gt;124 predicts mortality and CNS complications
    (e.g., need for intubation, seizures, cerebral edema)</li>
<li>HIV p24 Ag and HIV &frac12; Ab</li>
</ul>
</li>
<li>Imaging:<ul>
<li>RUQ abdominal ultrasound <strong>with doppler</strong> (important to assess
    vasculature!)</li>
<li>Consider CT with contrast in patients with normal renal function
    and high suspicion of Budd-Chiari syndrome or malignancy with
    negative ultrasound  (better for assessing the hepatic veins)
    and helps with transplant evaluation</li>
<li>Consider TTE to rule out cardiac dysfunction; helpful for
    transplant consideration</li>
</ul>
</li>
</ul>
<p>Criteria for Transplantation:</p>
<ul>
<li>King’s College criteria:
    helps identify patients needing transplant referral/consideration<ul>
<li>ALF due to acetaminophen:<ul>
<li>Arterial pH \&lt;7.3 after resuscitation and &gt;24 hr since
    ingestion, OR</li>
<li>Lactate &gt;3, OR</li>
<li>HE &gt; grade 3, SCr &gt;3.4, <strong>and</strong> INR &gt;6.5</li>
</ul>
</li>
</ul>
</li>
<li>ALF not due to acetaminophen: INR &gt; 6.5 OR 3 of the 5 following
    criteria:<ul>
<li>Indeterminate etiology, drug-induced hepatitis</li>
<li>Age \&lt;10 or &gt;40</li>
<li>Interval of jaundice to encephalopathy &gt;7 days</li>
<li>Bilirubin &gt; 3 or INR &gt;3.5</li>
</ul>
</li>
<li>No role for MELD-Na in acute liver failure</li>
</ul>
<p>Management</p>
<ul>
<li>Any pt with concern for ALF should be cared for in MICU</li>
<li>Pts with ALF die acutely from hypoglycemia, cerebral edema, and
    infection</li>
<li>ABC’s:<ul>
<li>Intubate for GCS \&lt;8, Grade 3 or 4 HE</li>
<li>IVF resuscitation with isotonic crystalloid (most pts are volume
    deplete; avoid hypotonic fluids due to risk of cerebral edema)</li>
<li>Vasopressive agents for persistent hypotension (norepinephrine
    preferred)</li>
</ul>
</li>
<li>Monitoring:<ul>
<li>Q1-2h neuro checks, Q1-2h glucose checks</li>
<li>Q8h INR (no mortality benefit from empiric FFP/coag products)</li>
<li>BID BMP, daily Mg, P</li>
<li>Daily Hepatic Function Panel (generally no need for more
    frequent trending)</li>
</ul>
</li>
<li>Treatment of Primary Injury<ul>
<li>IV N-acetylcysteine - improves transplant-free survival even in
    patients WITHOUT acetaminophen induced acute liver failure<ul>
<li>Initial loading dose = 150mg/kg over 1 hour, then 50mg/kg/hr
    for 4 hours, then 100mg/kg/hr for 16 hours ​​​​​​​</li>
<li>Patients with early stage hepatic encephalopathy (grade
    I/II) have increased transplant free survival, while those
    with grade III/IV do not</li>
</ul>
</li>
<li>See below for etiology-specific treatment; hepatology consult
    for LT eval</li>
<li>Early toxicology consultation if suspected ingestion/overdose<ul>
<li>For acute management contact Poison Control <strong>800-222-1222</strong></li>
</ul>
</li>
</ul>
</li>
<li>Treatment of Secondary Complications<ul>
<li>Infection: abx only if progressing HE, signs of infection, or
    development of SIRS; ppx abx do not reduce mortality</li>
<li>Cerebral edema/increased ICP:  elevated HOB to 30 degrees, quiet
    and dimly lit room, minimize IVF, goal Na 145-155,
    hyperventilation if concern for impending herniation. Consider
    3% saline (500mL) and/or mannitol (1g/kg, 20%) for pt at highest
    risk (serum ammonia &gt;150, grade III/IV HE, ARF, vasopressor
    support</li>
<li>Seizures: phenytoin (no evidence to support seizure ppx)</li>
<li>Renal Failure: early CRRT if persistent Metabolic Acidosis,
    Volume Overload, Hyperammonemia, falling UOP</li>
<li>Coagulopathy: IV Vit K; products for invasive procedures or
    active bleeding only</li>
</ul>
</li>
<li>Additional Supportive Care<ul>
<li>PPI for bleeding ppx</li>
<li>Enteral nutrition within 2-3 days; avoid TPN if possible; avoid
    NG feeds if progressive HE; NG should only be placed w/
    intubation as gagging increases ICP</li>
<li>Avoid sedation as able; if sedation required, prefer propofol
    for better neuro exams to evaluate encephalopathy</li>
<li>Lactulose possibly helpful in the early stages of encephalopathy</li>
</ul>
</li>
</ul>
<p>Specific Management by Etiology:</p>
<ul>
<li>Acetaminophen – IV N-acetylcysteine per protocol, look up
    Rumack-Mattew Nomogram and consult with tox; ideally, start NAC \&lt;8
    hours after ingestion for best results (hepatotoxicity develops 12
    hours post-ingestion)<ul>
<li>Search “N-acetylcysteine” and select order set “Acetaminophen
    overdose”</li>
<li>Plan for serial acetaminophen level, INR, LFTs to be drawn 2
    hours before the end of each N-acetylcysteine bag</li>
</ul>
</li>
<li>Amanita phalloides
    – PO charcoal, IV penicillin, IV acetylcysteine</li>
<li>AFLP/HELLP – delivery</li>
<li>Autoimmune – IV steroids following approval by hepatology.
    Azathioprine generally deferred until cholestasis resolved</li>
<li>HAV/HEV – supportive care</li>
<li>HBV – nucleoside analogue; orthotopic liver transplant</li>
<li>HCV – consider treatment if no viral clearance</li>
<li>Budd-Chiari – anticoagulation, consider stent before TIPS</li>
<li>HSV – acyclovir</li>
<li>Wilson’s – plasma exchange; orthotopic liver transplant</li>
</ul>
<p>Additional Information</p>
<p>Prognosis:</p>
<ul>
<li>Hyperacute (\&lt;7 days) = better prognosis<ul>
<li>Cerebral edema common</li>
</ul>
</li>
<li>Subacute (\&lt;28 days) = poorer prognosis<ul>
<li>Renal failure, portal hypertension more common</li>
</ul>
</li>
<li>By Etiology:<ul>
<li>Acetaminophen: 60% survival without transplant (100% if NAC
    started within 16 hrs)</li>
<li>Other drug related injury: 30% survival without transplant</li>
<li>Hepatitis A: 60% survival without transplant</li>
<li>Acute Hepatitis B: 25% survival without transplant</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-alcoholic-hepatitis"><h1 id="hepatology-hepatology-alcoholic-hepatitis-alcoholic-hepatitis">Alcoholic Hepatitis<a class="headerlink" href="#hepatology-hepatology-alcoholic-hepatitis-alcoholic-hepatitis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcoholic Hepatitis – Alex Wiles, Julie Cui</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>
<p>Acute onset of rapidly progressive jaundice in pt with heavy EtOH
    intake (&gt;40g in females or &gt;60g in males EtOH/day for &gt;6 mos, or
    within \&lt;60 days of abstinence).</p>
<ul>
<li>
<p>-</p>
</li>
<li>
<p>May present after they have quit drinking due to
    immunosuppressive effects of alcohol.</p>
</li>
<li>
<p>20-50% Mortality in hospitalized AH pts</p>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>AST &gt;60, AST/ALT &gt;1.5, both values \&lt;400 IU/L; TBili &gt;3.0 mg/dL,
    documentation of heavy EtOH use until 8 weeks prior to presentation</li>
<li>Prognostication with Maddrey’s Discriminant Function: 4.6 * (PT
    <sub>pt</sub> – PT <sub>ctrl</sub> ) + Tbili<ul>
<li>Maddrey
    >
    32 = poor 30d prognosis &amp; may benefit from steroids (see below)</li>
</ul>
</li>
<li>RUQ to rule out obstructive cause of jaundice</li>
<li>Biopsy is not typically required but will show neutrophilic lobular
    inflammation, hepatocyte ballooning, steatosis, and pericellular
    fibrosis.</li>
<li>Phosphatidylethanol (PEth) level is a biomarker of ethanol
    consumption over ~ 4wks; &gt;20 ng/mL can indicate chronic
    moderate/heavy alcohol intake<ul>
<li>A single episode consumption can result in detectable Peth for
    up to 12 days. Can be elevated for months with regular heavy
    alcohol intake.</li>
<li>In some studies, 99% sensitive and specific for alcoholism.</li>
<li>EtOH levels may be negative unless acutely intoxicated</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Supportive Care is essential! Consult Nutrition, start High protein,
    high calorie diet, high dose Thiamine x 3d, Folate, MVI</li>
<li>Full infection workup (CXR, UA, BCx, paracentesis) regardless of sxs</li>
<li>Steroids:
    STOP-AH Trial (NEJM 2015) showed improved mortality at 28 days but
    not at 90 days in patients with Maddrey <u>></u> 32 who received
    steroids; the decision to treat is very nuanced and should be
    discussed with hepatology attending<ul>
<li>Contraindications to steroids include: presence of infection
    (must rule out first
    including TB, uncontrolled GI bleeding, AKI w/ Cr &gt;2.5 mg/dL)
    ​​​​​​​</li>
<li>Prednisolone 40mg daily for pts who meet above criteria (2018
    ACG Guidelines)</li>
<li>The Lille score can be used to guide continuation or d/c  of
    steroids after 7 d of therapy</li>
<li>NAC can be considered as adjunctive therapy to steroids and may
    decrease 30-day mortality, though has not demonstrated longer
    mortality benefit at 3 nor 6 months</li>
<li>Recent analysis from STOP AH data has demonstrated that pts with
    neutrophil to lymphocyte ratio (NLR) 5-8 prior to steroids most
    likely to benefit from steroids</li>
</ul>
</li>
<li>Monitor on CIWA<ul>
<li>Psychiatry consultation as appropriate, consideration of medical
    therapy<ul>
<li>Disulfiram and naltrexone are both metabolized by the liver
    and can cause hepatic toxicity and therefore are not used in
    this population</li>
<li>Baclofen has been shown to improve alcohol abstinence in pts
    with EtOH cirrhosis</li>
<li>Acamprosate has not been studied in this population but can
    be considered</li>
<li>Gabapentin has also demonstrated efficacy and can be given
    up to 1200mg for AUD</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Liver transplantation</p>
<ul>
<li>Current VUMC policy: pts should be abstinent for no less than 3-6
    months, although exceptions may be made for early liver transplant
    based on a very strict protocol<ul>
<li>Sustained Alcohol use post- Liver Transplant (SALT) score
    ≤
    6<ul>
<li>+4 points if &gt;10 drinks/day at initial hospitalization</li>
<li>+4 points if multiple prior rehab attempts</li>
<li>+2 points if prior alcohol related legal issues</li>
<li>+1 points if prior illicit substance abuse</li>
</ul>
</li>
</ul>
</li>
<li>“Exceptions:”
    Severe AH as first liver-decompensating event in patients who are
    not expected to survive to complete treatment<ul>
<li>Presence of strong sober social support</li>
<li>Absence of severe uncontrolled coexisting psychiatric disorders</li>
<li>Agreement by patient and family to adhere therapy and lifelong
    abstinence</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-ascites"><h1 id="hepatology-hepatology-ascites-ascites">Ascites<a class="headerlink" href="#hepatology-hepatology-ascites-ascites" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascites and Hepatic Hydrothorax – Lauren Evers Carlini, Thomas Strobel</td>
</tr>
<tr>
<td>Ascites</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>US ~80% due to cirrhosis and associated portal hypertension</li>
<li>Less common causes: peritoneal or metastatic cancer, heart failure,
    tuberculosis, nephrotic syndrome, Budd-Chiari, sinusoidal
    obstructive syndrome (S.O.S), or complications from procedures and
    pancreatitis</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>Definition</td>
<td>Treatment</td>
</tr>
<tr>
<td>Grade 1 Ascites</td>
<td>Only seen on imaging</td>
<td>2g Na restriction</td>
</tr>
<tr>
<td>Grade 2 Ascites</td>
<td>Moderate, symmetric abdominal distension</td>
<td>2g Na restriction, diuretics</td>
</tr>
<tr>
<td>Grade 3 Ascites</td>
<td>Marked, tense abdominal distension</td>
<td>LVP + Na restriction, diuretics (unless refractory)</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Bedside ultrasound on admission to confirm presence of ascites</li>
<li>Diagnostic paracentesis in all pts with ascites on admission mainly
    to rule out occult SBP<ul>
<li>Initial paracentesis or when cause of ascites is uncertain:
    Total Protein, serum and BF Albumin, cell count w/diff, culture</li>
<li>Subsequent/Serial paracenteses: cell count w/diff, culture,
    protein</li>
<li>Always inoculate culture bottles at bedside (aerobic, then
    anaerobic)! Use luer-lock syringe and vacutainer, then hand
    deliver samples to 4 <sup>th</sup> floor lab to ensure
    proper/timely delivery</li>
</ul>
</li>
<li>There is no guideline for INR cutoff for paracentesis, although our
    procedure team often looks for INR \&lt; 3.5 (IR usually doesn’t care
    about INR)</li>
<li>Serum-ascites albumin gradient (SAAG
    ) = serum albumin - ascites albumin. SAAG ≥ 1.1 accurately predicts
    portal hypertension, but this may be due to either cardiac or
    hepatic causes which can be further evaluated with total protein in
    the ascites:</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Protein Ascites (not serum)</td>
<td>SAAG > 1.1 g/dL (Portal HTN )</td>
<td>SAAG \&lt; 1.1 g/dL (Non-portal HTN )</td>
</tr>
<tr>
<td>\&lt; 2.5 g/dL</td>
<td>Cirrhosis</td>
<td>Nephrotic Syndrome Myxedema</td>
</tr>
<tr>
<td>> 2.5 g/dL</td>
<td>Post-hepatic portal HTN: Cardiac Ascites Budd-Chiari</td>
<td>Malignant Ascites Pancreatic Ascites TB</td>
</tr>
</tbody>
</table>
<ul>
<li>Calculate PMNs from fluid: Total nucleated cells x percent
    neutrophils<ul>
<li>If ≥&gt; 250, diagnostic of SBP in cirrhosis</li>
</ul>
</li>
<li>Correction for RBCs: For every 250 RBCs in fluid, subtract 1 PMN</li>
<li>Other tests:<ul>
<li>
<ul>
<li>Triglycerides: if fluid is milky</li>
<li>Cytology: if very concerned for peritoneal carcinomatosis.
    May need up to 3 separate samples (50ml or more) to be able
    to detect malignant cells</li>
<li>ADA: if concern for peritoneal TB</li>
<li>Hematocrit: For bloody appearing fluid (not just
    serosanguinous) to rule out hemoperitoneum. There needs to
    be a recent serum HCT for comparison.</li>
<li>Amylase: If concerned for pancreatic ascites</li>
<li>Glucose, LDH if concern about secondary peritonitis (see
    below)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Cessation of alcohol, if applicable</li>
<li>2000mg sodium restriction per day for all ascites (Grade 1-3)</li>
<li>Diuretics (spironolactone and typically oral furosemide)<ul>
<li>Start at 100mg of spironolactone with up titration to 400mg</li>
<li>Furosemide is added if insufficient diuresis or if limited by
    hyperkalemia</li>
<li>Can then
    ↑
    to a max of 400:160</li>
<li>If poor response can change to torsemide 10 and
    ↑
    40 mg max for cirrhotics</li>
<li>Fluid restriction usually not necessary unless serum sodium
    \&lt;130 mmol/L</li>
</ul>
</li>
<li>Large volume paracentesis should be performed for tense ascites or
    refractory ascites (grade 3), regardless of serum Cr. PTs should be
    tapped dry with each paracentesis</li>
<li>6-8g of albumin per liter of ascites removed , even if \&lt; 5L<ul>
<li>
<ul>
<li>So, if 7L removed, you would give 42-56g of albumin</li>
</ul>
</li>
</ul>
</li>
<li>Target weight loss of 0.5kg/day when diuresing to avoid renal
    injury</li>
</ul>
<p>Refractory Ascites</p>
<p>:</p>
<ul>
<li>Two distinctions:<ul>
<li>Diuretic-resistant: lack of response to diuretics (max
    spironolactone 400mg/lasix160mg), Na restriction and rapid
    recurrence following paracentesis</li>
<li>Diuretic-intractable: unable to tolerate diuretic therapy 2/2
    adverse drug effects (unexplained HE, AKI, K abnormalities,
    hypoNa, intractable muscle cramps)</li>
</ul>
</li>
<li>Management aside from liver transplant:<ul>
<li>Discontinue of diuretics once refractory ascites has been
    established</li>
<li>Consider oral midodrine; can be especially helpful if pt is also
    hypotensive</li>
<li>Serial paracenteses, generally arranged OP with IR</li>
<li>Consider TIPS (trans jugular intrahepatic portosystemic shunt;
    has survival benefit)</li>
<li>Following TIPS, cessation or decrease in ascites should occur in
    4-6 weeks<ul>
<li>If pt with TIPS presents to hospital with accumulation of
    ascites, can signal that shunt is no longer patent. Obtain
    RUQ w/doppler or CTA abdomen/pelvis to look for patency. May
    require IR study if high enough concern</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Medications to avoid or discontinue with refractory ascites:<ul>
<li>ACE/ARB,
    NSAIDS,
    β Blockers (
    if Na \&lt;130, systolic \&lt;100, MAP \&lt;65 or AKI)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic Hydrothorax</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>transudative effusion, typically unilateral (right sided); reflects
    ascitic fluid that passes through a small defect in the diaphragm</li>
<li>present in 5% of cirrhosis with ascites and portends a poor
    prognosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Often suspected clinically, though must exclude
    pleural/cardiopulmonary process</li>
<li>Thoracentesis will demonstrate a transudative effusion and should be
    evaluated with standard pleural fluid lab tests:<ul>
<li>Cell count w/ diff</li>
<li>Culture (inoculated at the bedside!)</li>
<li>Protein, albumin, LDH, bilirubin</li>
<li>Other considerations: triglycerides, amylase, cytology</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Rule out SBE:<ul>
<li>Diagnosed by the following criteria:<ul>
<li>Positive pleural fluid culture, PMN&gt;250</li>
<li>Negative pleural fluid culture with PMN &gt;500</li>
<li>No evidence of pneumonia on imaging (to r/o parapneumonic
    effusion)</li>
</ul>
</li>
<li>½ of cases will present with concomitant SBP</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Similar management of ascites as noted above</li>
<li>AVOID chest-tube placement. Associated with increased morbidity and
    mortality due to extensive loss of fluid, electrolytes and protein
    as well as increased infection risk<ul>
<li>Once placed, may be impossible to remove due to constant
    reaccumulation of fluid</li>
<li>PleurX catheters can be considered for palliation (e.g., hospice
    patients)</li>
</ul>
</li>
<li>Tension hydrothorax with pronounced dyspnea and hemodynamic
    instability require immediate decompression with thoracentesis</li>
<li>Refractory Hydrothorax is defined similarly and managed similarly
    with serial thoracentesis or TIPS. For those who are not candidates,
    consider:<ul>
<li>Chemical pleurodesis (fraught w/ complications, not commonly
    performed at VUMC)</li>
<li>Thoracoscopic mesh repair in patients with clear diaphragmatic
    deficits, but again, this is not common practice at VUMC</li>
</ul>
</li>
<li>Management of spontaneous bacterial empyema is the same as in SBP,
    as noted below</li>
</ul></section><section class="print-page" id="hepatology-hepatology-cirrhosis"><h1 id="hepatology-hepatology-cirrhosis-cirrhosis">Cirrhosis<a class="headerlink" href="#hepatology-hepatology-cirrhosis-cirrhosis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis Overview – Lee Richardson</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>For any patient admitted with cirrhosis, know the etiology of their
    cirrhosis, whether they are compensated or decompensated, and their
    admission MELD score.</li>
<li>Etiology:<ul>
<li>Most common causes = Alcohol-associated liver disease,
    non-alcoholic steatohepatitis (NASH) and HCV (becoming less
    common with DAA success)</li>
<li>Less common causes: HBV, metabolic (hemochromatosis, Wilson’s
    disease), A1AT deficiency, autoimmune hepatitis, PSC, PBC,
    veno-occlusive disease, R sided heart disease (congestive
    hepatopathy), and medication-induced</li>
</ul>
</li>
<li>Decompensated Cirrhosis:  Cirrhosis + Ascites, Hepatic
    Encephalopathy or Gastroesophageal Variceal Hemorrhage (the presence
    of varices without prior hemorrhage is not decompensation)<ul>
<li>Average life expectancy of a patient with compensated cirrhosis
    = 10-13 years</li>
<li>Average life expectancy of a patient with decompensated
    cirrhosis = 2 years</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Goal is to establish the diagnosis of cirrhosis, determine the cause
    of cirrhosis and determine candidacy and necessary evaluation for
    transplantation.</li>
<li>History:<ul>
<li>Known history of prior liver disease (if so, from what, and when
    did they learn about it?). Presence/absence of: fatigue, easy
    bruising, lower extremity edema, weight loss, pruritus,
    yellowing of the skin or eyes, increasing abdominal girth, prior
    episodes of disorientation to place, person, or time, sleep
    disturbances.</li>
<li>Extensive social hx including alcohol (start year, quitting
    year, avg amt/day, prior treatment, DUI) and drug use hx (type
    and route plus the above elements in EtOH hx), family history of
    liver disease</li>
</ul>
</li>
<li>Physical exam: Splenomegaly, caput medusae, ascites, asterixis/HE,
    conjunctival icterus, spider angiomata, gynecomastia, palmar
    erythema, jaundice, testicular atrophy, easy bruising/bleeding,
    edema/anasarca</li>
<li>Labs:<ul>
<li>Initial Workup: CMP, CBC, U/A, HCV antibody, HBV panel, iron
    panel (ferritin, transferrin saturation), AFP, Peth</li>
<li>Unless requested by the hepatology team, the following tests can
    be deferred to the OP setting: AMA (PBC), ASMA (AIH), ANA w/
    reflex, IgG, A1AT phenotype, ceruloplasmin (wilson’s), generally
    defer anti-LKM, anti-SLA (type 2 AIH, requires attending
    approval) to Hep recs</li>
</ul>
</li>
<li>Imaging:<ul>
<li>Abdominal u/s with duplex unless done in past 6 months, or
    indication for repeating (e.g., concern for PVT w/ new EVH)</li>
<li>consider triple phase CTAP (contrasted study that looks at
    arterial and venous phases) vs MRI abdomen w/contrast if
    required by hep team (transplant eval)</li>
<li>HCC surveillance is further discussed below</li>
</ul>
</li>
<li>Liver biopsy: Gold standard for diagnosis not always needed if
    clinical picture, labs, and imaging consistent with cirrhosis (See
    Radiology Section for who to consult for biopsy)</li>
</ul>
<p>Management</p>
<ul>
<li>Malnutrition occurs in 20-60% of patients with cirrhosis<ul>
<li>Nutrition consult if ascites present (unless recently done)</li>
<li>High protein (1.2-1.5g/kg) diet</li>
<li>2g Na restriction, reinforce regularly</li>
<li>Consider MVI, folate, thiamine, particularly to pts w/ EtOH Use
    Disorder</li>
<li>Fluid restriction only needed for hyponatremia (as noted below)</li>
</ul>
</li>
<li>Ensure pts are up to date on required vaccines; these can be
    administered while inpatient before discharge. Indicated vaccines
    include HBV/HAV, PPSV23, Prevnar, Flu, COVID 19</li>
<li>Consider addiction psych (medical therapy) and SW c/s (behavioral
    therapy with IOP, AA) for EtOH use disorder</li>
</ul>
<p>Additional Information</p>
<p>Lab abnormalities in cirrhosis:</p>
<ul>
<li>Calculate daily MELD-Na scores in pts being considered for Liver
    transplant</li>
<li>Coagulopathies: thrombocytopenia (from both hypersplenism and
    increased PLT sequestration and
    ↓
    thrombopoietin production in liver),
    ↓
    coagulation factor production</li>
<li>Hyponatremia: Usually hypervolemic hyponatremia in cirrhotic
    patients; benefit from fluid restriction if hyponatremic</li>
<li>Hypoalbuminemia: Albumin transfusion is indicated in certain
    scenarios (detailed below) for volume expansion, anti-inflammatory
    and anti-oxidant properties<ul>
<li>Order 25% albumin and NOT 5% (5% albumin is only used to
    maintain effective circulating volume following major hepatic
    resection or hepatic transplant)</li>
</ul>
</li>
<li>Indications for albumin administration:<ul>
<li>SBP (see SBP section)</li>
<li>LVP (see Ascites section)</li>
<li>Diagnosis/Treatment  of HRS (see HRS section)</li>
<li>Hyponatremia (\&lt;125 and not responsive to fluid restriction)</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-coagulopathy"><h1 id="hepatology-hepatology-coagulopathy-coagulopathy">Coagulopathy<a class="headerlink" href="#hepatology-hepatology-coagulopathy-coagulopathy" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coagulopathy – Garren Montgomery, John Laurenzano</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>The liver is responsible for production of both pro- (factor II, V,
    VII, IV, X, and XI) and anti-coagulants (protein C, S) in hemostasis</li>
<li>Thrombocytopenia is caused by splenic sequestration 2/2 portal HTN,
    failure to produce thrombopoietin, and bone marrow failure</li>
</ul>
<p>Evaluation</p>
<ul>
<li>INR, PT, and PTT are poorly reflective of bleeding risk</li>
<li>TEG screens and other measures of comprehensive coagulation are more
    representative and are available, but are not universally used at
    VUMC</li>
</ul>
<p>Management</p>
<ul>
<li>Even in bleeding, there is no need to intervene on an INR or
    platelet value</li>
<li>Pre-procedural FFP is not recommended, even in the presence of
    bleeding, but is frequently requested by different proceduralists</li>
<li>There is no evidence of benefit, though there is significant risk.</li>
<li>Low risk procedures (i.e., paracentesis) do not require
    pre-procedural blood products</li>
<li>In bleeding pts, the following are recommended per AASLD and AGA
    guidelines<ul>
<li>Vitamin K 10mg x 3 days for those who are cholestatic (poor
    absorption),</li>
<li>FFP: Not recommended, unless as part of a balanced transfusion
    effort to avoid transfusion related coagulopathy, or if a TEG
    screen suggests potential benefit</li>
<li>Cryoprecipitate: if fibrinogen \&lt; 120</li>
<li>Platelets: No specific targets are recommended by the AASLD
    regardless of bleeding. Pre-procedurally the AGA has
    recommended &gt;50.</li>
</ul>
</li>
<li>Appropriate DVT ppx should be given in most pts with few exceptions
    (plts \&lt;50k, active variceal hemorrhage)</li>
</ul></section><section class="print-page" id="hepatology-hepatology-hepatic-encephalopathy"><h1 id="hepatology-hepatology-hepatic-encephalopathy-hepatic-encephalopathy">Hepatic Encephalopathy<a class="headerlink" href="#hepatology-hepatology-hepatic-encephalopathy-hepatic-encephalopathy" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic Encephalopathy</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Asterixis: inability to maintain stable posture; many ways to assess<ul>
<li>check for clonus</li>
<li>have pt “hold out hands like you are stopping traffic” (if
    following commands)</li>
<li>place pt in “frog leg” position and observe for flapping
    movement</li>
<li>check for pupillary changes which may herald increased ICP
    (helpful in ICU)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>Behavior change</td>
<td>Asterixis</td>
<td>Cerebral Edema in Acute Liver Failure:</td>
</tr>
<tr>
<td>I</td>
<td>Mild confusion, changes in behavior, increased sleep</td>
<td>No Asterixis</td>
<td>No cerebral edema</td>
</tr>
<tr>
<td>II</td>
<td>Moderate confusion, lethargic</td>
<td>Asterixis</td>
<td>Rare cerebral edema</td>
</tr>
<tr>
<td>III</td>
<td>Marked confusion, arousable but falls asleep, incoherent speech</td>
<td>Asterixis</td>
<td>~30% cerebral edema</td>
</tr>
<tr>
<td>IV</td>
<td>Coma</td>
<td>No Asterixis</td>
<td>~75% cerebral edema</td>
</tr>
</tbody>
</table>
<ul>
<li>Identify precipitants<ul>
<li>Infection (rule out SBP in addition to CXR, BCx, UA/Cx
    regardless of sxs),</li>
<li>Medication non-adherence (lactulose)</li>
<li>GI bleed (perform rectal exam and observe hgb trend)</li>
<li>Over-diuresis resulting in dehydration, lyte abnormalities
    (especially hypoK)</li>
<li>Sedatives/benzo/opiate administration (UDS)</li>
<li>Post-TIPS, other large but spontaneous shunt (imaging can be
    useful to determine if there is a shunt, and if an intervention
    is feasible on such a shunt).</li>
</ul>
</li>
<li>Ammonia (NH <sub>3</sub> ) levels do not play a role in the acute
    management of hepatic encephalopathy; if pt has AMS or HE, you will
    treat the HE regardless</li>
<li>Arterial NH <sub>3</sub> is used in acute liver failure for
    <strong>prognostication</strong> (not for management)</li>
</ul>
<p>Management</p>
<ul>
<li>Always determine precipitant and treat underlying condition</li>
<li>If GCS \&lt;8 (grade III/IV) transfer to MICU for intubation for airway
    protection. Consider discussing with fellow early in course if
    failing to respond mgmt below</li>
<li>Lactulose 30mL TID initially<ul>
<li>Titrate dose to at least 4 BMs daily, avoid excessive stool
    output which may exacerbate HE due to dehydration and
    electrolyte abnormalities</li>
<li>Consider lactulose enemas vs DHT placement if pt unable to
    tolerate PO<ul>
<li>DHT are <strong>not</strong> contraindicated in patients with esophageal
    varices, but should be avoided in patients with recent
    hemorrhage or banding</li>
<li>Golytely can be substituted for lactulose with DHT in and
    can halve the time to recovery</li>
</ul>
</li>
<li>Add Rifaximin after the second episode of HE, or if failure to
    respond to lactulose<ul>
<li>Frequently requires prior auth for OP approval and is
    expensive</li>
<li>Branched chain amino acids (0.25 gm/kg/day, available at
    Walmart) can be considered if unable to take rifaximin and
    recurrent HE (should discuss this w/ attending/fellow)</li>
<li>Rifaximin should be used for primary ppx of HE before and
    following TIPS</li>
<li>Recurrent HE after TIPS:  should investigate and consider
    TIPS constrainment</li>
</ul>
</li>
</ul>
</li>
<li>Lactulose is generally continued indefinitely after first episode of
    HE, though discontinuation can be considered if predisposing factors
    (recurrent infection, EVH, EtOH use) have resolved</li>
<li>Beware bowel mgmt systems in pts with severe portal HTN and place
    only if necessary<ul>
<li>Can disrupt rectal varices and lead to hemorrhage. D/w attending</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-hepatocellular-carcinoma"><h1 id="hepatology-hepatology-hepatocellular-carcinoma-hepatocellular-carcinoma">Hepatocellular Carcinoma<a class="headerlink" href="#hepatology-hepatology-hepatocellular-carcinoma-hepatocellular-carcinoma" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular Carcinoma (HCC) – Julie Cui</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Pts with HCV cirrhosis are at greatest risk (incidence 2-4% per
    year)</li>
<li>In chronic HBV, pts can develop HCC without having cirrhosis, as can
    patients with NASH</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Regular screening in pts w/ cirrhosis HCC</li>
<li>Also recommended to screen non-cirrhotic with chronic HBV<ul>
<li>U/S every 6 months (w/ or w/o AFP)</li>
<li>Routine screening with CT or MRI is not recommended</li>
</ul>
</li>
<li>Options If U/S not satisfactory:<ul>
<li>CT A/P w/contrast, in comments specify triple phase for HCC
    screening</li>
<li>MRI, specify Gadovist (preferred contrast agent)</li>
<li>Contrast-enhanced ultrasound</li>
</ul>
</li>
<li>AFP trend is more useful than 1 value in time <strong>,</strong> though AFP &gt;20
    should prompt multiphase CT or MRI for further evaluation</li>
<li>Diagnosis can be made either by imaging (most common) or biopsy
    (rarely).<ul>
<li>Triple phase CT demonstrates strong early uptake in arterial
    phase, with subsequent wash-out in portal-venous phase</li>
<li>If diagnosis remains unclear: can surveillance imaging or biopsy</li>
<li>LI-RADS system notes risk of malignancy based on imaging
    characteristics</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>LI-RADS</td>
<td>What does it mean?</td>
<td>What do we do?</td>
</tr>
<tr>
<td>LR-1 to LR-2</td>
<td>Definitely/Probably benign</td>
<td>Routine surveillance, consider diagnostic imaging within 6 mos</td>
</tr>
<tr>
<td>LR-3 to LR-4</td>
<td>Indeterminate/Probably HCC</td>
<td>Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4</td>
</tr>
<tr>
<td>LR-5</td>
<td>Definitely HCC</td>
<td>Plan treatment as noted below</td>
</tr>
<tr>
<td>LR-M</td>
<td>Cancer but may not be HCC</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Lesions that meet Milan criteria can qualify for MELD exception
    points and are considered transplant candidates<ul>
<li>This accounts for pts w/minimal synthetic dysfunction (and
    therefore low MELD)</li>
</ul>
</li>
<li>Milan criteria:<ul>
<li>Single tumor with diameter &gt;2cm but \&lt;5 cm, no more than 3
    tumors, each \&lt;3 cm</li>
<li>No signs of extra-hepatic involvement or vascular invasion</li>
</ul>
</li>
<li>Pts may remain transplant candidates if rx downstages their HCC to
    meet above criteria</li>
<li>Liver transplant is definitive treatment, although <strong>resection</strong> can
    also be curative<ul>
<li>Favored in pts w/early cirrhosis (Child Pugh A) and HCC amenable
    to resection</li>
</ul>
</li>
<li>Locoregional therapies: Pts w/ unresectable disease, or who are not
    surgical candidates</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy</td>
<td>Details</td>
</tr>
<tr>
<td>Radiofrequency ablation</td>
<td>If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies</td>
</tr>
<tr>
<td>Trans-arterial chemoembolization (TACE)</td>
<td>Chemotherapeutic agents injected into the tumor to occlude the feeding blood supply to the area.</td>
</tr>
<tr>
<td>Trans-arterial radioembolization (TARE)</td>
<td>Like TACE, though radioactive compound (i.e. Y-90) used to occlude the feeding blood supply.</td>
</tr>
<tr>
<td>Stereotactic body Radiation Therapy (SBRT)</td>
<td>Radiation therapy: can be used as an alternative to ablation and is generally performed in those meeting Milan criteria</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>For metastatic disease</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hepatology-hepatology-hepatorenal-syndrome"><h1 id="hepatology-hepatology-hepatorenal-syndrome-hepatorenal-syndrome">Hepatorenal Syndrome<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-hepatorenal-syndrome" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKI &amp; Hepatorenal Syndrome (HRS) – Garren Montgomery</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Circulatory dysfunction: Portal HTN causes shear stress on portal
    vessels; endothelium releases vasodilators (NO, prostanoids). This
    causes splanchnic vasodilation and reduced effective blood volume
    (decreased MAP) which activates RAAS and the sympathetic nervous
    system. This results in avid sodium and water retention and severe
    renal vasoconstriction.</li>
<li>Inflammation: Bacterial translocation (as seen in SBP) results in
    increased circulating pro-inflammatory cytokines which can worsen
    splanchnic vasodilation and also thought to act directly on proximal
    tubular cells to cause further intrarenal RAAS activation and
    ↓
    GFR</li>
<li>Definitions:<ul>
<li>HRS-AKI
    (formerly type I HRS): Absolute
    #
    in Cr ≥0.3 mg/dl within 48h OR Percent
    #
    in Cr ≥50% using last available value of outpatient Cr within 3
    months as baseline<ul>
<li>HRS-NAKI
    (“non-AKI”): (formerly type II HRS):</li>
<li>HRS-AKD
    : eGFR\&lt;60 for <strong>\&lt;</strong> 3 months in absence of other
    structural causes OR Percent
    #
    in Cr ≤50% using last available Cr over last 3 months as
    baseline</li>
<li>HRS-CKD
    : eGFR\&lt;60 for <strong>≥</strong> 3 months in absence of other
    structural causes</li>
</ul>
</li>
</ul>
</li>
<li>Diagnostic Criteria<ul>
<li>Presence of cirrhosis with ascites</li>
<li>Diagnosis of AKI (see above)</li>
<li>No response or inadequate response at 48 hrs after volume
    expansion w/ albumin and withdrawal of diuretics</li>
<li>Absence of shock</li>
<li>No current or recent use of nephrotoxic drugs</li>
<li>Absence of proteinuria (\&lt;500 mg/d), absence of hematuria (\&lt;50
    RBCs per HPF), normal renal ultrasound (this criterion would not
    be included if patient has known CKD such as diabetic or
    hypertensive nephropathy)</li>
<li>Suggestion of renal vasoconstriction with FeNa \&lt;0.2, FeUrea
    \&lt;20 (most sensitive diagnostic measure). UNa \&lt;20 is suggestive
    but not diagnostic given baseline sodium avidity in cirrhosis
    and inability to calculate FeNa</li>
<li>Cut off for ATN in cirrhosis is a FeNa &gt;0.5, rather than 1 in
    the general population</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Step 1: Exclude other obvious causes of renal injury<ul>
<li>DDx: Pre-renal (most common), ATN (2 <sup>nd</sup> most common),
    AIN, bile cast nephropathy, IgA nephropathy,
    cryoglobulinemia/MPGN (HCV), membranous nephropathy (HBV), post
    renal (rare)</li>
<li>Common precipitants of AKI: infection, overdiuresis, GI
    bleeding, recent LVP without subsequent volume expansion,
    nephrotoxic drugs/NSAIDs</li>
<li>Workup: BMP, UA w/ microscopy, Urine electrolytes (FeNa,
    FeUrea), urine protein/Cr ratio, renal ultrasound (to assess for
    chronicity)</li>
</ul>
</li>
<li>Step 2: Diuretic cessation/albumin challenge<ul>
<li>STOP all diuretics, beta blockers, NSAIDs, ACE/ARBs,
    anti-hypertensives, vasodilators, nephrotoxins</li>
<li>START volume expansion with albumin 1g/kg/day (up to a max of
    100 g/day) for 2 consecutive days</li>
<li>Infection is a common precipitant of HRS, assess for ascites and
    perform diagnostic para to r/o SBP</li>
</ul>
</li>
<li>Step
    3: Diagnosis of HRS<ul>
<li>If no other clear cause of AKI is identified and SCr has not
    improved after 48 hours of diuretic cessation and volume
    expansion proceed promptly to treatment. If suspicion for HRS is
    high, therapy can be started before the 48h mark</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Pharmacologic therapies: (in order of preference):</li>
<li>Terlipressin + albumin. Most effective combo based on clinical
    trials but not yet available in the U.S.</li>
<li>Norepinephrine (NE, levophed) + albumin (25-50 g/day).<ul>
<li>Most likely to be used at VUMC, requires central access (PICC vs
    triple lumen) but can be administered on stepdown unit/8MCE.</li>
<li>Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask
    fellow, attending or pharmacist for baseline. VUMC protocol for
    ICU and stepdown:<ul>
<li>Start NE gtt at 3mcg/min. If UOP is \&lt;200 or MAP \&lt;10mm Hg
    from baseline, increase gtt by 3mcg increments until those
    goals are met or max 20 mcg/min</li>
<li>Albumin will continue to be infused at 50gm per day until
    replete and then stopped or modified depending on decision
    on rounds.</li>
<li>The use of furosemide to supplement volume removal will be
    made on a clinical basis on rounds by the attending and
    resident on service.</li>
</ul>
</li>
</ul>
</li>
<li>Continue to hold diuretics. LVP is still generally considered safe
    even in HRS if indicated by tense ascites. This can be attending
    specific and would confirm prior to performing.</li>
<li>Therapy is generally continued until HRS is reversed or the
    hepatology attending deems it refractory to medical treatment</li>
<li>Complete response to therapy defined as return of SCr within 0.3
    mg/dL of baseline</li>
<li>Patients with HRS-NAKI (formerly type II HRS) may respond to the
    above therapies, but recurrence of renal dysfunction after
    withdrawal of vasoconstrictors is the norm and thus current
    guidelines do not recommend them for this scenario</li>
<li>TIPS: Generally contraindicated for most HRS pts given high MELD
    scores and not much data to support its use, but may improve renal
    function in patients with HRS-NAKI with refractory ascites</li>
<li>RRT: Dialysis can be considered for those who fail to respond to
    pharmacologic therapy, particularly as a bridge to liver transplant.
    Decision to initiate should be individualized</li>
<li>Liver transplant: The best and most definitive treatment regardless
    of response to pharmacologic therapy</li>
</ul>
<p>Prevention of HRS:</p>
<ul>
<li>Ensure that pts receive albumin after LVP and when diagnosed with
    SBP. Ensure pts with cirrhosis with suspected UGIB receive ppx abx</li>
<li>Avoid NSAIDs. Stop ACE/ARBs if possible. Stop beta blockers in
    patients with refractory ascites and AKI, hyponatremia or
    hypotension.</li>
</ul></section><section class="print-page" id="hepatology-hepatology-liver-transplantation"><h1 id="hepatology-hepatology-liver-transplantation-liver-transplantation">Liver Transplantation<a class="headerlink" href="#hepatology-hepatology-liver-transplantation-liver-transplantation" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver Transplant Workup – Lauren Evers Carlini</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Model
    for End-stage Liver Disease (MELD) score: initially developed to
    predict survival following TIPS placement, though is now used to
    objectively rank patients in terms of priority for liver transplant;
    factors in total bilirubin, creatinine, and INR. An updated version,
    the MELD-Na score, factors in the serum Na as well.<ul>
<li>Exception points given for complications like HCC and
    hepatopulmonary syndrome (HPS), leading to score in mid to high
    20’s even if biologic MELD is low</li>
</ul>
</li>
<li>Whether
    to list a pt for LT is determined by a multidisciplinary transplant
    committee (if interested, ask fellow/attending if you can sit in on
    meeting)<ul>
<li>The United Network for Organ Sharing (UNOS) manages and monitors
    the process.</li>
<li>US is divided into 11 geographic regions; organs are allocated
    within each</li>
<li>Acute liver failure pts take precedence over decompensated
    cirrhosis pts for LT</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>Contraindications*</td>
</tr>
<tr>
<td>Cirrhosis with MELD ≥ 15 or evidence of decompensation (ascites, variceal bleed, HE, HPS, portopulmonary HTN)</td>
<td>Ongoing substance abuse (must have documented abstinence ≥ 3 mos); some special considerations for pts who did not know of EtOH hepatitis or EtOH use d/o but highly variable</td>
</tr>
<tr>
<td>Acute Liver Failure</td>
<td>Untreated or recurrent malignancy</td>
</tr>
<tr>
<td>HCC that meets Milan criteria</td>
<td>Active Infection, AIDS</td>
</tr>
<tr>
<td>Pts with early hilar cholangio-carcinoma that meets specific criteria</td>
<td>Documented history of medical noncompliance</td>
</tr>
<tr>
<td>Other rare dz (e.g., familial amyloid polyneuropathy or hyperoxaluria)</td>
<td>Lack of Adequate social support</td>
</tr>
<tr>
<td>NaN</td>
<td>Anatomic Contraindications; Chronic cardiac/pulmonary conditions that significantly increase perioperative risk (e.g., severe pulm HTN)</td>
</tr>
</tbody>
</table>
<p>* <em>Advanced age (&gt;70) is not in itself a contraindication but
candidates > 70 should be almost free of comorbidities to be considered
for LT</em></p>
<p>Evaluation (ask upper level or fellow for detailed document)</p>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>Determine cause of cirrhosis or acute liver failure, if not done
    already</p>
</li>
<li>
<p>Abdominal CT (triple phase) or MRI (multiphase with contrast) to
    evaluate for hepatic malignancy and vascular anatomy.</p>
</li>
<li>
<p>Infectious workup: TB testing, HIV, RPR, VZV, CMV, EBV, and
    Hepatitis A, B, and C.</p>
</li>
<li>
<p>Cardiac evaluation (typically starts with non-invasive testing; TTE
    plus dobutamine stress echo are preferred). Coronary angiography and
    intervention may be necessary if significant CAD is suggested (pts
    with DM or atherosclerosis on abdominal/carotid imaging) or pts with
    multiple risk factors (e.g. age 45M, FF W), NASH, hx smoking</p>
</li>
<li>
<p>PFT’s</p>
</li>
<li>
<p>Appropriate cancer screenings (colonoscopy, pap smear, MMG, and PSA
    if applicable)</p>
</li>
<li>
<p>DEXA scan</p>
</li>
<li>
<p>Certification of completion of intensive outpatient program (IOP)
    for substance abuse</p>
</li>
<li>
<p>Evaluation by hepatobiliary surgical team after obtaining cross
    sectional imaging</p>
</li>
<li>
<p>Psychosocial evaluation (consult Psychiatry, social work)</p>
</li>
<li>
<p>Both living and deceased donor transplant are offered at VUMC. Donor
    evaluation, however, cannot be started before the potential
    recipient is deemed a candidate</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-medication-pearls"><h1 id="hepatology-hepatology-medication-pearls-medication-pearls">Medication Pearls<a class="headerlink" href="#hepatology-hepatology-medication-pearls-medication-pearls" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross Cover Pearls – Garren Montgomery</td>
</tr>
</tbody>
</table>
<p>Pain:</p>
<ul>
<li>General rule is to avoid opioids in cirrhosis as they are largely
    metabolized by the liver and can cause confusion, which may be
    mistakenly attributed to HE</li>
<li>Alternative options:<ul>
<li>Tylenol (up to 2g/day)</li>
<li>Tramadol 50mg BID or 25 mg q8h generally safe if not responsive
    to Tylenol</li>
<li>Increased risk of seizures and serotonin syndrome (avoid if on
    SSRI/SNRI)</li>
<li>Lidocaine patches for localized pain</li>
<li>Gabapentin, with added benefit of treating alcohol use d/o (up
    to 1200mg daily)</li>
<li>Pregabalin 50mg BID</li>
<li>Nortriptyline 10 mg qHS</li>
</ul>
</li>
</ul>
<p>Anxiety:</p>
<ul>
<li>Benzo’s should generally be avoided due to their risk for causing
    confusion<ul>
<li>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of
    chlordiazepoxide (librium) or diazepam (valium) due to its
    shorter half life</li>
</ul>
</li>
<li>Antihistamines such as Hydroxyzine (Atarax) are preferred for prn</li>
</ul>
<p>Pruritis:</p>
<ul>
<li>Cholestyramine 4g/day titrated up to 4 times daily = 16g/day max<ul>
<li>SE: poor taste, bloating, constipation, GI distress</li>
<li>very important NOT to dose around other medications given
    potential for interaction/blocking absorption</li>
</ul>
</li>
<li>Sertraline: 50-100 mg/day</li>
<li>Antihistamines: Benadryl, doxepin 10 mg qHS</li>
<li>Topicals such as sarna lotion</li>
<li>Rifampin 150-300 mg/day; second-line agent<ul>
<li>Side effects: N/V/D, HA, flushing, thrombocytopenia, turns body
    fluids orange</li>
<li>Be VERY mindful of potential drug/drug interactions with
    Rifampin (there are many); would talk to hepatology
    attending/pharmacist before initiating</li>
</ul>
</li>
</ul>
<p>Insomnia:</p>
<ul>
<li>Melatonin preferred; Hydroxyzine (12.5mg-25mg); Trazodone (100mg);
    <strong>avoid benzo's</strong></li>
</ul></section><section class="print-page" id="hepatology-hepatology-nash-and-nafld"><h1 id="hepatology-hepatology-nash-and-nafld-nash-and-nafld">NASH and NAFLD<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-nash-and-nafld" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>NASH and NAFLD – John Laurenzano</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Non-alcoholic fatty liver disease (NAFLD): presence of hepatic
    steatosis in the absence of secondary causes (e.g., EtOH)</li>
<li>Non-alcoholic steatohepatitis (NASH): evidence of active
    inflammation in conjunction with steatosis (elevated liver enzymes
    or evidence on bx)</li>
<li>Strong association with metabolic syndrome, T2DM, HTN, obesity,
    prior cholecystectomy</li>
<li>Generally asymptomatic</li>
<li>Considered to be a common cause of cryptogenic cirrhosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>NASH manifests with elevated liver enzymes, typically 2-5x the ULN,
    in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis),
    though ALT may be higher than AST</p>
</li>
<li>
<p>NAFLD is asymptomatic and frequently found incidentally via imaging</p>
</li>
<li>
<p>Can be diagnosed based on imaging alone (and frequently is)</p>
</li>
<li>
<p>Exclusion of alternative causes and comorbid liver conditions: HCV,
    HBV, EtOH</p>
</li>
<li>
<p>Liver biopsy</p>
</li>
<li>
<p>Generally only pursued with advanced disease and to evaluate extent
    of fibrosis, or to rule out competing etiologies, such as AIH</p>
</li>
<li>
<p>Note: Ferritin is frequently elevated, though not to the extent of
    HH. Low level auto-antibodies are also frequently present</p>
</li>
<li>
<p>Ultrasound is used most frequently for imaging, though MRI and CT
    also are acceptable;
    use risk scores to determine the risk of advanced fibrosis and
    identify those who would benefit from biopsy</p>
<ul>
<li>Fibrosis-4 (FIB 4) score</li>
<li>NAFLD fibrosis score</li>
<li>More accurate, non invasive fibrosis assessments can be done
    using elastography which can be vibration based (fibroscan)
    ultrasound based, or MR-based</li>
<li>MR is nearly as accurate as biopsy (quantifying fat and
    fibrosis)</li>
<li>Available at VUMC and can be ordered by anyone. Insurance will
    not cover if BMI \&lt;35</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>Aggressive risk factor modification and mgmt of comorbidities (HLD,
    HTN, T2DM)</p>
</li>
<li>
<p>Weight loss: Mediterranean diet&gt;Low fat diet, (dose dependent
    improvement)</p>
</li>
<li>
<p>No specific medications are FDA approved currently</p>
<ul>
<li>Pioglitazone has shown benefit in pts with T2DM and NASH</li>
<li>Vitamin E has shown benefit in pts w/o T2DM and proven NASH</li>
<li>Ongoing studies for SGLT-2i and GLP-1ra; some promise indicated
    for the latter</li>
</ul>
</li>
<li>
<p>While bariatric surgery is not a specific indication for NASH/NAFLD,
    increasing evidence demonstrates resolution of NASH and fibrosis in
    pts with clinically significant weight loss</p>
</li>
<li>
<p>Referral to the surgical weight loss clinic should be considered in
    any patient who meets obesity guidelines for bariatric surgery
    (BMI &gt;40, or &gt;35 with metabolic comorbidities)</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
<li>
<p>Statins: should be used for HLD in pts with NASH, NAFLD and NASH
    cirrhosis</p>
</li>
<li>
<p>Statin use in decompensated NASH cirrhosis is controversial, and
    they are less likely to derive benefit given overall poor prognosis.
    There is an increased risk of rhabdomyolysis in pts with acute on
    chronic liver failure and are considered contraindicated</p>
</li>
<li>
<p>Metformin is safe and may have a <strong>survival benefit</strong> in patients
    with diabetes and cirrhosis. Discontinue only in those who have
    increased risk for lactic acidosis (renal impairment and significant
    EtOH). Sulfonylureas are generally avoided.</p>
</li>
<li>
<p>While hepatic steatosis and hepatic fibrosis are diagnoses that can
    be made using radiologic tools, NASH requires bx as inflammation
    plays a key role and cannot be determined radiographically or
    biochemically</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-portal-vein-thrombosis"><h1 id="hepatology-hepatology-portal-vein-thrombosis-portal-vein-thrombosis">Portal Vein Thrombosis<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-portal-vein-thrombosis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Portal Vein Thrombosis (PVT) – John Laurenzano</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Sluggish flow within the portal system, localized endothelial
    inflammation, and alterations in the coagulation/fibrinolytic
    cascade</li>
<li>There is a bidirectional relationship between PVT and
    decompensation, as portal vein thrombosis can worsen decompensation
    (i.e. variceal hemorrhage), though at the same time PVT can result
    from worsening portal HTN and more sluggish flow</li>
</ul>
<p>Presentation</p>
<ul>
<li>Identified asymptomatically on ultrasound, but can be identified by
    new or worsening decompensation of portal HTN</li>
<li>Esophageal variceal hemorrhage—most common decompensating event
    assoc. w/ PVT</li>
<li>Intestinal ischemia (abdominal pain, hematochezia)—exceedingly rare
    but assoc. w/significant morbidity and mortality</li>
</ul>
<p>Evaluation</p>
<p>-
-   Initial: RUQ with doppler
-   Once identified, should be further assessed with ctriple phase CT or
    MRI w/Gadovist contrast to exclude HCC w/tumor thrombus (excludes
    pts from LT as noted above)
    -   AFP can be an adjunctive test to assess for HCC if significantly
        elevated
-   Pts with newly identified PVT should undergo EGD to evaluate for
    high-risk varices, both for diagnostic and therapeutic
    considerations
-   PVT in pts w/o cirrhosis should prompt evaluation for
    hypercoagulable disorders</p>
<p>Management</p>
<ul>
<li>Individualized and based on risk factors for bleeding; should be
    discussed with the attending/fellow. There is no need for urgent
    anticoagulation in the absence of signs/symptoms of intestinal
    ischemia</li>
<li>Anticoagulation with VKA, LMWH, or UFH<ul>
<li>DOAC’s not as extensively studied in cirrhosis, but may be
    considered Child A pts</li>
<li>If pt is to be listed for transplant and has normal INR,
    coumadin can give additional MELD points and is more easily
    reversed</li>
</ul>
</li>
<li>Anticoagulation is associated with improved recanalization in recent
    PVT (\&lt;6 mos), and may improve post-transplant outcomes in those
    awaiting transplantation; pts with chronic occlusive PVT (&gt;6 mos) or
    with cavernous transformation with collaterals do not generally
    benefit from anticoagulation</li>
<li>Pts with high-risk varices should undergo endoscopic management or
    be on BB for ppx for variceal hemorrhage, as noted above</li>
<li>TIPS with portal vein recanalization has recently emerged as a
    therapeutic modality for PVT</li>
<li>Pts should undergo follow up intermittently with ultrasound imaging
    to assess for recanalization. AC may be stopped if there is failure
    to recanalize.<ul>
<li>If pts are not candidates for AC, they'll simply be treated for
    complications of portal HTN</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-post-liver-transplant-management"><h1 id="hepatology-hepatology-post-liver-transplant-management-post-liver-transplant-management">Post-Liver Transplant Management<a class="headerlink" href="#hepatology-hepatology-post-liver-transplant-management-post-liver-transplant-management" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post Liver Transplant Management – Lauren Evers Carlini, Gabe Sandoval</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Immunosuppression (IS): pts typically start out on 2-3
    immunosuppression medications, including a calcineurin inhibitor
    (CNI, tacrolimus or cyclosporine), a glucocorticoid (prednisone),
    and potentially another agent (i.e., mycophenolate mofetil).
    Decreased over time, as long as there is no evidence of rejection</li>
<li>ID ppx:  PJP (trimethoprim-sulfamethoxazole), CMV if at risk for
    reactivation (valganciclovir or ganciclovir; highest risk is D+/R-;
    typically 3-6 months based on when ppx is stopped), and candida
    (fluconazole) for weeks to months after LT.</li>
<li>Screening for malignancy: post-transplant pts are at increased risk
    of malignancy due to IS. Pts must follow all standard cancer
    screening guidelines, as well as annual dermatology evaluation for
    skin cancers (high incidence of SCC).</li>
<li>Avoid live vaccines after transplantation; pts are given a list and
    in general admitted pts are not given vaccinations in house.</li>
<li>When admitted, LT recipients should have home IS meds continued
    (unless otherwise advised by attending or transplant pharmacist),
    with daily trough levels. See below.</li>
<li>Hepatology should always be consulted for these pts</li>
</ul>
<p>Transplant medications</p>
<p>Tacrolimus:</p>
<ul>
<li>Mainstay of post-transplant IS</li>
<li>Doses should be timed for 0600/1800 while admitted, regardless of
    home schedule</li>
<li>Pts need tacro levels QAM at 0500 while hospitalized(specific order
    in Epic);</li>
<li>Goal levels (generally):<ul>
<li>0-3 months post-transplant: 8-10 ng/mL</li>
<li>3-12 months: 6-8 ng/mL</li>
<li>>12 months: 3-6 ng/mL</li>
</ul>
</li>
<li>Side effects: Nephrotoxicity, neurotoxicity (HA, confusion, seizure,
    paresthesia’s, tremor; more common w/tacrolimus vs cyclosporine),
    N/V/D, hyperkalemia, hypomagnesemia, hyperglycemia, hyperuricemia,
    alopecia, HTN, HLD</li>
<li>Note: transplant pharmacists (on weekdays) are your go-to resource
    for adjusting dosage and goal levels; you will not be making these
    decisions independently</li>
</ul>
<p>Cyclosporine:</p>
<ul>
<li>Used in pts transplanted before tacrolimus was available, pts unable
    to tolerate tacrolimus, or those with a contraindication to
    tacrolimus</li>
<li>Doses should be timed for 0600/1800 while admitted, regardless of
    home schedule</li>
<li>Pts need cyclosporine levels QAM at 0500 while hospitalized
    (specific order in Epic)</li>
<li>Goal levels (generally):<ul>
<li>0-3 months post-transplant: 150-200 ng/mL</li>
<li>3-6 months: 150 ng/mL</li>
<li>6-12 months: 100 ng/mL</li>
<li>>12 months: 60-100 ng/mL</li>
</ul>
</li>
<li>Side effects: Nephrotoxicity, hypomagnesemia, hyperglycemia,
    neurotoxicity (HA, tremors, paresthesia, seizure), gingival
    hyperplasia, hirsutism, malignancy (lymphoma), HTN, HLD</li>
</ul></section><section class="print-page" id="hepatology-hepatology-sbp"><h1 id="hepatology-hepatology-sbp-sbp">SBP<a class="headerlink" href="#hepatology-hepatology-sbp-sbp" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous Bacterial Peritonitis (SBP) – Patricia Checinski</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Infection of ascitic fluid without evidence of a surgical
    intra-abdominal source</li>
<li>Presentation <strong>:</strong>
    fever, abdominal pain, encephalopathy, renal failure, acidosis, or
    leukocytosis, though may present with only one of the aforementioned
    symptoms</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Any pt w/cirrhosis and ascites who is admitted should have
    diagnostic paracentesis to rule out SBP. Delaying paracentesis &gt; 12
    hours is associated with a 2.7-fold increase in mortality.</li>
<li>Obtain cell count with diff. Calculate the PMNs: total nucleated
    cells x % neutrophils.</li>
<li>PMNs &gt; 250 cells is diagnostic of SBP. If there are greater than
    100k RBCs, you should correct for them: for every 250 RBCs, subtract
    1 PMN</li>
<li>A positive ascitic bacterial culture is diagnostic and should be
    treated regardless of PMN count. You will frequently see
    culture-negative SBP (neutrocytic ascites)</li>
<li>The absence of secondary causes of bacterial peritonitis is also
    required for diagnosis, but is assumed in pts w/ cirrhosis and known
    ascites (see below if concerned for secondary bacterial peritonitis)</li>
</ul>
<p>Management</p>
<ul>
<li>Immediately start empiric antibiotics.</li>
<li>Guidelines recommend cefotaxime IV 2gm q8 hours for 5 days, but we
    commonly use ceftriaxone IV 2gm q24h for 5-7 days at VUMC and
    Nashville VA.<ul>
<li>Most common culprits (E. coli, Klebsiella, streptococcal
    species, staphylococcal species)</li>
<li>If SBP developed while on ppx, hospital admission within 90 days
    or diagnosed &gt;48 hours of admission, consider zosyn or meropenem</li>
</ul>
</li>
<li>IV albumin 1.5 g/kg on day 1 and 1g/kg on day 3</li>
<li>Discontinue beta-blockers once SBP develops and do not restart until
    SBP is completely treated, Na &gt;130, BP is satisfactory (as noted
    above), and no AKI</li>
<li>PPI’s
    ↑
    risk for SBP in pts w/ cirrhosis, and should be reviewed for
    appropriateness (GERD, hx PUD, RYGB with anastamotic ulcers) and
    discontinued if not needed</li>
<li>It is not always necessary to perform repeat paracentesis to confirm
    resolution of infection or down trending cell counts, but this is
    attending-dependent and may be performed</li>
<li>Paracentesis should be repeated if pt continues to have signs or
    symptoms of infection<ul>
<li>PMN \&lt; 250 cells/ mm <sup>3</sup>
    
    do not restart antibiotics</li>
<li>PMN &gt; pre-treatment PMN count
    
    look for secondary source (hollow viscus injury or loculations),
    or reconsider choice of antibiotic</li>
<li>PMN \&lt; pre-treatment PMN count but &gt;250 cells/mm <sup>3</sup>
    
    continue abx, repeat tap in 48 hrs</li>
</ul>
</li>
</ul>
<p>Prophylaxis: <strong>Three Indications</strong></p>
<ul>
<li>Inpatient with GI bleed
    
    ceftriaxone 1g daily followed by ciprofloxacin 500mg BID (preferred)
    or Bactrim one DS tablet BID once able to take PO, for total of 5-7
    days.</li>
<li>Outpatient lifelong ppx for patients with prior SBP (Bactrim DS tab
    daily or cipro 500mg daily). Alternatives: cefdinir 300mg qd and
    augmentin 875/125qd—only use if contraindications to the others and
    would discuss with hepatology team</li>
<li>Outpatient lifelong ppx for patients with ascitic protein \&lt; 1.5
    <strong>AND</strong><ul>
<li>Child Pugh Class C cirrhosis + Bili &gt; 4</li>
</ul>
</li>
</ul>
<p>OR</p>
<ul>
<li>
<ul>
<li>Renal Dysfunction (Cr &gt; 1.2, Na \&lt;125, OR BUN &gt; 25)</li>
</ul>
</li>
</ul>
<p>If suspicion is high for secondary bacterial peritonitis:</p>
<ul>
<li>Examine serum-ascites albumin gradient (SAAG). SBP develops in pts
    with portal hypertension, defined by SAAG &gt; 1.1 g/dL. SBP is
    unlikely if SAAG is \&lt; 1.1 g/dL.</li>
<li>Runyon’s Criteria to distinguish, requires &#8532; criteria below
    (protein, glucose, LDH):</li>
<li>While not particularly sensitive, an ascitic leukocyte count of
    5-10k should prompt consideration of secondary peritonitis</li>
<li>Amylase from fluid can also be helpful to point towards pancreatic
    ascites, while bilirubin can indicate gallbladder perforation.
    Peritoneal fluid CEA and alkaline phosphatase can additionally help
    identify hollow viscus injury.</li>
<li>Evaluate with cross-sectional imaging and surgical consultation as
    appropriate</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Spontaneous</td>
<td>Secondary</td>
</tr>
<tr>
<td>Protein (g/dL)</td>
<td>\&lt; 1</td>
<td>> 1</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>≥50</td>
<td>\&lt; 50</td>
</tr>
<tr>
<td>LDH (U)</td>
<td>Elevated, but \&lt; 225</td>
<td>> 225</td>
</tr>
<tr>
<td>Organisms</td>
<td>0-1</td>
<td>Polymicrobial</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hepatology-hepatology-upper-gi-bleed-cirrhosis"><h1 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-upper-gi-bleed-in-cirrhosis">Upper GI Bleed in Cirrhosis<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-upper-gi-bleed-in-cirrhosis" title="Permanent link">&para;</a></h1>
<p>Gastroesophageal Varices and Hemorrhage – Patricia Checinski</p>
<p>Background</p>
<ul>
<li>Form due to portosystemic collaterals and enlarge in the setting of
    portal HTN, typically through the coronary and/or short gastric
    veins</li>
<li>Mechanistically: intrahepatic resistance to portal flow from
    regenerative nodules and fibrosis, as well as
    #
    intrahepatic vascular tone due to endothelial dysfunction</li>
<li>Variceal hemorrhage is the cause of ~ 70% of UGIB in pts with
    portal HTN</li>
<li>The risk of mortality with each episode of esophageal variceal
    hemorrhage (EVH) is 15-25%. Recurrence occurs in 60% of patients
    within 1-2 years of the index event</li>
</ul>
<p>Variceal Screening:</p>
<ul>
<li>Not all pts with cirrhosis require screening. Can be omitted with
    low liver stiffness (on elastography) and with platelets &gt;150;
    otherwise screening is necessary.</li>
<li>Compensated cirrhosis w/o varices
    
    EGD q3yr, unless active liver injury (obesity, EtOH use, ongoing
    viral infxn), then q2yr</li>
<li>Compensated cirrhosis w/small varices
    
    EGD q2yr unless active liver injury, then q1yr</li>
<li>Decompensated cirrhosis with no or small nonbleeding varices
    
    EGD q1yr, and at initial time of decompensation</li>
<li>If these pts are on Non-selective
    β
    -blocker (NSBB) for 1º ppx w/HR 55-60, no need to screen</li>
</ul>
<p>Management (Non-Bleeding Varices)</p>
<ul>
<li>Indicated for medium to large varices or high-risk small varices
    (with red signs)</li>
<li>Primary ppx with either NSBB (preferred) or endoscopic band ligation
    (EBL), not both</li>
<li>NSBB: decrease hepatic venous pressure gradient (HVPG) and portal
    venous flow by decreasing cardiac output (
    β
    1 blockade) and allowing unopposed alpha-adrenergic activity (
    β
    2 blockade). Start NSBB such as nadolol (given nightly as portal
    pressures are highest at night) or propranolol (BID). Carvedilol has
    been shown to have a greater reduction in portal pressures and may
    be most preferred if tolerated.<ul>
<li>
<ul>
<li>For 2 º ppx, initiate ~72hr after acute bleed has resolved
        and octreotide discontinued</li>
<li>Titrate dose to reduce resting HR by ~25% (or target HR
    55-60)</li>
<li>Ask pt to check their HR and BP 2-3 days after discharge or
    after clinic visit and contact provider for further
    titration</li>
<li>Discontinue if: hypotension, AKI, SBP or hyponatremia
    (w/refractory ascites)</li>
</ul>
</li>
</ul>
</li>
<li>EBL is performed in medium to large varices, any varices with red
    wale marks</li>
<li>For secondary ppx, pts should be on BB AND undergo EBL. BB are
    associated with reduced mortality, while EBL is not (EBL does not
    eradicate the HVPG)</li>
<li>TIPS should not be used for primary ppx</li>
</ul>
<p>Management (Variceal Bleeding)</p>
<ul>
<li>Assess severity: tachycardia suggests 10% volume loss, orthostatic
    hypotension 20% volume loss, shock 30% volume loss</li>
<li>Place two large-bore IVs (18G or larger), resuscitate w/ blood
    products and albumin</li>
<li>If hypotensive, try MAC placement and activate massive transfusion
    protocol (MTP)</li>
<li>Consider intubation if need for emergent EGD, change in mental
    status, ongoing hematemesis, concern of ability to protect airway</li>
<li>Start octreotide 50 mcg IV bolus followed by continuous infusion of
    50 mcg/h, to be continued for 3 days should EVH be confirmed on
    endoscopy</li>
<li>Ceftriaxone 1g IV q24h for SBP prophylaxis (reduced mortality), then
    transition to PO ciprofloxacin for total 7-day course</li>
<li>IV protonix 40 mg BID (can dc after EGD if no ulcer)</li>
<li>Consult GI or alert fellow for upper endoscopy. Endoscopic therapies
    performed include variceal band ligation and sclerotherapy. EBL is
    more effective than sclerotherapy to control bleeding, sclerotherapy
    is used when ligation is not feasible. Repeat endoscopy if
    re-bleeding occurs after initial successful therapy.</li>
<li>Consider balloon tamponade with Blakemore as temporizing measure
    before definitive management. Patient must be intubated before
    placement, and preferably GI should be made aware prior to
    placement.</li>
<li>No role for the correction of INR, even in the presence of bleeding
    as excessive blood products and FFP can increase portal pressures
    and cause worsening bleeding<ul>
<li>Vitamin K can be given w/
    ↑
    INR, though is unlikely to help in the acute setting</li>
<li>Check Fibrinogen and give cryo if fibrinogen is \&lt;120 given its
    low volume</li>
<li>AASLD does not recommend specific platelet targets during
    variceal hemorrhage</li>
<li>Administer blood products in balanced ratio to avoid transfusion
    related coagulopathy (VUMC MTP is 6:4:1 of RBC:FFP:PLT)</li>
</ul>
</li>
<li>Transjugular intrahepatic portosystemic shunt (TIPS) can be
    considered as a rescue therapy for rebleeding or refractory
    bleeding, or occasionally as preemptive therapy,<ul>
<li>Order TTE early in course, as well as triple phase CT for
    pre-procedural planning. Duplex of portal and hepatic veins can
    be substituted in the setting of severe AKI</li>
<li>TIPS is relatively contraindicated in pts with elevated MELD,
    evidence of R heart dysfunction, and active or difficult to
    control hepatic encephalopathy</li>
<li>TIPS can be considered “preemptively” if bleeding was controlled
    in pts at high risk of failure or rebleeding (Child B 8-9 with
    active bleeding on prior endoscopy or Child C 10-13 regardless
    of endoscopy findings)</li>
<li>For gastric varices, endoscopic management can be attempted with
    EBL or sclerotherapy. TIPS should be considered early in pts
    with cardiofundal varices, though other interventional options
    are coiling via IR with BATO and BRT<ul>
<li>Recent data supports BRTO over glue injection for gastric
    varices</li>
</ul>
</li>
</ul>
</li>
<li>Following TIPS placement, there is no need for NSBB or EVL, as the
    TIPS has decompressed the portal system and should be considered
    definitive management.<ul>
<li>Recurrent bleeding should prompt investigation of the TIPS</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Hepatology</h1>
                        <h1 class='nav-section-title' id='section-hospital-medicine'>
                            Hospital medicine <a class='headerlink' href='#section-hospital-medicine' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hospital-medicine-hospital-medicine-choosing-wisely"><h1 id="hospital-medicine-hospital-medicine-choosing-wisely-choosing-wisely">Choosing Wisely<a class="headerlink" href="#hospital-medicine-hospital-medicine-choosing-wisely-choosing-wisely" title="Permanent link">&para;</a></h1>
<p>Don’t use antimicrobials to treat bacteriuria in non-pregnant adults
unless specific urinary tract symptoms are present. Cohort studies have
found no adverse outcomes for older men or women associated with
asymptomatic bacteriuria.</p>
<p>In pts with low pretest probability of venous thromboembolism (VTE),
order a high-sensitive D-dimer as the initial diagnostic test; don’t
start with imaging.</p>
<p>Don’t prescribe medications for stress ulcer prophylaxis to medical
inpatients unless at high risk for GI complications.</p>
<p>Do not order folate levels at all. In adults, consider folate
supplementation instead of serum folate testing in patients with
macrocytic anemia</p>
<p>Don’t test for Clostridium difficile infection in the absence of
diarrhea. (The lab won’t even run the sample if stool is formed)</p>
<p>Don’t continue antibiotics > 72 hours</p>
<p>in hospitalized pts unless pt has clear evidence of infection.</p></section><section class="print-page" id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients"><h1 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-guidelines-for-pregnant-patients">Guidelines for Pregnant Patients<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-guidelines-for-pregnant-patients" title="Permanent link">&para;</a></h1>
<p>Acute Cystitis:</p>
<ul>
<li>Significantly increased prevalence in pregnancy</li>
<li>Symptoms: dysuria (urgency/frequency common in pregnancy)</li>
<li>Diagnosis: evidence of pyuria and &gt;10 <sup>3</sup> cfu/ml (note, if
    neg would test for g/c)</li>
<li>Treatment: same as asymptomatic bacteriuria</li>
</ul>
<p>Pyelonephritis:</p>
<ul>
<li>Symptoms: fever, flank pain, and nausea/vomiting, dysuria</li>
<li>Diagnosis: clinical suspicion + pyuria and bacteriuria</li>
<li>Treatment: IV antibiotics for 1 <sup>st</sup> 24-48hrs; beta-lactams
    preferred</li>
<li>Mild to moderate: ceftriaxone or cefepime</li>
<li>Moderate to severe: piperacillin-tazobactam or meropenem</li>
</ul>
<p>Hyperemesis Gravidarum:</p>
<ul>
<li>Presentation: Hormone mediated nausea/vomiting typically starting
    before 9wks GA</li>
<li>Differential: gastroenteritis, hepatitis, biliary tract disease,
    obstruction, pancreatitis, pyelonephritis, nephrolithiasis, ovarian
    torsion, DKA, hyperparathyroidism, migraines, preeclampsia</li>
<li>Workup: BMP, mg, phos, LFTs, lipase (may be mildly elevated in HG),
    UA,</li>
<li>Treatment:<ul>
<li>
<ul>
<li>First Line: Ginger, doxylamine (25mg PO q6), pyridoxine
        (20mg PO q6)</li>
<li>Second Line: metoclopramide (10mg q6), Promethazine (12.5mg
    q6)</li>
<li>Third Line: ondansetron (8mg q12hrs, after 1<sup>st</sup> trimester)</li>
<li>Hydration: 1L LR on admission + banana bag q24hrs</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Hypertension:</p>
<ul>
<li>Both gestational HTN and preeclampsia/HELLP are typically
    diagnosed &gt;20w GA</li>
<li>Tx options: nifedipine, labetalol, methyldopa, hydral (2
    <sup>nd</sup> line), clonidine (2 <sup>nd</sup> line)</li>
<li>Avoid: ACEs, ARBs, MRAs, Nitroprusside</li>
</ul>
<p>Diabetes:</p>
<ul>
<li>Due to hormonal changes associated with pregnancy, pregnant patients
    are at higher risk for poor control and DKA</li>
<li>Oral regimens are generally transitioned to insulin-based regimens.</li>
</ul>
<p>GERD:</p>
<ul>
<li>1<sup>st</sup> Line: Can use antacids; avoid sodium bicarbonate and magnesium
    trisilicate</li>
<li>2<sup>nd</sup> Line: Sucralfate 1g PO TID</li>
<li>3<sup>rd</sup> Line: Cimetidine 200mg (30min prior to eating)</li>
</ul>
<p>Asthma:</p>
<ul>
<li>Similar rescue and controller medications as in non-pregnant patient</li>
<li>Would favor using LABA over leukotriene receptor antagonists or
    theophylline for additional therapy</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-lines-and-catheters"><h1 id="hospital-medicine-hospital-medicine-lines-and-catheters-lines-and-catheters">Lines and Catheters<a class="headerlink" href="#hospital-medicine-hospital-medicine-lines-and-catheters-lines-and-catheters" title="Permanent link">&para;</a></h1>
<p>Foley Catheter</p>
<ul>
<li>Chronic Foleys generally should be exchanged at time of admission</li>
<li>Duration of use is biggest risk factor for CAUTI; consider removal
    on rounds daily</li>
<li>Any concern for catheter obstruction (particularly with blood clots)
    should prompt urgent urology consult for irrigation/intervention
    (typically after RN has attempted)</li>
</ul>
<p>PICC</p>
<ul>
<li>Single lumen: long term ABx, stable IV access with intermittent
    draws</li>
<li>Double lumen: special populations (ICU or chemo), TPN w/ lipids
    (incompatible with many IV medications)</li>
<li>Risk factors for CLABSI/VTE:
    ↑↑
    duration,
    ↑↑
    number of lumens, left arm, lower extremity</li>
<li>Removal at earliest time possible is key to preventing
    complications; patient comfort is not an indication for prolonging
    use</li>
</ul>
<p>G-Tube</p>
<ul>
<li>Troubleshooting: EGS consult for malposition/not functioning, wound
    consult for skin breakdown</li>
<li>G-tube study: 30mL Gastrograffin via tube [resident often must
    push], and order KUB</li>
</ul>
<p>Line Flushes</p>
<ul>
<li>PIV: heparin 10u/ml</li>
<li>Central line: heparin 100u/ml</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-mobility-and-hospital-therapy"><h1 id="hospital-medicine-hospital-medicine-mobility-and-hospital-therapy-mobility-and-in-hospital-therapy">Mobility and In-Hospital Therapy<a class="headerlink" href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy-mobility-and-in-hospital-therapy" title="Permanent link">&para;</a></h1>
<p>Add columns for “PT DC Recs” and “OT DC Recs” to see dispo plans on your
EPIC list, and consult PT/OT early in hospitalization!</p>
<ul>
<li>How to reach PT/OT/SLP in hospital:<ul>
<li>Check “Care Team” in Patient Summary tab for pts’ specific
    provider and page their associated pager</li>
<li>If provider is not listed:<ul>
<li>For PT/OT page Inpatient Rehab pager 835-1147</li>
<li>For SLP: see last note and page number at the bottom</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Physical Therapy: specifically targets mobility and activity to overcome
physical impairment. (Think: lower extremity and gait).</p>
<p>Occupational Therapy: aims to improve pt’s ability to participate in
daily activities, often involving use of the hands. Skills are tailored
to pt’s cognitive abilities. (Think: head and upper extremity).</p>
<p>Speech Language Pathology</p>
<ul>
<li>Perform fluoro-guided video swallow studies and provide guidance for
    mechanically altered solid and liquid diets</li>
<li>Can perform cognitive assessment on patients, helping in assessment
    of competency</li>
</ul>
<p>Ordering Home Health</p>
<ul>
<li>VU: CM typically coordinates this for you. If not, place ambulatory
    referral to home health in discharge orders. Select needed services
    on dropdown menu</li>
<li>VA: Orders
    à
    Consult Menu
    à
    “Services NOT offered by TVHS” (under Community Care on bottom
    right)
    à
    options for PT and OT under Skilled Home Health in rightmost column</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-telemetry"><h1 id="hospital-medicine-hospital-medicine-telemetry-telemetry">Telemetry<a class="headerlink" href="#hospital-medicine-hospital-medicine-telemetry-telemetry" title="Permanent link">&para;</a></h1>
<p>Background</p>
<ul>
<li>~43% of monitored pts do not have a true indication</li>
<li>Leads to alarm fatigue, unnecessary workups, and is expensive</li>
<li>Telemetry is not a substitute for more frequent vital signs</li>
<li>Discuss frequently on rounds: always reassess need and indication</li>
<li>HDS pts w/o troponin elevation or new arrythmias that admission are
    typically appropriate for transfer without telemetry</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Scenario</td>
<td>Duration</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Cardiac</td>
</tr>
<tr>
<td>ACS Post-MI</td>
<td>24-48h 48h after revascularization</td>
</tr>
<tr>
<td>Vasospastic angina</td>
<td>Until symptoms resolve</td>
</tr>
<tr>
<td>Any event requiring ICD shocks</td>
<td>Remainder of hospitalization</td>
</tr>
<tr>
<td>New/unstable atrial tachyarrhythmias</td>
<td>Until stable on medical therapies</td>
</tr>
<tr>
<td>Chronic AF w/ recurrence of RVR</td>
<td>Clinical judgement</td>
</tr>
<tr>
<td>Ventricular tachyarrhythmias</td>
<td>Until definitive therapy</td>
</tr>
<tr>
<td>Symptomatic bradycardia</td>
<td>Until definitive therapy</td>
</tr>
<tr>
<td>Decompensated CHF</td>
<td>Until underlying cause treated</td>
</tr>
<tr>
<td>Procedural</td>
<td>Procedural</td>
</tr>
<tr>
<td>Ablation (regardless of co-morbidities)</td>
<td>12-24h after procedure</td>
</tr>
<tr>
<td>Cardiac surgery</td>
<td>48-72h, or until discharge if high risk for decompensation</td>
</tr>
<tr>
<td>Non-cardiac major surgery in patient with AF risk factors</td>
<td>Until discharge from step-down or ICU</td>
</tr>
<tr>
<td>Conscious sedation</td>
<td>Until patient awake, alert, HDS</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Miscellaneous</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>Until clinically stable</td>
</tr>
<tr>
<td>CVA</td>
<td>24-48h</td>
</tr>
<tr>
<td>Electrolyte derangement (K, Mg)</td>
<td>Until normalization</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>Clinical judgement</td>
</tr>
<tr>
<td>Drug overdose</td>
<td>Until free of influence of substance</td>
</tr>
</tbody>
</table>
<p>Notable non-indications:</p>
<ul>
<li>PCI for non-ACS indication (i.e. pre-transplant), non-cardiac chest
    pain, Pt with AICD admitted for non-cardiac cause, non-cardiac
    surgery, chronic AF and clinically stable</li>
<li>Contraindicated in hospice/comfort care</li>
<li>Nearly all noncardiac conditions not in the ICU (i.e.,
    undifferentiated sepsis, stable GI bleed, alcohol withdrawal) upon
    transfer out of ICU</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-utilization-management"><h1 id="hospital-medicine-hospital-medicine-utilization-management-utilization-management">Utilization Management<a class="headerlink" href="#hospital-medicine-hospital-medicine-utilization-management-utilization-management" title="Permanent link">&para;</a></h1>
<p>Utilization Management (UM)</p>
<p>Facilitates appropriate reimbursement for hospitalized patients. The UM
team reviews each patient’s status daily and a hospitalist representing
UM participates in Huddle at both VU and the VA.</p>
<p>Patient Status: observation (OBS) vs inpatient (IP)</p>
<ul>
<li>OBS: short stays with frequent reassessments to determine IP versus
    discharge<ul>
<li>
<ul>
<li>May have ongoing treatments (i.e. IV antibiotics, nebs,
        etc.), not only monitoring</li>
<li>Same-day procedures admitted with complications</li>
</ul>
</li>
</ul>
</li>
<li>IP: longer stays (&gt;2 midnights) w/ high risk of adverse outcomes,
    inpatient-only procedure, need for inpatient testing, or ICU admits<ul>
<li>
<ul>
<li>LOS should cross 2 midnights</li>
<li>Do not use for custodial care, patient/physician
    convenience, or “while they are here” expedited workups</li>
<li>Do not change status if Pt dies, leaves AMA, transfers
    hospitals, or opts for hospice</li>
</ul>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Hospital medicine</h1>
                        <h1 class='nav-section-title' id='section-infectious-diseases'>
                            Infectious diseases <a class='headerlink' href='#section-infectious-diseases' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="infectious-diseases-infectious-diseases-aids-defining-conditions"><h1 id="infectious-diseases-infectious-diseases-aids-defining-conditions-aids-defining-conditions">AIDS Defining Conditions<a class="headerlink" href="#infectious-diseases-infectious-diseases-aids-defining-conditions-aids-defining-conditions" title="Permanent link">&para;</a></h1>
<p>AIDS Defining Clinical Conditions – Rebecca Choudhury</p>
<p>AIDS is defined by HIV infection with concurrent absolute CD4 count
\&lt;200, CD4 percentage \&lt;14%, or one of the following conditions,
predominately opportunistic infections and HIV associated malignancies</p>
<p>Neurologic</p>
<p>/Ophthalmologic</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CNS</p>
<p>toxoplasmosis</p>
<ul>
<li>Presentation: Variable, depending on disease burden/location, may
    include AMS, headache, seizure, ataxia, and focal neurologic
    deficits, &plusmn; fever and flu-like symptoms</li>
<li>Evaluation: MRI w/Ring-enhancing lesions on brain imaging ( <em>Note</em> :
    can appear similar to CNS lymphoma), serum Toxoplasma IgG/IgM and
    (ideally) CSF Toxoplasma PCR. Brain biopsy may be indicated if
    diagnostic uncertainty.</li>
<li>Management: Pyrimethamine, sulfadiazine, and leucovorin is the
    preferred regimen, discuss dosing with pharmacy. Alternative
    regimens: clindamycin, Bactrim, atovaquone, and/or azithromycin.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Progressive multifocal leukoencephalopathy (PML)</p>
<ul>
<li>Presentation: chronic (weeks to months), progressive neurologic
    dysfunction, particularly incoordination
    and other motor dysfunction, aphasia, sometimes cognitive impairment
    and personality changes</li>
<li>Evaluation:  MRI brain w/patchy areas of demyelination in the
    subcortical white matter; location is variable, but p
    arietal, occipital, and cerebellar involvement are common. JC virus
    PCR from CSF. Brain biopsy (uncommonly done)</li>
<li>Management: Initiation of ART may slow/stop progression. Fatal if
    HIV goes untreated.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>HIV-related encephalopathy</p>
<ul>
<li>Presentation: Similar to other progressive dementias, with short
    term memory loss followed by
    worsening global cognitive dysfunction, motor deficits, sometimes
    seizures in late stages</li>
<li>Evaluation: MRI w/diffuse cerebral atrophy and/or demyelinating
    lesions similar to PML. CSF w/elevated protein &plusmn; lymphocytic
    pleocytosis, with no alternative cause. Send HIV RNA from the CSF,
    usually + in HIV encephalopathy</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Cryptococcal meningitis</p>
<ul>
<li>Presentation: Subacute to chronically worsening HA and fevers;
    meningismus and photophobia may be present but are often absent;
    rarely, focal neurologic deficits</li>
<li>Evaluation: LP to check opening pressure and can send serum and CSF
    Cryptococcus Ag. Brain imaging may be non-diagnostic</li>
<li>Treatment: Induction therapy with amphotericin and flucytosine x14
    days (at least), with repeat LP close to end of
    induction to confirm CSF inflammation is improving and fungal
    culture is negative.
    Maintenance therapy consists of high dose fluconazole for at least 8
    weeks. Pts may require serial LP to manage ICP</li>
<li>Delay ART for several weeks after start of treatment to avoid risk
    of IRIS.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CMV retinitis (with vision loss)</p>
<ul>
<li>Presentation: Blurry vision, focal blind spots, visual field
    deficits, or scotomas and floaters. Typically begins unilateral,
    though often progresses to bilateral involvement.</li>
<li>Evaluation: Always consult ophtho if you suspect it! Hemorrhagic
    retinitis, “tomato soup and milk” appearance on dilated exam. May
    cause complete retinal detachment. Check CMV pcr serum (or vitreous)</li>
<li>Management:  PO valgancyclovir (+intravitreous ganciclovir or
    foscarnet in severe disease). If not on ART, must delay ART for at
    least 2 weeks after start of CMV retinitis treatment to prevent
    immune recovery uveitis</li>
</ul>
<p>Pulmonary</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Pneumocystis jirovecii pneumonia (PJP)</p>
<ul>
<li>Presentation: fever, shortness of breath, cough (usually
    non-productive), sometimes night sweats and weight loss. Hypoxia out
    of proportion to exam.</li>
<li>Evaluation: CT chest appearance usually bilateral and diffuse with
    GGOs and cystic lesions of varying size. Large cysts can rupture,
    causing pneumothorax.<ul>
<li>Induced sputum (or bronchoscopy sample) with cytology and GMS
    stain.</li>
<li>Send serum LDH and 1,3-BD-glucan:  should be elevated, but are
    nonspecific.</li>
</ul>
</li>
<li>Management: Bactrim is the preferred treatment; PO is preferable as
    Bactrim is 100% bioavailable. **If patient is hypoxic, need to
    consider of adding steroids, can measure A-a gradient. Alternative
    regimens may include primaquine + clindamycin or IV (NOT inhaled)
    pentamidine.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Pulmonary tuberculosis</p>
<ul>
<li>Presentation: With low CD4, can have upper lobe cavities but also
    atypical radiographic pattern, including a normal-appearing CXR.
    Have a high degree of suspicion in any patient with advanced HIV and
    respiratory complaints.</li>
<li>Evaluation: TB skin tests and IGRAs have a high false negative rate
    in advanced HIV. At VUMC, any pt with HIV and respiratory complaints
    must be placed on airborne until TB ruleout- 3 sputum mycobacterial
    cultures collected at least 8 hours apart. If concentrated smear is
    negative x3, TB is unlikely (though have to follow up final culture
    to be sure).</li>
<li>Management: RIPE therapy is the standard initial treatment, with
    adjustment if needed for drug resistance or contraindications</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Herpes simplex tracheobronchitis and/or pneumonitis/pneumonia</p>
<ul>
<li>Evaluation: bronchoscopy with positive HSV PCR from BAL &plusmn; lung
    biopsy. (Usually associated with HSV-1)</li>
<li>Management:  agent and duration not well defined for
    bronchopulmonary disease; depending on severity of presentation,
    likely IV acyclovir to start followed by transition to PO antiviral
    once evidence of clinical improvement, for a total of 10-14 days.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Recurrent pneumonia NOS</p>
<p>Histoplasmosis, cryptococcosis, coccidiomycosis, and non-TB
mycobacterial infections (including MAC) limited to the pulmonary system
are not AIDs defining illnesses, though pts with advanced HIV and other
severely immunosuppressed states are at higher risk.</p>
<p>Gastrointestinal</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Esophageal candidiasis</p>
<ul>
<li>Presentation: Dysphagia, odynophagia or both. Concurrent
    oropharyngeal candidiasis (“thrush’) is common but not universal.</li>
<li>Evaluation: Typically presumptive. Treatment is the test; start
    fluconazole and consider EGD if symptoms do not improve after
    several days (in which case candidiasis may be severe, or it might
    not be the cause)</li>
<li>Management: Fluconazole; nystatin is ineffective, especially in the
    severely immunocompromised</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Herpes simplex esophagitis</p>
<ul>
<li>Evaluation: EGD shows diffuse ulcerations throughout the esophagus;
    in severe disease ulcers may coalesce into dark patches, “black
    esophagus.” Esophageal biopsy is definitive, but can infer based on
    EGD appearance and serum studies.</li>
<li>Management: Similar to other mucocutaneous infections, consider IV
    acyclovir at first and transition to PO once clinically improved</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CMV esophagitis/enteritis/colitis</p>
<ul>
<li>Presentation: GI bleeding (colitis) or dysphagia and odynophagia
    (esophagitis)</li>
<li>Evaluation: serum CMV PCR, consult GI for consideration of
    EGD/colonoscopy</li>
<li>Management: (val)ganciclovir, foscarnet if ganciclovir resistance or
    contraindication</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Chronic (&gt;1 mo) intestinal isosporiasis</p>
<ul>
<li>Evaluation: Stool ova/parasite can capture Iospora belli (new name
    Cystoisospora belli), may need serial analysis due to intermittent
    shedding. Oocysts may also be seen on duodenal biopsy.</li>
<li>Management: Bactrim; pyrimethamine + leucovorin if Bactrim is
    contraindicated
    -</li>
</ul>
<p>Chronic intestinal cryptosporidiosis</p>
<ul>
<li>Presentation: Diarrhea; may infect respiratory tract, causing
    nonproductive cough</li>
<li>Evaluation: on GiPP or Cryptosporidium Ag</li>
<li>Management: Early initiation or optimization of ART; Monotherapy
    with nitazoxanide is preferred; raising CD4 count &gt;100 is necessary
    to cure infection</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Recurrent salmonella septicemia</p>
<ul>
<li>Generally sensitive to fluoroquinolones, but if not clinically
    improving as expected you can request sensitivities from the
    microbiology lab.</li>
</ul>
<p>Neoplastic</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Non-Hodgkin’s lymphoma - Burkitt’s, immunoblastic (subset of DLBCL), and
1º CNS</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Kaposi’s sarcoma</p>
<ul>
<li>Presentation: Distinctive mucocutaneous lesions, usually raised,
    papular, violaceous or darkly colored, non-tender and non-pruritic.
    Can also involve the visceral organs (esp lungs and GI tract) and
    deep lymphatic system.</li>
<li>Evaluation: clinical, tissue biopsy for staging, HHV-8 serum PCR.</li>
<li>Management: Limited mucocutaneous disease may resolve with
    initiation/optimization of ART, but widespread or resistant disease
    may require additional local therapies (ex radiation) or systemic
    chemo</li>
<li>Bacillary angiomatosis (caused by Bartonella) may present similarly,
    but can be distinguished from KS on biopsy. It is neither a cancer
    nor an AIDS defining clinical condition, and is usually treated with
    doxycycline.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Cervical cancer</p>
<ul>
<li>Presentation, diagnosis, and treatment are essentially the same as
    in HIV-negative patients, but incidence is higher and disease
    progression is often more rapid</li>
</ul>
<p>Multisystem/Miscellaneous</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extrapulmonary or disseminated Mycobacterial infection (TB and non-TB)</p>
<ul>
<li>TB can go everywhere; some notable extrapulmonary sites include
    lymph nodes (e.g., scrofula), bones and joints (e.g., Pott’s disease
    of the spine), pleura and pericardium, GU tract, and CNS. Dx can
    come from tissue culture and sometimes MTB PCR for more rapid
    detection (needs ID approval).</li>
<li>TB-IRIS may be severe (esp with high infection burden) and hard to
    distinguish from TB treatment failure; can also be seen in
    adequately treated TB (provoked by the presence of dead bacteria)
    and undiagnosed latent TB.</li>
<li>Disseminated MAC is usually diagnosed with AFB blood culture (only 1
    positive needed). Think about it in patients with uncontrolled HIV
    and severe immunosuppression (esp CD4 \&lt;50), with unintentional
    weight loss, chronic diarrhea and/or dyspnea, and evidence of GI
    malabsorption or with bone marrow suppression</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extrapulmonary or disseminated Histoplasmosis, Cryptococcocosis, and
Coccidiodomycosis</p>
<ul>
<li>Can be difficult to distinguish based on clinical presentation and
    imaging alone. Diagnosed by culture and/or antigen testing depending
    on the organism and site of infection, and diagnosis may be
    supported by serologic studies.</li>
<li>Initial treatment of choice: liposomal amphotericin B in almost all
    cases</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Chronic mucocutaneous HSV</p>
<ul>
<li>Defined as mucocutaneous lesions present for &gt;1 month, can be
    present at any site</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-antimicrobial-prophylaxis"><h1 id="infectious-diseases-infectious-diseases-antimicrobial-prophylaxis-antimicrobial-prophylaxis">Antimicrobial prophylaxis<a class="headerlink" href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis-antimicrobial-prophylaxis" title="Permanent link">&para;</a></h1>
<p>Antimicrobial Prophylaxis per CD4 Counts – Rachael Pellegrino</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 counts</td>
<td>Opportunistic Infection</td>
<td>Indication for Prophylaxis</td>
<td>Medication</td>
<td>Special Notes</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Pneumocystis Pneumonia (PJP)</td>
<td>CD4 \&lt; 200, or CD4 \&lt; 14%, or CD4 200-250 w/ delayed init. ART &amp; poor f/u</td>
<td>TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW</td>
<td>If intolerant of TMP-SMX: dapsone*, or pentamidine, or atovaquone</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Toxoplasma gondii encephalitis</td>
<td>Toxoplasma IgG + and CD4 \&lt; 100</td>
<td>TMP-SMX 1 DS tab daily</td>
<td>Alternative regimens: Dapsone, or Atovaquone (all regimens effect. for PJP )</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Mycobacterium avium- intracellulare (MAC, MAI)</td>
<td>Only if not on fully suppressive ART and active disseminated MAC is ruled out</td>
<td>- Azithromycin 1200 mg weekly, or -Clarithromycin 500 mg BID, or - Rifabutin 300 mg daily</td>
<td>NOT indicated for those initiating ART</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Infection</th>
<th>Screening Indication</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis A Virus (HAV)</td>
<td>Non-immune w/ ↑ risk for HAV infection (MSM, IVDU) or chronic liver disease</td>
<td>HAV vaccine</td>
</tr>
<tr>
<td>Hepatitis B Virus (HBV)</td>
<td>Pts w/o chronic HBV or non-immune</td>
<td>HBV vaccine. Ideally admin. before CD4 \&lt; 350</td>
</tr>
<tr>
<td>Human Papilloma virus (HPV)</td>
<td>Age 13-45</td>
<td>HPV vaccine series</td>
</tr>
<tr>
<td>Influenza A and B Virus</td>
<td>All patients</td>
<td>Yearly inactivated influenza vaccine</td>
</tr>
<tr>
<td>Latent Mycobacterium tuberculosis infection (LTBI)</td>
<td>-Pts with positive screening test for LTBI w/ no evidence of active disease. -Pts w/ known exposure</td>
<td>(INH 300mg + pyridoxine 25-50mg) PO daily for 9 months</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>All patients</td>
<td>PCV13 and PPV23 (order and timing depends on previous vaccination history and CD4)</td>
</tr>
<tr>
<td>Syphilis</td>
<td>All pts exposed to sex partner with syphilis diagnosis</td>
<td>Screening for syphilis and gonorrhea/chlamydia with treatment if indicated.</td>
</tr>
<tr>
<td>Varicella Zoster Virus (VZV)</td>
<td>Pre-exposure: CD4&gt;200, no previous vaccine.Shingrix (recombinant vaccine) is not live virus, only Zostavax (live virus) is contraindicated for CD4 \&lt;200). Post-exposure: Close contact, particularly if CD4 \&lt;200</td>
<td>Pre-exposure: Consider vaccination Post-exposure: Varicella-zoster immune globulin</td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-bacteremia"><h1 id="infectious-diseases-infectious-diseases-bacteremia-bacteremia">Bacteremia<a class="headerlink" href="#infectious-diseases-infectious-diseases-bacteremia-bacteremia" title="Permanent link">&para;</a></h1>
<p>Bacteremia: Interpreting Verigene® Results – VASP</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>When BCx turn positive, the lab reports Gm stain and Verigene®
    results to help guide empiric therapy, while awaiting further
    species identification and susceptibilities.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Start empiric antibiotic therapy (based on clinical picture and
    table below)</li>
<li>Consider ordering repeat BCx x2 based on organism to document
    clearance<ul>
<li>Repeat for: Staph (MRSA or MSSA), Strep lugdunensis</li>
</ul>
</li>
<li>If source control &amp; no endovascular infxn, <strong>no need to repeat</strong>
    (most other strep and GNR’s</li>
<li>VUMC antibiograms
    can be used to reference typical resistance patterns and most common
    organisms in blood cultures.</li>
<li>Consider clinical picture: Do you have a likely source of
    bacteremia? Do you need to consider/assess for additional sources of
    infection?</li>
<li>Candida in
    a blood culture is <strong>NEVER</strong> considered a contaminant</li>
<li>Do not hesitate to consult Infectious Diseases (or page
    <strong>615-317-GERM</strong> ) with questions <span id="section-2"></span></li>
<li>Species identification and susceptibility is available in 2-3 days
    from positive culture</li>
</ul>
<p><strong>GRAM POSITIVE COCCI</strong></p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organism</td>
<td>Resistance Marker</td>
<td>Preliminary Recommendation</td>
</tr>
<tr>
<td>Staphylococcus aureus or Staphylococcus lugdunensis</td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr>
<td>Staphylococcus aureus or Staphylococcus lugdunensis</td>
<td>No mecA detected</td>
<td>Start nafcillin or cefazolin Stop empiric vancomycin IV</td>
</tr>
<tr>
<td>Staphylococcus epidermidis - Often skin contaminant - Repeat cultures, start  therapy if uncertain</td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr>
<td>Staphylococcus epidermidis - Often skin contaminant - Repeat cultures, start  therapy if uncertain</td>
<td>No mecA detected</td>
<td>Start nafcillin or cefazolin Stop empiric vancomycin IV</td>
</tr>
<tr>
<td>Other coagulase negative Staph Often skin contaminant Repeat cultures start abx if uncertain</td>
<td>NaN</td>
<td>Start vancomycin IV</td>
</tr>
<tr>
<td>Streptococcus: agalactiae, pyogenes, anginosus</td>
<td>NaN</td>
<td>Start penicillin IV Stop empiric vancomycin</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>NaN</td>
<td>Start ceftriaxone Stop empiric vancomycin Await PCN sensitivity data</td>
</tr>
<tr>
<td>Other Streptococcus</td>
<td>NaN</td>
<td>Continue empiric vancomycin, awaiting susceptibilities</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>vanA or vanB detected</td>
<td>Start daptomycin 8-10mg/kg/day IV Don’t treat w vancomycin IV Contact precautions</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>No vanA or vanB</td>
<td>Start ampicillin Stop empiric vancomycin IV</td>
</tr>
<tr>
<td>Enterococcus faecium</td>
<td>vanA or vanB detected</td>
<td>Start daptomycin 8-10mg/kg/day IV Don’t treat w vancomycin IV Contact precautions</td>
</tr>
<tr>
<td>Enterococcus faecium</td>
<td>No vanA or vanB</td>
<td>Start vancomycin IV</td>
</tr>
</tbody>
</table>
<p>GRAM POSITIVE RODS</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organism</td>
<td>Preliminary Recommendation</td>
</tr>
<tr>
<td>Listeria monocytogenes</td>
<td>Start ampicillin Stop empiric vancomycin IV</td>
</tr>
<tr>
<td>Other Gram positive rod Often skin contaminant Repeat cultures, start therapy if uncertain</td>
<td>Start vancomycin IV</td>
</tr>
</tbody>
</table>
<p>GRAM NEGATIVE RODS *Consult ID if carbapenem resistance detected*</p>
<table>
<thead>
<tr>
<th>Organism</th>
<th>Resistance Marker</th>
<th>Preliminary Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acinetobacter species</td>
<td>None</td>
<td>Start IV meropenem 1g q8h IV until sensitivities available</td>
</tr>
<tr>
<td>Acinetobacter species</td>
<td>ESBL (CTX-M)</td>
<td>Start meropenem 1g q8h IV Consider ID consult Contact precautions</td>
</tr>
<tr>
<td>Acinetobacter species</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Citrobacter or Serratia species</td>
<td>None</td>
<td>Start cefepime 2g q8h IV</td>
</tr>
<tr>
<td>Citrobacter or Serratia species</td>
<td>ESBL (CTX-M)</td>
<td>Start carbapenem therapy contact precautions</td>
</tr>
<tr>
<td>Citrobacter or Serratia species</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Enterobacter species</td>
<td>None</td>
<td>Start cefepime 2g q8h IV</td>
</tr>
<tr>
<td>Enterobacter species</td>
<td>ESBL (CTX-M)</td>
<td>Start carbapenem therapy contact precautions</td>
</tr>
<tr>
<td>Enterobacter species</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>None</td>
<td>Start IV ceftriaxone 2g q24h IV</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>ESBL (CTX-M)</td>
<td>Start carbapenem therapy Contact precautions</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Klebsiella pneumoniae or oxytoca</td>
<td>None</td>
<td>Start ceftriaxone 2g q24h IV</td>
</tr>
<tr>
<td>Klebsiella pneumoniae or oxytoca</td>
<td>ESBL (CTX-M)</td>
<td>Start carbapenem therapy Contact precautions</td>
</tr>
<tr>
<td>Klebsiella pneumoniae or oxytoca</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Proteus species</td>
<td>None</td>
<td>Start ceftriaxone 2g q24h IV</td>
</tr>
<tr>
<td>Proteus species</td>
<td>ESBL (CTX-M)</td>
<td>Start carbapenem therapy Contact precautions</td>
</tr>
<tr>
<td>Proteus species</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>None</td>
<td>Start IV cefepime 2g q8h IV</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>ESBL (CTX-M)</td>
<td>Start meropenem (do not start ertapenem) Contact precautions</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>carbapenem resistance</td>
<td>Consult Infectious Diseases Contact precautions</td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-brief-overview-art"><h1 id="infectious-diseases-infectious-diseases-brief-overview-art-brief-overview-of-art">Brief Overview of ART<a class="headerlink" href="#infectious-diseases-infectious-diseases-brief-overview-art-brief-overview-of-art" title="Permanent link">&para;</a></h1>
<p>Overview of Antiretroviral Therapy – Joseph Quintana</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed Dose Combination regimens</td>
<td>Fixed Dose Combination regimens</td>
<td>Renal Dose Adj.</td>
<td>Specific Considerations</td>
</tr>
<tr>
<td>Biktarvy®</td>
<td>Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>d/c if CrCl \&lt; 30; ok w/HD</td>
<td>↑ Metformin levels Contraindicated w/: rifampin, dofetilide, rifabutin Avoid close admin. w/: laxatives, sucralfate, iron, calcium</td>
</tr>
<tr>
<td>Triumeq®</td>
<td>Abacavir/ Dolutegravir/ Lamivudine</td>
<td>Dose adj individual components \&lt;50 mg/min</td>
<td>Dolutegravir can ↑ metformin &amp; dofetilide levels; dose adj needed w/rifampin use Same absorption issues with polyvalent cation administration (as below with bictegravir) also apply to dolutegravir</td>
</tr>
<tr>
<td>Genvoya®</td>
<td>Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>d/c if CrCl \&lt; 30; ok in HD</td>
<td>Many DDI with Genvoya (and other regimens with pharmacologic booster [cobicistat] due to CYP 3A4 inhibition</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuceloside RTI</td>
<td>Dose adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
<td>Hepatic dysfunction</td>
<td>↑ LDL/TG ↑ risk MI</td>
<td>Tenofovir (df)</td>
<td>Requires testing for HLA B5701; Avoid if previous hyper-sensitivity</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td>Renal (adj by CrCl)</td>
<td>Rash, Insomnia, Rhabdomyolysis, Hyperpigmentation in palms/soles</td>
<td>Lamivudine</td>
<td>Active against HBV</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>Renal (adj by CrCl)</td>
<td>Nausea, HA, peripheral neuropathy, neutropenia, rash</td>
<td>Emtritabine</td>
<td>Active against HBV</td>
</tr>
<tr>
<td>Tenofovir Alafenamide (TAF)</td>
<td>D/c for CrCl \&lt; 15</td>
<td>↑ lipids in TAF vs TDF</td>
<td>AED’s may $ levels</td>
<td>Tx of choice for HBV; ↑ lipids</td>
</tr>
<tr>
<td>Tenofovir Disoproxil (TDF)</td>
<td>Renal (adj by CrCl)</td>
<td>N/V, # LFT, asymptomatic # CK</td>
<td>--</td>
<td>Active against HBV</td>
</tr>
</tbody>
</table>
<p>NRTI Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Tenofovir
    alone is indicated for HBV, in which case you should be mindful of
    renal clearance when dosing. In HIV, it is only indicated in
    combination with emtricitabine and fixed-dose combination
    formulations, in which it is contraindicated if CrCl\&lt;30</p>
</li>
<li>
<p>Class-wide Side Effect: Lactic acidosis, steatosis and lipoatrophy</p>
</li>
<li>
<p>Resistance: M184V confers high resistance to emtricitabine and
    lamivudine, mid-level resistance to abacavir</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrase Inhibitor</td>
<td>Dose Adj.</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Raltegravir (RAL)</td>
<td>--</td>
<td>--</td>
<td>Rifampin, AED’s</td>
<td>--</td>
</tr>
<tr>
<td>Dolutegravir (DTG)</td>
<td>*see special points*</td>
<td>Hyperglycemia Weight gain</td>
<td>Rifampin, Efavirenz ↑metformin lvls</td>
<td>Avoid close admin w/ laxatives, sucralfate,  iron, calcium May ↑Cr, w/o effect on renal fxn</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNRTIs</td>
<td>Hepatic Adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>D/c if Child Pugh B/C</td>
<td>Psychosis, vivid dreams, SI, mania, seizures; ↑ Lipids &amp; glucose</td>
<td>Plavix, Azole, antifungals, some statins * clarithromycin, Buprenorphine</td>
<td>Give before meals; d/c if rash develops</td>
</tr>
<tr>
<td>Etravirine (ETR)</td>
<td>NaN</td>
<td>Hypersensitivity  ↑ Lipids &amp; glucose</td>
<td>Plavix, clarithromycin</td>
<td>NaN</td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>D/c if Child Pugh B/C</td>
<td>Steven Johnson Syndrome</td>
<td>Azoles, OCP’s, statins, clarithro-mycin</td>
<td>Don’t start if CD4 >250 in women, CD4 >400 in men; Don’t admin w/antacids</td>
</tr>
<tr>
<td>Rilpivirine (RPV)</td>
<td>NaN</td>
<td>Depression</td>
<td>AED’s, PPI’s, dexamethasone</td>
<td>Must be taken w/ full meal; Don’t use if HIV RNA >100k + CD4 \&lt; 200; Don’t admin w/antacids</td>
</tr>
<tr>
<td>Doravirine</td>
<td>NaN</td>
<td>Nightmares</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>NNRTI Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Class-wide Side Effect: hepatitis, rashes</p>
</li>
<li>
<p>Resistance: K103N resistance to efavirenz and nevirapine</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protease inhibitors</td>
<td>Hepatic Dose adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Atazanavir (ATV)</td>
<td>Based on Childs Pugh</td>
<td>Jaundice, Kidney stones AV block, Pancreatitis Rhabdomyolysis</td>
<td>CYP3A4 Inhibitors PPI and H2 blockers</td>
<td>Admin w/ meals</td>
</tr>
<tr>
<td>Darunavir (DRV)</td>
<td>NaN</td>
<td>Rashes Pancreatitis</td>
<td>CYP3A4 Inhibitors Azoles can be used cautiously with drug level monitoring</td>
<td>Must d/c if rash</td>
</tr>
<tr>
<td>Lopinavir (LPV)</td>
<td>NaN</td>
<td>AV block, QT changes Pancreatitis Hepatitis</td>
<td>CYP3A4 Inhibitors</td>
<td>Admin w/ meals</td>
</tr>
</tbody>
</table>
<p>Protease Inhibitor Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>All protease inhibitors must be boosted:</p>
<ul>
<li>Ritonavir: can cause MSK pain, rhabdomyolysis, not expected at
    usual doses</li>
<li>Cobicistat: may increase Cr without effect on renal function</li>
</ul>
</li>
<li>
<p>Class-wide Side Effects: hepatitis, hypersensitivity reactions,
    #
    cholesterol/TG, hyperglycemia, GI upset, lipodystrophy</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-cns-infection"><h1 id="infectious-diseases-infectious-diseases-cns-infection-cns-infection">CNS Infection<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-cns-infection" title="Permanent link">&para;</a></h1>
<p>Central Nervous System Infection – VASP</p>
<p>Meningitis</p>
<p>Evaluation</p>
<ul>
<li>Blood cultures prior to antibiotics if possible</li>
<li>Head CT pre-LP, only if: Immunocompromised, hx of CNS diseases
    (shunts, trauma tumors), papilledema on exam or FND, AMS, or new
    onset seizure.</li>
<li>If there is a delay in obtaining head CT or LP, DO NOT delay
    antibiotics.</li>
<li>Lumbar puncture (See Procedures Section):<ul>
<li>Opening pressure</li>
<li>Cell count + differential</li>
<li>Glucose</li>
<li>Protein</li>
<li>Bacterial culture</li>
<li>Send an extra tube or two of CSF to the lab, if possible, to be
    frozen in case extra testing is needed (Order ‘Miscellaneous
    test’ and for test name put “Please freeze CSF in virology;”
    reference lab: VUMC, specimen type: CSF)</li>
<li>Additional studies to consider in select pts: HSV 1, 2 PCR (NOT
    antibodies), VZV PCR, VDRL, Crypto Ag, fungal and/or AFB
    cultures, MTB PCR, West Nile Virus Ab, Enterovirus PCR,
    Histoplasma Ag, or BioFire. These should not be performed
    routinely on all patients and consult ID where management
    questions exist.</li>
<li>If BioFire is performed, double check what is included to avoid
    sending duplicate individual tests (ie HSV, VZV, enterovirus,
    etc.)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>ANTIBIOTICS AS SOON AS POSSIBLE:<ul>
<li>Ceftriaxone 2g IV <strong>q12h</strong> + Vancomycin, adjusted for renal
    function</li>
<li>Piperacillin-tazobactam <strong>cannot</strong> be used due to poor CNS
    penetration</li>
<li>IV ampicillin 2g q4h for optional coverage of <em>Listeria</em> for
    immunocompromised patients, pregnant women, or age &gt;50 (adjust
    based on renal function)</li>
<li>IV acyclovir 10 mg/kg q8h, if suspected HSV or VZV meningitis,
    make sure to run with adequate pre-hydration with NS</li>
<li>Consider empiric PO/IV doxycycline 100mg BID if tick-borne
    illness is suspected</li>
</ul>
</li>
<li>Steroids: Based on IDSA guidelines and a recent meta-analysis,
    steroids (Dexamethasone 0.15 mg/kg q6h) should be given about 10-20
    minutes before the first dose of antibiotics, or at the same time,
    in patients with suspected bacterial meningitis. IF pneumococcus is
    isolated, continue IV steroids for 2-4 days; otherwise, can d/c</li>
<li>ID consultation:
    Duration should be guided by ID and varies based on organism
    recovered</li>
</ul>
<p>Encephalitis</p>
<p>Background</p>
<ul>
<li>The presence or absence of normal brain function/cognition is the
    important distinguishing clinical feature between encephalitis and
    meningitis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>MRI more sensitive that CT, although imaging may or may not
    demonstrate abnormal radiographic findings in patients with
    encephalitis</li>
<li>LP – similar studies as for meningitis (see above) + BioFire MEP for
    ALL pts</li>
<li>Consider ID consult prior to LP to assess what additional tests
    should be ordered.</li>
</ul>
<p>Management</p>
<ul>
<li>Acyclovir 10mg/kg IV q8hr, consideration of antibacterial therapy if
    unable to conclusively exclude a bacterial meningitis, consideration
    of doxycycline if tick-borne infection is in the differential, and
    further treatment as guided by ID</li>
<li>ID consult is strongly encouraged for all patients with suspected
    encephalitis</li>
</ul>
<p>Brain Abscess</p>
<p>Evaluation</p>
<p>/Management</p>
<ul>
<li>Consult: Neurosurgery and ID</li>
<li>Blood Cultures, HIV testing in any patient with a brain lesion</li>
<li>Empiric antibiotics:<ul>
<li>IV Vancomycin (target trough 15 - 20 mcg/mL) + ceftriaxone 2g IV
    q12h + metronidazole 500mg IV/PO q6h</li>
<li>If concern for extension from otitis externa, use an
    antipseudomonal cephalosporin (cefepime 2g IV Q8h) instead of
    ceftriaxone</li>
<li>Brain abscesses generally polymicrobial, thus broad-spectrum
    antibiotics indicated</li>
</ul>
</li>
<li>Aminoglycosides, macrolides, tetracyclines (e.g. doxycycline),
    clindamycin, beta-lactam/beta-lactamase combinations (e.g., Zosyn)
    and 1 <sup>st</sup> -generation cephalosporins (e.g., cefazolin)
    should NOT be used as they do not cross BBB at high concentration.</li>
<li>Antibiotic Duration: Based on surgical drainage and Infe
    ctious Diseases guidance</li>
</ul>
<p>Epidural Abscess</p>
<p>Management</p>
<ul>
<li>If spinal lesion, consult ‘Spine surgery’ and it will be directed to
    Ortho-Spine or Neurosurgery, depending on who is on call.</li>
<li>Antibiotics should be started as soon as the diagnosis of epidural
    abscess is suspected, immediately following the collection of two
    sets of blood cultures<ul>
<li>Vancomycin 15-20mg/kg IV q8-12h (adjusted for renal function) +
    ceftriaxone 2g IV q24h (or q12hr if there is secondary
    meningitis)</li>
<li>Use cefepime 2g IV q8h instead of ceftriaxone if concern for
    Pseudomonas</li>
</ul>
</li>
<li>ID consult is strongly encouraged and they will guide duration</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-diabetic-foot-infection"><h1 id="infectious-diseases-infectious-diseases-diabetic-foot-infection-diabetic-foot-infection">Diabetic Foot Infection<a class="headerlink" href="#infectious-diseases-infectious-diseases-diabetic-foot-infection-diabetic-foot-infection" title="Permanent link">&para;</a></h1>
<p>Diabetic Foot Infection – VASP</p>
<p>Evaluation</p>
<ul>
<li>Plain radiograph for all pts; MRI w/contrast if abscess/osteo
    suspected</li>
<li>BCx (prior to antibiotics) if systemic signs of infection, or severe
    infection<ul>
<li>Do not culture swab of lesions, as these generally only grow
    colonizing organisms.</li>
</ul>
</li>
<li>Consult podiatry if osteomyelitis present for bone specimen culture
    and pathology (either from debridement specimen or bone biopsy)
    prior to starting antibiotics.</li>
<li>Consult surgery if c/f abscess, gas in tissue, joint involvement</li>
<li>Assess peripheral vasculature, consider arterial flow
    studies/vascular surgery consult</li>
</ul>
<p>Management</p>
<ul>
<li>Assess Severity:<ul>
<li>Mild: Local infxn, skin/subQ tissue only, erythema &gt;0.5 cm but
    ≤2cm from ulcer</li>
<li>Moderate: Local infxn w/erythema &gt; 2 cm from ulcer or deeper
    structures included without SIRS</li>
<li>Severe: Local infxn with systemic inflammation as evidenced by ≥
    2 SIRS criteria</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Non-purulent, no MRSA risk factors</td>
<td>Purulent, MRSA risk factors</td>
</tr>
<tr>
<td>Mild</td>
<td>Cephalexin 500 QID OR Amoxicillin-clavulanate 875/125 BID</td>
<td>TMP-SMX DS 1-2 tabs BID OR Doxycycline 100 BID</td>
</tr>
<tr>
<td>Moderate</td>
<td>Amoxicillin-clavulanate 875/125 BID OR Ampicillin-sulbactam 3g q6h OR Piperacillin-tazobactam 3.375g q8h ext infusion Levofloxacin 500 daily</td>
<td>TMP-SMX DS 1-2 tabs BID + cephalexin 500 QID OR Amoxicillin-clavulanate 875/125 BID Vancomycin 15-20mg/kg q8-12h + ampicillin-sulbactam 3g q6h (anaerobic but NO Pseudomonas cvg*) OR cefepime 2g q8h (Pseudomonas cvg) + metronidazole 500 q8h (anaerobic cvg)</td>
</tr>
<tr>
<td>Severe</td>
<td>Vancomycin 15-20 mg/kg q8-12h + cefepime 2g q8h + metronidazole 500 q8h</td>
<td>Vancomycin 15-20 mg/kg q8-12h + cefepime 2g q8h + metronidazole 500 q8h</td>
</tr>
</tbody>
</table>
<p>*Consider anti-pseudomonal coverage if at risk for <em>Pseudomonas
aeruginosa</em> infection (e.g. wet; failure of prior antibiotic therapy;
chronic wound). Consider anaerobic coverage with metronidazole if
foul-smelling and/or necrotic.</p>
<p>Additional</p>
<p>Information</p>
<ul>
<li>If pt HDS, hold abx until deep tissue/operative cultures obtained.</li>
<li>Most diabetic foot infections are polymicrobial in nature.</li>
<li>Many wounds colonized with MRSA and/or <em>Pseudomonas</em> improve even
    when antibiotic treatment not directed at those pathogens are
    administered.</li>
<li>Culture results may guide therapy, but all pathogens identified may
    not require treatment. Do not swab superficial swabs of the lesion.</li>
<li>Treatment is multidisciplinary and may require orthopedics,
    vascular, and/or endocrinology assessment and intervention.</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-endocarditis"><h1 id="infectious-diseases-infectious-diseases-endocarditis-endocarditis">Endocarditis<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-endocarditis" title="Permanent link">&para;</a></h1>
<p>Endocarditis – Justin Smith</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Multiple etiologies of endocarditis:</p>
<ul>
<li>Typical Bacterial<ul>
<li>S. aureus, Enterococcus spp (E. faecalis most commonly),
    viridans group streptococci, Strep gallolyticus (formerly S.
    bovis)</li>
<li>HACEK
    : Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella,
    Kingella</li>
</ul>
</li>
<li>Other infectious<ul>
<li>Culture negative: often recent antimicrobial exposure, slow
    growing organism</li>
<li>Coxiella, Brucella, Bartonella, Chlamydia, Legionella,
    Mycoplasma, Tropheryma whipplei, Propionibacterium acnes</li>
<li>Fungal: <em>Candida</em> and <em>aspergillus</em> most common</li>
</ul>
</li>
<li>Non-infectious: a.k.a., marantic endocarditis, Libbman-Sacks
    Endocarditis<ul>
<li>Rare
    , most common in advanced malignancy, SLE, inflammatory
    conditions</li>
<li>Endothelial injury with associated hypercoagulability</li>
<li>Higher risk for embolization compared to IE</li>
<li>Risk factors: IV drug use, congenital heart disease, valve
    abnormalities, intracardiac devices, recent cardiac surgery</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Fever (90%), Murmur (85%), Other: splenomegaly, splinter
    hemorrhages, Janeway lesions, Osler Nodes, Roth Spots</p>
</li>
<li>
<p>Persistent bacteremia despite appropriate treatment, new onset
    cardiac dysfunction, new onset valve abnormalities, stroke, other
    thromboembolic events, metastatic infections/abscesses, splenic
    abscess, septic pulmonary emboli</p>
</li>
</ul>
<p>Duke Criteria:</p>
<ul>
<li>Pathologic Criteria<ul>
<li>Microorganisms: culture or histology proven: vegetation,
    embolus, or intracardiac abscess</li>
<li>Pathologic vegetations: vegetation of abscess with histology
    proven endocarditis</li>
</ul>
</li>
<li>Clinical Criteria<ul>
<li>Major:<ul>
<li>2x positive blood cultures from a typical organism</li>
<li>Evidence of endocardial involvement</li>
</ul>
</li>
</ul>
</li>
<li>Minor<ul>
<li>Predisposing heart condition/IVDU</li>
<li>Fever</li>
<li>Vascular phenomena (Glomerulonephritis)</li>
<li>Immunologic phenomena (Osler Nodes, Roth Spots, +Rheumatoid
    factor, GN)</li>
<li>Micro (Cultures that don’t fit the above, or serologic evidence
    of acute infection)<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Definite: 2 Major, 1 major and 3 minor, or 5 minor</li>
<li>Possible: 1 major and 1 minor, or 3 minor</li>
<li>Rejected: firm alternate diagnosis, resolution of evidence with \&lt;4
    days of antibiotics, or absence of pathologic evidence with \&lt;4days
    of antibiotics</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical exam: murmur, decreased peripheral perfusion, evidence of
    heart failure, petechiae, splinter hemorrhages, Janeway
    lesions/Osler nodes, organomegaly</li>
<li>Blood cultures: at least three sets from different sites over a span
    of several hours</li>
<li>Echo (TTE vs TEE)<ul>
<li>It can be reasonable to start with TEE if pretest probability is
    high enough, if patient has known valvular abnormalities, or TTE
    will be technically difficult
-</li>
</ul>
</li>
<li>EKG: new heart block or prolonged PR raises concern for
    endocardial/perivalvular abscess. Endocarditis patients should be on
    telemetry, monitored closely by team</li>
<li>CXR: infiltrates suggestive of septic pulmonary emboli, pulmonary
    edema, cardiomegaly</li>
<li>Imaging of distant affected site if concerned for septic emboli</li>
<li>Other advanced imaging in select scenario: cardiac CTA, cardiac MRI,
    FDG-PET/CT</li>
</ul>
<p>Management</p>
<ul>
<li>Empiric antibiotics:<ul>
<li>If bacteria isolated from blood, reference bacteremia section
    for abx choice</li>
<li>If awaiting cultures<ul>
<li>Native valve: Vancomycin</li>
<li>Prosthetic valve: Vancomycin and cefepime, consider
    gentamicin</li>
</ul>
</li>
</ul>
</li>
<li>Duration: determined by ID, often 4-6 weeks</li>
<li>Surgical consult, if valve dysfunction, perivalvular abscess, large
    (&gt;20mm) vegetations</li>
</ul>
<p>Additional Information:</p>
<ul>
<li>
<p>Complications</p>
<ul>
<li>Cardiac:<ul>
<li>Heart failure:  usually secondary to valve dysfunction. Most
    common when aortic valve involved, risk also depends on
    organism (worst is <em>Staph aureus</em> )</li>
<li>Perivalvular abscess: suspect when there are conduction
    abnormalities on EKG; most likely when aortic valve
    involved, less likely with mitral valve.</li>
<li>Pericarditis: can be suppurative or non-suppurative</li>
<li>Intracardiac Fistula</li>
</ul>
</li>
</ul>
</li>
<li>
<p>-</p>
<ul>
<li>Septic emboli and metastatic abscesses</li>
<li>Mycotic aneurysm: usually occurs at vessel branch points</li>
</ul>
</li>
<li>
<p>Follow
    Up</p>
<ul>
<li>Repeat TTE at completion of treatment to establish new baseline</li>
<li>Followed for valvular dysfunction with frequency determined by
    nature of the dysfunction. (MR caused by IE should be followed
    on a timeline like other MR)</li>
<li>Regular dental care, Prior IE is an indication for SBE
    prophylaxis with dental work.</li>
</ul>
</li>
<li>
<p>Episode of IE is an indication fo
    r PDA or VSD closure</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-febrile-neutropenia"><h1 id="infectious-diseases-infectious-diseases-febrile-neutropenia-febrile-neutropenia">Febrile Neutropenia<a class="headerlink" href="#infectious-diseases-infectious-diseases-febrile-neutropenia-febrile-neutropenia" title="Permanent link">&para;</a></h1>
<p><img src="/sites/default/files/inline-images/FN%20Algorithm%208_18-2.jpg" data-entity-type="file" data-entity-uuid="caec4a22-0ae5-4554-9e25-953d435ef2f4" alt="Febrile Neutropenia" /></p></section><section class="print-page" id="infectious-diseases-infectious-diseases-fungal-infections"><h1 id="infectious-diseases-infectious-diseases-fungal-infections-fungal-infections">Fungal Infections<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-fungal-infections" title="Permanent link">&para;</a></h1>
<p>Fungal Infections – Justin Smith</p>
<p>Histoplasmosis</p>
<p>Background</p>
<ul>
<li>Endemic to Ohio and Mississippi river valley</li>
<li>Most commonly presents as pulmonary disease but can be disseminated
    (see below)</li>
<li>Pulmonary infiltrate with hilar or mediastinal LAD, hilar or
    mediastinal LAD alone, pulmonary nodule/cavitary lesion, pulmonary
    syndrome with erythema nodosum</li>
<li>Differential: tuberculosis, malignancy, sarcoidosis (if considering
    sarcoidosis, rule out histoplasmosis as sarcoidosis treatment can
    induce disseminated histoplasmosis)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Antigen (requires attending approval): For acute pulmonary
    histoplasmosis, 65% urine sensitivity, 69% serum sensitivity, and
    83% sensitivity when co-tested. Thus, both serum and urine Ag are
    usually sent together<ul>
<li>Lower rates of positivity when disease is localized, versus
    diffuse throughout the lungs or disseminated.</li>
<li>There are relatively high rates of cross-reactivity, where
    histoplasma antigen will be positive with blastomycosis.
-</li>
</ul>
</li>
<li>Serology: Consider Histoplasma Ab if evaluating for pulmonary
    disease</li>
<li>Culture: most useful in chronic infections, sensitivity is low in
    acute/localized and may take &gt;6 weeks to grow.</li>
<li>Bronchoscopy: If clinical suspicion is high and work up negative,
    consider interventional pulmonology consult for consideration of
    bronchoscopy</li>
</ul>
<p>Management</p>
<ul>
<li>Outpatient/Mild disease:<ul>
<li>Tx not required if symptoms \&lt;4 weeks, initiate if symptomatic
    beyond 4 weeks</li>
<li>Itraconazole: 200mg TID x3 days loading, then BID (adjusted by
    levels which are drawn 2 weeks post-start) for 6-12 weeks
    minimum</li>
<li>Can use oral formulation or capsules (capsules require high
    acidity, give with food consumption or OJ or coke; do not use
    capsules if patient is on H2 blockers/PPI)</li>
<li>Voriconazole, Posaconazole: used if not tolerating itraconazole
    or as salvage therapy</li>
</ul>
</li>
<li>Inpatient/Moderate to Severe Disease:<ul>
<li>Amphotericin: 1-2 weeks induction, followed by PO itraconazole
    for 12 weeks (total)</li>
<li>Methylprednisolone: help to prevent ARDS with significant lung
    involvement</li>
</ul>
</li>
</ul>
<p>Additional</p>
<p>Information</p>
<ul>
<li>Complications
    :
    Pericarditis, Arthritis/Arthralgias with erythema nodosum, Chronic
    cavitary lesions, Fibrosing mediastinitis, Broncholithiasis</li>
</ul>
<p>Disseminated</p>
<p>Histoplasmosis:</p>
<ul>
<li>Typically found in immunocompromised populations (HIV, solid organ
    transplant recipient, TNF-alpha treatment). Rare in immunocompetent
    adults</li>
<li>Clinical presentations: FUO, weight loss, disseminated LAD,
    cutaneous manifestations, bone marrow suppression/pancytopenia,
    liver enzymes elevation, various solid organ involvement on imaging
    (liver, spleen, adrenals, nodes)</li>
<li>Diagnosis:<ul>
<li>Antigen: urine, serum, BAL, CSF (urine &amp; serum Ag 97-100&amp;
    sensitivity/specificity in AIDS patients)</li>
<li>Serology: less likely to be positive in immunocompromised host</li>
</ul>
</li>
<li>Management<ul>
<li>Mild: itraconazole</li>
<li>Moderate to Severe: amphotericin induction followed by
    itraconazole</li>
<li>CNS involvement: amphotericin for 4-6 weeks as induction</li>
</ul>
</li>
</ul>
<p>Blastomycosis</p>
<p>Background</p>
<ul>
<li>Endemic to Mississippi/Ohio river valley, southern and midwestern
    US, great lakes</li>
<li>Pulmonary syndrome: cough, fever, hemoptysis, chest pain, dyspnea<ul>
<li>Can result in both an acute or chronic pneumonia, as well as
    ARDS</li>
</ul>
</li>
<li>Cutaneous: raised verrucous lesion, varying in color, with irregular
    borders</li>
<li>MSK: osteolytic lesion, draining sinus, soft tissue swelling</li>
<li>Multi-system: up to 20-40% of cases, most typically lung/skin
    involvement.</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Culture: typically takes 1-4 weeks</li>
<li>Ag: urine &gt;serum. ~90% sensitive, but only 80% specific because of
    cross-reactivity</li>
<li>Serology: available, but not very useful because of high degree of
    cross-reactivity</li>
</ul>
<p>Management</p>
<ul>
<li>Mild pulmonary: PO itraconazole for 6-12 months with loading as
    described above, level at 2 weeks, and with same caveats re:
    capsules</li>
<li>Moderate to Severe: induction with Amphotericin, followed by 6-12
    months of PO itraconazole</li>
</ul>
<p>Candida</p>
<p>Background</p>
<ul>
<li>Oropharyngeal: white plaques in mouth, change in taste, erythema
    without plaques<ul>
<li>Usually seen in infants, older adults, immunocompromised host
    (HIV or chemotherapy), inhaled steroid users</li>
</ul>
</li>
<li>Esophageal: odynophagia, especially retrosternal pain (AIDS defining
    illness)</li>
<li>Vulvovaginitis: itching, burning, vaginal discharge, vulvar
    erythema, vulvar edema, dyspareunia, dysuria</li>
<li>Balanitis: painful white plaques with burning and itching on the
    glans penis</li>
<li>Mastitis: erythema, tenderness in breast feeding woman.</li>
</ul>
<p>Management</p>
<ul>
<li>Depends on specifics, but typically nystatin or fluconazole EXCEPT
    <em>C. glabrata</em> (proof of fluconazole susceptibility needed) and <em>C.
    krusei</em> (intrinsically R to fluconazole)</li>
<li>Cx generally not indicated unless complicated pt with extensive tx
    history for <em>Candida</em></li>
</ul>
<p>Additional Information</p>
<ul>
<li>Disseminated
    disease<ul>
<li>Presentation: Primarily immunocompromised populations
    (hematologic malignancies, solid organ transplant recipients,
    receiving chemotherapy, TPN, steroid use, broad spectrum
    antibiotics) and ICU settings (especially, burn, trauma, and
    neonatal)</li>
<li>Diagnosis: Candida in a bacterial blood culture (NEVER
    contaminant). Consider if Candida growth from 2 sites (ie sputum
    and urine)</li>
<li>Start micafungin 100mg IV and consult ID for candidemia or if
    concerned for disseminated disease</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-general-tips"><h1 id="infectious-diseases-infectious-diseases-general-tips-general-tips">General Tips<a class="headerlink" href="#infectious-diseases-infectious-diseases-general-tips-general-tips" title="Permanent link">&para;</a></h1>
<p>General tips</p>
<ul>
<li>Vanderbilt Antibiotics Stewardship Program (VASP) has a
    website
    with much of the below guidance as well as Vanderbilt antibiograms,
    with our resistance patterns</li>
<li>Does your pt need to be on precautions? Check the
    Infection Prevention Website
    under ‘isolation’ tab or page the infection control pager in E-star
    paging for additional questions</li>
<li>Page 317-4376 for approval of restricted antimicrobials at VUMC</li>
<li>At the VA, page the VA ID fellow</li>
<li>When calling outside hospitals, call microbiology lab directly to
    follow up on cultures and upload a copy of those culture results
    into the chart (see appendices section for how to upload records
    Faxed to your doximity account)</li>
<li>The lab will automatically update the Tennessee health department
    with reportable diseases</li>
<li>Updated
    COVID guidelines can be found at the
    VUMC COVID information site</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-gu-infection"><h1 id="infectious-diseases-infectious-diseases-gu-infection-gu-infection">GU infection<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-gu-infection" title="Permanent link">&para;</a></h1>
<p>Genitourinary Infection – VASP</p>
<p>Asymptomatic Bacteriuria</p>
<p>Background</p>
<ul>
<li>Isolation
    of bacteria in an appropriately collected urine specimen from an
    individual without symptoms or signs of urinary tract infection.
    Bacteriuria, foul odor, urine appearance, pyuria and/or bacteriuria
    alone are not indicative of infection.</li>
<li>Anuric ESRD patients may have bacteriuria from colonization due to
    lack of flushing of bladder, avoid sending UA/Ucx unless patient is
    symptomatic</li>
<li>Treatment
    only required for specific populations:<ul>
<li>Pregnant women (screening performed at 12 – 16 weeks)</li>
<li>Anticipated urologic intervention</li>
<li>Some
    renal transplant recipients, depending on time since transplant</li>
</ul>
</li>
</ul>
<p>Uncomplicated Urinary Tract Infection (UTI)</p>
<p>Background</p>
<ul>
<li>Clinical
    symptoms of UTI (dysuria/urgency/frequency/ hematuria) in
    non-pregnant, immunocompetent, neurologically-intact pts with normal
    urologic anatomy and no indwelling urinary catheters</li>
<li>Treatment \&lt; 5 days is not adequate when treating with a
    beta-lactam. Avoid amoxicillin or ampicillin due to increasing
    resistance</li>
<li>Nitrofurantoin cannot be used for ascending UTI or pyelonephritis</li>
<li>Antibiotics should be tailored if culture data are available.</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Assessment
    of urinary symptoms</li>
<li>UA
    + reflex urine Cx (Cx if pt is admitted or has recurrent UTIs)</li>
<li>Non
    -reflex urine Cx: pregnant pts, neutropenia, and pts undergoing
    urologic procedures</li>
</ul>
<p>Management</p>
<ul>
<li>Empiric
    therapy<ul>
<li>Nitrofurantoin monohydrate: 100 mg PO BID x 5 days (avoid if any
    concern for pyelonephritis or if creatinine clearance \&lt;60)</li>
<li>Cephalexin
    250-500mg q6h x5-7 days</li>
</ul>
</li>
<li>Alternative
    therapies<ul>
<li>Fosfomycin: 3 grams of powder mixed in water as a single PO dose
    (avoid if any concern for ascending UTI or pyelonephritis).
    Susceptibility test results must be requested of micro lab and
    are only possible for E. coli and E. Faecalis.</li>
<li>Amoxicillin
    -clavulanate: 500mg PO BID x5 days</li>
<li>Ciprofloxacin
    : 250mg PO BID x3 days<ul>
<li>FQ’s should be reserved for more serious infections than
    uncomplicated cystitis, and only after susceptibility
    results are confirmed given high rates of resistance from
    overuse (~25% of <em>E. coli</em> are resistant to ciprofloxacin
    at VUMC)</li>
<li>Adverse effect profile &gt;> beta-lactams (i.e.
    QT-prolongation, tendinopathies)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional</p>
<p>Information</p>
<ul>
<li>MDR cystitis: ESBL
    isolates are increasingly common due to antibiotic overuse</li>
<li>Before treating, decide if this is a TRUE UTI</li>
<li>If true, then for uncomplicated cystitis with ESBL organism,
    consider Fosfomycin (if <em>E. coli</em> ) or nitrofurantoin (if
    susceptibility is confirmed – <em>K. pneumoniae</em> and <em>Enterobacter</em> spp
    are usually resistant), or ID consultation</li>
<li>Ask the lab to check susceptibility results to these antibiotics,
    for the future reference</li>
</ul>
<p>Complicated UTI and Pyelonephritis</p>
<p>Background</p>
<ul>
<li>Fever
    , pyuria, and costovertebral angle tenderness suggest
    pyelonephritis. If any of the following are present, it is also
    considered a complicated UTI</li>
<li>UTI
    with any of the following present:<ul>
<li>Renal calculi or other obstructive disease, Immunosuppressed
    host, abnormal urological anatomy or physiology, presence of a
    urinary catheter</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>UA with reflex urine culture</p>
</li>
<li>
<p>BCx and UCx prior to antibiotics</p>
</li>
<li>
<p>If there is no pyuria, consider an alternative diagnosis, or
    proximal ureteral obstruction</p>
<ul>
<li>Pyuria
    is common in the presence of a urinary catheter, kidney stones,
    urostomy, ileal conduit and other invasive devices, and may not
    indicate infection</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Duration: 7-14 days, depending on antibiotic choice</li>
<li>Follow up culture to confirm clearance, especially if outpatient</li>
<li>Tailor therapy once/if cultures are available. If no improvement in
    48h, consider imaging to rule out complications (e.g., perinephric
    abscess)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>First Line</td>
<td>Alternative</td>
</tr>
<tr>
<td>Outpatient</td>
<td>Ciprofloxacin 750 BID (or 500 BID if bacteremia r/o)  x 7d</td>
<td>NaN</td>
</tr>
<tr>
<td>Inpatient</td>
<td>- CTX 2g q24h - Cefepime 2g q8h - Meropenem 2g q8h (if h/o or confirmed ESBL w/in last 90 d)</td>
<td>- Ertapenem 1g q24 instead of Meropenem if no Pseudomonas - Ciprofloxacin 750 PO BID (500 PO BID if bacteremia ruled out) OR 400 IV BID (if suscept confirmed)*</td>
</tr>
</tbody>
</table>
<p>*FQ’s have same bioavailability if given PO or IV so oral is preferred</p>
<p>Catheter Associated Urinary Tract Infection (CAUTI)</p>
<p>Background</p>
<ul>
<li>Culture growth of &gt; 10 <sup>3</sup> cfu/mL of uropathogenic
    bacteria + signs or symptoms consistent with infection (without
    another identified etiology) + indwelling urethral/suprapubic
    catheter or intermittent catheterization.<ul>
<li>This includes pts with catheters in place during the preceding
    48 hours</li>
</ul>
</li>
<li>Duration = greatest risk factor (Increases 3-10% per day of
    catheterization)<ul>
<li>Other risks: female sex, diabetes, elderly, colonization of
    catheter bag, poor care</li>
</ul>
</li>
<li>Bacteriuria, foul odor, pyuria, urine appearance and/or bacteriuria
    alone are not indicative of infection in patients who are otherwise
    asymptomatic.</li>
<li>Ensure clean sample collected<ul>
<li>Ideally, catheter is removed and midstream sample obtained</li>
<li>If catheterization required; removal of old catheter and sample
    taken from new</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Distinguish uncomplicated vs complicated UTI (see above)</p>
</li>
<li>
<p>Antimicrobial management:</p>
<ul>
<li>Guided by cultures and susceptibilities</li>
<li>Empiric guidance as per management of uncomplicated/complicated
    UTI and per prior culture data/susceptibilities when available</li>
<li>Duration: 7 – 14 days depending on antibiotic, clinical response
    and whether infection constitutes complicated vs uncomplicated
    UTI</li>
<li>Special note regarding <strong>Candida</strong> UTI management: Candida Is
    generally not pathogenic</li>
<li>Presence
    in urine does not indicate infection (unless perinephric
    abscess, renal transplant, or complex fistulous disease)</li>
<li>Fluconazole
    achieves excellent urinary penetration</li>
<li>Echinocandins do not, and other azoles are not well studied in
    UTIs</li>
<li>If
    fluconazole
    resistant Candida cultured or suspected, consult ID</li>
<li>Susceptibilities are not routinely run on Candida from urine
    cultures and would need to be requested if concern for true
    infection.</li>
</ul>
</li>
<li>
<p>Catheter management</p>
<ul>
<li>At the least, catheters should be replaced at the time of
    antibiotic initiation</li>
<li>Preferably, catheters should be removed</li>
<li>If catheterization is necessary, intermittent catheterization is
    preferred over continuous use. Condom catheters and pure wicks
    preferred over foley catheter</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-hiv-art-general-concepts"><h1 id="infectious-diseases-infectious-diseases-hiv-art-general-concepts-hiv-art-general-concepts">HIV &amp; ART General Concepts<a class="headerlink" href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts-hiv-art-general-concepts" title="Permanent link">&para;</a></h1>
<p>HIV/AIDS and ART – Joseph Quintana</p>
<p>Background</p>
<ul>
<li>Why is ART important?<ul>
<li>Clear morbidity and mortality benefits across all CD4 counts</li>
<li>Decreases subsequent infections (both common and opportunistic)</li>
<li>Decreased HIV related comorbid conditions and viral reservoirs</li>
<li>Reduced HIV transmission</li>
<li>Long term improvement in immune cell function and activation</li>
<li>Most patients will have their care at Comprehensive care clinic
    (CCC), the Vanderbilt HIV clinic, and these clinicians staff
    Rogers ID and HIV consult service</li>
</ul>
</li>
<li>New HIV Diagnosis<ul>
<li>ID consult (important for initiation, follow up [CCC], social
    work assistance)</li>
<li>ART is indicated for all HIV+ patients, regardless of CD4;
    however, starting ART requires appropriate outpatient follow up</li>
<li>Lab evaluation:</li>
<li>HIV viral load, genotype and resistance testing</li>
<li>T cell subsets (CD4 Count)</li>
<li>HLA*B5701 testing before using abacavir containing regimen</li>
<li>CBC with differential, CMP, UA</li>
<li>T-Spot</li>
<li>Pregnancy testing</li>
<li>Viral hepatitis serologies</li>
<li>Toxoplasma serologies</li>
<li>Other STI screening (Syphilis, Gonorrhea/chlamydia)</li>
</ul>
</li>
<li>Timing of ART initiation<ul>
<li>Engage ID, address social barriers, baseline laboratory
    evaluation, arrange follow up</li>
<li>Factors affecting timing<ul>
<li>Drug toxicity and interactions, risks for resistance,
    adherence</li>
<li>Barriers to medication adherence (homelessness, substance
    use disorder, behavioral health diagnosis)</li>
<li>Treatment of opportunistic infections may delay initiation
    of ART given associated risk of immune reconstitution
    inflammatory syndrome (IRIS)</li>
<li>Delay ART for several weeks after initiation of therapy for
    cryptococcal meningitis, in which IRIS can be fatal</li>
</ul>
</li>
</ul>
</li>
<li>ART plan for overnight admits<ul>
<li>Okay to continue home ART, special consideration for:<ul>
<li>Pts with hepatic or renal dysfunction, may need dose
    adjustment</li>
<li>If there is concern for non-adherence, can hold morning dose</li>
<li>Can be discussed with ID/outpt provider in the morning</li>
<li>Combination pills may need to be ordered as the separate
    components</li>
</ul>
</li>
</ul>
</li>
<li>Common key regimens for initiation<ul>
<li>Most regimens consist of an NRTI backbone (2 agents) plus a 3
    <sup>rd</sup> agent</li>
<li>Many patients are started on combination pill regimens,
    including Integrase Inhibitor based regimens: Biktarvy®,
    Triumeq®, dolutegravir + Descovy®<ul>
<li>Dolutegravir and bictegravir have high barriers to
    resistance relative to first-generation integrase inhibitors
    elvitegravir and raltegravir</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-orthopedic-infection"><h1 id="infectious-diseases-infectious-diseases-orthopedic-infection-orthopedic-infection">Orthopedic Infection<a class="headerlink" href="#infectious-diseases-infectious-diseases-orthopedic-infection-orthopedic-infection" title="Permanent link">&para;</a></h1>
<p>Joint Infection and Osteomyelitis – VASP</p>
<p>Evaluation</p>
<ul>
<li>Blood cultures prior to antibiotics</li>
<li>MRI is the most sensitive and specific imaging modality for
    osteomyelitis.</li>
<li>Ortho consult for Joint fluid aspirate or bone bx; send for culture
    and send fluid for cell count/differential. Ideally, joint fluid is
    inoculated into BCx bottle to improve recovery</li>
<li>Reserve some specimen to allow for cell count/differential and Gram
    stain.</li>
</ul>
<p>Management</p>
<ul>
<li>Hold antibiotics until culture obtained, if patient is clinically
    stable</li>
<li>Osteomyelitis is a 6-week treatment course, can consider early
    transition to oral if good bioavailability and susceptibility.</li>
<li>For prosthetic joint infection, procedure/retention of hardware
    determines duration</li>
<li>First line empiric: Vancomycin + ciprofloxacin 750mg BID</li>
<li>Antimicrobial
    therapy will be guided by culture data, ID consult recommended for
    joint infection treatment due to need for prolonged antibiotic
    therapy</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-pneumonia"><h1 id="infectious-diseases-infectious-diseases-pneumonia-pneumonia">Pneumonia<a class="headerlink" href="#infectious-diseases-infectious-diseases-pneumonia-pneumonia" title="Permanent link">&para;</a></h1>
<p>Pulmonary Infections – VASP, Evan Schwartz</p>
<p>Acute Bronchitis</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>1
    -3 wks productive cough, often preceded by URI, may have
    wheezing/rhonchi</p>
</li>
<li>
<p>Distinct from chronic bronchitis (&gt;3 mos of consecutive cough x 2
    consecutive yrs)</p>
</li>
<li>
<p>Distinct from PNA (parenchymal consolidation, fever &gt;100.4F,
    hypoxia, tachypnea)</p>
</li>
<li>
<p>DDx: COVID19, post-nasal drip, GERD, undertreated/new asthma, ACE-i
    induced bradykinin cough, undertreated CHF, acute PE, or new lung
    cancer</p>
</li>
<li>
<p>Typically clinical dx; CXR/labs not necessary unless PNA suspected</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Supportive: lozenges, cough suppressants (guaifenesin or
    dextromethorphan), smoking cessation. Consider albuterol inhaler for
    wheezing</p>
</li>
<li>
<p>No indication
    for antibiotics</p>
</li>
</ul>
<p>Influenza</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Dx often clinical w/cough, sore throat, #sputum/nasal discharge, HA,
    fever, myalgias, and malaise; ± N/V/D. Exam with increased flushing,
    rarely with lower respiratory symptoms</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>During flu season: Obtain RPP or dedicated Influenza PCR in pts
    w/immunocompromise, acute hypoxic respiratory failure, respiratory
    distress, worsening of COPD, asthma, CAD/CHF; testing more accurate
    if obtained within 96 hour of symptom onset</p>
</li>
<li>
<p>CXR if concerned for bacterial superinfection</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Antivirals most effective w
    hen given \&lt;48 hours from symptom onset; however,
    recommended
    to be given if symptomatic despite duration</p>
</li>
<li>
<p>Oseltamivir 75mg
    BID x 5 days or peramivir 600mg IV x 1 (needs renal adjustment)</p>
</li>
<li>
<p>Pain and fever: high-dose acetaminophen 1g TID are most effective;
    avoid aspirin,
    especially in children due to risk of Reye syndrome</p>
</li>
<li>
<p>There is
    emerging resistance to amantadine and rimantadine, and are no longer
    employed</p>
</li>
</ul>
<p>Community Acquired Pneumonia (CAP)</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>All PNA that does not otherwise meet criteria for Hospital Acquired
    Pneumonia (PNA that develops ≥48 hours after hospital admission),
    Ventilator Associated Pneumonia (PNA that develops ≥48-72 hours
    after endotracheal intubation), or aspiration PNA</p>
</li>
<li>
<p>Healthcare-associated pneumonia is no longer a clinical entity per
    2016 IDSA guidelines</p>
</li>
<li>
<p>MRSA Risk Factors: recent history, cavitary lesion, post-influenza
    bacterial PNA, pts with IDU, severe hypoxemia requiring intubation</p>
</li>
<li>
<p>Pseudomonas: Double coverage is not indicated in general population;
    LQ has 82% sensitivity so not recommended unless isolate proven
    susceptible</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Resting pulse oximetry, ± ambulatory pulse oximetry</li>
<li>Sputum cultures prior to abx, BCx prior to abx in select groups
    (severe pneumonia, ICU admission, cavitary disease,
    immunosuppression).</li>
<li>Rule out flu if the right season, COVID-19, consider RVP if it will
    change management</li>
<li>CURB-65 or PSI can aid in decision between outpatient vs inpatient
    therapy<ul>
<li>CURB65: Confusion, Uremia (BUN &gt;=19 mg/dL), RR (&gt;30/min),
    BP(\&lt;90/60 mmHg), Age ≥ 65 If ≥ 2, hospitalization is
    recommended.<ul>
<li>
<ul>
<li>Consider urine pneumococcal Ag, urine Legionella Ag in
        severe CAP and in certain pts (e.g., neutropenia,
        asplenia, obstructive lung disease, hyponatremia,
        diarrhea, or heavy alcohol use); these are performed at
        reference labs and will take several days to return.</li>
<li>CRP, ESR, and pro-calcitonin have not been shown to
    reliably improve outcomes; however, pro-calcitonin \&lt;
    0.25 suggests against bacterial respiratory infection
    and antibiotic discontinuation is encouraged</li>
<li>PA/ lateral CXR to evaluate for and localize infiltrate.
    If immunocompromised, consider CT chest w/o contrast
    (does not improve outcomes)</li>
</ul>
</li>
</ul>
</li>
<li>Lobar Consolidation - likely bacterial</li>
<li>Interstitial Infiltrate - likely atypical vs. viral vs.
    non-infectious</li>
<li>Cavitation - concerning for fungal vs. necrotizing vs.
    mycobacterial</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Duration
    : 5-7 days (at least 5 days and improvement with clinical stability)</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Outpatient</td>
<td>Outpatient</td>
<td>Inpatient (Non- ICU &amp; ICU)</td>
<td>Inpatient (Non- ICU &amp; ICU)</td>
</tr>
<tr>
<td>No MRSA or Pseudomonas suspected</td>
<td>Low Risk*: Amoxicillin 1g TID High Risk: - Amoxicillin-clavulanate 875/125 BID OR Cefdinir 300 BID + Macrolide - Amoxicillin 1g TID + Macrolide - Levofloxacin 750 daily</td>
<td>CTX 2g q24 + Azithromycin 500 daily OR Levofloxacin 750 daily</td>
<td>CTX 2g q24 + Azithromycin 500 daily OR Levofloxacin 750 daily</td>
<td>NaN</td>
</tr>
<tr>
<td>MRSA or Pseudomonas suspected</td>
<td>NaN</td>
<td>MRSA: Vancomycin OR Linezolid (if no bacteremia) Pseudomonas: Cefepime 2g q8h</td>
<td>MRSA: Vancomycin OR Linezolid (if no bacteremia) Pseudomonas: Cefepime 2g q8h</td>
<td>NaN</td>
</tr>
<tr>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>*</p>
<p>No chronic heart, lung, liver, renal disease, DM, alcoholism,
immunocompromise</p>
<p>Additional</p>
<p>Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>CTX is generally adequate coverage for aspiration PNA without
    evidence of abscess, empyema, or cavitary lesion on imaging</p>
</li>
<li>
<p>There is low sensitivity of S. pneumoniae to azithromycin (42%) and
    doxycycline (72%), so these should not be used as monotherapy</p>
</li>
<li>
<p>Check for DDI with Linezolid (e.g., SSRI)</p>
</li>
</ul>
<p>Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia
(VAP)</p>
<p>Background</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>HAP: Pneumonia that develops &gt;48 hours after admission</p>
</li>
<li>
<p>VAP: Pneumonia that develops &gt;48 hours after endotracheal intubation</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Cultures of blood, sputum, endotracheal aspirate and/or bronchoscopy
    specimen</p>
</li>
<li>
<p>Consider MRSA nares to help with de-escalation</p>
</li>
<li>
<p>If there is concern for respiratory viruses, influenza, COVID send
    RVP</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Duration: 7 days in uncomplicated cases, although specific pathogens
    (e.g., <em>Pseudomonas</em> ) may require longer duration and ID guidance</p>
</li>
<li>
<p>Consider ID consultation if the patient is not clinically improving
    on empiric therapy or if an MDR pathogen grows from culture</p>
</li>
<li>
<p>If no MRSA isolated and pt is improving, consider stopping
    vancomycin ASAP</p>
</li>
<li>
<p>Some concern for nephrotoxicity with combination Vancomycin and
    piperacillin-tazobactam, but data controversial</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>MRSA Coverage</td>
<td>Pseudomonas Coverage</td>
</tr>
<tr>
<td>First Line</td>
<td>Vancomycin (PMCY dosing)</td>
<td>Cefepime 2g q8h OR Piperacillin-tazobactam 3.375 q8h extended infusion OR Ceftazidime 2g q8h</td>
</tr>
<tr>
<td>Alternative</td>
<td>Vancomycin allergy: Linezolid 600 mg PO q12h</td>
<td>PCN allergy*: Aztreonam 2g q8h</td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-ssti"><h1 id="infectious-diseases-infectious-diseases-ssti-ssti">SSTI<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-ssti" title="Permanent link">&para;</a></h1>
<p>Skin and Soft Tissue Infection (SSTI) – VASP</p>
<p>Cellulitis</p>
<p>Background</p>
<ul>
<li>Differential
    : erysipelas, pyomyositis, necrotizing fasciitis, osteomyelitis,
    venous stasis, shingles, gout</li>
<li>Pathogens
    : Streptococcus species: Group A (most common), B, C, G,
    Staphylococcus aureus (including MSSA and MRSA)<ul>
<li>Think
    Streptococcus if non-purulent, lymphagitis, or erypsipelas, and
    Staphylococcus if purulent (i.e. associated with boil or
    abscess)</li>
</ul>
</li>
<li>Unique
    clinical scenarios and associated organisms/organisms to consider:<ul>
<li>Dog/cat bite: Pasteurella multicoda, Capnocytophaga canimorsus</li>
<li>Human bite: Eikenella corrodens, oral anaerobes, S. aureus</li>
<li>Fresh water exposure: Aeromonas hydropholia, Plesiomonas
    shigelloides</li>
<li>Salt water exposure: Vibrio vulnificus</li>
<li>Neutropenia, presence of ecthyma: Gram negatives (Pseudomonas
    aeruginosa)</li>
<li>Immunocompromised: Fungal (candida species, Cryptococcus),
    Nocardia, non-tubercular mycobacteria)</li>
<li>Burn patients
    : <em>Pseudomonas, Acinetobacter, Fusarium</em></li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Outline
    border of erythema and obtain urgent surgery consultation if rapid
    spread of infection, crepitus, air in tissues or pain dramatically
    out of proportion to exam</li>
<li>Blood
    cultures: ONLY needed if systemic signs/symptoms of infection or
    immunocompromised (most pts will not need Bcx or imaging)</li>
<li>Ultrasound
    for underlying abscess</li>
<li>CT/MRI w/contrast: if necrotizing fasciitis, pyomyositis or
    osteomyelitis suspected (but should not delay surgical consultation)</li>
</ul>
<p>Management</p>
<ul>
<li>5
    days
    for uncomplicated; 10-14 days for more extensive/serious infection,
    slow improvement, or if immunosuppressed</li>
<li>Anti-
    Staphylococcal
    antibiotics should be provided for purulent cellulitis in addition
    to I&amp;D, if abscess present</li>
<li>Clinical appearance may often appear to worsen initially despite
    adequate therapy</li>
<li>Always elevate the extremity for more rapid clinical improvement!</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>No Staphylococcus suspected</td>
<td>MSSA</td>
<td>MRSA (50% of inpt, 30% of outpt S. aureus cultures)</td>
</tr>
<tr>
<td>Mild Moderate (Outpatient)</td>
<td>- Cephalexin 500 QID - Amoxicillin 500 TID - Cefadroxil 1g BID</td>
<td>Cephalexin 500 QID Cefadroxil 1g BID Dicloxacillin 500 QID Clindamycin 300-450 q6</td>
<td>- TMP/SMX 1-2 DS tabs BID - Doxycycline 100 BID</td>
</tr>
<tr>
<td>Severe (Inpatient)</td>
<td>- Cefazolin 2g q8h - CTX 2g q24h</td>
<td>- Cefazolin 2g q8h - Nafcillin 2g q4h</td>
<td>-Vancomycin</td>
</tr>
</tbody>
</table>
<p>Necrotizing Fasciitis</p>
<p>Background</p>
<ul>
<li>Infection
    of the deeper soft tissues that causes necrosis along the muscle
    fascia and overlying subcutaneous fat that is rapidly progressive
    and lethal if not addressed</li>
<li>Clinical cues include pain out of proportion to exam, hemorrhagic
    bullae</li>
</ul>
<p>Evaluation</p>
<p>/Management</p>
<ul>
<li>SURGICAL
    EMERGENCY!<ul>
<li>STAT consult respective surgical service for emergent
    debridement (generally EGS, but see Wound Care Section of
    Appendices to confirm)</li>
<li>Imaging does NOT rule out necrotizing fasciitis and should not
    delay these consultations</li>
</ul>
</li>
<li>
<p>ID
    consult</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Blood cultures, but this should not delay antibiotic
    administration</p>
</li>
<li>
<p>Contact and droplet precautions x first 24h of abx therapy;
    after this, contact precautions only if draining or contained
    wounds</p>
</li>
<li>
<p>Vancomycin + either piperacillin-tazobactam 3.375g IV q8h
    extended infusion OR cefepime 2gm IV q8h + clindamycin
    600mg-900mg IV q8h (for antitoxin effects)</p>
</li>
<li>
<p>Duration
    : Not well defined Continue abx at least until HDS and no
    further surgical debridement is required. Clindamycin may be
    d/c’d when pt not critically ill and s/p first debridement. Plan
    must be determined on a case-by-case basis with ID guidance</p>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Infectious diseases</h1>
                        <h1 class='nav-section-title' id='section-nephrology'>
                            Nephrology <a class='headerlink' href='#section-nephrology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="nephrology-nephrology-acute-rejection"><h1 id="nephrology-nephrology-acute-rejection-acute-rejection">Acute Rejection<a class="headerlink" href="#nephrology-nephrology-acute-rejection-acute-rejection" title="Permanent link">&para;</a></h1>
<p>Acute Rejection</p>
<ul>
<li>T cell mediated (Cellular Rejection)<ul>
<li>Infiltration of the graft by <strong>lymphocytes</strong> and inflammatory
    cells</li>
<li>Treatment: high dose steroids (methyl pred) is first line (~ 5
    days <u>+)</u><ul>
<li>Thymoglobulin (polyclonal Ig anti-T cell)</li>
<li>Use depends on severity of rejection</li>
<li>Indicated if Cr fails to improve after steroids</li>
<li>T cell subsets are measured before and during treatment
    until depleted</li>
<li>Tacro target levels are <strong>reset to ~8</strong> if treated for
    acute T cell mediated rejection</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Antibody Mediated Rejection (ABMR)<ul>
<li>Acute tissue injury with circulating donor-specific antibodies
    (DSAs); requires evidence of <strong>antibody-mediated damage</strong><ul>
<li>Ig’s deposit and activate complement: key is C4d staining in
    the graft will be strongly positive</li>
</ul>
</li>
<li>Treatment:<ul>
<li>IV methyl prednisone (3-5 days)</li>
<li>Plasmapheresis</li>
<li>+
    IVIG<ul>
<li>Followed often by Rituxan before d/c</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-aki"><h1 id="nephrology-nephrology-aki-aki">AKI<a class="headerlink" href="#nephrology-nephrology-aki-aki" title="Permanent link">&para;</a></h1>
<p>Acute Kidney Injury (AKI) – Joseph Quintana, Mengyao Tang</p>
<p>Background</p>
<ul>
<li>Rise
    in Creatinine (Cr) <strong><u>></u> 0.3 mg/dL</strong> within 48 hours, or
    increase <strong><u>></u> 1.5 x baseline</strong> in 7 days<ul>
<li>Oliguria = \&lt; 0.3 mL/kg/hr or \&lt; 500 mL/day</li>
<li>Anuria = \&lt; 50 mL/day</li>
</ul>
</li>
<li>ACE
    -i’s and ARB’s alter the renal autoregulation and exacerbate
    pre-renal AKI</li>
<li>Acute
    Tubular Necrosis (ATN)
    and pre-renal disease comprise 66% of inpatient AKI<ul>
<li>Pre-
    renal:<ul>
<li>Fluid losses: GI, blood, Respiratory or metabolic losses
    [fevers, tachypnea, sepsis]</li>
<li>Decreased
    effective intravascular volume [HFrEF, Hepatorenal]</li>
<li>Afferent
    arteriole constriction [NSAIDs, Iodinated contrast]</li>
</ul>
</li>
<li>Intra-renal (Tubular and interstitial disease)
    :<ul>
<li>ATN =
    Most
    common
    ;
    Ischemia or nephrotoxin</li>
<li>ACE-i + NSAIDs, ACE-i + contrast, prerenal + ACE-i,
    prerenal + NSAIDs</li>
<li>Acute
    Interstitial
    Nephritis (AIN) usually drug-induced</li>
<li>Other
    causes
    :<ul>
<li>Crystalline nephropathy: IV acyclovir, tumor lysis</li>
<li>Small vessel disease: MAHA, TTP, HUS</li>
<li>Large vessel problems: Aortic dissection, renal artery
    stenosis</li>
<li>Glomerular disease: Nephritic pattern</li>
</ul>
</li>
</ul>
</li>
<li>Post-renal (Obstruction):<ul>
<li>Ureteral: obstructing stones (B/L or one with single
    kidney), external compression</li>
<li>Bladder: neurogenic bladder, malignancy, obstructing blood
    clot</li>
<li>Urethra: BPH</li>
<li>Misplaced Foley catheter</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urinalysis
    , Strict I/O’s</li>
<li>Fluid
    challenge:<ul>
<li>Improve
    w/ diuresis
    
    CHF</li>
<li>Improve
    w/ resuscitation
    
    hypovolemia</li>
</ul>
</li>
<li>Protein
    /Cr urine spot ratio
    : quantify tubular vs glomerular range proteinuria</li>
<li>Post
    Void R
    esidual bladder scan, great test, low cost, high reward<ul>
<li>Elevated PVRs = 250 cc plus</li>
</ul>
</li>
<li>Who
    needs imaging (Renal U/S)?<ul>
<li>No obvious cause of AKI, unremarkable history and bland urine</li>
<li>Abrupt oliguria or anuria</li>
<li>High suspicion for bladder outlet obstruction (PVRs might give
    you same data)</li>
<li>Add doppler to evaluate for renal artery stenosis (or if
    treating resistant hypertension)</li>
</ul>
</li>
<li>Urine
    Electrolytes<ul>
<li>FE
    Na
    &amp;
    FE Urea (if on diuretics): Can suggest pre-renal vs ATN<ul>
<li>Faults
    :
    validated in “fresh” <strong>oliguric</strong> patients (interpretation
    becomes more difficult after intervention with fluids,
    diuretics, etc.); 1% cutoff more accurate in severe AKI; Na
    <sup>+</sup> intake affects impression; one measurement may
    be inaccurate</li>
<li>Urine sodium can be used to assess tubular avidity
    (typically urine Na &gt; 40 in ATN and \&lt; 20 in pre-renal; note
    these are not absolute numbers, and there can be overlap)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Hold
    ACE-i/ARB (remember to determine plan to resume at/after discharge)</li>
<li>Avoid unnecessary nephrotoxins: antibiotics, amphotericin,
    tenofovir, chemotherapy</li>
<li>Dose
    -adjust renally cleared medications: gabapentin, cefepime, morphine,
    metformin</li>
<li>Relieve
    Obstruction: I/O cath, foley, Urostomy
    
    Urology,
    Percutaneous nephrostomy
    
    IR</li>
<li>When
    to consider Nephrology – AKI consult:<ul>
<li>Urgent indication for dialysis (see “Renal Replacement Therapy”
    below)</li>
<li>Cr worsening over 48-72 hrs w/o clear cause</li>
<li>Evaluate for need for dialysis in the near future</li>
<li>Concern for acute glomerulonephritis as cause</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Rhabdomyolysis:
    UA positive for blood but no RBCs on microscopy<ul>
<li>Serologic markers of muscle injury:  AST/ALT elevation with
    normal ALK Phos<ul>
<li>
<ul>
<li>Fluids:
        Goal of 6-12 L resuscitation in first 24 hrs if pt can
        tolerate (not well studied)</li>
<li>Traditional thought = Urine goal of 200-300 mL/hr, until
    CK \&lt;5000</li>
<li>Avoid calcium repletion for hypocalcemia unless
    symptomatic</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Post
    -obstructive diuresis<ul>
<li>Monitor pt after relief of obstruction due to possibility of
    severe polyuria (&gt;4-5 L/day)</li>
<li>Replete fluids to prevent volume contraction and hypokalemia</li>
<li>½ NS to replace about 50-75% of urinary losses</li>
<li>If pt develops hypo/hypernatremia, consider an alternative
    resuscitation fluid</li>
<li>Monitor calcium, phosphorus and magnesium in severe
    post-obstructive diuresis</li>
</ul>
</li>
<li>Iodinated
    Contrast
    :<ul>
<li>Does not need to be dialyzed; thought to be due to afferent
    arterial spasm which occurs immediately with contrast</li>
<li>Avoid giving if you are trying to preserve kidney function in
    CKD or AKI pts</li>
<li>No absolute cut-off in CKD, although GFR \&lt;30 is commonly used
    as a strong contraindication and GFR 30-45 as a relative
    contraindication</li>
<li>If there is time pre contrast you can ensure the patient is
    volume replete with isotonic fluid to decrease the risk of
    contrast nephropathy</li>
<li>If it is an emergency, you should not delay the contrasted
    procedure (i.e. STEMI)</li>
</ul>
</li>
<li>Avoid
    gadolinium contrast from MRI in any AKI or if <strong>GFR \&lt;30</strong> in CKD
    given <strong>risk of nephrogenic systemic fibrosis as an absolute
    contraindication</strong> ; GFR &gt;30 is fine</li>
<li>eGFR
    equations are based on stable kidney Fx, acute changes in Cr make it
    unreliable</li>
</ul></section><section class="print-page" id="nephrology-nephrology-approach-ckd"><h1 id="nephrology-nephrology-approach-ckd-approach-to-ckd">Approach to CKD<a class="headerlink" href="#nephrology-nephrology-approach-ckd-approach-to-ckd" title="Permanent link">&para;</a></h1>
<p>Approach to Chronic Kidney Disease – Taylor Riggs</p>
<p>Background</p>
<ul>
<li>Decreased
    kidney function or one or more markers of kidney damage for <strong>3 or
    more months</strong></li>
<li>GFR
    \&lt; 60; Staging helps risk-stratify pts likely to progress or develop
    complications of CKD</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>CKD IIIa: eGFR 45-60</li>
<li>CKD IIIb: eGFR 30-44</li>
<li>CKD IV: eGFR 15-30</li>
<li>CKD V: eGFR \&lt; 15</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Markers
    of kidney damage<ul>
<li>Albuminuria (albumin:creatinine &gt; 300mg/g or urine
    protein:creatinine &gt; 500mg/g)</li>
<li>Urine sediment: RBC cases, WBC casts, oval fat bodies or fatty
    casts, granular casts</li>
<li>Electrolytes or other abnormalities due to tubular disorders</li>
<li>Abnormalities on histology (glomerular, vascular or cystic
    disease, TIN)</li>
<li>Structural abnormalities: (cysts, hydronephrosis, scarring,
    masses, renal artery stenosis)</li>
<li>History of kidney transplant (rejection, drug toxicity 2/2
    calcineurin inhibitors, BK virus nephropathy, recurrent disease
    leading to transplant)</li>
</ul>
</li>
<li>Refer
    to AKI section for a detailed list of etiologies</li>
</ul>
<p>When to refer to nephrology clinic</p>
<ul>
<li>eGFR
    \&lt; 30</li>
<li>Persistent
    urine albumin/creatinine ratio &gt; 300 mg/g</li>
<li>Urine protein/creatinine ratio greater than 500 mg/g</li>
<li>Rapid
    loss of kidney function (&gt; 30% decline over 4 months)</li>
<li>Hematuria not 2/2 urologic condition or RBC casts</li>
<li>Inability
    to identify presumed cause of renal dysfunction</li>
<li>Difficult
    to manage complications (hyperkalemia, anemia, bone-mineral disease,
    HTN)</li>
<li>Confirmed
    or presumed hereditary kidney disease (PCKD suspected)</li>
</ul>
<p>Albuminuria</p>
<ul>
<li>Microalbuminuria
    : 30-300 mg/day</li>
<li>Macroalbuminuria
    : &gt; 300 mg/day (UA typically only detects these pts)<ul>
<li>In patients with albuminuria found on UA, confirm albuminuria
    with 2 repeat tests over 3-6 months. Early morning void sample
    is best. Ensure patient does not have UTI, fever, recent IV
    contrast, hematuria, or alkaline urine.</li>
<li>After confirmation, monitor annually.</li>
<li>For patients with CKD or DM but without albuminuria, monitor
    annually for development of albuminuria</li>
</ul>
</li>
<li>Treatment
    : reducing proteinuria can slow the progression of renal disease<ul>
<li>ACEi/ARBs: reduce intraglomerular pressure, thereby reducing
    proteinuria</li>
<li>Work over weeks to months. Not as rapid as anti-HTN effect.</li>
<li>Goal is to titrate ACEi/ARB to BP \&lt; 130/90</li>
<li>Most effective when used in conjunction with low Na diet
    (\&lt;2g/d) &plusmn; diuretics</li>
</ul>
</li>
<li>Can
    add other anti-hypertensives to achieve goal BP if ACEi/ARB alone
    not able to be tolerated due to side effects (e.g. hyperkalemia)</li>
</ul>
<p>Metabolic acidosis</p>
<ul>
<li>Goal
    bicarbonate: 23-30</li>
<li>Can
    calculate bicarbonate deficit (MDcalc has calculator) and use that
    to estimate dose</li>
<li>If
    bicarb
    \&lt; 22, consider starting:<ul>
<li>Sodium bicarb 650 mg TID (8mEq bicarb per 650mg tablet). Can
    titrate up to 5850mg/day (70 mEq or 3 tabs TID)</li>
<li>Sodium citrate (bicitra): 1mL = 1 mEq</li>
<li>Baking soda: 1 teaspoon = 59 mEq HCO3 (often well-tolerated by
    patient compared to bicitra in terms of taste)</li>
</ul>
</li>
</ul>
<p>HTN in CKD</p>
<ul>
<li>Goal
    BP \&lt; 130/80</li>
<li>CKD
    stage 1 or 2 without albuminuria or DM:<ul>
<li>Usual first line BP medications (ACEi/ARB, CCB, or HCTZ)</li>
</ul>
</li>
<li>CKD
    stage 3 or greater<ul>
<li>ACEi or ARB is first line</li>
<li>Can add diuretics to ACEi/ARB for adjunctive therapy in CKD 4-5</li>
<li>HCTZ not effective with eGFR \&lt; 30</li>
<li>Low sodium diet effective in volume and BP control</li>
</ul>
</li>
<li>Consider
    stopping ACEi/ARB if:<ul>
<li>GFR declines &gt;30% over 4 months and consider evaluation for
    renal artery stenosis with Duplex Doppler renal u/s vs CTA or
    MRA as initial screening</li>
<li>K &gt; 5.5 despite efforts to decrease potassium (i.e. low K diet,
    optimizing dose of diuretics, adding K-binders)</li>
<li>If patient has an AKI on CKD, especially if pre-renal</li>
</ul>
</li>
</ul>
<p>Anemia in CKD</p>
<ul>
<li>Etiology
    : reduced EPO, chronic inflammation, uremic platelets/platelet
    dysfunction, loss of blood in dialysis circuit</li>
<li>Indications
    for iron supplementation in non-dialysis patients:<ul>
<li>ALL patients with TSAT \&lt;20% and ferritin \&lt;100 ng/mL</li>
<li>Patients with Hb \&lt;13 and TSAT \&lt;30% and ferritin \&lt;500 ng/mL</li>
<li>Can consider oral iron supplementation unless severe anemia or
    iron deficiency</li>
<li>PO Iron dosing: New evidence shows that every other day oral
    iron leads to increased absorption and efficacy and decreased
    side effects<ul>
<li>
<ul>
<li>Ferrous sulfate 325mg (65mg elemental iron) every other
        day</li>
<li>Reassess iron levels in 1-3 mos; if not appropriately
    ↑
    , consider IV iron repletion</li>
</ul>
</li>
</ul>
</li>
<li>IV Fe dosing: 1000 mg IV, either via 1 dose or multiple doses
    depending on formulation<ul>
<li>
<ul>
<li>Ferric gluconate: max dose 250 mg over 1 hr, dosed
        weekly for 3-4 doses</li>
<li>Iron dextran: 1000
    mg in a single dose, infused over one hour (less
    preferred due to
    higher risk of allergic reactions; requires te
    s
    t dose 5 min prior)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Dialysis
    patients:<ul>
<li>IV Iron preferred method of repletion for HD patients with<ul>
<li>
<ul>
<li>TSAT \&lt; 20% and ferritin \&lt; 200</li>
<li>TSAT \&lt;30
    % and ferritin \&lt;500 AND with Hb \&lt; 10 OR are on EPO</li>
</ul>
</li>
</ul>
</li>
<li>Dosing: usually administered at HD sessions<ul>
<li>
<ul>
<li>125 mg ferric gluconate at consecutive HD sessions x 8
        doses</li>
<li>100 mg iron sucrose at consecutive HD sessions x 10
    doses</li>
<li>Ferumoxytol 510mg at the end of two HD sessions 1-4
    weeks apart</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Indications
    for EPO<ul>
<li>Pts w/ Hb \&lt;10 who are not iron deficient or who’s anemia
    persists despite adequate iron repletion</li>
</ul>
</li>
</ul>
<p>Hyperkalemia (Goal K \&lt; 5.5)</p>
<ul>
<li>Generally
    , only develops in patients who are oliguric or with other problems,
    such as high K diet or hypoaldosteronism (due to ACEi/ARB)<ul>
<li>Low K diet (\&lt; 40-70 mEq/day or 1500-2700 mg/day)</li>
<li>Add loop diuretics if hypertensive or hypervolemic; Can use
    thiazide if GFR &gt; 30</li>
<li>GI cation exchangers: work within hours<ul>
<li>
<ul>
<li>Patiromer (Veltassa): binds K in colon in exchange for
        calcium</li>
<li>Sodium zirconium cyclosilicate (Lokelma): binds K
    throughout intestine in exchange for sodium and H
    <sup>+</sup></li>
<li>Need nephrology
    attending approval for Lokelma</li>
</ul>
</li>
</ul>
</li>
<li>Do not use Kayexelate as chronic therapy</li>
<li>Ensure acidosis is treated due to resulting extracellular K
    <sup>+</sup> shift (see next section)</li>
<li>Consider discontinuing ACEi/ARB if K persistently &gt; 5.5</li>
</ul>
</li>
</ul>
<p>Mineral bone disease in ESRD</p>
<ul>
<li>Ca goal: \&lt; 9.5. Avoid supplementation in mild or asymptomatic
    hypocalcemia</li>
<li>Vit D25 goal: &gt; 20. Replete as in normal population</li>
<li>Phos
    goal: \&lt; 5.5. Start phosphate binders (sevelamer or noncalcium-based
    binders typically preferred) with goal Phos 3.5-5.5<ul>
<li>Sevelamer: use lowest dose effective to achieve Phos \&lt; 5.5<ul>
<li>
<ul>
<li>Phos 5.5-7.5: initial dose 800 TID with meals</li>
<li>Phos 7.5-9.0: initial dose 1200-1600 TID with meals</li>
<li>Phos &gt; 9: initial dose 1600 TID</li>
<li>Can titrate
    dosing by 400 to 800 mg per meal at 2 week intervals</li>
</ul>
</li>
</ul>
</li>
<li>Restrict dietary phos to 900 mg/day</li>
</ul>
</li>
<li>PTH
    goal: 2-9 x ULN, although exact goal unknown in assessing renal bone
    disease. Treatment involves calcimemetics, calcitriol, and synthetic
    vitamin D analogues.</li>
</ul>
<p>Diabetes in CKD</p>
<ul>
<li>A1c
    goal:<ul>
<li>\&lt; 7% in patients with long lifespan, few comorbidities, and
    minimal hypoglycemia</li>
<li>\&lt; 8% in patients with multiple comorbidities and frequent/high
    risk for hypoglycemia</li>
</ul>
</li>
<li>Treatment
    :<ul>
<li>Metformin remains first-line but should be dose-reduced based on
    eGFR<ul>
<li>
<ul>
<li>eGFR &gt; 45: Maximum daily dose of 2000mg/day (1000mg bid)</li>
<li>eGFR \&lt; 45: Reduce max daily dose to 1000mg/day (500mg
    bid)</li>
<li>eGFR \&lt; 30: Discontinue</li>
</ul>
</li>
</ul>
</li>
<li>SGLT-2 inhibitors for patients with eGFR &gt; 30 reduces
    progression to ESRD and death from renal or cardiovascular
    causes</li>
</ul>
</li>
</ul>
<p>Dialysis initiation</p>
<ul>
<li>Dialysis
    education is usually started once patients are in CKD IV with eGFR
    15-30, so earlier referral to nephrology may be helpful in patients
    with eGFR 30-45 who you think may be heading towards eGFR \&lt;30</li>
<li>Late
    referral to a nephrologist (ie, less than three months before the
    start of dialysis therapy) is associated with higher mortality after
    the initiation of dialysis</li>
</ul></section><section class="print-page" id="nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants"><h1 id="nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants-common-side-effects-of-renal-transplant-immune-suppresants">Common Side Effects of Renal Transplant Immune Suppresants<a class="headerlink" href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants-common-side-effects-of-renal-transplant-immune-suppresants" title="Permanent link">&para;</a></h1>
<p>Common Side Effects of Renal Transplant Immune Suppressants</p>
<p>Tacrolimus</p>
<ul>
<li>Toxicity
    mediated by vasoconstriction to the afferent arterioles</li>
<li>Symptoms
    /signs: Hand tremors, headache, nausea, thrombotic microangiopathy,
    hyperkalemia</li>
<li>Calcium
    channel blockers can prevent the
    ↑
    renal vasoconstriction thus most transplant patients with HTN are on
    dihydropyridine CCBs</li>
</ul>
<p>Mycophenolate</p>
<ul>
<li>Symptoms
    /signs: diarrhea, abdominal pain, nausea, leukopenia, anemia,
    thrombocytopenia, tremor</li>
<li>Can cause microscopic colitis</li>
</ul>
<p>Diarrhea</p>
<ul>
<li>Common
    SE in patients on Mycophenolate and Tacro [common regimen]<ul>
<li>Diarrhea [usually severe] can precede Tacro toxicity<ul>
<li>Diarrhea causes increased Tacro levels due to
    ↑
    absorption and
    ↓
    intraluminal metabolism</li>
</ul>
</li>
<li>Mechanism<ul>
<li>↓
    enzymatic activity of the CYP3A system + P-glycopeptide in
    enterocytes damaged by inflammation and infection lead to
    decreased intraluminal tacro metabolism</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information for Overnight Admits:</p>
<ul>
<li>Transplant
    teams do not want the night team to change transplant medications
    overnight</li>
<li>Exception
    : If pt has severe diarrhea, can hold night tacro dose and inform
    the day team</li>
<li>Ensure the pt gets a daily tacrolimus level (order q am at 5:00).
    Always order tacrolimus dose at 6:00 am and 6:00 pm (regardless of
    what time patient takes at home, lab can only run am tacro levels at
    a certain time in batches)</li>
<li>EXCEPTION
    : If late afternoon admission, consider paging the fellow (since its
    early) and ask if they want the evening dose held until the am level
    comes back</li>
<li>Transplant patients with normal kidney function can have regular
    diet</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hematuria"><h1 id="nephrology-nephrology-hematuria-hematuria">Hematuria<a class="headerlink" href="#nephrology-nephrology-hematuria-hematuria" title="Permanent link">&para;</a></h1>
<p>Hematuria – Laura Binari/Patrick Steadman</p>
<p>Background</p>
<ul>
<li>Definition
    :
    3 urinalyses with three or more RBC/hpf; 1 urinalysis with 100
    RBC/hpf or g
    ross hematuria (1 cc blood/L urine can induce color change)</li>
<li>Can be transient (exercise-induced, menses, trauma)</li>
<li>Hemoglobinuria: Hgb should be found only in intact RBCs, presence in
    urine suggests intravascular hemolysis AND fully saturated
    haptoglobin sites in serum</li>
<li>Myoglobinuria: should be found only in intact muscle, presence in
    urine suggests myonecrosis (serum haptoglobin has LOW affinity for
    myoglobin)</li>
<li>Concurrent pyuria/dysuria: consider urinary tract infection or
    bladder malignancy</li>
<li>Recent URI: think infection related glomerulonephritis, IgA,
    vasculitis, anti-GBM</li>
<li>Positive Family Hx of Hematuria: consider PKD, Sickle Cell Disease</li>
<li>Bleeding from other sites: think inherited/acquired bleeding
    disorder, anticoagulation</li>
<li>Unilateral Flank Pain: Ureteral calculus, renal malignancy, IgA
    Nephropathy</li>
<li>Microscopic hematuria
    – should be considered for CT Urography and cystoscopy</li>
<li>Malignancy Risk Factors: male sex, age &gt; 35, smoking Hx, exposures
    to benzene/aromatic amine, cyclophosphamide, indwelling foreign
    body, pelvis irradiation, chronic UTIs, h/o heavy NSAID use, h/o
    urologic disorders/disease (nephrolithiasis, BPH)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glomerular</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
</tr>
<tr>
<td>Glomerular</td>
<td>Kidney</td>
<td>Ureter/ Bladder</td>
<td>Prostate/ Urethra</td>
<td>Other</td>
</tr>
<tr>
<td>IgA Nephropathy IgA Vasculitis</td>
<td>Pyelo</td>
<td>Cystitis</td>
<td>BPH</td>
<td>Exercise-Induced</td>
</tr>
<tr>
<td>Lupus Nephritis</td>
<td>Renal Cell Carcinoma</td>
<td>Urothelial Malignancy</td>
<td>Prostate Cancer</td>
<td>Bleeding Diathesis</td>
</tr>
<tr>
<td>Infection-related glomerulonephritis</td>
<td>PKD</td>
<td>Nephrolithiasis</td>
<td>TURP</td>
<td>Meds (AC)</td>
</tr>
<tr>
<td>Anti-GBM Disease (Goodpasture’s)</td>
<td>Sickle Cell Papillary Necrosis</td>
<td>Ureteral Stricture</td>
<td>Urethritis (STI)</td>
<td>Menses</td>
</tr>
<tr>
<td>ANCA-associated</td>
<td>Malignant HTN</td>
<td>Hemorrhagic Cystitis (chemo/rads)</td>
<td>NaN</td>
<td>TB Schistoso-miasis</td>
</tr>
<tr>
<td>Genetic (Thin Basement Membrane Nephropathy/Alport Syndrome)</td>
<td>Arterial embolism Vein thrombus</td>
<td>Traumatic Foley/procedure</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Step 1: Confirm the presence of hematuria<ul>
<li>Dipstick positive heme: urinary RBCs (hematuria), free myoglobin
    or free hemoglobin</li>
<li>Centrifuge the urine<ul>
<li>
<ul>
<li>Red sediment -&gt; true hematuria (urinary RBCs)</li>
<li>Red supernatant +</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Positive dipstick: myoglobulin or hemoglobin</li>
<li>Negative dipstick porphyria, Pyridium, beets, rhubarb, or
    ingestion of food dyes</li>
</ul>
</li>
<li>
<p>Step 2: Determine if there is a GLOMERULAR or NON-GLOMERULAR source
    of bleeding</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Glomerular</td>
<td>Extraglomerular</td>
</tr>
<tr>
<td>Color (if gross hematuria)</td>
<td>Red, Cola, Smoky</td>
<td>Red/Pink</td>
</tr>
<tr>
<td>Clots</td>
<td>Absent</td>
<td>Present/Absent</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>May be > 500 mg/day</td>
<td>\&lt; 500 mg/day</td>
</tr>
<tr>
<td>RBC Morphology</td>
<td>Dysmorphic RBCs present</td>
<td>Normal (isomorphic)</td>
</tr>
<tr>
<td>RBC Casts</td>
<td>May be Present</td>
<td>Absent</td>
</tr>
</tbody>
</table>
<ul>
<li>
<ul>
<li>Glomerular Bleeding:
        -   -   Isolated Hematuria: Differential includes IgA
                Nephropathy, thin BM dx, Alport’s
            -   Nephritic syndrome (new proteinuria, pyuria, HTN, edema,
                rise in Cr): post-infectious GN, MPGN, ANCA vasculitis,
                Goodpasture’s, lupus nephritis
            -   Workup: anti-GMB, anti-DNase/ASO, ANA, ANCA, C3, C4,
                cryo, Hep B &amp; C, HIV
            -   Indications for Renal Biopsy: glomerular bleeding + risk
                factors for progressive disease, including albuminuria &gt;
                30 mg/day, new hypertension &gt; 140/90 or significant
                elevation over baseline BP, rise in serum creatinine</li>
<li>Extraglomerular Bleeding (Imaging Section)<ul>
<li>
<ul>
<li>If historical clues suggest nephrolithiasis, start with
        non-con CT A/P</li>
<li>Gross Hematuria otherwise should be evaluated with CT
    A/P w/ and w/o contrast (CT urography); consult urology
    for cystoscopy (often done as outpatient referral)</li>
<li>If clots are passed, more likely to be secondary to
    lower urinary source, and if a high burden of clots
    poses a risk of obstruction (urologic emergency)</li>
<li>If extraglomerular bleeding with clots: hematuria
    catheter needs to be placed ASAP (2 valve catheter,
    20-24 Fr (!); page urology if nursing unable to obtain)</li>
</ul>
</li>
</ul>
</li>
<li>CT Urography is more sensitive than IV pyelogram for renal
    masses and stones.</li>
<li>Prefer Renal and Bladder Ultrasound in pregnant patients</li>
<li>All pts w/gross hematuria that is non-glomerular in source, in
    whom infection has been ruled out, warrant cystoscopy
    . Additionally, all patients with clots need cystoscopy</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypercalcemia"><h1 id="nephrology-nephrology-hypercalcemia-hypercalcemia">Hypercalcemia<a class="headerlink" href="#nephrology-nephrology-hypercalcemia-hypercalcemia" title="Permanent link">&para;</a></h1>
<p>Hypercalcemia – Rebecca Choudhry, Trevor Stevens</p>
<p>Background</p>
<ul>
<li>Definition
    : Total serum Calcium (Ca <sup>+2</sup> ) &gt;10.5</li>
<li>REMEMBER
    : Most Ca <sup>+2</sup> in the serum is bound primarily to albumin</li>
<li>In a hypoalbuminemic pt, you can correct the total Ca <sup>+2</sup>
    level with the formula:
    -<ul>
<li>0.8 x (4 – albumin level) + uncorrected Ca <sup>+2</sup> =
    corrected Ca <sup>+2</sup></li>
</ul>
</li>
<li>Ca <sup>+2</sup>
    > 12 can cause shortened QT interval;
    Ca <sup>+2</sup>
    at high levels can cause 2
    nd
    and 3 <sup>rd</sup> degree heart block, ventricular arrhythmias, and
    ST elevations mimicking MI</li>
<li>Pts with
    Ca <sup>+2</sup>
    \&lt;12 or chronic moderate hypercalcemia are often asymptomatic</li>
<li>Severe
    manifestations uncommon at
    Ca <sup>+2</sup>
    \&lt;14</li>
</ul>
<p>Presentation</p>
<ul>
<li>“
    Stones
    , bones, thrones
    , belly groans, and psychiatric overtones”<ul>
<li>Bone pain</li>
<li>Polydipsia/polyuria</li>
<li>Nausea/constipation</li>
<li>Depressed mood/cognitive impairment</li>
<li>Decreased level of consciousness</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Step
    1: Stop any contributing medications: Ca <sup>+2</sup> supplements,
    vitamin D, HCTZ</li>
<li>Step
    2: Check PTH! Then check magnesium, phosphorus, total vitamin D.</li>
<li>Step
    3: Determine if PTH is low or normal/high<ul>
<li>
<ul>
<li>Normal or ↑
        PTH
        -   Primary hyperparathyroidism:
            ↑
            Ca <sup>+2</sup>
            and
            ↓
            PO <sub>4</sub> <sup>-3</sup>
        -   Tertiary hyperparathyroidism (autologous secretion of
            PTH in CKD/ESRD)
            -   PTH often &gt; 800 with
                ↑
                Ca <sup>+2</sup>
                and
                ↑
                PO <sub>4</sub> <sup>-3</sup>
        -   Familial
            hypercalciuric hypercalcemia (often asymptomatic, no
            treatment required)
        -   24-hour urine
            Ca <sup>+2</sup>
            \&lt; 200</li>
<li>↓
    PTH<ul>
<li>Humoral hypercalcemia of malignancy: PTHrP</li>
<li>Malignancy: Bone survey for blastic lesions, skeletal
    survey for lytic lesions</li>
<li>Excess vitamin D intake: 25 hydroxyvitamin D</li>
<li>Granulomatous disease: 1,25 dihydroxy vitamin D, 25
    hydroxyvitamin D, nl or ACE</li>
<li>Milk-alkali syndrome</li>
<li>Immobilization</li>
<li>Medications (HCTZ)</li>
<li>Thyrotoxicosis: TSH</li>
<li>Adrenal insufficiency: AM cortisol</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Step 4: Determine if
    Ca <sup>+2</sup>
    > 14 (corrected for albumin) or symptomatic and treat accordingly<ul>
<li>
<ul>
<li>If
        Ca <sup>+2</sup>
        \&lt; 14 and asymptomatic
        -   Encourage PO hydration
        -   Replete volume with IV normal saline if hypovolemic
        -   Address underlying cause as above</li>
<li>If
    Ca <sup>+2</sup>
    > 12 with symptoms or Ca &gt; 14<ul>
<li>Trend Ca q8 hrs, EKG, monitor on telemetry; strict I/Os
    <u>+</u>
    foley catheter</li>
<li>Replete volume w/ IV NS boluses then start maintenance
    IVF at ~ 200cc/hr<ul>
<li>Goal UOP is 100-150cc/hr</li>
</ul>
</li>
<li>Add loop diuretic (Lasix) only AFTER patient is volume
    replete</li>
<li>Bisphosphonate:<ul>
<li>Zoledronic acid 4mg IV (EGFR &gt;60), Pamidronate 90mg
    IV (EGFR 15-60)</li>
</ul>
</li>
</ul>
</li>
<li>If
    Ca <sup>+2</sup>
    >14 or neurologic symptoms, consider sub q (NOT
    intranasal!) calcitonin<ul>
<li>VUMC: requires approval from an oncology or endocrine
    attending<ul>
<li>Page VU/VA endocrine consult fellow to get approval</li>
<li>If cancer pt, page malignant heme or solid tumor
    fellow ​​​​​​​</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>­</p>
<p>Additional Information</p>
<ul>
<li>In
    CHF pt, consider early addition of a loop diuretic, especially if
    volume overloaded</li>
<li>In ESRD pt with hypercalcemia (rare), patient with oliguric AKI not
    responsive to IVF, or pt with severely elevated Ca 16-18, consult
    endocrine and nephrology early</li>
<li>In pts with sarcoid or lymphoma, consider high dose steroids (e.g.
    prednisone 60 mg daily although typically only need 15-25 mg/day)</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyperkalemia"><h1 id="nephrology-nephrology-hyperkalemia-hyperkalemia">Hyperkalemia<a class="headerlink" href="#nephrology-nephrology-hyperkalemia-hyperkalemia" title="Permanent link">&para;</a></h1>
<p>Hyperkalemia – Mengyao Tang, Amanda Morrison</p>
<p>Background</p>
<ul>
<li>Causes: excessive intake (iatrogenic, supplementation), insufficient
    loss (CKD, AKI, type IV RTA, adrenal insufficiency, intracellular
    release or shifts (rhabdo, TLS, acidosis)</li>
<li>Medication-related: ACEi, ARB, MRA, NSAIDs, TMP/SMX, digoxin,
    heparin</li>
<li>“Pseudo”: hemolysis, severe leukocytosis, hand exercises w/
    tourniquet on during labdraw</li>
<li>Can be asymptomatic, or develop parasthesias, hyporeflexia, muscle
    weakness, GI upset</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Confirm it is real: check for hemolysis, repeat BMP</li>
<li>Check EKG for hyperkalemic changes<ul>
<li>
<ul>
<li>K <sup>+</sup> 5.5-6.5:  peaked T waves, prolonged PR
        interval</li>
<li>K <sup>+</sup> 6.5-8: prolonged QRS, loss of P wave, ST
    elevation, ectopic beats</li>
<li>K <sup>+</sup> &gt;8: sine wave pattern, asystole, PEA, VF</li>
</ul>
</li>
</ul>
</li>
<li>To establish cause once confirmed:<ul>
<li>
<ul>
<li>Labs: CBC with diff, UA, urine electrolytes, Mg, VBG
        -   Also consider LDH, haptoglobin, uric acid, CK</li>
<li>Imaging: bladder scan, renal ultrasound</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If there are EKG changes<ul>
<li>
<ul>
<li>Calcium gluconate 1g IV (effective within 3-5 min)
        -   Stabilizes cardiac membrane for ~60mins
        -   SHOULD BE REPEATED HOURLY while Hyperkalemic</li>
</ul>
</li>
</ul>
</li>
<li>Correct acidosis: Can use NaHCO3 dosed based on bicarb deficit</li>
<li>Shift
    K <sup>+</sup>
    Intracellularly<ul>
<li>
<ul>
<li>D50 w/ regular insulin 10 units (can order using Adult
        Hyperkalemia order set in epic)
        -   Consider using 5 units if there is renal impairment
        -   Lasts for 4-6hrs (can be longer in renal impairment)</li>
<li>Beta Agonists (e.g. high-dose albuterol nebulizer); lasts
    2-4 hrs</li>
</ul>
</li>
</ul>
</li>
<li>Increase
    K <sup>+</sup>
    Excretion<ul>
<li>
<ul>
<li>Loop diuretic (e.g. lasix)
        -   If there is AKI or a volume deficit can administer with
            IVF (Don’t dry out an already dry patient! Sometimes a
            dry patient only needs fluids to start kaliuresis)
        -   Kayexalate 60g PO q2h until bowel movement (If using
            oral, ensure patient is having bowel movements and is
            not obstructed, could cause bowel injury/ necrosis)
            -   PO can take up to 2hrs to work
            -   Strongly consider per rectal administration for
                quicker onset of action or if unable to tolerate PO
                -   DO NOT GIVE WITH SORBITOL per rectum</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Hemodialysis<ul>
<li>
<ul>
<li>Can correct K <sup>+</sup> rapidly but will take time to set
        up, especially if pt does not have access</li>
<li>Consult nephrology early if severe hyper K <sup>+</sup> or
    concerned that pt will not respond</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypernatremia"><h1 id="nephrology-nephrology-hypernatremia-hypernatremia">Hypernatremia<a class="headerlink" href="#nephrology-nephrology-hypernatremia-hypernatremia" title="Permanent link">&para;</a></h1>
<p>Hypernatremia – Rebecca Choudhury, Trevor Stevens</p>
<p>Background</p>
<ul>
<li>Definition
    = Na <sup>+</sup> &gt;145;
    Hypernatremia is a lack of free water</li>
<li>Dehydration is both hypernatremia AND hypovolemia</li>
<li>New studies suggest there is no evidence that overcorrection of
    hypernatremia leads to adverse outcomes! Do not undertreat!</li>
<li>Common
    causes:
    Inadequate free water intake relative to solute intake (dementia,
    limited mobility, tube feeding/TPN (ICU), impaired thirst/adipsia
    from hypothalamic stroke)</li>
<li>Less common causes: Increased insensible losses, Upper GI losses,
    Na <sup>+</sup>
    overload (salt poisoning, iatrogenic from NS infusion,
    overcorrection)<ul>
<li>Renal losses: osmotic diuresis (hyperglycemia, SGLT-2
    inhibitors, urea, mannitol), central or nephrogenic diabetes
    insipidus</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lethargy, irritability, confusion, esp. if chronic</li>
<li>Seizures, coma, hemorrhagic stroke, or subarachnoid hemorrhage in
    severe acute hypernatremia (typically &gt;158)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>If
    Na <sup>+</sup>
    145-150 and free water deficit \&lt; 3L, trial free water first, and if
    no improvement perform workup as below:</li>
<li>If
    Na <sup>+</sup>
    > 150, check serum osm, UA, urine
    Na <sup>+</sup>
    and urine osm if etiology is unclear<ul>
<li>
<ul>
<li>UOsm &gt;600, U
        Na <sup>+</sup>
        low (typically \&lt;25): volume depletion</li>
<li>UOsm &gt;600, U
    Na <sup>+</sup>
    high (typically &gt;100):
    Na <sup>+</sup>
    overload</li>
<li>UOsm \&lt; SOsm (typically \&lt;300): DI</li>
<li>UOsm 300-600: osmotic diuresis and/or partial DI</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Step 1: Treat any underlying cause (vomiting, hyperglycemia,
    medications)</li>
<li>Step 2: Determine volume status: If severely volume deplete (i.e.
    hypotensive) the patient will need lactated ringers to restore
    volume first and then D5W to restore free water</li>
<li>Step 3: Estimate free water deficit (FWD) and replete as below:<ul>
<li>Online calculators available (MDCalc)
    : FWD = TBW x [(serum Na/140) - 1]</li>
</ul>
</li>
<li>Step 4: determine if chronic or acute</li>
</ul>
<p>Acute Hypernatremia</p>
<ul>
<li>Correction for severe
    hypernatremia (\&lt;48 in duration, Na &gt;158), Na <sup>+</sup> \&lt;145
    within 24h</li>
<li>Requires
    ICU level care:
    Trend
    Na <sup>+</sup>
    q 2-3 hrs (plus glucose, if using D5W)<ul>
<li>Once
    Na <sup>+</sup>
    \&lt;145, can space to q6-8hrs</li>
</ul>
</li>
<li>Start D5W at 3-6 cc/kg/hr ( <sup>1/</sup> <sub>2</sub> NS if pt is
    severely hyperglycemic), titrate to desired correction rate</li>
</ul>
<p>Chronic Hypernatremia</p>
<ul>
<li>Correction
    (&gt;48h, most common scenario), aim for slow correction of
    10 mEq/L per day</li>
<li>Use the free water deficit to guide your plan and total free water
    needs</li>
<li>Trend Na q8-12hrs until stable at desired correction rate, then can
    space to q12-24h</li>
<li>Start D5W and give based on free water deficit; for starting rate
    and length you can also use “Stone’s formula”: 2 x body weight in kg
    = rate [mL/hr], and 2 x change in
    Na <sup>+</sup>
    desired = length [hrs] (e.g. if you want to drop
    Na <sup>+</sup>
    by 6 then run for 12 hrs)</li>
<li>If severely hyperglycemic: Use &frac12;NS at 1.35 mL/hr x patient’s
    weight in kg if pt</li>
<li>If mild and pt neurologically intact, may be done with oral or
    enteral (if feeding tube) water</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Pts w/
    suspected DI: <strong>Consult Nephrology</strong> (may require desmopressin or
    may receive desmopressin once stabilized to differentiate between
    central and nephrogenic DI)</li>
<li>Consider Urine volume an ongoing loss of free water, and add it to
    the D5W replacement</li>
<li>Pts with hypokalemia: giving K decreases total amount of free water
    you are giving the pt</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyperphosphatemia"><h1 id="nephrology-nephrology-hyperphosphatemia-hyperphosphatemia">Hyperphosphatemia<a class="headerlink" href="#nephrology-nephrology-hyperphosphatemia-hyperphosphatemia" title="Permanent link">&para;</a></h1>
<p>Hyperphosphatemia – Peter Thorne, Amanda Morrison</p>
<p>Background</p>
<ul>
<li>Phosphate (
    PO <sub>4</sub> <sup>-3</sup>
    ) &gt;4.5mg/dL</li>
<li>Etiologies:<ul>
<li>Cellular lysis (TLS, Rhabdomyolysis)</li>
<li>Increased intake/absorption or iatrogenic hyperphosphatemia
    (Over repletion, Vitamin D toxicity, use of Fleet’s enemas,
    etc.)</li>
<li>Decreased phosphate clearance (Acute or chronic renal disease,
    hypoparathyroidism, pseudohypoparathyroidism)</li>
<li>Acute extracellular shifts of phosphate (DKA, severe Lactic
    acidosis)</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Symptoms are usually secondary to coexistent hypocalcemia
    (psychosis, seizure, perioral paresthesia’s, muscle weakness)</li>
<li>Can cause Acute phosphate nephropathy with phosphate containing
    laxatives</li>
<li>Calciphylaxis if concurrent hypercalcemia (high Ca <sup>+2</sup> x
    PO <sub>4</sub> <sup>-3</sup>
    product)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Labs: BMP (calcium, creatinine), Vit D, PTH, PTHrP, lactate</li>
</ul>
<p>Management</p>
<p>Acute</p>
<ul>
<li>If renal function normal, can often treat with IVF (promote
    PO <sub>4</sub> <sup>-3</sup>
    excretion)</li>
<li>Consider need for calcium supplementation (see hypocalcemia section)</li>
<li>If renal function impaired and severe hypocalcemia present =
    consider hemodialysis</li>
</ul>
<p>Chronic</p>
<ul>
<li>Usually secondary to chronic renal failure, goal
    PO <sub>4</sub> <sup>-3</sup>
    3.5-5.5 in CKD patients</li>
<li>Renal diet (low
    PO <sub>4</sub> <sup>-3</sup>
    )</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    binders: Ca <sup>+2</sup> containing (calcium carbonate and calcium
    acetate) and non Ca <sup>+2</sup> containing (sevelamer, lanthanum,
    and iron based such as ferric citrate)<ul>
<li>
<ul>
<li>Sevelamer is significantly more expensive than calcium
        containing binders
        -   Given 3 times daily with meals, started at 800mg (Can be
            ↑
            to 1,600mg TID)
        -   Should not be given if pt is not eating</li>
<li>Calcium acetate: started at 1334mg TID with meals</li>
</ul>
</li>
</ul>
</li>
<li>Limit dose changes to chronic binders upon discharge</li>
<li>Need to avoid calcium containing binders in patients with
    calciphylaxis</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypokalemia"><h1 id="nephrology-nephrology-hypokalemia-hypokalemia">Hypokalemia<a class="headerlink" href="#nephrology-nephrology-hypokalemia-hypokalemia" title="Permanent link">&para;</a></h1>
<p>Hypokalemia – Peter Thorne/Patrick Steadman</p>
<p>Background</p>
<ul>
<li>Potassium (K <sup>+</sup> ) \&lt; 3.5 mEq/L</li>
<li>98% of total body K <sup>+</sup> is intracellular (majority in
    muscle cells)</li>
<li>Goal: prevent life threatening complication (e.g. arrhythmia),
    replace deficit, elucidate cause</li>
<li>Insulin and catecholamines (Beta adrenoreceptors) are key drivers of
    transcellular shifts</li>
<li>H+ and K <sup>+</sup> will trade places to maintain
    electroneutrality</li>
</ul>
<p>Presentation</p>
<ul>
<li>Malaise, weakness, myalgias, decreased gastrointestinal motility</li>
<li>EKG changes:<ul>
<li>Mild: ST segment depression, decreased T wave amplitude</li>
<li>Severe: U-waves (most commonly seen in precordial leads V2 and
    V3)</li>
</ul>
</li>
<li>Severe hypokalemia can lead to rhabdomyolysis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>History: Consider decreased
    K <sup>+</sup>
    intake, increased entry into cells (ex: Increased cell production,
    elevated beta-adrenergic activity, hypothermia), GI losses, urinary
    losses (diuretics, hypomagnesemia, RTA, tubular defects,
    hyperaldosteronism)</li>
<li>If concomitant metabolic alkalosis: Normal/low BP suggests diuretic
    use, vomiting or Gitelman/Bartter syndromes</li>
<li>Hypertension suggests renovascular disease or primary
    mineralocorticoid excess</li>
<li>Labs: BMP, CBC, VBG, urine electrolytes, magnesium, POC glucose, CK</li>
<li>Imaging: Renal US, CT A/P</li>
<li>Other: aldosterone, renin, cortisol</li>
</ul>
<p>Management</p>
<ul>
<li>Check Mg <sup>+2</sup> , replete to 2; Give empirically while
    waiting for serum Mg <sup>+2</sup></li>
<li>K <sup>+</sup>
    preparation (route); replete to 4</li>
<li>Choice of agent:<ul>
<li>KCl is used for repletion in the hospital<ul>
<li>
<ul>
<li>PO tablets for mild asymptomatic hypokalemia</li>
<li>IV can be given through peripheral (
    rate is 10mEq/hr)
    or central access</li>
</ul>
</li>
</ul>
</li>
<li>K <sup>+</sup> bicarbonate can be dissolved and put through G
    tube<ul>
<li>
<ul>
<li>Useful in pts with hypokalemia and metabolic acidosis</li>
</ul>
</li>
</ul>
</li>
<li>K <sup>+</sup> acetate is given IV, rarely used (often additive
    to TPN)</li>
</ul>
</li>
<li>Dose:<ul>
<li>Normal renal function: 10 mEq K <sup>+</sup> is expected to
    raise serum [K <sup>+</sup> ] by 0.1 mEq/L</li>
<li>Significant CKD or AKI: at risk of overcorrection<ul>
<li>
<ul>
<li>Shortcut: multiply the mEq by the Cr = how much
        K <sup>+</sup>
        expected to rise</li>
</ul>
</li>
</ul>
</li>
<li>Once
    K <sup>+</sup>
    higher than 5.5,
    K <sup>+</sup>
    increases much faster and rules above do not apply</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypomagnesemia"><h1 id="nephrology-nephrology-hypomagnesemia-hypomagnesemia">Hypomagnesemia<a class="headerlink" href="#nephrology-nephrology-hypomagnesemia-hypomagnesemia" title="Permanent link">&para;</a></h1>
<p>Hypomagnesemia – Mike Tozier</p>
<p>Background</p>
<ul>
<li>Serum Magnesium (Mg <sup>+2</sup> ) \&lt; 1.8 mg/dL, most pts
    asymptomatic until \&lt;1.2 mg/dL<ul>
<li>
<ul>
<li>Severe [
        Mg <sup>+2</sup> ] \&lt; 1 mg/dL</li>
</ul>
</li>
</ul>
</li>
<li>Causes<ul>
<li>
<ul>
<li>GI: Diarrhea, malabsorption, acute pancreatitis, EtOH use,
        terminal cancer, TPN, vomiting, NG suction, GI fistulas,
        anorexia, short gut syndrome, small bowel bypass</li>
<li>Drugs: PPIs, loop diuretics, thiazides, digoxin,
    amphotericin, aminoglycosides, foscarnet, cisplatin,
    cetuximab, CNIs, laxatives, pentamidine</li>
<li>Renal: ATN recovery, transplant, others genetic or drugs as
    listed elsewhere</li>
<li>Extracellular-&gt;Intracellular shift: DKA treatment/recovery,
    refeeding, hungry bone syndrome, correction of metabolic
    acidosis, pancreatitis, EtOH withdrawal</li>
<li>Genetic: Gittleman, Bartter, multiple other rare conditions</li>
<li>Other: DM, hyperCa, hyperthyroid, hyperaldosteronism, burns,
    lactation, Vit D deficiency, heat, prolonged exercise,
    mitral valve prolapse, pseudohypomagnesemia 2/2 EDTA tube,
    lactation</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Consider in ICU pts, refractory hypocalcemia or hypokalemia, heart
    failure, any arrhythmia, chronic diarrhea/GI losses, refeeding, pts
    on PPIs or diuretics</li>
<li>Initial symptoms: nausea, vomiting, appetite loss, fatigue,
    weakness, paresthesia’s, contractions, cramps, depression,
    agitation, psychosis, dysphagia</li>
<li>Severe symptoms: seizures, drowsiness, confusion, coma, arrhythmias</li>
<li>Vertical nystagmus, tetany (Chvostek sign, Trousseau), tremors,
    fasciculations, seizures</li>
<li>EKG: Initially wide QRS, peaked Ts. Progresses to wide PR,
    diminished T, arrhythmias</li>
<li>Other labs: Ca <sup>+2</sup> , K <sup>+</sup> , can use FE
    Mg <sup>+2</sup>
    (order urine
    Mg <sup>+2</sup>
    and Cr, serum Cr and
    Mg <sup>+2</sup>
    ) or 24-hour urine for
    Mg <sup>+2</sup>
    to distinguish renal vs GI etiology (FE
    Mg <sup>+2</sup>
    >2% renal, \&lt;2% GI)</li>
<li>Urine studies need to be done when pt at steady state, if checked
    shortly after IV magnesium given you will see elevated magnesium
    excretion no matter the cause</li>
</ul>
<p>Management</p>
<ul>
<li>Correct
    underlying cause, replete based on severity (Dosing below for normal
    GFR)</li>
<li>Oral
    : asymptomatic pts, can cause GI symptoms, not well absorbed<ul>
<li>
<ul>
<li>Sustained release (
        Mg <sup>+2</sup>
        Chloride or
        Mg <sup>+2</sup>
        L-lactate) better tolerated and absorbed, though standard
        preparations (
        Mg <sup>+2</sup>
        oxide) are faster acting</li>
<li>Mg <sup>+2</sup>
    chloride: 3-4 tabs BID (total 30 to 56 meq [15 to 28
    mmol]) for severe hypo
    Mg <sup>+2</sup></li>
<li>2-4 tabs daily (total 10 to 28 meq [5 to 14 mmol]) for
    mild hypo
    Mg <sup>+2</sup></li>
<li>Mg <sup>+2</sup>
    oxide: 400-800 mg BID (20 to 40 mmol [40 to 80 meq]) for
    mod-severe hypo
    Mg <sup>+2</sup></li>
</ul>
</li>
</ul>
</li>
<li>Intravenous
    : for symptomatic patients or if GI intolerance to oral<ul>
<li>
<ul>
<li>Mg <sup>+2</sup>
        \&lt;1 mg/dL: 4 to 8g of MgSO4 (32 to 64 meq [16 to 32 mmol])
        over 12 to 24 hrs</li>
<li>Mg <sup>+2</sup>
    1 to 1.5 mg/dL: 4 g MgSO4 (16 to 32 meq [8 to 16 mmol])
    over 4 to 12 hrs</li>
<li>Mg <sup>+2</sup>
    1.6 to 1.9 give 1 to 2 grams MgSO4 (8 to 16 meq [4 to 8
    mmol]) 1-2 hrs</li>
<li>VUMC only has 4g bags of IV mag so would need to ask nurses
    to only infuse &frac12; bag</li>
<li>Infusion rate should not exceed 2 g/hr to minimize urinary
    excretion</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Renal impairment: replete with caution, reduce dose by 50-75% and
    monitor closely</li>
<li>If persistent hypo
    Mg <sup>+2</sup>
    in pts requiring diuresis, try K-sparing diuretic (e.g. Amiloride)</li>
<li>Treat concomitant hypokalemia, hypocalcemia or hypophosphatemia</li>
<li>In pts with concomitant hypophos and hypocalcemia, IV
    Mg <sup>+2</sup>
    alone -&gt; worse hypophos</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyponatremia"><h1 id="nephrology-nephrology-hyponatremia-hyponatremia">Hyponatremia<a class="headerlink" href="#nephrology-nephrology-hyponatremia-hyponatremia" title="Permanent link">&para;</a></h1>
<p>Hyponatremia – Kaitlyn Reasoner</p>
<p>Background</p>
<ul>
<li>Definition: Serum Na <sup>+</sup> \&lt;135 mEq/L. A problem of excess
    free water.</li>
<li>Can
    be due to
    ↑
    water intake or
    ↑
    ADH release</li>
<li>ADH
    is released in response to
    ↑
    serum osm or
    ↓
    volume (low cardiac output can also look like low volume to the
    body, e.g. heart failure exacerbation)</li>
<li>The
    body will protect volume over preserving a normal osmolarity and ADH
    will be released for low
    volume/low CO despite a low osm</li>
<li>Herniation almost exclusively occurs in acute settings including
    large volume H2O ingestion (ecstasy usage, runners, psychogenic),
    post-op, intracranial pathology</li>
<li>Severity:<ul>
<li>Mild
    :
    Na <sup>+</sup>
    130-134</li>
<li>Moderate
    :
    Na <sup>+</sup>
    125-129</li>
<li>Severe
    :
    Na <sup>+</sup>
    \&lt;125</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Mild to moderate symptoms include lethargy, N/V, dizziness,
    confusion, fatigue, cramping</li>
<li>Severe
    symptoms
    include obtundation, coma, respiratory arrest, seizure.</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Rule
    out pseudohyponatremia, review meds and infusions (often hypotonic)<ul>
<li>If pt also has hypokalemia, correcting the K <sup>+</sup> will
    also increase the
    Na <sup>+</sup>
    and this must
    be taken into account when calculating the amount of
    Na <sup>+</sup>
    needed</li>
</ul>
</li>
<li>Step 1:
    Rule out pseudohyponatremia<ul>
<li>Causes of pseudohyponatremia include hyperglycemia (most
    common), sorbitol, mannitol, sucrose, elevated lipids, TSH, or
    protein</li>
<li>Check glucose, TSH, lipids, and protein level</li>
<li>If hyperglycemic
    , corrected serum
    Na <sup>+</sup>
    = measured
    Na <sup>+</sup>
    + 1.6*[(glucose – 100)/100]<ul>
<li>
<ul>
<li>If corrected
        Na <sup>+</sup>
        is normal, treat hyperglycemia; there is not a water
        balance problem</li>
<li>If corrected
    Na <sup>+</sup>
    is low, there is hypotonic hyponatremia + coexisting
    hyperglycemia</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Step 2:
    Determine if ADH is high or low and treat accordingly<ul>
<li>Send urine osm and urine
    Na <sup>+</sup>
    at the same time you send serum osm</li>
<li>High ADH
    =
    ↑
    urine osm or urine osm&gt;serum osm</li>
<li>Low ADH
    , high free water intake =
    ↓
    urine osm or urine osm\&lt; serum osm<ul>
<li>
<ul>
<li>Causes: primary polydipsia, beer potomania, tea &amp; toast</li>
<li>Treatment <strong>:</strong> restrict free water</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Step 3:
    If ADH is high, determine if it is <strong>appropriate</strong> versus
    <strong>inappropriate</strong> elevation<ul>
<li>Appropriate
    ADH is due to
    ↓
    actual/perceived
    circulatory volume or
    ↓
    cardiac output<ul>
<li>
<ul>
<li>Causes:  hypovolemia, cirrhosis, heart failure/
        ↓
        CO, nephrotic syndrome, salt wasting (HCTZ, cerebral,
        SSRIs, etc.)</li>
<li>Urine
    Na <sup>+</sup>
    usually \&lt;30 mmol</li>
<li>Treatment: Stop offending medications &amp; Correct volume
    perturbation</li>
</ul>
</li>
</ul>
</li>
<li>Inappropriate
    ADH
    ↑
    , euvolemic or
    ↑
    ADH out of proportion to stimulus, urine
    Na <sup>+</sup>
    >30<ul>
<li>
<ul>
<li>Causes: SIADH (malignancy, meds, surgery, pulmonary
        disease, hormones, pain, or bladder distension)</li>
<li>Treatment: water restriction, can add NaCl tabs or urea
    if fluid restriction is severe</li>
<li>Calculate Water
    restriction for SIADH (L per day) = 600 / Urine osm<ul>
<li>600 is the
    average salt meq in an American diet per day</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<p>Consider nephrology consult if:</p>
<ul>
<li>Considering ddAVP clamp for overcorrection, or suspect this will
    happen, PO urea (a non-sodium osmole), Lasix if appropriate,
    vaptans, salt tablets</li>
<li>ICU care for pts with serum
    Na <sup>+</sup>
    \&lt;120</li>
<li>Pts at high risk for osmotic demyelination: chronic liver disease,
    chronic alcohol use, concurrent
    hypokalemia, malnourishment, serum sodium \&lt;105</li>
</ul>
<p>Acute (\&lt;48 hrs)</p>
<ul>
<li>If severe or symptomatic + not autocorrecting, give 50 cc bolus 3%
    NaCl (HTS)</li>
<li>Monitor
    Na <sup>+</sup>
    q1-2 hr</li>
<li>Goal is an initial rapid 4-6 mEq/L correction and then hold<ul>
<li>May
    require Hypertonic Saline
    infusion</li>
</ul>
</li>
</ul>
<p>Chronic (&gt;48 hrs or unknown, higher risk for osmotic demyelination if
corrected too quickly):</p>
<ul>
<li>Goal
    Na <sup>+</sup>
    correction rate 4-6 mEq/L over 24 hrs (Max 8mEq/L)<ul>
<li>8 mEq/L per 24 hrs thereafter</li>
</ul>
</li>
<li>If severe, proceed
    as under acute above</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypophosphatemia"><h1 id="nephrology-nephrology-hypophosphatemia-hypophosphatemia">Hypophosphatemia<a class="headerlink" href="#nephrology-nephrology-hypophosphatemia-hypophosphatemia" title="Permanent link">&para;</a></h1>
<p>Hypophosphatemia – Peter Thorne</p>
<p>Background</p>
<ul>
<li>PO <sub>4</sub>
    -3
    \&lt; 2.3mg/dL</li>
<li>Common Causes<ul>
<li>
<ul>
<li>Internal redistribution, reduced intestinal absorption</li>
<li>Malnourished pts: refeeding syndrome and intracellular
    movement/use of phos</li>
<li>Insulin moves phos intracellular as does respiratory
    alkalosis</li>
<li>Phos binders on purpose or inadvertently (calcium, aluminum,
    magnesium antacids)</li>
<li>Excessive loss (diarrhea, CRRT, increased urinary excretion)</li>
<li>Proximal tubular dysfunction such as in Fanconi Syndrome</li>
<li>Hyperparathyroidism causes renal phos wasting</li>
<li>Post-parathyroidectomy leading to hungry bone syndrome</li>
<li>Vitamin D deficiency or resistance</li>
</ul>
</li>
</ul>
</li>
<li>PO <sub>4</sub>
    -3
    is primarily found in bone and intracellular space</li>
<li>Required for metabolic pathways (ATP production!)</li>
<li>Most renal reabsorption occurs in proximal tubule via
    sodium-phosphate cotransporter</li>
</ul>
<p>Presentation</p>
<ul>
<li>Mild Hypophosphatemia (serum &gt;2.0) rarely symptomatic</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt; 2.0: Muscle weakness</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt; 1.0: Heart failure, respiratory failure, rhabdomyolysis, seizures</li>
<li>Failure to wean from ventilator</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urine
    PO <sub>4</sub> <sup>-3</sup>
    level if cause not readily apparent</li>
<li>Calculate
    Fe
    PO <sub>4</sub> <sup>-3</sup>
    ([U
    PO <sub>4</sub> <sup>-3</sup>
    x PCr x 100]/[P
    PO <sub>4</sub> <sup>-3</sup>
    x UCr]).<ul>
<li>
<ul>
<li>Fe
        PO <sub>4</sub> <sup>-3</sup>
        \&lt; 5% = normal renal response to hypophos: redistribution or
        ↓
        absorption</li>
<li>Fe
    PO <sub>4</sub> <sup>-3</sup>
    > 5% = renal phos wasting</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Caution repleting pts with impaired renal function: start with half
    suggested dose</li>
<li>If K <sup>+</sup> &gt; 4 and patient requires IV repletion, may need to
    use sodium
    PO <sub>4</sub> <sup>-3</sup>
    in place of K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    IV; po preferred unless severe or symptomatic, or patient cannot
    take po</li>
<li>K-
    Phos
    neutral: oral, each 250mg tablet has 8 mmol of
    PO <sub>4</sub> <sup>-3</sup>
    and 1.1mEq of K <sup>+</sup></li>
<li>K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    : IV, each mL has 3mmol
    PO <sub>4</sub> <sup>-3</sup>
    , 4.4 meq K <sup>+</sup></li>
<li>Na <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    : IV, each mL has 3mmol
    PO <sub>4</sub> <sup>-3</sup></li>
<li>IV
    repletion
    is diluted in 250mL NS or D5W and infused over 4-6 hrs</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    >1.5: PO: 40 – 80 mmol
    K <sup>+</sup>
    Phos neutral (aim for 1 mmol/kg) divided into 3-4 doses/day</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    1.25 - 1.5: oral 100 mmol
    K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    neutral in 3-4 divided doses if asymptomatic</li>
<li>IV: 30 mmol K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    over 6 hours
    (aim for 0.4mmol/kg)
    if symptomatic</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt;1.25: IV: 80mmol
    K <sup>+</sup>
    Phos over approximately 12 hours (aim for 0.5mmol/kg)<ul>
<li>
<ul>
<li>Check serum
        PO <sub>4</sub> <sup>-3</sup>
        2-12 hrs after last dose of
        PO <sub>4</sub> <sup>-3</sup>
        to determine if additional needs</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-metabolic-acidosis"><h1 id="nephrology-nephrology-metabolic-acidosis-metabolic-acidosis">Metabolic acidosis<a class="headerlink" href="#nephrology-nephrology-metabolic-acidosis-metabolic-acidosis" title="Permanent link">&para;</a></h1>
<p>Approach to Metabolic Acidosis – Ned Hardison</p>
<p>ABG (VBG) reference ranges:</p>
<ul>
<li>pH
    = 7.36-7.44 (~7.32-7.40)</li>
<li>PCO2
    = 36-44 mmHg</li>
<li>HCO3
    = 22-26 mEq/L</li>
<li>VBG
    can be used to screen for hypercarbia, but not to assess degree of
    hypercarbia</li>
<li>pH
    between ABG and VBG correlates well with mean difference 0.035 pH
    units</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Disorder</td>
<td>pH</td>
<td>PaCO2</td>
<td>HCO3</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>↓</td>
<td>↓</td>
<td>↓↓</td>
</tr>
<tr>
<td>Metabolic alkalosis</td>
<td>↑</td>
<td>↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Respiratory acidosis</td>
<td>↓</td>
<td>↑↑</td>
<td>↑</td>
</tr>
<tr>
<td>Respiratory alkalosis</td>
<td>↑</td>
<td>↓↓</td>
<td>↓</td>
</tr>
</tbody>
</table>
<p><img src="/sites/default/files/inline-images/Equations.png" data-entity-type="file" data-entity-uuid="a98df158-2416-441f-8fd3-0f2e195b5b56" alt="Equations" /></p>
<p>Non-anion gap metabolic acidosis (NAGMA)</p>
<ul>
<li>In
    practice
    , there are two sources of bicarb deficit – kidneys or gut<ul>
<li>
<ul>
<li>Urine anion-gap can differentiate between the two</li>
<li>It corresponds to unmeasured NH4+ which kidneys should
    excrete to remove acid excess if they are functioning
    appropriately</li>
</ul>
</li>
</ul>
</li>
<li>Urine
    anion gap = Unmeasured cations (NH4+) – unmeasured anions = U­Na +
    UK – UCl<ul>
<li>
<ul>
<li>Positive
        value, low NH4+, kidneys not working appropriately, = renal
        etiology</li>
<li>Ne-GUT-ive
    value, high NH4+, kidneys working appropriately = gut loss</li>
</ul>
</li>
</ul>
</li>
<li>Caveat
    : Proximal RTA has a normal distal urine acidification and has a
    negative urine AG</li>
</ul>
<p>Managing Metabolic Acidosis</p>
<ul>
<li>Metabolic acidosis is evidence of an underlying metabolic
    derangement</li>
<li>Severe
    metabolic acidosis due to shock and hypoperfusion can lead to poor
    response to vasopressors, arrhythmias, and cerebral edema<ul>
<li>
<ul>
<li>1 ampule NaHCO3 = 50 mEq NaHCO3, can give 1-3 amps</li>
<li>NaHCO3 solution alone is hypertonic; Administer in &frac12; NS or
    D5W to avoid hypernatremia but NS usually avoided b/c of
    risk of worsening acidosis</li>
<li>Or a bicarb gtt, order 3 amps of NaHCO3 in 1L of D5W</li>
</ul>
</li>
</ul>
</li>
<li>Evidence
    for use of bicarbonate is mixed: No proven benefit in lactic
    acidosis or DKA, but some experts suggest use in DKA when pH\&lt;7.1<ul>
<li>
<ul>
<li>In acute NAGMA, reasonable to give bicarbonate when bicarb
        \&lt;12 or pH \&lt;7.1-7.2</li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Anion Gap</td>
<td>Non-anion gap</td>
</tr>
<tr>
<td>Etiologies</td>
<td>Glycols (ethylene, diethylene, propylene) Oxoproline (d/t APAP overdose) L-lactate (std. measured lactate) D-lactate (d/t short bowel syndrome) Methanol (and other alcohols) Aspirin Renal failure (uremia, PO4, SO4) Ketoacidosis (DM, EtOH, starvation)</td>
<td>Gut Losses: Diarrhea Renal Losses: - AKI, CKD - Renal tubular acidosis - Crystalloid infusion - Carbonic anhydrase inhibitors</td>
</tr>
<tr>
<td>Further Workup</td>
<td>For all cases: BMP, consider ABG, UA, &plusmn; EKG</td>
<td>For all cases: BMP, consider ABG, UA, &plusmn; EKG</td>
</tr>
<tr>
<td>Further Workup</td>
<td>- Elevated osmolar gap (&gt;10) can suggest ingestion (G or M, above) - Calculate ∆∆ , interpret as above - Consider UA (ketonuria), LFTs, lactate, Utox, β-OH-butyrate, APAP/ASA/EtOH levels - Evaluate medication list for causes(e.g. Metformin, Linezolid)</td>
<td>- Urine anion gap - &plusmn; further w/u of AKI/RTA</td>
</tr>
</tbody>
</table></section><section class="print-page" id="nephrology-nephrology-peritonitis-patients-pd"><h1 id="nephrology-nephrology-peritonitis-patients-pd-peritonitis-in-patients-on-pd">Peritonitis in patients on PD<a class="headerlink" href="#nephrology-nephrology-peritonitis-patients-pd-peritonitis-in-patients-on-pd" title="Permanent link">&para;</a></h1>
<p>Peritonitis in patients on PD</p>
<p>Background</p>
<ul>
<li>Etiology
    likely 2/2 contamination with pathogenic skin bacteria during
    exchanges or due to exit-site or tunnel infection</li>
<li>Usually present with cloudy effluent fluid and abdominal pain but
    can be present even in the absence of one of these</li>
<li>Important
    history to obtain: recent contamination, accidental disconnection,
    endoscopic or gynecologic procedure, as well as the presence of
    constipation or diarrhea</li>
<li>Definitive
    diagnosis requires 2 of the following:<ul>
<li>Clinical features consistent with peritonitis</li>
<li>Positive dialysis effluent culture</li>
<li>Dialysis effluent with WBC &gt; 100 with PMN &gt; 50%<ul>
<li>
<ul>
<li>Even
        if WBC count \&lt; 100, presence of &gt; 50% PMNs is still
        strong evidence of peritonitis in pts with rapid cycle
        PD</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Culture
    peritoneal fluid (requires training and equipment, performed by
    Nephrology)</li>
<li>Peritoneal
    cell count with diff, gram stain and culture</li>
<li>Obtain
    peripheral blood cultures if there is concern for sepsis</li>
</ul>
<p>Management</p>
<ul>
<li>All
    PD orders, intraperitoneal antibiotics, and prescription adjustments
    should be directed by ESRD consult service (page them overnight if
    concerns)</li>
<li>Treatment
    with intraperitoneal antibiotics should be started immediately after
    specimens have been obtained if there is high clinical suspicion</li>
<li>Empiric
    antibiotics regimen should cover both gram positive and gram
    negative organisms, typically with Vanc and third generation
    Cephalosporin</li>
<li>Systemic
    antibiotics are generally not necessary unless pts have systemic
    signs of sepsis</li>
<li>Pts
    with relapsing, recurrent or repeat peritonitis will likely need
    catheter removal</li>
</ul>
<p>Secondary prevention</p>
<ul>
<li>Treatment
    with intraperitoneal OR IV antibiotics (for any infection
    requiring &gt; 1 dose of antibiotics) requires prophylaxis for fungal
    peritonitis with either:<ul>
<li>Nystatin 400,000 to 500,000 units orally TID</li>
<li>Fluconazole 200 mg every other day or 100 mg qdaily</li>
</ul>
</li>
<li>Dialysate
    should be drained the day of endoscopies or gynecological procedures</li>
</ul></section><section class="print-page" id="nephrology-nephrology-renal-replacement-therapy"><h1 id="nephrology-nephrology-renal-replacement-therapy-renal-replacement-therapy">Renal Replacement Therapy<a class="headerlink" href="#nephrology-nephrology-renal-replacement-therapy-renal-replacement-therapy" title="Permanent link">&para;</a></h1>
<p>Renal Replacement Therapy – Joseph Quintana, David Li, Taylor Riggs</p>
<p>Indications</p>
<p>for Acute Renal Replacement Therapy [</p>
<p>AEIOU</p>
<p>]</p>
<ul>
<li>Acidosis
    : intractable severe pH \&lt;7.1 <u>and</u> hypervolemia<ul>
<li>Unless
    acidemia quickly reversible like DKA</li>
</ul>
</li>
<li>Electrolytes:
    K, Na, Ca, Phos, Uric acid which are unable to correct by
    noninvasive or temporizing measures<ul>
<li>Hyperkalemia
    : &gt;6.5 mEq/L, cardiac changes, warrant urgent dialysis;
    Temporize them until dialysis (insulin D5/D50, IV calcium,
    albuterol, potassium binders)</li>
</ul>
</li>
<li>Intoxication
    : methanol, ethylene glycol, Lithium, ASA</li>
<li>Overload
    : fluid overload, particularly hypervolemia and pulmonary edema, and
    particularly with renal failure (AKI or ESRD)<ul>
<li>Try IV Lasix challenge 240 mg IV (if &gt;200 mL in 2 hrs urine,
    then no need for dialysis);<ul>
<li>Can discuss sequential nephron blockade with nephrology</li>
</ul>
</li>
<li>If anuric w/o pulmonary edema: nephrology will give things 24
    hours to settle out</li>
</ul>
</li>
<li>Uremia
    : pericarditis, seizure, functional platelet dysfunction in advance
    of a pending procedure, or decline in mental status</li>
</ul>
<p>ESRD Admits</p>
<ul>
<li>Consult
    ESRD in the morning for routine dialysis unless more urgently needed</li>
<li>Routine
    orders include MWF phos checks and Renal diet</li>
<li>For
    peritoneal dialysis pts, their diet can be more liberal and include
    low phos only or even regular diet (Can just ask what diet he/she
    follows at home)</li>
</ul></section><section class="print-page" id="nephrology-nephrology-transplant-aki"><h1 id="nephrology-nephrology-transplant-aki-transplant-aki">Transplant AKI<a class="headerlink" href="#nephrology-nephrology-transplant-aki-transplant-aki" title="Permanent link">&para;</a></h1>
<p>Transplant</p>
<p>AKI</p>
<p>Background</p>
<ul>
<li>Allograft
    dysfunction<ul>
<li>Increase in serum <strong>Cr <u>></u> 25 %</strong> from baseline in 1-3
    months</li>
<li>Failure of creatine to decrease post-transplant</li>
<li>Proteinuria &gt;1g/day</li>
</ul>
</li>
<li>How
    to think of transplant AKI?  Categorize dysfunction relative to
    transplant date<ul>
<li>Don’t forget about: Pre-, intra- and post- renal</li>
</ul>
</li>
<li>Dysfunction
    by time course:<ul>
<li>\&lt; 1-week
    post-transplant: [usually managed within transplant
    hospitalization]<ul>
<li>Often delayed graft function, can require dialysis in week 1
    until graft function</li>
<li>Vascular thrombosis of graft vessels, ATN (common in
    deceased donors)</li>
</ul>
</li>
<li><strong>> 1-week</strong> post-transplant (
    HIGH YIELD)<ul>
<li>Pyelonephritis/complicated UTI: Fever, abdominal pain, graft
    tenderness</li>
<li>Medication changes: hold new medications if possible<ul>
<li>Common offenders: NSAIDs, ACE, diuretics, azole
    antifungals</li>
<li>Medication non-compliance: Tacro and cyclosporine
    (rejection)</li>
</ul>
</li>
<li>Tacrolimus (FK) or cyclosporine (CsA) level:
    supra-therapeutic CNI causes arteriolar constriction and
    decreased GFR<ul>
<li>FK levels increase with n/v, diarrhea. FK toxicity also
    causes n/v, diarrhea (chicken vs egg argument)</li>
<li>FK or CsA should be dosed at 6 AM and 6 PM. FK levels
    must be drawn at 5 am (12-hour trough level) to be
    reliable for dosing adjustments</li>
</ul>
</li>
<li>Hypovolemia: fluids</li>
<li>Proteinuria: Transplant patients with 1 g/day proteinuria
    usually get biopsies<ul>
<li>Pts are commonly admitted for proteinuria found during
    chronic monitoring</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Check
    <strong>Cr nadir</strong> post-transplant</li>
<li>Obtain donor characteristics (CMV status, PRA, % HLA antibodies
    present)</li>
<li>Urinalysis
    , Protein/Cr spot ratio</li>
<li>Always
    schedule Tacro and cyclosporine level lab draws</li>
<li>Check
    prev. labs for <strong>donor-specific antibodies</strong> (DSAs)</li>
<li>BK &amp; CMV PCR: consider only if unclear source of AKI and no recent
    titers<ul>
<li>Avoid
    Ig assays, if evaluating for disease PCRs are test of choice</li>
</ul>
</li>
<li>Renal
    transplant U/S
    ($$)
    ? Are you answering a question?<ul>
<li>\&lt; 1 week:
    If acute graft dysfunction, look for thrombosis or urine/ureter
    leak</li>
<li>> 1 week
    :<ul>
<li>Cr does not respond to 48 hours of current management</li>
<li>Lack of clear, reversible causes</li>
<li>Hydronephrosis (can occur after stent removal 4-6 wks after
    transplant or due to perinephric fluid collection)</li>
<li>Arterial stenosis (
    ↑
    velocities in renal artery, tardus parvus waveforms)</li>
<li>Perinephric abscess with recurrent UTI/pyelonephritis</li>
<li>Urinoma (usually first 2-3 weeks), hematoma (after a biopsy)</li>
</ul>
</li>
<li>Unique findings:<ul>
<li>Resistive indices
    : reflect central renal vascular compliance</li>
<li>High indices in transplant patients signify parenchymal
    problem (rejection, infection, ATN)</li>
</ul>
</li>
</ul>
</li>
<li>Still
    Stumped?<ul>
<li>Viral infections: BK, CMV: check PCRs</li>
<li>Adenovirus associated with hemorrhagic cystitis, hepatitis, and
    nephritis in transplant patients. Check PCRs (Nasopharynx,
    blood, GI pathogen panel) positivity may suggest</li>
<li>Post-transplant lymphoproliferative disease (PTLD): lymphoid
    proliferations in transplants due to immunosuppression<ul>
<li>Serious and potentially fatal; Majority occur in the
    presence of EBV</li>
</ul>
</li>
<li>Biopsy: if renal u/s unremarkable likely warrant biopsy to guide
    therapy<ul>
<li>ATN vs rejection vs Adenovirus vs recurrent disease (FSGS,
    lupus, etc.)</li>
</ul>
</li>
</ul>
</li>
<li>Post
    Biopsy Care:
    -<ul>
<li>Watch for bleeding and HTN<ul>
<li>Blood can get into collecting system, then the capsule, and
    into the perinephric space</li>
<li>Page Kidney aka Pressure Tamponade: blood in the capsule
    compresses renal vessels</li>
<li>RAAS surge &rarr; <strong>rapid, severe HTN</strong> (STAT page the renal
    fellow)</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-ua"><h1 id="nephrology-nephrology-ua-ua">UA<a class="headerlink" href="#nephrology-nephrology-ua-ua" title="Permanent link">&para;</a></h1>
<p>Approach to Urinalysis – Laura Binari, Patrick Steadman</p>
<p>Background</p>
<ul>
<li>3
    components
    : Gross Evaluation, Dipstick Analysis, Microscopic Exam</li>
<li>Indications: dysuria, gross hematuria, fever, encephalopathy, AKI,
    volume overload</li>
<li>Technique: collect in clear, dry container; Pts instructed to clean
    external genitalia, provide midstream specimen; If Foley, obtain
    sample from catheter, not the urine bag</li>
<li>Spinning
    Urine<ul>
<li>
<ul>
<li>At VUMC, take sample to lab on 4 <sup>th</sup> floor to
        centrifuge the sample at 1500 rpm for 5 minutes, remove
        supernatant and then resuspend sediment, place drops of
        urine on the slide (there are slides with several discs),
        examine with microscope</li>
<li>At the VA, there is a microscopy room where you can spin
    urine as well- the renal fellow should be happy to help]
    Ideally, the specimen should be a fresh catch (\&lt;2-4 hours
    old); Beware: casts like to migrate to the edges of the
    coverslip!</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Gross Evaluation</p>
<ul>
<li>Turbid: DDx Is infection, precipitated crystals, chyluria</li>
<li>Color: Red Urine (broad DDx, see Hematuria section, includes certain
    meds such as rifampin/phenytoin), White (polyuria, phosphate
    crystals), Green (methylene blue), Pink (uric acid crystals,
    post-propofol infusion), Black (hemoglobinuria/myoglobinuria)</li>
</ul>
<p>Dipstick Analysis</p>
<ul>
<li>Quality of sample: should have zero squamous epithelial cells</li>
<li>Specific gravity
    : normal = 1.010<ul>
<li>
<ul>
<li>Surrogate for urine osmolality &amp; hydration status: can have
        falsely high specific gravity if large particles (contrast,
        glucose) present</li>
<li>Trick: Last 2 digits of S.G. x 30 = Uosm. For example; S.G.
    is 1.013; 13 x 30 = 390 mOsm/L</li>
</ul>
</li>
</ul>
</li>
<li>Urinary pH
    : normal pH is 5.5-6.5<ul>
<li>
<ul>
<li>Alkaline pH: bicarb suppl., vegan diet, urease producing
        organisms (staghorn calculi)</li>
<li>Acidic pH: uric acid stones, appropriate response to
    acidemia</li>
</ul>
</li>
</ul>
</li>
<li>Proteinuria
    : dipstick detects albumin ONLY (not paraproteins)<ul>
<li>
<ul>
<li>Mild albuminuria (30-300 mg/day) not detected by standard
        dipsticks</li>
<li>F/u with spot protein to Cr ratio or 24 hr urine collection
    (nephrotic range &gt;3.5 g/day); consider UPEP/SPEP based on
    clinical presentation.</li>
<li>Transient: due to volume depletion, CHF, fever, postural,
    exercise-induced</li>
<li>Ddx: primary glomerular dx, secondary glomerular dx (DM,
    amyloid, infxn, sickle cell, etc.) vs tubular vs overflow
    (multiple myeloma)</li>
</ul>
</li>
</ul>
</li>
<li>Heme
    (see hematuria section): False(+) if semen, false(-) w/ ascorbic
    acid</li>
<li>WBC
    :<ul>
<li>
<ul>
<li>False(+) 2/2 contamination with squamous cells. If bacteria
        -&gt; consider UTI/pyelo w/hematuria -&gt; inflammation; May have
        sterile pyuria</li>
<li>Ddx includes chlamydia, ureaplasma, TB, malignancy, viral
    infxn, kidney stones, GN, urethritis, steroid,
    cyclophosphamide use</li>
</ul>
</li>
</ul>
</li>
<li>Ketones
    : detects acetic acid (not beta-hydroxybutyrate)<ul>
<li>
<ul>
<li>Never normal in urine; only detects acetic acid</li>
<li>Ddx: DKA, starvation ketoacidosis, pregnancy, keto diet</li>
</ul>
</li>
</ul>
</li>
<li>Glucose
    : max threshold at proximal tubule exceeded (~serum glucose 180
    mg/dL)<ul>
<li>
<ul>
<li>DM, Cushing’s, liver/pancreatic dx, SGLT2i use; or a primary
        defect of proximal reabsorption (w/phosphaturia, uricosuria,
        amino aciduria think Fanconi syndrome)</li>
</ul>
</li>
</ul>
</li>
<li>Leukocyte
    <strong>esterase</strong> : enzyme released by lysed neutrophils, macrophages<ul>
<li>
<ul>
<li>Associated with pyuria and infections; false(-) from
        hematuria or glucosuria</li>
</ul>
</li>
</ul>
</li>
<li>Nitrites
    : reduction of urinary nitrates by nitrate reductase<ul>
<li>
<ul>
<li>Certain bacteria (e.g. Enterobacteriaceae) express, others
        (e.g. Enterococci) do not</li>
<li>Specific but not sensitive for UTI</li>
</ul>
</li>
</ul>
</li>
<li>Bilirubin
    : conjugated = water soluble (passes through glomerulus), unlike
    unconjugated<ul>
<li>
<ul>
<li>Liver dysfunction and biliary obstruction</li>
</ul>
</li>
</ul>
</li>
<li>Urobilinogen
    : end product of conjugated bilirubin, normally ~1.0mg/dL is normal<ul>
<li>
<ul>
<li>Can be elevated due to hepatocellular dx or hemolysis</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Microscopic Examination of the Urine Sediment</p>
<ul>
<li>Purpose
    : confirm/quantify dipstick findings + additional information in
    form of cells, casts, or crystals; Casts are cylindrical structures
    formed in tubule lumen</li>
<li>Cells
    :<ul>
<li>
<ul>
<li>Dysmorphic RBCs (sign of GN), squamous epithelial cells
        (contamination), tubular cells (abnormal, indicates renal
        dx), neutrophils (UTI, AIN, TB, sterile pyuria), eosinophils
        (think AIN, not sensitive thus cannot exclude diagnosis)</li>
</ul>
</li>
</ul>
</li>
<li>Casts
    :<ul>
<li>
<ul>
<li>Hyaline (pyelo; CKD, normal subjects), RBC (GN), WBC (GN,
        pyelo, interstitial dx, inflammation), epithelial - renal
        tubular cells (ATN, interstitial nephritis, nephritic sx,
        heavy metal ingestion), granular or waxy (presence of kidney
        disease, but nonspecific), muddy brown casts (ATN); fatty
        (nephrotic syndrome)</li>
</ul>
</li>
</ul>
</li>
<li>Crystals
    :<ul>
<li>
<ul>
<li>Ca++ oxalate (envelope/dumbbell shape), uric acid
        (rhombic/rosette shaped, classically formed in acidic
        urine), cystine (hexagonal, found in cystinuria), Mg ++
        ammonium phosphate (aka struvite stones, from increased
        ammonia production, in setting of urease producing bacteria
        such as Proteus or Klebsiella UTIs)</li>
<li>Calcium oxalate crystals + AKI, consider ethylene glycol
    intoxication</li>
<li>Uric Acid crystals + AKI, consider tumor lysis syndrome</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-uti-renal-transplant"><h1 id="nephrology-nephrology-uti-renal-transplant-uti-in-renal-transplant">UTI in Renal Transplant<a class="headerlink" href="#nephrology-nephrology-uti-renal-transplant-uti-in-renal-transplant" title="Permanent link">&para;</a></h1>
<p>UTI in Renal Transplant</p>
<p>Background</p>
<ul>
<li>Most
    common post-renal transplant infection</li>
<li>Associated
    with increased risk of rejection, allograft dysfunction and
    morbidity/mortality</li>
<li>Risk
    Factors
    /Unique Considerations for Transplant Patients:<ul>
<li>Vesicoureteral
    reflex is common in transplant patients due to short transplant
    ureter and no valve at vesicoureteral junction</li>
<li>Native
    kidneys/ureteral stumps (particularly if history of PKD), renal
    calculi, urinary tract abnormalities such as vesicoureteral
    reflex</li>
<li>Catheterization or indwelling urinary stents, defunctionalized
    bladder (related to prior oliguria/prolonged dialysis), deceased
    donor transplant, delayed graft function, transplant
    immunosuppression and/or systemic illness on steroids and
    immunosuppression (may mask symptoms of sepsis)</li>
</ul>
</li>
<li>Common
    organisms:<ul>
<li>GNRs: E. Coli most common, Pseudomonas, Enterococcus, Klebsiella</li>
<li>Increasing resistance to ciprofloxacin and Bactrim due to
    frequent use for prophylaxis</li>
</ul>
</li>
<li>Prevention
    :<ul>
<li>Prophylactic antibiotics: Bactrim DS daily, often used 6
    months-1year after transplant<ul>
<li>
<ul>
<li>If unable to tolerate Bactrim, consider cephalosporins
        or nitrofurantoin (if GFR&gt;60 and typically for 1 month
        only) in effort to prevent fluoroquinolone resistance</li>
</ul>
</li>
</ul>
</li>
<li>Basic infection prevention measures: hydration, frequent
    voiding, wiping front to back, voiding after sexual intercourse</li>
<li>Removal of indwelling devices/catheters as able</li>
<li>Consider post-coital antibiotics for women with recurrent UTI
    after sexual intercourse</li>
<li>Estrogen cream for peri/postmenopausal women (restores
    epithelial barrier)</li>
<li>Inconclusive data on cranberry juice</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Simple cystitis:
    dysuria, frequency/urgency, hematuria, suprapubic tenderness. No
    systemic symptoms and no indwelling catheters/stents/tubes.</li>
<li>Acute pyelonephritis/complicated UTI:
    above symptoms + fever/chills, malaise, nausea or allograft pain,
    leukocytosis<ul>
<li>Also includes urinary tract anomalies and/or indwelling
    catheters/stents/tubes</li>
</ul>
</li>
<li>The transplanted kidney is denervated, and pts may be not have upper
    urinary symptoms</li>
</ul>
<p>Evaluation</p>
<ul>
<li>UA
    with culture (midstream collection or “clean catch”)</li>
<li>Examine
    the native kidneys (CVA tenderness) AND the allograft (RLQ or LLQ)</li>
<li>Renal
    U/S (of both allograft and native kidneys) if: early post-op (1
    month), recurrent (2+ episodes in year), history of nephrolithiasis
    or if sepsis/bacteremia</li>
<li>Blood cultures if signs/symptoms of complicated UTI (systemic
    symptoms) OR if urine culture are consistent w/ hematogenous spread
    to the bladder (such as Staph aureus)</li>
<li>Consider
    testing for C. urealyticum if UA positive but culture negative</li>
</ul>
<p>Management</p>
<ul>
<li>Always
    get UA with culture (midstream collection)</li>
<li>Remove
    or replace indwelling catheters</li>
<li>Review
    prior culture susceptibilities (if available)</li>
<li>Empiric
    antibiotic regimens:<ul>
<li>
<ul>
<li>Simple cystitis
        : Fluoroquinolones (ciprofloxacin 250 BID or Levaquin 500 mg
        daily), Augmentin (500 mg BID), 3 <sup>rd</sup> gen
        cephalosporin (cefpodoxime 100 mg BID or cefixime 400 mg
        daily) or nitrofurantoin 100 mg BID (if GFR&gt;30)</li>
<li>Complicated UTI/Pyelonephritis
    (cover <em>Pseudomonas,</em> gram negatives and <em>Enterococcus</em> ):
    Rocephin 2g daily (preferred), Cefepime 2g q8hrs or Zosyn
    3.75g q6hrs, can also use meropenem 1g q8h (need ID
    approval)<ul>
<li>Note, Dr. Langone does not like Rocephin, but prefers:
    Cefepime if LE+, nitrite +, Zosyn if LE+ and nitrite –
    (covers enterococcus), or LVQ</li>
</ul>
</li>
<li>For stable pts with mild complicated UTI, can consider
    giving more narrow empiric antibiotics: Augmentin 875 mg BID
    or ciprofloxacin 500 mg q12h</li>
<li>MDR UTI: Consult transplant ID<ul>
<li>Options: meropenem-vaborbactam, ceftolozone-tazobactam,
    ceftazidime-avibactam</li>
</ul>
</li>
<li>If pts w/PCKD, include lipophilic antibiotic (such as
    ciprofloxacin) to penetrate cysts</li>
</ul>
</li>
</ul>
</li>
<li>Duration
    :<ul>
<li>
<ul>
<li>Simple cystitis: \&lt;6 months post-transplant: 10-14 d; &gt;6
        months post-transplant: 5-7 d</li>
<li>Complicated UTI: 14-21 d</li>
<li>Transition to oral if susceptible to Levaquin or Cipro
    (bioavailable in urinary tract)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Asymptomatic
    bacteriuria: no consensus; recommend getting 2 <sup>nd</sup> culture
    to confirm prior to treating<ul>
<li>
<ul>
<li>Often treated if \&lt;1-3 months since transplant. &gt; 3 months
        post-transplant likely do not require UA screenings and/or
        treatment for asymptomatic bacteriuria</li>
</ul>
</li>
</ul>
</li>
<li>Positive
    Blood Cultures Related to UTI<ul>
<li>
<ul>
<li>Repeat blood cultures are NOT typically indicated for
        uncomplicated gram negative bacteremia or for bacteremia
        from a localized source (such as pyelonephritis)</li>
<li>Consider repeating cultures when: concern for endovascular
    involvement, MDR gram negative bacilli, persistence of
    fever/leukocytosis &gt;72 hours after initiation of appropriate
    antibiotic
    regimen, new sepsis, concern for abscess or no source
    control</li>
</ul>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Nephrology</h1>
                        <h1 class='nav-section-title' id='section-neurology'>
                            Neurology <a class='headerlink' href='#section-neurology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="neurology-neurology-aidp"><h1 id="neurology-neurology-aidp-aidp">AIDP<a class="headerlink" href="#neurology-neurology-aidp-aidp" title="Permanent link">&para;</a></h1>
<p>Acute Inflammatory Demyelinating Polyneuropathy (AIDP)</p>
<p>Background</p>
<ul>
<li>Rapid onset polyneuropathy that manifests most often with ascending
    weakness and numbness that can involve the respiratory and facial
    musculature also</li>
<li>Usually
    preceded by infectious illness a few weeks prior, some flu
    vaccination associations</li>
</ul>
<p>Presentation</p>
<ul>
<li>Acute
    , progressive extremity weakness, weak or absent reflexes, and
    potentially subjective sensatory changes</li>
<li>Often, infectious symptoms precede AIDP symptoms by a few weeks<ul>
<li>There are a TON of variants of AIDP, with some having cranial
    nerve weakness early, proximal weakness, sensory ataxia,
    primarily sensory loss, or rapid muscle weakness; <strong>do not use</strong>
    lack of classic ascending weakness to dismiss the idea of AIDP</li>
<li>Sensory loss is common in an ascending pattern too</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LP
    – albuminocytologic dissociation = high protein &amp; normal cell count<ul>
<li>One exception is HIV, which can cause AIDP but also have a high
    cell count and high protein count</li>
</ul>
</li>
<li>EMG/NCS
    – shows a demyelinating pattern (temporal dispersion and decreased
    conduction velocities). This can be normal in the first few days and
    may need to be repeated 2 weeks after if the diagnosis is not clear</li>
<li>Differential diagnosis <strong>:</strong> spinal cord lesions can mimic GBS
    including with areflexia, LEMS, sometimes MG, acute HIV or HCV,
    viral myelitis (entero/West Nile)</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs! NIF at baseline then Q4-6 hours<ul>
<li>NIF \&lt; -30 with good effort generally warrants ICU monitoring</li>
</ul>
</li>
<li>IVIG
    or PLEX (PLEX requires central line)</li>
<li>Can get worse if you give them steroids</li>
</ul></section><section class="print-page" id="neurology-neurology-als"><h1 id="neurology-neurology-als-als">ALS<a class="headerlink" href="#neurology-neurology-als-als" title="Permanent link">&para;</a></h1>
<p>Amyotrophic Lateral Sclerosis (ALS)</p>
<p>Background</p>
<ul>
<li>Progressive weakness, often asymmetric and profound with no sensory
    loss</li>
<li>Combination of LMN and UMN findings<ul>
<li>LMN findings: weakness, flaccidity, absent/decreased reflexes,
    fasciculations</li>
<li>UMN findings: weakness, spasticity, hyperreflexia, pathologic
    reflexes (e.g. extensor plantar response), slow movements</li>
</ul>
</li>
<li>Pts with bulbar symptoms may complain of difficulty swallowing,
    changes in their voice, or increased saliva production (they just
    aren’t swallowing it)</li>
<li>Tongue fasciculations are fairly uncommon in other disorders and is
    a good clue for ALS if present (these can be hard to be certain of –
    tongue movements that are symmetric are typically not
    fasciculations)</li>
<li>Pseudobulbar affect – inappropriate laughing or crying; relatively
    common in ALS</li>
<li>FVC is an important marker for function</li>
</ul>
<p>Evaluation</p>
<ul>
<li>EMG/NCS is gold standard; El Escorial Criteria looks for evidence of
    UMN and LMN findings at cranial, cervical, thoracic and lumbosacral
    levels to determine if ALS or not</li>
<li>Exclude mimicking lesions, which may be treatable (see below)</li>
</ul>
<p>Management</p>
<ul>
<li>Patients with ALS are ideally treated with a multidisciplinary team
    of Neurologists, Pulmonologists, Speech therapists, PT, OT and
    mobility</li>
<li>Two medications have been shown to add a few months to survival:<ul>
<li>Riluzole - PO med; have to track CBC/LFTs. Side effects: GI and
    general weakness</li>
<li>Edaravone (Radicava) – IV, given daily for 2 weeks every month.
    SE = HA, bruising</li>
</ul>
</li>
</ul>
<p>Mimics of ALS</p>
<ul>
<li>High cervical spine lesions –UMN changes in upper extremity with LMN
    pattern in LE</li>
<li>Primary Lateral Sclerosis – UMN-only disease, much less common with
    much slower progression. Many transition to ALS in the first 1-2
    years, which then is likely a spectrum of the same disease</li>
<li>Multifocal Motor Neuropathy – rare autoimmune disorder that looks
    like ALS with LMN signs only, responds to IVIG. Can have anti-GM1 Ab
    in blood. EMG/NCS pattern is different with conduction block</li>
<li>Kennedy Disease – X-linked genetic disorder with progressive LMN
    pattern of weakness and endocrine disorders w/androgen resistance
    profile (gynecomastia, defective spermatogenesis)</li>
<li>Inclusion Body Myositis – can be asymmetric with grip weakness and
    quadriceps weakness. Biopsy and atrophy pattern usually
    distinguishes it. CPK 500-800.</li>
<li>Polymyositis/dermatomyositis – proximal weakness in arms/legs, CPK &gt;
    1000, usually younger onset (30-40s), no UMN signs</li>
</ul></section><section class="print-page" id="neurology-neurology-ams"><h1 id="neurology-neurology-ams-ams">AMS<a class="headerlink" href="#neurology-neurology-ams-ams" title="Permanent link">&para;</a></h1>
<p>Delirium &amp; Altered Mental Status (AMS)</p>
<p>Background</p>
<ul>
<li>Why delirium matters:<ul>
<li>Increased morbidity</li>
<li>Hospital complications, falls, infection, prolonged mechanical
    ventilation</li>
<li>ADL dependence and long-term functional impairment</li>
<li>Long-term cognitive impairment</li>
<li>Psychiatric (depression 4x more common than PTSD) and impaired
    Quality of Life</li>
</ul>
</li>
<li>Departure
    from pt’s baseline cognition: hypoactive (lethargic) or hyperactive
    (agitated)</li>
<li>Risk factors:<ul>
<li>Functional impairment</li>
<li>Age &gt; 75</li>
<li>Dementia</li>
<li>Depression</li>
<li>ETOH use disorder</li>
<li>Sensory impairment</li>
<li>Surgery (repair of aortic aneurysm, trauma, NSGY, thoracic
    surgery)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Consider MOVE STUPID mnemonic:<ul>
<li>Metabolic
    (Hypo/hypernatremia, Hypercalcemia)</li>
<li>Oxygen
    (Hypoxia)</li>
<li>Vascular
    (CVA, Bleed, MI, CHF)</li>
<li>Endocrine
    (Hypoglycemia, Thyroid)</li>
<li>Seizure
    (postictal state)</li>
<li>Trauma (concussion)</li>
<li>Uremia</li>
<li>Psychogenic</li>
<li>Infection</li>
<li>Drugs
    - intoxication or withdrawal</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Screening
    Tools:<ul>
<li>Wards
    : bCAM: Brief-Confusion Assessment Method</li>
<li>ICU: CAM-ICU: Confusion Assessment Method for ICU</li>
</ul>
</li>
<li>Broad toxic/metabolic/infectious workup<ul>
<li>TSH, Vitamin B12, CMP, UA, chest X-ray, seasonal infection
    testing</li>
</ul>
</li>
<li>Review
    of medications-&gt; sedatives, anticholinergics, central alpha
    agonists/antagonists, benzos/EtOH toxicity or withdrawal (check home
    med list to ensure something like chronic benzos weren’t held on
    admission)</li>
<li>Head imaging in the setting of focal neurologic findings<ul>
<li>CT helps to identify hemorrhage and large structural lesions;
    strokes take up to 24 hours to show up on CT<ul>
<li>Some strokes can cause AMS without other obvious focal signs</li>
</ul>
</li>
<li>MRI: stroke, inflammatory changes or infectious changes more
    clearly w/ contrast</li>
</ul>
</li>
<li>LP should be performed if there is any concern for meningitis<ul>
<li>For meningitis, empirically treat with acyclovir/vanc/CTX at
    minimum, + ampicillin if old or young for Listeria coverage</li>
</ul>
</li>
<li>EEG is reasonable with fluctuating mental status or seizure-like
    activity</li>
<li>Catatonia (Bush-Francis scale is a 24-point scale that covers
    features of catatonia)</li>
</ul>
<p>Management</p>
<ul>
<li>First line, Nonpharmacologic interventions: <strong>HOMMEEESS</strong><ul>
<li>H
    ydration/nutrition:<ul>
<li>Ensure patient fed, hold diuretics if poor PO intake, rule
    out constipation and urinary retention</li>
</ul>
</li>
<li>O
    rientation</li>
<li>M
    obilize out of bed 3x/daily as able, PT/OT</li>
<li>M
    anage pain</li>
<li>E
    liminate unnecessary devices (restraints, catheters, tele,
    lines) and meds</li>
<li>E
    nvironmental modification<ul>
<li>Minimize devices, lights on/windows open during day</li>
</ul>
</li>
<li>E
    ngage family</li>
<li>S
    ensory restoration: use eyeglasses and hearing aids and reorient</li>
<li>S
    leep protocol<ul>
<li>Minimize nighttime vitals, earplugs, sleep mask and no TV at
    nigh</li>
</ul>
</li>
</ul>
</li>
<li>​​​​​​​​​​​​​​
    Second line, Pharmacologic approaches, see "Management of Agitation"</li>
</ul></section><section class="print-page" id="neurology-neurology-basic-seizures"><h1 id="neurology-neurology-basic-seizures-seizures">Seizures<a class="headerlink" href="#neurology-neurology-basic-seizures-seizures" title="Permanent link">&para;</a></h1>
<p>Seizure without Status Epilepticus</p>
<p>Background</p>
<ul>
<li>Risk factors: birth trauma, prematurity, TBI with loss of
    awareness &gt; 1 hour, strokes/tumors/abscesses, history of
    meningitis/encephalitis</li>
<li>Key for seizures: stereotyped event with sudden onset/offset<ul>
<li>Generally, if full body systems are involved (e.g., jerking or
    tonic activity, then there will also be loss of awareness)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>A clear description or recording of seizure semiology is helpful</li>
<li>Provoked seizures can develop with medications, hypo/hyperglycemia,
    significant electrolyte abnormalities (e.g. hyponatremia), and CNS
    infections</li>
<li>EEG is necessary for spell capture</li>
<li>MRI brain with and without contrast</li>
</ul>
<p>Management</p>
<ul>
<li>Common AEDs with indications and typical side effects (SE):<ul>
<li>Levetiracetam/Keppra (PO/IV): general or focal sz. SE: sedation
    and agitation, can worsen underlying mood disorders</li>
<li>Valproic acid/Depakote (PO/IV): general or focal sz. SE:
    sedation, hirsutism, PCOS like symptoms, P450 inhibitor, nausea,
    liver injury, hyperammonemia</li>
<li>Phenytoin/Dilantin (PO/fosphenytoin is IV): focal or general sz.
    SE: sedation, unsteadiness, gingival hyperplasia</li>
<li>Lacosamide/Vimpat (PO/IV): focal or general. SE: heart block
    (don’t use if pt has pre-existing blocks), dizziness, ataxia</li>
<li>Topiramate/Topamax (PO) –general or focal sz. SE: kidney stones,
    metabolic acidosis, paresthesia’s, weight loss, cognitive
    slowing</li>
<li>Carbamazepine/Tegretol (PO) –focal and general sz. SE: hypoNa,
    in Han Chinese HLA testing is recommended due to risk of SJS,
    rare reports of bone marrow suppression</li>
<li>Oxcarbazepine/Trileptal (PO) –focal and general sz. SE similar
    to carbamazepine, hypoNa</li>
<li>Lamotrigine/Lamictal (PO) –general or focal sz. Benefit of mood
    stabilization. SE: SJS/TEN, nausea. One of the least sedating
    AEDs</li>
<li>Zonisamide/Zonegran (PO) –general and focal. SE: somnolence,
    ataxia, nausea, confusion</li>
</ul>
</li>
</ul>
<p>Non-Epileptic Spells (aka PNES, psychogenic non-epileptic spells)</p>
<ul>
<li>Can be very difficult to distinguish from epileptic seizures</li>
<li>Retained awareness with bilateral extremities “seizing” is very
    unusual for epileptic sz’s</li>
<li>Other red flags: opisthotonus (arching the back), talking during a
    spell, excessively long spells (if historically patient has
    “seizures lasting for hours or days” at home), forced eye closure,
    coachability during a spell or reacting to external stimuli, very
    heavy breathing during a spell with lots of rigorous movement,
    immediately returning to normal after a spell</li>
<li>Things that are hard to be non-epileptic: seizures arising out of
    sleep, highly stereotyped, incontinence, severe injuries (e.g.
    burns)</li>
<li>If high concern for PNES, try to avoid excessive BZD use. This
    requires good clinical judgement as you wouldn't want to withhold
    Ativan and discover that the pt was having true atypical seizures.
    The compromise would be: do not repeatedly administer BZDs when
    there is suspicion for PNES as well as no evidence of response to
    prior BZD administration.</li>
<li>Notably, <strong>syncopal convulsions</strong> are very common, with posturing
    and tonic-clonic movements happening for a few moments after syncope<ul>
<li>Should not last for more than 10-15 seconds</li>
<li>These are just related to syncope and do not typically require
    seizure medications</li>
<li>Workup:<ul>
<li>
<ul>
<li>Two-hour EEG and MRI (with and without contrast)</li>
<li>Infectious workup, BMP, CBC, blood glucose,
    toxicology/drug screen</li>
<li>If there is concern for convulsive syncope, (carefully)
    check orthostatic vitals</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-brain-masses"><h1 id="neurology-neurology-brain-masses-brain-masses">Brain Masses<a class="headerlink" href="#neurology-neurology-brain-masses-brain-masses" title="Permanent link">&para;</a></h1>
<p>Brain Masses</p>
<p>Background</p>
<ul>
<li>Neoplasm is the biggest concern: ~ 90% of malignant brain masses
    are metastatic</li>
<li>Other etiologies: abscess, tumefactive demyelinating lesions,
    vascular malformations, sometimes other causes of edema (e.g.
    paraneoplastic)</li>
<li>Most common metastatic brain tumors: lung, RCC, breast, and melanoma</li>
<li>Tumors with high bleeding risk: melanoma, thyroid, choriocarcinoma,
    and RCC</li>
<li>Gliomas: WHO Grade I-IV, with IV being glioblastoma multiforme (GBM)<ul>
<li>GBM appears as large heterogeneous masses with edema;
    heterogenous contrast enhancement; can cross the corpus callosum</li>
<li>Lower grade gliomas, which includes oligodendrogliomas and
    astroytomas</li>
</ul>
</li>
<li>Meningioma – usually low grade and either left alone and monitored,
    but can be symptomatic in which they are resected/radiated</li>
<li>Ependymoma – uncommon, usually lower grade can cause CSF outflow
    obstruction</li>
<li>CNS lymphoma – diffuse WM involvement, with mass effect, restricts
    diffusion on MRI with prominent contrast enhancement. Can also cross
    the corpus callosum<ul>
<li>Usually B-cell, initially responds significantly to steroids</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>A significant number of brain lesions are detected incidentally</li>
<li>If a pt has a first-time seizure, brain mass needs to be ruled out</li>
<li>HA (usually constant, severe), seizure and focal neurologic deficits</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Imaging: MRI w/ and w/o contrast provides the most information<ul>
<li>Findings suggesting malignant lesions: marked edema, multifocal
    lesions, or presence at gray-white junctions</li>
</ul>
</li>
<li>LP may be indicated if herniation risk is low, particularly if
    concerned for infection</li>
<li>Biopsy will ultimately be needed in most cases, which is done
    through NSGY</li>
</ul>
<p>Management</p>
<ul>
<li>Work up for primary malignancy, CT C/A/P <u><sub>+</sub></u> PET</li>
<li>Steroids are generally indicated for treatment of edema<ul>
<li>Decadron 10 mg IV to start; then transition to 4mg IV q6h with
    SSI</li>
</ul>
</li>
<li>If seizure develops would treat as outlined in seizure section</li>
<li>Symptomatic tumors need eval by NSGY for resection consideration</li>
<li>Other options include radiation, which does happen as inpatient but
    it is rare</li>
</ul></section><section class="print-page" id="neurology-neurology-elevated-icp-and-hydrocephalus"><h1 id="neurology-neurology-elevated-icp-and-hydrocephalus-elevated-icp-and-hydrocephalus">Elevated ICP and Hydrocephalus<a class="headerlink" href="#neurology-neurology-elevated-icp-and-hydrocephalus-elevated-icp-and-hydrocephalus" title="Permanent link">&para;</a></h1>
<p>Elevated Intracranial Pressure and Hydrocephalus</p>
<p>Background</p>
<ul>
<li>Communicating hydrocephalus: can be 2/2 subarachnoid granule
    scarring after subarachnoid hemorrhage or meningitis, ependymoma
    producing excess CSF, venous sinus thrombosis</li>
<li>Non
    -communicating hydrocephalus (i.e. obstructive) - usually due to a
    mass lesion such as a tumor, abscess, or hematoma in the midline
    ventricular structures</li>
<li>Eventually, elevated intracranial pressures will cause herniation of
    brain</li>
</ul>
<p>Presentation</p>
<ul>
<li>Headache
    , blurred vision, visual field reduction, enlarged blind spot, may
    pass out, develop nausea or vomiting followed by coma</li>
<li>Sixth nerve palsies are common with elevated ICP</li>
<li>Compressive 3 <sup>rd</sup> nerve palsies are classically associated
    with uncal herniation</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Need a good visual exam: look for restricted visual fields, enlarged
    blind spot, papilledema (may not be present if very rapid ICP
    increase, even with vision loss), and 6 <sup>th</sup> nerve palsies</li>
<li>Stat head CT to look for obstructions, mass lesions</li>
<li>Venous imaging is also usually necessary: CTV or MRV to look for
    venous sinus thrombosis<ul>
<li>Venous sinus thrombosis needs AC, even if there is some degree
    of hemorrhagic infarction</li>
</ul>
</li>
<li>Obstructive lesions require NSGY eval for either removal of the
    lesion or a ventricular drain</li>
<li>If
    no
    obstructive lesion, then LP will be needed for opening pressure</li>
<li>If workup is normal, except for elevated opening pressure, it is IIH</li>
</ul>
<p>Management</p>
<ul>
<li>Idiopathic intracranial hypertension (IIH) is treated with diamox
    and/or topiramate<ul>
<li>Patients with IIH will need ophthalmology evaluation emergently,
    if there is severe disc edema then nerve sheath fenestrations or
    urgent VPS placement may be needed.</li>
<li>If there is clinical concern for herniation:<ul>
<li>Mannitol – 50 grams IV, can be given peripherally. Has risks
    of renal injury</li>
<li>Hypertonic saline – 3%, 7% or 23% saline can be given, needs
    central access</li>
<li>Maintain
    head of bed at least 30° and loosen neck obstructions
    (c-collars) as able</li>
<li>NSGY consult for shunt consideration</li>
</ul>
</li>
<li>Hyperventilation is controversial but can be done with goal
    PaCO2 30-34 mm Hg or ETCO2 20-30 mmHg<ul>
<li>If lower, there is concern for cerebral ischemia</li>
<li>After 4-6 hrs, compensatory pH changes in the blood prevent
    vasoconstrictive affects</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-inpatient-headache"><h1 id="neurology-neurology-inpatient-headache-inpatient-headache">Inpatient Headache<a class="headerlink" href="#neurology-neurology-inpatient-headache-inpatient-headache" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient Headache (HA)</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Important to distinguish 1º° and 2º° headache</li>
<li>Red flags for
    2º° <strong>headaches (SNOOP):</strong> <strong>S</strong> ystemic symptoms, <strong>N</strong> eurologic
    symptoms, <strong>O</strong> nset that is sudden (thunderclap), <strong>O</strong> lder age
    (new headache &gt;40), <strong>P</strong> rogression or evolution in previous
    headaches [the ‘P’ is also used for <strong>P</strong> ositional component]<ul>
<li>Other red flags: preceding trauma, HA awakening pt from sleep,
    no HA-free intervals</li>
<li>Thunderclap suggests that maximal HA intensity develops within
    10 seconds</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Get a good description of where the pain is, when, associated
    symptoms, and assess for “red flag” features listed above</li>
<li>If there are any red flag features imaging and workup are necessary</li>
<li>Imaging depends on highest suspicions, but CTA head/neck is
    appropriate to evaluate for aneurysm (including neck to consider
    dissection). If any focal signs, MRI is generally preferred; venous
    imaging can be beneficial in headaches with features of elevated ICP</li>
<li>If no red flag features, then workup is not necessary, and focus is
    on treatment</li>
</ul>
<p>Management</p>
<ul>
<li>NSAIDs and Tylenol for infrequent headaches, but consistent use
    (&gt;2-3 a week) runs the risk of rebound headaches</li>
<li>Triptans for migraine, but contraindicated in patients with CAD,
    uncontrolled HTN, previous stroke<ul>
<li>There are theoretical concerns of serotonin syndrome when used
    with SSRI/SNRIs</li>
</ul>
</li>
<li>Acute migraine in hospital: “migraine cocktail” -&gt; 1 L fluid bolus,
    2-4 grams of magnesium sulfate, IV Compazine
    (10mg)/Phenergan(20mg)/Reglan (20mg) with Benadryl (25mg)<ul>
<li>If that does not work: Depakote 1000 mg IV, decadron 10mg IV ,
    &plusmn; toradol 30mg IV, flexeril 10mg PO</li>
</ul>
</li>
<li>Cluster headache – also responds to triptans, high flow O2 (&gt;10 L),
    sometimes intranasal lidocaine if no arrhythmia history</li>
</ul></section><section class="print-page" id="neurology-neurology-ms"><h1 id="neurology-neurology-ms-ms">MS<a class="headerlink" href="#neurology-neurology-ms-ms" title="Permanent link">&para;</a></h1>
<p>Multiple Sclerosis</p>
<p>Background</p>
<ul>
<li>Progressive inflammatory disorder primarily manifesting with
    demyelination of the central white matter</li>
<li>Optic neuritis and transverse myelitis (spinal cord lesion) are
    common presentations</li>
<li>Generally develop over a few days; very uncommon to happen suddenly
    ( e.g., patients will complain about a dark spot appearing in their
    vision that expands over several days)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>MRI w/ and w/o contrast can identify plaques and determine if they
    are more acute<ul>
<li>“Active” MS plaque will enhance, and continues to for weeks
    (even after treatment)</li>
</ul>
</li>
<li>Modified MacDonald Criteria:
    ≥
    3 characteristic demyelinating lesions (&gt;1 cm, periventricular,
    infratentorial (brainstem/cerebellum/cord) or juxtacortical in
    location) with evidence of separation in time (active and chronic)</li>
<li>LP can be done to look for oligoclonal bands, IgG index, cell count
    and protein</li>
</ul>
<p>Management</p>
<ul>
<li>Treat flares with steroids: speeds up recovery but does not improve
    the degree of recovery<ul>
<li>Would confirm with Neurology (as primary or consulting team)
    preferred dose, which is often methylpred 1g to start</li>
<li>Current guidelines are for optic neuritis to be treated with IV
    steroids, but recent data challenges this</li>
</ul>
</li>
<li>If a patient with known MS has worsening symptoms that are not new,
    then recrudescence is the likely cause -&gt; infectious/toxic/metabolic
    workup and imaging is needed</li>
<li>Several long-term medications, with common side effects listed
    below:<ul>
<li>Interferon (SQ injections) – flu-like symptoms, injection site
    reactions</li>
<li>Glatiramer acetate (SQ) – injection site reactions</li>
<li>Fingolimod (PO) – macular edema, liver injury, increased risk of
    skin cancer</li>
<li>Teriflunomide (PO) – liver injury, hair loss, immunosuppression,
    teratogenic</li>
<li>Dimethyl fumarate (PO) – GI side effects, lymphocytopenia, liver
    injury</li>
<li>Natalizumab (IV) – PML concern, immunosuppression</li>
<li>Ocrelizumab (IV) – contraindicated in active HBV infection,
    cannot give live vaccines</li>
<li>Alemtuzumab (IV) – autoimmune disease, rash, headache</li>
</ul>
</li>
</ul>
<p>Neuromyelitis Optica and Spectrum Disorder:</p>
<ul>
<li>Demyelinating disease due to Ab against aquaporin-4 (on
    oligodendrocytes)</li>
<li>Classically causes optic neuritis and longitudinally extensive
    transverse myelitis</li>
<li>Can be more aggressive than MS and needs steroids but in severe or
    refractory cases PLEX</li>
<li>NMO antibodies and MS workup as above is done</li>
</ul></section><section class="print-page" id="neurology-neurology-myasthenia-etc"><h1 id="neurology-neurology-myasthenia-etc-myasthenia-etc">Myasthenia etc<a class="headerlink" href="#neurology-neurology-myasthenia-etc-myasthenia-etc" title="Permanent link">&para;</a></h1>
<p>Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>Both are disorders at the neuromuscular junction</li>
<li>MG
    affects
    the post-synaptic cleft at the acetylcholine receptor</li>
<li>LEMS
    affects
    the pre-synaptic cleft at the calcium channels</li>
</ul>
<p>Presentation</p>
<ul>
<li>Double
    vision, ptosis, dysarthria, dysphagia</li>
<li>Dyspnea looks different than in other conditions: air hunger,
    usually also with dysphagia</li>
<li>Initially
    , the patient may not look sick or distressed, but may have a short
    inspiratory time or difficulty speaking in complete sentences due to
    shallow breathing</li>
<li>Most pts have a known history of myasthenia, but up to 20% present
    initially with crisis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exam: Look closely for ptosis, nasal speech, weak neck
    flexion/extension (same nerve roots as diaphragm), interrupted
    speech to take extra breaths</li>
<li>These patients do not exhibit “huffing and puffing” work of
    breathing in the way that pts with COPD/asthma exacerbations or post
    exercise may look<ul>
<li>Patients with NMJ disease can go from talking to intubated
    within several hours!</li>
<li>LEMS: less ocular weakness, but do have extremity weakness and
    absent reflexes. Many cases are paraneoplastic (classically
    small cell carcinoma of the lung)</li>
<li>Pulmonary compromise is very rare in LEMS</li>
</ul>
</li>
<li>EMG
    /NCS - MG will show decremental response to rapid stim, and single
    fiber EMG (gold standard) can be done. SFEMG cannot be done in ICU
    settings due to electrical artifact</li>
<li>Myasthenia
    antibody panels can be ordered (send prior to IVIG/PLEX being given)</li>
<li>Chest CT -&gt; looking for thymic hyperplasia</li>
</ul>
<p>Management</p>
<ul>
<li>NIF (negative inspiratory force, a measurement of diaphragmatic
    strength; normal is \&lt; -60) at baseline on arrival and then Q4-6H<ul>
<li>If getting below -30 consider elective intubation, certainly ICU</li>
<li>Can see NIF under flowsheets on Epic</li>
<li>Some pts’ effort can be impaired resulting in poor NIF values</li>
</ul>
</li>
<li>IVIG or PLEX -&gt; both have similar supportive evidence; IVIG is
    usually easier to do<ul>
<li>PLEX
    has the risks you would expect with dialysis (e.g. fluid shifts)
    and coagulopathy</li>
<li>IVIG
    -&gt; have to check IgA levels (deficiency is a rare cause of
    anaphylaxis) and can increase risk of DVT, has risk of aseptic
    meningitis and provides and significant fluid load so not ideal
    for pts with CHF</li>
</ul>
</li>
<li>Steroids are also usually up-titrated SLOWLY (by 10-20 mg prednisone
    daily, not much more of an increase) and pyridostigmine is continued</li>
<li>Rapid increases in steroids can worsen patients with MG</li>
<li>Too much pyridostigmine can make patients worse, so for those doing
    poorly on &gt;90 mg per dose, consider lowering the dose</li>
<li>Treat underlying causes of exacerbations: usually infections or
    other toxic/metabolic insults</li>
<li>Remove/avoid exacerbating medications: fluoroquinolones,
    aminoglycosides, beta blockers, and magnesium</li>
<li>LEMS
    : 3,4-diaminopyridine and can respond to IVIG or pyridostigmine</li>
</ul></section><section class="print-page" id="neurology-neurology-outpatient-headache"><h1 id="neurology-neurology-outpatient-headache-outpatient-headache">Outpatient Headache<a class="headerlink" href="#neurology-neurology-outpatient-headache-outpatient-headache" title="Permanent link">&para;</a></h1>
<p>Outpatient Headache</p>
<p>Background</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Presentation</td>
<td>First line meds</td>
</tr>
<tr>
<td>Tension type (most common)</td>
<td>Generally bilateral, pressure/tightness, mild/moderate pain, no significant photophobia/phonophobia, nausea</td>
<td>Acetaminophen, TCA’s, SNRI’s, anticonvulsants</td>
</tr>
<tr>
<td>Migraine</td>
<td>Unilateral/pulsating, moderate/severe pain, lasting 4-72hr, associated nausea, photophobia or phonophobia; ± aura, worse with physical activity, often improves with sleep</td>
<td>Acute: triptans Preventive: TCAs, propranolol, topiramate, VPA</td>
</tr>
<tr>
<td>Cluster</td>
<td>Severe, often extreme unilateral orbital/supra-orbital/temporal pain, often with lacrimation, rhinorrhea, sweating/swelling of face, visual change</td>
<td>Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans Preventive: verapamil; some data for nightly melatonin to regulate circadian rhythms</td>
</tr>
<tr>
<td>Medication Overuse</td>
<td>HA at least ½ the days of the month, w/medication intake at least ½ the days of the month; often presents as worsening HA despite increased intake of medication. Often seen with meds that include caffeine (excedrine, fioricet)</td>
<td>Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans Preventive: Verapamil *STOP offending medication, typically via taper. HA will worsen before it gets better (can be alleviated with naproxen taper and/or steroid dose pack)</td>
</tr>
</tbody>
</table>
<p>Medication Overview:</p>
<ul>
<li>Abortive<ul>
<li>Sumatriptan or rizatriptan are generally first choices. Cannot
    be used more than 10 days/month. Avoid in pts with
    hypertension/CAD</li>
</ul>
</li>
<li>Preventative – generally start low and increase dose every few weeks<ul>
<li>Amitriptyline: indicated for both migraine and tension-type.
    Helps with sleep and comorbid depression. Most common side
    effects (SE) = dry mouth, sedation</li>
<li>Topiramate: has the best evidence among migraine meds. Can
    theoretically help with weight loss. Most common SE = sodas
    taste bad, sedation</li>
<li>Propranolol: useful for relative lack of interactions. Mild
    cardiac/blood pressure effects compared to other beta-blockers.
    Most common SE = drowsiness</li>
<li>Magnesium oxide: reduces headache frequency with almost no SE.
    Start 400mg daily, can go up to 800mg BID. Patients can increase
    dose until they get diarrhea.</li>
<li>Riboflavin (vitamin B2): mild effect but effectively has no side
    effects. 400mg daily.</li>
<li>Gabapentin: can be useful if HAs have stabbing/electric quality.
    Main SE = sedation</li>
<li>Venlafaxine: useful for migraines with significant vestibular
    symptoms (dizziness)
    -<ul>
<li>Major
    SE = insomnia, hypertension/tachycardia</li>
</ul>
</li>
<li>Verapamil: can be used for migraine and cluster headaches. Can
    use ER formulation</li>
<li>Botox: can be administered every 3 months. Can be very
    effective, but pts generally will have had to fail multiple
    medications for insurance to approve</li>
<li>CGRP receptor modulators (mostly injections) such as Rimegepant
    are newer options</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-parkinson"><h1 id="neurology-neurology-parkinson-parkinson">Parkinson<a class="headerlink" href="#neurology-neurology-parkinson-parkinson" title="Permanent link">&para;</a></h1>
<p>Parkinson’s Disease</p>
<p>Background</p>
<ul>
<li>Tremor is typically a very early symptom, and worse on one side</li>
<li>Cogwheel rigidity can be confused for paratonia, which is seen in
    demented or encephalopathic patients who have involuntary variable
    resistance movements during passive ROM assessment</li>
<li>Gait, speech changes (low volume), hand-writing changes of slow
    small movements</li>
<li>Festination – slow start with movements that gradually build up
    speed</li>
<li>En bloc turning – taking multiple steps to turn around</li>
<li>Anosmia and REM behavior sleep disorders are very common</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical diagnosis; there are some supportive imaging studies like
    DaTscan that looks for activity of substantia nigra (usually not
    necessary)</li>
<li>Clinical response to dopamine replacement is so typical that if a
    patient does not respond, it is important to consider a Parkinson
    plus syndrome (see below)</li>
</ul>
<p>Management</p>
<ul>
<li>Dopamine replacement – carbidopa/levodopa; dosed at regular
    intervals several times a day. These generally do not need to be
    held on admission.<ul>
<li>If pt is altered, can hold anticholinergics, MAO-B inhibitors or
    COMT inhibitors</li>
</ul>
</li>
<li>Dopamine agonists – can cause confusion, hallucinations, dyskinesias</li>
<li>MAO-B inhibitors (MAOIs): can cause confusion, hallucinations,
    insomnia and dyskinesias<ul>
<li>Theoretical risk of Serotonin Syndrome (usually need both MAO-A
    and MAO-B for serotonin syndrome risk)</li>
</ul>
</li>
<li>COMT inhibitors – can cause confusion, hallucinations, insomnia, and
    dyskinesias</li>
<li>Anticholinergics – useful for tremor when there is not much
    bradykinesia or gait disturbances. In older pts cognitive changes
    are a bigger concern along with hallucinations</li>
<li>PD medications are rarely titrated in the hospital because acute
    medical illness makes PD symptoms worse and everything will need to
    be re-adjusted as an outpatient</li>
<li>Be cautious with PRN anti-emetics in patients with PD
    . Many work via dopamine antagonism. Zofran is generally the safest
    option.</li>
<li>Similarly, many antipsychotics have dopamine antagonism. Safest
    options include seroquel, nuplazid (less effective in acute setting)
    and clozapine.</li>
</ul>
<p>Parkinson Plus Syndromes</p>
<ul>
<li>Atypical features such as bilateral symmetric onset, early
    cognitive/personality changes, cerebellar findings, or prominent
    autonomic dysfunction early</li>
<li>Progressive Supranuclear Palsy – PD symptoms with early falls and
    minimal tremor, vertical eye movement abnormalities</li>
<li>Multisystem Atrophy (there are three types)<ul>
<li>Each typically has profound orthostatic hypotension without any
    increase in HR</li>
<li>MSA-A – autonomic features prominent (previously Shy-Drager
    Syndrome)</li>
<li>MSA-P – prominent atypical Parkinsonism features</li>
<li>MSA-C – prominent cerebellar dysfunction</li>
</ul>
</li>
<li>Lewy Body Dementia – Parkinsonism with prominent early cognitive
    impairment and hallucinations</li>
</ul></section><section class="print-page" id="neurology-neurology-status-epilepticus"><h1 id="neurology-neurology-status-epilepticus-status-epilepticus">Status Epilepticus<a class="headerlink" href="#neurology-neurology-status-epilepticus-status-epilepticus" title="Permanent link">&para;</a></h1>
<p>Status Epilepticus</p>
<p>Background</p>
<ul>
<li>Either a single seizure &gt;5 minutes or
    ≥
    2 seizures occurring without a return to baseline in between
    [previous guidelines used 30 minutes as a marker, but this has been
    updated]</li>
<li>Differentiating convulsive seizures from non-epileptic events
    (“pseudoseizure”):<ul>
<li>Features that suggest non-epileptic/psychogenic event include
    moaning or talking throughout the event, “no-no” head shake,
    repetitive movements of opposing muscle groups, very arrhythmic
    or purposeful-looking movements, or seizures that have been
    ongoing for “hours”</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Fingerstick
    glucose, BMP/CBC, and UDS</li>
<li>Consult Neurology</li>
<li>EEG (start with 2hr) to determine if it is seizure or not and for
    titration of medications</li>
<li>Consider a non-contrasted head CT; MRI cannot be obtained while EEG
    is attached</li>
<li>Up to half of pts presenting in status epilepticus have no history
    of seizure, so they need urgent head imaging, consideration for
    lumbar puncture, infectious and toxic workup, tox screen, and
    sometimes rheumatologic or paraneoplastic workup</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs
    !
    Start with <strong>benzos</strong> : 2 mg lorazepam IV every minute or 5 mg of
    diazepam IV every minute (they do take a few minutes to work,
    though) up to 0.1 mg/kg of lorazepam</li>
<li>After
    2 rounds of benzos, would shift to antiepileptics if pt is still in
    status (neurology should be contacted here if not already):<ul>
<li>IV fosphenytoin 20 mg/kg</li>
<li>IV levetiracetam 30-60 mg/kg (generally 3 grams is good)</li>
<li>IV valproic acid 30 mg/kg</li>
</ul>
</li>
<li>If
    still seizing at this point, the pt will likely need be intubated</li>
<li>These pts MUST be placed on EEG if they get paralyzed or sedated
    because <strong>convulsive status often continues as nonconvulsive status,
    which still damages the brain!</strong><ul>
<li>If still seizing, pts should be on midazolam, propofol or
    barbiturate infusions for burst suppression</li>
<li>Focal seizures, such as arm or face twitching with <strong>retained</strong>
    awareness do not always need to be treated to the point of
    initiating coma</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-stroke-0"><h1 id="neurology-neurology-stroke-0-stroke">Stroke<a class="headerlink" href="#neurology-neurology-stroke-0-stroke" title="Permanent link">&para;</a></h1>
<p>Background</p>
<ul>
<li>Former, nonpreferred term: <strong>cerebrovascular accident</strong></li>
<li>Sudden onset, focal (usually one-sided) neurologic deficits:
    weakness, sensory loss, vision loss, ataxia/unsteadiness, vertigo,
    double vision, facial droop, dysarthria, aphasia</li>
<li>Differential:<ul>
<li>stroke (ischemic or hemorrhagic)</li>
<li>seizure or post-ictal paralysis</li>
<li>headache phenomena</li>
<li>cervical spinal cord lesions, though these more commonly cause
    bilateral symptoms</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Stroke-like symptoms can also develop as recrudescence – previous
    stroke or brain lesion symptoms worsening with systemic
    toxic/metabolic/infectious processes (or hypotension)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Critical
    decision-making information: last known normal (LKN), time symptoms
    first observed, anticoagulation status, why pt is admitted, recent
    surgeries, history of bleeding (severe GIB or ICH), recent
    medications, last platelet count, and baseline neuro exam</li>
<li>If symptoms developed with LKN within 24 hours -&gt; stroke alert!<ul>
<li>VUMC: call 11111 and tell the operator stroke alert and current
    pt location</li>
</ul>
</li>
<li>NAVA: call an RRT and stat page <strong>835-5137</strong> , include in the page
    <strong>911</strong> at the end of the call back number to signal it is a stroke
    alert</li>
<li>Stat head CTP (order CTH/CTA) for consideration of tPA or
    endovascular therapy<ul>
<li>If renal fx is abnormal, discuss with neurology</li>
<li>Generally, go for CTA if the pt is a thrombectomy candidate</li>
<li>MRI/MRA is an option but takes longer (MRAs are also better with
    Gadolinium)</li>
<li>Neurology service should be leading this portion</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Blood pressure goals<ul>
<li>Ischemic stroke: in general SBP \&lt;220</li>
<li>Pts with intracranial atherosclerosis may require higher BP to
    maintain perfusion, which may necessitate discontinuing BP meds</li>
<li>Hemorrhagic strokes (which will be obvious on CTH): SBP \&lt; 140
    (BP management is key)<ul>
<li>These pts are managed in Neuro ICU</li>
<li>Reverse coagulopathies and keep platelets &gt;100,000</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-vertigo"><h1 id="neurology-neurology-vertigo-vertigo">Vertigo<a class="headerlink" href="#neurology-neurology-vertigo-vertigo" title="Permanent link">&para;</a></h1>
<p>Vertigo</p>
<p>Background</p>
<ul>
<li>Sensation of the room spinning or moving, or themselves spinning or
    moving</li>
<li>Distinguishing between vertigo and orthostasis/presyncope via
    history is important<ul>
<li>Ask about triggers, exacerbating factors, duration, if it has
    happened before</li>
<li>Ask about vascular risk factors, as stroke is an uncommon cause
    of isolated vertigo</li>
<li>Presentation based on Cause:<ul>
<li>BPPV – short duration, very positional, classically
    nystagmus is horizontal and torsional with the posterior
    canal being most commonly involved</li>
<li>Vestibular Neuronitis/labyrinthitis – typically follows URI
    or ear infections; often self-limited, but can be
    severe/prolonged, in which case it is treated with steroids</li>
<li>Menière’s Disease – tinnitus and low range frequency hearing
    loss, generally progressive and treated with diuretics,
    meclizine and sometimes surgeries or intratympanic
    injections</li>
<li>Endolymphatic Leak – usually following trauma or concussive
    blasts, requires ENT eval and management. Classically a loud
    sound will cause vertigo and nystagmus</li>
<li>Vertigo may also be caused by migraines, possibly without
    associated headache</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Careful exam of vertigo will be more helpful than random scans, but
    pt has to be symptomatic for exam to mean anything:<ul>
<li>HINTS Battery
    – head impulse test, nystagmus pattern, test of skew<ul>
<li>Central pattern – no corrective saccade, multidirectional
    nystagmus, skew present</li>
<li>Peripheral pattern –
    corrective saccade, unidirectional nystagmus, no skew
    present</li>
</ul>
</li>
<li>Dix-Hallpike Test</li>
<li>Cerebellar testing: FNF, HKS, mirroring, gait</li>
</ul>
</li>
<li>Central patterns will need head imaging with vessel imaging (looking
    for vertebral dissection or basilar clots)<ul>
<li>Often, central vertigo is due to centrally acting medications</li>
</ul>
</li>
<li>Peripheral causes are varied and often require eval by ENT as an
    outpatient</li>
<li>Treatment with anticholinergics like meclizine or scopolamine is
    often helpful</li>
<li>Vestibular therapy with OT is also very beneficial</li>
<li>Example of HINTS test</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Neurology</h1>
                        <h1 class='nav-section-title' id='section-outpatient-medicine'>
                            Outpatient medicine <a class='headerlink' href='#section-outpatient-medicine' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="outpatient-medicine-outpatient-medicine-asthma"><h1 id="outpatient-medicine-outpatient-medicine-asthma-asthma">Asthma<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-asthma-asthma" title="Permanent link">&para;</a></h1>
<p>Asthma – Trent Goodin, Stacy Blank</p>
<p>Background</p>
<ul>
<li>Ask about triggers: cold, exercise, URIs, allergens, inhaled
    irritants</li>
<li>Ask about family history or personal history of atopy, eczema,
    allergic rhinitis</li>
<li>Exam: wheezing, prolonged expiratory phase; nasal polyps, rhinitis,
    eczema</li>
<li>Evidence of reversible airflow obstruction (i.e. improvement of
    obstruction post-bronchodilator) or airway hyper-reactivity
    (methacholine challenge)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Spirometry (PFT’s) with reversible obstruction<ul>
<li>FEV1/FVC \&lt;0.7;
    #
    FEV1 12% and 200 mL after bronchodilator</li>
</ul>
</li>
<li>“All That Wheezes Is Not Asthma” rule out alternative diagnoses:<ul>
<li>Panic attacks, upper airway obstruction, foreign body, vocal
    cord dysfunction, CHF (cardiac asthma), COPD, ILD</li>
</ul>
</li>
</ul>
<p>Classify Severity and Assess for Symptom Control with the RULE OF 2s:</p>
<ul>
<li>Does the patient have symptoms or require rescue inhaler
    ≥
    2 times per week?</li>
<li>Does the patient endorse nighttime symptoms
    ≥
    2 times per month?</li>
<li>Does the patient have to refill rescue inhaler
    ≥
    2 times per year?</li>
<li>Does the patient ever have to limit activity due to asthma symptoms?</li>
</ul>
<p>Initial Assessment of Severity:</p>
<ul>
<li>Intermittent: No to all of the above and FEV1&gt; 80% predicted. Start
    at step 1</li>
<li>Persistent: Yes to any question above. Start at Step 2</li>
<li>Mild
    :  Less than daily symptoms, less than weekly nighttime symptoms,
    minor limitation to activities<ul>
<li>FEV
    >80% predicted</li>
</ul>
</li>
<li>Moderate:  Daily symptoms, weekly nighttime symptoms, some
    limitation to activities<ul>
<li>FEV
    60-80% predicted</li>
</ul>
</li>
<li>Severe: More severe symptoms than above, FEV1 \&lt;60% predicted<ul>
<li>Consider
    referral to pulmonary</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Aim to use the lowest possible step to maintain symptom control.
    Also consider stepping down therapy if pt has been well-controlled
    for &gt;3 months</li>
<li>Prior to escalating therapy, consider:<ul>
<li>Adherence to therapy (including inhaler technique), uncontrolled
    comorbidities (allergies, GERD, OSA, etc), and alternative
    diagnoses</li>
<li>Ensure patients receive MDI and spacer teaching for full effect.</li>
</ul>
</li>
<li>Updated Guidelines: prn ICS - LABA &gt; prn SABA Step 1 (mild
    intermittent) and Step 2 (mild persistent)<ul>
<li>Reduces exacerbations, easier to schedule does in future if
    needed</li>
<li>SYGMA Trial showed rescue/prn Budesonide-formoterol (ICS - LABA)
    non-inferior to daily ICS-LABA + prn SABA in preventing
    exacerbations</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Follow-up<ul>
<li>Repeat
    PFTs q3-6 mosafter beginning therapy and q1-2 yrs thereafter</li>
<li>Regular follow up at least q6 mos for all patients with asthma</li>
</ul>
</li>
<li>VA specific guidance:<ul>
<li>Mometasone
    is the formulary ICS and Symbicort (budesonide-formoterol) is
    the formulary ICS/LABA</li>
<li>Ordering
    PFTs: Refer to Pulm section on PFTs for VUMC and VA specifics</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/Asthma.png" data-entity-type="file" data-entity-uuid="f657a07a-26a7-49a4-8f74-4b4bac5b73a7" alt="Asthma" /></p></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-coding-and-informatics"><h1 id="outpatient-medicine-outpatient-medicine-coding-and-informatics-coding-and-informatics">Coding and Informatics<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-coding-and-informatics-coding-and-informatics" title="Permanent link">&para;</a></h1>
<p>Coding and Informatics – Babatunde Carew, Elizabeth Ann Yakes</p>
<p>Background</p>
<ul>
<li>ICD 10 Codes: International Classification of Disease Codes, 10<sup>th</sup>
    Revision. Used to categorize all diseases and symptoms.</li>
<li>CPT Codes: Current Procedural Terminology Codes: Numeric codes
    assigned to every task and service a physician may provide to a
    patient including medical, surgical, and diagnostic services. They
    are used by insurers to determine the amount of reimbursement that a
    practitioner will receive.</li>
<li>E&amp;M Codes: Evaluation and Management Codes. These are a category of
    CPT codes and are the most frequently used. There are different
    levels of E&amp;M codes, which are determined by the complexity of a
    patient visit and documentation requirements. Example: 99204 (new
    patient, level 4) or 99213 (established patient, level 3).</li>
<li>Preventive Service Codes: A category of CPT codes used for annual
    wellness exams. Example: 99395 (established patient, age 18-40).</li>
</ul>
<p>Problem Oriented Visits</p>
<ul>
<li>Return and new patients for which you are mainly addressing one or
    more acute or chronic problems should be filed under an E&amp;M code.</li>
<li>Documentation for these visits only need to include what you as a
    physician think is medically appropriate.</li>
<li>The correct E&amp;M code for the visit will depend on three
    categories: (1) medical complexity, (2) level of risk with
    testing/treatment, and (3) the amount/complexity of data reviewed.
    To meet criteria for a given code, the visit must meet the criteria
    in at least 2 of the 3 aforementioned categories.</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
</tr>
<tr>
<td>Low Problem Complexity</td>
<td>Low Risk of Diagnostic Testing/Treatment</td>
<td>Limited Data (1 Subcategory Required)</td>
</tr>
<tr>
<td>Two or more self-limited or minor problems OR One stable or chronic illness OR One acute of uncomplicated injury</td>
<td>Low risk of morbidity from additional diagnostic testing/treatment</td>
<td>Subcategory 1 (any 2 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test Subcategory 2 You obtained additional history from someone other than the patient</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>NaN</td>
</tr>
<tr>
<td>Moderate Problem Complexity</td>
<td>Moderate Risk of Diagnostic Testing/Treatment</td>
<td>Moderate Risk of Diagnostic Testing/Treatment</td>
<td>Moderate Data (1 Subcategory Required)</td>
<td>Moderate Data (1 Subcategory Required)</td>
<td>NaN</td>
</tr>
<tr>
<td>Two or more stable chronic illnesses OR One or more chronic illnesses with exacerbation, progression, or side effect of treatment OR One undiagnosed new problem with uncertain diagnosis OR One acute illness with systemic symptoms OR One acute complicated injury</td>
<td>Moderate risk of morbidity from additional diagnostic testing/treatment Examples: You are managing prescription drugs Decision regarding minor surgery with identified patient or procedure risk factors Decision regarding major elective surgery without identified patient or procedure risk factors Diagnosis or treatment significantly limited by social determinants of health</td>
<td>Moderate risk of morbidity from additional diagnostic testing/treatment Examples: You are managing prescription drugs Decision regarding minor surgery with identified patient or procedure risk factors Decision regarding major elective surgery without identified patient or procedure risk factors Diagnosis or treatment significantly limited by social determinants of health</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>NaN</td>
</tr>
<tr>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
</tr>
<tr>
<td>High Problem Complexity</td>
<td>High Problem Complexity</td>
<td>High Risk of Diagnostic Testing/Treatment</td>
<td>High Risk of Diagnostic Testing/Treatment</td>
<td>Extensive Data (2 Subcategories Required)</td>
<td>Extensive Data (2 Subcategories Required)</td>
</tr>
<tr>
<td>One or more chronic illnesses with severe exacerbation, progression, or side effects of treatment OR One acute or chronic illness or injury that poses a threat to life or bodily function</td>
<td>One or more chronic illnesses with severe exacerbation, progression, or side effects of treatment OR One acute or chronic illness or injury that poses a threat to life or bodily function</td>
<td>High risk of morbidity from additional diagnostic testing/treatment Examples: Drug therapy requiring intensive monitoring for toxicity Decision regarding hospitalization Decision regarding elective major surgery with identified patient or procedure risk factors Decision regarding emergency major surgery Decision to make DNR or deescalate care due to poor prognosis</td>
<td>High risk of morbidity from additional diagnostic testing/treatment Examples: Drug therapy requiring intensive monitoring for toxicity Decision regarding hospitalization Decision regarding elective major surgery with identified patient or procedure risk factors Decision regarding emergency major surgery Decision to make DNR or deescalate care due to poor prognosis</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
</tr>
<tr>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Annual Wellness Visits (Not Medicare)</p>
<ul>
<li>Return and new patients you are seeing for a preventive annual exam
    should be filed under a preventive service code.</li>
<li>Documentation for this visit MUST include a comprehensive update of
    PMH, Surgical Hx, Meds/Allergies, Social Hx and Family Hx, a
    14-point ROS (i.e. your note must say something along the lines of
    “14 systems were reviewed and pertinent positives are noted in the
    HPI), and anticipatory guidance/risk factor reduction.</li>
<li>The correct preventive service code will depend on patient age and
    the ICD-10 code should be Z00.00</li>
<li>This visit can only be coded for once every 365 days (although some
    insurances may allow you to code an annual each calendar year, every
    365 days is a safe bet)</li>
<li>CPT Codes:<ul>
<li>Code 99395 (established) or 99385 (new): Preventive Annual Exam,
    age 18-40.</li>
<li>Code 99396 (established) or 99386 (new):Preventive Annual Exam,
    age 40-65.</li>
<li>Code 99397 (established) or 99387 (new): Preventive Annual Exam,
    age 65+ (NOT Medicare patients).</li>
</ul>
</li>
</ul>
<p>Annual Wellness Visits (Medicare)</p>
<ul>
<li>Return and new Medicare patients (not Medicare managed plans like
    Cigna Medicare, etc) you are seeing for a preventive annual exam
    should be filed under a Medicare specific preventive service code.</li>
<li>Patient must complete a health assessment form.</li>
<li>Documentation must include: (1) age specific screening questions
    (cognition, depression, and function, (2) family and social
    history, (3) medication reconciliation (include DME).</li>
<li>Personalized prevention plan services (PPPS) information
    (recommendations for screening/prevention) must be included in the
    after-visit summary (AVS).</li>
<li>Much of this can be completed by the nurse during intake.</li>
<li>Talk to your preceptor before seeing the pt if you need help with
    the logistics!!</li>
<li>G Codes:<ul>
<li>Code G0402: Welcome to Medicare Visit, a one-time benefit visit
    only available within the first 12 months of Medicare Part B.</li>
<li>Code G0439 (established) or G0438 (new): Medicare Preventive
    Annual Exam. Does NOT include a physical exam. PPPS must be
    included in AVS. Ask your fellow residents or attending to share
    a PPPS dot phrase which may be inserted into patient
    instructions.</li>
</ul>
</li>
</ul>
<p>Modifiers</p>
<ul>
<li>Modifiers are numbers/letters that are attached to CPT code for
    billing purposes<ul>
<li>25 Modifier: Alerts the payer that a significant, separately
    identifiable E&amp;M service was provided by the same physician on
    the same day of the procedure or other service. (annual plus
    problem based visit or E&amp;M visit plus procedure)</li>
<li>GC Modifier: Seen by a resident and attending physician (must
    use for PGY-I during first six months)</li>
<li>GE Modifier: Seen by resident alone. If this modifier is used,
    the highest level billable is a level 3 (Note: due to COVID-19
    restrictions, residents (and interns after January) can “solo”
    bill for Level &#8536; with CR (catastrophic response) modifier.</li>
<li>CR: Catastrophic Response (see above).</li>
<li>GT: Telemedicine encounter</li>
</ul>
</li>
</ul></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-hypertension"><h1 id="outpatient-medicine-outpatient-medicine-hypertension-hypertension">Hypertension<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-hypertension-hypertension" title="Permanent link">&para;</a></h1>
<p>Hypertension (HTN) – Jonathan Davis</p>
<p>Background</p>
<ul>
<li>
<h1 id="outpatient-medicine-outpatient-medicine-hypertension-sbp-20-or-dbp-10-doubles-risk-of-stroke-and-cvd">SBP &gt;20 or #DBP &gt;10 doubles risk of stroke and CVD<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-hypertension-sbp-20-or-dbp-10-doubles-risk-of-stroke-and-cvd" title="Permanent link">&para;</a></h1>
</li>
<li>Prevalence ~45% with new cutoff (≥130/80); control achieved in
    ~50%</li>
<li>Definitions<ul>
<li>Resistant HTN:
    Uncontrolled BP despite taking 3 antihypertensive medications
    including a diuretic, OR 4 total medications</li>
<li>Whitecoat HTN
    :  Mean BPs lower than threshold of HTN based upon out-of-office
    measurements (falsely elevated measurements during visits). If
    SBP &gt; 130 but \&lt; 160, consider screening for white coat HTN with
    home monitoring</li>
<li>Masked HTN
    : Mean BP at/above threshold for hypertension based upon
    out-of-office measurements (falsely decreased measurements
    during visits). If office SBPs consistently 120-129 consider
    screening for masked HTN with home monitoring</li>
</ul>
</li>
<li>Diagnosis<ul>
<li>Requires ≥2 elevated pressures on ≥2 occasions<ul>
<li>Home and ambulatory BP monitoring recommended to confirm
    diagnosis</li>
<li>Ideally, measurements with legs uncrossed, arm at level of
    heart, after 5 minutes of rest and with empty bladder; avoid
    caffeine or tobacco 30 minutes prior</li>
<li>Screening</li>
</ul>
</li>
<li>Grade A USPTF rec: Screen all adults &gt;18. Screen adults at least
    semiannually if have risk factors for HTN (obesity, AA), or if
    previously measured SBP 120-129</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA-AHA guidelines (2017) (based on SPRINT trial)</td>
<td>ACA-AHA guidelines (2017) (based on SPRINT trial)</td>
</tr>
<tr>
<td>Normal</td>
<td>\&lt;120/80 mmHg</td>
</tr>
<tr>
<td>Elevated BP</td>
<td>systolic 120-129 mmHg AND diastolic \&lt;80 mmHg</td>
</tr>
<tr>
<td>Stage 1</td>
<td>systolic 130-139 mmHg OR diastolic 80-89 mmHg</td>
</tr>
<tr>
<td>Stage 2</td>
<td>systolic ≥140 mmHg OR diastolic ≥90 mmHg</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing
    including TTE, urine Alb:Cr ratio, or uric acid.</li>
<li>Distinguish between primary (90% incidence) and secondary HTN (10%):<ul>
<li>Suspect 1º if gradual onset, family hx, associated with weight
    gain &amp; lifestyle factors</li>
<li>Suspect 2º if early onset (\&lt; 30yo), late onset (&gt; 65 y/o),
    abrupt onset, disproportionate end-organ damage, resistant HTN</li>
</ul>
</li>
<li>Uncommon causes: Pheochromocytoma, Cushing’s syndrome, thyroid
    dysfunction, aortic coarctation, primary hyperparathyroidism,
    acromegaly, congenital adrenal hyperplasia</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common 2o Causes</td>
<td>Suggestive Feature</td>
<td>Diagnostic Testing</td>
</tr>
<tr>
<td>Primary Kidney Disease</td>
<td>Hypervolemia, ↑ Cr, abnormal UA, fhx of PKD</td>
<td>UA, Urine Alb:Cr ratio, Renal US</td>
</tr>
<tr>
<td>Renovascular disease (RAS or FMD)</td>
<td>Renal bruit, ↑ Cr after ACE-I or ARB, young age</td>
<td>Doppler renal US</td>
</tr>
<tr>
<td>OSA</td>
<td>Apneic events, somnolence, obesity</td>
<td>Polysomnography</td>
</tr>
<tr>
<td>Primary Hyperaldosteronism</td>
<td>Hypokalemia, metabolic alkalosis, resistant HTN, etc.</td>
<td>Start with plasma aldosterone/renin levels</td>
</tr>
<tr>
<td>Drug or Alcohol Induced</td>
<td>Hx of substance use (cocaine, caffeine, nicotine, medications)</td>
<td>UDS, BP improvement after withdrawal of suspected agent</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>JNC 8 recommends treating to a <strong>goal BP \&lt;140/90</strong> in all pts \&lt; 60</li>
<li>Consider intervenable contributing factors:<ul>
<li>Obesity
    , High Na diet (canned foods, fast foods, processed meats)</li>
<li>Excess
    alcohol intake</li>
<li>Medications (e.g., NSAIDs, decongestants, MAOs, clonidine
    withdrawal, cyclosporine, steroids)</li>
<li>Substance use (e.g., caffeine, cocaine, amphetamines)</li>
</ul>
</li>
<li>Lifestyle interventions (first line for any stage of elevated BP):<ul>
<li>8-14 mmHg
    ↓
    :
    DASH diet (fresh produce, whole grains, low-fat dairy)</li>
<li>5-10 mmHg
    ↓
    :
    Weight loss (10 kg or 22 lbs), expect 1mm Hg for every 1kg
    reduction in body weight</li>
<li>3-9 mmHg
    ↓
    :
    Na+ restriction (1.5 g / day), aerobic exercise for 90-150
    min/week, increased intake of K+ rich foods</li>
<li>2-4 mmHg
    ↓
    :
    Moderate EtOH (2 drinks/day for men; 1 drink/day for women)</li>
</ul>
</li>
<li>Medications (See table below):<ul>
<li>Initiate pharmacological therapy with Hypertension Stage I
    (ACC/AHA guideline) and ASCVD score &gt; 10% or Stage II pts
    (regardless of ASCVD score)</li>
<li>Use
    first
    line agents from the following classes<ul>
<li>ACE-I or ARB</li>
<li>Thiazide
    Diuretics (preferred in AAs)</li>
<li>Dihydropyridines
    CCB (preferred in AAs)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<p>VA Specific Guidance:</p>
<p><a href="https://www.healthquality.va.gov/guidelines/CD/htn/">https://www.healthquality.va.gov/guidelines/CD/htn/</a></p>
<ul>
<li>Preferred Agents/Agents that <strong>don’t require PADR</strong> :<ul>
<li>Diuretics – Any</li>
<li>ACEIs – Lisinopril, Benazepril, Enalapril, Ramipril, Captopril</li>
<li>ARBs – Losartan, Valsartan</li>
<li>Beta Blockers – Carvedilol, Metoprolol tartrate/succinate,
    atenolol, propranolol</li>
<li>DHP – Amlodipine</li>
<li>Non-DHTs – Verapamil, Diltiazem</li>
<li>Aldosterone
    Receptor Antagonist – Spironolactone</li>
<li>Alpha1 Antagonist – Doxazosin, Prazosin, Terazosin</li>
<li>Direct
    Acting Vasodilators – Minoxidil, Hydralazine</li>
<li>Alpha2 Agonist – Clonidine tablet, methyldopa</li>
</ul>
</li>
<li>Agents
    that <strong>require PADR</strong> :<ul>
<li>ACEIs - Quinapril</li>
<li>ARBs – Candesartan, Irbesartan, Olmesartan, Telmisartan</li>
<li>Beta blockers – Labetalol, Nebivolol</li>
<li>DHP – Nifedipine SA</li>
<li>Aldosterone Receptor Antagonist – Eplerenone</li>
<li>Alpha2 Agonist – Clonidine patch</li>
</ul>
</li>
<li>How
    to get BP cuff at the VA<ul>
<li>Consult
    tab: New Consult
    →
    Select Campus
    →
    Select Inpatient or Outpatient
    →
    Prosthetics Main</li>
<li>Consult Menu
    →
    Select Y/N for requirement of discharge
    →
    BP Cuff TVH</li>
<li>*Must answer all questions in the consult, including blood
    pressure cuff size.</li>
</ul>
</li>
</ul>
<p>Cost:</p>
<ul>
<li>Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan,
    metoprolol tartrate, HCTZ)</li>
<li>Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine,
    HCTZ, irbesartan, lisinopril, losartan, ramipril)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Class</td>
<td>Common Drugs</td>
<td>Side effects/ comments</td>
</tr>
<tr>
<td>Thiazide diuretics</td>
<td>HCTZ 12.5-50 mg Chlorthalidone 12.5-25 mg (Preferred agent based on RCT evidence)</td>
<td>- HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia, orthostatic hypotension Ok to use in pregnancy per ACOG (2019), but considered 2<sup>nd</sup> or 3<sup>rd</sup> line</td>
</tr>
<tr>
<td>ACE-I</td>
<td>Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg daily) Ramipril, 2.5-20 mg in 1-2 doses</td>
<td>-Angioedema (more common in AA) AKI, hyperkalemia, cough -Don’t use with ARB -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>ARBs</td>
<td>Losartan 25-100 mg in 1-2 doses Candesartan 8-32 mg in 1-2 doses Irbesartan 150-300 mg Valsartan 80-320 mg</td>
<td>-AKI, hyperkalemia -Angioedema (less frequent than ACE-I) -Don’t combine with ACE-I -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>CCB</td>
<td>Dihydropyridine: Amlodipine 2.5-10 mg 1-2 doses Nifedipine 30-120 mg in 1-2 doses Nondihydropyridine: Diltiazem ER 120-480 mg Verapamil ER 100-480 mg</td>
<td>Dihydropyridine: -Peripheral edema -Worsening proteinuria Nondihydropyridine: -Constipation -Heart block if used with BB -Contraindicated in HFrEF</td>
</tr>
<tr>
<td>Aldosterone receptor antagonists</td>
<td>Spironolactone 12.5-50 mg Eplerenone 25-50 mg</td>
<td>-Good choice for resistant HTN -AKI, hyperkalemia -Spironolactone—gynecomastia &amp; sexual side effects -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>BB</td>
<td>Carvedilol 6.25-25 mg bid Metoprolol succinate 25-200 mg qd Nebivolol 5-10 mg Labetalol 100-300 bid</td>
<td>Reserve for CHF/CAD -Hyperglycemia, fatigue, ↓ HR β 1-selective may be safer in pts with COPD, asthma, diabetes</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>Hydralazine 25-100 mg bid or tid Minoxidil 5-10 mg</td>
<td>Reflex tachycardia, fluid retention</td>
</tr>
<tr>
<td>Centrally- acting agents (alpha 2 agonists)</td>
<td>Clonidine 0.1-0.2 qd, (Weekly transdermal patch is preferred to avoid non- compliance and subsequent reflex HTN) Methyldopa 250-500 mg qd</td>
<td>Rebound hypertension, withdrawal Reserved for resistant hypertension due to unfavorable side effect profile</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions</td>
<td>Drug Class</td>
</tr>
<tr>
<td>Heart failure</td>
<td>ACE-I/ARB or ARNI + BB + spironolactone + diuretics</td>
</tr>
<tr>
<td>CAD</td>
<td>ACE-I or BB</td>
</tr>
<tr>
<td>Diabetes</td>
<td>All first line agents, ACE-I/ARB if presence of albuminuria</td>
</tr>
<tr>
<td>CKD</td>
<td>ACE-I/ARB</td>
</tr>
<tr>
<td>Recurrent stroke prevention</td>
<td>ACE-I, thiazide diuretic</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Labetalol (first-line), nifedipine, methyldopa, hydralazine</td>
</tr>
</tbody>
</table></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-lipids"><h1 id="outpatient-medicine-outpatient-medicine-lipids-lipids">Lipids<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-lipids-lipids" title="Permanent link">&para;</a></h1>
<p>Lipids – Jonathan Davis</p>
<p>Background</p>
<ul>
<li>1º Prevention: pts  at increased risk who have not yet had a
    vascular event</li>
<li>2º Prevention: pts  with pre-existing occlusive vascular disease or
    ASCVD (e.g., stroke, TIA, CAD + angina, ACS, coronary or arterial
    revascularization, PAD)</li>
<li>Screening:
    USPSTF 2016 Guidelines: adults 40-75yrs<ul>
<li>ACC/AHA 2018 Guideline: adults 21-75 q 4-6yrs; \&lt;21yrs  if
    strong fam hx</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Fasting vs Non-Fasting Lipid Panel.<ul>
<li>Triglycerides
    are most impacted by non-fasting testing which can artificially
    lower LDL-C depending on how the laboratory measures/calculates
    LDL. Consider fasting lipid panels when triglyceride levels are
    high</li>
</ul>
</li>
<li>Consider 2º causes of HLD in initial workup: hypothyroidism, DM,
    EtOH use, smoking, liver disease, nephrotic syndrome, CKD, meds
    (e.g., thiazide, glucocorticoids)</li>
</ul>
<p>Management</p>
<ul>
<li>Lifestyle changes:<ul>
<li>Heart Healthy Diet:
    ↓
    trans/saturated fats, choose skim milk, low-fat dairy products</li>
<li>Emphasizes fruits, vegetables, whole grains, poultry, fish, nuts
    and olive oil, while limiting
    red
    and processed meats, sodium and sugar-sweetened foods and
    beverages</li>
<li>Promote a healthy weight, regular exercise, smoking cessation,
    limit EtOH</li>
</ul>
</li>
</ul>
<p>Statin Therapy</p>
<ul>
<li>Initiate as outlined in the following algorithms (Note: check
    AST/ALT prior to initiation)</li>
</ul>
<p><img src="/sites/default/files/inline-images/LipidOne.png" data-entity-type="file" data-entity-uuid="cf7f75ad-7e26-48a4-9605-0edc0ced7181" alt="Lipid One" /></p>
<p><img src="/sites/default/files/inline-images/LipidTwo.png" data-entity-type="file" data-entity-uuid="f8a5c2ae-1d7e-4258-97af-0daea5129a13" alt="Lipid Two" /></p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Intensity ( $LDL-C by > 50%)</td>
<td>Moderate Intensity ($LDL-C by 30% - 49%)</td>
<td>Low Intensity ($LDL-C by \&lt;30%)</td>
</tr>
<tr>
<td>Atorvastatin (40mg) 80mg* Rosuvastatin 20mg (40mg)</td>
<td>Atorvastatin 10mg (20mg) Rosuvastatin (5mg) 10mg Simvastatin 20 - 40mg</td>
<td>Simvastatin 10mg</td>
</tr>
<tr>
<td>NaN</td>
<td>Pravastatin 40mg (80mg) Lovastatin 40mg (80mg) Fluvastatin XL 80mg Fluvastatin 40mg BID Pitavastatin 1-4mg</td>
<td>Pravastatin 10-20mg Lovastatin 20 mg Fluvastatin 20-40mg</td>
</tr>
</tbody>
</table>
<p>*Bold denotes dosing with RTC proven LDL lowering benefit</p>
<p>Statin Side effects</p>
<p>:</p>
<ul>
<li>Myalgias: bilateral involving large muscle groups, onset within
    weeks of initiation of therapy and should resolve within weeks of
    cessation</li>
<li>Spectrum of statin associated muscle symptoms (SAMS) include
    myalgias, myopathy, rhabdomyolysis, autoimmune myopathy, etc.<ul>
<li>Consider
    evaluation with CK, BMP, TSH, and vitamin D</li>
<li>ACC has a “Statin Intolerance Calculator” to help assess
    etiology of symptoms</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>If patient is not tolerating a statin, consider:<ul>
<li>Holding statin until symptoms resolve and trialing lower dose or
    alternative statin (Pravastatin and Fluvastatin may have lower
    risks of myopathy)</li>
<li>Every other day dosing with atorvastatin and rosuvastatin
    (longer half-lives)</li>
</ul>
</li>
<li>If repeated
    failed attempts, consider <strong>alternative agents</strong> : Ezetimibe
    10mg daily</li>
</ul>
<p>Hypertriglyceridemia</p>
<p>:</p>
<ul>
<li>Moderate: TG 175-499 mg/dL; Severe: TG &gt; 500 mg/dL<ul>
<li>Focus
    on addressing lifestyle factors and stopping medication that
    increase TG’s  (HCTZ, some BB’s, estrogens, some ART,
    antipsychotics)</li>
<li>Consider
    medical therapy when TG&gt; 500mg/dL to $ risk of pancreatitis
    with:<ul>
<li>Omega
    -3-fatty acids: 4gms daily or Vascepa 4gm daily</li>
<li>Fibrates
    : Fenofibrate 120mg daily (avoid in CKD), Gemfibrozil 600mg
    daily (increased risk of myopathy with concomitant statin)</li>
</ul>
</li>
</ul>
</li>
<li>PCSK9
    inhibitor
    requires referral to Lipid Clinic</li>
</ul>
<p>VA-</p>
<p>Specific</p>
<p>Guidelines</p>
<ul>
<li><a href="https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp">https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp</a></li>
<li>Lowest
    LDL goal recognized for VA Criteria for Use is 100</li>
<li>Preferred statins:
    Atorvastatin, Simvastatin, Lovastatin</li>
<li>Statins
    that require PADR:
    Pravastatin, Rosuvastatin (2<sup>nd</sup> line high intensity statin)<ul>
<li>Must
    have documented intolerances or drug-drug interaction to all
    preferred statins</li>
</ul>
</li>
<li>Other agents that require PADR:<ul>
<li>Ezetimibe<ul>
<li>pt has tried and failed or not tolerated all statins
    (allergy, AE, etc.)</li>
<li>pt not meeting goal on max dose of statin PLUS bile acid
    sequestrants or niacin</li>
</ul>
</li>
<li>Fenofibrate<ul>
<li>Pt has tried all formulary alternatives or has
    contraindication to use of formulary alternatives (statin,
    niacin, gemfibrozil, cholestyramine, fish oil)</li>
<li>If TG &gt; 500 mg/dL, fenofibrate should be approved</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-obesitynutrition"><h1 id="outpatient-medicine-outpatient-medicine-obesitynutrition-obesitynutrition">Obesity/Nutrition<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-obesitynutrition-obesitynutrition" title="Permanent link">&para;</a></h1>
<p>Obesity/Nutrition – Nina Hill</p>
<p>Background</p>
<ul>
<li>BMI = Body Weight (kg) + Height (meters) squared</li>
<li>Overweight = BMI 25.0-29.9</li>
<li>Obesity:<ul>
<li>Class I 30-34.9</li>
<li>Class II 35-39.9</li>
<li>Class IIIA 40-44.9</li>
<li>Class IIIB 45-49.9</li>
<li>Class IIIC 50+</li>
</ul>
</li>
</ul>
<p>​​​​​​​​​​​​​​</p>
<p>Management</p>
<ul>
<li>Goals: Target initial weight loss of 5-7% body weight, schedule
    frequent follow up to assess progress. Request pts send 48 hr food
    log. Encourage accountability “buddies.” Consider weight loss apps:
    My Fitness Pal, Lose it</li>
<li>Diet:<ul>
<li>Calorie
    restriction &gt; macronutrient composition (e.g., low fat, low
    carb)</li>
<li>Mediterranean
    : high in unsaturated fats, fruit/veg, legumes, grains; moderate
    dairy &amp; EtOH; less meat (decreased overall mortality and CV
    mortality; may decrease diabetes incidence independent of weight
    loss)</li>
<li>Dot phrases
    below for pictoral representation of cultural diets adapted to
    fit Mediterranean guidelines (Asian, African, Latin American)</li>
</ul>
</li>
<li>DASH
    : High in fruits/vegetables, moderate dairy, \&lt; 25% caloric intake
    from fat (decreases SBP/DBP)</li>
<li>Exercise: &gt;30 min, 5-7 days per week, ideally a combo of aerobic +
    resistance training.<ul>
<li>​​​​​​​
    Exercise alone is not sufficient for weight loss.</li>
<li>Medications: If BMI
    ≥30 or
    BMI ≥27 with
    ≥1 comorbidity. Significant short term weight loss (~ 5-15
    lbs), but weight is typically gained back when stopped</li>
</ul>
</li>
<li>Referral to medical weight loss: If BMI
    ≥ 30
    or BMI
    ≥27
    with comorbid conditions (fatty liver disease, diabetes mellitus,
    HTN, OSA)</li>
<li>Referral to surgical weight loss: If BMI
    ≥40
    or BMI
    ≥35
    with comorbid conditions</li>
</ul>
<p>​​​​​​​</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Mechanism</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Orlistat (Xenical)</td>
<td>Reduces fat adsorption</td>
<td>Diarrhea, gas, leakage of oily stools, stomach pain</td>
</tr>
<tr>
<td>Phentermine-topiramate (Qsymia)</td>
<td>Phentermine: appetite suppression Topiramate (anticonvulsant, migraine txt): ?appetite suppression, ?altered satiety perception</td>
<td>Constipation, dizziness, dry mouth, taste changes, tingling of hands and feet, insomnia</td>
</tr>
<tr>
<td>Naltrexone-bupropion (Contrave)</td>
<td>Naltrexone (partial opioid antagonist; used for alcohol dependence): ?altered satiety perception Bupropion (antidepressant): ?altered satiety perception</td>
<td>Constipation, diarrhea, dizziness, dry mouth, headache, BP, tachycardia, insomnia, liver damage, nausea/vomiting</td>
</tr>
<tr>
<td>Liraglutide (Saxenda)</td>
<td>Appetite suppression; quickens satiety (Victoza: lower dose formulation, FDA-approved for T2DM)</td>
<td>Nausea, diarrhea, constipation, abdominal pain, headache, tachycardia</td>
</tr>
<tr>
<td>Phentermine (Ionamin)</td>
<td>Reduces appetite Note: FDA-approved only for short-term use—up to 12 weeks</td>
<td>Dry mouth, constipation, insomnia, dizziness, nervousness/ restlessness headache, HTN, tachycardia</td>
</tr>
<tr>
<td>Semaglutide (Ozempic/Rybelsus)</td>
<td>Glucagon-like peptide-1 receptor agonist; reduces appetite</td>
<td>Nausea, vomiting, diarrhea, abdominal pain, constipation</td>
</tr>
</tbody>
</table></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-preventative-medicine"><h1 id="outpatient-medicine-outpatient-medicine-preventative-medicine-preventative-medicine">Preventative Medicine<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-preventative-medicine-preventative-medicine" title="Permanent link">&para;</a></h1>
<p>Preventive Medicine/Screening: (USPSTF) – Toaa Abuelenen, Emily Camp</p>
<ul>
<li>Recommend
    downloading the “CDC Vaccine Schedules” App on your phone to more
    easily filter by medical condition or look at contraindications</li>
<li><a href="https://www.cdc.gov/vaccines/schedules/index.html">https://www.cdc.gov/vaccines/schedules/index.html</a></li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventative Measures for ALL patients</td>
<td>Preventative Measures for ALL patients</td>
<td>Preventative Measures for ALL patients</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Men >35 or 20-35 with CV risk Women >45 or 20-45 with CV risk</td>
<td>Grade A UpToDate: Grade 2C</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>All adults age 50-75 - FOBT annually - FIT annually  - FIT-DNA (Cologuard) q 1 or 3 years - Colonoscopy q 10 years - Flexible sigmoidoscopy q 5 years Screen earlier if: family hx of CRC or adenomatous polyps at age \&lt; 60, a personal hx of IBD, a confirmed or suspected hereditary CRC syndrome, or a hx of abdominal or pelvic radiation</td>
<td>Grade A</td>
</tr>
<tr>
<td>Diabetes screening</td>
<td>Adults age 40-70 who are overweight or obese</td>
<td>Grade B</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Blood pressure screening annually adults >18</td>
<td>Grade A</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Aspirin 81 mg in age 50-59 with ASCVD risk >10% in 10 years, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Statin: See section on Lipids</td>
<td>Grade B</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>Adults aged 18 to 79 years (one time screening).</td>
<td>Grade B</td>
</tr>
<tr>
<td>HIV</td>
<td>All adolescents and adults 15-65 (one time screening)</td>
<td>Grade A</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Low-dose CT adults 55-80 w/30 pack year smoking history and currently smoke or quit within the past 15 years Should discuss risk vs benefits, particularly in pts with serious co-morbidities who may not tolerate/desire surgery or aggressive treatment.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Obesity</td>
<td>BMI annually in all adults</td>
<td>Grade A</td>
</tr>
<tr>
<td>Depression</td>
<td>All adults including pregnant and post-partum women</td>
<td>Grade B</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventative Measures for WOMEN:</td>
<td>Preventative Measures for WOMEN:</td>
<td>Preventative Measures for WOMEN:</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>Ages 21-29: q 3 yrs with cervical cytology alone. Ages 30-65: q 3 yrs with cervical cytology alone, every 5 years w/ high-risk human papillomavirus (hrHPV) testing alone or q 5 yrs with hrHPV testing in combination with cytology (co-testing) ***ACS 2020 guideline change –Age 25-65: preferred HPV test alone q 5 years (or HPV/Pap co-test every 5 years or a Pap every 3 years)***</td>
<td>Grade A</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Women 50-74: q2 years ACS recommends beginning at age 40, Yearly If family or personal history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated BRCA&frac12; gene mutations - should assess risk and refer to genetic counseling.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Chlamydia Gonorrhea</td>
<td>All sexually active women \&lt; 24, older women with increased risk</td>
<td>Grade B</td>
</tr>
<tr>
<td>Osteoporosis (DEXA)</td>
<td>Women >65, postmenopausal women \&lt;65 with increased osteoporosis risk (can use FRAX tool)</td>
<td>Grade B</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventive Measures for MEN</td>
<td>Preventive Measures for MEN</td>
<td>Preventive Measures for MEN</td>
</tr>
<tr>
<td>Abdominal aortic aneurysm (AAA) screening</td>
<td>Men Ages 65-75 who ever smoked (at least 100 cigarettes total): one-time screening by ultrasonography</td>
<td>Grade B</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Outpatient medicine</h1>
                        <h1 class='nav-section-title' id='section-pain-and-palliative'>
                            Pain and palliative <a class='headerlink' href='#section-pain-and-palliative' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="pain-and-palliative-pain-and-palliative-acute-and-chronic-pain"><h1 id="pain-and-palliative-pain-and-palliative-acute-and-chronic-pain-acute-and-chronic-pain">Acute and Chronic Pain<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain-acute-and-chronic-pain" title="Permanent link">&para;</a></h1>
<p>Acute and Chronic Pain – Thomas Horton, Soibhan Kelley</p>
<ul>
<li>There are physiological AND emotional components to pain.
    Biopsychosocial factors must be addressed. Examples include
    anxiety/depression, physical debility, and poor social support. 
    Many pts will not be completely free of pain, so it is important to
    set realistic boundaries and goals along with each individual.</li>
<li>Central sensitization is a phenomenon where the nervous system
    persists in a state of high reactivity which lowers the threshold
    for pain stimuli.  Two characteristics of centralized pain are
    allodynia (pain from non-painful stimuli) and hyperalgesia (painful
    stimuli perceived as more painful).</li>
<li>You must ask “why does this particular patient have pain?” Cancer
    patient vs degenerative disc disease will have different therapeutic
    plans.</li>
</ul>
<p>Pharmacologic Therapy</p>
<p>Acetaminophen</p>
<p>:  650mg q6hr or 1g q8h. \&lt;3g/day. (\&lt;2g in liver patients)</p>
<ul>
<li>Avoid if you are worried about masking fevers.</li>
</ul>
<p>NSAIDs</p>
<p>:  A great option for acute pain, especially musculoskeletal, HA, and
nephrolithiasis in eligible patients (ex: IV/po ketorolac, ibuprofen,
naproxen, etc)</p>
<ul>
<li>Avoid in acute or chronic kidney disease and
    ↑
    risk of bleeding. Caution in CAD/PVD</li>
</ul>
<p>Topical</p>
<dl>
<dt>Analgesics</dt>
<dd>
<p>Best for localized pain but utilized frequently as part of a
multimodal regimen</p>
</dd>
</dl>
<ul>
<li>Lidocaine ointment, patches (PADR needed at VA for patches. Can get
    by saying contraindication to TCA/gabapentinoids/SNRIs due to
    sedation risk)</li>
<li>Menthol
    salicylate gel</li>
<li>Diclofenac Gel (PADR needed at VA)</li>
<li>Capsaicin gel</li>
<li>Morphine gel (typically limited to oncology patients with tumor
    breakdown through skin)</li>
</ul>
<p>Neuropathic Agents</p>
<p>:</p>
<p>Best for neuropathic pain but can be tried for other chronic pain or as
part of acute pain regimen. SNRIs and TCAs can provide additional
benefit if a pt has comorbid depression, anxiety or insomnia (TCA). 
Most agents take 6-8 weeks for peak effect.</p>
<ul>
<li>Gabapentin
    (Initial: 100 to 300 mg 1 to 3 times daily). Can be used for acute
    pain.</li>
<li>Pregabalin
    (Initial: 25 to 150 mg/day in 2 to 3 divided doses). Has better
    bioavailability. May work in patients who did not tolerate or did
    not have success with gabapentin.</li>
<li>Duloxetine
    (
    Initial: 30 mg daily for 1 to 2 weeks, then increase to 60 mg daily
    as tolerated)</li>
<li>Amitriptyline (
    Initial: 10 to 25 mg once daily at bedtime)</li>
</ul>
<p>Muscle Relaxants</p>
<p>:</p>
<p>Should be used temporarily and intermittently but some benefit from
longer term use. Great for paraplegia, spinal injury, spasticity.</p>
<ul>
<li>Methocarbamol (Initial: 1.5 g 3 to 4 times daily for 2 to 3 days
    then decrease dose to ≤4.5 g/day in 3 to 4 divided doses). Preferred
    initial agent as has least SE.</li>
<li>Tizanidine (
    Initial: 2 to 4 mg every 6 to 12 hours as needed and/or at bedtime )
    – important to watch out for withdrawal in patients that take
    frequently at home.</li>
<li>Cyclobenzaprine
    (Initial: 5 to 10 mg once daily before bedtime)</li>
<li>Metaxalone (Oral: 800 mg 3 to 4 times daily)</li>
</ul>
<p>Opioids:</p>
<p>Frequently used in hospital for acute pain. Limit use as much as
possible in chronic pain as contributes to long-term central
sensitization.  May benefit some patient populations but should always
be used as a</p>
<p>component of a comprehensive, multimodal, patient-specific treatment
plan.</p>
<ul>
<li>Refer to section under Opioids: General Principles &amp; Conversions for
    OME equivalents<ul>
<li>If &gt;
    80
    OME per day, ensure patient is prescribed naloxone</li>
<li>If &gt;120 OME per day, refer to pain clinic</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Common choices for acute pain in hospital (always start at low end
    for opioid naïve):<ul>
<li>Oxycodone (PO) 5-10mg q4 to 6 hours prn</li>
<li>Hydromorphone (IV) 0.25 to 1mg q2 to 3 hours prn</li>
</ul>
</li>
<li>For pts on opioids at home, should always continue in hospital to
    avoid withdrawal unless clinically contraindicated (e.g.,
    respiratory depression). Can always titrate dose as needed</li>
<li>Tramadol
    : Has opioid &amp; NSAID properties. Of note, tramadol also inhibits
    serotonin and norepinephrine reuptake. Metabolized by
    CYP3A4 and CYP2D6 so there is variability between patients. Typical
    dose: 25 to 50mg q4 to 6 hours prn.</li>
</ul>
<dl>
<dt>NMDA Antagonists</dt>
<dd>
<p>Usually prescribed by our pain management colleagues but worthwhile to
think about as a potential option if a patient’s pain continues to be
difficult to control.</p>
</dd>
</dl>
<ul>
<li>Ketamine (IV infusion). SE includes AMS/delirium, hallucinations,
    and dissociation.</li>
<li>Memantine (PO)</li>
</ul>
<dl>
<dt>Alpha 2 agonists (central pain)</dt>
<dd>
<p>Not commonly utilized in everyday practice, but helpful in certain
patients with chronic pain (off-label). Guanfacine vs clonidine</p>
</dd>
</dl>
<p>Non-pharmacologic therapies</p>
<dl>
<dt>Procedural Intervention</dt>
<dd>
<p>Best utilized when there is a specific, targetable</p>
</dd>
</dl>
<ul>
<li>Referral
    to chronic/interventional pain management (Nerve blocks or
    Radio-ablative therapy)</li>
</ul>
<dl>
<dt>Adjunct Therapies</dt>
<dd>
<p>Patient’s will have varying opinions and responses on adjunctive
therapies, but these can be as important as any pharmacologic therapy.
CBT, personalized exercise regimen, PT/OT, chiropractor, acupuncture</p>
</dd>
</dl>
<p>Additional Resources for Residents</p>
<ul>
<li>Pain Management Center at VUMC</li>
<li>Pain Clinic at the VA. Would specify whether or not you are OK with
    them initiating opioids.</li>
<li>Osher Center for Integrative Health at Vanderbilt. (VA pts may
    utilize this service if they have private insurance)</li>
</ul>
<p>Acute pain for special populations</p>
<dl>
<dt>Renal dysfunction</dt>
<dd>
<p>Check meds are renally dosed and start with non-sedating options.
Always avoid NSAIDs, morphine and codeine. Acetaminophen and topicals
are safe.</p>
</dd>
</dl>
<ul>
<li>Opioids: oxycodone 2.5 to 5 mg, IV dilaudid 0.25-0.5mg, fentanyl IV
    25 to 50mcg</li>
<li>Gabapentin: start with spot 100mg. Be extremely careful with quick
    uptitration in CKD due to sedation risk.</li>
<li>Methocarbamol: no specific renal dosing, try 500-750mg initially</li>
</ul>
<p>Cirrhosis:</p>
<p>Always avoid NSAIDs, morphine, codeine, hydromorphone (may be OK in mild
to moderate cirrhosis)</p>
<ul>
<li>Acetaminophen (2g max/d) &amp; topicals are safe</li>
<li>Gabapentin: start with spot 100mg</li>
<li>Methocarbamol: no specific hepatic dosing, try 500 mg initially</li>
<li>Other options: consider tramadol 25-50 mg vs oxycodone 2.5 mg</li>
</ul>
<p>History of substance use disorder:</p>
<p>Overnight, always review handoff as day team likely has specific plan in
place.</p>
<ul>
<li>With substance use history, opioids should be avoided. Rely on
    multimodal agents as above</li>
<li>Patients who are in recovery may prefer to avoid opioids themselves<ul>
<li>Pts <strong>can</strong> <strong>and</strong> <strong>do</strong> have acute, severe pain due to
    injury, infections, procedures, et</li>
<li>NEVER withhold
    opiates if clinically appropriate, regardless of substance use
    history</li>
</ul>
</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-code-status-discussion"><h1 id="pain-and-palliative-pain-and-palliative-code-status-discussion-code-status-discussion">Code Status Discussion<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-code-status-discussion-code-status-discussion" title="Permanent link">&para;</a></h1>
<p>Code Status Discussion – Katie Sunthankar</p>
<ul>
<li>The approach to obtaining someone’s code status should be thoughtful
    and pertinent to their current admission or recent change in
    clinical status. First ask yourself “Why would this pt code?  Is
    resuscitation a reversible treatment in this pt’s case?  What are
    the chances that this pt will survive to discharge following CPR? Is
    the anticipated outcome in line with the pt’s goals? After you have
    made your assessment, then make a recommendation based on both the
    efficacy of resuscitation and the patient’s goals. (90-year-old male
    with an MI may survive CPR but may wish to die a natural death. A
    35-year-old with advanced cancer may be willing to endure CPR even
    if the chance of success is miniscule) Sometimes it is difficult to
    ascertain, and you can ask your attending his/her thoughts. For
    example, a 40 y/o pt admitted with cellulitis should probably be
    full code however an 83 y/o pt with class IV NYHA heart failure,
    CKD4 and significant frailty should probably be DNR/DNI. It is
    important that you are incorporating 1) the pt’s goals with 2) your
    understanding about the efficacy of CPR for that pt and help them
    come to an educated decision.</li>
</ul>
<!-- -->

<ul>
<li>Below are examples of phrases that can be used in framing code
    status. It is important to do this step wise. <strong>NEVER say “Do you
    want us to do everything?”</strong> This is a question very few people are
    okay with saying no to. It is more helpful to give examples of when
    these situations would arise.</li>
</ul>
<p>Admitting a patient:</p>
<ul>
<li>Introduction
    : Normalize the conversation by stating that “these are questions we
    routinely ask everyone when they come into the hospital.  This is a
    way for us to understand your wishes in the event you are unable to
    make your own decisions.” Otherwise, they can be caught off guard
    and not be able to meaningfully participate in the conversation.</li>
<li>Surrogate
    : “If you were unable to make decisions for yourself for whatever
    reason, who would you trust to make your decisions?  The person you
    pick does not have to be family but should be able to speak to your
    wishes and make the same choices you would make for yourself. [In a
    cirrhotic] For example, if you were to get confusion from your
    liver disease?”</li>
<li>Intubation
    : Always do this first so you can avoid the sticky DNI but not DNR
    situation. Again, normalize the question.  “Everyone has different
    opinions on what types of medical care they would want if they
    became sicker. One of the things we like to talk about are
    ventilators or breathing machines. Some tell us to try a breathing
    machine for a trial, but they would not want to be kept alive on a
    ventilator.” Now make a recommendation.  “In your case I think if
    you were to need a ventilator, based on your health I think it would
    [work, not work,]” Pause and allow them to ask questions. Also
    remember that if they say DNI, then they <em>must</em> be DNR because
    intubation occurs with ACLS (this is not allowed at VUMC but is at
    the VA… I don’t recommend getting in this situation).</li>
<li>CPR
    : Prime this question with “The next question I have to ask you can
    be hard to think about, but it is important that we know what you
    would want. In the event you had a cardiac arrest, that is, when
    your heart stops beating, which would mean you died? This is
    different from a heart attack. [pause]. We know based on the
    evidence that CPR is not always successful.  It really depends on
    the situation.  In your case, I think CPR would be (make a
    recommendation here). Knowing this, would you want us to attempt CPR
    or try to resuscitate you?”</li>
</ul>
<p>What if you don’t agree with your patient’s decision…</p>
<ul>
<li>At the end of the day, it is their decision (attendings may change
    the code status out of medical futility in Tennessee).</li>
<li>If you think the pt didn’t understand, or was overwhelmed, or the
    clinical situation has changed, you may want to go back and revisit
    the conversation, perhaps with another family or friend present. 
    Some pts have seen CPR on a loved one and seen it be successful and
    others have only seen it on TV. These experiences greatly influence
    their decision.</li>
<li>Consider framing the discussion differently and offer your
    recommendation: “While you are in the hospital, we will support you
    with interventions and medications that we think are helpful based
    on what you have told us important to you. However, we are worried
    that some of the interventions you are asking for may do more harm
    than good. Many people think that CPR works like it does on TV. 
    Unfortunately, we know that the vast majority of patients who need
    CPR in the hospital do not survive like they do on TV.  In your
    case, we do not think it would bring you back to your current
    state.  I worry that this is not something that will be helpful to
    you.”</li>
<li>Sometimes it can be more of a discussion after a patient says “Yes I
    would want CPR” you can respond “I understand and respect your
    choice… maybe we can talk more about this later, in particular if
    your health changes.”</li>
<li>Worried they may not understand CPR? Note that it is important to
    share at the beginning of the conversation otherwise the patient may
    feel like you are trying to coerce them into a decision. “Can I
    share some numbers about how often CPR can help?” Sometimes using
    fingers to show these numbers helps. “If you take 10 people in this
    hospital and all of their hearts stop beating, which would mean they
    have died, and we get to them as fast as possible, only 3 of them
    would have their hearts restarted and only 1 of them would ever
    leave the hospital.”</li>
<li>Another phrase that is helpful (and when the discussion occurs with
    surrogates leads to higher rates of changing code status than saying
    DNR): “allow for a natural death”. For example, “I worry that given
    how sick your [loved one] is, that the additional interventions of
    CPR if she were to die, would prevent her from having a natural
    death”</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-death-pronouncement"><h1 id="pain-and-palliative-pain-and-palliative-death-pronouncement-the-death-pronouncement">The Death Pronouncement<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-death-pronouncement-the-death-pronouncement" title="Permanent link">&para;</a></h1>
<p>The Death Pronouncement – Michael J. Neuss</p>
<p>This scenario arises in a variety of contexts, including the units,
wards, and cross-cover. You might know the patient and family well, but
particularly when cross covering, that may not be the case</p>
<p>This approach to the death pronouncement is based in part on the AAFP’s
“Death Pronouncement: Survival Tips for Residents” (Am Fam Physician.
1998 Jul 1;58(1):284-285.)</p>
<p>Before Entering:</p>
<ul>
<li>Familiarize yourself with the most important points of the patient’s
    hospitalization; it is ok to take a moment to read about the
    patient’s course and inquire about the day’s events with the
    patient’s nurse or other staff.</li>
<li>Inquire as to which family is present prior to entering, including
    whether the POA is currently at bedside.</li>
<li>Be aware of the circumstances of the patient’s death, particularly
    whether death was expected or sudden.</li>
<li>In general, it is best to enter accompanied, ideally with the
    patient’s nurse. It is rare for the chaplain to be present but that
    might also be a consideration.</li>
<li>Inquire with the nurse if Tennessee Donor Services (TDS) has been
    notified; often, when death is anticipated, the nurse will already
    have done this, although that is not always the case. Remember that
    it is not your position/role to approach the family regarding organ
    donation, but TDS should have been notified and there should be a
    case number, which in Epic you will have to document.</li>
</ul>
<p>In The Room:</p>
<ul>
<li>Especially when cross-covering, make sure to introduce yourself to
    family, and allow them time to introduce themselves to you.</li>
<li>Less is more when it comes to what you say: it can be good to be
    empathetic (consider only short statements such as “I am sorry for
    your loss”) but focus mainly on the task at hand, allowing time for
    families to be present with their loved one.</li>
<li>Explain that you have been called to examine the patient to confirm
    that they have passed. Allow a brief time for questions; it is rare
    (but not impossible) that someone may wish to excuse themselves for
    the pronouncement, and although I do not commonly inquire if family
    would like to be present, this is a consideration.</li>
<li>Note the location of a working clock when you enter; your watch is
    ok too but do make sure to avoid looking at your smartphone to check
    the time of death.</li>
</ul>
<p>The Exam And Pronouncement:</p>
<ul>
<li>Identify the patient by wrist band.</li>
<li>Note general appearance.</li>
<li>Confirm that the patient does not respond to stimuli; one discreet
    way to confirm a lack of response to tactile stimuli is to hold the
    hand, and apply pressure to a nailbed, appearing to hold the hand
    while looking at/visually inspecting the face or other part of the
    body. You should avoid any obvious painful stimuli, out of respect
    for the deceased as well as out of deference to family who may be
    present.</li>
<li>Confirm the absence of spontaneous respirations.</li>
<li>Confirm the absence of heart sounds.</li>
<li>Examine the pupils and note the absence of pupillary light reflex.</li>
<li>Note the time at which your examination is completed. This is the
    time of death. It is ok (although not required; this is merely a
    consideration) to speak the time of death quietly and respectfully,
    for the family’s reference as well as staff’s.</li>
<li>Make sure to ask for an autopsy. This is often overlooked, and as
    awkward as it might feel to ask for this, it is a requirement and
    asking later (if overlooked) feels more awkward.</li>
<li>Often phrased as something that must always be offered to all
    families, but not often requested by families of patients.</li>
<li>Make sure you have notified the attending of record</li>
</ul>
<p>*Please see further VA- and VUMC-specific guidance below.</p>
<p>Death Process at the VA</p>
<p>Nurse will notify physician at time of death for pronouncement.</p>
<p>THEN:</p>
<p>Physician will arrive to pronounce patient’s death within 1 hour of
notification by nursing staff.</p>
<p>THEN:</p>
<p>Physician to examine patient and pronounce death—offering family
chaplain support and informing family of death. Chaplain is notified by
calling the Administrative officer on duty (AOD).  Physician informs
nursing staff of time of death so that they can call TN donor services.</p>
<p>THEN:</p>
<p>Physicians at time of pronouncement will ask family regarding the
request for autopsy. VA pays for the autopsy and this is provided as a
benefit to the family if desired.  Family can decline this benefit. 
Physician should document if the family agreed to or declined the
autopsy benefit.</p>
<p>THEN:</p>
<p>Death note is documented in CPRS by physician pronouncing death using
the template provided to house staff.  Death note documents the time of
death, cause of death, family notified, and autopsy request with family
response to the autopsy request.</p>
<p>THEN:</p>
<p>Physician pronouncing death will complete additional death report
paperwork which includes the cause of death.  This death paperwork is
provided to the physician by the charge nurse or clerk and is available
at the nursing station.  Once completed, this paperwork is returned to
the nursing staff.</p>
<p>THEN:</p>
<p>Nursing staff notifies TN donor services.  Nursing staff contacts the VA
decedent affairs clerk during business hours.  Nursing staff may contact
the AOD instead of the decedent affairs clerk if the death occurs after
hours or on weekends.  The decedent affairs clerk or AOD provides
information to family regarding veteran death and funeral benefits.</p>
<p>THEN:</p>
<p>The body of the patient is removed from the room within 4 hours of death
and taken to the morgue to await transfer to the families’ choice of
funeral homes</p>
<p>Death</p>
<p>Process</p>
<p>in EPIC</p>
<ul>
<li>The key thing is to ensure that all components are completed in the
    “Discharge as Deceased” tab under the Transfer-Discharge screen</li>
<li>EACH AND EVERY
    component of this tab must be completed before Decedent Affairs will
    accept the body</li>
</ul>
<p>Required steps:</p>
<ul>
<li>Cardiopulmonary Death Charting
    
    Select “New Reading” and complete.</li>
<li>Cardiopulmonary Death
    
    Select “+Create Note”</li>
<li>Medical Examiner Criteria
    
    Select “+New Reading”; note that in general deaths that we expect
    and have an established medical cause generally do not need to go to
    the Medical Examiner (ME). If there is any concern for harm, foul
    play, drug overdose, etc, have a low threshold to contact the ME.
    The Vanderbilt Operator can assist with connecting you to the ME;
    alternatively, you can call 615-743-1800 during business hours (M-F
    8am – 4:30pm) or the after-hours pager at 800-216-0107.</li>
<li>Autopsy Criteria
    
    Select “+New Reading”</li>
<li>Preliminary Cause of Death and Date/Time of Death
    
    Select the ribbon at the top of this and enter a cause of death.
    Rather than list “Cardiopulmonary arrest” do try to be specific (eg
    Pulmonary Embolism, Myocardial Infarction, Metastatic Colon Cancer,
    etc) if you know the underlying cause of death.</li>
<li>Deceased’s Info – Report of Death. This will ask many questions.<ul>
<li>If you need to leave this and return later after collecting
    information, you can access your partially complete entries by
    clicking on the date/time text that appears under the ribbon.
    This is not intuitive because the numbers listing the date/time
    do not at all appear as though they act like a hyperlink (but
    they do).</li>
<li>Be specific; TDS will want you to have listed the name of the
    family you notified, the TDS Case Number (which the RN should
    have or can assist in collecting), and your attending
    physician’s name (to sign the death certificate; give their
    pager number in this subsection).</li>
</ul>
</li>
<li>Report of Death Note
    
    Select “+New Reading” and complete.</li>
<li>Complete Synopsis + Hospital Course and then at the very bottom
    under Summary of Death select “+Create Note.”</li>
<li>Once all of this paperwork is finished, be sure to touch base with
    the patient’s nurse, as s/he is often the contact for Decedent
    Affairs and can assist in making sure the body is moved
    expeditiously</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-medications-dying-patients"><h1 id="pain-and-palliative-pain-and-palliative-medications-dying-patients-medications-for-dying-patients">Medications for Dying Patients<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-medications-dying-patients-medications-for-dying-patients" title="Permanent link">&para;</a></h1>
<p>Medications for IMMINENTLY dying patients</p>
<p>General recommendations:</p>
<ul>
<li>At VUMC, there is a very helpful order set titled “Comfort Care
    Orders (Trauma, MICU, SICU, NEURO ICU, Palliative Care”</li>
<li>No order set at VA</li>
<li>Clean up orders: make sure to remove unnecessary medications,
    nursing text orders, etc.</li>
<li>Do make sure to order PRNs in anticipation of their need so that
    they become available to RN, particularly in the unit if you
    anticipate rapid progression of events following extubation, etc.</li>
</ul>
<p>Pain:</p>
<ul>
<li>Morphine 2mg IV or SQ q1h PRN</li>
<li>Hydromorphone 0.25 – 0.5mg IV or SQ q1h PRN</li>
<li>Write as PRN, as needed for pain &gt; 2/10 or for air hunger</li>
<li>Hydromorphone is preferable to morphine in patients with renal
    impairment</li>
<li>If ineffective after 1 hours, increase by 50-100%</li>
<li>If given every hour for 3-4 hours, consider an infusion (given PRN
    dose as hourly rate)</li>
<li>Fentanyl is not a great option in ICU unless it is a continuous
    drip. Bolus lasts only 15 mins</li>
</ul>
<p>Dyspnea/Tachypnea:</p>
<ul>
<li>Assess for volume overload, considering decrease or stopping IVFs or
    tube feeds</li>
<li>Opioids are the treatment of choice for dyspnea</li>
<li>Consider Benzodiazepines for air hunger not controlled by opiates</li>
<li>Supplemental oxygen for comfort (do not base on O2 sat)</li>
<li>Consider use of cool air and/or fan to the face/patient</li>
<li>Diuresis, bronchodilators, steroids, other mgmt as indicated if
    underlying cause identified</li>
</ul>
<p>Restlessness/Agitation:</p>
<ul>
<li>Assess for urinary retention, constipation, pain, other modifiable
    factors before initiating medical therapy</li>
<li>Haloperidol (Haldol) 0.5 – 1 mg PO, IV or SQ q4h PRN</li>
<li>Lorazepam (Ativan) 0.5 – 1 mg PO or IV q4h PRN (tablet can be made
    into slurry if patient is experiencing dysphagia)</li>
<li>CAUTION: Benzos can worsen delirium</li>
</ul>
<p>Nausea:</p>
<ul>
<li>Ondansetron (Zofran) 4mg IV q4h or 8mg q8h PRN</li>
<li>Promethazine (Phenergan) 25mg PO or PR q6h PRN; caution can be very
    sedating</li>
<li>Prochlorperazine (Compazine) 10mg PO or IV q4h PRN</li>
<li>Haloperidol (Haldol); see dosing above</li>
<li>If felt to be obstructive in etiology, try Dexamethasone 4mg IV or
    SQ q8-12h with Octreotide 100-400mcg IV or SQ q8h</li>
<li>If felt to be related to anxiety, try Lorazepam; see dosing above</li>
<li>Scopolamine is highly anti-cholinergic and takes time to be
    effective, so would NOT use in imminently dying patients</li>
</ul>
<p>Secretions:</p>
<ul>
<li>Position for comfort; side lying if possible to move sections</li>
<li>Remember: the patient is NOT bothered by their own secretions, and
    it is often the family and caregivers who are likely disturbed, so
    avoid deep suctioning</li>
<li>Glycopyrrolate (Robinol) 0.2 – 0.4 mg SQ or IV q6h PRN (can
    schedule; but use caution as it does cause confusion or other mental
    status changes like many anti-sialagogues)</li>
<li>Atropine 1% Ophthalmic Solution 2 drops SL 2-4h PRN</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-opiate-principles"><h1 id="pain-and-palliative-pain-and-palliative-opiate-principles-opiate-principles">Opiate Principles<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-opiate-principles-opiate-principles" title="Permanent link">&para;</a></h1>
<p>Opioids: General Principles &amp; Conversion – Brian Grieb</p>
<p>Oral Morphine Equivalent (OME) Conversion Table:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td>PO</td>
<td>IV</td>
<td>APAP</td>
<td>IR</td>
<td>ER</td>
<td>Notes</td>
</tr>
<tr>
<td>Tramadol</td>
<td>0.1x</td>
<td>-</td>
<td>-</td>
<td>Tramadol</td>
<td>Ultram ER™</td>
<td>NSAID properties</td>
</tr>
<tr>
<td>Morphine</td>
<td>1x</td>
<td>3x</td>
<td>-</td>
<td>Morphine IR</td>
<td>MS-Contin™</td>
<td>Renally cleared</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>1x</td>
<td>NaN</td>
<td>Lortab</td>
<td>Hydrocodone</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>1.5x</td>
<td>-</td>
<td>Percocet</td>
<td>Roxicodone™</td>
<td>Oxycontin™</td>
<td>NaN</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>4x</td>
<td>20x</td>
<td>-</td>
<td>IV, Oral</td>
<td>-</td>
<td>Oral is $</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>300x</td>
<td>300x</td>
<td>-</td>
<td>IV’ Buccal, Nasal</td>
<td>Patch</td>
<td>Dosed in ug, not mg</td>
</tr>
</tbody>
</table>
<p>Abbreviations: ER, extended release; IR, immediate release; IV,
intravenous; PO, oral; APAP, Acetaminophen</p>
<p>Conversion:</p>
<ul>
<li>Transition between opiates is done using oral morphine equivalents
    (OMEs), in which each drugs’ potency is compared to oral morphine
    (see table).  For example, 1 mg of IV morphine is equal to 3 mg of
    oral morphine.</li>
<li>When transitioning, doses are traditionally reduced by &frac14; to &#8531;
    due to cross tolerance. (Oxycodone 5 is a pretty standard dose,
    which converts to 7.5 mg of oral morphine, 2.5 mg of iv morphine,
    and 0.375 of iv hydromorphone.)</li>
</ul>
<p><img src="/sites/default/files/inline-images/Opiate_Conversion.jpg" data-entity-type="file" data-entity-uuid="595c75af-cf20-4122-824d-7cd00bea8472" alt="Opiate Conversions" /></p>
<p>Patient Controlled Analgesia (PCAs) aka Pain Pumps:</p>
<ul>
<li>Pumps
    can be programmed to deliver a continuous rate and/or a bolus dose.
    The basal rate is a continuous infusion dosed per hour that cannot
    be adjusted by the patient. The demand dose is a patient-directed
    bolus that is given at a prescribed frequency (whenever the pt
    presses the button).  Both the actual dose and frequency of bolus
    dose can be adjusted. The general rule of thumb is to calculate the
    total OME delivered through the demand when a pt is in steady state
    and convert 75% of this dose into the total continuous rate or basal
    infusion. Alternatively, if a pt is chronically on a long-acting
    opioid, this total amount of OME (sustained release) can be
    converted into a basal rate of opioid.  The demand dose is 25% of
    the hourly rate given every 15 minutes.</li>
<li>Remember that the basal rate will not get to steady state for at
    least 8 hrs; therefore, when you admit pts or are transitioning pts
    to a PCA, always initiate the PCA pump with a bolus (or loading)
    dose.</li>
</ul>
<p>How to Order PCA at VUMC</p>
<p>:</p>
<ul>
<li>Select Analgesic:<ul>
<li>Hydromorphone
    (most common): Order “Hydromorphone (DILAUDID) PCA”</li>
<li>Fentanyl
    (if on at home; not a good inpatient PCA): Order “Fentanyl PCA”</li>
<li>Morphine
    : Order “Morphine PCA”</li>
</ul>
</li>
<li>
<p>Select “[Analgesic] PCA syringe” and adjust the following to pt
    needs:</p>
<ul>
<li>PCA
    Dose (“Demand”): amount the pt gets when s/he presses the button</li>
<li>Lockout
    Interval: time between which “demand” doses will not be
    administered if s/he presses the button (i.e., the PCA “locks
    out”)</li>
</ul>
</li>
<li>
<ol>
<li>Optional: many palliative care providers may not include this to
        allow patients more liberty to control their pain, depending on
        the situation</li>
</ol>
</li>
<li>
<ul>
<li>Continuous
        Dose (“Basal”): amount the pt gets per hr in continuous infusion</li>
<li>Max
    Dose: maximum amount of analgesic (Basal + Demand) pt can get in
    24 hours</li>
</ul>
</li>
<li>
<p>Select “IV Carrier Fluid Options”&gt; Choose Fluid option</p>
</li>
<li>
<p>Select all “PCA Nursing Orders”</p>
</li>
</ul>
<p>How to Order PCA at VA:</p>
<ul>
<li>Under Orders, select “Pain/Sedation Infusions”</li>
<li>Under “PCAs,” select Analgesic of choice (Hydromorphone or Morphine)</li>
<li>Adjust the following:<ul>
<li>Load
    : amount the pt will receive on initial set up of PCA</li>
<li>Basal
    : amount the pt gets per hour in continuous infusion</li>
<li>Demand
    : amount the pt gets when s/he presses the button</li>
</ul>
</li>
</ul>
<p>Interrogating PCA (to determine amount of analgesia pt received):</p>
<ul>
<li>Look at IV pump display. If it does not display info about PCA, hit
    “Channel Select” on PCA</li>
<li>Select “Options” in bottom left of IV pump</li>
<li>Select “Patient History” on the left of the screen. This shows the
    administration history for a certain time period (e.g., 24h, 12h,
    4h, etc)</li>
<li>Hit “Zoom” on bottom of screen to change time period to 24 hours.
    Should show:<ul>
<li>Total
    Drug: total amount of drug received in last 24 hours</li>
<li>Total
    Demands: amount of times the pt has pushed the button for demand
    dose</li>
<li>Delivered
    : amount of times the pt actually received a demand dose</li>
<li>The
    difference between “Total Demands” and “Delivered” is the number
    of times the patient pushed the button without receiving a dose
    (due to pushing the button during the lockout interval).</li>
</ul>
</li>
<li>If you have questions about interrogating the PCA, ask the nurses!
    They are a great resource!</li>
</ul>
<p>Opioid Side effects</p>
<ul>
<li>Constipation: dose-dependent and will not develop tolerance. If pt
    has opioids, they need robust bowel regimen (miralax, senna) with
    goal of BM
    ≥
    every 3 days. For opioid-specific constipation can do SQ Relistor
    (methylnaltrexone) but this is expensive and can only be given in
    the PCU or oncology floors at VUMC. For patients with chronic
    opioid-induced constipation as an outpatient can trial oral agents
    like Movantik (naloxgeol). Can also consider PO naloxone but it does
    have small amount of bioavailability so watch for systemic reversal.</li>
<li>Nausea: occurs with opiate naïve pts. Consider starting an
    anti-emetic concurrently.  Most pts will develop tachyphylaxis with
    this over a day, so the antiemetic can be discontinued.</li>
<li>Urinary retention: Consider role of opioids in pts with new-onset or
    worsening urinary retention. Try to de-escalate opioid dosing if
    possible.</li>
<li>Overdose: In pts with apneic emergency, IV 0.4 mg Naloxone; however,
    low threshold for multiple doses until response. With respiratory
    depression in chronic opioid pts start with IV 0.02 mg q2-3min to
    avoid profound withdrawal. This helps prevent acute pain crisis. In
    pts taking long-acting opioids, may need to redose q30min and
    consider IV infusion for them. For pts prescribed opioids as
    outpatient, need naloxone 4 mg intransasal.</li>
<li>Pruritis: due to histamine release from mast cells; can be treated
    with antihistamines. The opioid can also be rotated. Some but not
    all pts will develop tachyphylaxis to this symptom.</li>
<li>Toxicity: hyperalgesia and neuroexcitatory effects (AMS, myoclonic
    jerking, seizures). Risk   factors for neuroexcitatory effects are
    rapid titration, dehydration or renal failure.</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations"><h1 id="pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations-video-examples-for-navigating-difficult-conversations">Video Examples for Navigating Difficult Conversations<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations-video-examples-for-navigating-difficult-conversations" title="Permanent link">&para;</a></h1>
<p>Video Examples for Navigating Difficult Conversations – Mohana Karlekar</p>
<p>Navigating difficult conversations with patients can be daunting
especially if you have never seen someone do one well before. 
Conversations should follow a logical and sequential approach. much like
any procedure we perform in medicine.  Like all procedures, practice
makes us better</p>
<p>Scan the QR Code To View Video Examples Or Search The Learning Exchange
“Navigating Difficult Conversations With Patients”</p>
<p><img src="/sites/default/files/inline-images/QR_Code.png" data-entity-type="file" data-entity-uuid="2c524db5-5c53-4ef3-b775-3b4829476db2" alt="QR Code" /></p>
<p>Good communicators have both <strong>formulated</strong> their message and
<strong>identified</strong> which communication strategy to use before they initiate
a conversation</p>
<p>Here are some suggestions for “Navigating Difficult Conversations”</p>
<ul>
<li>Step 1. Determine your message-keep it simple and short</li>
<li>Step 2. Identify what type of news you are communicating: breaking
    bad news, assessing understanding of information, communicating
    prognosis or navigating goals of care</li>
<li>Step 3. Pick the video that best suits your purpose</li>
</ul>
<p><img src="/sites/default/files/inline-images/SPIKES.jpg" data-entity-type="file" data-entity-uuid="abfa6510-5644-4853-86bb-786aabd5480f" alt="Spikes" /></p></section><h1 class='nav-section-title-end'>Ended: Pain and palliative</h1>
                        <h1 class='nav-section-title' id='section-physical-medicine-rehabilitation'>
                            Physical medicine rehabilitation <a class='headerlink' href='#section-physical-medicine-rehabilitation' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain-back-pain">Back Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain-back-pain" title="Permanent link">&para;</a></h1>
<p>Acute Back Pain – Christian Roehmer</p>
<p>Background</p>
<ul>
<li>Lifetime risk ~ 70% of Americans</li>
<li>RF: age, obesity, smoking, socioeconomic status, and psychological
    factors</li>
<li>>90% of back pain is nonspecific and musculoskeletal in nature</li>
<li>Can’t Miss: Spinal cord compression, cauda equina, cancer, spinal
    abscess, or osteomyelitis</li>
<li>Extra-axial causes: Pancreatitis, nephrolithiasis, pyelonephritis,
    AAA, zoster</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lumbar strain: diffuse pain in lumbar muscles, may radiate</li>
<li>Degenerative disk or facet process: localized lumbar pain, similar
    to lumbar strain</li>
<li>Inflammatory arthritis: morning stiffness, improves with movement,
    systemic symptoms</li>
<li>Osteoarthritis: pain with use, improves with rest</li>
<li>Herniated disk: radiating pain to legs, often below the knees</li>
<li>Compression fracture: older patients, trauma, spine tenderness on
    exam</li>
<li>Spinal stenosis: pain improves with flexion, shopping cart sign</li>
<li>Spondylolysis: pain with extension</li>
<li>Spondylolisthesis: pain with activity, improves with rest, can be
    seen with imaging</li>
<li>Scoliosis: abnormal spine curvature, seen on physical exam
    inspection</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection: Should include posture, Adam’s Forward Bend Test
    (screens for scoliosis), and limb length discrepancy
    
    kyphosis, lordosis, or scoliosis</li>
<li>Palpation/Percussion: Sensitive for identifying spinal
    infection, metastases, or compression fractures<ul>
<li>Spinous processes, lumbar “step-offs,” paravertebral muscles
    and SI joint</li>
</ul>
</li>
<li>Range of Motion: Pain with extension and relieved by flexion
    suggests spinal stenosis</li>
<li>Neurologic Examination:<ul>
<li>L2: hip flexion; L3: knee extension; L4: dorsiflexion; L5:
    great toe flexion</li>
<li>S1: plantarflexion</li>
</ul>
</li>
<li>Waddell’s Signs:  Raise suspicion of <strong>non-organic pain</strong><ul>
<li>Superficial tenderness, pain that improves with
    distraction (attention diverted)</li>
<li>Pain with sham maneuvers (simulation)</li>
<li>Overreaction (disproportionate psychomotor responses)</li>
<li>Non-physiologic neurologic deficits</li>
</ul>
</li>
</ul>
</li>
<li>ESR/CRP: Can be used if concern for infection or malignancy</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Straight Leg Raise</td>
<td>Lumbosacral nerve roots</td>
<td>Pt is supine, lift one leg (keep straight) while the other leg is resting flat</td>
<td>Positive for radiculopathy if pt experiences radiating pain to the leg being lifted</td>
</tr>
<tr>
<td>Slump Test</td>
<td>Lumbosacral nerve roots</td>
<td>Pt is sitting, have them slump forward w/chin touching chest. Then passively extend knee and dorsiflex foot</td>
<td>Positive for radiculopathy if any of the steps reproduces radicular pain Use with straight leg raise</td>
</tr>
<tr>
<td>Gaenslen’s Test</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, brings knee of leg of side not being tested to chest and holds it; examiner extends straight leg being tested over edge of bed</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Patrick’s (Fabers) Test</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, passively flex hip to 90º, maximally abduct and externally rotate at hip</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Sacral Thrust</td>
<td>Sacroiliac Joint</td>
<td>Pt prone, apply anteriorly directed thrust over sacrum</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Distraction</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, apply pressure directed postero-laterally to both anterior and superior iliac spine</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Compression</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, apply pressure directed postero-laterally to both anterior and superior iliac spine</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
</tbody>
</table>
<ul>
<li>Imaging:<ul>
<li>AP and lateral plain films; Bilateral oblique films (evaluate
    for spondylolysis)<ul>
<li>Indications: Pts at risk of fracture, Red flag symptoms,
    Evaluate for ankylosing spondylitis, No improvement in pain
    after conservative therapy after 6-12 weeks</li>
</ul>
</li>
<li>Non-contrasted MRI (Preferred)<ul>
<li>Indications: Suspicion for spinal cord/cauda equina
    compression, Severe neurological deficits, concern for
    infection, Unexplained inflammatory marker
    ↑</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>First line: conservative therapy for 4 to 6 weeks, <strong>avoid</strong> bedrest<ul>
<li>Physical therapy</li>
<li>NSAIDs: Ibuprofen 600 – 800 mg q 4-6 hr, Diclofenac (topical) 2
    g TID-QID (7 days)</li>
<li>Heat, massage <u>+</u> acupuncture</li>
</ul>
</li>
<li>Adjuncts for pain:<ul>
<li>Robaxin: 750 mg – 1.5 g 3-4 times daily for 2-3 days, then
    <u>\&lt;</u> 4.5 g/day over 3-4 doses</li>
<li>Flexeril: 5 mg tid, or 5 once qhs with Tylenol or NSAID</li>
</ul>
</li>
<li>Pts with neuro deficits or spinal cord compression warrant urgent
    surgical evaluation</li>
<li>Refer to Spine PT program at VUMC</li>
<li>Refractory or Severe Pain: Referral to orthopedics or PM&amp;R spine
    specialist</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain-knee-pain">Knee Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain-knee-pain" title="Permanent link">&para;</a></h1>
<p>Knee Pain – Samuel Lazaroff</p>
<p>Background</p>
<ul>
<li>Key features of the history include location: have patient point to
    the area that hurts most</li>
<li>Septic arthritis can also present indolently, with well-appearing,
    afebrile, patients</li>
<li>History of trauma, swelling, systemic symptoms, weight-bearing</li>
<li>Consider mechanism of injury
    à
    presence/absence of effusion
    à
    location<ul>
<li>High-energy trauma:  high risk of bony and/or ligamentous injury</li>
<li>Low-Energy Trauma and Atraumatic etiologies organized by
    location</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knee Location</td>
<td>Low-Energy Trauma</td>
<td>Atraumatic</td>
</tr>
<tr>
<td>Anterior</td>
<td>Patellar subluxation or dislocation (instability) Patellar fracture Patellar tendon rupture Quadriceps tendon rupture</td>
<td>Tendinopathy: patellar or quadricep Hoffa’s fat pad syndrome (inflammation of post-patellar fat) Bursitis OA</td>
</tr>
<tr>
<td>Medial</td>
<td>MCL tear Acute medial meniscus tear</td>
<td>Medial meniscus degenerative tear Pes anserine bursitis OA</td>
</tr>
<tr>
<td>Lateral</td>
<td>LCL tear Acute lateral meniscus tear</td>
<td>IT band syndrome Lateral meniscus degenerative tear OA</td>
</tr>
<tr>
<td>Posterior</td>
<td>PCL tear Hyperextension</td>
<td>Baker’s cyst Popliteal art. aneurysm/entrapment</td>
</tr>
<tr>
<td>Generalized</td>
<td>ACL tear PCL tear Intra-articular fracture</td>
<td>Patellofemoral pain syndrome OA Patellar stress fracture Referred from hip or ankle</td>
</tr>
</tbody>
</table>
<p>Presentation</p>
<ul>
<li>Traumatic Effusion:<ul>
<li>Differential is ACL or PCL rupture, meniscus tear, patellar
    instability (dislocation of subluxation), bone bruise, fracture</li>
</ul>
</li>
<li>Atraumatic Effusion:<ul>
<li>Activity related or pain w/activity: Osteoarthritis,
    Osteochondral injury</li>
</ul>
</li>
<li>Not activity-related: Consider autoimmune causes, crystalline
    arthropathy, Lyme disease, Septic arthropathy (including gonococcal)</li>
<li>Less common causes: primary bone tumor, viral infection
    (Parvo), hyperparathyroidism, hemochromatosis, syphilis, sarcoid,
    Whipple’s</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection, palpation, AROM, PROM, strength, check for effusion,
    neurovascular exam (incl. reflexes if applicable), provocation
    (of ligaments), gait</li>
<li>Examine the back, hip, and ankle as well</li>
</ul>
</li>
<li>Aspirate if effusion present</li>
<li>Ottawa Knee Rule = Imaging if 1 of following:<ul>
<li>>
    55 y/o</li>
<li>Isolated tenderness of patella</li>
<li>Tenderness of fibular head</li>
<li>Unable to flex 90° º</li>
<li>Unable to ambulate 4 steps at time of injury and at time
    of evaluation</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Anterior Drawer</td>
<td>ACL</td>
<td>Hip flexed and knee in 90° of flexion, pull anteriorly on tibia</td>
<td>Tibia translates forward</td>
</tr>
<tr>
<td>Pivot Shift</td>
<td>ACL</td>
<td>With knee extended, internally rotate the foot and apply valgus force</td>
<td>Translation of femur or tibia</td>
</tr>
<tr>
<td>Lachman</td>
<td>ACL</td>
<td>With knee flexed 20°, hold thigh down with one hand while pulling anteriorly on tibia with your other hand (with thumb on tibial joint line)</td>
<td>Soft end point of tibial translation</td>
</tr>
<tr>
<td>Posterior drawer</td>
<td>PCL</td>
<td>With hip flexed and knee in 90° of flexion, push posteriorly on tibia</td>
<td>Tibia translates backwards</td>
</tr>
<tr>
<td>Joint line tenderness</td>
<td>Meniscus</td>
<td>Palpate</td>
<td>Reproduces pain at site</td>
</tr>
<tr>
<td>McMurray</td>
<td>Meniscus</td>
<td>With hip &amp; knee flexed, apply: Medial: valgus force and internal rotate foot Lateral: varus force and externally rotate foot</td>
<td>Click, pop, or reproduces pain</td>
</tr>
<tr>
<td>Noble Compression</td>
<td>IT band</td>
<td>Patient lies on unaffected side, flex knee while pressure applied to distal IT band (lateral epicondyle)</td>
<td>Click, pop, or reproduces pain</td>
</tr>
<tr>
<td>Patellar compression</td>
<td>Patello-femoral pain</td>
<td>With knee extended and quads relaxed, apply direct pressure to anterior patella as patient tightens quads</td>
<td>Reproduces pain</td>
</tr>
<tr>
<td>Patellar apprehension</td>
<td>Patello-femoral pain</td>
<td>With knee flexed to 30°, displace patella laterally</td>
<td>Patient grimaces or tries to straighten leg</td>
</tr>
</tbody>
</table>
<p>Imaging</p>
<ul>
<li>X-ray: b/l AP, unilateral, lateral, b/l sunrise view</li>
<li>Obtain X-rays in standing position (or joint space narrowing may not
    be apparent)</li>
<li>MSK U/S: allows for dynamic imaging and is ≈100% sensitive
    for effusion</li>
<li>Also visualizes ligaments, muscles/tendons, joint space,
    and vasculature</li>
<li>MRI:  indicated after failure of conservative management or when
    considering surgical repair</li>
</ul>
<p>Treatment:</p>
<ul>
<li>RICE (rest, ice, compression, elevation) for acute injuries</li>
<li>Bracing</li>
<li>NSAIDs: see prior section for anti-inflammatory dosing</li>
<li>Physical therapy for 4-6 weeks for ligamentous, muscular, or
    meniscal injury</li>
<li>Antibiotics may be appropriate for bursitis if infection
    is suspected</li>
<li>Referral to orthopedics/sports medicine if no improvement after
    conservative therapy<ul>
<li>Surgery reserved for young, athletic people with
    ligamentous injury</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain-neck-pain">Neck Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain-neck-pain" title="Permanent link">&para;</a></h1>
<p>Neck Pain – Samir Khan</p>
<p>Background</p>
<ul>
<li>Neck pain has a prevalence of 10 to 20 percent in the adult
    population</li>
<li>The most common cause of neck pain in adults: Degenerative changes
    of the cervical spine</li>
<li>Most atraumatic neck pain does not require imaging</li>
</ul>
<p>Presentation</p>
<ul>
<li>Cervical muscle strain:  pain <u>+</u> stiffness with movement 2/2
    muscular injury</li>
<li>Degenerative disc disease/osteoarthritis: pain <u>+</u> stiffness
    with movement from derangement in disc architecture leads to
    inability to distribute pressure in the joint</li>
<li>Cervical Radiculopathy: neuropathic pain, sensory abnormalities,
    and/or weakness in an upper extremity (often radiating to hand)</li>
<li>Cervical myelopathy: spinal cord compression causing neurologic
    dysfunction<ul>
<li>Earliest symptom is gait disturbance. Pain is uncommon</li>
</ul>
</li>
<li>Non-cervical conditions: shoulder pathology, migraine/headaches,
    occipital neuralgia, torticollis, thoracic outlet syndrome, angina
    pectoris/MI, bony metastases, vertebral artery or carotid artery
    dissection, fibromyalgia, meningitis, transverse myelitis</li>
<li>Posterior neck pain<ul>
<li>Axial only
    
    MSK (sprain vs degenerative disc disease)</li>
<li>Axial + Extremity Pain -&gt; Radiculopathy</li>
</ul>
</li>
<li>Anterior neck pain<ul>
<li>Common sources: esophageal, thyroiditis, carotidynia,
    lymphadenitis, Ludwig’s angina</li>
</ul>
</li>
<li>Red flags
    : recent trauma, lower extremity weakness, gait abnormality,
    bowel/bladder incontinence, fever, weight loss</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Determine MSK (axial pain) vs Radiculopathy/Myelopathy) vs
    Non-spinal</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Spurling’s test</td>
<td>Cervical radiculopathy</td>
<td>Downward pressure applied to top of head with extended neck and rotates to affected side</td>
<td>Reproducible pain beyond shoulder Neck pain alone is not specific</td>
</tr>
<tr>
<td>Elvey's upper limb tension test</td>
<td>Cervical radiculopathy</td>
<td>Head turn contralaterally, arm is abducted while the elbow extended</td>
<td>Reproduction of symptoms</td>
</tr>
<tr>
<td>Hoffman sign</td>
<td>Corticospinal lesion (UMN)</td>
<td>Loosely hold middle finger and flick the fingernail downward, allowing the middle finger to flick upward reflexively</td>
<td>There is flexion &amp; adduction of thumb/index finger on the same hand</td>
</tr>
</tbody>
</table>
<ul>
<li>Imaging indications: Neuro deficits, Red flags, persistent
    pain (&gt; 6 weeks)</li>
<li>Cervical Plain films, 2-view (AP and lateral)</li>
<li>Cervical MRI: visualizes spinal cord, nerve roots, bone marrow,
    discs and soft tissues<ul>
<li>Usually <strong>w/o contrast</strong> ; can consider contrast if malignancy
    or infection suspected</li>
</ul>
</li>
<li>EMG/Nerve Conduction Studies: not routinely used for neck pain eval,
    but can be used to distinguish cervical radicular pain from
    peripheral causes of extremity dysesthesia</li>
</ul>
<p>Management</p>
<ul>
<li>Cervical strain, Cervical radiculopathy: Physical therapy<ul>
<li>5 d course of oral prednisone 60-80 mg, followed by 7-14 day
    taper</li>
<li>Anti-spasmodic prn: Flexeril or Robaxin</li>
<li>If not improving or progressive symptoms refer to Ortho Spine
    <u>+</u> PM&amp;R</li>
</ul>
</li>
<li>Cervical myelopathy urgent surgical evaluation</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation-pmr-consultation">PM&amp;R Consultation<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation-pmr-consultation" title="Permanent link">&para;</a></h1>
<p>PM&amp;R Consultation – Evan Berlin, Scott Miller, Adam Epps, Lauren Massey</p>
<p>Reasons for Consultation/Referral to PM&amp;R:</p>
<ul>
<li>If PT/OT recommends Inpatient Rehabilitation (IPR) for post-acute
    disposition<ul>
<li>Recommended for pts with: SCI, TBI, Poly-trauma, CVA,
    Amputation, Burns, Critical Illness /Acute Polyneuropathies or
    Myopathies, Prolonged Hospitalization</li>
</ul>
</li>
<li>Benefits
    of PM&amp;R Consults include:<ul>
<li>Confirms
    and facilitates post- acute rehab disposition (SNF vs IPR
    refined opinion)</li>
<li>Provides
    comprehensive document for Insurance and Post-Acute provider
    resource</li>
<li>Facilitates
    communication avenue between PM&amp;R consultant, Primary Team, TMO</li>
<li>Case
    management, PT/OT, and Post- acute rehab provider</li>
<li>Provision
    of bedside MSK ultrasound-guided injections: joint injections
    (small and large), bursa injections, peripheral nerve injections
    (lateral femoral cutaneous, carpal tunnel, cubital tunnel) and
    diagnostic joint aspirations</li>
<li>Co-management for ac
    ute or chronic spasticity, neurogenic bowel and bladder,</li>
<li>Can
    be helpful in identifying equipment required for discharge<ul>
<li>
<ul>
<li>Gait impairments of uncertain etiology impacting post-
        acute care disposition safety</li>
<li>Autonomic dysreflexia</li>
<li>Paroxysmal sympathetic hyperactivity associated with
    brain injury</li>
<li>Contracture, pressure wound insight or prevention</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options-rehabilitation-options">Rehabilitation Options<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options-rehabilitation-options" title="Permanent link">&para;</a></h1>
<p>Rehabilitation Options – Evan Berlin, Scott Miller, Adam Epps, Lauren
Massey</p>
<ul>
<li>Physical
    medicine and rehabilitation (PM&amp;R) physicians focus on restoring
    function and quality of life to those with physical impairments or
    disabilities affecting the brain, spinal cord, nerves, bones,
    joints, ligaments, muscles and tendons</li>
<li>Physiatrists
    specialize in determining appropriate rehab options for hospitalized
    patients</li>
</ul>
<!-- -->

<ul>
<li>Acute Inpatient Rehabilitation (IPR) or Inpatient Rehabilitation
    facility (IRF):<ul>
<li>IPR involves a multidisciplinary team of physicians, physical
    therapists, occupational therapists, speech and language
    pathologists</li>
<li>Pts admitted to IPR must be able to tolerate a minimum of 3 hrs
    of rehab per day for 5 days a week</li>
<li>Pts must have medical complexity warranting medical supervision
    by a physician</li>
<li>Physicians are required to evaluate admitted patients at least 3
    times a week</li>
<li>Average length of stay (LOS) in acute inpatient rehab is 12 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Skilled Nursing Facility (SNF):<ul>
<li>Patients admitted to SNF require skilled needs: Wound care, IV
    therapy, Catheter care, PT, OT, and/or SLP</li>
<li>There are no minimal requirements for daily therapy, but
    patients may receive up to 1.5 hrs/day, depending on
    availability at the facility (in practice it is often less than
    this)</li>
<li>Physicians are required to evaluate admitted patients at least
    once every 30 days</li>
<li>Average length of stay is 26 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Long-Term Acute Care Hospital (LTACH):<ul>
<li>Pts admitted to LTACH require extended hospitalization and
    include pts who will be receiving prolonged mechanical
    ventilation</li>
<li>Pts will be recommended for transfer to an LTACH when no
    reasonable functional or medical improvement can be expected in
    an acute inpatient stay</li>
<li>LTACHs can be within a hospital or may be free-standing</li>
<li>Average length of stay must be greater than 25 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Assisted Living:<ul>
<li>Pts receive a combination of long-term housing, personal care
    services, and health care</li>
<li>Designed for individuals who need assistance with activities of
    daily living</li>
<li>Can be provided in freestanding communities, near or integrated
    with SNFs,  hospitals or retirement communities</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Outpatient Services:<ul>
<li>Can be ordered at discharge with or without official PT/OT
    recommendations</li>
<li>Home health (HH): wide range of healthcare services provided in
    patients home ranging from wound care to IV antibiotics</li>
<li>HH PT/OT: pts can receive therapy at home when unable to attend
    outpatient PT/OT</li>
<li>HH nursing services: required for IV antibiotics or PICC line
    maintenance; consider for wound care, other services include
    medication adherence and reconciliation</li>
<li>HH non-skilled aide: outside the scope of acute hospitalization,
    but helps with ADLs</li>
<li>Outpatient PT/OT: Consider for those who would benefit from
    therapy but do not meet the qualifications for other
    dispositions or would prefer outpatient therapy<ul>
<li>Pt would attend therapy sessions at an outpatient clinic</li>
<li>If a pt is receiving other HH services, they do not qualify
    for outpatient PT/OT</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain-shoulder-pain">Shoulder Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain-shoulder-pain" title="Permanent link">&para;</a></h1>
<p>Shoulder Pain – Joseph Nowatzke</p>
<p>Background</p>
<ul>
<li>Bones:
    Clavicle, Scapula (Acromion and Coracoid process) and Proximal
    Humerus</li>
<li>Rotator Cuff: Supraspinatus, Infraspinatus, Teres minor,
    subscapularis</li>
<li>Neurovascular: anterior and posterior circumflex humeral arteries,
    branching off axillary artery; Innervated by axillary,
    suprascapular, subscapular nerve off
    brachial plexus</li>
<li>Labrum is a cup-shaped rim of cartilage lining and reinforces the
    shoulder joint by surrounding the glenoid fossa, allowing extra
    support to the head of the humerus</li>
</ul>
<p>Presentation</p>
<ul>
<li>Brachial Plexus Palsies</li>
<li>Vascular Pathology (e.g. thoracic outlet syndrome, thrombus,
    atherosclerosis, vasculitis)<ul>
<li>Typical symptoms are tightness, heaviness, cramping, or weakness
    in arm</li>
</ul>
</li>
<li>Rotator Cuff Injuries:<ul>
<li>Impingement Syndrome: supraspinatus is most susceptible</li>
<li>Tendinopathy: develops after repetitive motions; pain worsens
    with active movement</li>
<li>Tendon Tear: develop as a progression of tendinopathy; develops
    weakness</li>
</ul>
</li>
<li>Labral Tear &amp; SLAP (superior labral tear from anterior to
    posterior): develop in repetitive overhead motions (swimming,
    baseball, tennis); often described as a “catching” sensation</li>
<li>Adhesive capsulitis: “frozen shoulder” stiffened glenohumeral joint,
    loss of both active and passive RoM. Increased frequency in
    diabetics</li>
<li>AC (acromioclavicular) joint pain: joint often affected by OA, RA
    and common cause for anterior shoulder pain shoulder separations
    and osteoarthritis</li>
<li>Glenohumeral OA: degeneration of articular cartilage and subchondral
    bone with narrowing of the glenohumeral joint. Presents in older
    adults with progressively worsening anterior shoulder pain and
    stiffness in both passive and active ROM</li>
<li>Biceps Tendinopathy: localized anterior shoulder pain, worsened with
    overhead lifting; when rupture develops, will often have a “lump”
    and acute worsening of symptoms</li>
<li>Posterior shoulder pain often related to cervical radiculopathy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection: Symmetry, erythema, ecchymosis, swelling, deformity,
    muscle atrophy (deltoid, infraspinatus), scapular winging</li>
<li>Palpation: warmth, landmarks, tenderness: SC joint, clavicle, AC
    joint, acromion, spine of scapula, bicipital groove, biceps
    tendon, greater tuberosity of humerus, common myofascial trigger
    points (trapezius, levator scapulae, rhomboids, supraspinatus)</li>
<li>Passive ROM: performed by the examiner without patient
    assistance<ul>
<li>Helps to distinguish motion limitations caused by a
    structural constraint (adhesive capsulitis) vs. motion
    limitations caused by pain</li>
</ul>
</li>
<li>Active ROM: performed by the pt on their own. Loss of active
    motion usually indicates weakness due to either muscular (tears)
    or nerve injury</li>
<li>C-spine: evaluate the C-spine as the origin of pain that may be
    referred to the shoulder</li>
<li>Provocation tests: see Below</li>
</ul>
</li>
<li>Imaging:<ul>
<li>Not as useful as a thorough physical exam, especially if
    non-traumatic pain</li>
<li>XR: AP (Internal Rotation, External Rotation), Lateral, Scapular
    and axillary views</li>
<li>CT: often reserved for traumatic fracture and artificial joint
    assessment</li>
<li>MRI w/out contrast: used to evaluate soft tissues, tendons,
    muscle and bursae</li>
<li>Ultrasound: becoming more useful for initial evaluation of
    rotator cuff</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Empty Can Test</td>
<td>Supraspinatus</td>
<td>Place arms at 80⁰ abduction, 30⁰ forward flexion and pronate hand with thumbs down; exert downward force at elbows</td>
<td>Pain -&gt; tendinopathy Weakness + pain -&gt; tear</td>
</tr>
<tr>
<td>Neer sign</td>
<td>Subacromial impingement</td>
<td>Passively flex arm with hand pronated (similar to empty can)</td>
<td>If pain -&gt; subacromial impingement</td>
</tr>
<tr>
<td>External Rotation</td>
<td>Infraspinatus, teres minor</td>
<td>Arms at side, flex 90⁰ elbow, exert medial force to distal forearm</td>
<td>Weakness, pain</td>
</tr>
<tr>
<td>Lag sign &amp; Lift-Off test</td>
<td>Subscapularis</td>
<td>Place dorsum of hand on lumbar area of back and actively and passively move hand off of back</td>
<td>Pain or failure to perform indicates subscapularis pathology</td>
</tr>
<tr>
<td>Cross arm test</td>
<td>AC joint</td>
<td>Active abduction of arm across torso</td>
<td>Pain -&gt; AC joint dysfunction</td>
</tr>
<tr>
<td>Speed’s Test</td>
<td>Biceps Tendon</td>
<td>Have pt extend arm in full supination with the shoulder flexed. Ask pt to elevate arm while applying downward force</td>
<td>Pain in the anterior shoulder  Biceps tendon pathology</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Fractures: require assessment by orthopedics for reduction and
    surgical intervention</li>
<li>Soft Tissue Injuries, Arthritis</li>
<li>Conservative management: referral to physical therapy for muscle
    strengthening, flexibility, and postural improvement.</li>
<li>Consider short course of NSAIDs, 7-10 days (meloxicam, diclofenac)
    for pain relief</li>
<li>Injections can often be diagnostic and therapeutic – refer to ortho</li>
<li>Sports Medicine referral for surgical evaluation if pt fails
    conservative therapy</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Physical medicine rehabilitation</h1>
                        <h1 class='nav-section-title' id='section-procedures'>
                            Procedures <a class='headerlink' href='#section-procedures' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="procedures-procedures-anesthesia"><h1 id="procedures-procedures-anesthesia-anesthesia">Anesthesia<a class="headerlink" href="#procedures-procedures-anesthesia-anesthesia" title="Permanent link">&para;</a></h1>
<ul>
<li>May be used in which a pt’s pain or anxiety may impede performance
    and success</li>
<li>Relative Contraindications: old age, dementia, respiratory
    difficulty</li>
<li>Aim to use local anesthesia and minimize procedural sedation</li>
<li>Local Anesthesia: lidocaine 1% or 2% – add Epi if &gt;30 mins of
    analgesia required</li>
<li>Creating wheal: clean surface w/ chlorhexidine or alcohol swab; with
    22-25G needle, advance needle parallel to skin and aspirate to
    ensure no blood vessel involved, then inject anesthetic to create
    1-2 cm of raised skin; If deeper subcutaneous anesthesia is needed,
    advance needle perpendicular to skin, aspirate as advancing then
    inject the tract. Inject anesthetic as needle withdrawn.</li>
<li>Local anesthesia can alter landmarks, always double check anatomy
    after injection</li>
<li>Minimal Sedation: 0.25mg-2mg Ativan IV or 1mg-2.5mg Midazolam IV</li>
<li>Midazolam (Versed): faster on (2-5 min) and faster off (30-60 min)</li>
<li>Lorazepam (Ativan): onset 5-10 min; Duration 4-8 hours</li>
</ul></section><section class="print-page" id="procedures-procedures-anticoagulation-parameters"><h1 id="procedures-procedures-anticoagulation-parameters-anticoagulation-parameters">Anticoagulation Parameters<a class="headerlink" href="#procedures-procedures-anticoagulation-parameters-anticoagulation-parameters" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure</td>
<td>PLT &amp; INR</td>
</tr>
<tr>
<td>Paracentesis</td>
<td>PLT > 20k, INR \&lt; 4 *</td>
</tr>
<tr>
<td>Central Line</td>
<td>PLT > 20k, INR \&lt; 3</td>
</tr>
<tr>
<td>Thoracentesis</td>
<td>PLT > 50k, INR \&lt; 2 *</td>
</tr>
<tr>
<td>Lumbar Puncture</td>
<td>PLT > 50k, INR \&lt; 1.6</td>
</tr>
<tr>
<td>US PIV</td>
<td>PLT > 10k, no INR</td>
</tr>
<tr>
<td>DHT</td>
<td>PLT > 10k, no INR</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulant</td>
<td>When to Hold</td>
</tr>
<tr>
<td>Heparin gtt</td>
<td>4-8 hours, ensure PTT wnl</td>
</tr>
<tr>
<td>LMWH</td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Dabigitran</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Eliquis</td>
<td>1-2 day</td>
</tr>
<tr>
<td>Xarelto</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Warfarin</td>
<td>5-7 days</td>
</tr>
</tbody>
</table></section><section class="print-page" id="procedures-procedures-arterial-line"><h1 id="procedures-procedures-arterial-line-arterial-line">Arterial Line<a class="headerlink" href="#procedures-procedures-arterial-line-arterial-line" title="Permanent link">&para;</a></h1>
<p>Pre-procedure considerations</p>
<ul>
<li>Palpate of artery of interest to best understand anatomy and
    surrounding structures</li>
<li>Allen Test if placing radial artery access: goal to assess
    collateral ulnar blood flow to avoid ischemia. Hold both radial and
    ulnar artery 10-15 sec to allow blanching of palm, then release
    ulnar artery to assess perfusion. If blanching quickly resolve,
    ulnar artery will allow distal perfusion</li>
<li>If attempting radial access, ensure wrist is adequately extended,
    often using towel roll under wrist and taping hand to bed or table</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>Types of Kits<ul>
<li>Arrow kit: all-in-one device that has arterial catheter over
    introducer needle</li>
<li>A-line kit: individual introducer needle, guidewires, and
    sutures; multiple steps</li>
<li>Micropuncture kit: atraumatic guidewire, microcatheter and
    introducer sheath</li>
</ul>
</li>
<li>Reconfirm location with US after lidocaine</li>
<li>Ensure arterial access (pulsatile flow of bright red blood)</li>
</ul>
<p>Post- procedure considerations</p>
<ul>
<li>Immediately connect pressure tubing to catheter while maintaining
    sterile technique</li>
<li>If persistent bleeding, hold pressure for 15 mins.</li>
<li>Can use for frequent ABG checks</li>
</ul></section><section class="print-page" id="procedures-procedures-central-line"><h1 id="procedures-procedures-central-line-central-line">Central line<a class="headerlink" href="#procedures-procedures-central-line-central-line" title="Permanent link">&para;</a></h1>
<p>Video guide:</p>
<p><a href="https://www.youtube.com/watch?v=qeVdRCqy_mo">https://www.youtube.com/watch?v=qeVdRCqy_mo</a></p>
<p>Indications</p>
<ul>
<li>Extracorporeal therapies: HD, CRRT, Plasma (PLEX) or RBC exchange
    transfusion</li>
<li>Venous access for: Vasopressors, Chemotherapy, Parenteral nutrition,
    Hemodynamic monitoring (CVP, ScvO2), and cardiac parameters (via
    pulmonary artery catheter)</li>
</ul>
<p>Contraindications: No true absolute contraindications</p>
<p>Pre-procedural considerations</p>
<ul>
<li>All patients need to have telemetry &amp; pulse oximetry monitoring</li>
<li>With every pt, consider LENGTH, LOCATION, LUMENS, and LINE TYPE!</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Line</td>
<td>Short Stature (\&lt;5’5”)</td>
</tr>
<tr>
<td>Right IJ, Subclavian</td>
<td>\&lt;15 cm</td>
</tr>
<tr>
<td>Left IJ, Subcalvian</td>
<td>\&lt;20 cm</td>
</tr>
<tr>
<td>Femoral</td>
<td>\&lt;25 cm</td>
</tr>
<tr>
<td>Confirm length of catheter in your kit before you open/place the line!</td>
<td>Confirm length of catheter in your kit before you open/place the line!</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td>Internal Jugular Vein</td>
<td>Minimal risk of PTX; improve target with positioning and use of US; easily compressible if bleeding occurs</td>
<td>Risk of carotid puncture; difficult in obese pt; vein collapsibility with hypovolemia</td>
</tr>
<tr>
<td>Subclavian</td>
<td>More comfortable for pts; landmark driven approach; lowest risk of infection</td>
<td>Increased risk of PTX, harder to control bleeding with pressure; technically more difficult</td>
</tr>
<tr>
<td>Femoral</td>
<td>Easiest to access; no risk of PTX; can be placed during CPR and intubation</td>
<td>High risk of infection and difficult to sterilize; patient unable to move; higher thrombotic risk</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Line</td>
<td>Uses</td>
<td>Special Consideration</td>
</tr>
<tr>
<td>Triple Lumen (7Fr)</td>
<td>Most common line placed; used for central access for vasopressors, caustic infusions (chemo)</td>
<td>Consider lumens needs; triple lumen is most versatile but can warrant dual lumen</td>
</tr>
<tr>
<td>MAC or Cordis*</td>
<td>‘Short and fat’ allowing rapid transfusion; MAC has two ports</td>
<td>MAC is placed with dilator still in introducer</td>
</tr>
<tr>
<td>Dialysis Catheter (Trialysis, 12 Fr)</td>
<td>Dialysis line with two 12 Ga. Lumens for dialysis with a third 17 Ga. lumen for added access</td>
<td>Two serial dilations</td>
</tr>
</tbody>
</table>
<p>*Can place triple lumen in MAC for additional ports; lose ability to
rapidly transfuse</p>
<p>Procedural considerations</p>
<ul>
<li>Numb pt right after draping, then set up everything to allow time
    for lidocaine to work</li>
<li>Set supplies up in exactly the order of use to ensure all are
    present and functioning</li>
<li>Cap side ports with blue claves (not included in Trialysis kit)
    prior to flushing</li>
<li>For IJ access, place patient in slight Trendelenburg position to
    engorge vein</li>
<li>While advancing needle, ensure constant negative pressure with
    aspiration of plunger and visualization of needle tip with US</li>
<li>Always ensure guidewire is secured while it is inside a vein</li>
<li>Always ensure target for venous cannulation is visualized and
    guidewire is placed correctly prior to dilation: 1) Compression of
    target vessel 2) Non-pulsatile dark blood return (unless on
    100%FiO2, may be brighter red) 3) US visualization or needle and
    wire 4) can use pressure tubing and angiocath to confirm CVP or
    obtain venous O2 sat</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>Every IJ or subclavian central line needs a confirmation CXR to
    confirm no PTX</li>
<li>Ideal placement of distal tip: in SVC just outside the right atrium.
    Approximately near/superior to carina and right tracheobronchial
    angle</li>
<li>Troubleshooting Complications:<ul>
<li>Arterial Access or puncture: immediately remove needle and place
    non-occlusive pressure for 15 mins to prevent hematoma
    formation; if uncontrolled bleeding or artery was dilated, STAT
    vascular surgery consult</li>
<li>Bleeding: place direct pressure; subclavian access precludes
    ability to compress and confers highest bleeding risk; if
    uncontrolled, STAT vascular surgery consult</li>
<li>Pulmonary Complications: if free air aspirated into syringe,
    consider PTX vs poor seal of syringe &amp; needle. Close attention
    to pulmonary complication &amp; STAT CXR to assess PTX. If rapid
    deterioration, needle decompression and chest tube placement
    required</li>
<li>Venous Air Embolism: can occur if air introduced to system
    during placement, flushing, or if left open to the atmosphere.
    Effects are variable, but if suspected, place pt in left lateral
    decubitus position to trap air in right apex and place pt on
    100% O2 to speed resorption</li>
<li>Arrhythmia: rationale for telemetry monitoring as guidewire
    often leads to atrial or ventricular arrhythmias; Immediately
    withdraw wire to lesser depth. If arrythmia persists, abort
    procedure and treat patient and determine cause</li>
</ul>
</li>
</ul></section><section class="print-page" id="procedures-procedures-consent"><h1 id="procedures-procedures-consent-consent">Consent<a class="headerlink" href="#procedures-procedures-consent-consent" title="Permanent link">&para;</a></h1>
<ul>
<li>When printing Consents at VUMC, use MedEx (on the virtual
    machine/desktop)</li>
<li>Ensure pt’s signature; Telephone consent requires second physician
    as witness</li>
<li>Use CSN (not the MRN) to locate the pt information for that specific
    admission or office visit – ensure patient current room number on
    MedEx screen</li>
<li>When consenting pts at NAVA, use the COW with pen pad and the
    I-Consent program</li>
<li>Video guide:
    <a href="https://www.youtube.com/watch?v=6yXOEkFqk2o">https://www.youtube.com/watch?v=6yXOEkFqk2o</a></li>
</ul>
<p>Lumbar Puncture</p>
<ul>
<li>Common risks: backache (~66%), severe headache</li>
<li>Rare risks: spinal hematoma (\&lt;0.001%), weakness, numbness, brain
    function problems, CNS infection, brain herniation</li>
</ul>
<p>Paracentesis</p>
<ul>
<li>Risks: abdominal wall hematoma (1%), hemoperitoneum, organ puncture,
    infection</li>
</ul>
<p>Thoracentesis</p>
<ul>
<li>Common risks (&gt; 5%): coughing, fainting, PTX</li>
<li>Rare risks (\&lt; 1%): hemothorax, emergency surgery, re-expansion
    pulmonary edema</li>
</ul>
<p>Arthrocentesis</p>
<ul>
<li>Common risks: pain during procedure, repeat needle insertion</li>
<li>Rare: damage to surrounding vessels, nerves; iatrogenic septic
    arthritis: (\&lt;0.1%)</li>
</ul>
<p>Dobhoff Tube Placement</p>
<ul>
<li>Common risks: Malpositioned (lung)/coiled tube; perforation anywhere
    along the tract; cranial placement; aspiration, gastritis, bleeding,
    vagal response, significant discomfort</li>
<li>Contraindications: SBO, ileus; use large bore NGT instead (placed by
    bedside nurse)</li>
</ul>
<p>US-Guided PIV Placement</p>
<ul>
<li>Common risks: arterial puncture, nerve irritation/damage
    during/after procedure, infection, infiltration, thrombus formation</li>
</ul></section><section class="print-page" id="procedures-procedures-dht"><h1 id="procedures-procedures-dht-dht">DHT<a class="headerlink" href="#procedures-procedures-dht-dht" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=qUh5AJ5uIZo">https://www.youtube.com/watch?v=qUh5AJ5uIZo</a></p>
<p>Indications</p>
<ul>
<li>Enteral feeding if unable to swallow; passing meds</li>
<li>DHT deliver meds and fluids, NGT provide suction to decompress (can
    also deliver meds/fluids); nurses place NGT, residents (and ICU
    nurses) place DHT</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>Esophageal varices or strictures (most hepatologists say this is not
    a contra-indication)</li>
<li>Other altered gastric anatomy that may prevent passage. (i.e.
    gastric bypass, esophageal hernias, tumors or other possible
    obstructions).</li>
</ul>
<p>Absolute Contraindications for blind approach</p>
<ul>
<li>Facial (increased risk of intracranial placement), pharyngeal or
    esophageal trauma</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>Silicone-based, flexible tubing, less than 12fr in size, can be left
    in place for longer periods of time. NGTs are PVC-based, more rigid,
    and larger allowing gastric decompression</li>
<li>Prior to placement, fully fasten the stylet in the fully-hubbed
    position to reduce bending and folding over of the weighted tip
    while advancing</li>
<li>Make sure DHT and bridle sizes correlate</li>
</ul>
<p>Group consensus and recommendations</p>
<ul>
<li>Anesthetic use with lidocaine gel (order Lidocaine uro-jet) and
    nasal swab; reduces pt discomfort, reduces gag reflex, and assists
    with clearance of the nasal passages</li>
<li>Have the patient sit upright with the head tilted toward the chest
    to encourage posterior oropharynx positioning of the DHT while
    advancing.</li>
<li>If pt can participate safely, have the patient swallow before
    advancement; pt can suck on straw to utilize pharyngeal muscles to
    position DHT into esophagus</li>
<li>Excessive coughing, difficulty phonating, or resistance may indicate
    trachea placement. Withdraw tube and re-attempt. Consider Duoneb to
    reduce bronchospasms</li>
<li>3 failed attempts should be made at the bedside before sending for
    fluoro-guidance</li>
<li>When post-pyloric placement is requested, 1 attempt at post-pyloric
    placement with the blind approach at the bedside is acceptable
    before referring to fluoroscopic guidance</li>
</ul>
<p>Placement Tips &amp; Tricks</p>
<ul>
<li>Insufflation of air and auscultation of bowel sounds over the
    gastric area can be reassuring of correct placement of DHT prior to
    bridling and leaving the bedside.  Always obtain KUB for
    radiological confirmation of placement. Leaving the stylet in for
    confirmation can make it easier to see on KUB and can allows
    re-advancement</li>
<li>Place bridle and dog-bone tape while at the bedside to reduce
    dislodgement</li>
<li>When placing bridle, keep alignment markers (as clearly marked on
    both probes) together so magnetic tips will align once past the
    nasal septum</li>
<li>When placing the bridle, remove the green stylet housed within the
    white probe before retracting back and removing the white probe</li>
</ul>
<p>Post-pyloric placement</p>
<ul>
<li>Consider in patients with high pulmonary aspiration risk and severe
    esophageal reflux/esophagitis, recurrent emesis, impaired gastric
    motility, and pancreatitis</li>
<li>Post-pyloric placement has been shown up to 90% successful with
    intermittent insufflation of 10-20cc of air ~every 10cm of
    advancement after 55cm to promote pylorus opening. IV Reglan or
    Erythromycin may also help</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>ALWAYS confirm the position radiographically before medications are
    given!</li>
<li>Most mispositioned/coiled tubes have to be removed and re-attempted,
    but it is ok to advance or withdraw if Stylet is still in place.
    However, once removed, a stylet should not be re-introduced to a
    mispositioned/coiled tube due to risk of GI perforation</li>
<li>Listen to the patient, repeat imaging (Plain film or CT) if concern
    for any perforation, and notify appropriate surgical service.</li>
<li>In case of cranial placement, don’t remove, consult NSGY</li>
<li>De-clogging: Clog Zapper Kit (can type this into Epic directly);
    Coca cola</li>
</ul></section><section class="print-page" id="procedures-procedures-lumbar-puncture"><h1 id="procedures-procedures-lumbar-puncture-lumbar-puncture">Lumbar Puncture<a class="headerlink" href="#procedures-procedures-lumbar-puncture-lumbar-puncture" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=xnH9gECy_wU">https://www.youtube.com/watch?v=xnH9gECy_wU</a></p>
<p>Absolute Contraindications</p>
<ul>
<li>Increased intracranial pressure from space occupying lesions</li>
<li>Infection over puncture side or epidural abscess</li>
<li>Trauma to mass or lumbar vertebrae</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>↑
    intracranial pressure, thrombocytopenia, bleeding diatheses,
    anticoagulation</li>
</ul>
<p>Pre-procedure considerations:</p>
<ul>
<li>Consider sending to fluoro-guided if: Attempts without imaging are
    unsuccessful, morbidly obese pts with no palpable anatomy, severe
    scoliosis, prior spine surgery, borderline low Plts and multiple
    sticks might be needed, or pt requires heavy sedation</li>
<li>IR guidelines require Plavix to be off 5 days; ASA alone is OK</li>
<li>Full dose LMWH must be off 24h, ppx LMWH off 12h, ppx heparin off
    8h, hep gtt off 4-8hrs with repeat lab demonstrating normalized PT</li>
<li>P2Y12 inhibitors should be held for 7 days to avoid bleeding risks</li>
<li>Labs: cell count w/diff, BF culture, glucose, protein; if infectious
    or neurological labs are needed, consider consult first Try to
    freeze sample for future labs (order in epic).</li>
<li>Ensure lateral decubitus position for open pressure with glass
    pressure manometer</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>US Probe: Linear (can use curvilinear in obese pts) in transverse
    axis to establish midline &amp; in sagittal axis to identify spinous
    processes</li>
<li>Volume removal for studies: Basic only 2mL per tube in 1-4. Many
    studies ordered: 3mL per tube (*consider calling lab to confirm).
    Cytology desired: call lab to confirm amount needed (rule of thumb
    2/2/6/2mL); Tube 4 is sent for micro to reduce contamination.
    Therapeutic high volume: 30mL max</li>
<li>Anesthetic use: Lidocaine 1-2% (likely need more than what is
    provided in kit; consider empiric anesthetization of 2 spaces &plusmn;
    Pain-Ease spray.</li>
<li>Increased number of attempts = increased success rates</li>
<li>Higher rate of success if stylet is removed before entering
    subarachnoid space to better observe flow of CSF once in the
    subarachnoid space. Stylet should be replaced prior to LP needle
    removal</li>
<li>Aspiration of CSF = increase risk of bleeding. Don
    ’
    t do that!</li>
</ul>
<p>Post-procedural considerations <span id="_Hlk64109621"></span></p>
<ul>
<li>Post-LP headache
    (~10%): encourage pt to lay flat to reduce the intensity of
    symptoms (but does not prevent it); if prolonged, consider blood
    patch (c/s Anesthesia)</li>
<li>Neuro changes OR bleeding complications: STAT non-contrast MRI
    lumbar spine for epidural hematoma, q1 neuro-checks x4hrs then q2
    for 24-48hrs &amp; consult NSGY</li>
<li>Sample cannot be tubed; someone must walk fluid to the lab</li>
<li>Resuming anticoagulation: 1h UFH, 4h LMWH, 4-6h
    rivaroxaban/apixaban, 6h dabigatran/fondaparinux. Longer periods
    should be considered after traumatic tap, and post-procedure
    monitoring of neurological function is recommended for all pts</li>
</ul></section><section class="print-page" id="procedures-procedures-paracentesis"><h1 id="procedures-procedures-paracentesis-paracentesis">Paracentesis<a class="headerlink" href="#procedures-procedures-paracentesis-paracentesis" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s">https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s</a></p>
<p>Indications</p>
<ul>
<li>Diagnostic: Evaluation of new onset ascites, or known ascites in pts
    with clinical decompensation, fever, abdominal pain/tenderness, HE,
    leukocytosis, AKI</li>
<li>Therapeutic: large volume ascites resistant to diuretics causing pt
    discomfort</li>
</ul>
<p>Pre-Procedural considerations</p>
<ul>
<li>If therapeutic, determine volume pt typically gets drained so you
    have enough bottles</li>
<li>Labs (order before so nurse can print off labels): cell count
    w/diff, BF culture, BF &amp; serum albumin, total protein; cytology if
    c/f malignancy; BF/serum Hct if bloody</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>Ultrasound Probe: curvilinear, to identify safe pocket (~2 cm)</li>
<li>Kit: 6 Fr Safe-T-Centesis Kit</li>
<li>If only diagnostic, use 18G needle with 20-50cc syringe rather than
    kit</li>
<li>If high bleeding risk, use long 18 g. needle &amp; attach to syringe
    instead of 6 Fr. Catheter</li>
<li>Avoid surgical scars out of concern for nearby adhesions and
    superficial veins</li>
<li>Z-track
    method: may reduce post-paracentesis ascitic fluid leakage. Once
    into subcutaneous tissue, move superior/inferior to allow tissue
    overlap.</li>
<li>Attempt as lateral as possible to avoid inferior epigastric vessels</li>
<li>Roll patient to left or right side to promote pooling of fluid for
    easier/safer access</li>
<li>Inoculate culture bottles at bedside rather than sending fluid
    samples to lab for inoculation to increase yield 50%
    
    80% (VA does not allow bedside inoculation.)</li>
<li>If hernia present, have patient reduce it while draining fluid to
    prevent incarceration</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>Albumin for large volume (&gt;5L): give 8 grams per liter removed</li>
<li>Ascitic leak: roll pt on opposite side; place 1 figure-of-eight
    stitch with 4.0 vicryl</li>
<li>Bleeding complication – Hold pressure with quick-clot and gauze
    for &gt;5-10 if persistent bleeding at site; if profuse bleeding or
    concern for organ injury, STAT page EGS</li>
</ul></section><section class="print-page" id="procedures-procedures-thoracentesis"><h1 id="procedures-procedures-thoracentesis-thoracentesis">Thoracentesis<a class="headerlink" href="#procedures-procedures-thoracentesis-thoracentesis" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=ivTyH09BcHg">https://www.youtube.com/watch?v=ivTyH09BcHg</a></p>
<p>Indications</p>
<ul>
<li>New pleural effusion (that has no obvious explanation)</li>
<li>Any respiratory symptoms that would positively respond to large
    volume thoracentesis</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>If loculations present on US, high risk, or any question about
    indication, refer to Pulm</li>
<li>Labs (order before so nurse can print labels): cell count w/diff; BF
    culture, BF &amp; serum LDH, BF &amp; serum total protein; BF &amp; serum Hct if
    bloody; cytology if c/f malignancy</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>US Probe: Cardiac (or Linear) to identify safe pocket between lung
    and diaphragm</li>
<li>Kit:  6Fr Safe-T-Centesis kit</li>
<li>Upright position is typically preferred; lateral to mid-scap/mid-ax.
    If patient unable to sit upright, refer to procedure team vs
    pulmonology</li>
<li>Effusion size: if unable to tap above 9 <sup>th</sup> rib, too
    small; CXR with costophrenic angle blunting should correlate to
    ~250-500mL</li>
<li>Keep patient in same position throughout</li>
<li>Superior to rib to avoid nerve bundles and vessels</li>
<li>Stop if pt has any new/increased chest discomfort, aggressive
    unremitting cough, frank purulence or air on aspiration,
    lightheadedness, hypotension, or vagal response.</li>
<li>Stop fluid removal after 1.5 L of chronic pleural effusion to reduce
    re-expansion pulmonary edema. May also reduce PTX. Check U-shaped
    manometry every 400-500 cc to assess intrathoracic pressure; avoid
    pressures more negative than -15-20 cm H2O</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>If needing cytology, send at least 60
    –
    100cc</li>
<li>Bleeding complication: STAT page Thoracic Surgery</li>
<li>PTX: if pt stable &amp; asymptomatic, supplemental O2 and repeat CXR in
    4hrs; if unstable/symptomatic STAT page to Thoracic Surgery</li>
<li>Re-expansion pulmonary edema: persistent cough, frothy sputum.
    Diffuse GGO on side of thoracentesis. Supportive management (oxygen,
    monitor); most resolve in 24-48 hrs. If respiratory distress
    progresses, may need mechanical ventilation.</li>
<li>Documentation:  Effusion US characteristics (anechoic, laying
    debris, septations) Reason for ending procedure (stopped early due
    to chest discomfort/cough, complication vs tapped dry); presence of
    lung sliding/whether more than scant residual effusion remains
    post-procedure by ultrasound</li>
<li>A routine chest radiograph after thoracentesis is no longer
    indicated for most asymptomatic, non-ventilated patients. Check lung
    slide with US in 2D and M-mode</li>
</ul></section><section class="print-page" id="procedures-procedures-ultrasound-guided-peripheral-iv"><h1 id="procedures-procedures-ultrasound-guided-peripheral-iv-ultrasound-guided-peripheral-iv">Ultrasound-Guided Peripheral IV<a class="headerlink" href="#procedures-procedures-ultrasound-guided-peripheral-iv-ultrasound-guided-peripheral-iv" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=GQGhciB6TvM">https://www.youtube.com/watch?v=GQGhciB6TvM</a></p>
<p>Relative Contraindications</p>
<ul>
<li>Infection over the site, Hemodialysis in that arm (unless cleared by
    renal), Severe bleeding diathesis</li>
<li>We avoid EJs due to airway compromise if extravasation occurs</li>
</ul>
<p>Pre-procedure considerations</p>
<ul>
<li>Location selection: anuric AKI or ESRD patients – d/w renal</li>
<li>Target selection should follow the rule of 2s. Vein must be at least
    twice the diameter of the catheter being placed, should be no more
    than 2 inches in depth from the surface of the skin, and should have
    at least 2 inches of straight (non-tortuous) length</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>US Probe: Linear</li>
<li>Kit: IV start kit; ideally 18G needle</li>
<li>Anesthetic use: Consider EMLA</li>
<li>1 <sup>st</sup> choice: basilic vein; 2 <sup>nd</sup> choice:
    brachial vein</li>
<li>Use tourniquet; start at 45
    ° angle</li>
<li>Going too shallow could use up too much catheter leaving nothing to
    put in the vein.</li>
<li>Going too steep can cause catheter kinking at the hub where it
    sticks out of the skin</li>
<li>Hold probe close to skin, holding probe far from the end allows too
    much movement</li>
<li>Center the vessel on the ultrasound probe screen prior to sticking</li>
<li>Use both short axis and long axis views to ensure correct placement</li>
<li>Short axis- Vessel looks round like a target, helps to scout out the
    tip, and is best for ensuring the vein is entered as opposed to a
    neighboring artery</li>
<li>Long axis- The length of the vessel is viewed. This view is intended
    for the final few millimeters of catheter advancement into the vein
    to ensure both bevel and plastic sheath lumen traverse the
    endothelial layer before threading catheter</li>
</ul>
<p>Post-procedure considerations</p>
<ul>
<li>DON’T FORGET TO REMOVE TOURNIQUET!! Remove before flushing to
    prevent blowing vein</li>
<li>Bleeding complication: if arterial, remove catheter &amp; hold pressure
    at least 5 mins</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Procedures</h1>
                        <h1 class='nav-section-title' id='section-psychiatry'>
                            Psychiatry <a class='headerlink' href='#section-psychiatry' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="psychiatry-psychiatry-agitation-management"><h1 id="psychiatry-psychiatry-agitation-management-agitation-management">Agitation Management<a class="headerlink" href="#psychiatry-psychiatry-agitation-management-agitation-management" title="Permanent link">&para;</a></h1>
<p>Agitation Management – Jonathan Constant, Jonathan Smith</p>
<p>Background</p>
<ul>
<li>Agitation
    in the hospital result from discomfort, illness, medication effects
    or frustrations the pt is unable to meaningfully communicate</li>
<li>Anticipate issues, monitor (COWS, CIWA) and pre-emptively treat
    withdrawal</li>
</ul>
<p>Presentation</p>
<ul>
<li>Impulsive aggression: spontaneous, explosive, reactive/reflexive,
    not pre-meditated<ul>
<li>Delirium, psychosis, cognitive deficits,
    withdrawal/intoxication, pain, post-ictal</li>
</ul>
</li>
<li>Instrumental aggression: pre-meditated, controlled, purposeful
    behaviors<ul>
<li>Personality disorders, secondary gain, delusional thought</li>
</ul>
</li>
<li>Differential diagnosis for aggression:<ul>
<li>Psychoses: mania, depression, schizophrenia, delusional disorder</li>
<li>Personality disorder: antisocial, borderline, paranoid,
    narcissistic</li>
<li>Substance use disorder: alcohol, PCP, stimulants, cocaine,
    synthetics</li>
<li>Epilepsy, Delirium, Dementia</li>
<li>Frontal lobe syndromes (TBI, CVA, neoplasm, neurodegenerative
    process)</li>
<li>Behavior/Developmental: Intermittent explosive, XYY genotype,
    Intellectual Disability</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Examine
    (when calm) for source of pain, signs of infection, obstructions,
    toxidromes</li>
<li>Neurological exam for focal deficits, ataxia, nystagmus, tremor,
    rigidity, aphasias</li>
<li>Review medication list and perform med reconciliation of home meds</li>
<li>UDS + review of CSMD for evaluation of intoxication/withdrawal</li>
<li>CBC, BMP, hepatic function, UA</li>
<li>CT head <u>+</u> EEG if focal neurologic deficits or acute change in
    clinical status</li>
<li>If suspicion: Blood cultures, RPR,  B12, folate, CK (
    ↑
    w/ restraints &amp; aggression)</li>
</ul>
<p>Management</p>
<ul>
<li>Environment<ul>
<li>Periodic room searches; search personal belongings</li>
<li>Virtual or 1:1 sitter placement, VUPD presence if warranted</li>
<li>Delirium precautions</li>
<li>Disposable trays and utensils (
    minimize
    potential weapons in the room)</li>
</ul>
</li>
<li>De-
    escalation
    : Always first line,
    although impractical if pt is unable to communicate effectively, is
    explosive or already engaging in violent/potentially harmful
    behavior<ul>
<li>Nonverbal:<ul>
<li>Maintain safe distance, avoid sudden movements, don't touch
    the pt<ul>
<li>Maintain neutral posture, neutral, sincere eye contact,
    same height</li>
</ul>
</li>
</ul>
</li>
<li>Verbal:<ul>
<li>Speak in calm, clear tone, avoid confrontation, and offer to
    solve problem if possible</li>
<li>Do not insist on having the last word</li>
</ul>
</li>
</ul>
</li>
<li>Tactics<ul>
<li>Redirection:
    Acknowledge pt's frustrations; shift focus on how to solve the
    problem</li>
<li>Aligning goals:
    Emphasize common ground and big picture; make small concessions</li>
<li>B
    e wary of transference, countertransference and situational
    tension</li>
</ul>
</li>
<li>Know when to disengage/leave room</li>
<li>Restraints<ul>
<li>Should be used only when necessary to protect patient or others
    from harm</li>
<li>Should not be used to coerce patient to accept or remain in
    treatment</li>
</ul>
</li>
<li>Mechanically restrained patients <strong>cannot be left unmonitored</strong><ul>
<li>De-escalate (4 point to 2 point, etc) and remove restraints as
    soon as possible</li>
<li>Documentation
    of restraint:</li>
</ul>
</li>
<li>Face-to-face assessment has to be completed within an hour of
    violent restraint</li>
<li>“Restraint Charting” tab – typically in rarely used tab drop down<ul>
<li>Mechanical Restraints:</li>
</ul>
</li>
<li>Soft restraints – most commonly used</li>
<li>Hard restraints – reserved for severe behavioral health (only 2 sets
    in house)</li>
<li>Mittens</li>
<li>Posey Vest – prevents exiting bed, allows limbs to be free</li>
<li>Posey Bed – wandering patient (TBI, severe dementia
    )<ul>
<li>VUMC Orders: “restraint” &rarr; order set</li>
</ul>
</li>
<li>Non-violent non-self-destructive (order lasts up to 48 hrs)<ul>
<li>Most pts needing restraint: non-psychiatric, delirium, dementia,
    intubation</li>
</ul>
</li>
<li>Restraint violent self- destructive adult<ul>
<li>Order
    lasts up to 24hr with assessment every 4 hours</li>
<li>Mainly
    severe psychiatric symptoms</li>
</ul>
</li>
</ul>
<p>Pharmacological Management for Agitation</p>
<p>Acute Agitation</p>
<ul>
<li>Antipsychotics<ul>
<li>Widely effective for acute agitation, especially in delirium and
    psychotic disorders</li>
<li>Choice of agent depends on patient characteristics (movement
    disorders, QTc)</li>
<li>Moderate agitation options:<ul>
<li>Olanzapine 2.5 - 5mg po q6h prn typical starting dose (ODT
    available</li>
<li>Quetiapine 12.5 - 25mg q6h po prn for patients at higher
    risk of EPS</li>
</ul>
</li>
</ul>
</li>
<li>Severe agitation<ul>
<li>Haldol 0.5 - 1mg IV/IM q6h prn for older/frail individuals</li>
<li>Haldol 2-3mg IV/IM q6h prn for other patients</li>
<li>Titrate up to 5 mg and can increase frequency as warranted</li>
<li>When using IV Haldol obtain daily EKG, Mg and K levels</li>
<li>Stop IV Haldol if QTcF greater than 500 msec (
    QTcB overestimates at HR &gt;60)</li>
</ul>
</li>
<li>Benzodiazepines<ul>
<li>May have fewer adverse effects compared to antipsychotics
    (dystonia, akathisia, EPS)</li>
<li>Can use alone or in addition to antipsychotic agent</li>
<li>Can worsen delirium, disinhibit patients with
    neurocognitive-related agitation</li>
<li>Preferred for agitation related to intoxication/withdrawal of
    sedatives<ul>
<li>Lorazepam preferentially used due to PO, IV and IM
    availabilit</li>
<li>Lorazepam 2mg PO/IM/IV q6h prn typical starting dose (1mg if
    older/frail)<ul>
<li>Can increase frequency if warranted though monitor
    respiratory suppression when combined with other
    respiratory suppressing agents</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>If severe agitation not responsive to above, may require sedation
    with infusion:<ul>
<li>Dexmedetomidine, Propofol or Midazolam</li>
</ul>
</li>
</ul>
<p>Maintenance medications:</p>
<ul>
<li>Antipsychotics<ul>
<li>Reserve antipsychotics for severe aggression that pose
    significant risk</li>
<li>Aim to wean as soon as safely possible</li>
<li>Adverse effects: metabolic, EPS, increased mortality in dementia</li>
<li>Most commonly used: Olanzapine, Quetiapine, Risperidone</li>
</ul>
</li>
<li>Antiepileptic
    agents<ul>
<li>May be effective in reduction of impulsive aggression</li>
<li>Most commonly used: Depakote<ul>
<li><strong>​​​​​​​​​​​​​​​​​​​​​​​​​​​​</strong> Levetiracetam could worsen
    aggression/agitation</li>
</ul>
</li>
</ul>
</li>
<li>Beta Blockers and Alpha Agonists<ul>
<li>Noradrenergic over-activity implicated in aggression expression</li>
<li>Commonly Used: Propranolol, Clonidine, Guanfacine</li>
</ul>
</li>
<li>Serotonergic agents: SSRI/SNRI/Buspar<ul>
<li>Some studies supporting use, though weeks to benefit</li>
<li>Useful if co-occurring depression/anxiety disorders</li>
</ul>
</li>
</ul>
<p>Agitation/Aggression due to personality disorder/secondary gain:</p>
<ul>
<li>Behavioral plan development (see Borderline Personality Disorder
    chapter)</li>
<li>Environmental safety precautions and medication management as
    outlined above</li>
<li>If continued disruptions, may require multidisciplinary team meeting
    with treating team(s) &plusmn; ethics, psychiatry, palliative care to
    determine appropriateness of administrative discharge vs. enforced
    treatment</li>
</ul>
<p>​​​​​​​</p></section><section class="print-page" id="psychiatry-psychiatry-inpatient-insomnia"><h1 id="psychiatry-psychiatry-inpatient-insomnia-inpatient-insomnia">Inpatient Insomnia<a class="headerlink" href="#psychiatry-psychiatry-inpatient-insomnia-inpatient-insomnia" title="Permanent link">&para;</a></h1>
<p>Inpatient Insomnia – Julian Raffoul, Jose Alberto Arriola Vigo</p>
<p>Background</p>
<ul>
<li>Sleep disturbances in the hospital are multifactorial</li>
<li>Consequences of sleep disturbances in the hospital include changes
    in cognition, behavior, anxiety, pain perception, respiratory
    function, inflammation, and metabolism</li>
<li>Goals while inpatient: optimize sleep environment, minimize
    stimulating or sleep-related side effects of concomitant
    medications, utilizing non-pharmacologic strategies</li>
</ul>
<p>Management</p>
<ul>
<li>Non-pharmacologic interventions:<ul>
<li>Noise reduction:
    use of ear protection, sound masking (white noise), sound
    proofing acoustic materials, and behavioral modifications (or
    "quiet time" protocols)</li>
<li>Light therapy
    : Use of eye masks in conjunction with ear plugs will improve
    sleep, however, nocturnal light appears to be less of an issue
    compared with inadequate daytime light exposure, which improves
    circadian rhythms, nocturnal sleep, and minimizes delirium<ul>
<li>Light exposure typically consists of two to five hours of
    daytime to early evening light in the range of 2000 to 5000
    lux</li>
</ul>
</li>
<li>Reducing nighttime interruptions:
    Alter workflow/lab draws, if possible, to permit 8-hr nocturnal
    "quiet time"</li>
<li>Relaxation techniques:
    Music or white noise may
    ↑
    subjective sleep quality and duration</li>
<li>Equipment:
    for severely ill pts, minimize hardware and tubes that can alter
    sleep due to physical presence and alarms</li>
</ul>
</li>
<li>Pharmacotherapy:<ul>
<li>Melatonin:
    1-5 mg PO qhs; (dosing is not standardized); the best first-line
    choice based on mild side-effect profile, low potential for
    drug-drug interactions, and improves circadian rhythms; Most
    effective 2-3hrs before bedtime</li>
<li>Ramelteon:
    8 mg PO qhs; a melatonin-receptor agonist; May also play a role
    in preventing delirium in older adult inpatients</li>
<li>Trazodone:
    25-50 mg PO qhs (max 200 mg/day); a serotonin modulator w/
    significant sedation as a side effect, also headache, dry mouth,
    and nausea are common<ul>
<li>Monitor for orthostasis and infrequent atrial arrhythmias;
    use lowest effective dose</li>
</ul>
</li>
<li>Mirtazapine:
    7.5-15 mg PO qHS; a primary alpha-2 antagonist with 5-HT2 and H1
    antagonism, consider when insomnia appears to be related to
    primary depression<ul>
<li>Advise that appetite and weight gain may also occur</li>
</ul>
</li>
<li>Minimize
    medications such as vasopressors, sedatives/hypnotics, opioids,
    glucocorticoids, beta blockers, and certain antibiotics that
    disturb sleep architecture</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Avoid the following in the inpatient setting:<ul>
<li>Benzodiazepines
    :  While effective at reducing sleep latency and increasing
    total sleep time, benzodiazepines are associated with
    significant adverse effects, particularly in older adults, e.g.,
    respiratory depression, cognitive decline, delirium, daytime
    sleepiness, and falls, particularly in hospitalized adults</li>
<li>Non
    -
    benzodiazepines
    : Benzodiazepine receptor agonists (e.g., zolpidem,
    eszopiclone/zopiclone, zaleplon) are effective in the outpatient
    setting and commonly used in the inpatient setting; however,
    they may be associated with cognitive dysfunction, delirium, and
    falls in hospitalized patients</li>
<li>Diphenhydramine
    : Trials evaluating their effectiveness as sleep aids are
    limited and show mixed results w/ many potential side effects
    that are enhanced in the inpatient setting: <em>impaired cognition</em>
    , <em>anticholinergic effects</em> (constipation, urinary retention)</li>
<li>Others
    : ( <strong>anticonvulsants</strong> , <strong>antidepressants</strong> ,
    <strong>antipsychotics</strong> , <strong>barbiturates</strong> ) are usually used in
    outpatient setting, but have not been well studied in the
    inpatient setting</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-medical-decision-making-capacity"><h1 id="psychiatry-psychiatry-medical-decision-making-capacity-medical-decision-making-capacity">Medical Decision-Making Capacity<a class="headerlink" href="#psychiatry-psychiatry-medical-decision-making-capacity-medical-decision-making-capacity" title="Permanent link">&para;</a></h1>
<p>Medical Decision-Making Capacity – Chelsea Sprick, Neil Phillips,
Jonathan Smith</p>
<ul>
<li>Capacity can be assessed by any physician regarding a pt’s ability
    to make a <strong><em>specific</em></strong> medical decision at a <strong><em>specific</em></strong> point
    in time</li>
<li>Competency:
    “global decision-making capacity,” a legal determination made by a
    judge</li>
<li>If the patient does not have medical decision-making capacity:<ul>
<li>Identify and remedy cause of impairment if possible (if decision
    is non-urgent)</li>
<li>Identify surrogate decision maker</li>
</ul>
</li>
</ul>
<p>Assessing medical decision-making capacity</p>
<ul>
<li>Choice: patient must clearly indicate a consistent choice<ul>
<li>“Have you decided whether to follow the recommendation for the
    treatment?”</li>
<li>“Can you tell me what your decision is?”</li>
</ul>
</li>
<li>Understand
    : pt must grasp the fundamental meaning of the information
    communicated by the medical team<ul>
<li>“Please tell me in your own words what you were told about:<ul>
<li>The problem with (1) your health now and (2) the recommended
    treatment</li>
<li>The risks/benefits of (3) treatment, (4) alternative
    treatments and (5) no treatment”</li>
</ul>
</li>
</ul>
</li>
<li>Appreciate: the medical condition and likely consequences of
    treatment options<ul>
<li>“What do you believe is wrong with your health now?”</li>
<li>“What is treatment likely to do for you?”</li>
<li>“Do you believe you need treatment?”</li>
<li>“What do you believe will happen if you’re not treated”</li>
<li>“Why do you think this treatment was recommended?”</li>
</ul>
</li>
<li>Reason: patient must rationally manipulate relevant information<ul>
<li>“What makes the chosen option better than the alternative?”</li>
<li>“How did you decide to accept or reject the recommended
    treatment?”</li>
</ul>
</li>
</ul>
<p>Documenting medical decision-making capacity:</p>
<p>Use</p>
<p>a <strong>dot phrase .Capacity that lists the four components</strong> and document
your thought process citing evidence from your interview</p></section><section class="print-page" id="psychiatry-psychiatry-medical-hold"><h1 id="psychiatry-psychiatry-medical-hold-medical-hold">Medical Hold<a class="headerlink" href="#psychiatry-psychiatry-medical-hold-medical-hold" title="Permanent link">&para;</a></h1>
<p>Medical Hold – Chelsea Sprick, Barrington Hwang</p>
<p>Background</p>
<ul>
<li>6404: applies when there is a need for psychiatric hospitalization<ul>
<li>Can only be completed by a licensed physician<ul>
<li>Psychiatry residents can write these due to their special
    training licenses</li>
</ul>
</li>
</ul>
</li>
<li>No AMA Medical Hold: useful when a pt does not have capacity to
    leave the hospital against medical advice and needs to remain in the
    hospital<ul>
<li>Can be ordered by any physician</li>
</ul>
</li>
<li>6401 vs. 6404: Tennessee Title 33, Chapter 6, Part 4 is the legal
    code<ul>
<li>"6401": the form needed for emergency detention, examination and
    admissio<ul>
<li>One person completes this</li>
</ul>
</li>
</ul>
</li>
<li>"6404": the certificates for emergency involuntary admission<ul>
<li>The first 6404 is needed to transport a patient to a psychiatric
    facility and the second 6404 is needed for an involuntary
    admission</li>
<li>Pt must have mental illness or serious emotional disturbance,
    excluding intellectual/developmental disabilities and pose an
    immediate substantial likelihood of serious harm because of
    this, as evidenced by current/past SI/HI/SIB or deterioration at
    point of inability to care for self at significant risk to self
    or others</li>
<li>Treatment must be necessary for symptom reduction and lack of
    treatment would lead to deterioration, with no less drastic
    alternative to inpatient hospitalization.</li>
<li>Two different qualified persons must each complete a form</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>VUH-specific procedures<ul>
<li>A physical copy of (at least) the first 6404 is required to
    accompany the patient when they are transported to a psychiatric
    facility after medical discharge</li>
<li>Once completed, 6404s should be given to the medical
    receptionist on the unit for scanning into the medical record
    and for safe-keeping</li>
</ul>
</li>
<li>Consider whether a pt has a conservator or activated healthcare POA</li>
<li>If the conservator/POA is willing and able to complete the consent
    for admission, the pt can be admitted voluntarily<ul>
<li>The first 6404 would still be necessary for transportation to a
    psychiatric facility</li>
</ul>
</li>
<li>Unless the pt has a mental health-related condition or qualifies
    under the criteria above, pt is NOT committable under the
    involuntary admission</li>
<li>Just because someone wants to leave to use substances does not in
    itself mean they are committable, even if it does not seem like a
    good decision</li>
<li>While this may seem obvious, a 6404 or No AMA/Medical Hold takes
    away the personal liberties of an individual and this is a serious
    decision</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-motivational-interviewing"><h1 id="psychiatry-psychiatry-motivational-interviewing-motivational-interviewing">Motivational Interviewing<a class="headerlink" href="#psychiatry-psychiatry-motivational-interviewing-motivational-interviewing" title="Permanent link">&para;</a></h1>
<p>Motivational Interviewing (MI) – Barrington Hwang, <span
id="_Hlk41769139">Jose Arriola Vigo</span></p>
<p>Background</p>
<ul>
<li>MI:  an evidence-based form of non-judgmental, pt-centered
    counseling that elicits change in pt behavior by guiding pt through
    own motivations for change</li>
<li>For inpatients, MI is most useful for encouraging medication
    compliance before discharge or substance use cessation</li>
<li>Assumptions/principles:<ul>
<li>Pt is in state of ambivalence, whether outwardly expressed or
    not</li>
<li>Ambivalence is expressed with conflict between multiple courses
    of action</li>
</ul>
</li>
<li>Pt may go between stages of change at any given time, some pts may
    benefit from explaining this model of behavior change</li>
<li>Techniques to identify ambivalence:<ul>
<li>Focus
    on reasons to change ("why") as opposed to specific actions
    ("how")</li>
<li>Express empathy: discussion about values, hopes, emotions, and
    goals surrounding behavior</li>
<li>Empower self-efficacy: ask about other times they have made
    changes in life</li>
<li>Develop discrepancy - between current and desired behavior</li>
<li>Avoid argument and authoritarian mentality - consider "asking"
    for permission to give your own thoughts, don't "give advice"</li>
<li>Defuse resistance to change - emphasize pt autonomy and reflect
    on resistance</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Stages of behavior change:<ul>
<li>Precontemplation - pt does not intend to change and has not
    taken action toward behavior change; could be related to
    demoralization from prior attempts</li>
<li>Contemplation - pt intends to change, but has not taken action,
    usually related to awareness of risks vs benefits of change</li>
<li>Preparation - pt intends to change, has taken steps to create
    plan and mental action, but no current physical action toward
    behavior change</li>
<li>Action - pt intends to change, currently following through on
    plan</li>
<li>Maintenance - pt intends to change, has changed, and is taking
    steps to prevent relapse</li>
</ul>
</li>
<li>Continuing the Conversation:<ul>
<li>May be effective to have SMART goal-setting if pt is in any
    stage except precontemplation: Specific, Measurable, Attainable,
    Realistic, Time-limited</li>
<li>Pts may benefit from discussion on specific defense mechanisms</li>
<li>"OARS" interviewing skills: Open-ended questions, Affirm,
    Reflect, Summarize</li>
<li>Most effective in conjunction with other treatments, when pts
    are willing, and when pts express ideas for change themselves</li>
<li>Least effective in
    group format and when pt feels change comes from authority</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-personality-disorders"><h1 id="psychiatry-psychiatry-personality-disorders-personality-disorders">Personality Disorders<a class="headerlink" href="#psychiatry-psychiatry-personality-disorders-personality-disorders" title="Permanent link">&para;</a></h1>
<p>Personality Disorders – Jonathan Constant, Jonathan Smith</p>
<p>Background</p>
<ul>
<li>Caring for pts with personality disorder symptoms can result in pt
    and provider frustration, delays in treatment and at times,
    sub-optimal care and AMA discharges</li>
<li>An understanding of personality disorders can mitigate some of these
    barriers</li>
<li>How do personality disorders develop?<ul>
<li>Genetic/temperament component, early traumatizing and shaping
    experiences</li>
<li>Development of maladaptive perceptions and responses to other
    individuals</li>
<li>Pathological interaction styles and response to stressors (fear
    of abandonment, dependence, rejection) are developed and become
    self-fulfilling and re-enforced leading to pervasive
    interpersonal difficulties</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Borderline Personality Disorder:<ul>
<li>Unstable and intense relationships; “splitting” between
    idealization and devaluation</li>
<li>Frantic efforts to avoid real or imagined abandonment</li>
<li>Impulsivity: substance use, binge eating, reckless behavior</li>
<li>Recurrent suicidal behavior or gestures</li>
<li>Mood instability: quick onset and short-lived intense dysphoria,
    irritability, anxiety</li>
<li>Difficulty controlling anger (displays of temper, aggression)</li>
</ul>
</li>
<li>Narcissistic Personality Disorder:<ul>
<li>Grandiosity: exaggerates achievements and expects to be
    recognized as superior</li>
<li>Preoccupied with unlimited power, success, brilliance</li>
<li>Sense of entitlement: expects favorable treatment and compliance
    with expectations</li>
<li>Exploits others and lacks empathy</li>
</ul>
</li>
<li>Antisocial personality disorder:<ul>
<li>Failure to conform to social norms with respect to lawful
    behavior</li>
<li>Deceitfulness, lying, conning others for personal profit or
    pleasure</li>
<li>Impulsivity and reckless disregard for others</li>
<li>Irritability, aggressiveness and lack of remorse</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult Psychiatry</li>
<li>Create a behavioral plan<ul>
<li>Outline the pt, as well as the team’s, responsibilities and
    goals of care with identification of the concerning behavior and
    a firm plan for if the agreement is broken</li>
<li>Ideally, the pt should sign this plan and consider it as a
    contract</li>
<li>Dot Phrase/Sample:
    .IMBehavioralPlan (go to dot phrases under user Joseph Quintana)<ul>
<li>Adjust, add and remove content based on patient</li>
</ul>
</li>
</ul>
</li>
<li>Behavioral interventions:<ul>
<li>Aim for consistency w/ providers &amp; nursing; limit consultants to
    ↓
    splitting behaviors</li>
<li>Acknowledge pt's grievance/frustrations and shift focus on how
    to solve the problem</li>
<li>Align goals by emphasizing common ground and find ways to make
    small concessions</li>
<li>Be aware of progress and know when to disengage (if behaviors
    are escalating)</li>
<li>Monitor countertransference (the emotions the pt is eliciting in
    the provider): irresponsible and child-like behavior may prompt
    the provider to become angry or act in ways to limit the pt's
    control in their care, further perpetuating the behavior</li>
</ul>
</li>
<li>Gold standard = Psychotherapy<ul>
<li>Dialectical Behavioral therapy, Cognitive behavioral therapy,
    Psychodynamic</li>
<li>If the patient is willing, SW should assist with establishing at
    discharge</li>
</ul>
</li>
<li>Pharmacotherapy <strong>:</strong><ul>
<li>Unclear benefit in pharmacological management of Personality
    Disorder</li>
<li>Treatment of comorbid psychiatric disorders if present would be
    most appropriate</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-substance-use-disorder"><h1 id="psychiatry-psychiatry-substance-use-disorder-substance-use-disorder">Substance Use Disorder<a class="headerlink" href="#psychiatry-psychiatry-substance-use-disorder-substance-use-disorder" title="Permanent link">&para;</a></h1>
<p>Substance Use Disorder (SUD)– Barrington Hwang, Kristopher Kast</p>
<p>Background</p>
<ul>
<li>SUDs are common, complex, and chronic neuropsychiatric
    disorders
    with well-described inherited risk, dysregulated neurophysiology,
    and multiple effective treatment modalities</li>
<li>Pts w/SUD
    face significant stigma, prior traumatic experiences in healthcare
    environments</li>
<li>Approaching pts respectfully and fostering partnership is important
    to quality care</li>
<li>Using
    the term “abuse” undermines the disease model of addiction,
    connoting volitional “bad” behavior driving recurrent substance use</li>
<li>Person
    -centered, specific terminology: “person with opioid and alcohol use
    disorders”</li>
<li>Avoid the qualifier “Polysubstance,” suggests the specific diagnoses
    are less important data</li>
<li>Clarify specific diagnoses for each substance category:<ul>
<li>Identify
    the
    current substance exposures and distinguish use
    disorder
    from unhealthy use and episodic use</li>
</ul>
</li>
<li>DSM 5 Criteria (same for most substance categories): Requires 2+
    criteria met in past year; use must cause clinically significant
    impairment and/or distress:<ul>
<li>Loss of control – larger amounts, longer time, ongoing use
    despite consequences, efforts/desire to reduce use</li>
<li>Physiologic changes -- tolerance, withdrawal (these 2 alone do
    not necessarily imply a disorder if they result from prescribed
    therapy), craving</li>
<li>Consequences – hazardous use, interpersonal problems, medical
    problems, failed role obligations, lost activities</li>
</ul>
</li>
<li>In the general hospital, SUD management first requires identifying
    and stabilizing withdrawal states to mitigate risks of severe
    sequelae (seizure, delirium), unintended iatrogenic harm (opioid
    abstinence leading to lost tolerance and post-discharge overdose),
    and distress-driven AMA discharge</li>
</ul>
<p>General Management:</p>
<ul>
<li>Consider Addiction Psychiatry consultation for management of complex
    withdrawal states, substance use disorders and co-occurring
    psychiatric diagnoses, assistance with risk stratification for
    hospital misuse and/or hospital discharge with PICC lines for
    outpatient antibiotics, and differentiation of pain requiring opioid
    therapy and opioid use disorder<ul>
<li>At VUMC: In Epic, “Inpatient Consult to Psychiatry, Addiction
    Medicine”</li>
<li>Team consists of addiction psychiatrists, nurse practitioners,
    fellows/residents, social workers, and recovery coaches</li>
</ul>
</li>
<li>If in the emergency room and not admitted, consult PAS</li>
</ul>
<p>Opioid</p>
<p>Use Disorder – Rita Hurd, David Marcovitz</p>
<p>Background</p>
<ul>
<li>Standard
    of care is opioid stabilization with buprenorphine or methadone (in
    OUD) or other full agonist opioids (in chronic opioid therapy)</li>
<li>Methadone
    and buprenorphine can be ordered by any physician for inpatients</li>
<li>Maintenance
    agonist therapy should be offered to every patient, with preference
    for an “opt-out” approach (even for uninsured patients through state
    grant funding)</li>
</ul>
<p>Presentation (Withdrawal)</p>
<ul>
<li>Restlessness
    /psychomotor activation, anxiety, irritability, nausea, abdominal
    cramping, loose stool, diffuse musculoskeletal pain, chills,
    Insomnia, yawning</li>
<li>Pupillary
    dilation, piloerection, tearing, nasal congestion, diaphoresis,
    restless legs</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical
    Opioid Withdrawal Scale (COWS): quantifies severity of opioid
    withdrawal and allows for safer buprenorphine inductions</li>
<li>Asking
    about opioid exposure: “You’re uncomfortable. I work with a lot of
    people in the hospital, and some come with regular exposure to
    opioids from a lot of different places (their doctors, friends),
    should we be treating any withdrawal for you?”</li>
</ul>
<p>Medications for Opioid Use Disorder (MOUD)</p>
<p>Buprenorphine</p>
<ul>
<li>Partial
    agonist at the mu opioid receptor with high binding affinity</li>
<li>Long
    half-life (24-36 hours) allows for daily dosing</li>
<li>TID
    dosing is more effective for <strong>acute pain</strong> (as the analgesic effect
    is shorter-lived)</li>
<li>OK
    to use in renal failure/HD; may reduce dose in hepatic injury</li>
<li>All non-pregnant pts should receive buprenorphine-naloxone (e.g.
    Suboxone)
    formulations
    to mitigate risk of diversion/injection</li>
<li>Induction
    :<ul>
<li>Hold all opioid medication 12+ hours prior to first
    buprenorphine dose (typically, this opioid-free period is
    overnight from 9 PM to 9 AM), with a recorded COWS score &gt;8-10;</li>
<li>4 mg is given SL, monitoring for oversedation; additional 4 mg
    is given in 1 hour, and final 4 mg at 4 hours (total of 12 mg in
    first day)<ul>
<li>Only sedation or hypopnea should prevent a full 12 mg dose</li>
</ul>
</li>
<li>Typical
    starting
    dose: 12-16 mg/day</li>
</ul>
</li>
<li>Maintenance
    :
    4-32 mg daily; 16mg and above to suppress opioid use<ul>
<li>Requires waivered-provider</li>
</ul>
</li>
<li>Acute
    Pain Management in pts using Buprenorphine:<ul>
<li>There is no contraindication to full-agonist opioid analgesia
    for breakthrough pain<ul>
<li>If the etiology of pts pain would require opioid therapy in
    a non-OUD patient, do not avoid opioids; these may be used
    safely in the hospital</li>
</ul>
</li>
<li>Peri-operative pain management: continue buprenorphine at
    reduced and split doses (4 mg BID or TID); will prevent
    withdrawal and cravings, but NOT manage new pain</li>
<li>Post-operatively: reduce opioid requirements and increase
    buprenorphine to home dose<ul>
<li>If buprenorphine was discontinued, will require induction
    procedure</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Methadone</p>
<ul>
<li>Full mu opioid agonist with additional NMDA-receptor activity</li>
<li>FDA-approved for OUD when dispensed from a licensed opioid treatment
    program</li>
<li>Better option for individuals who cannot tolerate the buprenorphine
    induction procedure, with significant chronic or escalating pain<ul>
<li>Long t <sup>1/</sup> <sub>2</sub> : 12-36 hrs; max 10 mg/d q7d,
    to prevent dose-stacking and delayed overdose</li>
</ul>
</li>
<li>Safe in renal failure; dose reduction for hepatic injury</li>
<li>Potential for QT prolongation at higher doses, warrants QTc
    monitoring</li>
<li>Induction
    :<ul>
<li>In the hospital, start at 10 mg TID, holding doses for sedation
    or hypopnea; lower doses if concerned for respiratory compromise
    or concurrent CNS depressant therapy</li>
<li>Limit 40 mg in first 24 hours; then titrate 5 mg/d q3d while
    admitted</li>
</ul>
</li>
<li>Maintenance
    :<ul>
<li>Must confirm dose with methadone clinic before restarting
    outpatient dose; until then, do not give more than initial doses
    (30 mg in single dose, 40 mg in first 24 hours)</li>
<li>After confirming home dose, continue as single daily dose</li>
</ul>
</li>
</ul>
<p>Naltrexone</p>
<ul>
<li>Mu opioid antagonist; Half-life oral ~4 hours but clinically active
    ~24 hrs</li>
<li>IM maintains clinically effective levels up to 30 days</li>
<li>High affinity for mu receptor &rarr; CAN precipitate withdrawal
    requiring 7-10 days opioid abstinence prior to initiation</li>
<li>If due for monthly injection while admitted, may substitute oral
    formulation until discharged to outpatient provider to receive
    injection</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Psychosocial Interventions that complement MOUD:<ul>
<li>Consider referral to SUD counseling, mutual help (self-help,
    12-step, AA), intensive outpatient, and short- or long-term
    residential treatment</li>
<li>Use of other drugs NOT a contraindication to MOUD, however
    should encourage abstinence from other drugs during therapy
    (especially benzodiazepines)</li>
</ul>
</li>
<li>Prescribe intranasal naloxone for overdose prevention to all OUD
    patients discharging from hospital, regardless of MOUD status</li>
</ul>
<p>Alcohol Use Disorder – Barrington Hwang , Kristopher Kast</p>
<p>Background</p>
<ul>
<li>50% of hospitalized pts drink alcohol; at-risk alcohol use is &gt;14
    drinks/week or &gt;5 drinks in a sitting (for men; for women and
    men &gt;65, 7 per week, &gt;4 per sitting)</li>
<li>Alcohol
    withdrawal onset occurs 6-12 hours after last drink, with 90% having
    non-severe course; CIWA score \&lt;10 at 24-48 hours indicates low risk
    of worsening symptoms</li>
<li>Risk
    of seizures greatest at 12-24 hrs, occurring in ~3% of pts; risk of
    delirium greatest at 48-72 hrs, occurring in ~5%</li>
<li>Risk
    assessment<ul>
<li>RF: prior seizures/delirium, co-substance use (especially
    benzodiazepines), no abstinent days in past month, presenting
    BAL &gt;200, dysautonomia</li>
<li>CIWA symptom-triggered protocol appropriate for pts at <strong>low</strong>
    <strong>risk</strong> of severe withdrawal</li>
<li>For non-low risk pts, consider benzodiazepine/barbiturate load
    and standing taper;</li>
</ul>
</li>
<li>Indications
    for
    admission: prior severe withdrawal (withdrawal seizures or
    delirium), comorbidities (medical and psychiatric illness),
    pregnancy, significant impairment in social/occupational
    functioning, communication barriers, social barriers</li>
</ul>
<p>Presentation</p>
<ul>
<li>Acute
    intoxication: disinhibition, slurred speech, ataxia, nystagmus</li>
<li>Acute
    Withdrawal:  nausea, vomiting, anxiety, agitation, audio-visual and
    tacticle
    hallucinations
    , headache, diaphoresis, fine motor tremor while arms and fingers
    outstretched, autonomic hyperactivity</li>
<li>Chronic
    heavy use:<ul>
<li>Sequelae of chronic liver disease &amp; malnutrition, including
    thiamine deficiency</li>
</ul>
</li>
<li>Caine
    criteria for Wernicke’s encephalopathy:<ul>
<li>2 or more: (1) malnutrition, (2) ataxia, (3) oculomotor
    abnormalities, (4) AMS</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Identify
    last use, quantity per day/week, other sedative-hypnotic use,
    history of withdrawal, social/occupational dysfunction, other toxic
    forms of alcohol compounds including methanol, ethylene glycol</li>
<li>Acute
    Alcohol
    Withdrawal<ul>
<li>Labs: Blood alcohol level, urine toxicology (&plusmn; ethyl
    glucuronide to detect use in prior 3 days), BMP, CBC, HFTs
    (AST:ALT elevation 2:1), CK and
    β
    - hCG</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>CIWA
    score quantifies severity, though subject to inflation by subjective
    symptoms</li>
<li>Objective Alcohol Withdrawal Scale (OAWS) is an alternative for pts
    at risk of over-reporting symptoms</li>
</ul>
<p>Management</p>
<p>Acute Alcohol Withdrawal</p>
<ul>
<li>Most patients are appropriate for diazepam-based protocols:<ul>
<li>CIWA-based symptom-triggered for low-risk patients</li>
<li>Diazepam load + standing taper for non-low risk patients</li>
</ul>
</li>
<li>Substitute lorazepam for pts with hepatic impairment (risk of long
    acting accumulation)</li>
<li>Benzodiazepine resistance: likely due to poor cross-tolerance, these
    pts  require phenobarbital load ( 8-12 mg/kg (up to 15 mg/kg)
    divided into 3 doses 3 hours apart)</li>
<li>Add folate, multivitamin, and electrolyte repletion</li>
<li>If &gt;2 Caine criteria, treat empirically for Wernicke’s
    encephalopathy with high-dose IV thiamine (500 mg TID IV x 3-5 days)</li>
</ul>
<p>-      Consider Addiction Psychiatry consultation for complex
presentations</p>
<p>Alcohol Use Disorder</p>
<ul>
<li>After withdrawal stabilization, engage pt in discussion around use
    and educate on connection between use and presenting medical
    problems</li>
<li>All patients with AUD should be initiated on pharmacotherapy (MAUD)
    prior to discharge to mitigate risk of relapse, if consistent with
    patient’s goals</li>
<li>Additional psychosocial treatments effective for AUD include
    motivational interviewing, 12-step groups (AA, SMART Recovery),
    cognitive behavioral therapy, sober living facilities, family
    therapy, contingency management, and IOP/residential facilities</li>
<li>If patient does not have abstinence goal, reduced or controlled
    drinking may allow for harm reduction; naltrexone and topiramate
    have evidence for non-abstinence outcomes</li>
</ul>
<!-- -->

<ul>
<li>Pharmacologic
    Interventions:<ul>
<li>Naltrexone
    (cannot be on opioid agonist):<ul>
<li>Need 7-10 days since last opioid before starting</li>
<li>25 mg x1 day, then titrate up to 50 mg daily; also available
    in q30d IM</li>
<li>Monitor liver enzymes; AST/ALT must be \&lt; 3-5x ULN</li>
</ul>
</li>
<li>Acamprosate
    (cannot be used in severe renal impairment)<ul>
<li>Head-to-head, inferior to naltrexone (see COMBINE trial)</li>
<li>333 mg TID, titrating to 666 mg TID dosing</li>
<li>Difficult TID dosing may be helpful if framed as
    commitment/mindfulness practice</li>
</ul>
</li>
<li>Disulfiram<ul>
<li>Infrequently used outside of extreme motivation (e.g.
    professional under monitoring); would not use outside
    specialist care</li>
<li>Must abstain from alcohol ~2 weeks after last dose, given
    risk of disulfiram-ethanol reaction (DER), which can be
    fatal depending upon disulfiram and ethanol doses</li>
</ul>
</li>
<li>Topiramate<ul>
<li>Not FDA-approved for AUD, but has significant supporting
    evidence</li>
<li>Useful for individuals without abstinence goal</li>
<li>Titrate slowly over 8 weeks to 200-300 mg/d</li>
</ul>
</li>
<li>Gabapentin
    :<ul>
<li>Not FDA-approved for AUD, but with some evidence</li>
<li>Useful for post-acute withdrawal anxiety, insomnia, or
    co-occurring neuropathy</li>
<li>Titrate to 900-1800 mg/d divided into TID dosing, monitoring
    for sedation</li>
<li>Risk
    of sedation/apnea if concomitant alcohol use; ensure pt
    educated about risk</li>
</ul>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Psychiatry</h1>
                        <h1 class='nav-section-title' id='section-pulmonary'>
                            Pulmonary <a class='headerlink' href='#section-pulmonary' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="pulmonary-pulmonary-acute-asthma-exacerbation"><h1 id="pulmonary-pulmonary-acute-asthma-exacerbation-acute-asthma-exacerbation">Acute Asthma Exacerbation<a class="headerlink" href="#pulmonary-pulmonary-acute-asthma-exacerbation-acute-asthma-exacerbation" title="Permanent link">&para;</a></h1>
<p>Acute Asthma Exacerbation – Stacy Blank</p>
<p>Background</p>
<ul>
<li>History of asthma or a history concerning for asthma</li>
<li>Progressive worsening of symptoms:  dyspnea, chest tightness,
    wheezing, and cough</li>
<li>Physical exam with wheezing, poor air movement (if severe
    obstruction may just not hear good breath sounds, which is worse
    than wheezing), tachypnea, increased work of breathing (accessory
    muscle use), hypoxemia</li>
<li>Often use of peak flows is cited in the literature (PEF \&lt;200 L/min
    or PEF \&lt;50% predicted indicates severe obstruction, PEF \&lt;70%
    predicted indicates moderate exacerbation)<ul>
<li>These can be ordered as an RT order and may be useful; although
    often does not change management acutely</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Generally aimed at ruling out causes for exacerbation and other
    diagnoses; these are not required but should be considered in pts
    being admitted for inpatient management:<ul>
<li>EKG, trop, BNP, D-dimer to assess for cardiac cause (ACS, HF,
    PE)</li>
<li>CXR to rule out underlying process (PNA, PTX, atelectasis)</li>
<li>ABG/VBG not routinely needed but if pt ill-appearing,
    tachypneic, or lethargic/altered</li>
</ul>
</li>
<li>Dangerous signs and possible ICU if:<ul>
<li>Tachypnea &gt;30 and/or significantly increased work-of-breathing</li>
<li>Hypercapnia or even normocapnia (these pts are usually
    hyperventilating; a normal CO2 in a severe asthma exacerbation
    could indicate impending respiratory failure)</li>
<li>Altered mental status</li>
<li>Requiring continuous nebulizers</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Continuous pulse ox with oxygen therapy to maintain O2 &gt;92 %</li>
<li>Continuous albuterol nebulizer or Duonebs until able to space to
    q1h&gt;>q2h, etc (ED almost always starts with continuous if pt is
    severe enough to warrant inpatient management)</li>
<li>Steroids with dosing base on severity of illness (there is no data
    behind exact dosing of steroids).  Start with IV methylpred 125mg
    q6h in severe exacerbation/ICU patients. Can start with oral
    prednisone 60mg q12h in less severe exacerbation/floor pts. Plan to
    transition from IV to PO and then likely to send pt home to finish
    course of 40-60 mg pred daily for 5-7 days.</li>
<li>IV mag sulfate 4g over 20 minutes for severe exacerbation (anyone
    going to the ICU)</li>
<li>Keep pt NPO until off continuous nebs/respiratory effort is improved
    to safely swallow, consider IV fluids with pt’s comorbidities
    (HFrEF, renal disease) vs. increased insensible losses with resp
    effort</li>
<li>If pt is not responding to therapies, has worsening respiratory
    status or blood gas concerning for respiratory acidosis: use BiPAP
    in patients whose mental status is appropriate vs. intubation/MV
    (i.e., it’s time to call your MICU fellow)</li>
<li>Note:  We do not start empiric antibiotics unless there is concern
    for bacterial infection</li>
</ul>
<p>Prior to discharge:</p>
<ul>
<li>Ensure that pt is on appropriate controller medications (see
    outpatient management)</li>
<li>Evaluate for causes of acute exacerbation to prevent future events
    (noncompliance, resp viruses, allergies, exposures, etc.)</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-blood-gases"><h1 id="pulmonary-pulmonary-blood-gases-blood-gases">Blood Gases<a class="headerlink" href="#pulmonary-pulmonary-blood-gases-blood-gases" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basics of Blood Gases – Lexi Haugh</td>
</tr>
</tbody>
</table>
<p>Did you order an ABG or VBG?</p>
<ul>
<li>If you need to assess oxygenation (PaO2), then must order an ABG. An
    ABG is also the most accurate way to assess PaCO2 and pH</li>
<li>If you want to assess hypoventilation, a VBG is informative and
    usually similar, but it may be inaccurate in some cases such as
    shock or severe hypercapnia</li>
<li>The pH on a VBG usually correlates with an ABG (i.e. venous pH is
    ~0.05 lower than arterial pH), but this is less accurate in shock
    or severe acid-base disturbance</li>
<li>ABGs are obtained by respiratory both at VUMC and the VA. VBGs can
    be ordered the same as any other lab. Alternatively the nurses can
    obtain a VBG (+lactate) with the iSTAT in the ICU at either VUMC or
    VA, which will return considerably faster<ul>
<li>To order iSTAT at VUMC, order "Respiratory Lab Panel" and choose
    selections</li>
<li>To order VBG at VA, order POC CG4+ (standard), POC CG8+ (loaded
    VBG), or simply enter a free text order "please obtain VBG"</li>
</ul>
</li>
</ul>
<p>Assessing Oxygenation:</p>
<p>On an ABG, can use the arterial PaO2 (measurement of O2 dissolved in
plasma) to assess oxygenation and calculate the A-a gradient.</p>
<p>A-a gradient = PAO2 (alveolar O2) – PaO2 (arterial O2)</p>
<ul>
<li>P <sub>A</sub> O <sub>2</sub> = FiO <sub>2</sub> (P
    <sub>barom</sub> - P <sub>H2O</sub> ) - PaCO <sub>2</sub> /R<ul>
<li>FiO2 = 0.21 on room air otherwise obtain from ventilator</li>
<li>P <sub>barom</sub> = 760, P <sub>H2O =</sub> 47</li>
<li>R (respiratory quotient) = 0.8</li>
<li>PaCO <sub>2</sub> = arterial CO2 measured on ABG</li>
<li>Normal A-a gradient = (Age +10)/4</li>
</ul>
</li>
<li>Common Reasons for an Increased A-a Gradient:<ul>
<li>V/Q Mismatch: PE, atelectasis, PNA, pulmonary edema,
    pneumothorax, ILD, COPD</li>
<li>Diffusion limitation: interstitial lung disease</li>
<li>R
    à
    L Shunt Physiology:<ul>
<li>Cardiac: PFO, VSD, ASD, AVMs</li>
<li>Pulmonary: blood, pus, water(edema), cells, protein in the
    Alveoli</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Assessing Acid/Base Status and Ventilation:</p>
<ul>
<li>Look at the pH (normal = 7.35 – 7.45)<ul>
<li>pH \&lt; 7.35 = acidosis</li>
<li>pH &gt; 7.45 = alkalosis<ul>
<li>Look at the pCO2 (normal = 35-45 mmHg <em>)</em></li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>Primary Disorder</th>
<th>pH</th>
<th>pCO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Acidosis</td>
<td>\&lt; 7.35</td>
<td>>45</td>
</tr>
<tr>
<td>Respiratory Alkalosis</td>
<td>> 7.45</td>
<td>\&lt;35</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>\&lt; 7.35</td>
<td>\&lt;45</td>
</tr>
<tr>
<td>Metabolic Alkalosis</td>
<td>> 7.45</td>
<td>>35</td>
</tr>
</tbody>
</table>
<ul>
<li>Is the primary disorder acute vs. chronic?</li>
<li>Is the primary disorder appropriately compensated?</li>
<li>If not appropriately compensated, what additional process is
    present?</li>
</ul>
<p>Primary Respiratory Acidosis:</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Acute respiratory acidosis and hypercarbia will often present
    with somnolence or AMS</li>
<li>Similarly, if a PCO2 is 80, and the patient is talking to you,
    it is most likely chronic</li>
</ul>
</li>
<li>Common Acute Causes: Decreased respiratory drive (opiates,
    intoxication) or respiratory muscle weakness (i.e. myasthenia gravis
    exacerbation)</li>
<li>Common Chronic Causes: COPD, sleep apnea</li>
<li>Appropriate metabolic compensation?<ul>
<li>If acute, every 10 mmHg increase in pCO2 above normal (40)
    should raise HCO3 by 1<ul>
<li>Expected HCO3 = 24 + ((pCO2 -40)/10))
    If chronic, every 10 mm Hg
    ↑
    in pCO2 above normal (40) should raise HCO3 by 3.5</li>
<li>Expected HCO3 = 24 + 3.5 ((pCO2-40/10)).</li>
</ul>
</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
<li>If HCO3 lower than expected
    à
    additional metabolic acidosis</li>
</ul>
<p>Primary Respiratory Alkalosis</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Common Acute Causes: Mechanical ventilation, anxiety/panic
    attack, pain, PE</li>
<li>Common Chronic Causes: Pregnancy, CNS disorder, hormones
    (thyroid, progesterone)</li>
</ul>
</li>
<li>Appropriate metabolic compensation?<ul>
<li>If acute, every 10 mmHg change in pCO2 should decrease the HCO3
    by 2<ul>
<li>Expected HCO3 = 24 – 2*((40-pCO2/10)</li>
</ul>
</li>
<li>If chronic, every 10 mmHg change in pCO2 should decrease the
    HCO3 by 4<ul>
<li>Expected HCO3 = 24 – 4*((40-pC02)/10)</li>
</ul>
</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
<li>If HCO3 lower than expected
    à
    additional metabolic acidosis</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Respiratory Acidosis</td>
<td>Respiratory alkalosis</td>
</tr>
<tr>
<td>Acute</td>
<td>10:1</td>
<td>10:2</td>
</tr>
<tr>
<td>Chronic</td>
<td>10:3.5</td>
<td>10:4</td>
</tr>
<tr>
<td>NaN</td>
<td>For every ↑of 10 in pCO2, HCO3 ↑ by 1 or 3.5</td>
<td>For every ↓ of 10 in pCO2 HCO3 ↓ by 2 or 4</td>
</tr>
</tbody>
</table>
<p>Primary Metabolic Alkalosis</p>
<ul>
<li>Appropriate Respiratory Compensation?<ul>
<li>Expected pCO2 = 0.7*(HCO3) + 20 (&plusmn;5)</li>
</ul>
</li>
<li>Etiologies: Majority of causes are associated with high aldosterone
    (either appropriate or inappropriate)<ul>
<li>Chloride Responsive
    = appropriate hyperaldosteronism, can usually be fixed with NaCl
    administration/ volume resuscitation<ul>
<li>Etiologies: Volume contraction i.e vomiting, over-diuresis
    which stimulates kidneys to reabsorb Na (and Cl absorbed
    with Na)</li>
<li>Urine Cl \&lt;20</li>
</ul>
</li>
</ul>
</li>
<li>Chloride Unresponsive
    = inappropriate hyperaldosteronism, cannot fix with NaCl
    administration/ volume resuscitation as already likely volume
    overloaded<ul>
<li>
<ul>
<li>Etiologies: Steroids, Cushing’s, Conn’s, RAS, CHF, cirrhosis</li>
<li>Urine Cl &gt;20.</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Primary Metabolic Acidosis</p>
<ul>
<li>See nephrology section, “Metabolic Acidosis”</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-cf-exacerbation"><h1 id="pulmonary-pulmonary-cf-exacerbation-cf-exacerbation">CF Exacerbation<a class="headerlink" href="#pulmonary-pulmonary-cf-exacerbation-cf-exacerbation" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic Fibrosis (CF) Exacerbation</td>
</tr>
</tbody>
</table>
<p>All admissions:</p>
<ul>
<li>“Cystic Fibrosis” Admission order set in epic, contains most orders
    and labs below</li>
<li>Enter “Pulmonary, Cystic Fibrosis” Consult in Epic, exception is on
    Rogers Pulmonary if the attending specializes in CF</li>
<li>Pancreatic enzymes (most pts are on them), order at bedside for pt
    administration</li>
<li>Always continue ADEK vitamins</li>
<li>Consult nutrition (There is a specific Radio Button in the nutrition
    consult order for CF)</li>
<li>Send sputum culture for bacterial, AFB and Fungus if not sent from
    clinic<ul>
<li>Specify “CF Resp” when prompted</li>
</ul>
</li>
<li>CXR PA and Lat – especially if new sharp chest pains</li>
<li>Order all home inhaler and airway clearance (AWC) therapies (See
    Sputum Clearance below), ask about compliance with these therapies
    at home</li>
<li>All CF pts are placed on contact precautions</li>
<li>Always ask about coughing up blood and amount -- see 'Hemoptysis'
    section if present</li>
<li>Sputum clearance: albuterol nebs, pulmozyme (if on at home),
    hypertonic saline (if on at home), Vest and/or Acapella, CPD as last
    choice since not as effective (pts like it)</li>
<li>CF modulators (e.g., ivacaftor/tezacaftor/elaxacaftor): continue if
    on at home;  place non-formulary order so pt can use own supply;
    time with fat rich meal for absorption</li>
</ul>
<p>Malnutrition:</p>
<ul>
<li>Common and improves with treatment of infectious exacerbation</li>
<li>Daily to 3 times a week weight checks</li>
<li>Nutrition consult as above</li>
</ul>
<p>DIOS - Distal Intestinal Obstruction Syndrome:</p>
<ul>
<li>Treat with Miralax and/or Golytely</li>
<li>Often looks like mechanical obstruction</li>
<li>RARELY surgery, try medical management first</li>
</ul>
<p>CF Pneumonia admission:</p>
<ul>
<li>Continue tobramycin nebs (if on that month) and MWF Azithromycin
    unless otherwise contraindicated if they are on these therapies at
    home</li>
<li>Check RVP, and treat with oseltamivir if flu+</li>
<li>Use Epic Order Adult Cystic Fibrosis order set for Antibiotic/dosing</li>
<li>Look at last admission, last CF note, culture data – MRSA, MSSA, and
    Pseudomonas are by far the most common<ul>
<li>If they were recently admitted and improved on that antibiotic
    regimen, it is usually a good empiric choice</li>
</ul>
</li>
<li>If MRSA then Vancomycin 1G q8h (okay to consult Pharm for dosing)<ul>
<li>if Vanc allergic then Bactrim DS-2 TID or Linezolid</li>
</ul>
</li>
<li>Assume all pts are colonized with Pseudomonas. Empirically double
    cover with:<ul>
<li>Something from Penicillin class (Cephalosporin, carbapenem,
    extended penicillin)</li>
<li>Aminoglycoside or Ciprofloxacin</li>
</ul>
</li>
<li>CF team -- there is no fellow for this, so don’t worry when you have
    to page an attending<ul>
<li>They will guide all antibiotics decisions following admission
    (check outpt clinic note)</li>
<li>Doses are not normal, do not use Sanford:<ul>
<li>Aztreonam: 2 gm q 6 hours (good for Pen allergic)</li>
<li>Cefepime 2 gm q 8 hours</li>
<li>Ceftazidime 4 gms q 8 hours</li>
<li>Cipro 750 mg po bid or 400 mg IV q 8</li>
<li>Imipenem 1 gm q 6-8 hours</li>
<li>Meropenem 2 gm q 8 hours 2 hr infusion</li>
<li>Doripenem 1 gm q 8 hours 2 hr infusion</li>
<li>Piperacillin/tazo (Zosyn) 4.750 gm q 6 hours 4 h infusion</li>
<li>Tobramycin 10mg/kg q 24 hours</li>
<li>Can consult pharmacy for Tobramycin dosing, but check renal
    function first</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-copd-exacerbation-management"><h1 id="pulmonary-pulmonary-copd-exacerbation-management-copd-exacerbation-management">COPD Exacerbation Management<a class="headerlink" href="#pulmonary-pulmonary-copd-exacerbation-management-copd-exacerbation-management" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD Exacerbation – Taylor Coston</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Diffuse wheezing, distant breath sounds, barrel-shaped chest,
    tachypnea, tachycardia, smoking &gt;20 pack years</li>
<li>Features of severe respiratory insufficiency: accessory muscle use;
    fragmented speech; inability to lie supine; profound diaphoresis;
    agitation; asynchrony between chest and abdominal motion with
    respiration; failure to improve with initial emergency treatment</li>
<li>Features of impending respiratory arrest: Inability to maintain
    respiratory effort, cyanosis, hemodynamic instability, and depressed
    mental status</li>
<li>Remember: Patients with COPD can have other causes of respiratory
    distress including acute coronary syndrome, decompensated heart
    failure, PE, PNA, PTX, sepsis, acidosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Initial Assessment: ABCs<ul>
<li>Airway/Breathing<ul>
<li>Ensure patient is protecting airway. If obtunded or in
    severe respiratory distress (see above) call anesthesia
    early for consideration of endotracheal intubation. <em>(If in
    the</em> MICU during the day, just call the MICU fellow)<ul>
<li>Noninvasive ventilation (NIV), particularly BiPAP:
    Appropriate for most patients with severe COPD
    exacerbation unless immediate intubation is needed or
    other contraindication (vomiting, too obtunded to take
    off mask if necessary, facial trauma). Necessitates MICU
    admission</li>
<li>Remember: BiPAP is ordered as IPAP and EPAP. I.e. if the
    pt is on 12/5 the mask will deliver a pressure of 12
    when breathing in and 5 when breathing out.</li>
<li>12/5 is a good start, in comments write “auto-titrate”
    and the RT will have some leeway to change settings</li>
</ul>
</li>
<li>Immediate pharmacotherapy, in tandem with diagnostics and
    airway mgmt</li>
</ul>
</li>
<li>Circulation<ul>
<li>For hemodynamic instability, HR \&lt; 50, call anesthesia for
    immediate rapid sequence intubation (RSI). Pt’s can be
    hypotensive for a host of reasons including pneumothorax,
    sepsis, circulatory collapse from hypoxia and bradycardia,
    etc.</li>
</ul>
</li>
</ul>
</li>
<li>Subsequent Workup:<ul>
<li>Continuous pulse oximetry, ABG/VBG, EKG, CXR, CBC, BMP,
    troponin, BNP (if considering HF dx), Sputum cx, consider blood
    cx if concern for sepsis, rapid flu.</li>
<li>Lung Ultrasound to differentiate COPD from pulmonary edema when
    a pt presents with wheezing and respiratory failure (pulmonary
    edema will have Kerley B lines)</li>
<li>During evaluation, consider triggers for COPD exacerbation:
    viral infection (70%), PNA, PE. <strong>Have a high index of suspicion
    for PE in these pts</strong> .</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Manage airway
    as above - many pts will need BiPAP if severe respiratory distress
    or hypercapnia are present</li>
<li>Bronchodilators<ul>
<li>Order “Respiratory Care Therapy Management Protocol” at VUMC</li>
<li>When ordered, an RT evaluates the pt and based on physical exam
    will give a duoneb</li>
<li>The RT will then continue to assess the pt based on severity of
    the exacerbation</li>
<li>If ordering bronchodilators individually (this is discouraged)
    order:<ul>
<li>Albuterol 2.5 mg diluted to 3 mL via nebulizer or 4 to 8
    inhalations from MDI every 4 hours while awake (RT), or more
    frequently if needed</li>
<li>Ipratropium 500 mcg via nebulizer, or 4-8 inhalations from
    MDI q 4 hrs while awake</li>
<li>Can additionally order "duoneb" at VUMC</li>
<li>There is no respiratory order protocol at the VA, order
    individually as above. RT is available to assess if needed</li>
</ul>
</li>
</ul>
</li>
<li>Steroids<ul>
<li>For severe exacerbation give methylprednisolone 125 mg IV BID
    (or 60mg IV q6h)</li>
<li>For moderate to mild COPD exacerbations give prednisone 40mg PO
    daily for 5 days (including the initial IV dose if pt received
    one in the ER)</li>
</ul>
</li>
<li>Antibiotics<ul>
<li>Benefit less clear in mild to moderate exacerbations</li>
<li>Azithromycin 500mg x 1 then 250mg daily for 4 days or
    doxycycline 200 mg BID if concern for QT prolongation. Can also
    consider Levaquin 750mg PO daily for 5 days, however this is
    often too broad for a standard COPD exacerbation.</li>
<li>Refer to “Pneumonia” if treating a separate PNA in addition to
    COPD</li>
</ul>
</li>
<li>Discharge Planning:<ul>
<li>Teaching on medication compliance and appropriate use. Ensure pt
    has a spacer</li>
<li>Pulmonary Rehab</li>
<li>Vaccinations (see outpatient management COPD in handbook)</li>
<li>Controller medications/inhalers (see outpatient management COPD
    in handbook)</li>
<li>Exacerbation Action plans: No consensus as to what the
    components should be, but instead a patient-specific plan can be
    made should the pt’s symptoms recur</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-cxrs"><h1 id="pulmonary-pulmonary-cxrs-cxrs">CXRs<a class="headerlink" href="#pulmonary-pulmonary-cxrs-cxrs" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>How to Interpret Chest Radiographs (CXR) – Gautam Babu</td>
</tr>
</tbody>
</table>
<p>An X-ray is a density-gram where “white” is “dense” and “black” is “not
dense”.  Determine a systematic method you use every time you interpret
a CXR to ensure you don’t miss anything.</p>
<ul>
<li>
<p>Start every CXR you interpret by assessing the quality of the film:</p>
<ul>
<li>Penetration: You should be able to see vertebral bodies through
    the cardiac silhouette but not into the abdomen. If you cannot
    see them through the heart the film is “under-penetrated” and
    everything will appear more “white.” If you can see them through
    the abdomen the film is “over-penetrated” and everything will
    appear more “black”</li>
<li>Rotation: The spinous processes should be in the middle of the
    clavicular heads, if not then the film is rotated</li>
</ul>
</li>
<li>
<p>Two Different Systematic Methods:</p>
<ul>
<li>ABCDE method<ul>
<li>Airway – Trachea midline and patent</li>
<li>Bones – Bone density and obvious fractures</li>
<li>Cardiac Silhouette – You should be able to see the L and R
    heart border, if not there may be an adjacent opacity (Right
    Middle Lobe, Lingula)</li>
<li>Cardiomegaly defined as heart size
    ≥
    &frac12; width of the hemithorax <em>on a PA film</em></li>
<li>Diaphragm – Look for pleural effusions at the costo-phrenic
    angle. If you cannot see the diaphragm along the way there
    may be an adjacent opacity (Lower Lobe)</li>
<li>“Everything else” – Refers to the lung fields but if you
    wanted to continue the alphabet mnemonic</li>
<li>Extra-Thoracic Soft Tissue – Subcutaneous emphysema</li>
<li>Fields and Fissures –lung fields should appear symmetric and
    “black.” Asymmetry suggests there is an issue on one side.</li>
<li>Great Vessels – Tortuosity of the aorta and the outlines of
    the pulmonary vessels</li>
<li>Hilum – Hilar masses, LAD and pulmonary arteries, the left
    hila is higher than the right normally because of the heart</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Working around the film method:</p>
<ul>
<li>Imagine the entire CXR film as a square and an inner “box” as
    the pleural lining</li>
</ul>
</li>
<li>
<ul>
<li>Outside the box: Looking for lines, tubes, EKG/tele leads,
        subcutaneous emphysema, stomach bubble, sub diaphragmatic air</li>
<li>The edge of the box: Looking for pleural thickening, pleural
    effusion, pneumothorax, visualization of the diaphragm</li>
<li>The middle of the box: aka Mediastinum -&gt; trachea, vascular
    pedicle, hila, heart borders, great vessels, retrocardiac space</li>
<li>The lung fields</li>
</ul>
</li>
</ul>
<p>One important concept to know is the <strong>silhouette sign:</strong> Two things of
different densities will show a clear border on a chest x-ray. In the
contrapositive, the loss of a border you expect to see suggests there
has been</p>
<p>a change in density of one of the structures. For example, the heart and
the lung are different densities and as such you have a sharp border.
Loss of this border suggests that the adjacent lung “increased” in
density from a PNA (in the right clinical scenario).</p>
<ul>
<li>Often try to distinguish PNA from pulmonary edema, as these are two
    of the most common causes of abnormal opacities seen on CXR<ul>
<li>PNA<ul>
<li>"fluffy" opacities and air bronchograms frequently indicate
    alveolar filling</li>
<li>typically asymmetric</li>
</ul>
</li>
<li>Pulmonary Edema<ul>
<li>linear opacities, fluid in the fissure, Kerley B lines,
    cephalization, bilateral pleural effusions</li>
<li>Typically symmetric</li>
<li>atypical or viral PNA can similarly present with linear
    opacities</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Web Resources:</p>
<ul>
<li>UVA Department of Radiology “Introduction to Chest Radiology”<ul>
<li><a href="https://www.med-ed.virginia.edu/courses/rad/cxr/index.html">https://www.med-ed.virginia.edu/courses/rad/cxr/index.html</a></li>
<li>Website includes specific examples of lung pathology as well as
    CXR interpretation exercises in the “post test” section</li>
</ul>
</li>
<li>Life in the Fast Lane CXR Self-Assessment Quiz:
    <a href="https://litfl.com/top-100/cxr/">https://litfl.com/top-100/cxr/</a></li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-hemoptysis"><h1 id="pulmonary-pulmonary-hemoptysis-hemoptysis">Hemoptysis<a class="headerlink" href="#pulmonary-pulmonary-hemoptysis-hemoptysis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoptysis – Henry Brems</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Distinguish between massive (&gt;600cc/24hr or &gt;100cc/hr) and
    non-massive hemoptysis; however, due to practical difficulties
    quantifying expectorated blood and limitations in quantifying blood
    in lungs that is not expectorated, verbiage is falling out of favor</li>
<li>Massive is potentially life-threatening due to impaired ventilation
    not necessarily due to hemodynamic compromise</li>
<li>Remember UGIB (hematemesis) and nasopharyngeal bleeds can easily
    mimic hemoptysis and require different management</li>
<li>Presentation based on source of bleed:</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structure</td>
<td>Etiologies</td>
</tr>
<tr>
<td>Airways</td>
<td>Bronchitis (common cause of non-massive), bronchiectasis (especially in CF pts), neoplasm</td>
</tr>
<tr>
<td>Alveolar/ Parenchymal</td>
<td>Infectious (bacterial PNA, abscess, TB, fungal, aspergilloma), Rheumatic (Goodpasture’s, GPA, Behcet’s)</td>
</tr>
<tr>
<td>Vascular</td>
<td>PE, AVM, CHF, mitral stenosis</td>
</tr>
<tr>
<td>Other</td>
<td>Coagulopathy, traumatic, foreign-body, iatrogenic, cocaine-induced</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Assess anticoagulation status</li>
<li>Labs: CBC, BMP, Coags, UA (for hematuria), ABG (evaluate
    oxygenation), type and screen<ul>
<li>Also consider ANA, ANCA, Anti-GBM, sputum culture (bacteria,
    fungal, AFB), sputum cytology as indicated to further evaluate
    etiology</li>
</ul>
</li>
<li>Imaging: CXR first (to evaluate etiology and to localize the source
    to a side). May likely require Chest CT pending prior workup,
    severity of bleed, and stability of patient</li>
<li>Bronchoscopy is sometimes indicated to localize bleeding source</li>
</ul>
<p>Management</p>
<ul>
<li>Hemoptysis that is non-massive and does not impair ventilation can
    generally be evaluated and treated non-urgently</li>
<li>Urgent evaluation needed if there is any hemodynamic compromise,
    hypoxia, hypercarbia, or respiratory distress</li>
<li>Reverse underlying coagulopathy if present. Consider trending HCT</li>
<li>Make NPO</li>
<li>If unilateral bleed, place <strong>bleeding lung down</strong> (i.e. if the
    source is left lung, place pt on left side) to prevent filling
    'good' lung with blood ( <strong>Include this info in sign-out</strong> if known)</li>
<li>Ensure a secure airway: Massive hemoptysis may require intubation
    and MICU transfer</li>
<li>Urgent pulmonary consult if clinical instability: Bronchoscopy is
    diagnostic and therapeutic</li>
<li>Obtain CT Bronchial Artery Protocol if concern for bronchial artery
    source (especially in CF patients) so embolization can be planned<ul>
<li>Order this at VUMC with a CTA Chest (NOT a CTA PE as that will
    be timed incorrectly) and include "bronchial artery protocol" in
    comments for the study</li>
</ul>
</li>
<li>Consider IR consult for angiography as diagnostic and therapeutic
    option<ul>
<li>Consult early if there is massive hemoptysis; If bronchoscopy is
    attempted but fails to stop the bleed, they can get to
    angiography fastest if IR has already been made aware</li>
</ul>
</li>
<li>Consider GI and/or ENT evaluation if source of bleed is unclear</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-home-oxygen-therapies"><h1 id="pulmonary-pulmonary-home-oxygen-therapies-home-oxygen-therapies">Home Oxygen Therapies<a class="headerlink" href="#pulmonary-pulmonary-home-oxygen-therapies-home-oxygen-therapies" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home Oxygen Therapies – Taryn Boyle</td>
</tr>
</tbody>
</table>
<p>Summary of Medicare Part B Guidelines for Home Oxygen:</p>
<ul>
<li>Conditions for Which Oxygen Therapy May Be Covered:<ul>
<li>Severe lung disease including COPD and ILD (regardless of known
    etiology), CF, bronchiectasis, widespread pulmonary neoplasms</li>
<li>Hypoxia related symptoms or findings expected to improve with
    O2: pulmonary hypertension, recurring CHF secondary to chronic
    cor pulmonale, erythrocytosis, impaired cognition, nocturnal
    restlessness, morning headache</li>
</ul>
</li>
<li>Qualifying Tests and Requirements:<ul>
<li>Testing must be performed with a pt in chronic stable condition
    (i.e. outpatient clinic) or within two days of discharge from an
    inpatient hospital stay (after treatment of acute exacerbating
    conditions have been trialed, ie. infection, bronchospasm)</li>
<li>Medicare requires that test results must be documented in a pt’s
    medical record and made available to the oxygen provider</li>
</ul>
</li>
<li>Patient can be tested under either of these conditions:<ul>
<li>At rest: SpO2 ≤ 88% (or PaO2 \&lt;55)</li>
<li>If no hypoxia at rest, perform with exercise (“Ambulatory Sats”)<ul>
<li>Ask RN or RT to perform and document in Epic—they have a
    template:<ul>
<li>SpO2 at rest</li>
<li>SpO2 on room air with ambulation (must desat ≤ 88%)</li>
<li>Amount of O2 (in L) required to maintain SpO2 &gt; 89%</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Special Considerations:<ul>
<li>Medicare requires an additional walk on 4L/min showing
    desaturation if the patient needs a flow rate of  5L/min or
    higher</li>
<li>Because of the risk of desaturation with exertion and the
    intrinsic error in the pulse ox (around 3%), patients with
    resting saturations of ≤ 92% should be walked to assess O2 needs</li>
<li>Be aware that if the patient has Raynaud’s or poor circulation,
    a finger pulse oximeter reading may be inaccurate and read lower
    than the patient’s actual saturations.  A head saturation
    monitor should be used in these circumstances</li>
</ul>
</li>
<li>Try to perform any of these diagnostic tests 1-2 days prior to
    anticipated discharge. Be sure to touch base with your CM about the
    need for home oxygen, as they will help arrange</li>
<li>VA Specific Guidance: Will need to document ambulatory saturations
    in notes as above. Call the Oxygen Clinic (number listed in all team
    rooms) and talk with your case manager</li>
</ul>
<p>Summary of Medicare Part C Guidelines for Home Respiratory Assist
Devices i.e CPAP/BiPAP:</p>
<ul>
<li>Restrictive Thoracic Disorders: Covered if the following criteria
    are met:<ul>
<li>There is documentation in the MR of a neuromuscular disease or a
    severe thoracic cage abnormality and one of the following:<ul>
<li>An arterial blood gas PaCO2 ≥ 45mmHg, performed while awake
    and on home O2 requirement, OR</li>
<li>Sleep oximetry demonstrates oxygen saturation ≤ 88%, for ≥ 5
    minutes of nocturnal recording time (minimum recording time
    of 2 hours), performed while on home O2 requirement, OR</li>
<li>For a neuromuscular disease (only), either:<ul>
<li>Maximal inspiratory pressure \&lt; 60cm H2O or</li>
<li>Forced vital capacity \&lt; 50% predicted and</li>
</ul>
</li>
<li>COPD may not contribute significantly to the patient’s
    limitations</li>
</ul>
</li>
</ul>
</li>
<li>Severe COPD: Covered if the following criteria are met:<ul>
<li>An arterial blood gas PaCO2 ≥ 52mmHg, performed while awake and
    on patient’s prescribed home O2</li>
</ul>
</li>
<li>Sleep oximetry demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes
    of nocturnal recording time (minimum recording time of 2 hours),
    performed while breathing oxygen at 2LPM or patient’s prescribed
    FIO2 (whichever is higher), AND<ul>
<li>Prior to initiating therapy, sleep apnea and treatment with a
    continuous positive airway pressure (CPAP) device has been
    considered and ruled out (formal sleep testing not required)</li>
</ul>
</li>
<li>Hypoventilation Syndrome: covered if criteria 1, 2, AND either 3 or
    4 are met:<ul>
<li>An initial arterial blood gas PaCO2 ≥45 mm Hg, performed while
    awake and on home O2 requirement, AND</li>
<li>Spirometry shows an FEV1/FVC ≥ 70% AND</li>
<li>An arterial blood gas PaCO2, performed during sleep or
    immediately upon awakening that demonstrates worsening PaCO2 of
    ≥ 7mm Hg compared to the original result in criterion 1 OR</li>
<li>A facility-based PSG or HST demonstrates oxygen saturation ≤ 88%
    for ≥ 5 minutes of nocturnal recording time (minimum recording
    time of 2 hours) that is not caused by obstructive upper airway
    events, i.e., AHI \&lt;5</li>
</ul>
</li>
<li>OSA:<ul>
<li>An initial screening for OSA in the hospital is nocturnal pulse
    oximetry. The distinct “saw-tooth” pattern representing
    intermittent hypoxia is suggestive of OSA, and a formal NPSG or
    home sleep test is recommended to evaluate for OSA.  This is
    done on an outpatient basis only once acute issues have fully
    resolved</li>
<li>Home CPAP/BiPAP covered IF:<ul>
<li>The diagnosis of central sleep apnea or complex sleep apnea
    and</li>
<li>Significant improvement of the sleep-associated
    hypoventilation occurs with the use of the device</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-hypoxia"><h1 id="pulmonary-pulmonary-hypoxia-hypoxia">Hypoxia<a class="headerlink" href="#pulmonary-pulmonary-hypoxia-hypoxia" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxia – Henry Brems</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Two major ways to measure oxygenation, which are similar but
    distinct:<ul>
<li>SpO2 or "pulse ox" - most common measurement in the hospital or
    clinic, which measures the O2 saturation of Hgb at capillary
    level<ul>
<li>\&lt;95% is abnormal, but may not need supplemental O2 until
    \&lt;90-92% in most pts</li>
</ul>
</li>
<li>PaO2 -- the partial pressure of oxygenation measured on an ABG<ul>
<li>\&lt;80 mmHg is abnormal</li>
</ul>
</li>
</ul>
</li>
<li>The relationship between SpO2 and PaO2 is the classic S-shaped
    curve.</li>
<li>Below an SpO2 of ~88%, PaO2 begins to fall off dangerously fast
    thus necessitating quick intervention for pts with SpO2 below this
    level</li>
</ul>
<p>Mechanisms of Hypoxia:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Pathophysiology</td>
</tr>
<tr>
<td>Decreased barometric pressure</td>
<td>- Normal A-a gradient - This is unlikely to be seen except at high altitudes</td>
</tr>
<tr>
<td>Hypoventilation</td>
<td>- Normal A-a gradient - Hypoxia easily correctable with supplemental O2</td>
</tr>
<tr>
<td>V/Q Mismatch</td>
<td>- Increased A-a gradient - Processes that lead to areas of lung where V/Q \&lt;1, i.e. where there is relatively less ventilation than perfusion. - Common examples include PNA, ARDS, pulmonary edema</td>
</tr>
<tr>
<td>Right-to-left Shunt</td>
<td>- Increased A-a gradient - Can be anatomic (e.g intracardiac, AVMs) or physiologic (water/pus/blood filling alveoli) - Classically does not easily correct with supplemental O2</td>
</tr>
<tr>
<td>Diffusion Limitation</td>
<td>- Increased A-a gradient - Often related to diseases affecting interstitium -- e.g., ILD</td>
</tr>
</tbody>
</table>
<p>Differential diagnosis for hypoxia based on anatomical location:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anatomical Location</td>
<td>Differential Diagnosis</td>
</tr>
<tr>
<td>Airways</td>
<td>- COPD most common, Asthma in very severe cases - CF, bronchiectasis in patients with appropriate history</td>
</tr>
<tr>
<td>Alveoli</td>
<td>- Any process that fills the alveoli with: Blood Pus -- infection from bacterial, viral, fungal agents Water -- pulmonary edema Protein/Cells/Other -- ARDS, pneumonitis (e.g. aspiration, drug-induced)</td>
</tr>
<tr>
<td>Interstitium/Parenchyma</td>
<td>- Interstitial Lung Diseases (see section)</td>
</tr>
<tr>
<td>Vascular</td>
<td>- Pulmonary Emboli - particularly suspect these in patients with significant hypoxia and a clear CXR</td>
</tr>
<tr>
<td>Pleural Space and Chest Wall</td>
<td>- Pleural Effusions, Pneumothorax, Neuromuscular weakness, tense ascites - These are more likely to cause significant dyspnea and usually need to be quite severe to cause hypoxia</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Confirm true hypoxia with good pleth. Can press pulse-ox on pt’s
    finger for better transmission</li>
<li>CXR is almost always the first step</li>
<li>Other common initial workup: CBC, BMP, BNP, troponin, EKG, ABG/VBG</li>
<li>TTE -- particularly useful if suspected new pulmonary edema or
    pulmonary HTN<ul>
<li>Obtain with 'bubble study' if any concern for shunt</li>
<li>Obtain “limited” if patient had recent “complete” TTE</li>
</ul>
</li>
<li>Chest CT<ul>
<li>Order CTA ('CTA PE' in Epic) if concerned for PE<ul>
<li>V/Q scan if unable to receive IV contrast</li>
</ul>
</li>
<li>CT Chest without contrast otherwise generally preferred for
    evaluation of lung parenchyma</li>
</ul>
</li>
<li>PFTs are useful if there is suspected obstructive (e.g. COPD) or
    restrictive disease (e.g. ILD), or if the cause remains otherwise
    unknown after initial workup<ul>
<li>These are almost always done as an outpatient</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Should be directed at underlying cause. See other sections for
    information relevant to particular diagnoses</li>
<li>If acutely decompensating, Duonebs, IV lasix, Antibiotics depending
    on clinical picture</li>
<li>Supplemental O2 for goal SpO2:<ul>
<li>>90-92% for most patients (There is generally no need to make
    SpO2 100%)</li>
<li>Between 88-92% for patients with chronic hypoxia from COPD
    (i.e., on home O2)</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-ild"><h1 id="pulmonary-pulmonary-ild-ild">ILD<a class="headerlink" href="#pulmonary-pulmonary-ild-ild" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial Lung Disease – Gaby Schroeder</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>MANY CAUSES, one mnemonic to use:<ul>
<li>S
    arcoidosis</li>
<li>H
    ypersensitivity Pneumonitis</li>
<li>I
    diopathic Interstitial Pneumonias (IIPs- UIP/IPF, NSIP, OP,
    RB-ILD, DIP, LIP, AIP)</li>
<li>T
    uberculosis</li>
<li>F
    ungal</li>
<li>A
    spiration/ Asbestosis (and other Pneumoconiosis)</li>
<li>C
    onnective Tissue Disease + Cancer</li>
<li>E
    osinophilic Pneumonia</li>
<li>D
    rugs</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>History: Ask about 1) Duration, timing, severity of primary
    respiratory symptoms 2) Exposures: Pets, Occupation, Residence,
    Mold, Feathers, Smoking, Illicits, Travel, Hobbies, Medications
    (especially amiodarone, nitrofurantoin and chemotherapies) 3)
    Symptoms of systemic autoimmune disease 4) Family history</li>
<li>Chest Imaging: HRCT is best for characterization, but often not
    achievable or desirable in inpatient setting when patients are
    critically ill.</li>
<li>Labs:<ul>
<li>Rule out fungal infection: Histo Antigen, Blasto Antigen,
    Aspergillus Galactomannan, 1,3-
    β
    -D-Glucan, sputum GMS (orderable as 'Cytology/Pneumocystis
    Stain')</li>
<li>Rheumatologic Work Up: ANA w/ Reflex, CK, Aldolase, consider
    full myositis panel<ul>
<li>
<ul>
<li>RA: RF, Anti-CCP</li>
<li>Scleroderma: Anticentromere, Anti-SCL-70</li>
<li>Mixed Connective Tissue Disease: Anti-ribonuclear
    protein</li>
<li>DM/PM: Anti-Jo</li>
<li>SLE: Anti-ds DNA, Anti-sm, APL</li>
<li>Sjogren: Anti-SS-A (Ro), Anti-SS-B (La)</li>
</ul>
</li>
</ul>
</li>
<li>If risk factors present: Sputum AFB, Hypersensitivity Panel</li>
</ul>
</li>
<li>PFTs, 6-minute walk test</li>
<li>Bronchoscopy: BAL (Cell counts, cultures, cytology) + Tissue Biopsy
    (Transbronchial vs. Cryobiopsy vs. surgical/VATS)</li>
</ul>
<p>Management</p>
<ul>
<li>Treat underlying condition</li>
<li>In the inpatient setting, often determine if a patient would benefit
    from immunosuppression therapy (i.e. steroids) initially, but will
    need to rule out to infection first</li>
<li>Consider lung transplantation for rapidly progressive or refractory
    cases in appropriate candidate</li>
</ul>
<p>Primary Respiratory Acidosis:</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Acute respiratory acidosis and hypercarbia will often present
    with somnolence or AMS</li>
<li>Similarly, if a PCO2 is 80, and the patient is talking to you,
    it is most likely chronic</li>
</ul>
</li>
<li>Common Acute Causes: Decreased respiratory drive (opiates,
    intoxication) or respiratory muscle weakness (i.e. myasthenia gravis
    exacerbation)</li>
<li>Common Chronic Causes: COPD, sleep apnea</li>
<li>Appropriate metabolic compensation?</li>
<li>If acute, every 10 mmHg increase in pCO2 above normal (40) should
    raise HCO3 by 1<ul>
<li>Expected HCO3 = 24 + ((pCO2 -40)/10))</li>
</ul>
</li>
<li>If chronic, every 10 mm Hg
    ↑
    in pCO2 above normal (40) should raise HCO3 by 3.5<ul>
<li>Expected HCO3 = 24 + 3.5 ((pCO2-40/10)).</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pfts"><h1 id="pulmonary-pulmonary-pfts-pfts">PFTs<a class="headerlink" href="#pulmonary-pulmonary-pfts-pfts" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Function Tests (PFTs) – Peter Edmonds</td>
</tr>
</tbody>
</table>
<p>PFTs should rarely be ordered in inpatient setting as acute illness can
lead to suboptimal results.</p>
<p>Full PFTs include and can be ordered as the following:</p>
<ul>
<li>Spirometry: FVC, FEV1, with or without bronchodilator<ul>
<li>Outpatient evaluation of patients with new shortness of breath,
    chronic cough, or upper airway obstruction</li>
</ul>
</li>
<li>Plethysmography: TLC, RV<ul>
<li>Evaluation of restrictive diseases (ILD, neuromuscular disease)
    and/or hyperinflation (COPD, asthma)</li>
</ul>
</li>
<li>Diffusion (DLCO) can be added to plethysmography.<ul>
<li>Full PFTs' = Spirometry + Plethysmography + DLCO</li>
</ul>
</li>
</ul>
<p>Tips for ordering:</p>
<ul>
<li>Initial diagnostic workup<ul>
<li>Order full PFTs with bronchodilator challenge</li>
</ul>
</li>
<li>Chronic Lung disease:<ul>
<li>Order spirometry only to track FEV1/FVC over time &plusmn; DLCO to
    evaluate ILD</li>
</ul>
</li>
</ul>
<p>Interpretation:</p>
<ul>
<li>Distinguish between Obstructive and Restrictive Disease<ul>
<li>FEV1/FVC \&lt; 0.7 indicates obstructive disease<ul>
<li>Normal to increased FVC &amp; TLC is consistent with isolated
    obstructive disease</li>
</ul>
</li>
<li>TLC \&lt; 80% is diagnostic of restrictive disease<ul>
<li>Reduced FVC is suggestive, but not diagnostic of restrictive
    disease</li>
<li>FEV1 commonly reduced as well, but FEV1/FVC ratio should be
    normal in isolated restrictive disease</li>
</ul>
</li>
<li>Decreased FEV1/FVC and TLC suggests a mixed obstructive and
    restrictive picture</li>
</ul>
</li>
<li>Assess DLCO -- abnormal is \&lt;75%</li>
<li>Decreased DLCO can help differentiate between causes of Obstructive
    or Restrictive PFTs</li>
</ul>
<p>Causes of common abnormalities:</p>
<ul>
<li>Obstruction<ul>
<li>DDx if DLCO decreased: COPD, CF, bronchiectasis</li>
<li>DDx if DLCO normal: asthma, early stages of COPD or CF</li>
<li>Asthma: spirometry may be normal, +bronchodilator response (an
    increase in FEV1 by 12% and 200ml after bronchodilator),
    +methacholine challenge</li>
<li>Though we use FEV1/FVC to <strong>diagnose</strong> , we track <strong>disease
    severity</strong> using FEV1</li>
</ul>
</li>
<li>Restriction:<ul>
<li>DDx if DLCO decreased:  ILD</li>
<li>DDx if DLCO normal: pleural disease, chest wall (e.g. obesity,
    scoliosis), Neuromuscular disorders</li>
</ul>
</li>
<li>Decreased DLCO:<ul>
<li>If PFTs otherwise normal, DDx includes pulmonary vascular
    disease, pulmonary edema, or mixed obstructive/restrictive
    disease (with pseudo-normalization of other PFTs)</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pleural-effusions"><h1 id="pulmonary-pulmonary-pleural-effusions-pleural-effusions">Pleural Effusions<a class="headerlink" href="#pulmonary-pulmonary-pleural-effusions-pleural-effusions" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pleural Effusions – Eddie Qian</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>There is a normal influx of fluid into the pleural space due to
    leaky capillary membranes and the pleural space’s negative pressure.
    This fluid is constantly reabsorbed by lymphatics. An imbalance in
    the system will result in accumulation.</li>
<li>Some examples:<ul>
<li>Increased Influx: increased filtration from the capillaries from
    high intravascular hydrostatic pressure (i.e., heart failure,
    renal failure, volume overload) or low intravascular oncotic
    pressure</li>
<li>Other liquid entry into the pleural space through anatomic
    deficits: CSF, chyle, urine, blood, ascites (the diaphragm is
    naturally porous and you will not uncommonly see pleural
    effusions with ascites)</li>
<li>Decreased Efflux: obstruction of the parietal pleural stoma
    (from protein or cellular debris in exudative pleural effusions)</li>
<li>Increased systemic venous pressure (lymphatic system drains into
    the systemic venous circulation so if there is high venous
    pressure this prevents the lymphatics from draining
    appropriately)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Imaging:<ul>
<li>CXR: lateral decubitus position (if effusion moves with gravity,
    suggests free flowing)</li>
<li>Ultrasound: assess size, location, loculations (fibrinous
    septations which may prevent simple drainage)</li>
<li>CT Chest with contrast (not always indicated; helpful to eval
    septations)</li>
</ul>
</li>
<li>Thoracentesis (see Procedures section):<ul>
<li>Will it change management?</li>
<li>Pleural LDH, protein, cell count/diff, culture</li>
<li>Consider: pleural cytology, hematocrit, triglycerides, glucose,
    amylase</li>
<li>Don’t forget serum LDH &amp; protein!</li>
<li>If septated or empyema,  consider pulm consult for chest tube</li>
</ul>
</li>
<li>
<p>Interpretation:</p>
<ul>
<li>
<p>Lights criteria: 1 of  the following to be considered an
    exudative effusion</p>
</li>
<li>
<ul>
<li>Pleural to serum protein ratio &gt; 0.5</li>
<li>Pleural to serum LDH ratio &gt; 0.6</li>
<li>Pleural LDH &gt; &#8532; upper limit of normal range of serum LDH</li>
</ul>
</li>
<li>
<p>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis
    (caused by increased intrapleural negative pressure),
    hypoalbuminemia, renal failur</p>
</li>
<li>
<p>Exudative: infections (bacterial, TB, fungal), malignant,
    rheumatologic, PE</p>
</li>
<li>
<p>Pearls about your initial tests:</p>
<ul>
<li>Protein: &gt;5 think TB or malignancy, \&lt; 0.5 think urine, CSF,
    peritoneal dialysate<ul>
<li>Glucose: \&lt; 60 think about malignancy, TB,
    rheumatologic, and less specific hemothorax or
    parapneumonic</li>
<li>Cell count/differential: polys represent an acute
    process, monocytes represent a chronic process,
    lymphocytes think about TB or malignancy, eosinophils
    think about air/blood, TB, malignancy, asbestos, drugs</li>
</ul>
</li>
</ul>
</li>
<li>Two separate process may co-occur and a transudate may mask an
exudative effusion; if  concerned for this and you have clinical
stability, trial diuresis prior to thoracentesis</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pulmonary-hypertension"><h1 id="pulmonary-pulmonary-pulmonary-hypertension-pulmonary-hypertension">Pulmonary Hypertension<a class="headerlink" href="#pulmonary-pulmonary-pulmonary-hypertension-pulmonary-hypertension" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Hypertension – Kaele Leonard</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Symptoms: dyspnea, exertional chest pain, fatigue, edema (legs,
    abdomen), exertional lightheadedness or syncope, palpitation</li>
<li>Exam: JVD, increased P2, split S2, RV heave, TR murmur,
    hepatomegaly, ascites, edema</li>
<li>Signs of RV failure: low cardiac output (hypotension, renal failure,
    hepatic congestion), arrhythmias, refractory hypoxemia (R→L shunt),
    effusions (pericardial &gt; pleural)</li>
<li>
<p>WHO Groups and Causes:</p>
</li>
<li>
<p>Pulmonary arterial hypertension (PAH): obliteration of blood vessels
    in the lung</p>
<ul>
<li>Idiopathic, heritable</li>
<li>Drugs/toxins (methamphetamine)</li>
<li>Associated with CTD, HIV, portal HTN, congenital heart disease,
    schistosomiasis</li>
<li>Pulmonary veno-occlusive disease (PVOD), pulmonary capillary
    hemangiomatosis</li>
</ul>
</li>
<li>Left heart disease: back pressure and passive congestion<ul>
<li>HFrEF, HFpEF, valvular disease, LA stiffness</li>
</ul>
</li>
<li>Chronic lung disease: chronic hypoxemia
    à
    chronic pulmonary vasoconstriction<ul>
<li>COPD, ILD, OSA, chronic high-altitude, developmental lung
    disorders</li>
</ul>
</li>
<li>Pulmonary artery obstruction and thrombi: obstruction due to chronic
    clot material<ul>
<li>Chronic thromboembolic pulmonary hypertension (CTEPH)</li>
</ul>
</li>
<li>Unclear or multifactorial mechanisms<ul>
<li>Hematologic disorders, chronic hemolytic anemia, sarcoidosis,
    pulmonary Langerhans cell histiocytosis, fibrosing
    mediastinitis, metabolic disorders</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Consult pulmonary hypertension with any questions or assistance with
    workup. Below are studies to consider ordering to determine
    etiology/group of pulmonary hypertension</li>
<li>Labs: BNP, rheumatologic studies (ANA, RF), HIV</li>
<li>CXR: increased right heart border, increased PA</li>
<li>EKG: RVH
    , RAD</li>
<li>TTE w/ bubble: RVSP &gt;35-40, RV dilation and dysfunction, RA
    dilation, septal flattening, pericardial effusion, evaluate for L
    heart disease and shunt</li>
<li>PFTs: decreased DLCO in PH, evaluate for parenchymal lung disease</li>
<li>VQ scan
    or CTA chest: evaluate for CTEPH<ul>
<li>Pulmonary angiogram (evaluate for surgical candidacy for
    pulmonary endarterectomy)</li>
</ul>
</li>
<li>+
    CT chest: evaluate for parenchymal lung disease</li>
<li>+
    ABG: evaluate for hypoxemia or hypercarbia</li>
<li>+
    Sleep
    study: evaluate for OSA</li>
</ul>
<p>Right heart catheterization (RHC): diagnose PH and determine pre- vs
post-capillary</p>
<ul>
<li>See RHC section for hemodynamic assessment</li>
<li>Nitric oxide challenge assess for drug response</li>
<li>Fluid challenge
    →
    assess left heart compliance</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions</td>
<td>Characteristics</td>
<td>Causes</td>
</tr>
<tr>
<td>Pre-capillary PH</td>
<td>mPAP > 20 mmHg PAWP ≤ 15 mmHg PVR ≥ 3 WU</td>
<td>Groups 1, 3, 4, 5</td>
</tr>
<tr>
<td>Post-capillary PH</td>
<td>mPAP > 20 mmHg PAWP > 15 mmHg PVR \&lt; 3 WU</td>
<td>Group 2</td>
</tr>
<tr>
<td>Combined pre- and post- capillary PH</td>
<td>mPAP > 20 mmHg PAWP > 15 mmHg PVR ≥ 3 WU</td>
<td>Group 2, 5</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>General: treat underlying cause; Diuretics for right heart failure;
    Oxygen goal SpO2 &gt; 90%</li>
<li>PAH medicines: Consult pulmonary hypertension for consideration to
    start or change thes<ul>
<li>Oral treatments may be used as monotherapy or in combination<ul>
<li>Calcium-channel blockers
    →
    patients with + vasoreactive challenge</li>
<li>NO-cGMP enhancers: PDE5-inhibitors sildenafil or tadalafil,
    riociguat</li>
<li>Endothelin receptor antagonists (ERAs): bosentan,
    macitentan, ambrisenta</li>
<li>Prostacyclins:</li>
<li>Epoprostenol: IV (Veletri) or inhaled (Flolan), half-life 4
    minutes</li>
<li>Treprostinil: IV/subcutaneous/inhaled/PO, half-life 4 hours</li>
<li>Iloprost: inhaled, half-life minutes</li>
<li>Selexipag (Uptravi): PO, half-life hours</li>
<li>Side effects: headache, jaw pain, flushing, diarrhea,
    arthralgias</li>
</ul>
</li>
</ul>
</li>
<li>Treatment based on NYHA functional classification:<ul>
<li>Class I: no treatment or monotherapy</li>
<li>Class II: monotherapy or combination oral therapy</li>
<li>Class III: combination oral therapy or prostacyclin</li>
<li>Class IV: prostacyclin &plusmn; oral therapy</li>
</ul>
</li>
<li>Lung transplant for patients who are candidates and failing maximal
    medical therapy</li>
<li>V-A ECMO can be used as bridge to medical therapy or lung transplant</li>
<li>Palliative
    measures<ul>
<li>Atrial septostomy – serves as “pop-off” valve and allows for
    decompression of failing RV; used as definitive palliative
    procedure or bridge to lung transplant</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Pulmonary</h1>
                        <h1 class='nav-section-title' id='section-radiology'>
                            Radiology <a class='headerlink' href='#section-radiology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="radiology-radiology-consults-radiology-procedures"><h1 id="radiology-radiology-consults-radiology-procedures-consults-for-radiology-procedures">Consults for Radiology Procedures<a class="headerlink" href="#radiology-radiology-consults-radiology-procedures-consults-for-radiology-procedures" title="Permanent link">&para;</a></h1>
<ul>
<li>Radiology Procedures are performed by three separate consult
    services depending on the clinical indication or procedure requested</li>
<li>Knowing the correct service will save you time when placing consults
    to reach the right service on first attempt</li>
<li>Contacting the <strong><em><u>pager</u></em></strong> for the appropriate service is the
    best way to speak directly with one of the physicians covering these
    services (MD’s are most often performing procedures or seeing
    patients, not located at the service desks)</li>
<li>These pagers are covered 24/7, often by the same person for up to a
    week at a time ( <strong><em>not a nightfloat</em></strong> ), so kindly <strong>reserve
    overnight pages for true urgent / emergent indications</strong> , and delay
    other non-emergent communications until the morning</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consult Service</td>
<td>Vascular IR</td>
<td>Body Procedures  (CT or US guided)</td>
<td>Body/Neuro/MSK fluoroscopy</td>
</tr>
<tr>
<td>EPIC Order</td>
<td>“Inpatient Consult to Interventional Radiology”</td>
<td>“Inpatient Consult for Adult Image-Guided Procedures (CT/US)”</td>
<td>Call 20878 (Fluoroscopy) for scheduling &amp; orders.</td>
</tr>
<tr>
<td>Contact Number (week days)</td>
<td><a class="magiclink magiclink-github magiclink-issue" href="https://github.com/vanderbilt-internal-medicine/vimbook/issues/20840" title="GitHub Issue: vanderbilt-internal-medicine/vimbook #20840">#20840</a> (MD desk)</td>
<td><a class="magiclink magiclink-github magiclink-issue" href="https://github.com/vanderbilt-internal-medicine/vimbook/issues/20120" title="GitHub Issue: vanderbilt-internal-medicine/vimbook #20120">#20120</a> (MD desk)</td>
<td><a class="magiclink magiclink-github magiclink-issue" href="https://github.com/vanderbilt-internal-medicine/vimbook/issues/20878" title="GitHub Issue: vanderbilt-internal-medicine/vimbook #20878">#20878</a> (Fluoro techs)</td>
</tr>
<tr>
<td>Contact Number (nights &amp; weekends)</td>
<td>Pager only</td>
<td>Pager only</td>
<td><a class="magiclink magiclink-github magiclink-issue" href="https://github.com/vanderbilt-internal-medicine/vimbook/issues/3" title="GitHub Issue: vanderbilt-internal-medicine/vimbook #3">#3</a>-7185 (ER reading room)</td>
</tr>
<tr>
<td>Service Pager</td>
<td>835-5105</td>
<td>835-0770</td>
<td>NaN</td>
</tr>
<tr>
<td>Procedure Requested</td>
<td>Active bleeding; Embolization’s Cholecystostomy PTC (biliary drains) Nephrostomy Tunneled lines Dialysis interventions G-tube placement IVC Filter Drain repositioning</td>
<td>Abscess drainage Biopsy requests Paracentesis** Thoracentesis**</td>
<td>Dobhoff tube placements** Lumbar punctures** Joint injections / aspirations Esophograms Upper GI Series Small bowel follow-through Contrast enemas</td>
</tr>
</tbody>
</table>
<p>**Typically requires prior attempt by medicine or procedure service on
the floor</p>
<p>Specific Procedural Questions:</p>
<p>Pre-Procedure</p>
<p>(contact consult services for case-specific requirements, guidelines
below):</p>
<ul>
<li>NPO @ MN prior to procedure if sedation is to be used (majority of
    cases)</li>
<li>Labs required morning of procedure:<ul>
<li>INR (\&lt;1.5 for most procedures)</li>
<li>Plts (&gt;50K)</li>
</ul>
</li>
<li>Anticoagulation<ul>
<li>Hold Lovenox for 12h prior to procedure</li>
<li>Hold AM dose of SQH prior to procedure</li>
<li>Search “SIR anticoagulation guidelines 2019” for hold times for
    other AC</li>
</ul>
</li>
<li>Para/thora/LP: typically requires <strong>prior failure</strong> by floor team or
    procedure services. Please describe why initial procedure failed so
    that radiology can avoid that issue.</li>
<li>Inpatient biopsies for malignancy
    : due to schedule and resource availability, it is rare that this is
    approved as an inpatient.<ul>
<li>Consider placing outpatient consult for “adult image-guided
    procedures” team.</li>
<li>The pt will get an outpatient slot, and if they happen to still
    be inpatient, they will receive the biopsy at that time
    regardless to prevent keeping patient hospitalized only for
    biopsy</li>
</ul>
</li>
</ul>
<dl>
<dt>Drain management</dt>
<dd>
<p>Best to discuss directly with service that placed the drain</p>
</dd>
</dl>
<ul>
<li>Flush with 10mL NS BID (flush into drain, then put back to gravity
    or accordian suction)</li>
<li>If drain output decreases, either:<ul>
<li>The drained area (e.g. abscess) is empty</li>
<li>The drain is clogged/malfunctioning /malpositioned</li>
</ul>
</li>
<li>Start with ensuring the drain is adequately flushed/flushing. If
    still no output, CT w/ IV contrast to re-evaluate area of the drain,
    then page 835-0770 (Body Procedures) for abscess drains or page
    835-5105
    (Vascular IR) for rec’s regarding PCNs, PTCs, or G-tubes.<ul>
<li>If an abscess drain is malfunctioning, first ensure proper
    suction/3-way direction. Next instill tPA into the catheter for
    2 hours. Epic order: “Alteplase (TPA) injection/infusion
    options” -&gt; Percutaneous drainage -&gt; 2mg or 4mg (20mL or 40mL,
    1mg/10mL concentration). Reach out to Body Procedures service
    (835-0770) with any questions.</li>
<li>If drain is at an operative site, confirm drain tPA is
    acceptable by surgery team.</li>
<li>If this doesn’t improve output in 48 hours, consider
    repositioning drain (VIR consult).</li>
</ul>
</li>
</ul></section><section class="print-page" id="radiology-radiology-radiology-exams-diagnosis"><h1 id="radiology-radiology-radiology-exams-diagnosis-radiology-exams-by-diagnosis">Radiology Exams by Diagnosis<a class="headerlink" href="#radiology-radiology-radiology-exams-diagnosis-radiology-exams-by-diagnosis" title="Permanent link">&para;</a></h1>
<p>Common Radiology Exams by Suspected Diagnosis – Ryan Adams, Leah Brown</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest</td>
<td>Chest</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>CT angiogram chest pulmonary embolism with contrast</td>
</tr>
<tr>
<td>Lung mass, mets</td>
<td>CT chest with contrast</td>
</tr>
<tr>
<td>Pulmonary nodule</td>
<td>CT chest without contrast</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>X-ray chest portable (or 2 view), SPECIFY UPRIGHT</td>
</tr>
<tr>
<td>Abdomen/Pelvis</td>
<td>Abdomen/Pelvis</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>Ultrasound abdomen limited (specify cholecystitis)</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>CT abdomen pelvis with contrast</td>
</tr>
<tr>
<td>Appendicitis</td>
<td>CT abdomen pelvis with contrast</td>
</tr>
<tr>
<td>Bowel obstruction</td>
<td>X-ray abdomen 1 view, CT abdomen pelvis with contrast</td>
</tr>
<tr>
<td>HCC</td>
<td>CT abdomen with contrast, specify HCC in comments MRI abdomen with contrast, specify HCC in comments</td>
</tr>
<tr>
<td>Mesenteric ischemia AAA</td>
<td>CT angiogram abdomen and pelvis</td>
</tr>
<tr>
<td>Crohn’s/IBD</td>
<td>CT abdomen pelvis enterography w contrast</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuro</td>
<td>Neuro</td>
</tr>
<tr>
<td>Brain mass/mets</td>
<td>MRI brain with and without IV contrast</td>
</tr>
<tr>
<td>Stroke</td>
<td>MRI brain without contrast</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>MRI brain with and without contrast</td>
</tr>
<tr>
<td>Aneurysm or vascular injury</td>
<td>CT angiogram head and neck with and without contrast</td>
</tr>
<tr>
<td>Dural venous sinus thrombosus</td>
<td>CT venogram head</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>CT head without contrast</td>
</tr>
<tr>
<td>Spine trauma</td>
<td>CT (c/t/l) spine without contrast, MRI spine wo contrast</td>
</tr>
<tr>
<td>Spine tumor, infection, post-op</td>
<td>MRI (C/T/L) spine with and without contrast</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Musculoskeletal</td>
<td>Musculoskeletal</td>
</tr>
<tr>
<td>Fracture</td>
<td>X-rays, CT (extremity) without contrast</td>
</tr>
<tr>
<td>Soft tissue infection</td>
<td>CT (extremity) with contrast MRI (extremity) with and without contrast</td>
</tr>
<tr>
<td>Osteomyelitis</td>
<td>X-ray (extremity) MRI (extremity) with and without contrast</td>
</tr>
<tr>
<td>Bone or soft tissue tumors</td>
<td>MRI (extremity) with and without contrast</td>
</tr>
<tr>
<td>DVT</td>
<td>Ultrasound doppler (extremity) venous (laterality)</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urogenital</td>
<td>Urogenital</td>
</tr>
<tr>
<td>Ovarian/testicular torsion</td>
<td>Ultrasound scrotal with complete doppler Ultrasound pelvic transvaginal</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>Ultrasound transvaginal and pelvic</td>
</tr>
<tr>
<td>Kidney stones</td>
<td>Ultrasound renal CT abdomen pelvis without contrast</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>Ultrasound renal CT abdomen pelvis with contrast</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Radiology</h1>
                        <h1 class='nav-section-title' id='section-rheumatology'>
                            Rheumatology <a class='headerlink' href='#section-rheumatology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="rheumatology-rheumatology-biologic-overview"><h1 id="rheumatology-rheumatology-biologic-overview-biologic-overview">Biologic Overview<a class="headerlink" href="#rheumatology-rheumatology-biologic-overview-biologic-overview" title="Permanent link">&para;</a></h1>
<p>Biologic Overview – Hannah Lomzenski</p>
<p>Background</p>
<ul>
<li>"-cept" refers to fusion of a receptor to the Fc part of human
    immunoglobulin G1 (IgG1)</li>
<li>"-mab" indicates a monoclonal antibody (mAb)</li>
<li>"-ximab" indicates a chimeric mAb</li>
<li>"-zumab" indicates a humanized mAb</li>
<li>"-umab" indicates a fully human mAb</li>
<li>“-tinib” indicates a tyrosine kinase inhibitor (TKIs are small
    molecule inhibitors rather than true biologics)</li>
</ul>
<p>​​​​​​​</p>
<p>Kinase inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Xeljanz</td>
<td>JAK-1 and JAK-3 inhibitors</td>
<td>RA, UC, JIA, psoriatic arthritis</td>
<td>infections, nasopharyngitis, skin rash, GI sx, GU sx; \&lt;1% lymphoma</td>
</tr>
<tr>
<td>Baracitinib</td>
<td>Olumiant</td>
<td>JAK-1 and JAK-2 inhibitor</td>
<td>RA; off-label: COVID-19</td>
<td>infections, URI, nausea, ÝAST/ALT; \&lt;1% lymphoma</td>
</tr>
<tr>
<td>Upadacitinib</td>
<td>Rinvoq</td>
<td>non-specific JAK inhibitor</td>
<td>RA</td>
<td>URI, nausea, neutropenia, ÝAST, ÝCPK</td>
</tr>
</tbody>
</table>
<p>IL-1 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Anakinra</td>
<td>Kineret</td>
<td>IL-1 receptor antagonist</td>
<td>IL-1 receptor antagonist deficiency, neonatal multi-system inflammatory Dz, RA; off-label: gout flares, FMF, recurrent pericarditis, HLH</td>
<td>HA, vomiting, infections, nasopharyngitis, Ab development; in RA: eosinophilia, decreased WBC</td>
</tr>
<tr>
<td>Canakinumab</td>
<td>Ilaris</td>
<td>mAb against IL-1β</td>
<td>cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
<td>weight gain, GI sx, HA, vertigo, serious infections</td>
</tr>
<tr>
<td>Rilonacept</td>
<td>Arcalyst</td>
<td>binds to IL-1β (some binding of IL-1α and IL-1 receptor antagonist)</td>
<td>CAPS, deficiency of IL-1 receptor antagonist</td>
<td>URI, infections, hypoesthesia, Ab development</td>
</tr>
</tbody>
</table>
<p>TNF-inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Adalilumab</td>
<td>Humira</td>
<td>mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
<td>skin rash, HA, URI, infections, Ý CPK, +ANA titer (12%), Ab development (3-26%)</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Cimzia</td>
<td>humanized mAb Fab fragment against TNFα</td>
<td>RA, Crohn’s, AS, psoriasis; *approved for use during pregnancy</td>
<td>skin rash, nausea, URI, infections</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Enbrel</td>
<td>tumor necrosis factor receptor linked to Fc portion of IgG1; binds TNF</td>
<td>RA, AS, psoriasis, JIA</td>
<td>skin rash, diarrhea, infections, +ANA titer (11%)</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Remicade</td>
<td>chimeric mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis</td>
<td>abd pain, URI sx, anemia, Ý ALT, Ab development (10-50%), infections</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Simponi</td>
<td>mAb against TNFα</td>
<td>RA, UC, AS, psoriasis, JIA</td>
<td>URI, infections, Ab development (16-38%), +ANA titer (4-17%)</td>
</tr>
</tbody>
</table>
<p>IL-17 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Cosentyx</td>
<td>human IgG1 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>infections, nasopharyngitis, GI, IBD (\&lt;1%)</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>Taltz</td>
<td>human IgG4 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>neutropenia, Ab development, infections, URI, Crohn’s (\&lt;1%)</td>
</tr>
</tbody>
</table>
<p>Costimulation blockade</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Orencia</td>
<td>inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 ixn between APCs and T cells.</td>
<td>RA, psoriasis, JIA</td>
<td>nausea, UTI, HA, infections, URI, Ab development</td>
</tr>
</tbody>
</table>
<p>B-cell depletion and inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Rituxan</td>
<td>mAb against the CD20 antigen on surface of B-lymphocytes</td>
<td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica)</td>
<td>HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, Ý ALT, infections, hypophosphatemia, hematologic abnormalities</td>
</tr>
<tr>
<td>Belimumab</td>
<td>Benlysta</td>
<td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes</td>
<td>lupus nephritis, SLE</td>
<td>GI sx, hypersensitivity rxn, infections, psychiatric disturbances</td>
</tr>
</tbody>
</table>
<p>IL-6 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Actemra</td>
<td>IL-6 receptor antagonist</td>
<td>cytokine release syndrome, giant cell arteritis, RA, JIA</td>
<td>Ý serum cholesterol, Ý AST/ALT, infusion rxn, HSV infection (\&lt;2%)</td>
</tr>
<tr>
<td>Sarilumab</td>
<td>Kevzara</td>
<td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
<td>RA</td>
<td>Ý AST/ALT, HSV infection (\&lt;2%)</td>
</tr>
</tbody>
</table>
<p>IL-12/23 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Stelara</td>
<td>mAb against IL-12 + IL-23</td>
<td>IBD, psoriasis</td>
<td>infections, nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx</td>
</tr>
<tr>
<td>Guselkumab</td>
<td>Tremfya</td>
<td>human IgG1 mAb against IL-23</td>
<td>psoriasis</td>
<td>infections, URI, tinea, GI sx</td>
</tr>
</tbody>
</table></section><section class="print-page" id="rheumatology-rheumatology-common-rheumatologic-diseases"><h1 id="rheumatology-rheumatology-common-rheumatologic-diseases-common-rheumatologic-diseases">Common Rheumatologic Diseases<a class="headerlink" href="#rheumatology-rheumatology-common-rheumatologic-diseases-common-rheumatologic-diseases" title="Permanent link">&para;</a></h1>
<p>Common Rheumatologic Diseases</p>
<p>Rheumatoid Arthritis – Greg Jackson</p>
<p>Background</p>
<ul>
<li>Proliferation of synovial tissue, mediated by TNF, IL-1, IL-6
    leading to joint destruction</li>
<li>Chronic, inflammatory polyarthritis affecting the small joints of
    the hands, wrists, and feet</li>
<li>Pain and swelling of joints, typically symmetric MCP, wrists, MTP
    affected</li>
<li>Ulnar deviation, swan neck, boutonniere deformities are late
    manifestations of untreated disease</li>
<li>Morning stiffness lasting &gt;1 hr suggests inflammatory arthritis like
    RA, but is not specific</li>
<li>C1-C2 instability: pts need evaluation with imaging prior to
    surgical procedure/intubation</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical diagnosis and positive RF, anti-CCP (as described in labs
    section above), though up to 30% patients have seronegative RA ,
    elevated ESR and CRP</li>
<li>CBC, CMP, HIV, Hepatitis B and C screening; Quantiferon Gold (for
    possible biologics)</li>
<li>Obtain hand films to assess for osteopenia &amp; erosions</li>
</ul>
<p>Management</p>
<ul>
<li>The majority of joint damage occurs early in the disease so early
    treatment paramount</li>
<li>DMARDs: start with MTX; if inadequate response, add biologic such as
    TNF inhibitors<ul>
<li>Dosing
    : MTX 7.5-20 mg weekly; need to supplement with folic acid 1 mg
    daily</li>
<li>Requires
    routine lab monitoring for bone marrow suppression, lung and
    liver toxicity</li>
<li>Contraception
    must be used in women of childbearing age on MTX</li>
</ul>
</li>
<li>Symptomatic/Flare treatment (no impact on disease progression):<ul>
<li>NSAIDs
    : high doses required for anti-inflammatory effects (ie
    ibuprofen 3200 mg/day or 1000 mg/day naproxen), usually treat
    for 2 wks to achieve maximum analgesic effect</li>
<li>Prednisone
    5-10 mg/day for 2 weeks and then slow wean off or low-dose (5 mg
    or less)</li>
</ul>
</li>
</ul>
<p>Anti-Phospholipid Syndrome – Gautam Babu</p>
<p>Background</p>
<ul>
<li>Development of antiphospholipid antibodies (aPLs) = a heterogenous
    group of autoantibodies, which interact with endothelial
    cells through binding of
    β
    2GPI receptor</li>
<li>APLs induce a procoagulant and proinflammatory
    endothelial phenotype, resulting in arterial, venous, or small
    vessel thromboembolic events and/or pregnancy losses</li>
</ul>
<p>Presentation</p>
<ul>
<li>Common features: DVTs, thrombocytopenia, and livedo reticularis</li>
<li>Arterial thromboses: renal, mesenteric, coronary and cerebral
    vasculature</li>
<li>Pulmonary embolism, CTEPH, nonbacterial vegetations (Libman-Sacks
    endocarditis)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Revised Sapporo classification criteria are used to diagnose
    patients with APS</li>
<li>At least one of the clinical criteria and one of the laboratory
    criteria are met:<ul>
<li>Vascular thrombosis (arterial, small vessel, or venous)</li>
<li>Pregnancy morbidity</li>
<li>LA (lupus anticoagulant) present, on 2 or more occasions at
    least 12 weeks apart</li>
<li>aCL (anticardiolipin antibody) of IgG and/or IgM isotype in
    serum or plasma, present in medium or high titer, on two or more
    occasions, at least 12 weeks apart</li>
<li>Anti-beta-2 glycoprotein-I antibody of IgG and/or IgM isotype in
    serum or plasma, present on two or more occasions, at least 12
    weeks apart</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Mainstay is anticoagulation for treatment and secondary prevention</li>
<li>Do not use (ASA or AC) for primary thrombosis prevention</li>
<li>Acute thromboembolism: Heparin gtt with bridge to warfarin</li>
<li>Secondary thrombosis prevention, anticoagulation with warfarin is
    preferred<ul>
<li>Studies
    suggest that DOACs are less effective than warfarin</li>
<li>Goal INR 2-3 regardless of whether arterial or venous
    thromboembolism present</li>
</ul>
</li>
<li>ASA 81 mg + warfarin for pts w/arterial events and risks for ASCVD</li>
</ul>
<p>Systemic Lupus Erythematous</p>
<p>– Greg Jackson</p>
<p>Presentation</p>
<ul>
<li>Characterized by multisystem inflammation, precise etiology of
    disease unknown</li>
<li>Constitutional: fatigue, fevers, weight loss</li>
<li>Neurologic: cerebritis, myelitis, psychosis</li>
<li>Skin: malar rash, discoid rash, photosensitive rashes</li>
<li>Hematologic: leukopenia, anemia, thrombocytopenia</li>
<li>Pulmonary: pleuritis, pleural effusion, ILD</li>
<li>Cardiac: pericarditis/myocarditis (also due to underlying
    inflammatory condition have increased risk for coronary artery
    disease, similar to RA); Libman-Sacks endocarditis</li>
<li>Renal: nephritic/nephrotic syndrome</li>
<li>MSK: arthralgias/myalgias/arthritis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>See section on rheumatology labs for specific
    sensitivity/specificity of tests</li>
<li>SLICC criteria not initially developed to diagnose SLE but often
    used:  need &gt;/= 4/17 of SLICC criteria with &gt;/=1 clinical and &gt;/= 1
    immunologic</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Criteria</td>
<td>Laboratory Criteria</td>
</tr>
<tr>
<td>Acute cutaneous rash (is Malar rash, etc.)</td>
<td>Elevated ANA</td>
</tr>
<tr>
<td>Chronic cutaneous Rash (i.e. Discoid rash, etc.)</td>
<td>Elevated anti-dsDNA</td>
</tr>
<tr>
<td>Alopecia, non-scarring</td>
<td>Positive Anti-Sm</td>
</tr>
<tr>
<td>Joint disease (Two or more joints with inflammatory characteristics)</td>
<td>Positive Anti-phospholipid Screen</td>
</tr>
<tr>
<td>Oral/nasal ulcers</td>
<td>Low C3/C4</td>
</tr>
<tr>
<td>Serositis (usually pleural or pericardial)</td>
<td>NaN</td>
</tr>
<tr>
<td>Neurologic (seizures, psychosis, AMS)</td>
<td>NaN</td>
</tr>
<tr>
<td>Anemia, leukopenia (\&lt;1000), thrombocytopenia (\&lt;100,000)</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Hydroxychloroquine mainstay of treatment, 200-400 mg/day, dose 5
    mg/kg/day for long term to decrease risk of retinal toxicity<ul>
<li>Monitor
    for retinal toxicity with yearly retinal exam</li>
</ul>
</li>
<li>Glucocorticoids for flares (Similar dosing to RA)<ul>
<li>Usually
    started with hydroxychloroquine and tapered once
    hydroxychloroquine has taken effect for symptom control</li>
</ul>
</li>
<li>Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with
    rheumatology consultation: MMF, cyclophosphamide used in SLE with
    renal involvement</li>
</ul>
<p>Catastrophic Anti-phospholipid Syndrome (CAPS) – Gautam Babu</p>
<p>Background</p>
<ul>
<li>Occurs in a small subset of patients with APS</li>
<li>Rapid development of thromboses in multiple small blood vessels in
    various organs resulting in multiorgan failure</li>
</ul>
<p>Presentation</p>
<ul>
<li>Similar presentation to APS, but multiple organs are involved in a
    short period of time</li>
<li>Renal (hypertension, proteinuria, hematuria, acute renal failure),
    Pulmonary (ARDS, PE), Central Nervous System (encephalopathy,
    stroke, cerebral venous thrombosis), Cardiac (coronary thrombosis),
    and Cutaneous (livedo reticularis, acrocyanosis, purpura,
    ecchymosis, splinter hemorrhages, and necrosis resulting in
    ulceration)</li>
<li>Pts can develop systemic inflammatory response syndrome 2/2
    extensive tissue damage</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exclude other causes of small vessel occlusion: HIT, DIC or TMA</li>
<li>Definite
    diagnosis of CAPS is made when all four diagnostic criteria are
    present</li>
<li>Diagnosis is <strong>probable</strong> when a combination of these criteria is
    present<ul>
<li>Evidence
    of involvement of three or more organs, systems, and/or tissues</li>
<li>Development
    of manifestations simultaneously or in less than a week</li>
<li>Confirmation
    by histopathology of small vessel occlusion in at least one
    organ or tissue</li>
<li>Laboratory
    confirmation of the presence of antiphospholipid antibodies:</li>
</ul>
</li>
<li>Lupus anticoagulant, anticardiolipin antibodies, and/or
    anti-beta2-glycoprotein I</li>
</ul>
<p>Management</p>
<ul>
<li>Anticoagulation
    : Heparin gtt acutely</li>
<li>Transition
    to warfarin:
    If hemodynamically stable; no
    bleeding or
    recurrent thromboses</li>
<li>Immunosuppression: methylprednisolone 0.5 to 1 g intravenously daily
    for 3 days, subsequently followed by oral prednisone therapy at 1
    mg/kg/day</li>
<li>Severe cases may require PLEX &plusmn; IVIG</li>
<li>Refractory CAPS may require rituximab or eculizumab</li>
</ul>
<p>Sarcoidosis – Jared Freitas</p>
<p>Background</p>
<ul>
<li>Multisystem
    disordered defined by forming noncaseating granulomas in different
    tissues</li>
<li>Cardiac
    and neuro manifestations can be isolated</li>
</ul>
<p>Presentation</p>
<ul>
<li>Constitutional
    symptoms: fatigue, night sweats, weight loss, fevers, arthralgias,
    myalgias</li>
<li>Pulmonary
    symptoms (most common): dyspnea, cough, and wheezing</li>
<li>Extrapulmonary
    manifestations:<ul>
<li>Cutaneous<ul>
<li>Highly variable, but present in 25% of patients</li>
<li>Papules, macules, plaques that can be isolated or in groups,
    commonly involving neck, upper back, extremities; in African
    Americans can leave scars and depigmented areas</li>
<li>Lupus pernio: indurated, violaceous bumps on nose, lips,
    cheeks, ears</li>
<li>Erythema nodosum</li>
</ul>
</li>
</ul>
</li>
<li>Neuro<ul>
<li>Affects 5-10% pts; involving any part of CNS or PNS, causing CN,
    hypothalamic, seizures, myelopathy or radiculopathy,
    hydrocephalus, aseptic meningitis</li>
</ul>
</li>
<li>Cardiac<ul>
<li>Granulomas can affect pericardium, myocardium and endocardium
    resulting in valvular disorders, conduction system and
    cardiomyopathy</li>
</ul>
</li>
<li>Liver/Spleen<ul>
<li>Granulomas in liver and spleen can lead to elevated LFTs,
    cirrhosis, anemia, leukopenia and thrombocytopenia (splenic
    sequestration)</li>
</ul>
</li>
<li>Ocular<ul>
<li>Photophobia, red eye, pain, blurry vision</li>
<li>Pts need eye exams to look for ocular involvement: uveitis
    (anterior and posterior), secondary glaucoma, retinal
    vasculitis, keratoconjunctivitis</li>
</ul>
</li>
</ul>
<p>Work Up</p>
<ul>
<li>Requires
    combination of clinical presentation, radiographic manifestations,
    exclusion of other similarly presenting diseases, and noncaseating
    granulomas on pathology</li>
<li>CXR: hilar and mediastinal lymphadenopathy
    ±
    pulmonary infiltrates</li>
<li>High-Resolution Chest CT<ul>
<li>Lymphadenopathy (bilateral and symmetric), with micro or
    macronodules, fibrotic changes (reticular opacities, traction
    bronchiectasis, volume loss)</li>
</ul>
</li>
<li>PFTs<ul>
<li>Typical findings: most sensitive is reduced DLCO, followed by
    reduced TLC, and then reduced VC (need to do full PFTs not just
    spirometry)</li>
</ul>
</li>
<li>Labs:<ul>
<li>CBC w/ diff, CMP, and urinalysis</li>
<li>ACE level is of limited clinical use</li>
<li>Testing for TB: Quant-Gold</li>
</ul>
</li>
<li>Biopsy<ul>
<li>Important to rule out mimics. The differential for “noncaseating
    granulomas” is extensive, including lymphoma and fungal
    infections</li>
<li>Not required for pts w/ asymptomatic bilateral hilar adenopathy
    or <strong>Lofgren syndrome</strong> (fever, erythema nodosum, arthralgias,
    and bilateral hilar LAD)</li>
<li>Target accessible lesions, like skin lesions or lymph nodes. May
    need bronchoscopy</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Most
    pts do not require therapy<ul>
<li>Monitor symptoms, CXR, PFTs at 3-6 month intervals</li>
</ul>
</li>
<li>Indications for treatment
    : progressive disease or severe disease at presentation</li>
<li>Mainstay of treatment is oral steroids:<ul>
<li>Dosing usually 0.3-0.6 mg/kg daily for 4-6 weeks</li>
<li>If only symptoms is cough, could consider inhaled
    glucocorticoids</li>
</ul>
</li>
<li>If unresponsive or unable to tolerate steroids may require
    alternative agents (MTX, AZA)</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-crystal-arthropathy"><h1 id="rheumatology-rheumatology-crystal-arthropathy-crystal-arthropathy">Crystal Arthropathy<a class="headerlink" href="#rheumatology-rheumatology-crystal-arthropathy-crystal-arthropathy" title="Permanent link">&para;</a></h1>
<p>Crystalline Arthropathies – Arissa Young</p>
<p>Gout</p>
<p>Presentation</p>
<ul>
<li>Red, hot, swollen joint (Classically affects 1 <sup>st</sup>
    metatarsal phalangeal joint [podagra])</li>
<li>May evolve
    to involve knees, elbows, and small joints of hand if untreated</li>
<li>Flares
    may
    become polyarticular over time</li>
<li>Gout is diagnosed with combination of clinical
    presentation and arthrocentesis results</li>
<li>Lifestyle factors:<ul>
<li>Protective: Low fat dairy, hydration</li>
<li>Promoting:  Meat, seafood, alcohol, high fructose corn syrup,
    medications that lead to hyperuricemia (consider discontinuing
    diuretics when using as antihypertensive)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid Analysis:<ul>
<li>Order cell count and differential<ul>
<li>WBC 20,000-100,000, &gt; 50% neutrophils</li>
</ul>
</li>
<li>Order gram stain/culture (It is possible to have septic
    arthritis and gout)</li>
<li>Examination for crystals under polarizing light microscopy:
    (order “Synovial Fluid Eval” so the lab knows to look for
    crystals)<ul>
<li>Monosodium urate crystals: needle-shaped and negatively
    birefringent and appear yellow when parallel to the
    polarizer</li>
</ul>
</li>
</ul>
</li>
<li>Imaging: generally unnecessary<ul>
<li>MSK ultrasound: Double contour sign (hyperechoic band = urate
    crystals deposits)</li>
<li>Dual energy CT scan: gout crystal aggregates appear green<ul>
<li>Not routinely necessary; Do not order without rheumatology
    consult</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>Acute:</p>
<ul>
<li>Do not discontinue allopurinol during an acute gout attack</li>
<li>NSAIDs (if not contraindicated):<ul>
<li>Short course of any at full anti-inflammatory dose: ibuprofen
    800 mg TID, indomethacin 50 mg TID, naproxen 500 mg BID</li>
</ul>
</li>
<li>Colchicine (only for use in patients without CKD):<ul>
<li>Best if used within the first 36 hours of an attack. Much less
    effective if started later</li>
<li>Dosing: 1.2 mg then 0.6 mg one hour later, then 0.6 mg daily
    until clinical improvement<ul>
<li>Important drug interactions (may require dose adjustment of
    colchicine): CYP3A4 inhibitors and P-glycoprotein/ABCB1
    inhibitors</li>
<li>E.g. statins, diltiazem, fluconazole, cyclosporine,
    tacrolimus, clarithromycin</li>
</ul>
</li>
</ul>
</li>
<li>Steroids: Ideally intra-articular if single joint affected and
    infection has been ruled out<ul>
<li>Oral prednisone - moderate dose 0.5mg/kg/day until clinical
    improvement and then taper over 7-14 days</li>
</ul>
</li>
<li>Anakinra (Requires Rheumatology consult): once daily for three days<ul>
<li>Reserved for patients who have contraindications to all other
    treatments</li>
</ul>
</li>
</ul>
<p>Chronic:</p>
<ul>
<li>Urate Lowering Therapy (ULT)<ul>
<li>Indications: 2-3 attacks/year, tophi, radiologic changes, gout
    with CKD, urolithiasis</li>
<li>Goal serum urate: \&lt;6.0 mg/dL or \&lt;5.0 mg/dL in patients with
    tophi</li>
<li>ULT can precipitate an acute gout flare, thus it should always
    be started with: low-dose NSAIDs, low-dose colchicine (0.6 mg)
    or low-dose prednisone (5 mg daily)<ul>
<li>Prophylaxis should be continued for 3-6 months after
    initiation of urate-lowering therapy (Can stop once uric
    acid is \&lt;6 for 6 months on a constant ULT dose)</li>
</ul>
</li>
<li>Allopurinol (xanthine oxidase inhibitor): Start low at 100 mg
    per day and increase as needed for target uric acid \&lt;6 (most
    patients will need 400-800 mg daily)<ul>
<li>Adjust dose monthly (in kidney dysfunction go slower)</li>
<li>Can be used in patients with kidney dysfunction: 50 mg/day,
    then
    ↑
    by 50 mg</li>
<li>Titration of allopurinol
    ↓
    both the risk of acute gout attacks and DRESS syndrome</li>
<li>Genetic testing (HLA-B*5801) recommended prior to starting
    for pts of Asian and African descent given
    ↑
    incidence of DRESS among pts with positive allel</li>
</ul>
</li>
<li>Febuxostat: alternative xanthine oxidase inhibitor that is
    metabolized by the liver for pts at risk for or with a history
    of DRESS or SJS related to allopurinol<ul>
<li>Has black box warning for
    ↑
    cardiovascular risk; more expensive than allopurinol</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>VUMC guidance: there is a microscope in the rheumatology clinic (TVC
    2);  You can page the rheumatology fellow and they are happy to help
    you use it</li>
<li>VA specific guidance:<ul>
<li>Dr. Birchmore is excellent at teaching residents how to use the
    polarizing microscope</li>
<li>Colchicine is non-formulary but is easily approved</li>
<li>For steroid intra-articular injections triamcinolone is the
    formulary option</li>
</ul>
</li>
<li>Uric acid level is often normal during acute gout flare</li>
<li>Shifts in uric acid may be the trigger of the flare: Diuresis,
    dietary changes, hospital stays</li>
<li>Eliminating uric acid from the diet will only reduce uric acid by
    ~1 mg/dL, so urate lowering therapy will be needed in most patients
    even if diet changed</li>
</ul>
<p>Pseudogout</p>
<p>Presentation</p>
<ul>
<li>Red, hot, swollen joint usually in the wrists, knees, or MCP joints</li>
<li>Cannot distinguish from gout based on clinical features alone</li>
<li>Like gout, diagnosis is based on exam and arthrocentesis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid:<ul>
<li>Order cell count and differential</li>
<li>WBC 20,000 to 100,000, &gt;50% neutrophils</li>
</ul>
</li>
<li>Order gram stain/culture (It is possible to have septic arthritis
    and CPPD)</li>
<li>Examination for crystals under polarizing light microscopy</li>
<li>CPPD crystals: rhomboid-shaped, weakly positively birefringent and
    appear blue when parallel to the polarizer</li>
<li>Imaging:<ul>
<li>XR: chondrocalcinosis in knee and wrists (thin calcified line
    present in fibrocartilage)</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>Typically follows the same treatment used for acute gout attacks (see
above, little evidence)</p></section><section class="print-page" id="rheumatology-rheumatology-inflammatory-myopathies"><h1 id="rheumatology-rheumatology-inflammatory-myopathies-inflammatory-myopathies">Inflammatory Myopathies<a class="headerlink" href="#rheumatology-rheumatology-inflammatory-myopathies-inflammatory-myopathies" title="Permanent link">&para;</a></h1>
<p>Inflammatory Myopathies – Greg Jackson</p>
<p>Background</p>
<ul>
<li>Inflammation and damage of skeletal muscle primarily leading to
    weakness</li>
<li>Subtypes: Dermatomyositis, polymyositis, statin-induced myositis,
    inclusion body myositis, metabolic (hypothyroid, electrolyte)
    myositis, viral/infection myositis, diabetic myonecrosis</li>
<li>Important point: this differs from PMR in that myopathy presentation
    is usually painless weakness whereas PMR will have myalgias with
    preserved strength</li>
<li>Hypomyopathic (or amyopathic) variants: skin and/or lungs are
    affected &gt;> muscles</li>
</ul>
<p>Presentation</p>
<ul>
<li>Proximal, symmetric muscle weakness in upper and lower extremities
    in all but inclusion body myositis which is typically more distal
    and asymmetric</li>
<li>Dermatomyositis: skin involvement can include heliotrope rash of
    upper eyelids, Gottron’s papules (on MCP, PIP), “mechanic’s hands,”
    and shawl sign</li>
<li>Raynaud’s and arthralgias can also be present</li>
</ul>
<p>Evaluation</p>
<ul>
<li>BMP &amp; TSH ; CK level</li>
<li>Anti Jo-1 most common specific antibody</li>
<li>EMG: findings indicate myopathy</li>
<li>MRI extremity/affected muscle group: muscle edema</li>
<li>Skin biopsy in dermatomyositis: “interface dermatitis.”</li>
<li>Muscle biopsy (do not do biopsy in same muscle as EMG done)<ul>
<li>Polymyositis, inclusion body myositis: T cell mediated muscle
    injury</li>
<li>Dermatomyositis: immune complex/B cell mediated muscle injury</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Prednisone 1 mg/kg/day for 4-6 weeks with subsequent taper</li>
<li>Consult Rheumatology</li>
<li>MTX or AZA used if refractory to steroids, may need IVIG, rituximab</li>
<li>If statin induced: stop statin or switch to lower intensity</li>
<li>If dermatomyositis: evaluate for underlying malignancy</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-rheumatology-lab-testing"><h1 id="rheumatology-rheumatology-rheumatology-lab-testing-rheumatology-lab-testing">Rheumatology Lab Testing<a class="headerlink" href="#rheumatology-rheumatology-rheumatology-lab-testing-rheumatology-lab-testing" title="Permanent link">&para;</a></h1>
<p>Rheumatology Lab Testing – Ben Boone</p>
<ul>
<li>Rheumatologic labs must be interpreted in the context of the
    clinical situation</li>
<li>It is challenging to interpret positive/abnormal labs with low
    pretest probability</li>
<li>Sensitivities and specificities referenced below refer to scenarios
    with moderate-to-high probability clinical situations</li>
</ul>
<p>Rheumatoid Factor (RF)</p>
<ul>
<li>A group of antibodies targeted against the Fc region of IgG</li>
<li>When positive in RA patients, called “seropositive RA” (typically
    more symptomatic)</li>
<li>A higher RF level is more specific for RA</li>
<li>70 - 80% sensitive for RA, but not very specific<ul>
<li>Present in 5-15% of healthy people</li>
<li>Commonly positive in Sjogren’s, Mixed Connective Tissue Disease
    (MCTD), Mixed Cryoglobulinemia, SLE, and rarely inflammatory
    myopathies</li>
<li>Can be positive some infectious diseases (i.e. malaria, hep B/C,
    rubella)</li>
<li>Often positive in RA patients before Anti-CCP and even before
    symptoms/diagnosis</li>
<li>Can be used as a surrogate when mixed cryoglobulinemia is
    suspected, since cryoglobulins can take up to a week to result
    and RF results in \&lt;48 hour</li>
</ul>
</li>
</ul>
<p>Anti-cyclic Citrullinated Peptides (Anti-CCP)</p>
<ul>
<li>Very specific for RA (&gt;95%); only 70% sensitive for RA</li>
<li>When positive in RA patients, called “seropositive RA” (typically
    more symptomatic)</li>
<li>A high titer is associated with more aggressive disease in RA</li>
</ul>
<p>Anti-nuclear Antibodies (ANA)</p>
<ul>
<li>Don't order for nonspecific symptoms – High Value Rheumatology Care
    Recommendation</li>
<li>Should always be ordered with the reflex survey <strong>(ANA w/ Rfx
    ENA/DNA)</strong></li>
<li>Reported as both a titer and a pattern<ul>
<li>Titer<ul>
<li>At VUMC, 1:80 is considered “positive”; however, a higher
    titer is more specific (albeit less sensitive) for
    ANA-associated rheumatologic disease</li>
<li>~30% of the general population has a “positive” ANA at
    1:40, whereas only ~1% of people have a true ANA-associated
    rheumatologic disease</li>
</ul>
</li>
<li>Pattern
    (three clinically significant ones)<ul>
<li>Smooth/homogenous – associated with Anti-dsDNA and
    Anti-histone antibodies</li>
<li>Speckled – associated with Anti-RNP, Anti-Smith,
    Anti-SSA/Ro, Anti-SSB/La</li>
<li>Nucleolar – associated with Anti-Scl-70</li>
</ul>
</li>
</ul>
</li>
<li>If ANA is
    ≥
    1:80 the following studies will be sent:<ul>
<li>Anti-dsDNA (Quantitative and Qualitative)<ul>
<li>Classical teaching is
    anti-dsDNA antibodies are specific for SLE. However, this
    depends on lab methodology; VUMC uses ELISA assay (less
    specific)</li>
<li>In some pts, dsDNA varies with disease activity</li>
<li>If dsDNA is positive, there is an increased risk of renal
    lupus</li>
</ul>
</li>
<li>Positive
    if <u>></u> 25 IU/mL ~70% sensitive and specific for SLE</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Anti-SSA/Ro (Qualitative)
        -   Non-specific; ~70% sensitive for Sjogren’s; present in
            ~30% of SLE and MCTD pts
        -   Present in ~20% of RA and idiopathic inflammatory myopathy
            pts
        -   Maternal positivity for SSA is associated with congenital
            heart block in infants</li>
<li>Anti-SSB/La (Qualitative)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Similar profile to Anti-SSA/Ro but less common</li>
<li>~50% of Sjogren’s and ~20% of SLE/MCTD pts</li>
<li>Very rare to have Anti-SSB w/o Anti-SSA in a pt with true Sjogren’s
    disease<ul>
<li>Anti-Scl-70 (Qualitative)<ul>
<li>Very specific for systemic sclerosis (&gt;99%); 20-60%
    sensitive for systemic sclerosis</li>
<li>~70% sensitive for diffuse cutaneous systemic sclerosis</li>
<li>Only ~10% sensitive for CREST syndrome</li>
</ul>
</li>
<li>Anti-Smith (Qualitative)</li>
</ul>
</li>
<li>Very specific &gt;99% for SLE; but only ~20% sensitive for SLE<ul>
<li>Anti-RNP (Qualitative)</li>
</ul>
</li>
<li>Required for MCTD diagnosis; present in ~40% of SLE; rarely in
    systemic sclerosis</li>
</ul>
<p>Other notable ANAs</p>
<ul>
<li>Anti-histone: Associated w/drug-induced lupus (VUMC order: <strong>Histone
    IgG-ARUP</strong> )</li>
<li>Anti-centromere: Seen in limited scleroderma (CREST syndrome)</li>
<li>Anti-neutrophil Cytoplasmic Antibodies (ANCA)<ul>
<li>Qualitative: p-ANCA, c-ANCA, negative, or indeterminate</li>
<li>Quantitative titers: anti-proteinase 3 (PR3),
    anti-myeloperoxidase (MPO) IgG antibodies</li>
</ul>
</li>
</ul>
<p>C3 and C4</p>
<ul>
<li>Complement
    levels should be checked in any pt in whom you suspect active SLE</li>
<li>Complement may also be low in diseases that decreases the liver’s
    synthetic function</li>
<li>↓
    C3
    /C4 in diseases that form immune complexes, activating the classic
    complement pathway: mixed cryoglobulinemia, Sjogren’s, MPGN, and
    antiphospholipid syndrome</li>
</ul>
<p>C-reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)</p>
<ul>
<li>
<ul>
<li>Both tests are non-specific markers of inflammation</li>
<li>Should be ordered alongside other rheumatology labs to
    corroborate disease activity</li>
</ul>
</li>
<li>
<p>CRP
    measures a specific protein made by the liver that activates the
    complement pathway</p>
<ul>
<li>CRP is IL-6 dependent</li>
<li>↓
    IL-6 (pts on tocilizumab or tofacitinib) results in
    ↓
    CRP regardless of disease activity</li>
</ul>
</li>
<li>
<p>ESR is the rate that RBCS settle in a standardized tube in one hour</p>
<ul>
<li>Fibrinogen is the primary driver of the ESR</li>
<li>The positive fibrinogen binds to the negatively-charged RBCs,
    allowing them to settle faster in the tube as RBCs no longer
    repel each other (both negatively charged)</li>
<li>Both Low fibrinogen (DIC or HLH) and anemia falsely lower the
    ESR</li>
</ul>
</li>
</ul>
<p>Creatinine Kinase (CK)</p>
<ul>
<li>CK can be elevated by exercise, rhabdomyolysis, endocrinopathy,
    cardiac disease, renal disease, malignancy, medication effect,
    neuromuscular disease, connective tissue disease<ul>
<li>Vigorous exercise can elevate CK up to 30-times the upper limit
    of normal</li>
</ul>
</li>
<li>CK can be elevated in asymptomatic pts (should be rechecked in 1 wk
    to ensure resolution)</li>
<li>Elevated
    CK in pts with objective proximal muscle weakness can direct the
    differential diagnosis to inflammatory myopathies (dermatomyositis,
    inclusion body myositis, polymyositis, and immune-mediated
    necrotizing myopathy)<ul>
<li>Notably, CK is normal in polymyalgia rheumatica</li>
</ul>
</li>
</ul>
<p>Cryoglobulin Evaluation</p>
<ul>
<li>Clinical context drives interpretation of the test:<ul>
<li>The presence of detectable cryoglobulins
    ≠
    cryoglobulinemic vasculitis</li>
</ul>
</li>
<li>Reported
    as qualitative (positive or negative) and quantitative (percentage =
    “cryocrit”)<ul>
<li>This test is highly prone to collection error</li>
<li>To perform this test, you need 6 full red-top tubes, kept
    between 37-39°C from the moment they are collected. This is
    accomplished using a thermos with a thermometer aka the “Cryo
    Kit”. At VUMC, this kit can be found in the immunopathology lab
    on the 4<sup>th</sup> floor. Place water at 39°C in the kit, then collect
    the blood at bedside with a nurse, placing each labeled tube
    directly into the water. Once all 6 tubes are collected, take
    the Cryo Kit back to the lab. If the temperature is less than
    37°C, the lab won’t accept it</li>
</ul>
</li>
<li>Essential Cryoglobulinemia (rare ~ 10%): cryoglobulinemia w/o
    associated disease</li>
<li>Cryoglobulinemic
    vasculitis: small vessel vasculitis with a highly variable
    presentation<ul>
<li>Arthralgias, peripheral neuropathy and renal disease (usually
    MPGN) are common</li>
<li>Skin involvement (purpura and erythematous macules, usually in
    colder areas of the body like the lower extremities)</li>
</ul>
</li>
<li>Type
    I Cryoglobulins<ul>
<li>Monoclonal immunoglobulins (Igs); usually IgG or IgM; rarely IgA
    or light chains</li>
<li>Classically associated with digital ischemia, skin necrosis, and
    livedo reticularis</li>
<li>Associated with Waldenström macroglobulinemia, multiple myeloma,
    MGUS, and CLL</li>
</ul>
</li>
<li>Mixed Cryoglobulins (these do not produce a single monoclonal
    antibody like Type I)<ul>
<li>Type II<ul>
<li>A mixture of a monoclonal Ig (IgG, IgM, or IgA) combined
    with polyclonal Igs</li>
<li>Associated with chronic viral infections HCV (most common),
    HBV, and HIV</li>
<li>Less commonly seen in autoimmune diseases like SLE and
    Sjogren’s</li>
</ul>
</li>
<li>Type III<ul>
<li>A mixture of polyclonal IgG and polyclonal IgM</li>
<li>Associated with the reverse profile of Type II; most
    commonly with autoimmune diseases; less commonly with
    infections</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extended Myositis Panel</p>
<ul>
<li>Can be sent when suspecting various forms of myositis such as
    dermatomyositis, polymyositis, anti-synthetase syndrome, etc.</li>
<li>Ordered as “ <strong>Myositis extended Pnl-ARUP</strong> ”<ul>
<li>Includes 19 separate antibodies with a summary interpretation
    provided at the end</li>
</ul>
</li>
<li>P155 (TIF1-gamma) and P140 (NXP-2) antibodies are particularly
    associated with malignancy in pts &gt; 30 y/o (ensure age-appropriate
    cancer screening)<ul>
<li>PET/CT and pelvic U/S in female patients should be pursued to
    search for malignancy</li>
</ul>
</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-vasculitis"><h1 id="rheumatology-rheumatology-vasculitis-vasculitis">Vasculitis<a class="headerlink" href="#rheumatology-rheumatology-vasculitis-vasculitis" title="Permanent link">&para;</a></h1>
<p>Vasculitides – Trever Stevens and Greg Jackson</p>
<p>Background</p>
<ul>
<li>Large
    vessel vasculitides
    - affect the Aorta and its major branches:<ul>
<li>Takayasu's
    Arteritis: most commonly affects \&lt;50 years old and young Asian
    Females<ul>
<li>Branches of the aorta and aortic arch (subclavian,
    innominate, and carotid arteries)</li>
</ul>
</li>
<li>Giant
    Cell: most commonly affects adults &gt;50 years old<ul>
<li>Almost never seen under the age of 50; and affects F&gt;M
    slightly</li>
<li>Cranial arteries like the temporal artery, although can
    involve aorta and its branches</li>
</ul>
</li>
</ul>
</li>
<li>Medium
    vessel vasculitides
    - affect the muscular arteries that supply visceral organs:<ul>
<li>PAN: Necrotizing vasculitis, involves muscular arteries
    including the renal arteries, mesenteric artery, and arteries
    that supply neurons and the skin<ul>
<li>PAN <strong>spares the lung</strong> (consider other process if pulmonary
    complaints)</li>
<li>Affects middle age to older adults (peaks at 5<sup>th</sup> decade of
    life)</li>
<li>Can be associated with HBV infection and HBsAg</li>
</ul>
</li>
<li>Kawasaki’s: most commonly affects children (not addressed here)</li>
</ul>
</li>
<li>Small
    Vessel Vasculitides
    - affect arterioles, capillaries, and venules<ul>
<li>Cryoglobulinemic vasculitis and Henoch Schonlein Purpura - not
    discussed here</li>
<li>GPA
    : Necrotizing and granulomatous; involves the nasopharynx,
    lungs, and kidneys</li>
<li>MPA
    :
    Necrotizing
    ; affects multiple organs, predilection for lungs and kidneys<ul>
<li>Nasopharyngeal involvement and granulomas are <strong>absent</strong>
    (contrast to GPA)</li>
</ul>
</li>
<li>EGPA: Granulomatous
    necrotizing inflammation with eosinophilia<ul>
<li>Uncommon over the age of 65; predilection for heart and
    lungs</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Takayasu's Arteritis</p>
<p>Presentation</p>
<ul>
<li>Unequal pulses, arterial bruits, or different BP in both arms (known
    as “pulseless disease”)</li>
<li>Constitutional symptoms: fevers, arthralgias, myalgias, rash, weight
    loss</li>
<li>Can also cause carotidynia (tenderness of carotid artery),
    lightheadedness, vertigo, headaches, syncope, and strokes due to
    involvement of carotid arteries</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Inflammatory markers: ESR &amp; CRP (usually elevated)</li>
<li>Arteriography: MRA or CTA of head/neck, chest, and abdomen</li>
</ul>
<p>Management</p>
<ul>
<li>If signs of aortitis/carotidynia or arterial stenosis: 1mg/kg
    prednisone daily (max 60-80mg/kg) for 2-4 weeks followed by steroid
    taper</li>
<li>Organ threatening disease or ischemia: 500-1000 mg IV
    methylprednisolone (1-3 days) then 1mg/kg prednisone daily (2-4
    weeks) followed by steroid taper</li>
<li>MTX, immunomodulators</li>
</ul>
<p>Giant Cell Arteritis</p>
<p>Presentation</p>
<ul>
<li>In a pt &gt;65 with headache and vision changes (diplopia or amaurosis
    fugax) this needs to be ruled out!</li>
<li>Classically presents as headache, jaw claudication, tenderness to
    palpation of scalp in addition to constitutional symptoms</li>
<li>Polymyalgia rheumatica will often accompany GCA<ul>
<li>B/l shoulder and hip pain and stiffness (elevated ESR but normal
    CK)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Order ESR, CRP, CK level, TSH</li>
<li>Detailed vascular exam for (4 limb blood pressures with attention to
    symmetry, abdominal/neck/chest auscultation for bruit)</li>
<li>Ophthalmology eval if there is ocular involvement.</li>
<li>Temporal artery biopsy – evaluating for evidence of vasculitis or
    giant cells<ul>
<li>(Vascular surgery can assist with timely biopsy)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If ESR is elevated in a moderate to high probability setting, give
    steroids without delay (biopsy results will be unaffected if done
    within ~2 weeks)</li>
<li>Without visual loss: prednisone 1mg/kg (max of 60 mg) daily</li>
<li>With visual loss or diplopia: 100-1000mg of IV methylprednisolone
    daily for 3 days, followed by prednisone 1mg/kg daily (max of 60mg)</li>
<li>Duration: daily high-dose steroids as above for 2-4 weeks, then
    begin to taper steroids</li>
</ul>
<p>Polyarteritis Nodosa (PAN)</p>
<p>Presentation</p>
<ul>
<li>Constitutional symptoms: fevers, arthralgias, myalgias, rash, weight
    loss</li>
<li>Asymmetric polyneuropathy (most common symptom) &amp; <strong>both</strong> motor and
    sensory deficits</li>
<li>Foot drop, radial and ulnar neuropathies</li>
<li>Hypertension if renal artery involvement</li>
<li>Abdominal pain and melena if mesenteric artery inflammation</li>
<li>Skin manifestations: livedo reticularis, palpable purpura, or tender
    erythematous nodules</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ESR, CRP, CK level, TSH</li>
<li>Arteriography: MRI or CT or catheter based angiogram - “string of
    pearls” appearance</li>
<li>Histology: fibrinoid necrosis and vasculitis in target tissue</li>
</ul>
<p>Management</p>
<ul>
<li>Hepatitis screening if not previously done to evaluate for HBsAg</li>
<li>Mild disease or isolated cutaneous disease: Glucocorticoids</li>
<li>Moderate disease: Up to 1mg/kg prednisone daily (up to 60-80mg max)
    for 2-4 weeks followed by steroid taper &plusmn; DMARD</li>
<li>Severe disease or life threatening disease (evidence of renal
    insufficiency, significant proteinuria, gastrointestinal, cardiac,
    or neurologic involvement): 500-1000mg IV methylprednisolone daily
    for up to 3 doses followed by prednisone as above for 4 weeks with
    taper plus cyclophosphamide</li>
</ul>
<p>Granulomatosis with Polyangiitis (GPA)</p>
<p>Presentation</p>
<ul>
<li>Sinus and respiratory symptoms, sinusitis/ulcers, hemoptysis</li>
<li>Renal involvement – elevated Cr, hematuria, or proteinuria from RPGN</li>
<li>Less commonly affects eyes (scleritis: red, painful, light
    sensitive), skin (palpable purpura), peripheral nerves (mononeuritis
    multiplex)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA + (Usually PR3-cANCA &gt; MPO-pANCA)</li>
<li>U/A with urine microscopy: need to spin the urine to evaluate for
    active renal disease</li>
<li>Biopsy of a site of suspected disease activity (necrotizing
    granulomatous vasculitis)</li>
</ul>
<p>Management</p>
<ul>
<li>If treating inpatient, has 20x increase risk of DVT/PE – ensure DVT
    ppx</li>
<li>Mild to moderate disease: MTX + glucocorticoids</li>
<li>Severe disease: rituximab or cyclophosphamide, then maintenance w/
    Rituxan or DMARD</li>
</ul>
<p>Microscopic Polyangiitis (MPA)</p>
<p>Presentation</p>
<ul>
<li>Similar to GPA but will only involve kidneys and lungs (less sinus
    involvement)</li>
<li>Hemoptysis with bilateral nodular lung involvement and
    hematuria/proteinuria common</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA +, typically MPO-pANCA</li>
<li>U/A with urine microscopy: need to spin the urine to evaluate for
    active renal disease</li>
<li>Biopsy of a site of suspected diseased activity</li>
</ul>
<p>Management</p>
<ul>
<li>DVT ppx is important as patients are at higher risk for DVTs/PE</li>
<li>Mild to moderate disease: MTX (or similar DMARD) + glucocorticoids</li>
<li>Severe disease: rituximab or cyclophosphamide, then maintenance
    w/Rituxan or DMARD</li>
</ul>
<p>Eosinophilic Granulomatosis with Polyangiitis (EGPA or Churg-Strauss
Syndrome)</p>
<p>Presentation</p>
<ul>
<li>Similar to MPA and GPA; unique symptoms include atopic symptoms
    (asthma, etc.)<ul>
<li>Asthma is the most common symptom with involvement in over 90%
    of patients</li>
</ul>
</li>
<li>Can have Peripheral eosinophilia</li>
<li>More likely small vessel vasculitis to cause cardiac tissue
    involvement: Coronary arteritis, myocarditis, heart failure and
    arrhythmias</li>
<li>Skin lesions: tender subcutaneous nodules</li>
<li>Renal involvement: hematuria and proteinuria</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA + (typically MPO-pANCA) and peripheral eosinophilia</li>
<li>Histology: Eosinophilic infiltrates with fibrinoid necrosis</li>
</ul>
<p>Management</p>
<ul>
<li>DVT prophylaxis as patients are high risk for DVTs/PE</li>
<li>Mild to moderate disease: MTX (or similar DMARD) + glucocorticoids</li>
<li>Severe disease (cardiac or neurologic involvement): cyclophosphamide
    induction with maintenance DMARD, Rituximab</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Rheumatology</h1>
                        <h1 class='nav-section-title' id='section-zcbh'>
                            zCBH <a class='headerlink' href='#section-zcbh' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="zcbh-cprs"><h1 id="zcbh-cprs-cprs">CPRS<a class="headerlink" href="#zcbh-cprs-cprs" title="Permanent link">&para;</a></h1>
<p>FYI, the Cerner transition has a goal completion date of 2028.</p>
<p>This is a <em>goal</em> completion date, and this is a project of the US Government.</p>
<p>CPRS skills are likely to be useful for a good while yet.</p>
<h2 id="zcbh-cprs-shortcuts">Shortcuts<a class="headerlink" href="#zcbh-cprs-shortcuts" title="Permanent link">&para;</a></h2>
<p>CPRS has a rather staggering amount of keyboard shortcuts.</p>
<p>The full list is available in this
<a href="http://www.va.gov/vdl/documents/Clinical/Comp_Patient_Recrd_Sys_(CPRS)/cprsguium.pdf">pdf</a>.</p>
<h2 id="zcbh-cprs-task-management">Task management<a class="headerlink" href="#zcbh-cprs-task-management" title="Permanent link">&para;</a></h2>
<p>One of the beautiful and awful things
about CPRS is that it is self-contained.</p>
<p>It does not interface with the outside world -
no push notifications,
no easy way to check things on your phone.</p>
<p>Within its walled garden,
it is also not easy to figure out
what has been done and what needs doing.</p>
<p>There are a few approaches to task management
more-or-less built into CPRS.</p>
<h3 id="zcbh-cprs-tracker-reminder-notes">Tracker Reminder Notes<a class="headerlink" href="#zcbh-cprs-tracker-reminder-notes" title="Permanent link">&para;</a></h3>
<p>One of the available note types
is called "Tracker Reminder."
These are unsignable notes (try to sign one and it will fail),
that remain in your inbox until deleted.
They are a great way to prechart,
and you can use them to make notes to yourself about whatever.</p>
<p>No one else, including your preceptor, can see what's in them
(maybe there's some way for some admin to introspect them,
but I haven't heard of anyone who both knows how to do this and cares to look at your personal scribblings).</p>
<p>I used to also use them as a general to-do list,
and I know some residents live by them throughout training.
I don't use them as a catch-all anymore (instead preferring Ticklers, outlined below),
and now essentially only use them for pre-charting.
In your inbox,
all you can see is the patient for whom you have a Tracker Reminder,
and the note title ("UNSIGNED Tracker Reminder") -
there is no good way to differentiate between a precharted note,
a to-do item,
or anything else you may have written.</p>
<p>CPRS is very slow,
so clicking into each Tracker Reminder
to see what's in there is much too expensive in terms of time.</p>
<h3 id="zcbh-cprs-ticklers">Ticklers<a class="headerlink" href="#zcbh-cprs-ticklers" title="Permanent link">&para;</a></h3>
<p>Yes, self-assigned alerts in CPRS are called "Ticklers."
Because "Alerts" is not nearly descriptive enough.</p>
<p>To set up Ticklers for yourself, get into a new note or make an addendum.</p>
<p>(shout out to Paige, RN extraordinaire, for showing me her approach -
it's A-OK to make an addendum with the content of only "setting alert")</p>
<p>Click "Templates" on the bottom left.
The first "Shared Template" should have the word "Tickler."
Double-click it,
and it will open up a simple dialogue
that asks you when you want to be alerted,
and any text you would like within the alert.</p>
<p>Then, when the time comes for that alert,
it will show up in your universal CPRS inbox.
When you click into it,
it will show you the text you entered,
and give you three options -
copy the text of the alert to the clipboard,
renew the alert,
or close it out.</p>
<p>One advantage to this approach over
a huge list of Tracker Reminder notes
is that your inbox does not become nearly as cluttered,
and you can tell more easily what is time-sensitive.
I also prefer it over some third-party solution,
such as a OneNote page, Word doc, or Excel sheet
(all HIPAA-compliant if using your institutional OneDrive account),
because all of my VA work and data lives in a single system,
so I don't have something else to (forget to) check.</p>
<h3 id="zcbh-cprs-leave-one-behind-alert-method">Leave-one-behind alert method<a class="headerlink" href="#zcbh-cprs-leave-one-behind-alert-method" title="Permanent link">&para;</a></h3>
<p>The most common scenario:
see a patient, order some studies.
Study results roll in,
you need to discuss next steps with the patient.
Something is still processing,
and/or you don't have time right now to have a phone call.
Instead of leaving 6 or 7 alerts for the same person cluttering your inbox,
remove all but one
(highlight the alerts you want to get rid of and click "Remove").
That lone remaining alert functions as a reminder.
When the stars align, click into that alert,
go through all the recent results,
and communicate however makes sense for the situation.</p>
<h2 id="zcbh-cprs-remote-access-qol">Remote Access QoL<a class="headerlink" href="#zcbh-cprs-remote-access-qol" title="Permanent link">&para;</a></h2>
<h3 id="zcbh-cprs-text-expansion">Text expansion<a class="headerlink" href="#zcbh-cprs-text-expansion" title="Permanent link">&para;</a></h3>
<p>One of the best categories of quality-of-life improvements
you can make for using CPRS remotely
is text expansion/macros.</p>
<p>On Windows, PhraseExpress is great.
On Mac, aText is also great.</p>
<p>Set up an expansion to [enter your passcode (123456) and hit "Enter"].</p>
<p>I have it set to <code>,c</code>. (I have <code>,e</code> mapped to my Epic password).</p>
<p>This saves so much time and hassle.
For example, to sign a note,
I hit <code>Ctrl+Shift+g</code> to open the "Sign Note" dialog (this is a built-in CPRS shortcut),
then I tap <code>,c</code>, and the note is signed.
Takes far less than a second,
fingers stay close to home row.</p>
<p>The VA made their own tool to do this,
called "CPRSBooster" (it's somewhere under the Star folder on every desktop).
It works.</p>
<p><img alt="totally works" src="https://media.giphy.com/media/l2JI8Ao9q7hkqWuD6/giphy.gif" /></p>
<p>The main utility of CPRSBooster
is to give you ideas for other text expansions you could set up,
such as your nurse's name for tagging on notes.</p>
<h2 id="zcbh-cprs-vista">VistA<a class="headerlink" href="#zcbh-cprs-vista" title="Permanent link">&para;</a></h2>
<p>VistA is the (rather insane) software and database system that undergirds CPRS.
I get the sense that the deepest magicks rest in VistA,
waiting for the intrepid explorer,
seeking a grail filled with
automated data extraction and sane clinical workflows.</p>
<p>The documentation is scattered.
<a href="https://www.va.gov/vdl/">This</a> is one of the official sources.
I've only taken a cursory look, but it seems less technical and mostly snarky.</p>
<p>There's also a <a href="http://www.vistapedia.com/index.php/Main_Page#VistApedia">wiki</a> devoted to VistA,
though it is not restricted to the official USGovt version
(since the software is federally mandated to be open source,
it has been forked and developed in several countries worldwide).</p>
<p>If you have been inducted into the cult of VistA,
and need an acolyte,
let me know.
I make pretty kickass chocolate chip cookies.</p></section><h1 class='nav-section-title-end'>Ended: zCBH</h1>
                        <h1 class='nav-section-title' id='section-appendices'>
                            Appendices <a class='headerlink' href='#section-appendices' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="appendices-appendices-how-discharges-va"><h1 id="appendices-appendices-how-discharges-va-how-to-on-discharges-at-va">"How to" on Discharges at VA<a class="headerlink" href="#appendices-appendices-how-discharges-va-how-to-on-discharges-at-va" title="Permanent link">&para;</a></h1>
<p>Complete the following steps <em>in this order</em> to ensure info will be
accurately reflected on the DIPN.</p>
<ul>
<li>Medication reconciliation<ul>
<li>The list of outpatient medications at the end of your
    reconciliation is the final medication discharge list.</li>
<li>In the medication tab, transfer new inpatient medications to the
    outpatient medication list by right-clicking and select
    ‘Transfer’</li>
<li>Select “Pick up at window,” as this will ensure the patient will
    have the medication prior to leaving the hospital</li>
<li>Review the existing outpatient medications to determine if they
    need to be continued and if the pt has an adequate supply at
    home - refill meds if necessary</li>
<li>Discontinue any outpatient medications that you do not want the
    pt to continue taking. Right-click and select ‘Discontinue’</li>
</ul>
</li>
</ul>
<p>-</p>
<p>​​​​​ <strong>Return to clinic (Primary care)</strong></p>
<ul>
<li>
<ul>
<li>Look at the pt banner to determine where he/she receives primary
        care (top of screen)</li>
<li>PCC codes should start with a location (ex. NA, MU, CA etc)
    followed by the MD and number which designates the proper
    primary care physician</li>
<li>Place an order for ‘Return to clinic’ with the appropriate
    physician and be sure to select the date of follow-up</li>
<li>PCP, consultants, and office coordinators (RNs) can be cc’d to
    DC summary by resident</li>
</ul>
</li>
</ul>
<p>-</p>
<p><strong>Complete DIPN</strong></p>
<ul>
<li>The DIPN contains all of the discharge instructions</li>
<li>Start a new note and select ‘DIPN’ template. This will open a
    pre-templated note - follow the prompts and select finish. All
    sections need to be addressed to proceed.</li>
<li>Discharge related orders will generate after you finish the DIPN
    prompts, which includes vaccinations, removing IV, removing Foley
    catheter, etc.</li>
<li>The DIPN is valid for 24 hrs; thus the DIPN may be pre-signed one
    day prior. If DIPN is pre-signed, final changes to pt instructions
    and medications need to be addended.</li>
</ul>
<p>-</p>
<p><strong>Sign the DFF (discharge from facility) order</strong></p>
<ul>
<li>The DFF order is found under the “Discharge Orders” tab in CPRS
    orders</li>
<li>Once all steps are completed, DFF can be signed and pt will be
    discharged from facility</li>
</ul></section><section class="print-page" id="appendices-appendices-how-discharges-vumc"><h1 id="appendices-appendices-how-discharges-vumc-how-to-on-discharges-at-vumc">"How to" on Discharges at VUMC<a class="headerlink" href="#appendices-appendices-how-discharges-vumc-how-to-on-discharges-at-vumc" title="Permanent link">&para;</a></h1>
<ul>
<li>Verify the correct pharmacy with the pt and if refills of existing
    medications are needed</li>
<li>Select ‘Transfer-Discharge’ on the navigator panel on eStar</li>
<li>Select ‘Discharge’ tab on the top of the page</li>
<li>Select ‘Rx Routing’ on the left panel. Choose one of the three
    options. This choice will set the default prescribing choice for new
    medications at discharge or refilled medications. This can be
    changed manually within each Rx order.<ul>
<li>Default = will e-prescribe to pt’s pharmacy</li>
<li>Print = will print all Rx’s and not e-prescribe (printed to
    nursing station on pt’s floor)</li>
<li>Do not print and do not e-prescribe (This is used for pt going
    to SNF or IPR)</li>
</ul>
</li>
<li>Select ‘Discharge Orders’ on the left panel. This will open a
    reconciliation navigator.</li>
<li>Reconcile the home medications with the current inpatient
    medications. The red tab on the right side of the screen will become
    green when all medications are addressed.<ul>
<li>For new medications or refills, make sure the ‘Class’ in the
    prescription is set to ‘Normal’ for electronic prescriptions.
    Otherwise, to add the medication to the list without a
    prescription, choose ‘No Print’.</li>
<li>The medications will e-prescribe to the pharmacy selected at the
    bottom of the order panel on the right side of your screen.</li>
<li>To send to multiple pharmacies, select the primary pharmacy at
    the bottom of the order panel on the right side of your screen,
    then choose ‘Send to Multiple Pharmacies’.</li>
</ul>
</li>
<li>Next, select ‘Order Sets’ at the top of the Discharge Orders panel</li>
<li>In the order box on the right, type “Adult General Discharge”<ul>
<li>Right-click on the option and select “Add to Favorites”. Now,
    this option will be available on the Order Set page for future
    patients.</li>
<li>Open Adult General Discharge order set<ul>
<li>Select the appropriate choices pertinent to current pt</li>
<li>On the right side of the screen, you can add Ad Hoc orders
    such as:</li>
</ul>
</li>
<li>Hospital Follow-up with "X" service</li>
<li>Ambulatory Referrals</li>
<li>Post-discharge labs</li>
<li>*Important for ID labs in addition to INR checks, place fax
    number for which provider that will be following up results in
    the comments section. If labs will be done outside of Vanderbilt
    system, must select "External Non-VMG"</li>
<li>Medications not listed on reconciliation list</li>
</ul>
</li>
<li>When all sections are completed, click ‘Sign – Print and/or
    E-prescribe Now’</li>
<li>Select ‘Follow-up Providers’ on the left panel.<ul>
<li>Select the providers that you want to receive the discharge
    summary.</li>
</ul>
</li>
<li>[Optional but strongly recommended] Providing personal
    instructions to the patient<ul>
<li>Select ‘Instructions’ on the left-hand panel</li>
<li>Free-text your personal comments and instructions to the
    patient, such as:<ul>
<li>A simple statement for why the pt was admitted</li>
<li>Changes made to pt’s medications that you feel are important
    to highlight</li>
<li>Home instructions (daily weights, diet changes, wound care,
    etc)</li>
</ul>
</li>
<li>This section appears FIRST in the pt’s printed AVS</li>
</ul>
</li>
</ul></section><section class="print-page" id="appendices-appendices-interns-guide-rotations-va"><h1 id="appendices-appendices-interns-guide-rotations-va-interns-guide-to-rotations-at-va">Interns' Guide to Rotations at VA<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-va-interns-guide-to-rotations-at-va" title="Permanent link">&para;</a></h1>
<p>VA: Veterans Affairs Rotations</p>
<p>Always make sure that your VA login works a few days before you are
scheduled to start!</p>
<p><strong>Conference Schedule</strong></p>
<p>VA Morning Report: Mon-Tues-Wed-Fri (just like VU except Tuesday also
has CXR rounds)</p>
<p>Noon Conference – Mon, Wed &amp; Friday on 7T; 12:00 – 1:00: Lunch with
various lectures.</p>
<p>Fox and Hedgehog – Light Hall 208; Tuesdays 12:00 – 1:00; Chief Resident
Conference</p>
<p><strong>VA General Wards (1A – 6B)</strong></p>
<ul>
<li><strong>Team</strong> : 1 Res, 2 Interns with patient cap of 8 each (16 total)</li>
<li>Pick up list 6:30 AM; Admit every other day; Can sign-out on
    non-admit days at 2 PM</li>
<li><strong>Rounds</strong> alternates at 7 AM on admitting days, 8 AM on
    non-admitting days, meet at workrooms<ul>
<li>Workroom:<ul>
<li>Teams 1-3 on 2N</li>
<li>Team 4 at 2<sup>nd</sup> floor main elevators</li>
<li>Team 5 on 3N</li>
<li>Team 6 2<sup>nd</sup> floor off ICU hallway</li>
</ul>
</li>
</ul>
</li>
<li><strong>Conferences</strong> : VA Morning Report; Noon conference, Fox; don’t
    forget CXR rounds on Tuesdays!</li>
<li><strong>Review</strong> : Many admissions for falls (review Geriatrics sections),
    chest pain, ACS/NSTEMI, syncope (review cardiology), COPD
    exacerbation, Pneumonia (ID), Skin and Soft Tissue Infections (ID),
    diabetic foot infections.</li>
<li><strong>Tips</strong> : Admission days can be very busy and anything you can get
    done on the non-admitting days will make your life easier
    (especially DIPNs for people leaving the next day); start your own
    patient list in a word document to use as your pre-rounding sheet as
    well as sign-out; Roll your pagers via Vanderbilt operator (same as
    at VU); ensure all orders on patients still in the ED are “Delayed”
    or they will disappear once on the floor (ask your resident); All
    consults must be accompanied by page to the covering fellow (see
    synergy for medicine subspecialties, TVHS website for surgery/other)</li>
</ul>
<p><strong>VA MICU</strong></p>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap (typically 10-12)</li>
<li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU is on 2<sup>nd</sup>
    floor between 2N and 2G<ul>
<li>Night intern presents the old patients on morning rounds</li>
</ul>
</li>
<li>Excused from Conferences</li>
<li><strong>Review</strong> : ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis,
    Management of Shock, MICU/CCU Drips, Basics of blood gases (Pulm)
    Stress Dose Steroids (Endo), Cirrhosis (Hep)</li>
<li><strong>Tips</strong> : Night intern presents all of the old patients in the
    morning and signs the notes. The day intern owns the A&amp;P of the
    notes by keeping them updated. Never hesitate to relay information
    to your resident overnight if you are concerned</li>
</ul>
<p><strong>VA Nights</strong></p>
<ul>
<li><strong>Team</strong> : 1 Res, 2 Interns, total of 10 admissions overnight</li>
<li>Start at 7 PM, Admit until 5:30 AM, present new patients to teams at
    7 AM, leave by 8 AM</li>
<li><strong>Start on Sunday night</strong> ; Off day is Saturday night for interns</li>
<li><strong>Tips</strong> : Admissions typically bolus at the start of shift and stop
    later in the night, so worry about seeing patients, formulating
    plans with resident and putting in orders as the notes can be
    finished once it slows downs; the cafeteria at VU closes at 2 AM;
    communicate everything you do with your resident who is supervising
    a second intern as well; ensure all orders on patients still in the
    ED are “Delayed” or they will disappear once on the floor (ask your
    resident)</li>
</ul></section><section class="print-page" id="appendices-appendices-interns-guide-rotations-vumc"><h1 id="appendices-appendices-interns-guide-rotations-vumc-interns-guide-to-rotations">Interns' Guide to Rotations<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-interns-guide-to-rotations" title="Permanent link">&para;</a></h1>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-structure-overview">Structure Overview<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-structure-overview" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Teaching Service</th>
<th>Structure</th>
<th>Patient Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morgan 1-6</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Geriatrics</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Rogers (Hep, ID, Pulm, Renal)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Heart Failure (CHF 1 &amp; 2 ) (one team)</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>Cardiology (Harrison 1 &amp; 2) (two teams)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Hematology (Brittingham A &amp; B) (one team)</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>Oncology (Onc A &amp; B)  (two teams)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>VU MICU 1 &amp; 2   (two teams)</td>
<td>3 residents, 3 interns</td>
<td>no cap (typically 10-12)</td>
</tr>
<tr>
<td>VU Night: Admitting Morgan/Rogers</td>
<td>1 resident, 2 interns</td>
<td>10</td>
</tr>
<tr>
<td>VU Night: Admitting Harrison/Heme/Onc</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>VU Night: Crosscover</td>
<td>1 resident, 1 intern</td>
<td>N/A</td>
</tr>
<tr>
<td>VA Wards 1-5</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>VA Wards 6</td>
<td>2 residents</td>
<td>8 per resident (16 total)</td>
</tr>
<tr>
<td>VA MICU</td>
<td>3 residents, 3 interns</td>
<td>no cap (typically 10-12)</td>
</tr>
<tr>
<td>VA Night: Admitting</td>
<td>1 resident, 2 interns</td>
<td>10</td>
</tr>
<tr>
<td>VA Night: Crosscover</td>
<td>1 resident</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-service-details">Service Details<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-service-details" title="Permanent link">&para;</a></h2>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-morgan-1-6">Morgan (1 –  6)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-morgan-1-6" title="Permanent link">&para;</a></h2>
<ul>
<li>Pick up list at 6 - 6:30 AM, admit until 5:30 PM, sign-out 6 PM</li>
<li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days (just
        like VA)</li>
<li>Non-admitting teams can sign-out at 2PM on weekdays and 12PM on
        weekends</li>
<li>Rounds at 8 AM, teams usually meet at 8N Nursing stations; coordinate with
    attendings</li>
<li>Workroom: team-specific rooms on hall behind 7N Nursing station
        (Code 24300)</li>
<li>Review: read about each pt as you admit them, you will see a variety of
    different diseases</li>
<li>Tips: Call consults as soon as possible; keep a column on your pt list
    for Labs and New Notes easily track updates without entering chart
    to check; Your team pharmacist is a valuable resource, get her/his
    number the first day; Close communication with your team SW and CM
    help with discharges (upper level’s responsibility); Enter
    meds-2-beds ASAP</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-geriatrics">Geriatrics<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-geriatrics" title="Permanent link">&para;</a></h2>
<ul>
<li>Rounds at 8 AM, team meets in the Round Wing workroom 7434<ul>
<li>Workroom: 7434</li>
</ul>
</li>
<li>Review: Geriatrics Section, Altered mental status (Neuro), genitourinary
    infection (ID)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-rogers-subspecialty-services">Rogers (Subspecialty Services)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-subspecialty-services" title="Permanent link">&para;</a></h2>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-all-rogers-services">All Rogers services<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-all-rogers-services" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 1 Intern with patient cap of 10</li>
<li>Pick up list at 6 - 6:30 AM, admit daily until 5:30 PM, sign-out 6
    PM</li>
<li>Each HPI usually requires special info about the patient’s
    subspecialty diagnosis (See Tips)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-hepatology">Rogers Hepatology<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-hepatology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets on 6MCE</li>
<li>Work room: 6MCE, 6755 – north end (No Code)</li>
<li>Review: Hepatology Section, Paracentesis (Procedures)</li>
<li>Tips: Present pts as “Cirrhosis secondary to ____ decompensated by
    ___ (EVs, Ascites, SBP, HE, HRS)”; use the MELD-Na dot phrase;
    almost never should give cirrhosis patient crystalloid, consider
    albumin instead (25%, not 5%), consult procedure service during
    rounds to get your pts on the list for therapeutic paracenteses</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-id">Rogers ID<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-id" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets in Resident Library (8N)</li>
<li>Work room: 6 Round Wing, 2 <sup>nd</sup> door on left after
        coming out of elevator (No Code)</li>
<li>Review
    : Infectious Diseases Section, specifically HIV and ART General
    Concepts</li>
<li>Tips
    : Each HPI for pt with HIV should include most recent CCC provider,
    CD4/Viral Load, prior AIDS-defining illnesses and compliance to ART;
    Use ‘Notifications’ tab on main screen in Epic to keep track of lab
    orders as patients can have long stays with send-out labs that can
    take up to two weeks to result (can also hit ‘Notify Me’ in dropdown
    box of Order); consider doxy in lieu of Azithro for CAP in HIV/AIDS
    (MAC Coverage)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-pulmonology">Rogers Pulmonology<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-pulmonology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets at 8N nursing station</li>
<li>Workroom: 8South 8216 (Code 2430)</li>
<li>Review: Pulmonary Section, specifically Home Oxygen Therapies</li>
<li>Tips: Each HPI should include most recent PFTs (FEV1%most important,
    include other relevant data or recent changes); For CF, Use the CF
    admission order set, know typical organisms in patient’s sputum (ex:
    MDR Pseudomonas, Burkholderia, MRSA) and consult CF team; for PH
    know the therapies they are on (typically Flolan or Veletri)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-renal">Rogers Renal<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-renal" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically start 7-7:30 AM, team meets at resident/fellow work room
    on 6MCE</li>
<li>Workroom: 6MCE 6772, behind nursing station with renal fellows
        (No Code)</li>
<li>Review: Nephrology section, specifically Renal Transplant</li>
<li>Tips: Each HPI should have renal transplant history with year, type of
    tpx, PRA, Ag MM, CMV D/R; 6MCE charge nurse can get pts transferred
    there; alert the night resident to patients with renal biopsy and
    low threshold to contact renal fellow; transplant pts should have
    daily tacro level one hour before AM tacro dose (5:00 am),
    regardless of pt’s home schedule and be cautious with first dose
    timing of IS to keep things on schedule</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-heart-failure-chf-1-2">Heart Failure (CHF 1 &amp; 2)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-heart-failure-chf-1-2" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 2 Interns on one team with pt cap of 8 per intern (16
    total)</li>
<li>Pick up list at 6 AM, admit until 5PM (alternate admissions,
    resident to help assign)</li>
<li>Rounds typically at 7 AM, team meets at 7MCE nursing station</li>
<li>Workroom: 7N 7024 right before bridge to 7MCE. (Code 145)</li>
<li>Review: Advanced heart failure; RHC and swan numbers (useful in assessing
    volume status in hard to examine pts, and CCU transfers), post-cath
    care, valvular disease</li>
<li>Tips: Know each patient’s dry weight (usually found in outpatient cards
    notes or at last discharge), Know current outpatient diuretic
    regimen and most recent TTE (weight at the time helps too); order
    strict I&Os; Daily <strong><em><u>Standing</u></em></strong> Weights, and fluid
    restriction of 2L/day; Always assess JVP before rounds</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-harrison-1-2">Harrison (1 &amp; 2)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-harrison-1-2" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pick up list at 6 AM, admit until 5 PM (Long) or 2 PM (Short)
    alternating with other team</li>
<li>Weekends: Only long team admits new patients</li>
<li>Rounds typically at 7 AM, team meets at 7MCE Nursing station</li>
<li>Workroom: 5MCE 5181 (Code 0701); hard to hear stats so keep door
        propped</li>
<li>Review: post-cath care, ACS, chest pain, valvular disease, arrhytmia’s,
    PE’s.</li>
<li>Tips: To order heart cath, must be in the cardiology context in Epic
    “VUMC Cardiology VIR” (order listed as “Case Request Cath Lab” and
    use provider “Surgeon, Generic”)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-hematology-brittingham">Hematology (Brittingham)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-hematology-brittingham" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 2 Interns with patient cap of 8 per intern (16 total)</li>
<li>Pick up list at 6 AM, admit until 5 PM (alternate admissions with
    second intern)</li>
<li>Rounds at 8 AM, team meets on 10T</li>
<li>Workroom: Brittingham</li>
<li>Review: Neutropenic Fever, TLS, DIC, Acute Leukemia, Lymphoma, Plasma Cell
    Dyscrasia</li>
<li>Tips: Each HPI should include malignancy history (dx, prior tx, current
    tx); know the febrile neutropenia algorithm; if possible, enter
    orders/write notes while the other intern and attending are at
    bedside; low threshold to work any complaints up as bleeds and
    infections are common and can be rapidly lethal.</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-oncology-onc-a-b">Oncology (Onc A &amp; B)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-oncology-onc-a-b" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pick up list at 6 AM, admit daily 6 AM until 5 PM, sign-out 6 PM</li>
<li>Rounds at 8 AM, team meets on 11N at nursing station</li>
<li>Workroom: No assigned room, typically library, 11N or 10T, or 7MCE Conference room</li>
<li>Review: Opiates (Pain &amp; Palliative Care), Oncologic emergencies,
    Paraneoplastic Syndromes, Chemotherapy Toxicity/Side Effects</li>
<li>Tips: Each HPI should have Onc history (Dot Phrase “.onchist”) including
    dx, prior treatments, most recent imaging; 10T and 11N charge nurse
    can get pts transferred there, you can write delayed admission
    orders for pts seen in infusion clinic (ask your resident)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-vu-micu">VU MICU<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-vu-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap (typically 10-12)</li>
<li>Day Intern: 8 AM - 10 PM; Night Intern 9 PM - 11 AM; MICU is on 8T</li>
<li>Review: ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis, Management
    &amp; Types of Shock, MICU/CCU Drips, ABGs (Pulm) Stress Dose Steroids
    (Endo), Cirrhosis, ACLS</li>
<li>Tips: Night intern presents all the old patients in the morning and
    signs the notes. The day intern owns the A&amp;P of the notes by keeping
    them updated. Trust the nurses and never hesitate to relay info to
    your resident overnight if you’re concerned (wake him/her up!)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-vu-nights">VU Nights<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-vu-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Start on Sunday night for interns, Wednesday night for residents; off Saturday
    night</li>
<li>Harrison/Heme/Onc: Start at 6 PM, admit until 5 AM, sign-out by 6 AM</li>
<li>Morgan/Rogers: Start at 6:30 PM, admit until 5:30 AM, sign-out by 6:30 AM</li>
<li>Cross cover: Start at 6 PM (Be on time!) sign-out 6:30 AM</li>
<li>Tips: ensure you communicate all orders and plans with the resident;
    Writing “To do” boxes on the first pages of each printed H&amp;P might
    help you communicate the important aspects of each plan to the day
    intern when they arrive the next morning; cafeteria closes at 2 AM.
    For cross cover, make sure to document any significant events in
    Epic. Useful to follow-up on pts admitted previous nights to reflect
    on your diagnosis and workups</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-general-wards-1a-6b">VA General Wards (1A – 6B)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-general-wards-1a-6b" title="Permanent link">&para;</a></h2>
<ul>
<li>Always make sure that your VA login works a few days before you are
    scheduled to start!</li>
<li>Team: 1 Res, 2 Interns with patient cap of 8 each (16 total)</li>
<li>Pick up list by 6:30 AM; Admit every other day; Can sign-out on
    non-admit days at 2 PM</li>
<li>Rounds alternate at 7 AM on admitting days, 8 AM on non-admitting days,
    meet at workrooms; night admitting team presents to attendings at 7
    AM (depending on team)</li>
<li>Workrooms:</li>
<li>Team 1 – pulm &amp; ID fellow workroom outside MICU on 2G</li>
<li>Teams 3 on 2N</li>
<li>Team 4 at 2<sup>nd</sup> floor main elevators</li>
<li>Team 5 on 3N</li>
<li>Team 6 – 2N hallway (Old team 1 workroom)</li>
<li>Review:  Geriatrics, chest pain, CHF, ACS/NSTEMI, syncope , COPD
    exacerbation, Pneumonia, Skin and Soft Tissue Infections, diabetic
    foot infections, AMS</li>
<li>Tips: Admission days can be very busy and anything you can get done on
    the non-admitting days will make your life easier (especially DIPNs
    for people leaving the next day); start your own patient list in a
    word document to use as your pre-rounding sheet as well as sign-out;
    Roll your pagers via Vanderbilt operator (same as at VU); ensure all
    orders on patients still in the ED are “Delayed” or they will
    disappear once on the floor (ask your resident); All consults must
    be accompanied by page to the covering fellow (see synergy for
    medicine subspecialties, TVHS website for surgery/other)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-micu">VA MICU<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Combined CCU and MICU; 7AM CCU rounds followed by 8AM MICU rounds</li>
<li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU between 2N
    and 2G (2 <sup>nd</sup> floor)</li>
<li>Review
    : ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis, Management
    of Shock, MICU/CCU Drips, ABGs (Pulm) Stress Dose Steroids (Endo),
    Cirrhosis (Hep), ACLS</li>
<li>Tips
    : Night intern presents all of the old patients in the morning and
    signs the notes. The day intern owns the A&amp;P of the notes by keeping
    them updated. Never hesitate to relay information to your resident
    overnight if you are concerned (wake him/her up!)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-nights">VA Nights<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Start at 7 PM, Admit until 5:30 AM, present new patients to teams at
    7 AM, leave by 8 AM</li>
<li>Start Sunday night for interns, Wednesday night for residents; Off day is Saturday night for interns/cross-cover resident
    (covered by clinic resident), Friday night for admitting resident
    (covered by BMT resident)</li>
<li>Tips: Admissions typically bolus at the start of shift and stop later in
    the night, so worry about seeing pts, formulating plans with
    resident and putting in orders as notes can be finished once it
    slows down; cafeteria at VU closes at 2 AM; communicate everything
    you do with your resident who is supervising a second intern as
    well; ensure all orders on pts still in the ED are “Delayed” or they
    will disappear once on the floor (ask your resident)</li>
</ul></section><section class="print-page" id="appendices-appendices-staging-wounds"><h1 id="appendices-appendices-staging-wounds-staging-wounds">Staging Wounds<a class="headerlink" href="#appendices-appendices-staging-wounds-staging-wounds" title="Permanent link">&para;</a></h1>
<p>Wound Staging adapted from Dr. Duggan's Geriatrics Guide</p>
<p>Wound Care by Amanda Bailey, NP</p>
<ul>
<li>Document ALL wounds that are present on admission. This affects
    reimbursement.</li>
<li>Use the Haiku app on your cellphone to document images of wounds in
    pt chart</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feature</td>
<td>Deep Tissue Injury</td>
<td>Stage 1</td>
<td>Stage 2</td>
<td>Stage 3</td>
<td>Stage 4</td>
</tr>
<tr>
<td>Skin Consistency</td>
<td>Boggy</td>
<td>Boggy</td>
<td>Variable</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Skin color/nature of lesion</td>
<td>Non-blanching purple or maroon, may appear as blood-filled blister</td>
<td>Non-blanching erythema</td>
<td>Abrasion, blister, or shallow crater</td>
<td>Variable</td>
<td>Variable. If eschar, must be removed in order to stage, or is unstageable</td>
</tr>
<tr>
<td>Depth</td>
<td>Epidermis intact</td>
<td>Epidermis intact</td>
<td>Through surface of epidermis and outer dermis</td>
<td>SQ tissue to, but not through, fascia</td>
<td>Full-thickness loss w/ destruction, necrosis, or damage to muscle, bone, supporting structures</td>
</tr>
</tbody>
</table>
<p><img src="/sites/default/files/inline-images/Pressure%20Ulcer%20Stages.jpg" data-entity-type="file" data-entity-uuid="0f963d7f-b572-42a2-946a-66fd4dc6e89b" alt="Pressure Ulcer Stages" /></p>
<p>Recall other types of ulcers to consider in your differential:</p>
<ul>
<li>Arterial
    : shallow, well-defined borders, pale/necrotic wound bed, minimal
    exudate due to poor blood flow, cramping pain or a constant deep
    ache</li>
<li>Diabetic
    : Plantar surface of foot, callused wound margins; usually painless
    due to neuropathy</li>
<li>Venous
    : medial malleolus, irregular edges, ruddy red with yellow slough
    and copious exudate</li>
</ul>
<p>Non Acute Wound</p>
<ul>
<li>Order “Inpatient Consult to Adult <strong>Simple</strong> Wound Ostomy VUH” for:<ul>
<li>Pressure Injuries – stage 1, stage 2, deep tissue injury</li>
<li>Skin tears – partial thickness</li>
<li>Moisture Associated Skin Damage – diarrhea, tube drainage, skin
    folds</li>
<li>Partial thickness wounds – other</li>
<li>Peri-tube skin problems – peg, trach skin issues</li>
<li>Fistulas</li>
</ul>
</li>
<li>Order “Inpatient Consult to <strong>Complex</strong> Wound” for:<ul>
<li>Pressure injuries – stage 3, 4, unstageable</li>
<li>Wounds with pathology<ul>
<li>Diabetic – areas of pressure<ul>
<li>For routine diabetic foot wounds even if they need
    debridement but are not frankly infected, consult
    COMPLEX WOUND</li>
<li>Caveat
    : If frank pus or erythema is spreading up leg, consult
    “Ortho foot-ankle”</li>
<li>Caveat
    : If pt is being followed by Drs. Hicks, Trenner or
    Deeter, consult “Ortho Foot-Ankle.” Use the Epic search
    tool to determine this</li>
</ul>
</li>
</ul>
</li>
<li>Arterial – distal on digit</li>
<li>Venous – gravity dependent areas</li>
<li>Calciphylaxis</li>
<li>Pyoderma Gangrenosum</li>
<li>Fungating Lesion</li>
<li>Vasculitis</li>
<li>Abscess ( <strong><em>already</em></strong> drained, just needs packing
    instructions)</li>
<li>Surgical wounds (for pts <strong><em>without</em></strong> VUMC surgeon)</li>
<li>If pt has VUMC surgeon, consult appropriate surgical team (see
    below)</li>
<li>Hematoma with no active bleeding but with overlying skin
    necrosis/wound</li>
<li>Wound with underlying osteomyelitis</li>
<li>IV infiltrate –contact team pharmacist or inpatient pharmacy
    (615-875-6337) for protocol</li>
</ul>
</li>
</ul>
<p>Acute Wound</p>
<ul>
<li>Abscess, Hematoma, Osteomyelitis with overlying wound<ul>
<li>Whom to consult for drainage/debridement:<ul>
<li>Face – Face</li>
<li>Chest/Sternum – CT surgery</li>
<li>Breast – General Surgery</li>
<li>Spine – Spine</li>
<li>Arm (hand to elbow) – Hand</li>
<li>Lower leg (foot to knee) – Ortho</li>
<li>Labial – OB/GYN</li>
<li>Scrotal – Urology</li>
<li>Buttock, thigh (knee to hip), arm (elbow to shoulder)– EGS
    consult</li>
<li>Perirectal/Rectal<ul>
<li>Acute abscess – EGS</li>
<li>Chronic due to IBD – Colorectal surgery</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Necrotizing Fasciitis</p>
<ul>
<li>Whom to consult for URGENT/EMERGENT surgical eval:<ul>
<li>Genitalia – Urology</li>
<li>Buttocks, perineum, abdomen – EGS</li>
<li>Upper extremity (shoulder to hand) – Hand</li>
<li>Lower extremity (hip to toes) – Ortho</li>
</ul>
</li>
</ul>
<p>Pressure Injury</p>
<ul>
<li>If concerned for sepsis, consult EGS</li>
<li>If EGS deems no URGENT or EMERGENT surgical needs, consult Complex
    Wound</li>
<li>If EGS recommends consult to plastic surgery for “flap, debridement,
    wound care, etc.” and there are no URGENT or EMERGENT surgical
    needs, consult Complex Wound</li>
</ul>
<p>Simple and Complex Wound Service Hours:</p>
<ul>
<li>Both services are Monday through Friday</li>
<li>Consults placed on weekends and holidays are addressed on the next
    business day</li>
<li>If there is an urgent/emergent wound need i.e. needs surgery for
    debridement or I&amp;D then consult the appropriate surgical service</li>
<li>While awaiting consultation, utilize the wound orders below to
    initiate topical care</li>
</ul>
<p>Order Wound Care Until Consult Complete:</p>
<ul>
<li>Superficial wounds<ul>
<li>Stage 1 or 2 Pressure injuries, Moisture Associated Skin Damage,
    Skin Tears<ul>
<li>Order “Adult skin Care Guidelines” and use the order set to
    guide you</li>
</ul>
</li>
<li>Shallow Stage 3 (i.e., \&lt;1cm deep), diabetic foot ulcers<ul>
<li>Order “Wound Care”: Frequency 2x weekly and prn; Cleanse
    with NS; Protect periwound with Mepilex foam (type in
    comments)</li>
</ul>
</li>
</ul>
</li>
<li>Painful superficial wounds no infection (i.e. vasculitis, PG,
    calciphylaxis)<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS;
    Apply Vaseline; Protect periwound with Xeroform and dry gauze
    (type in comments)<ul>
<li>If wound is on the hand, arm, foot, or lower leg consider
    wrapping in Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks),
    consider covering with an ABD pad and secure with medipore
    tape</li>
</ul>
</li>
</ul>
</li>
<li>Infected superficial wounds<ul>
<li>NOTE
    : Odor alone is NOT infection; wounds with necrotic tissue may
    have odor</li>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS,
    Apply Silvadene; Protect periwound with Xeroform and dry gauze
    (type in comments)<ul>
<li>If wound is on hand, arm, foot, or lower leg consider
    wrapping in a Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks),
    consider covering with an ABD pad and secure with medipore
    tape</li>
</ul>
</li>
<li>Medication order required: Silvadene q12h; in Admin Inst put
    “per wound care orders”</li>
</ul>
</li>
<li>All Deep wounds &gt; 1cm deep (i.e., deep stage 3, 4 or deep diabetic
    foot wound)<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS,
    pack with Dakin’s 0.025% (1/20 strength) soaked continuous
    Kerlix roll; Protect Periwound with ABD pad &amp; medipore tape
    (type in comments).</li>
<li>If wound care is painful, consider changing to daily dressing
    changes</li>
<li>Medication order required: Dakin’s 0.025% solution q12h; in
    Admin Inst put “per wound care orders”</li>
</ul>
</li>
<li>Deep tissue injury Pressure injury<ul>
<li>Medication order required: Venelex (balsam peru- castor oil)
    ointment q4h; in Admin Inst put location to apply ointment and
    put “no dressing”</li>
</ul>
</li>
<li>Fungating mass<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with baby
    shampoo and water, NS, Metrogel (type in comments); Protect with
    Xeroform, ABD pad, medipore tape</li>
<li>Medication order required: metrogel q12h; in Admin Inst put “per
    wound care orders”</li>
</ul>
</li>
<li>Wound VAC present<ul>
<li>Vanderbilt surgeon – consult Vanderbilt provider to provide care<ul>
<li>Ensure connected to VUMC wound VAC. Pt shouldn’t use home
    unit while admitted</li>
<li>Order “nursing communication” to “Obtain wound VAC hospital
    machine and canister from service center to connect pt to
    hospital machine.”</li>
<li>Wound VAC should not be left without suction for more than 2
    hours</li>
<li>Settings: 125 mmHg continuous</li>
</ul>
</li>
<li>Non VUMC surgeon (i.e., gets wound care at outside
    hospital/wound care center)<ul>
<li>Discontinue wound VAC as soon as possible</li>
<li>Remove all of the clear plastic drape just like you would
    remove tape</li>
<li>Remove all of the sponge just like you would remove gauze
    packing</li>
<li>Examine the wound to ensure no residual sponge by gently
    probing site</li>
<li>Rinse with saline, initiate care based wound type as above</li>
</ul>
</li>
</ul>
</li>
<li>Leg Wrap present (i.e., Unna’s boot, ACE and 2, 3, or 4 layer
    compression)<ul>
<li>Remove by cutting the wrap off</li>
<li>Assess the wound and order dressing based on type of wound as
    above</li>
<li>Order ACE bandage wrapped toe-to-knee. Remove q12h to assess
    skin</li>
</ul>
</li>
<li>Debridement Needed<ul>
<li>Complex wound care can provide non-urgent/non-emergent bedside
    debridement</li>
<li>The presence of necrotic, odorous, black, grey, yellow or loose
    dead debris does not require emergent or urgent debridement by a
    surgical service and in most cases can be managed with dressings
    described above until wound consult team can assess pt</li>
</ul>
</li>
</ul></section><section class="print-page" id="appendices-appendices-uploading-records"><h1 id="appendices-appendices-uploading-records-uploading-records">Uploading Records<a class="headerlink" href="#appendices-appendices-uploading-records-uploading-records" title="Permanent link">&para;</a></h1>
<ul>
<li>Request outside records to your Doximity account Fax</li>
<li>Open Doximity in Epic virtual desktop browser window (internet
    explorer)</li>
<li>Open faxed documents. Save as PDF to desktop of the virtual desktop</li>
<li>Return to Epic</li>
<li>Click the "Epic" dropdown menu (the same one where you "Change
    Context")</li>
<li>Hover over “Patient Care” than click "Media Manager" (pin to avoid
    extra clicks next time)</li>
<li>Select your patient</li>
<li>Click "Scan." A popup window will appear</li>
<li>On the popup window. Click "File"&gt;"Import File"</li>
<li>In the bottom right hand corner, change the File type from "Image
    Files" to "PDF Files"</li>
<li>Search for your saved document under "Downloads" or “desktop” and
    select "Open"</li>
<li>The documents should appear in the popup window. On the right hand
    side, under "store images As:" scroll down and select "Outside
    Medical Records"</li>
<li>Click "Upload Images" Name them as you choose</li>
<li>Exit out of Media Manager. Refresh chart</li>
</ul></section><section class="print-page" id="appendices-appendices-va-phone-numbers"><h1 id="appendices-appendices-va-phone-numbers-va-phone-numbers">VA Phone Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-phone-numbers" title="Permanent link">&para;</a></h1>
<h2 id="appendices-appendices-va-phone-numbers-administrative-numbers">Administrative Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-administrative-numbers" title="Permanent link">&para;</a></h2>
<ul>
<li>AOD: 67010</li>
<li>NOD (text or call): 615-456-0362</li>
<li>Flow coordinator (text or call): 615-712-5316</li>
<li>Transfer coordinator: 22516 (6:30a-4:45p)</li>
<li>VA inpatient chief office: 67112</li>
<li>VA outpatient chief office: 615-936-7080</li>
<li>IT Help Desk: 26500</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-resident-team-work-roomsareas">Resident Team Work Rooms/Areas<a class="headerlink" href="#appendices-appendices-va-phone-numbers-resident-team-work-roomsareas" title="Permanent link">&para;</a></h2>
<ul>
<li>Team 1: 68628/67147/66091</li>
<li>Team 2: 67146/68128/66090</li>
<li>Team 3: 66088/66089/66087</li>
<li>Team 4: 67662/68637/66081</li>
<li>Team 5: 66826/68427/66563</li>
<li>Team 6: 68687/67115/68696</li>
<li>BMT (Team 7): 67979</li>
<li>MICU/CCU: 67599</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-team-pager-numbers">Team Pager Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-team-pager-numbers" title="Permanent link">&para;</a></h2>
<ul>
<li>Team 1 Resident: 317-1303</li>
<li>Team 1 Intern A: 317-1201</li>
<li>Team 1 Intern B: 317-1205</li>
<li>Team 2 Resident: 317-1245</li>
<li>Team 2 Intern A: 317-1207</li>
<li>Team 2 Intern B: 317-1209</li>
<li>Team 3 Resident: 317-1304</li>
<li>Team 3 Intern A: 317-1213</li>
<li>Team 3 Intern B: 317-1206</li>
<li>Team 4 Resident: 317-1307</li>
<li>Team 4 Intern A: 317-1225</li>
<li>Team 4 Intern B: 317-1226</li>
<li>Team 5 Resident: 317-1261</li>
<li>Team 5 Intern A: 317-1216</li>
<li>Team 5 Intern B: 317-1144</li>
<li>Team 6 Resident: 317-1210</li>
<li>Team 6 Intern A: 317-1223</li>
<li>Team 6 Intern B: 317-1150</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-hospital-unit-secretariesreceptionists">Hospital Unit Secretaries/Receptionists<a class="headerlink" href="#appendices-appendices-va-phone-numbers-hospital-unit-secretariesreceptionists" title="Permanent link">&para;</a></h2>
<ul>
<li>2N: 68030</li>
<li>3N: 68040</li>
<li>2G: 68010</li>
<li>MICU/CCU: 67470</li>
<li>SICU: 67930</li>
<li>PACU: 67746</li>
<li>Dialysis: 66860</li>
<li>VA triage charge RN: 66849</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-va-consult-team-numbers-ppager">VA Consult Team Numbers (p=pager)<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-consult-team-numbers-ppager" title="Permanent link">&para;</a></h2>
<p>Most of the surgical/procedural services maintain
an Excel spreadsheet of on-call clinicians,
updated monthly,
available for download on the VA Intranet.</p>
<p>The main on-call page is available <a href="https://vaww.v09.va.gov/tennessee-valley/Clinical/On-Call-Schedules-Contacts">here</a>,
and individual on-call pages are linked below.</p>
<p>Cardiac and thoracic surgery have NPs
that field most of the consults, their pagers are included below as well.</p>
<ul>
<li>Cardiac Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Cardiac">VA website</a>; Bo Mistak, NP (p): 831-4101</li>
<li>Cardiology (24/7 p): 317-0520</li>
<li>Dermatology: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Dermatology">VA website</a></li>
<li>ENT: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-ENT">VA website</a></li>
<li>General Surgery (p): 835-7338</li>
<li>Hepatology transplant (Dr. Awad’s pager): 835-4967</li>
<li>IR: 68552 (call before placing orders)</li>
<li>Neurology (p): 835-5137</li>
<li>Neurosurgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Neurosurgery">VA website</a></li>
<li>Ophthalmology: call eye clinic 67279 (7a-5p); night/weekend (p): 831-4433</li>
<li>Oral Surgery (p): 317-0571</li>
<li>Orthopedic Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Orthopaedic">VA website</a></li>
<li>Palliative Care (p): 317-3040</li>
<li>Podiatry: 68425 (RN, first call); 615-708-5658 (Dr. Sieber’s cell, second call)</li>
<li>Plastic Surgery: [VA website]</li>
<li>Psychiatry (p): 317-1506 (first call); 615-476-9004 (Emergencies/second call)</li>
<li>SATP: 67880</li>
<li>Thoracic Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Plastic-Surgery">VA website</a>; Pinkerman, NP (p): 317-3138</li>
<li>Urologic Surgery (p): 831-8038</li>
<li>Vascular Surgery (p): 835-7358</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-va-triageer">VA Triage/ER<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-triageer" title="Permanent link">&para;</a></h2>
<ul>
<li>MD areas: 66892/67173/68192/68199</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-other-services">Other Services<a class="headerlink" href="#appendices-appendices-va-phone-numbers-other-services" title="Permanent link">&para;</a></h2>
<ul>
<li>Anti-coagulation Clinic: 66772</li>
<li>Blood Bank: 67025 (supervisor: 67029)</li>
<li>Cardiology Services</li>
<li>Cath lab: 68057/68283/68325/68358</li>
<li>Echo: 67982 (66705 for reading room)</li>
<li>Heart station (including EKG’s): 67370/66025</li>
<li>Stress test results: 66811 (nuc med reading room)</li>
<li>Nutrition Consult:</li>
<li>2N, MICU: 66730</li>
<li>3N, SICU: 67471</li>
<li>2G, PCU: 67613</li>
<li>Chaplain: 66983</li>
<li>Dental Clinic: 67120</li>
<li>Diabetes Educator: 67518, (p) 317-3210</li>
<li>Dietary: 66996</li>
<li>GI lab: 67240</li>
<li>Home Oxygen: 68402</li>
<li>Infection Control: 66759</li>
<li>Infusion Clinic: 67318</li>
<li>Medical Records: 67830</li>
<li>Physical Therapy (inpt): 67690</li>
<li>PICC (third-party, Lee Medical): 866-599-3819</li>
<li>Police: 67740</li>
<li>Prosthetics: 67770</li>
<li>Pulmonary Function Tests (PFT): 67780</li>
<li>Respiratory Therapy</li>
<li>Wards: 615-651-3939 (supervisor at 651-3583)</li>
<li>MICU: 615-651-9923</li>
<li>Social work: varies per team</li>
<li>Speech pathology: 67193</li>
<li>Telemetry: 67377</li>
<li>TPN: 67164</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-labs">Labs<a class="headerlink" href="#appendices-appendices-va-phone-numbers-labs" title="Permanent link">&para;</a></h2>
<ul>
<li>Chemistry: 67004</li>
<li>Hematology/Serology/Coag/Urine: 67045/66948</li>
<li>Microbiology: 67049 (supervisor at 66982)</li>
<li>Specimen processing: 66975</li>
<li>Cytology: 67062</li>
<li>Surgical pathology: 67064</li>
<li>Hematopathology: 68588</li>
<li>Occupational Therapy (inpt): 67560</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-pharmacy">Pharmacy<a class="headerlink" href="#appendices-appendices-va-phone-numbers-pharmacy" title="Permanent link">&para;</a></h2>
<ul>
<li>Inpatient: 67660</li>
<li>Outpatient: 67680</li>
<li>2N med rec room: 66093</li>
<li>3N med rec room: 68223</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-radiology">Radiology<a class="headerlink" href="#appendices-appendices-va-phone-numbers-radiology" title="Permanent link">&para;</a></h2>
<ul>
<li>XR: 67810</li>
<li>CT: 67007</li>
<li>MRI: 66366</li>
<li>Nuclear Medicine: 66813</li>
<li>PET: 67615</li>
<li>Ultrasound: 67550</li>
</ul></section><section class="print-page" id="appendices-appendices-vumc-phone-directory"><h1 id="appendices-appendices-vumc-phone-directory-vumc-phone-directory">VUMC Phone Directory<a class="headerlink" href="#appendices-appendices-vumc-phone-directory-vumc-phone-directory" title="Permanent link">&para;</a></h1>
<p>Shorthand</p>
<p>1xxxx</p>
<p>– 615-421-xxxx</p>
<p>2xxxx</p>
<p>– 615-322-xxxx</p>
<p>3xxxx</p>
<p>– 615-343-xxxx</p>
<p>5xxxx</p>
<p>– 615-875-xxxx</p>
<p>6xxxx</p>
<p>– 615-936-xxxx</p>
<p>Labs</p>
<p>Blood Bank</p>
<p>– 22233</p>
<p>Cytology Lab</p>
<p>– 22721</p>
<p>Flow Cytometry Lab</p>
<p>– 39081</p>
<p>Hematology Lab</p>
<p>– 39125</p>
<p>Hematology Smear Lab</p>
<p>– 33905</p>
<p>Lab Operator</p>
<p>– 55227</p>
<p>Microbiology Lab</p>
<p>– 23406</p>
<p>Cardiology</p>
<p>Cardiac Access Center</p>
<p>– 33255</p>
<p>Cardiac MRI</p>
<p>– 68111</p>
<p>Cath Lab</p>
<p>– 34808</p>
<p>Echo Lab</p>
<p>– 20624</p>
<p>Echo Reading Room</p>
<p>– 60705</p>
<p>EP Lab</p>
<p>– 35036</p>
<p>TEE</p>
<p>– 67431</p>
<p>Telemetry</p>
<p>– 65945</p>
<p>Neurology</p>
<p>831</p>
<p>- <strong>4790</strong> – Page this to discuss a patient admitted to the neurology
general service</p>
<p>831</p>
<p>- <strong>4792</strong> – Page this to discuss a patient admitted to the neurology
stroke service</p>
<p>835</p>
<p>- <strong>5137</strong> – Page this for any neurology issues/questions at the
Nashville VA</p>
<p>831</p>
<p>- <strong>4793</strong> – Page this to for any other neurology question (When in
doubt, pager this #)</p>
<p>Units</p>
<p>A Pod</p>
<p>– 35914</p>
<p>B Pod</p>
<p>– 27173</p>
<p>C Pod</p>
<p>–64593</p>
<p>TCU</p>
<p>–34893</p>
<p>3 Round Wing</p>
<p>– 25120</p>
<p>4 North</p>
<p>– 22255</p>
<p>4 Round Wing</p>
<p>– 22244</p>
<p>4 South</p>
<p>– 32736</p>
<p>5 North</p>
<p>– 35030</p>
<p>5 Round Wing</p>
<p>– 23895</p>
<p>5 South</p>
<p>– 24710</p>
<p>6 North</p>
<p>– 32482</p>
<p>6 Round Wing</p>
<p>– 28900</p>
<p>6 South</p>
<p>– 22000</p>
<p>6 Tower</p>
<p>– 35232</p>
<p>7 East -</p>
<p>56801</p>
<p>7 North</p>
<p>– 20942</p>
<p>7 Round Wing</p>
<p>– 35302</p>
<p>7 South</p>
<p>– 32271</p>
<p>7 Tower</p>
<p>– 20911</p>
<p>8 East</p>
<p>– 53700</p>
<p>8 North</p>
<p>– 20948</p>
<p>8 South</p>
<p>– 20946</p>
<p>8 Tower</p>
<p>– 20938</p>
<p>9 North</p>
<p>– 20918</p>
<p>9 South</p>
<p>– 20916</p>
<p>9 Tower</p>
<p>– 20988</p>
<p>10 North</p>
<p>– 30398</p>
<p>10 South</p>
<p>– 28920</p>
<p>10 Tower</p>
<p>– 24545</p>
<p>11 North</p>
<p>– 55333</p>
<p>11 South</p>
<p>– 24590</p>
<p>Radiology</p>
<p>Body Reading Room</p>
<p>– 26011</p>
<p>Chest Reading Room</p>
<p>– 28485</p>
<p>CT Scanner A Pod</p>
<p>– 36055</p>
<p>CT Tech</p>
<p>– 38074</p>
<p>CTA Reading Room</p>
<p>– 32162</p>
<p>ED Reading Room</p>
<p>– 37185</p>
<p>Fluoroscopy Reading Room</p>
<p>– 30951</p>
<p>Fluoroscopy Tech</p>
<p>– 20878</p>
<p>IR Reading Room</p>
<p>– 20840</p>
<p>MRI Tech</p>
<p>– 34557</p>
<p>Nuclear Med Reading Room</p>
<p>– 31577</p>
<p>Nuclear Med Tech</p>
<p>– 20893</p>
<p>Neuroradiology Reading Room</p>
<p>– 30900</p>
<p>PET Reading Room</p>
<p>– 37523</p>
<p>Radiology Library</p>
<p>– 20866</p>
<p>Ultrasound Reading Room</p>
<p>– 20853</p>
<p>Ultrasound Tech</p>
<p>– 34970</p>
<p>Vascular Lab</p>
<p>– 39205</p>
<p>X-ray Tech ED</p>
<p>– 28804</p>
<p>X-ray Tech Floor Pager</p>
<p>– 615-835-5647</p>
<p>X-ray Tech Tower Pager</p>
<p>– 615-835-5597</p>
<p>Miscellaneous</p>
<p>Admitting</p>
<p>– 30179</p>
<p>Anesthesia STAT Phone</p>
<p>– 615-887-7369</p>
<p>Bed Management (Option 5)</p>
<p>– 54000</p>
<p>Bronchoscopy Lab</p>
<p>– 39647</p>
<p>Dialysis</p>
<p>– 20912</p>
<p>EEG Tech Pager</p>
<p>– 615-835-8847</p>
<p>GI Lab</p>
<p>– 39716</p>
<p>Inpatient Pharmacy</p>
<p>– 56337</p>
<p>Language Line</p>
<p>– (866) 874-3972 (218443)</p>
<p>Meds to Beds</p>
<p>– 20804</p>
<p>Nutrition Services</p>
<p>– 39761</p>
<p>PICC Service</p>
<p>– 22772</p>
<p>Resident Library</p>
<p>– 56205</p>
<p>Service Center</p>
<p>– 39600</p>
<p>The MAC</p>
<p>– 615-540-4213</p>
<p>Transfer Center</p>
<p><strong>(Option 4)</strong> – 54000</p>
<p>Vanderbilt Operator</p>
<p>– 615-322-5000 or 0</p>
<p>Vanderbilt Inpatient Team Pagers</p>
<p>Brittingham (Heme) 1: 831-4785</p>
<p>Brittingham (Heme) 2: 831-4788</p>
<p>CHF-A: 831-6485</p>
<p>CHF-B: 831-6486</p>
<p>Harrison 1: 831-4769</p>
<p>Harrison 2: 831-4770</p>
<p>Morgan 1: 831-4765</p>
<p>Morgan 2: 831-4766</p>
<p>Morgan 3: 831-4767</p>
<p>Morgan 4: 831-4768</p>
<p>Morgan 5: 831-8481</p>
<p>Morgan 6: 831-4781</p>
<p>Oncology A: 831-4786</p>
<p>Oncology B: 831-4787</p>
<p>Rogers Hepatology: 831-4782</p>
<p>Rogers ID: 831-4779</p>
<p>Rogers Pulmonary: 831-4777</p>
<p>Rogers Renal: 831-4783</p></section><h1 class='nav-section-title-end'>Ended: Appendices</h1></div>

              
            </article>
          </div>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
    <div class="md-copyright__highlight">
      Copyright &copy; 2022 Vanderbilt University Medical Center <br>
Vanderbilt University Medical Center is committed to principles of equal opportunity and affirmative action. <br>
EOE/AA/Women/Minority/Vets/Disabled <br>

    </div>
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    <script id="__config" type="application/json">{"base": "/", "features": ["search.suggest", "search.highlight", "search.share"], "search": "../assets/javascripts/workers/search.2a1c317c.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.config.lang": "en", "search.config.pipeline": "trimmer, stopWordFilter", "search.config.separator": "[\\s\\-]+", "search.placeholder": "Search", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version.title": "Select version"}}</script>
    
    
      <script src="../assets/javascripts/bundle.3a4b43e5.min.js"></script>
      
        <script src="../js/print-site.js"></script>
      
    
  </body>
</html>